

CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1216 TCTGTCAGACCTCCA 1231
DB 16 TCTGTCAGGCTCTCCA 1

RESULT 360

ADA9494/C
ID ADA9494 standard; DNA; 17 BP.

AC ADA9494;

DT 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 483.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KM developmental disorder; ss.

OS Homo sapiens.

PN EP1281758-A2.

PD 05-FEB-2003.

PF 30-JUL-2002; 2002EP-00016874.

PR 02-AUG-2001; 2001US-00922181.

XX (ABOM-) ABOMICA INC.

PA Shannon M, Gu Y, Nguyen C;

PI WPI; 2003-423107/40.

PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.

XX Example 8; SEQ ID NO 483; 103bp; English.

XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.

SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1216 TCTGTCAGACCTCCA 1231
DB 17 TCTGTCAGGCTCTCCA 2

RESULT 361

AB264765
ID AB264765 standard; RNA; 17 BP.

AC AB264765;

DT 21-MAR-2003 (first entry)

DE Human HER2 DNAzyme substrate #222.

XX Human, ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.

OS Homo sapiens.

PN WO200297114-A2.

PD 05-DEC-2002.

PF 29-MAY-2002; 2002WO-US016840.

PR 29-MAY-2001; 2001US-0294140P.

PR 06-JUN-2001; 2001US-0296249P.

PR 10-SEP-2001; 2001US-0318477P.

PA (RIBO-) RIBOZYME PHARM INC.

PI Mcwigggen J;

DR WPI; 2003-140484/13.

PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX Claim 4; Page 137; 185bp; English.

XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265531, AB266520 - AB266524,
CC AB266530 - AB266585 represent substrate/target sequences for the human
CC ribozymes of the invention.

SQ Sequence 17 BP; 2 A; 4 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.4e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1305 GTCATCTGTGACGAC 1320
DB 2 GGCAUCUGUGAGCUGC 17

RESULT 362

AB265195
ID AB265195 standard; RNA; 17 BP.

AC AB265195;

XX

DT 21-MAR-2003 (first entry)
XX
DE Human HER2 DNAzyme substrate #652.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KW anti-tumoral; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN MO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 4; Page 145; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB265524,
CC AB266530 - AB266585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
XX
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2,4e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
OY 1392 GCTGAGCTGCTGACA 1407
||:||||:||||
DB 1 GCUCCGUCUGUGACA 16
XX
RESULT 363
ACD62279
ID ACD62279 standard; RNA; 17 BP.
XX
AC ACD62279;
XX
DT 23-SEP-2003 (first entry)
XX
DE HCV minus strand DNAzyme substrate sequence #478.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinozyme;
KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytosolic;

KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN MO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0286876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 283; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinozymes, amberyne, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 6 A; 6 C; 5 G; 0 T; 0 U; 0 Other;
XX
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2,4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1334 CTCGAGGACGAGAC 1349
|||||||
DB 2 CGCCAGGACGAGAC 17
XX
RESULT 364
ACD60646
ID ACD60646 standard; RNA; 17 BP.
XX
AC ACD60646;
XX

DT 24-SEP-2003 (first entry)
XX HCV DNAzyme substrate sequence #1944.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM amberyyme; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
PN
XX 17-OCT-2002.
PD
XX 26-MAR-2002; 2002WO-US009187.
PF
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX WPI; 2003-229207/22.
DR
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 268; 387pp; English.
PS
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1265 GCTGGAAGAGCTGAG 1280
DB 1 GCTGGAAGAGACACUGAG 16
RESULT 365
ACD61199
ID ACD61199 standard; RNA; 17 BP.
ACD61199;
XX 24-SEP-2003 (first entry)
DT
XX HCV DNAzyme substrate sequence #217.
DE
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM amberyyme; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
PN
XX 17-OCT-2002.
PD
XX 26-MAR-2002; 2002WO-US009187.
PF
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX WPI; 2003-229207/22.
DR
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 273; 387pp; English.
PS
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene

CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Oy 1205 GAGGGCAGCCATCTGT 1220
Db 2 GAGGGCCGCCACCTUGU 17
RESULT 366
ACD61470/C
ID ACD61470 standard; RNA; 17 BP.
XX
AC ACD61470;
XX
DT 23-SEP-2003 (first entry)
XX
DE HCV minus strand DNAzyme substrate sequence #61.
XX
KM Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT-) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI: 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 276; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense

CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1205 GAGGGCAGCCATCTGT 1220
Db 17 GAGGGCCGCCACCTGT 2
RESULT 367
ACD60390/C
ID ACD60390 standard; RNA; 17 BP.
XX
AC ACD60390;
XX
DT 24-SEP-2003 (first entry)
XX
DE HCV DNAzyme substrate sequence #1800.
XX
KM Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT-) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX

DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
PS Claim 1; Page 266; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC incyzymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer 1 region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention.
SQ Sequence 17 BP; 0 A; 5 C; 5 G; 0 T; 7 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1334 CTCGAGGAGAGAC 1349
DB 17 CGCCAGGAGAGAGAC 2
RESULT 368
ACCG8548
ID ACCG8548 standard; DNA; 17 BP.
XX
AC ACCG8548;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5795.
XX
XX Cytostatic; antiviral; neuroprotective; neurotropic; neuroleptic; murine;
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-1B004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumour and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX

PS Disclosure; Page 708; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACCG2754-
CC ACCG8806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia.
SQ Sequence 17 BP; 3 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1234 ATGCTGCTGCTGCTGCT 1249
DB 2 ATCTCTGCTGCTGCTGCT 17
RESULT 369
ACCG8691/C
ID ACCG8691 standard; DNA; 17 BP.
XX
AC ACCG8691;
XX
DT 26-AUG-2003 (first entry)
XX
DE Human ADAMTS14 gene exon 16 3' acceptor splice site.
XX
XX A disintegrin and metalloproteinase with thrombospondin repeats;
XX ADAMTS14; human; enzyme; neuroprotective; immunosuppressive; neurotropic;
XX antiferility; osteopathic; antiarthritic; antineumatic;
XX antiinflammatory; antiasthmatic; immunomodulator; antiallergic;
XX cytosstatic; antilicer; vasotropic; antirretroviral; cardiac;
XX anticonvulsant; antiparkinsonian; cerebroprotective; antimigraine;
XX antidepressant; analgesic; ophthalmological; vulnary; antidiabetic;
XX dermatological; transgenic; chromosome 10q21.3; gene; ds.
XX
OS Homo sapiens.
XX
XX
XX Key Location/Qualifiers
XX FH 1.12
XX FT intron /tag= a
XX FT exon /partial
XX FT 13.17
XX FT /tag= b
XX FT /partial
XX
PN WO2003042379-A2.
XX
PD 22-MAY-2003.
XX
PF 08-NOV-2002; 2002WO-EP012534.
XX
PR 13-NOV-2001; 2001EP-00204335.
XX
PA (UNIV-) UNIV LIEGE.
XX
PI Collige A, Lapierre C, Nugens B;
XX
DR WPI; 2003-482347/45.
XX
XX New isolated and purified A disintegrin and metalloproteinase with
PT thrombospondin type I repeats polynucleotide, useful for manufacturing a
PT medicament for the treatment of e.g. neurodegenerative, autoimmune, and
PT cell proliferation diseases.
XX
PS Disclosure; Page 39; 67pp; English.

```
XX The present sequence is that of the 3' acceptor splice site of exon 16 of
CC a novel human A Disintegrin and Metalloproteinase with Thrombospondin
CC type I repeats (ADAMTS) gene, denoted ADAMTS14, on chromosome 10q21.3. A
CC cDNA sequence for ADAMTS14 is given in ACC58643. ADAMTS14 (see AB842736)
CC is an aminoproteoglycan peptidase that functions in procollagen
CC processing. ADAMTS14 polynucleotides, polypeptides, vectors, cells
CC transfected by the vectors, and inhibitors directed against ADAMTS14 are
CC used in the treatment and/or prevention of a range of diseases
XX
SQ Sequence 17 BP; 2 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1271 AGAGCTGAGGCGCAGA 1286
Db      17 AGAGCTGAGGCGGAGA 2

RESULT 370
ADC37821
ID ADC37821 standard; DNA; 17 BP.
XX
AC ADC37821;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:170.
XX
KW human; angiotomtin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
PI WPI; 2003-430501/40.
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiotomtin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 170; 172pp; English.
XX
CC The present invention describes the human angiotomtin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 6 C; 5 G; 0 T; 0 U; 0 Other;

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1253 GCTGCGACACAGCTG 1268
Db      17 GCTGCGACACAGCTG 1268
```

```
Db      1 GCAGCAGCAACACAGC 16

RESULT 371
ADC37818
ID ADC37818 standard; DNA; 17 BP.
XX
AC ADC37818;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:167.
XX
KW human; angiotomtin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
PI WPI; 2003-430501/40.
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiotomtin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 167; 172pp; English.
XX
CC The present invention describes the human angiotomtin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 6 C; 5 G; 0 T; 0 U; 0 Other;

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1251 CGGCTGACGACACAGC 1266
Db      2 CAGCAGCAGCAACAGC 17

RESULT 372
ADC37819
ID ADC37819 standard; DNA; 17 BP.
XX
AC ADC37819;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:168.
XX
KW human; angiotomtin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
```

OS Synthetic.
OS Homo sapiens.
XX
XX WO2003037931-A2.
XX
XX 08-MAY-2003.
XX
XX 01-NOV-2002; 2002WO-US035129.
XX
XX 01-NOV-2001; 2001US-0334773P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Shannon M, Phan T;
XX
XX WPI; 2003-430501/40.
XX
XX
XX New isolated nucleic acid molecule encoding a human angiotensin-like
XX protein, useful for treating or preventing a disorder associated with
XX decreased or increased expression or activity of AMLP1.
XX
XX Example 2; SEQ ID NO 168; 172bp; English.
XX
XX The present invention describes the human angiotensin-like protein 1
XX (AMLPI). human AMLPI has cytostatic activity, and can be used in gene
XX therapy. The AMLPI protein, nucleic acid molecules, antibodies, and
XX compositions of the present invention can be used for treating or
XX preventing a disorder associated with decreased or increased expression
XX or activity of AMLPI. The present sequence represents a scanning
XX oligonucleotide for human AMLPI, which is used in an example from the
XX present invention.
XX
XX Sequence 17 BP; 7 A; 6 C; 4 G; 0 T; 0 U; 0 Other;
XX
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1251 CGGCTGCGACCAAGC 1266
DB 1 CAGCAGCAGCAACAGC 16
RESULT 373
ADC37820
ID ADC37820 standard; DNA; 17 BP.
XX
XX ADC37820;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human AMLPI scanning 17-mer oligonucleotide SEQ ID NO:169.
XX
XX human; angiotensin-like protein 1; AMLPI; cytostatic; gene therapy;
XX AMLPIa; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX WO2003037931-A2.
XX
XX 08-MAY-2003.
XX
XX 01-NOV-2002; 2002WO-US035129.
XX
XX 01-NOV-2001; 2001US-0334773P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Shannon M, Phan T;
XX
XX WPI; 2003-430501/40.
XX

PT New isolated nucleic acid molecule encoding a human angiotensin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLPI.
XX
XX Example 2; SEQ ID NO 169; 172bp; English.
XX
XX The present invention describes the human angiotensin-like protein 1
XX (AMLPI). human AMLPI has cytostatic activity, and can be used in gene
XX therapy. The AMLPI protein, nucleic acid molecules, antibodies, and
XX compositions of the present invention can be used for treating or
XX preventing a disorder associated with decreased or increased expression
XX or activity of AMLPI. The present sequence represents a scanning
XX oligonucleotide for human AMLPI, which is used in an example from the
XX present invention.
XX
XX Sequence 17 BP; 7 A; 5 C; 5 G; 0 T; 0 U; 0 Other;
XX
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1253 GCTGCGACCAACGCTG 1268
DB 2 GCAGCAGCAACAGCAG 17
RESULT 374
AD152233/C
ID AD152233 standard; DNA; 17 BP.
XX
XX AD152233;
XX
XX 15-APR-2004 (first entry)
XX
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID4736.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
XX primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; SEQ ID NO 4736; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1418 TGAGCGGCATCATC 1433
16 TGAGAGCGCCATGATC 1

Db

RESULT 375
ADL46982/C
ID ADL46982 standard; RNA; 17 BP.

AC ADL46982;

DT 20-MAY-2004 (first entry)

XX Human NOGO receptor inozyme substrate sequence #415.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor inozyme; substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PD 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeberli P, Mcswigen J, Fossnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.

PS Claim 9; SEQ ID NO 515; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.

XX Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1356 AGGCGACGTGAGCCTT 1371
17 AGGCGACCTGAGCCTT 2

Db

RESULT 376
ADM09619/C
ID ADM09619 standard; RNA; 17 BP.

AC ADM09619;

DT 20-MAY-2004 (first entry)

XX Human NOGO receptor amberyze substrate sequence #174.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor amberyze; substrate; ss.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PD 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeberli P, Mcswigen J, Fossnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.

PS Claim 9; SEQ ID NO 1014; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor antibody substrate sequence.

XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1356 AGGCGAGCTGAGCTT 1371
DB 16 AGGCGAGCTGAGCTT 1

RESULT 377
AD184554/C

ID AD184554 standard; RNA; 17 BP.

AC AD184554;

DT 03-JUN-2004 (first entry)

XX HCV DNAzyme substrate sequence #1800.

XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;

XX HCV infection; type I interferon; DNAzyme.

XX Hepatitis C virus.

XX US2003125270-A1.

XX 03-JUL-2003.

XX 18-DEC-2000; 2000US-00740332.

XX 18-DEC-2000; 2000US-00740332.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGEN J.

XX (ROBE/) ROBERTS E.

XX (PAVC/) PAVCO P A.

XX (MACE/) MACEJACK D.

XX Blact L, Mcswigen J, Roberts E, Pavco PA, Macejack D;

XX WPI; 2004-031273/03.

XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.

XX Claim 1; SEQ ID NO 1800; 198pp; English.

XX The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX the binding arms of the enzymatic nucleic acid molecule comprises
XX sequences complementary to any of the defined substrate sequences given
XX in the specification. The nucleic acid molecule may be administered for
XX the treatment of HCV infections, especially in combination with type I
XX interferons. The present sequence represents a HCV DNAzyme substrate
XX sequence.

XX Sequence 17 BP; 0 A; 5 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1334 CTCGAGGAGAGAGAC 1349

DB 17 CCGCGAGGAGAGAGAC 2

RESULT 378
AD184971

ID AD184971 standard; RNA; 17 BP.

AC AD184971;

DT 03-JUN-2004 (first entry)

XX HCV DNAzyme substrate sequence #2217.

XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;

XX HCV infection; type I interferon; DNAzyme.

XX Hepatitis C virus.

XX US2003125270-A1.

XX 03-JUL-2003.

XX 18-DEC-2000; 2000US-00740332.

XX 18-DEC-2000; 2000US-00740332.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGEN J.

XX (ROBE/) ROBERTS E.

XX (PAVC/) PAVCO P A.

XX (MACE/) MACEJACK D.

XX Blact L, Mcswigen J, Roberts E, Pavco PA, Macejack D;

XX WPI; 2004-031273/03.

XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.
XX Claim 1; SEQ ID NO 2217; 198pp; English.
XX The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX the binding arms of the enzymatic nucleic acid molecule comprises
XX sequences complementary to any of the defined substrate sequences given
XX in the specification. The nucleic acid molecule may be administered for
XX the treatment of HCV infections, especially in combination with type I
XX interferons. The present sequence represents a HCV DNAzyme substrate
XX sequence.

XX Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY 1205 GAGGCGAGCCATCTGT 1220
DB 2 GAGGCGCGCCACCTGU 17

RESULT 379
AD185092/C

ID AD185092 standard; RNA; 17 BP.

AC AD185092;

DT 03-JUN-2004 (first entry)

XX HCV DNAzyme substrate sequence #2338.

XX

KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNazyme.
XX
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PS (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
DR WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 2338; 198pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
XX
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1205 GAGGCGAGCATCTGT 1220
DB 17 GAGGCGCGCACCTGT 2
XX
RESULT 380
AD185509
ID AD185509 standard; RNA; 17 BP.
XX
AC AD185509;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNazyme substrate sequence #2755.
XX
KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNazyme.
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PS (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
DR WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 2755; 198pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
SQ Sequence 17 BP; 6 A; 6 C; 5 G; 0 T; 0 U; 0 Other;
XX
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1334 CTCGAGCGCAGAGAC 1349
DB 2 CGCCAGCGCAGAGAC 17
XX
RESULT 381
AD184698
ID AD184698 standard; RNA; 17 BP.
XX
AC AD184698;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNazyme substrate sequence #1944.
XX
KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNazyme.
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PS (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
DR WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 1944; 198pp; English.

XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 1265 GCTGGAAGAGCTGAG 1280
DB 1 GCUGAGAGACACUGAG 16
RESULT 382
AAT50738/C
ID AAT50738 standard; RNA; 18 BP.
XX
AC AAT50738;
XX
DT 07-MAR-1997 (first entry)
XX
DE Rabbit CERP hairpin ribozyme target sequence #1423.
XX
KW Hairpin ribozyme; cholesterol ester transfer protein; RNA cleavage;
KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW reverse cholesterol transport; high density lipoprotein; therapy; CERP;
KW familial hypercholesterolaemia; dyslipidaemia; hypolipidoproteinaemia;
KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
KW LDL; BS.
XX
XX Oryctolagus cuniculus.
OS
XX
PN WO9620279-A1.
XX
PD 04-JUL-1996.
XX
XX 11-DEC-1995; 95WO-US016000.
XX
XX 23-DEC-1994; 94US-00363240.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (WARN) WARNER LAMBERT CO.
XX
PI Couture L, Stinchcomb D, Mcswiggen J, Biegaier C, Pape M;
XX
DR WPI, 1996-321852/32.
XX
XX New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA -
PT useful for preventing or treating initial development, progression or
PT regression of vascular diseases, esp. familial hypercholesterolaemia.
XX
PS Claim 4; Page 56; 72pp; English.
XX
CC AAT50699-750754 represent target sequences for the rabbit cholesterol
CC ester transfer protein (CERP) hairpin ribozymes (see AAT50643-750698).
CC CERP is a 74 kD glycoprotein that facilitates neutral lipid transfer
CC between plasma lipoproteins. The numbering of the targets refers to the
CC position of the cleavage site in full length CERP. The ribozyme then
CC binds to 4-6 nucleotides 5', and a variable number 3' of this site. The
CC ribozymes are able to cleave mRNA from the gene encoding CERP, thereby
CC blocking synthesis and/or expression of the mRNA. By inhibiting CERP, the
CC reverse cholesterol transport (RCT) pathway can be inhibited (or
CC eliminated) thereby preventing the reduction in size density of the high
CC density lipoproteins (HDL), prolonging HDL half life, and therefore

CC increasing HDL levels. The ribozymes can be used to treat conditions
CC associated with abnormal levels of CERP, specifically atherosclerosis,
CC peripheral vascular disease, hyperbetalipoproteinaemia, dyslipidaemia,
CC familial hypercholesterolaemia, hypolipidoproteinaemia, vascular
CC complications of diabetes, transplant, atherosclerosis and angioplastic
CC restenosis. By inhibiting CERP, the levels of HDL and low density
CC lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a
CC decrease in LDL levels, and a corresponding increase in HDL levels). The
CC ribozymes can also be used diagnostically to study genetic drift and
CC mutations in diseased cells, and to detect CERP mRNA. As the ribozymes
CC target specific regions of the CERP gene, they have low non-specific
CC activity
XX
SQ Sequence 18 BP; 1 A; 5 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1202 GCAGAGGCGAGCCATC 1217
DB 16 GCAGAGGCGAGCCATC 1
RESULT 383
AAH91892/C
ID AAH91892 standard; DNA; 18 BP.
XX
XX AAH91892;
XX
XX
DT 09-OCT-2001 (first entry)
XX
DE Human inflammatory bowel disease associated polymorphic site #967.
XX
XX Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
XX single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
XX chromosome 5q31-33; forensic test; gene therapy; ds.
XX
XX Homo sapiens.
OS
XX
FH Key Location/Qualifiers
FT misc_feature 10
FT /*tag= a
FT /note= "SNP, optionally T or A at this position"
XX
XX WO200142511-A2.
XX
XX 14-JUN-2001.
XX
XX 11-DEC-2000; 2000WO-US033632.
XX
XX 10-DEC-1999; 99US-0170257P.
XX
XX 10-APR-2000; 2000US-0196046P.
XX
PA (MHED) WHITEHEAD INST BIOMEDICAL RES.
PA (ELLIPSIS) BIORHAPREUTICS CORP.
XX
XX Daly M, Hudson TJ, Lander ES, Rioux J, Siminovitch K;
XX
DR WPI, 2001-367874/38.
XX
XX Testing for the presence of polymorphisms associated with inflammatory
PT bowel disease, using a hybridization assay.
XX
XX Claim 1; Page 79; 463pp; English.
XX
CC The present invention describes a method for detecting the presence of
CC polymorphisms associated with inflammatory bowel diseases such as
CC ulcerative colitis and Crohn's disease. The methods can be used to detect
CC the presence of genetic polymorphisms associated with inflammatory bowel
CC disease and correlating their occurrence with disease states. They may be
CC used in this way for phenotypic correlations, forensics, paternity
CC testing, medicine and genetic analysis. The present sequence is a

CC polymorphic site described in the exemplification of the invention
XX Sequence 18 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 1 Other;
SQ Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1254 CTGCAGCAACAGCTGGA 1270
DB 17 CTGCATCTCTCAGCTGGA 1
RESULT 384
ABL43550/C
ID ABL43550 standard; DNA; 18 BP.
AC ABL43550;
XX
XX 11-APR-2002 (first entry)
XX
XX Human chromosome 1p36-35 PCR primer SEQ ID NO:594.
DE
XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KM PCR primer; 88.
XX
XX Homo sapiens.
OS
XX JP2001321190-A.
PN
XX 20-NOV-2001.
PD
XX 12-MAR-2001; 2001JP-00068285.
PF
XX 10-MAR-2000; 2000JP-0006716.
PR
XX (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
XX WPI; 2002-144136/19.
DR
XX Arraying genome clones.
PT
XX Claim 4; Page 16; 528bp; Japanese.
PS
XX
XX The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
CC
XX
XX Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1207 GGGCAGCCATCTGTCA 1222
DB 17 GAGCCGCCATCTGTCA 2
RESULT 385
ABL43552/C
ID ABL43552 standard; DNA; 18 BP.
AC ABL43552;
XX
XX 11-APR-2002 (first entry)
XX
XX Human chromosome 1p36-35 PCR primer SEQ ID NO:596.
DE
XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KM PCR primer; 88.
XX
XX Homo sapiens.
OS
XX JP2001321190-A.
PN
XX 20-NOV-2001.
PD
XX 12-MAR-2001; 2001JP-00068285.
PF
XX 10-MAR-2000; 2000JP-0006716.
PR
XX (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
XX WPI; 2002-144136/19.
DR
XX Arraying genome clones.
PT
XX Claim 4; Page 16; 528bp; Japanese.
PS
XX
XX The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
CC
XX
XX Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1207 GGGCAGCCATCTGTCA 1222
DB 17 GAGCCGCCATCTGTCA 2
RESULT 386
ADC03075/C
ID ADC03075 standard; DNA; 18 BP.

XX AC ADC03075;
XX DT 18-DEC-2003 (first entry)
XX DE Ex vivo stem-cell expansion related polynucleotide #510.
XX KW cytostatic; antineoplastic; immunomodulator; immunostimulant;
XX KW immunosuppressive; antiinflammatory; interleukin agonist 3;
XX KW interleukin antagonist 3; gene therapy; ex vivo expansion of stem cell;
XX KW modified human interleukin-3; cell proliferation;
XX KW acute myelogenous leukaemia; cell proliferation; TF-1 cell proliferation;
XX KW methylcellulose assay; haematopoietic disorder; cancer;
XX KW acute myelogenous leukaemia; B lymphoid cancer; leukopenia; neutropenia;
XX KW aplastic anaemia; Chediak-Higashi's syndrome;
XX KW systemic lupus erythematosus; myelodysplastic syndrome; myelofibrosis;
XX KW bone marrow; blood cell activation; blood cell growth; ds.
XX OS Synthetic.
XX PN US6479261-B1.
XX PD 12-NOV-2002.
XX PF 15-NOV-1995; 95US-00559390.
XX PR 24-NOV-1992; 92US-00981044.
XX PR 22-NOV-1993; 93WO-US011198.
XX PR 06-APR-1995; 95US-00411796.
XX PA (PHAA) PHARMACIA CORP.
XX PI Bauer SC, Abrams MA, Braford-Goldberg SR, Caparon MH, Easton AM;
XX PI Klein BK, McCrean JP, Olin P, Paik K, Polazzi J, Thomas JW;
XX DR WPI; 2003-655574/62.
XX PT Selective ex vivo expansion of stem cells, useful for treating a patient
XX PT having hematopoietic disorder, e.g. leukemia, neutropenia or aplastic
XX PT anemia, comprises using recombinant human interleukin-3 variant or mutant
XX PT proteins.
XX PS Example 66; SEQ ID NO 535; 288bp; English.
XX CC The invention describes selective ex vivo expansion of stem cells
XX CC comprising separating stem cells from other cells, culturing the cells
XX CC with modified human interleukin-3 polypeptide with at least 3 times
XX CC greater cell proliferative activity than native human interleukin-3 in at
XX CC least one assay selected from the group of acute myelogenous leukaemia
XX CC cell proliferation, TF-1 cell proliferation, and methylcellulose assay,
XX CC and harvesting the cultured cells. The method is useful for selective ex
XX CC vivo expansion of stem cells. The recombinant human interleukin-3 variant
XX CC or mutant proteins are useful for treating a patient having a
XX CC haematopoietic disorder, such as cancer (e.g. acute myelogenous leukaemia
XX CC or certain types of B lymphoid cancers), leukopenia, neutropenia,
XX CC aplastic anaemia, Chediak-Higashi's syndrome, systemic lupus
XX CC erythematosus, myelodysplastic syndrome, or myelofibrosis. The
XX CC interleukin-3 mutants are also useful as antagonists for producing
XX CC antibodies used in immunoassay and immunochemotherapy protocols, or for
XX CC stimulating bone marrow and blood cell activation and growth before
XX CC infusion into patients. This sequence represents an ex vivo stem cell
XX CC expansion method associated polynucleotide.
XX SQ Sequence 18 BP; 6 A; 5 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1337 CAAGCAGAGACTTT 1352
DB 17 CATGCAGAGACTTT 2

RESULT 387
ID ADF13027/C
XX ID ADF13027 standard; DNA; 18 BP.
XX AC ADF13027;
XX DT 12-FEB-2004 (first entry)
XX DE Human PCMI exon 34 splice acceptor fragment.
XX KW schizophrenia; chromosome 8p21-22; pericentriolar material 1; PCMI;
XX KW marker; microsatellite repeat; NT 000501 contig; polymorphic marker;
XX KW linkage disequilibrium; D8S2615; D8S2616;
XX KW single nucleotide polymorphism; SNP; ds.
XX OS Homo sapiens.
XX PN WO2003050301-A2.
XX PD 19-JUN-2003.
XX PF 12-DEC-2002; 2002WO-GB005630.
XX PR 12-DEC-2001; 2001GB-00029758.
XX PA (GURL/) GURLING H M D.
XX PI Gurling HMD;
XX DR WPI; 2003-532919/50.
XX PT Determining the susceptibility of an individual to a neuropsychiatric
XX PT disorder (e.g. schizophrenia) or diagnosing or prognosing the disorder
XX PT comprises using a pericentriolar material 1 marker in the chromosomal
XX PT region 8p21-22.
XX PS Claim 9; Fig 6; 108bp; English.
XX CC This invention describes a novel method of determining the susceptibility
XX CC to or diagnosis of schizophrenia comprising using a marker located in the
XX CC chromosomal region 8p21-22. The method involves determining the presence
XX CC or absence in a test sample of a pericentriolar material 1 (PCMI) marker
XX CC which is selected from any of the microsatellite repeats present in the
XX CC NT 000501 contig on chromosome 8p21-22 or a polymorphic marker which is
XX CC in linkage disequilibrium with the chromosome. The PCMI marker is
XX CC preferably D8S2615, D8S2615 or D8S2616 and lies within the PCMI gene. The
XX CC novel method involves assessing two or more of the PCMI markers single
XX CC nucleotide polymorphisms (SNPs). The PCMI gene is amplified, particularly
XX CC within the intronic sequence 3' to exon 4, in exon 4, or in the intronic
XX CC sequence 5' of exon 5. The PCMI marker is assessed by strand conformation
XX CC polymorphic marker analysis, heteroduplex analysis or restriction
XX CC fragment length polymorphism (RFLP) analysis. Schizophrenia therapy
XX CC comprises screening an individual for a genetic predisposition to
XX CC schizophrenia, where the predisposition is correlated with the PCMI
XX CC marker and if a predisposition is identified, providing therapeutic
XX CC treatment for the individual. Alternatively, the method comprises
XX CC administering to a patient a substance that modulates the expression from
XX CC the PCMI gene or a gene located within 1000 kbase of the PCMI locus. This
XX CC sequence represents the human PCMI exon 34 splice acceptor region.
XX SQ Sequence 18 BP; 8 A; 3 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1303 TGGTCATCTGTCATCA 1318
DB 16 TGGTCATCTGTCATCA 1

RESULT 388

XX	ACC57596/C
ID	ACC57596 standard; DNA; 18 BP.
XX	
AC	ACC57596;
XX	
DT	28-JUL-2003 (first entry)
XX	
DE	Mouse MAP kinase--interacting kinase Mnk1 gene forward primer.
XX	
KW	Mouse; MAP kinase-interacting kinase 1; Mnk1; enzyme; anorectic;
KM	antidiabetic; antipyretic; hypotensive; cardiant; antiipaeamic;
KV	antiarrhythmic; litholytic; hepatotropic; gene therapy; PCR; primer; ss.
XX	
OS	Mus sp.
XX	
PN	WO2003037362-A2.
XX	
PD	08-MAY-2003.
XX	
PF	29-OCT-2002; 2002MO-EP012075.
XX	
PR	29-OCT-2001; 2001EP-00125812.
XX	
PR	17-MAY-2002; 2002EP-00011073.
XX	
PA	(DEVE-) DEVELOPEN ENTWICKLUNGSHIOLOGISCHE FORSCH.
XX	
PI	Stevemagel A, Eulenbergr K, Broenmer G, Ciossek T, Rudolph B;
XX	
PI	Rudolph D, Belgore F, Jaekel S;
XX	
DR	WPI; 2003-430470/40.
XX	
PT	New pharmaceutical composition having a MAP kinase interacting kinase
XX	nucleic acid or polypeptide, useful for diagnosing, preventing and/or
PT	treating disorders related to weight-regulation and thermogenesis.
XX	
PS	Example 8; Page 64; 120pp; English.
XX	
CC	The present sequence is a forward primer for the mouse MAP kinase-
CC	interacting kinase 1 (Mnk1) gene. It was used in a Tagman analysis of
CC	Mnk1 expression. Mnk1 was ubiquitously expressed. The invention relates
CC	to Mnk proteins, and the nucleic acids encoding them, and their use in
CC	the diagnosis, study, prevention and treatment of diseases and disorders
CC	related to body weight regulation and thermogenesis, for example
CC	metabolic disease such as obesity and related disorders such as an eating
CC	disorder, cachexia, diabetes mellitus, hypertension, coronary heart
CC	disease, hypercholesterolaemia, dyslipidaemia, osteoarthritis, gallstones
CC	and sleep apnoea, and disorders related to ROS defence, such as diabetes
CC	mellitus, neurodegenerative disorders and cancer, e.g. cancers of the
CC	reproductive organs, and others, in cells, cell masses, organs and/or
CC	subjects (all claimed)
XX	
SQ	Sequence 18 BP; 1 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
	Query Match 5.1%; Score 12.8; DB 1; Length 18;
	Best Local Similarity 87.5%; Pred. No. 2.8e+02;
	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0
OY	1280 GGGCAGAGACCTCGAG 1295
DB	17 GAGCAGAGGCGCTCAG 2
RESULT 389	
ADM57496	
ID	ADM57496 standard; DNA; 18 BP.
XX	
AC	ADM57496;
XX	
DT	03-JUN-2004 (first entry)
XX	
DE	M. tuberculosis PCR primer RD11-Rv2646F.
XX	
KX	antibacterial; vaccine; mmp16; Mycobacterium; BCG; Tbp1; ss; PCR; primer.

XX	Mycobacterium tuberculosis.
OS	EP1338657-A1.
PN	27-AUG-2003.
PD	25-FEB-2002; 2002EP-00290458.
PP	25-FEB-2002; 2002EP-00290458.
XX	25-FEB-2002; 2002EP-00290458.
XX	(INSP) INST PASTEUR.
PA	Cole S, Brosch R, Gordon S, Eiglmeier K, Garnier T;
P1	WP1; 2003-699254/67.
DR	New TbD1 nucleic acids having the mutation CTG to CGG at codon 463 of
XX	gene katG, useful for distinguishing Mycobacterium tuberculosis infection
PT	from M. africanum, M. canettii, M. microti, M. bovis BCG
PT	infection.
PS	Disclosure; Page 20; 73pp; English.
XX	The invention relates to a novel isolated or purified nucleic acid. A
CC	polypeptide encoded by a nucleic acid of the invention has antibacterial
CC	activity, and may have a use in a vaccine. The nucleic acid is a TbD1
CC	nucleic acid having a fully defined sequence of 3953 bp given in the
CC	specification. The TbD1 deletion or mmpL6 551 polymorphism is useful as a
CC	genetic marker for the differentiation of Mycobacterium strain of M.
CC	tuberculosis complex. The genetic marker in association with at least one
CC	genetic markers selected from RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8,
CC	RD9, RD10, RD11, RD13, RD14, RVD1, RVD2, RVD3, RVD4, RVD5, katG463 ,
CC	gyrA295 , oxyR285 , and pncA57, may be used for the differentiation of
CC	Mycobacterium strain of M. tuberculosis complex. The nucleic acids may
CC	also be used to distinguish an infection resulting from M. tuberculosis
CC	from an infection resulting from M. africanum, M. canettii, M. microti, M.
CC	bovis, M. bovis BCG. The present sequence is used in the exemplification
CC	of the invention.
XX	
SQ	Sequence 18 BP; 4 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match	5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity	87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	1316 GCAGTAGGGGACCTC 1331
DB	
	3 GCAGTAGACGACCCTC 18
RESULT 390	
ADP92301/C	
ID ADP92301 standard; DNA; 18 BP.	
XX	
AC ADP92301;	
DT	26-FEB-2004 (first entry)
XX	
DE Human cytokeratin 19-related loop F PCR primer - SEQ ID 389.	
XX	
KW human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;	
KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;	
KW PCR; Loop F.	
XX	
OS Homo sapiens.	
XX	
PN WO2003097878-A1.	
XX	
PD 27-NOV-2003.	
XX	
PF 20-MAY-2003; 2003WO-JP006256.	
XX	

PR 21-MAY-2002; 2002JP-00145689.
PR 17-JUN-2002; 2002JP-00175271.
PR 09-JUL-2002; 2002JP-00197959.
XX
XX (SYSM-) SYSMEX CORP.
XX
XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
XX WPI; 2004-012543/01.
XX
XX LAMP nucleic acid amplification primers for detection of cytokeratin
PT expression as indicator in diagnosis of tumour metastasis.
XX
XX Claim 19; SEQ ID NO 389; 266bp; Japanese.
XX
XX The invention relates to novel nucleic acid amplification primers for the
CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
CC (loop mediated isothermal amplification) method. The primers of the
CC invention may be useful for the detecting cytokeratin 18-20 expression as
CC an indicator for the diagnosis of tumour metastasis, particularly
CC prostate cancer and lymphoma. The amplification using the primers is
CC highly efficient and allows very sensitive detection of tumour
CC metastasis. The current sequence is that of the human CK19-related PCR
CC primer of the invention.
XX
SQ Sequence 18 BP; 1 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1371 TACCAGAGCAGCTGC 1386
Db 16 TACCAGAGCAGGGGC 1

RESULT 391
AD158750/C
ID AD158750 standard; DNA; 18 BP.
XX
AC AD158750;
XX
DT 22-APR-2004 (first entry)
XX
DE Human interleukin 3 expressing vector related DNA seq id 535.
XX
XX immunostimulant; anti-anemic; immunomodulator; anti-inflammatory;
KW dermatological; immunosuppressive; cytoskeletal; neuroprotective;
KW gene therapy; interleukin-agonist-3; cultured stem cell;
KW ex-vivo cell expansion; interleukin-3 mutant; aplastic anaemia;
KW cyclic neutropenia; idiopathic neutropenia; Chediak-Higashi syndrome;
KW systemic lupus erythematosus; leukaemia; myelodysplastic syndrome;
KW myelofibrosis; interleukin 3; IL-3; mutagenesis; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX US2004018618-A1.
XX
XX 29-JAN-2004.
XX
XX 19-JUN-2002; 2002US-00179940.
XX
XX 24-NOV-1992; 92US-00981044.
PR 22-NOV-1993; 93WO-US011198.
PR 06-APR-1995; 95US-00411796.
PR 15-NOV-1995; 95US-00559390.
XX
XX (BAUE/) BAUER S C.
PA (ABRA/) ABRAMS M A.
PA (BRAU/) BRAFORD-GOLDBERG S R.
PA (CAPA/) CAPARON M H.
PA (EAST/) EASTON A M.

PA (KLEI/) KLEIN B K.
PA (MCKE/) MCKEARN J P.
PA (OLIN/) OLINS P.
PA (PAIK/) PAIK K.
PA (POLA/) POLAZZI J.
PA (THOM/) THOMAS J W.
XX
XX Bauer SC, Abrams MA, Braford-Goldberg SR, Caparon MH, Easton AM,
PI Klein BK, Mckearn JP, Olins P, Paik K, Polazzi J, Thomas JW;
XX WPI; 2004-122043/12.
XX
XX Culturing stem cells using a recombinant human interleukin-3 mutant
PT polypeptide, useful for treating aplastic anemia, neutropenia, Chediak-
PT Higashi syndrome, systemic lupus erythematosus, leukemia and
PT myelodysplastic syndrome.
XX
XX Example 65; SEQ ID NO 535; 328bp; English.
XX
XX The invention describes cultured stem cells obtained by a method for
CC selective ex-vivo expansion of stem cells comprising separating stem
CC cells from other cells, culturing the separated stem cells with a
CC selected media which comprises a human interleukin-3 mutant polypeptide
CC comprising defined amino acid sequences SEQ ID NO 15 or 19 given in the
CC specification, and harvesting the cultured cells. The methods and
CC compositions of the present invention are useful for treating aplastic
CC anaemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi
CC syndrome, systemic lupus erythematosus, leukaemia, myelodysplastic
CC syndrome and myelofibrosis. This sequence represents a DNA used in the
CC construction of human interleukin 3 (IL-3) mutants.
XX
SQ Sequence 18 BP; 6 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1337 CAGGCGAGAGACTTT 1352
Db 17 CAGGCGAGAGATTIT 2

RESULT 392
AD132584
ID AD132584 standard; DNA; 18 BP.
XX
XX AD132584;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human declin reverse PCR primer SEQ ID NO:42.
XX
XX detection; cancer; 8q22.3; chromosome 8; human; EMD; tumour suppressor;
KW cell cycle modulator; DNA repair; DNA damage; nuclear targeting protein;
KW progesterone receptor; cytoskeletal; gene therapy; squamous cell carcinoma;
KW hepatocellular carcinoma; ovarian cancer; breast cancer; melanoma;
KW head and neck cancer; adenocarcinoma; squamous lung cancer;
KW gastrointestinal cancer; renal cell cancer; bladder cancer;
KW prostate cancer; non-squamous carcinoma; glioblastoma; medulloblastoma;
KW declin; PCR; primer; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004022750-A1.
XX
XX 18-MAR-2004.
XX
XX 05-SEP-2003; 2003WO-AU001164.
PF
XX 05-SEP-2002; 2002AU-00951346.
PR 07-NOV-2002; 2002US-0425218P.
PR
XX

XX	Antisense gene therapy; RAIDD; death domain; caspase recruitment domain;
KW	CARD; hyperproliferative disorder; cancer; growth disorder; mouse;
KW	metabolic disorder; infection; inflammation; tumour formation;
KW	RIP associated ICH-1/CED-3-homologous protein with death domain;
KW	receptor interacting protein; antisense oligonucleotide; ss.
XX	
OS	Mus musculus.
XX	
PN	WO200248314-A2.
XX	
PD	20-JUN-2002.
XX	
PF	29-OCT-2001; 2001WO-US050914.
XX	
PR	01-NOV-2000; 2000US-00705267.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Zhang H, Freier SM, Watt AT;
DR	WPI; 2002-583496/62.
XX	
PT	Novel antisense compound that hybridizes and inhibits nucleic acid
PT	encoding RAIDD which is an adaptor molecule containing both death domain
PT	and caspase recruitment domains, for treating hyperproliferative
PT	disorder.
XX	
PS	Claim 3; Page 95; 144pp; English.
XX	
CC	The invention describes a compound (I) 8-50 nucleobases in length
CC	targeted to a nucleic acid molecule (II) encoding RAIDD which is an
CC	adaptor molecule containing both death domain (DD) and caspase
CC	recruitment domains (CARD), where (I) specifically hybridises with and
CC	inhibits expression of RAIDD, or specifically hybridises with at least an
CC	8-nucleobase portion of an active site on (II). (I) is useful for
CC	inhibiting the expression of RAIDD (Receptor interacting protein (RIP)
CC	associated ICH-1/CED-3-homologous protein with death domain) in cells or
CC	tissues, and for treating an animal having a disease or condition
CC	associated with RAIDD, where the disease or condition is a
CC	hyperproliferative disorder such as cancer, or a growth or metabolic
CC	disorder. (I) is also useful for diagnostics, therapeutics, prophylaxis,
CC	as research reagents and kits, for distinguishing functions of various
CC	members of a biological pathway, and in antisense gene therapy. (I) is
CC	also useful prophylactically, e.g. to prevent or delay infection,
CC	inflammation or tumour formation. This sequence represents a mouse RAIDD
CC	antisense oligonucleotide used to control expression of the RAIDD protein
CC	
SO	Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
XX	
Query Match	5.1%; Score 12.8; DB 1; Length 20;
Best Local Similarity	87.5%; Pred. No.3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0	
QY	1227 CTCGACATGCTGG 1242
DB	18 CTCGACGACATGCTGG 3
RESULT 394	
ABX97662/C	
ID	ABX97662 standard; DNA; 20 BP.
XX	
AC	ABX97662;
XX	
DT	16-MAY-2003 (first entry)
XX	
DE	Novel human protein NOVX associated reverse PCR primer #9.
XX	
KW	Human, NOV; adrenoleukodystrophy; congenital adrenal hyperplasia;
KW	haemophilia; hypercoagulation; autoimmune disease; allergy;
KW	immunodeficiency; transplantation; Von Hippel-Lindau syndrome;
KW	Alzheimer's disease; stroke; tubercous sclerosis; hypercalcaemia;

KW Parkinson's disease; Huntington's disease; cancer; fertility; diabetes;
KW adult respiratory distress syndrome; infection; tissue typing;
KW forensic identification; gene; PCR; primer; ss.
OS Homo sapiens.
XX WO200290500-A2.
XX 14-NOV-2002.
XX 02-MAY-2002; 2002WO-US014256.
XX 03-MAY-2001; 2001US-0288395P.
XX 07-MAY-2001; 2001US-0289087P.
XX 08-MAY-2001; 2001US-0289619P.
XX 09-MAY-2001; 2001US-0289817P.
XX 09-MAY-2001; 2001US-0289818P.
XX 11-MAY-2001; 2001US-0290194P.
XX 14-MAY-2001; 2001US-0290753P.
XX 15-MAY-2001; 2001US-0291189P.
XX 21-MAY-2001; 2001US-0292374P.
XX 23-MAY-2001; 2001US-0293107P.
XX 25-MAY-2001; 2001US-0293747P.
XX 29-MAY-2001; 2001US-0294110P.
XX 30-MAY-2001; 2001US-0294434P.
XX 10-SEP-2001; 2001US-0318346P.
XX 17-SEP-2001; 2001US-0322646P.
XX 01-MAY-2002; 2002US-00136728.
PA (CURA-) CURAGEN CORP.
XX
XX Splytek KA, Li L, Edinger SR, Stone DJ, Guo X, Anderson DW;
PI Paturajan M, Gerlach VL, Taupier RJ, Pena CE, Pedigaru M;
PI Kerkuda R, Gorman L, Zehusen BD, Smithson G, MacDougall JR;
PI Mezes PS, Peyman JA, Zhong M;
XX WPI; 2003-103511/09.
XX
XX New NOVX polypeptides and polynucleotides useful for treating or
PT preventing e.g. congenital adrenal hyperplasia, hemophilia,
PT hypercoagulation, autoimmune disease, allergies, immunodeficiencies,
PT transplantation.
XX
XX Example H; Page 239; 300pp; English.
XX
XX The invention describes an isolated polypeptide, NOVX, comprising a
CC sequence or a mature form of one of 21 51-1543 residue amino acid
CC sequences (P1-P21), given in the specification. The NOVX polypeptides,
CC polynucleotides and antibodies are useful in the manufacture of a
CC medicament for treating or preventing e.g. adrenoleukodystrophy,
CC congenital adrenal hyperplasia, hemophilia, hypercoagulation, autoimmune
CC disease, allergies, immunodeficiencies, transplantation, Von Hippel-
CC Lindau syndrome, Alzheimer's disease, stroke, tuberculous sclerosis,
CC hypercalcaemia, Parkinson's disease, Huntington's disease, cancer,
CC fertility, diabetes, adult respiratory distress syndrome, viral,
CC bacterial, and parasitic infections. The nucleic acid sequences may be
CC used in chromosome mapping, identifying individual from minute biological
CC samples (tissue typing), and in forensic identification of a biological
CC sample. This sequence represents a primer used to isolate DNA encoding a
CC novel human protein (NOV)
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 5.0%; Score 12.6; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

AAV97210/c
ID AAV97210 standard; RNA; 14 BP.
XX
XX AAV97210;
AC
XX 01-MAR-1999 (first entry)
XX
XX Potato citrate synthase target sequence position 988.
DE
XX Solanidine; glucosyltransferase; potato; citrate synthase; target;
KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW flower formation; cleavage; solanaceous plant; ss.
XX
XX Solanum tuberosum.
OS
XX WO9832843-A2.
XX 30-JUL-1998.
XX 14-JAN-1998; 98WO-US000738.
XX
XX 28-JAN-1997; 97US-0036545P.
XX 28-JAN-1997; 97US-0036599P.
XX 24-NOV-1997; 97US-00979416.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PI Zwick MG, Mcswiggen JA;
XX WPI; 1998-427939/36.
XX
XX New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT biosynthesis or regulating flowering.
XX
PS Claim 54; Page 59; 79pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules with RNA
CC -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC AAV96734 represent potato solanidine glucosyltransferase target
CC sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC synthase target sequences. Ribozymes of the present invention can be used
CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC particularly potato but also tomato, pepper, aubergine and ditura or to
CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC artichoke, kale, collard, chard, beet, turnip, sweet potato and turf
CC grass. Also the ribozymes can be used for RNA manipulation in the same
CC way that restriction endonucleases are for DNA, as well as to examine
CC genetic drift and mutations in plants and to detect specific RNA. The
CC ribozymes can be targeted to specific genes or to consensus sequences
CC within a family of related genes, and being catalytic need to be present
CC at only very low concentrations
XX
SQ Sequence 14 BP; 3 A; 6 C; 3 G; 0 T; 2 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1242 GCAAGTGTCCGGCT 1255
DB 14 GAAAGTGTCCGGCT 1
RESULT 396
AD030281
ID AD030281 standard; DNA; 14 BP.
XX

AC	ADQ30281;
XX	
DT	09-SEP-2004 (first entry)
XX	
DE	Murine VRI exon 1d transcription factor binding fragment #173.
XX	
KW	ds; VRI receptor; vanilloid receptor type 1; modulator;
KM	pain transmission; primary sensory neuron; transcription factor;
KM	detection; MZ1; NKappaB; NFAT; GATA1; sensitivity disorder; analgesia;
KM	hypalgesia; hyperalgesia; neuralgia; myalgia; murine.
XX	
OS	Mus sp.
XX	
PN	MO2004053120-A2.
PD	
XX	24-JUN-2004.
PF	
XX	01-DEC-2003; 2003WO-BP03522.
PR	
XX	09-DEC-2002; 2002DE-01057421.
PA	
XX	(CHEF) GRUENTHAL GMBH.
PI	
XX	Weilhe E, Bieller A, Schaefer MKH;
DR	
XX	WPI; 2004-468868/44.
PT	
XX	New nucleic acid that modulates expression of the vanilloid receptor-1,
PS	useful for control of pain or sensitivity disorders, comprises sequences
XX	from control regions of the receptor gene.
XX	
PS	Disclosure; Page 51; 68pp; German.
XX	
CC	This invention describes a novel nucleic acid containing a specific
CC	segment having at least one region that modulates expression of the VRI
CC	(vanilloid receptor type 1) receptor, or a functional derivative, allele
CC	or fragment of this region, or a sequence that hybridizes to it under
CC	standard conditions. The VRI modulator is derived from one or more of
CC	positions 221931-223444 of Genbank AL670399, 31673-36359 of AL663116, or
CC	44731-43231 or 36616-33151 of AF168787 and is involved in transduction of
CC	pain, particularly in primary sensory neurons. The invention also
CC	describes a vector that contains the VRI modulator, host cells containing
CC	this vector (other than human germ or embryonal stem cells) and a method
CC	for modulating expression of the VRI receptor by introducing the
CC	modulator or the vector into a cell that contains the VRI gene. The
CC	products of the invention are used for detecting a transcription factor
CC	from its binding to a regulatory sequence (or a double-stranded
CC	oligonucleotide fragment of it), e.g. by Western blotting or enzyme-
CC	linked immunosorbent assay, particularly for diagnosis of diseases
CC	associated with overexpression or underexpression of the transcription
CC	factor. The region that modulates VRI receptor expression includes a
CC	binding site for a transcription factor, e.g. MZF1, NFKappA, NFAT or
CC	GATA1. The nucleic acids of the invention, or vectors containing them,
CC	are used for prevention or treatment of pain, also for treating
CC	sensitivity disorders, e.g. analgesia, hyperalgesia or hyperalgesia, also
CC	neuralgia and myalgia, that are associated with activity of the VRI
CC	receptor. This sequence represents a fragment of murine VRI exon 1d DNA
CC	which is capable of binding to a transcription factor.
XX	
SQ	Sequence 14 BP; 5 A; 3 C; 5 G; 1 T; 0 U; 0 Other;
	Query Match 4.9%; Score 12.4; DB 1; Length 14;
	Best Local Similarity 92.9%; Pred. No. 1.6e+02;
	Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0
OY	1252 GGCTGCAGCAACAG 1265
DB	
	1 GGCTGAGCAACAG 14
RESULT 397	
AAV48765/C	
AAV48765 standard; DNA; 15 BP.	

XX	AAV48765;	
XX	15-OCT-1998	(first entry)
XX	ErbB-2 gene antisense oligonucleotide	ErbB-2-57.
XX	ErbB-2; antisense oligonucleotide;	modulate; gene expression; ss.
XX	Synthetic.	
XX	Homo sapiens.	
XX	EP856579-A1.	
XX	05-AUG-1998.	
XX	31-JAN-1997;	97EP-00101531.
XX	31-JAN-1997;	97EP-00101531.
XX	(BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.	
XX	Schlingensiepen K, Brysch W;	
XX	WPI; 1998-400910/35.	
XX	Preparation of antisense oligo:nucleotide(s) which lack long runs of	
XX	consecutive guanosine or inosine - and have specific ratio of residues	
XX	able to form two or three hydrogen bonds, have greater activity and	
XX	reduced toxicity, used therapeutically or to modulate growth of cells in	
XX	culture.	
XX	Claim 10; Fig 6b; 286pp; English.	
XX	AAV48709-886 represent antisense oligonucleotides directed against the	
XX	ErbB-2 gene. Of these, only oligonucleotides AAV48709-91 resulted in	
XX	significant reduction in ErbB-2 protein expression, while	
XX	oligonucleotides AAV48792-886 had little effect. The oligonucleotides	
XX	exemplify the invention. The specification describes oligonucleotides	
XX	that contain 8-30 nucleotides, which contain at most 8 nucleotides that	
XX	can each form three hydrogen bonds to cytosine; do not contain four	
XX	consecutive nucleotides able to form three H-bonds each to four	
XX	consecutive cytosines; do not contain two sequences of three consecutive	
XX	nucleotides each able to form three H-bonds to three consecutive	
XX	cytosines, and the ratio between residues able to form two H-bonds each	
XX	(2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The	
XX	oligonucleotides are used to modulate expression of genes, particularly	
XX	the genes for p53, ErbB-2, JunB, JunD, TGF-beta 1 or beta 2 to control	
XX	proliferation of primary cell cultures (e.g. bone marrow stem, liver or	
XX	kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The	
XX	oligonucleotides can also be used to analyse function of proteins (by	
XX	altering their expression or activity) and therapeutically, e.g. in cases	
XX	of cancer or (targeting TGF) for stimulating the immune system	
XX	Sequence 15 BP; 4 A, 5 C; 4 G; 2 T; 0 U; 0 Other;	
XX	Query Match	4.9%; Score 12.4; DB 1; Length 15;
XX	Best Local Similarity	92.9%; Pred. No. 2e+02;
XX	Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
XX	1307 CATCTGTGAGCACC 1320	
XX	14 CATCTGTGAGCTGC 1	
XX	RESULT 398	
XX	AAFA9271	
XX	ID AAF49271 standard; DNA; 15 BP.	
XX	AC AAF49271;	
XX	DT 30-MAR-2001 (first entry)	

DE IGF-1 oligonucleotide #331.
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytoskeletal; dermatological; cardiant; vitruclide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 62; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, ptyriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1329 CTCTTCTCGAAGC 1342
DB 2 CTCATCTCGAAGC 15
RESULT 399
AAF50722
ID AAF50722 standard; DNA; 15 BP.
XX AAF50722;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #1682.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytoskeletal; dermatological; cardiant; vitruclide; ophthalmological; keloid;

KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 71; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, ptyriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 6 A; 5 C; 3 G; 1 T; 0 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1260 CAACAGCTGAGAGA 1273
DB 2 CAACAGCTGAGACA 15
RESULT 400
AAF49272
ID AAF49272 standard; DNA; 15 BP.
XX AAF49272;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #232.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytoskeletal; dermatological; cardiant; vitruclide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX PD 28-DEC-2000.
XX
XX PE 21-JUN-2000; 2000WO-AU000693.
XX
XX PR 21-JUN-1999; 99US-0140345P.
XX
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX DR WPI; 2001-041421/05.
XX
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX
XX Example 8; Page 62; 201pp; English.
XX
XX PS The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX
XX SQ Sequence 15 BP; 3 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1329 CTTCTTCCAAAGC 1342
DB 1 CTTCTTCCAAAGC 14
RESULT 401
AAF49377
ID AAF49377 standard; DNA; 15 BP.
XX
XX AC AAF49377;
XX
XX DT 30-MAR-2001 (first entry)
XX
XX DE IGF-I oligonucleotide #337.
XX
XX KM Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KM cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KM hyperneovascular condition; hyperplasia; kidney disease;
XX KM neovascular condition of the retina; ss.
XX
XX OS Homo sapiens.
XX

XX
XX PN WO200078341-A1.
XX
XX PD 28-DEC-2000.
XX
XX PE 21-JUN-2000; 2000WO-AU000693.
XX
XX PR 21-JUN-1999; 99US-0140345P.
XX
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX DR WPI; 2001-041421/05.
XX
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX
XX Example 8; Page 63; 201pp; English.
XX
XX PS The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX
XX SQ Sequence 15 BP; 3 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1326 GACCTCTTCCAA 1339
DB 1 GACCTCTTCCCA 14
RESULT 402
AAF49376
ID AAF49376 standard; DNA; 15 BP.
XX
XX AC AAF49376;
XX
XX DT 30-MAR-2001 (first entry)
XX
XX DE IGF-I oligonucleotide #336.
XX
XX KM Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KM cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KM hyperneovascular condition; hyperplasia; kidney disease;
XX KM neovascular condition of the retina; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200078341-A1.
XX
XX PD 28-DEC-2000.
XX

```
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 63; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 7 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 4.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1326 GACCTCTTCTCCAA 1339
Db |||||
2 GACCTCTTCTCCAA 15

RESULT 403
AAF50723
ID AAF50723 standard; DNA; 15 BP.
XX
XX AAF50723;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #1683.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX OS
XX
XX WO200078341-A1.
XX
XX PD
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX PF
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX PR
```

```
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 71; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 6 A; 4 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 4.9%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1260 CAACAGCTGAGAGA 1273
Db |||||
1 CAACAGCTGAGAGA 14

RESULT 404
AAF45157/C
ID AAF45157 standard; RNA; 15 BP.
XX
XX AAF45157;
XX
XX 30-MAR-2001 (first entry)
XX
XX Antisense oligonucleotide #6.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX OS
XX
XX WO200078341-A1.
XX
XX PD
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX PF
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
```

XX WPI; 2001-041421/05.
XX
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX
PS Claim 15; Page 115; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is one such
CC antisense oligonucleotide. The method is useful for ameliorating the
CC effects of psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhea,
CC keloids, keratosis, neoplasias, scleroderma, warts, benign growths,
CC cancers of the skin, a hyperneovascular condition such as a neovascular
CC condition of the retina, brain or skin, growth factor-mediated
CC malignancies, other sclerotic disease, kidney disease, hyperproliferation
CC of the inside of blood vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1329 CTCCTCTCCAGGC 1342
DB 14 CTCATCTCCAGGC 1
AAH18762/c
AAH18762 standard; DNA; 15 BP.
AC AAH18762;
XX
XX
DT 25-JUN-2001 (first entry)
XX
XX Human IL4 allele-specific primer SEQ ID NO: 21.
DE Human IL4 allele-specific primer SEQ ID NO: 21.
XX
XX Human; interleukin-4; IL4; single nucleotide polymorphism; SNP; atopy;
KW inflammatory disorder; immune disorder; population diversity;
KW paternity test; forensic test; cytokine; chromosome 5q31.1; probe;
KW PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
PN WO200123404-A1.
XX
XX 05-APR-2001.
PD
XX
XX 28-SEP-2000; 2000WO-US026608.
PF
XX
XX 30-SEP-1999; 99US-0156825P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
PI Chew A, Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX
XX WPI; 2001-316132/33.
DR
XX
XX polynucleotide comprising novel single nucleotide polymorphisms in human
PT interleukin-4 gene for use in studying expression, function of
PT interleukin-4, in developing drugs, diagnosis and treatment of immune
PT disorders.
XX
XX Claim 12; Page 16; 71pp; English.
PS
XX

CC The present invention provides the protein, cDNA and gene of human
CC interleukin-4 (IL4). The coding sequences for this protein contain single
CC nucleotide polymorphisms (SNPs) which may be associated with differences
CC in susceptibility to atopy, inflammatory and immune diseases and
CC different drug responses. They may also be used in applications such as
CC forensic and paternity testing and studying population diversity and
CC anthropological lineage. The IL4 gene is found on human chromosome 5q31.1
XX
SQ Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1231 AGCATGTCGCGCA 1244
DB 14 AGCATGTCGCGCA 1
AAH18762/c
AAH18762 standard; DNA; 15 BP.
AC AAH18762;
XX
XX
DT 24-SEP-2002 (first entry)
XX
XX Interleukin-3 (IL-3) allele specific oligonucleotide probe #4.
DE Interleukin-3 (IL-3) allele specific oligonucleotide probe #4.
XX
XX Interleukin 3; colony-stimulating factor; IL3; transgenic animal;
KW IL3 isogene; central nervous system disorder; multiple sclerosis;
KW Alzheimer's disease; Parkinson's disease; CNS injury; immune disorder;
KW inflammatory disorder; allele specific oligonucleotide; ASO; probe; ss.
XX
XX Homo sapiens.
OS
XX
PN WO200244410-A1.
XX
XX 06-JUN-2002.
PD
XX
XX 28-NOV-2000; 2000WO-US032381.
PF
XX
XX 28-NOV-2000; 2000WO-US032381.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
PI Chew A, Denton RR, Nandabalan K, Stephens JC;
XX
XX WPI; 2002-519590/55.
DR
XX
XX Novel isolated polynucleotide comprising a sequence which is a
PT polynucleotide variant for a reference sequence for interleukin 3 gene
PT useful for studying the expression and biological function of the
PT protein.
XX
XX
PS Claim 11; Page 15; 62pp; English.
XX
XX The invention describes an isolated polynucleotide (I) comprising a
CC sequence which is a polymorphic variant for a reference sequence for
CC interleukin 3 (colony-stimulating factor) (IL3) gene or its fragment. (I)
CC is useful for studying the expression and biological function of IL3, as
CC well as in developing drugs targeting the IL3 protein. A transgenic
CC animal is useful for studying expression of IL3 isogenes in vivo, for in
CC vivo screening and testing of drugs targeted against IL3 protein, and for
CC testing the efficacy of therapeutic agents and compounds for diseases of
CC the central nervous system e.g. multiple sclerosis, Alzheimer's disease,
CC Parkinson's disease and CNS injury, and immune or inflammatory disorders.
CC The method described in the invention is useful in developing diagnostic
CC tests and therapeutic treatments for diseases of the central nervous
CC system and immune or inflammatory disorders. This sequence represents an
CC allele specific oligonucleotide probe for detecting polymorphisms in the
CC IL-3 gene
XX

DT 28-JUL-1999 (first entry)
 XX Human KDR VEGF receptor hammerhead ribozyme substrate #104.
 DE
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO9715662-A2.
 PN
 XX 01-MAY-1997.
 PD
 XX 25-OCT-1996; 96WO-US017480.
 PF
 XX 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI, 1997-259017/23.
 DR
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 PI
 XX
 PS Claim 4; Page 100; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 CC
 SQ Sequence 17 BP; 3 A; 3 C; 5 G; 0 T; 6 U; 0 Other;
 XX
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 57.1%; Pred. No. 2.8e+02;
 Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
 OY 1302 ATGGTCATCTGTGA 1315
 DB 1 AUGGUCUCUGUGA 14
 ||:|:|:|:|:|:|
 RESULT 410
 AAT64712/C
 ID AAT64712 standard; DNA; 17 BP.
 XX
 AC AAT64712;
 XX
 DT 25-MAR-2003 (revised)
 DT 12-FEB-1998 (first entry)
 XX
 DE Primer E15 for mapping prostate/colon tumour suppressor gene.
 KW prostate/colon tumour suppressor; allelic loss; prostate cancer;
 KW colorectal cancer; microsatellite analysis; sequence tagged site; STS;
 KW amplification; chromosomal location 8q22-21; probe; primer; gene mapping;
 KW diagnosis; treatment; ss.
 XX
 OS Synthetic.

OS Homo sapiens.
 XX
 XX JP09098790-A.
 PN
 XX 15-APR-1997.
 PD
 XX 22-FEB-1996; 96JP-00062144.
 PF
 XX 22-MAY-1995; 95US-00445515.
 PR
 XX
 PA (CANJ-) CANJI INC.
 PA (UYJO) UNIV JOHNS HOPKINS.
 PI Isacs WB, Bookstein R;
 XX WPI, 1997-275447/25.
 DR
 XX
 PT New prostate/colon tumour suppressor gene - mapped to a locus on human
 PT chromosome 8.
 PI
 XX
 PS Disclosure; Page 26; 45pp; Japanese.
 XX
 CC The present primer was used in the mapping of a gene encoding 2 forms of
 CC a prostate/colon tumour suppressor (P/CTS). The P/CTS gene was isolated
 CC by analysis of allelic loss in patients with prostate cancer, and was
 CC putatively located to the chromosomal location 8q22-21 via microsatellite
 CC analysis and the use of sequence tagged sites (STS). Primers and probes
 CC derived from the gene can be used to screen lambda cDNA libraries for
 CC genes encoding P/CTS form 1 and 2. The P/CTS or its cDNA can be used in
 CC the diagnosis and treatment of prostate and colorectal cancers. (Updated
 CC on 25-MAR-2003 to correct PA field.) (updated on 25-MAR-2003 to correct
 CC PI field.)
 CC
 SQ Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
 XX
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2.8e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1373 CCAGAGCAGCTGC 1386
 DB 17 CCAGAGCAGATGC 4
 |||||
 RESULT 411
 AAX62300/C
 ID AAX62300 standard; RNA; 17 BP.
 XX
 AC AAX62300;
 XX
 DT 16-JUL-1999 (first entry)
 DT
 XX
 DE Granule bound starch synthase hammerhead substrate SBQ ID NO:175.
 XX
 KW Maize; corn; Zea mays; delta-9 desaturase; GBS; target; substrate;
 KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
 KW modulation; gene expression; transgenic plant; cleavage; canola plant;
 KW caffeine synthesis; coffee plant; nicotine production; tobacco;
 KW fruit ripening; flower pigmentation; lignin production; ss.
 XX
 OS Zea mays.
 XX
 PN WO9710328-A2.
 PN
 XX 20-MAR-1997.
 PD
 XX 12-JUL-1996; 96WO-US011689.
 PF
 XX 13-JUL-1995; 95US-0001135P.
 PR
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (DOMC) DOWELANCO.
 XX

PI Zwick MG, Edington BE, Mcswigen JA, Merlo PAO, Guo L, Skokut TA;
PI Young SA, Folkerts O, Merlo DJ;
XX WPI; 1997-202224/18.
XX Ribozyme which modulates plant gene expression - preferably modulates
PT expression of DELTA-9 desaturase or granule bound starch synthase in
PT maize or canola.
XX
XX Claim 41; Page 74; 155pp; English.
XX
XX The present invention describes an enzymatic nucleic acid molecule (I)
CC with RNA cleaving activity, which modulates the expression of a plant
CC gene. Also described is a gene comprising a cDNA sequence encoding maize
CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
CC gene, in a plant (preferably a maize or canola plant). (I) can be used to
CC modulate caffeine synthesis in a coffee plant, nicotine production in a
CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
CC marigold plant or lignin production in a tobacco, aspen, poplar or pine
CC plant
XX
XX Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1263 CAGCTGGAAGAGGC 1276
Db 15 CAGCTGAGTGAAGC 2
RESULT 412
AAV95089
ID AAV95089 standard; RNA; 17 BP.
XX
XX AAV95089;
XX
XX 24-FEB-1999 (first entry)
XX
XX Canine IL-2 receptor g-chain substrate position 150.
XX
XX Human, IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW hamsterhead ribozyme; halpin ribozyme; substrate; expression; cancer;
KW autoimmune disease; psoriasis; allergy; inflammatory disease;
KW graft rejection; ss.
XX
XX Synthetic.
OS Canis sp.
XX
XX WO9824913-A2.
XX
XX 11-JUN-1998.
XX
XX 02-DEC-1997; 97WO-US021748.
XX
XX 03-DEC-1996; 96US-00758306.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswigen JA;
XX
XX WPI; 1998-33332/29.
XX
XX Ribozymes targeted to interleukin 2 - useful for treating e.g. cancer.
PT autoimmune disease and allergies.
XX
XX Claim 4; Page 45; 61pp; English.
XX
XX The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.

CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC from the present invention. The ribozymes can be used for the treatment
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy
CC and other inflammatory conditions. The ribozymes are also used to induce
CC tolerance in a recipient to alloantigen from a donor
XX
XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1285 GAGACCCACAGGT 1298
Db 1 GAGACCCUACAGU 14
RESULT 413
AAV08617
ID AAV08617 standard; DNA; 17 BP.
XX
XX AAV08617;
XX
XX 15-FEB-1999 (first entry)
XX
XX Primer ACP/8RB for human ACE gene.
XX
XX PCR primer; human; ACE; angiotensin converting enzyme; angiotensinogen;
KW cardiovascular status; AGT; AT1; type 1 angiotensin II receptor; stroke;
KW polymorphic pattern; blood pressure; electrocardiographic profile;
KW cardiac condition diagnosis; myocardial infarction; atherosclerosis;
KW hypertension; cardiovascular disease; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9845477-A2.
XX
XX 15-OCT-1998.
XX
XX 01-APR-1998; 98WO-IB000475.
XX
XX 04-APR-1997; 97US-0042930P.
XX
XX (EURO-) EURONA MEDICAL AB.
XX
XX Norberg LT, Andersson MK, Lindstroem PHR;
XX
XX WPI; 1998-568361/48.
XX
XX Assessing cardiovascular status in humans by polymorphic analysis - of
PT genes for angiotensin converting enzyme, angiotensinogen and angiotensin
PT II receptor, used to diagnose predisposition to disease and to predict
PT effect of therapy.
XX
XX Example 1; Page 29; 71pp; English.
XX
XX This sequence represents a PCR primer for the human ACE (angiotensin
CC converting enzyme) gene, and can be used in the method of the invention.
CC The method is for assessing cardiovascular status in humans by
CC determining the sequence of at least one polymorphic site in the ACE
CC (angiotensin converting enzyme), AGT (angiotensinogen) and/or AT1 (type 1
CC angiotensin II receptor) genes, and comparing the polymorphic pattern
CC with that in patients with predetermined markers of status. The method is
CC used to assess blood pressure or electrocardiographic profile, to
CC diagnose a cardiac condition such as (silent) myocardial infarction (MI),
CC hypertension, atherosclerosis or stroke. They can also be used to predict
CC response to treatments with ACE inhibitors, angiotensin II receptor
CC antagonists, diuretics, alpha- or beta-adrenergic receptor antagonists,
CC etc. It is also used to identify susceptibility to cardiovascular
CC disease. Libraries of nucleic acids containing polymorphic positions in
CC the 3 genes, and libraries of targets corresponding to the peptides from

CC the genes are used to screen for cardiovascular agents. The nucleic acids
CC contained in the library can be used as source of probes
XX
SQ Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1251 CCGCTGCAGCAACA 1264
|||||
Db 4 CGGCAGCAGCAACA 17

RESULT 414
AAV08623
ID AAV08623 standard; DNA; 17 BP.

XX AAV08623;

DT 15-FEB-1999 (first entry)

XX Primer ACP/16RT for human ACE gene.

XX PCR primer; human; ACE; angiotensin converting enzyme; angiotensinogen;
KW cardiovascular status; AGT; AT1; type 1 angiotensin II receptor; stroke;
KW polymorphic pattern; blood pressure; electrocardiographic profile;
KW cardiac condition diagnosis; myocardial infarction; atherosclerosis;
KW hypertension; cardiovascular disease; ss.

XX Synthetic.

OS Homo sapiens.

XX MO9845477-A2.

PD 15-OCT-1998.

PF 01-APR-1998; 98WO-IB000475.

XX 04-APR-1997; 97US-0042930P.

PA (EURO-) EURONA MEDICAL AB.

PI Norberg LT, Andersson MK, Lindstroem PFR;

DR WPI; 1998-568361/48.

PT Assessing cardiovascular status in humans by polymorphic analysis - of
PT genes for angiotensin converting enzyme, angiotensinogen and angiotensin
PT II receptor, used to diagnose predisposition to disease and to predict
PT effect of therapy.

XX Example 1; Page 29; 71pp; English.

XX This sequence represents a PCR primer for the human ACE (angiotensin
CC converting enzyme) gene, and can be used in the method of the invention.
CC The method is for assessing cardiovascular status in humans by
CC determining the sequence of at least one polymorphic site in the ACE
CC (angiotensin converting enzyme), AGT (angiotensinogen) and/or AT1 (type 1
CC angiotensin II receptor) genes, and comparing the polymorphic pattern
CC with that in patients with predetermined markers of status. The method is
CC used to assess blood pressure or electrocardiographic profile, to
CC diagnose a cardiac condition such as (silent) myocardial infarction (MI),
CC hypertension, atherosclerosis or stroke. They can also be used to predict
CC response to treatments with ACE inhibitors, angiotensin II receptor
CC antagonists, diuretics, alpha- or beta-adrenergic receptor antagonists,
CC etc. It is also used to identify susceptibility to cardiovascular
CC disease. Libraries of nucleic acids containing polymorphic positions in
CC the 3 genes, and libraries of targets corresponding to the peptides from
CC the genes are used to screen for cardiovascular agents. The nucleic acids
CC contained in the library can be used as source of probes
XX Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1251 CCGCTGCAGCAACA 1264
|||||
Db 4 CGGCAGCAGCAACA 17

RESULT 415
AAA22888
ID AAA22888 standard; RNA; 17 BP.

XX AAA22888;

DT 19-JUN-2000 (first entry)

XX Integrin subunit beta 3 substrate sequence SEQ ID NO:6114.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;
KW dermatologic; antiinflammatory; antirheumatic; antipsychotic; AMD;
KW ophtalmologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberos sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trennau-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX MO9950403-A2.

PD 07-OCT-1999.

PF 24-MAR-1999; 99WO-US006507.

XX 27-MAR-1998; 98US-0079678P.

PA (RIBO-) RIBOZYME PHARM INC.

PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;

DR WPI; 1999-591315/50.

PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.

XX Claim 54; Page 248; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer diabetic retinopathy, age related
CC macular degeneration (AMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberos sclerosis, pot-wine stains, Sturge Weber

CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX

Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1222 AGACCTCCAGCAT 1235

DB 2 AGAATCCACGCAU 15

RESULT 416

AAV91008

AAV91008 standard; RNA; 17 BP.

AAV91008;

18-FEB-1999 (first entry)

Human C-raf target site nucleotide position 591.
Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
target; substrate; catalyst; modulation; expression; Raf gene; delivery;
screening; identification; synthesis; deprotection; purification; cancer;
inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
restenosis; rheumatoid arthritis; ss.

Homo sapiens.

WO9850530-A2.

12-NOV-1998.

05-MAY-1998; 98WO-US009249.

09-MAY-1997; 97US-0046059P.

09-JUN-1997; 97US-0049002P.

03-JUL-1997; 97US-0051718P.

22-AUG-1997; 97US-0056808P.

02-OCT-1997; 97US-0061321P.

02-OCT-1997; 97US-0061324P.

05-NOV-1997; 97US-0064866P.

19-DEC-1997; 97US-0068212P.

(RIBO-) RIBOZYME PHARM INC.

Jarvis T, Matulic-Adamic J, Reynolds M, Kisch K, Bellon L;
Perry T, Beigelman L, Mcswigen JA, Karpelisky A, Burgin A;
P Thompson J, Workman CT, Beaudry A, Sweedler D;

Identifying new catalytic nucleic acid that modulates selected processes
- especially ribozymes that cleave Raf RNA for treating cancer,
restenosis, and also new ribozymes and modified nucleoside triphosphates
used as antiviral agents and synthons.

Claim 177; Page 147; 259pp; English.

A method has been developed for the identification of a nucleic acid
capable of modulating a process in a biological system. The method
comprises: (a) introducing into the system a random library of nucleic
acid catalysts (NAC) having a substrate binding domain (SBD), comprising
a random sequence, and a catalytic domain (CD); and (b) identifying NAC
in systems where modulation has occurred and/or determining the sequence
of at least part of the SBDs in such systems. Nucleic acid molecules with
endonuclease activity and catalytic activity, from the present invention,
are used to modulate gene expression in plant and mammalian cells and to
cleave target nucleic acid, particularly for treating systemic diseases

CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
ascites and infection. They may also be used to detect genetic drift and
CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC with RNA-cleaving activity that modulate expression of the Raf gene, are
CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC generally any condition associated with the level of c-raf. Introduction
CC of sugar/phosphate modifications increases stability against nuclease and
activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC method, specifically for modulating the expression of a Raf gene

Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;

Best Local Similarity 71.4%; Pred. No. 2.8e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1212 GCCATCTGTCTAGAA 1225

DB 4 GACAUCUCGACGAA 17

RESULT 417

AAA38251

AAA38251 standard; DNA; 17 BP.

AAA38251;

21-AUG-2000 (first entry)

Human ACE regulatory region PCR primer, SEQ ID NO:51.
Angiotensin-converting enzyme gene; ACE; regulatory region; polymorphism;
polymorphic marker; cardiovascular disease; myocardial infarction;
unstable angina; hypertension; atherosclerosis; stroke; prognosis;
drug screening; treatment outcome; human; PCR primer; ss.

Homo sapiens.

WO200022166-A2.

20-APR-2000.

13-OCT-1999; 99WO-1B001678.

14-OCT-1998; 98US-0104286P.

14-OCT-1998; 98US-0104302P.

(EURO-) EURONA MEDICAL AB.

Norberg LT, Andersson MK, Lindstrom PRR, Jonsson L;
WPI; 2000-318010/27.

Assessing cardiovascular status in humans involves comparing test
PT polymorphic pattern comprising polymorphic positions within genes
PT encoding specific proteins, with reference polymorphic pattern.

Example 1; Page 51; 126pp; English.

The invention relates to a novel method of assessing the cardiovascular
status in an individual and to newly identified polymorphisms in the
CC genes encoding angiotensin-converting enzyme (ACE), angiotensin II
CC receptor type 1 (AT1) and type 2 (AT2), angiotensinogen (AGT), renin,
CC aldosterone synthase, endothelin receptor type A and beta-adrenergic
CC receptors 1 and 2. The method comprises determining the sequence at one
CC or more polymorphic positions within these genes, and comparing the
CC pattern of polymorphisms from the individual with a reference polymorphic
CC pattern obtained from a population of individuals exhibiting a
CC predetermined cardiovascular disease status. The polymorphic markers are
CC useful for determining the predisposition of an individual to
CC cardiovascular disorders such as myocardial infarction, unstable angina,
CC hypertension, atherosclerosis and stroke. They are also useful for
CC predicting the likely cardiovascular status of a patient given a

treatment regimen comprising administration of cardiovascular drugs (e.g., ACE inhibitors, beta-adrenergic receptor antagonists (beta-blockers) or calcium channel blockers). One or more polymorphic markers provides a basis for predicting the outcome of a treatment regimen. Fragments of the genes comprising a polymorphic site may be used as primers and probes for detecting genetic polymorphisms or in molecular library arrays for high throughput screening. The genes, and the proteins they encode are useful in the screening of potential cardiovascular drugs. Determination of an individual's polymorphic pattern reduces or eliminates trial and error in selecting a treatment for a particular individual cardiovascular patient. It also provides the ability to eliminate patients from clinical trials who are predicted to be non-responsive, or at a risk for an adverse response, to a particular treatment regimen. Adverse results in an early trial can be evaluated to identify polymorphic patterns so that the adverse results can be correlated with a sub-population of the test population, permitting exclusion of such sub-populations from the treatment group. Beneficial drugs can be approved for use in the appropriate population, thereby decreasing the number of patients required for a clinical trial, which in turn decreases the duration and cost of such trials. Sequences AAB38240-CC represent PCR primers used in an exemplification of the invention to amplify short fragments of the human ACE gene regulatory region (AAB38329) for sequence determination

Sequence 17 BP: 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;

Query Match	4.9%; Score 12.4; DB 1; Length 17;
-------------	------------------------------------

```

      GC content: 22.2%; GC: 21.87%;
      Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1251 CGGCTGCAGCACA 1264

Db 4 CGGCAGCAGCACA 17

AAA38245

XX

XX

XX 5

[illegible]

KM polymorphic marker; cardiovascular disease; myocardial infarction;

KW drug screening; treatment outcome; human; PCR primer; ss.

OS Homo sapiens.

PN WO200022166-A2.

PD 20-APR-2000

PF 13-OCT-1999; 99MO-IB001678.

PR 14-OCT-1998; 98US-0104286P.

XX

XX

XX

2000

PT encoding specific proteins, with reference polymorphic pattern.

PS Example 1; Page 50; 126pp; English.

...

The invention relates to a novel method of assessing the cardiovascular status in an individual and to newly identified polymorphisms in the genes encoding angiotensin-converting enzyme (ACE), angiotensin II receptor type 1 (AT1) and type 2 (AT2), angiotensinogen (AGT), renin, aldosterone synthase, endothelin receptor type A and beta-adrenergic receptors 1 and 2. The method comprises determining the sequence at one or more polymorphic positions within these genes, and comparing the pattern of polymorphisms from the individual with a reference polymorphic pattern obtained from a population of individuals exhibiting a predetermined cardiovascular disease status. The polymorphic markers are useful for determining the predisposition of an individual to cardiovascular disorders such as myocardial infarction, unstable angina, hypertension, atherosclerosis and stroke. They are also useful for predicting the likely cardiovascular status of a patient given a treatment regimen comprising administration of cardiovascular drugs (e.g., ACE inhibitors, beta-adrenergic receptor antagonists (beta-blockers) or calcium channel blockers). One or more polymorphic markers provides a basis for predicting the outcome of a treatment regimen. Fragments of the genes comprising a polymorphic site may be used as primers and probes for detecting genetic polymorphisms or in molecular library arrays for high throughput screening. The genes, and the proteins they encode are useful in the screening of potential cardiovascular drugs. Determination of an individual's polymorphic pattern reduces or eliminates trial and error in selecting a treatment for a particular individual cardiovascular patient. It also provides the ability to eliminate patients from clinical trials who are predicted to be non-responsive, or at a risk for an adverse response, to a particular treatment regimen. Adverse results in an early trial can be evaluated to identify polymorphic patterns so that the adverse results can be correlated with a sub-population of the test population, permitting exclusion of such sub-populations from the treatment group. Beneficial drugs can be approved for use in the appropriate population, thereby decreasing the number of patients required for a clinical trial, which in turn decreases the duration and cost of such trials. Sequences AAA38240-AAA38251 represent PCR primers used in an exemplification of the invention to amplify short fragments of the human ACE gene regulatory region (AAA38329) for sequence determination.

Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;

Query Match	4.9%	Score 12.4	DB 1	Length 17
-------------	------	------------	------	-----------

```

best local similarity      22.58;      (seed: no: 2:00002)
Matches      13; Conservative      0; Mismatches      1; Indels      0; Gaps      0;

```

QY 1251 CCGCTGCAGCAACA 1264

Db 4 CGGCAGCAGCAACA 17

AAC61251

XX

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1

[illegible][illegible]

cardiovascular system; nervous system; glaucoma; PCR primer; ss.

Homo sapiens.

PN WO2000056922-A2

PD 28-SEP-2000.

PF 23-MAR-2000; 2000WO-GB001102.

23-MAR-1999; 99US-0126046P.

PR 24-MAR-1999; 99US-0126243P.

PR 23-DEC-1999; 99US-00471890.
XX (GEMI-) GEMINI GENOMICS AB.
XX Lindstrom PHR, Norberg LT, Jonsson L, Olaiasson E, Sanders R;
PI WPI; 2000-638268/61.
DR
XX Assessing disease status in individual by determining sequence(s) at one
PT or more polymorphic positions within the human genes encoding the
PT protein(s) involved in physiological pathway associated with treatment
PT regime.
XX
PS Example 1; Page 58; 141pp; English.
XX The present invention is related to methods for determining the
CC polymorphic pattern of an individual and using the results to determine
CC their risk of a number of diseases, including cancer, cardiovascular
CC diseases, glaucoma and nervous system disorders such as depression and
CC neurodegenerative diseases. In addition, the methods can be used to
CC determine the effects of different types of treatment for individuals,
CC and thus enables appropriate therapies to be prescribed. The PCR primers
CC shown in sequences AAC61201-C61371 were all used to demonstrate the
CC methods of the invention
XX
SQ Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1251 CGGCTGCAGCAACA 1264
DB 4 CGGCGAGCAGCAACA 17
RESULT 420
AAC61245
ID AAC61245 standard; DNA; 17 BP.
XX AAC61245;
XX 30-JAN-2001 (first entry)
DT
XX Human ACE, AGT and ATI genes polymorphisms PCR primer SEQ ID NO: 45.
DE
XX Human; genetic polymorphism; disease diagnosis; treatment; cancer;
KW cardiovascular system; nervous system; glaucoma; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200056922-A2.
XX 28-SEP-2000.
PD
XX 23-MAR-2000; 2000WO-GB001102.
PF
XX 23-MAR-1999; 99US-0126046P.
PR 23-MAR-1999; 99WO-IB000497.
PR 24-MAR-1999; 99US-0126243P.
PR 23-DEC-1999; 99US-00471890.
XX (GEMI-) GEMINI GENOMICS AB.
PA
XX Lindstrom PHR, Norberg LT, Jonsson L, Olaiasson E, Sanders R;
PI WPI; 2000-638268/61.
DR
XX Assessing disease status in individual by determining sequence(s) at one
PT or more polymorphic positions within the human genes encoding the
PT protein(s) involved in physiological pathway associated with treatment
PT regime.
XX

PS Example 1; Page 57; 141pp; English.
XX The present invention is related to methods for determining the
CC polymorphic pattern of an individual and using the results to determine
CC their risk of a number of diseases, including cancer, cardiovascular
CC diseases, glaucoma and nervous system disorders such as depression and
CC neurodegenerative diseases. In addition, the methods can be used to
CC determine the effects of different types of treatment for individuals,
CC and thus enables appropriate therapies to be prescribed. The PCR primers
CC shown in sequences AAC61201-C61371 were all used to demonstrate the
CC methods of the invention
XX
SQ Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1251 CGGCTGCAGCAACA 1264
DB 4 CGGCGAGCAGCAACA 17
RESULT 421
AAF02397/C
ID AAF02397 standard; DNA; 17 BP.
XX AAF02397;
AC AAF02397;
DT 16-FEB-2001 (first entry)
DT
XX Hammerhead ribozyme substrate #692.
DE
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX 19-OCT-2000.
PD
XX 11-APR-2000; 2000WO-US009721.
PF
XX 12-APR-1999; 99US-0129390P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
PI WPI; 2000-647423/62.
DR
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 71; 164pp; English.
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor. EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 protein, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1304 GGTGATCTGTGAGC 1317
DB 4 GGTGATCTGTGACC 17
|||||
|||||

RESULT 424
ABN08786
ID ABN08786 standard; DNA; 17 BP.
XX AC ABN08786;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8778.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024283.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (ABOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX DR WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX Disclosure; SEQ ID NO 8778; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acid can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1304 GGTGATCTGTGAGC 1317
DB 2 GGTGATCTGTGACC 15
|||||
|||||

RESULT 425
ABN08316
ID ABN08316 standard; DNA; 17 BP.
XX AC ABN08316;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8308.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024283.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.

XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AECOM-) AECOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX DR WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 8311; 214pp; English.
XX SQ

The present invention describes a human genome-derived myosin-like protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-1 can be used in gene therapy and vaccine production. The hGDMLP-1 nucleic acids can be used as probes to detect, characterize and quantify hGDMLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a disorder associated with the expression of hGDMLP-1, in particular heart and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence

Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
SQ

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1373 CCAAGAGCAGCTGC 1386
Db 14 CCAAGAGCAGCTGC 1

RESULT 428
ABN00940

ID ABN00940 standard; DNA; 17 BP.
XX ABN00940;
AC
XX 29-MAY-2002 (first entry)
XX DT
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:932.
XX KW Human, genome-derived myosin-like protein 1; GDMLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AECOM-) AECOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX DR WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 932; 214pp; English.
XX SQ

The present invention describes a human genome-derived myosin-like protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-1 can be used in gene therapy and vaccine production. The hGDMLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a disorder associated with the expression of hGDMLP-1, in particular heart and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence

Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
SQ

```
Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1267 TCGAAGAGGCTGAG 1280
        |||||
Db       1 TGAAGAGGCTGAG 14

RESULT 429
ABN08318/C
ID      ABN08318 standard; DNA; 17 BP.
XX
XX
AC      ABN08318;
XX
XX      29-MAY-2002 (first entry)
XX
DE      Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8310.
XX
XX      Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW      muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW      skeletal muscle disorder; amplicon; screening; ss.
XX
XX      Homo sapiens.
OS
XX
XX      WO200192524-A2.
XX
XX      06-DEC-2001.
XX
XX      25-MAY-2001; 2001WO-US016981.
XX
XX      26-MAY-2000; 2000US-0207456P.
XX      21-SEP-2000; 2000US-0234687P.
XX      27-SEP-2000; 2000US-0236359P.
XX      04-OCT-2000; 2000GB-00024263.
XX      30-JAN-2001; 2001WO-US000661.
XX      30-JAN-2001; 2001WO-US000662.
XX      30-JAN-2001; 2001WO-US000663.
XX      30-JAN-2001; 2001WO-US000664.
XX      30-JAN-2001; 2001WO-US000665.
XX      30-JAN-2001; 2001WO-US000666.
XX      30-JAN-2001; 2001WO-US000667.
XX      30-JAN-2001; 2001WO-US000668.
XX      30-JAN-2001; 2001WO-US000669.
XX      30-JAN-2001; 2001WO-US000670.
XX      05-FEB-2001; 2001US-0266860P.
XX
XX      (ABOM-) ABOMITCA INC.
XX
XX      Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI      WPI; 2002-179446/23.
XX
XX      New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT      or as specific biomolecule capture probes for surface-enhanced laser
PT      desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX      Disclosure; SEQ ID NO 8310; 214pp; English.
XX
XX      The present invention describes a human genome-derived myosin-like
XX      protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX      1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX      nucleic acids can be used as probes to detect, characterize and quantify
XX      hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX      provide initial substrates for the recombinant engineering of hGDMLP-1
XX      protein variants having desired phenotypic improvements, and for
XX      expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX      used as immunogens to raise antibodies that specifically recognise hGDMLP
XX      -1 proteins, as standards in assays used to determine the concentration
XX      and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX      capture probes for surface-enhanced laser desorption ionisation, as
XX      therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX      production, and in vaccines or for replacement therapy. The
```

```
CC      polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC      disorder associated with the expression of hGDMLP-1, in particular heart
CC      and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC      The present sequence represents an oligomer used in the screening of the
CC      hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC      The sequence data for this patent did not form part of the printed
CC      specification, but was obtained in electronic format directly from WIPO
CC      at ftp.wipo.int/pub/published_pct_sequence
XX
XX      Sequence 17 BP; 1 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX      Query Match          4.9%; Score 12.4; DB 1; Length 17;
XX      Best Local Similarity 92.9%; Pred. No. 2.8e+02;
XX      Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1373 CCAGAGAGGCTGC 1386
        |||||
Db       15 CCAGAGAGGCTGC 2

RESULT 430
ABN08785
ID      ABN08785 standard; DNA; 17 BP.
XX
XX
AC      ABN08785;
XX
XX      29-MAY-2002 (first entry)
XX
XX      Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8777.
XX
XX      Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW      muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW      skeletal muscle disorder; amplicon; screening; ss.
XX
XX      Homo sapiens.
OS
XX
XX      WO200192524-A2.
XX
XX      06-DEC-2001.
XX
XX      25-MAY-2001; 2001WO-US016981.
XX
XX      26-MAY-2000; 2000US-0207456P.
XX      21-SEP-2000; 2000US-0234687P.
XX      27-SEP-2000; 2000US-0236359P.
XX      04-OCT-2000; 2000GB-00024263.
XX      30-JAN-2001; 2001WO-US000661.
XX      30-JAN-2001; 2001WO-US000662.
XX      30-JAN-2001; 2001WO-US000663.
XX      30-JAN-2001; 2001WO-US000664.
XX      30-JAN-2001; 2001WO-US000665.
XX      30-JAN-2001; 2001WO-US000666.
XX      30-JAN-2001; 2001WO-US000667.
XX      30-JAN-2001; 2001WO-US000668.
XX      30-JAN-2001; 2001WO-US000669.
XX      30-JAN-2001; 2001WO-US000670.
XX      05-FEB-2001; 2001US-0266860P.
XX
XX      (ABOM-) ABOMITCA INC.
XX
XX      Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI      WPI; 2002-179446/23.
XX
XX      New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT      or as specific biomolecule capture probes for surface-enhanced laser
PT      desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX      Disclosure; SEQ ID NO 8777; 214pp; English.
XX
XX      The present invention describes a human genome-derived myosin-like
XX      protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX      1 can be used in gene therapy and vaccine production. The hGDMLP-1
```

CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPL-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPL-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPL-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPL
CC -1 protein, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPL proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionization, as
CC therapeutic supplement in patients having specific deficiency in hGDMPL-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPL-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPL-1, in particular heart
CC and skeletal muscle disorders. hGDMPL-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPL-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC
XX

SO Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1304 GGTCATCTGTGAGC 1317

Db 3 GGTCATCTGTGACC 16

RESULT 431

ABA02327
ID ABA02327 standard; DNA; 17 BP.

AC ABA02327;

DT 22-FEB-2002 (first entry)

DE Human hepatoma-associated protein c63R-related oligonucleotide 926-1.

XX Human; hepatoma-associated protein; c63R; chromosome 17p13.1; hepatocyte;

KW diagnosis; detection; liver cancer; tumour; cytosolic; ss.

XX Unidentified.

OS

PN WO200185775-A1.

PD 15-NOV-2001.

PF 17-APR-2001; 2001WO-CN000559.

PR 17-APR-2000; 2000CN-00115401.

PA (SHAN-) SHANGHAI CANCER INST.

PI Gu J, Yang S;

DR WPI; 2002-041585/05.

PT Human hepatoma-associated protein C63R produced by recombinant methods

PT and its encoded polynucleotides, applicable in diagnosis and treatment of

PT diseases e.g. cancer.

PS Claim 5; Page 13; 33pp; Chinese.

CC The invention relates to a novel human hepatoma-associated protein,
CC designated c63R (AAW52674, AAW52679), and nucleic acids encoding it
CC (ABW02326, ABA02327). The c63R protein has cytosolic activity, and the
CC gene encoding it is located on chromosome 17p13.1. The invention also
CC relates to recombinant vectors and host cells containing c63R nucleic
CC acids, the recombinant production of c63R, an antibody against c63R, and
CC drug compositions comprising c63R. The invention also encompasses a

CC method for detecting mutagenesis or a susceptibility to tumorigenesis in
CC hepatocytes by comparing c63R expression or activity in a test sample
CC with that in normal hepatocytes, and a kit for the diagnosis of liver
CC cancer comprising a primer specific for the c63R gene and reagents for
CC the detection and characterisation of amplification products. The c63R
CC protein and nucleic acids encoding it may be used in the diagnosis and
CC treatment of cancer, particularly liver cancer. The present sequence
CC represents a specifically claimed oligonucleotide designated 926-1
XX

SO Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1420 AGCGGCGCATCATC 1433

Db 3 AGTGGGCGCATCATC 16

RESULT 432

AB576194/C
ID AB576194 standard; DNA; 17 BP.

AC AB576194;

DT 27-DEC-2002 (first entry)

DE Human PAP-P-Eb associated 17-mer SEQ ID 1720.

XX PAP-P-E; human; pregnancy associated plasma protein E; abortive;

KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;

KW dysgenetic pregnancy; primer; ss.

OS Homo sapiens.

PN US2002102252-A1.

PD 01-AUG-2002.

PF 06-APR-2001; 2001US-00827998.

PR 26-MAY-2000; 2000US-0207456P.

PA (GUYY/) GU Y.

PA (SHAN/) SHANNON M E.

PI Gu Y, Shannon ME;

DR WPI; 2002-697817/75.

PT New isolated nucleic acid encoding an isoform of human pregnancy

PT associated plasma protein E, for preventing or aborting pregnancy.

PS Example 2; Page 301; 353pp; English.

CC This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAP-P-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAP-P-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAP-P-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAP-P-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAP-P-E genes described in the disclosure of the invention
XX

SO Sequence 17 BP; 1 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;

Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1256 GCAGCAGAGCTGG 1269
14 GCAGCAACTGG 1
DB

RESULT 433
ABST6191/C
ID ABST6191 standard; DNA; 17 BP.

AC ABST6191;

DT 27-DEC-2002 (first entry)

XX Human PAP-Eb associated 17-mer SEQ ID 1717.

XX PAP-E; human; pregnancy associated plasma protein E; abortive;

KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;

KW dyegenetic pregnancy; primer; ss.

OS Homo sapiens.

XX US2002102252-A1.

XX 01-AUG-2002.

XX 06-APR-2001; 2001US-00827998.

XX 26-MAY-2000; 2000US-0207456P.

XX (GUYY/) GU Y.

XX (SHAN/) SHANNON M E.

XX Gu Y, Shannon ME;

XX WPI; 2002-697817/75.

XX New isolated nucleic acid encoding an isoform of human pregnancy

XX associated plasma protein E, for preventing or aborting pregnancy.

XX Example 2; Page 301; 353pp; English.

XX This invention describes a novel isolated nucleic acid that encodes one

CC of three new isoforms of human pregnancy associated plasma protein E,

CC hPAP-E. The products of the invention have abortive and contraceptive

CC activity and can be used for gene therapy or in a vaccine. The nucleic

CC acid, polypeptide encoded by it, or antibody to the polypeptide can be

CC used in pharmaceutical compositions or vaccines for preventing or

CC aborting pregnancy. PAP-E is used in the antenatal diagnosis of

CC the level of PAP-E isoform mRNA in chorionic villus samples, and the

CC antibodies can be used to assess the expression levels of PAP-E isoform

CC proteins in chorionic villus samples, to diagnose dyegenetic pregnancies

CC antenatally. This sequence represents an oligomer used in scanning the

CC human PAP-E genes described in the disclosure of the invention

XX SQ Sequence 17 BP; 3 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCAGAGCTGG 1269
17 GCAGCAACTGG 4
DB

RESULT 434
ABST6193/C
ID ABST6193 standard; DNA; 17 BP.
XX

AC ABST6193;
XX 27-DEC-2002 (first entry)
DT
XX Human PAP-Eb associated 17-mer SEQ ID 1719.

XX PAP-E; human; pregnancy associated plasma protein E; abortive;

KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;

KW dyegenetic pregnancy; primer; ss.

OS Homo sapiens.

XX US2002102252-A1.

XX 01-AUG-2002.

XX 06-APR-2001; 2001US-00827998.

XX 26-MAY-2000; 2000US-0207456P.

XX (GUYY/) GU Y.

XX (SHAN/) SHANNON M E.

XX Gu Y, Shannon ME;

XX WPI; 2002-697817/75.

XX New isolated nucleic acid encoding an isoform of human pregnancy

XX associated plasma protein E, for preventing or aborting pregnancy.

XX Example 2; Page 301; 353pp; English.

XX This invention describes a novel isolated nucleic acid that encodes one

CC of three new isoforms of human pregnancy associated plasma protein E,

CC hPAP-E. The products of the invention have abortive and contraceptive

CC activity and can be used for gene therapy or in a vaccine. The nucleic

CC acid, polypeptide encoded by it, or antibody to the polypeptide can be

CC used in pharmaceutical compositions or vaccines for preventing or

CC aborting pregnancy. PAP-E is used in the antenatal diagnosis of

CC the level of PAP-E isoform mRNA in chorionic villus samples, and the

CC antibodies can be used to assess the expression levels of PAP-E isoform

CC proteins in chorionic villus samples, to diagnose dyegenetic pregnancies

CC antenatally. This sequence represents an oligomer used in scanning the

CC human PAP-E genes described in the disclosure of the invention

XX SQ Sequence 17 BP; 1 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCAGAGCTGG 1269
15 GCAGCAACTGG 2
DB

RESULT 435
ABST6192/C
ID ABST6192 standard; DNA; 17 BP.
AC ABST6192;
XX 27-DEC-2002 (first entry)
DT
XX Human PAP-Eb associated 17-mer SEQ ID 1718.
XX PAP-E; human; pregnancy associated plasma protein E; abortive;
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KW dyegenetic pregnancy; primer; ss.
XX OS Homo sapiens.
XX

PN US2002102252-A1.
XX
PD 01-AUG-2002.
XX
PF 06-APR-2001; 2001US-00827998.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PA (GUTY/) GU Y.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Shannon ME;
XX WPI; 2002-697817/75.
DR
XX New isolated nucleic acid encoding an isoform of human pregnancy
PT associated plasma protein E, for preventing or aborting pregnancy.
XX
PS Example 2; Page 301; 353pp; English.
XX
CC This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAP-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAP-E genes described in the disclosure of the invention
XX
SQ Sequence 17 BP; 2 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1256 GCAGCAGAGCTGG 1269
DB 16 GCAGCAGAGCTGG 3
RESULT 436
ACN11988/C
ID ACN11988 standard; RNA; 17 BP.
XX
AC ACN11988;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV minus strand Inozyme substrate SEQ ID NO 11991.
XX
XX MNV, West Nile Virus; antiinflammatory; cytosolic; hepatotropic;
KM virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; infection; hepatitis;
KM liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KM Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
PA

PA (MCSW/) MCSWIGEN J A.
XX
PI Blatt L, Mcswigen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 11991; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1239 CTGGCAGAGTCTCG 1252
DB 17 CTGGCAGAGTCTCG 4
RESULT 437
ACN09283/C
ID ACN09283 standard; RNA; 17 BP.
XX
AC ACN09283;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9286.
XX
XX MNV, West Nile Virus; antiinflammatory; cytosolic; hepatotropic;
KM virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; meningitis; infection; hepatitis;
KM liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KM Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J A.
XX
PI Blatt L, Mcswigen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus

PT	(MNV), useful for treating a condition related to MNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX	
PS	Claim 23; SEQ ID NO 9286; 495bp; English.
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-leaver, DNazyme, Amberzyme and Zinzyme. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least three 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3',-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
XX	
SQ	Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
	Query Match 4.9%; Score 12.4; DB 1; Length 17;
	Best Local Similarity 92.9%; Pred No. 2.8e+02;
	Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0
OY	1239 CTGGCAGTGTGCG 1252 Db 15 CTGCACAGAGTGCG 2
RESULT 438	
ID ACN05643	ACN05643 standard; RNA; 17 BP.
XX ACN05643;	
DT 22-APR-2004	(first entry)
XX	
DE WNV Amberzyme substrate SEQ ID NO 5646.	
XX	
KM WNV, West Nile Virus; antiinflammatory; cytostatic; hepatotropic; viralicide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.	
XX	
OS West Nile Virus.	
XX	
PN WO200268637-A2.	
XX	
PD 06-SEP-2002.	
XX	
PF 19-OCT-2001; 2001WO-US048350.	
XX	
PR 20-OCT-2000; 2000US-0242411P.	
XX	
PA (RIBO-) RIBOZYME PHARM INC. (BLATT) BLATT L. (MCSW) MCSWIGEN J A.	
XX	
PI Blatt L, Mcswigen JA;	
DR	
WIPI	2002-706994/76.
XX	
FT New nucleic acid molecule that modulates replication of West Nile Virus (MNV), useful for treating a condition related to MNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.	
PT	
XX	
B5 Claim 23; SEQ ID NO 5646; 495bp; English.	
CC	The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC	treating a condition related to MNV infection e.g. pancreatitis.
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
CC	nucleic acid molecules comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorochloate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3',-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
XX	
SQ	Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
OY	
DB	Query Match 4.9%; Score 12.4; DB 1; Length 17; Best Local Similarity 78.6%; Pred. No. 2.8e+02; Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0 1239 CTGGCAGTGTGTCGC 1252 3 CUGGCAGAGGUCCG 16
RESULT 439	
ID	ACN05644 standard; RNA; 17 BP.
AC	ACN05644;
XX	
DT	22-APR-2004 (first entry)
XX	
DE	MNV Amberzyme substrate SEQ ID NO 5647.
XX	
KM	MNV, West Nile Virus; anti-inflammatory; cytostatic; hepatotropic;
KM	virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM	encephalitis; myocarditis; meningitis; infection; hepatitis;
KM	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KM	Amberzyme; Zinzyne; ss.
XX	
OS	West Nile Virus.
PN	WO200268637-A2.
PD	06-SEP-2002.
PF	19-OCT-2001; 2001MO-US048350.
PR	20-OCT-2000; 2000US-0242411P.
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLATT/) BLATT L.
PA	(MCSW/) MCSWIGEN J A.
PI	Blatt L, Mcswigen JA;
PJ	
DR	WPI, 2002-706994/76.
PT	New nucleic acid molecule that modulates replication of West Nile Virus
PT	(MNV), useful for treating a condition related to MNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PS	Claim 23; SEQ ID NO 5647; 495pp; English.
XX	
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC	treating a condition related to MNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorochloate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3',3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
CC
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1239 CTGGCAGTGTCCG 1252
|||:|||||
1 CUGGCGAGAGGUCG 14
Db

RESULT 440
ACN01507
ID ACN01507 standard; RNA; 17 BP.
XX
AC ACN01507;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV Inozyme substrate SEQ ID NO 1497.
XX
KW MNV, West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 1497; 495bp; English.
PS
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1396 AGCTGCTGGACAGA 1409
|||:|||||
3 AGCUGCGAGAAAGA 16
Db

RESULT 441
ACN11990/C
ID ACN11990 standard; RNA; 17 BP.
XX
AC ACN11990;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV minus strand Inozyme substrate SEQ ID NO 11993.
XX
KW MNV, West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 11993; 495bp; English.
PS
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1239 CTGGCAGTGTCCG 1252
|||:|||||

Db 14 CTGGCAGAGTCCG 1

RESULT 442
ACN11989/C
ID ACN11989 standard; RNA, 17 BP.
XX
XX ACN11989;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV minus strand Inozyme substrate SEQ ID NO 11992.
DE
XX MNV, West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX virucide; neutroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX MO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J A.
XX
XX Blatt L, Mcswigen JA;
PI
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 11992; 495pp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

QY 1239 CTGGCAGAGTCCG 1252
DB 16 CTGGCAGAGTCCG 3

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 443
ACN12143/C
ID ACN12143 standard; RNA, 17 BP.
XX

AC ACN12143;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV minus strand Inozyme substrate SEQ ID NO 12146.
DE
XX MNV, West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX virucide; neutroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX MO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J A.
XX
XX Blatt L, Mcswigen JA;
PI
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 12146; 495pp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 2 A; 5 C; 3 G; 0 T; 7 U; 0 Other;

QY 1396 AGCTGCTGACAGA 1409
DB 15 AGCTGCTGAAAGA 2

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 444
ACN01611
ID ACN01611 standard; RNA, 17 BP.
XX
XX ACN01611;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV Inozyme substrate SEQ ID NO 1601.
DE
XX MNV, West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PI Blatt L, Mcswiggen JA;
PI WPI; 2002-706994/76.
XX
DR The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1239 CTGGCAGTGTCTCCG 1252
DB 4 CUGGCAGAGGUCCG 17
RESULT 445
ACN13555/C
ID ACN13555 standard; RNA, 17 BP.
XX
XX ACN13555;
XX
DT 22-APR-2004 (first entry)
XX
XX WNV minus strand Zinzyme substrate SEQ ID NO 13558.
XX
XX WNV, West Nile Virus; antiinflammatory; cytosolic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX

PN WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
PI Blatt L, Mcswiggen JA;
PI WPI; 2002-706994/76.
XX
DR The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 5 C; 3 G; 0 T; 7 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1396 AGCTGCTGGACAGA 1409
DB 14 AGCTGCTGAAAAGA 1
RESULT 446
ABT35664
ID ABT35664 standard; DNA, 17 BP.
XX
XX ABT35664;
XX
DT 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID NO 1301.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; de.
XX
OS Homo sapiens.
XX
XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
XX
XX 17-SEP-2001; 2001FR-00011978.
XX

PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 185; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1292 TCAGGTCGCATGG 1305
DB 3 TCAGAGTCCCATGG 16
RESULT 447
ABT36507/C
ID ABT36507 standard; DNA; 17 BP.
XX
AC ABT36507;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 2144.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX Homo sapiens.
XX OS
XX PN WO2003025175-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004208.
XX
XX PR 17-SEP-2001; 2001FR-00011978.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX

PI Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 283; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1266 CTGGAAGAGGCTGA 1279
DB 16 CTGGAAGAGGCGGA 3
RESULT 448
ABT39779
ID ABT39779 standard; DNA; 17 BP.
XX
AC ABT39779;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5416.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX Homo sapiens.
XX OS
XX PN WO2003025175-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004208.
XX
XX PR 17-SEP-2001; 2001FR-00011978.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijnder M;
XX

DR WPI; 2003-31353/30.
 XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 XX Disclosure; Page 667; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2.8e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1264 AGCTGAGAGAGGCT 1277
 Db 2 ATCTGGAGAGGCT 15
 ACACAA07728 standard; RNA; 17 BP.
 ACACAA07728;
 DT 03-JUN-2003 (first entry)
 XX
 DE NFkB sub-unit modulating zinzyme substrate #127.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-00864785.

XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00281932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 PA (STIN/) STINCHOMB D T.
 PA (MCSM/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 PI Stinchomb DT, Mcswigen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 39; 72pp; English.
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotheraphy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2.8e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1392 GCTGAGCTGCTGGA 1405
 Db 15 GCTGAGCTGCGGGA 2
 ACACAA06453 standard; RNA; 17 BP.
 ACACAA06453;
 DT 03-JUN-2003 (first entry)
 XX
 DE NFkB sub-unit modulating inozyme substrate #272.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW

KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS Homo sapiens.
XX
PN US2002177568-A1.
XX
PD 28-NOV-2002.
XX
PF 23-MAY-2001; 2001US-00864785.
XX
PR 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-00245466.
PR 15-AUG-1994; 94US-00291932.
PR 23-DEC-1996; 96US-00777916.
XX
PA (STIN/) STINGCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
PI Stinchcomb DT, Mcswiggen J, Draper KG;
XX
XX WPI; 2003-340953/32.
XX
PT Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS Claim 3; Page 31; 72pp; English.
XX
CC The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFkB), where (I) is an inozyme, zinczyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
SQ Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1392 GCTGAGCTGCTGGA 1405
Db 16 GCTGAGCTGCGGGA 3
RESULT 451
ADB05259
ID ADB05259 standard; DNA; 17 BP.

XX
AC ADB05259;
XX
XX 20-NOV-2003 (first entry)
DT
XX
XX Human MD212 scanning oligonucleotide SEQ ID 6245.
DE
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KM developmental disorder; ss.
XX
XX
OS Homo sapiens.
XX
PN EPI281758-A2.
XX
PD 05-FEB-2003.
XX
PR 30-JUL-2002; 2002EP-00016874.
PR
XX 02-AUG-2001; 2001US-00922181.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
XX WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
PS Example 8; SEQ ID NO 6245; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX acids can also be used as probes to detect and characterize gross
XX alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1279 AGGGCAGAGACCT 1292
Db 4 AGGGCAGAGACCT 17
RESULT 452
ADB05260
ID ADB05260 standard; DNA; 17 BP.
XX
XX ADB05260;
XX
DT 20-NOV-2003 (first entry)
XX
XX Human MD212 scanning oligonucleotide SEQ ID 6246.
DE
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;

KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.
OS Homo sapiens.
XX EPI281758-A2.
XX
XX EPI281758-A2.
XX
XX 05-FEB-2003.
XX
XX 30-JUL-2002; 2002EP-00016874.
XX
XX 02-AUG-2001; 2001US-00922181.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M, Gu Y, Nguyen C;
XX
XX WPI; 2003-423107/40.
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 6246; 103bp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
XX Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1279 AGGCGAGAGACCT 1292
DB 3 AGGCGAGAGACCT 16
RESULT 453
ADBO5262
ID ADBO5262 standard; DNA; 17 BP.
XX
XX ADBO5262;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human MD212 scanning oligonucleotide SEQ ID 6248.
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX EPI281758-A2.
XX
XX EPI281758-A2.
XX

PD 05-FEB-2003.
XX
XX 30-JUL-2002; 2002EP-00016874.
XX
XX 02-AUG-2001; 2001US-00922181.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M, Gu Y, Nguyen C;
XX
XX WPI; 2003-423107/40.
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 6248; 103bp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
SQ
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1279 AGGCGAGAGACCT 1292
DB 1 AGGCGAGAGACCT 14
RESULT 454
ADBO5261
ID ADBO5261 standard; DNA; 17 BP.
XX
XX ADBO5261;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human MD212 scanning oligonucleotide SEQ ID 6247.
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX EPI281758-A2.
XX
XX EPI281758-A2.
XX
XX 05-FEB-2003.
XX
XX 30-JUL-2002; 2002EP-00016874.
XX
XX 02-AUG-2001; 2001US-00922181.
XX
XX (AEOM-) AEOMICA INC.
XX

PI Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MD212, e.g. cancer.
XX
PS Example 8; SEQ ID NO 6247; 103bp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Oy Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 1279 AGGGAGAGACCT 1292
||| ||| ||| ||| |||
2 AGGGAGAGACCT 15
DE
RESULT 455
ACD63053
ID ACD63053 standard; RNA; 17 BP.
XX
AC ACD63053;
XX
DT 24-SEP-2003 (first entry)
XX
DE HCV minus strand DNAzyme substrate sequence #860.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virocid; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
PD
XX 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 290; 387bp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
XX invention
XX
SQ Sequence 17 BP; 1 A; 1 C; 10 G; 0 T; 5 U; 0 Other;
Oy Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Db 1412 GGGTGTGACGGG 1425
||| : ||| |||
4 GGGUGUGAGCGCG 17
DE
RESULT 456
ACD63054
ID ACD63054 standard; RNA; 17 BP.
XX
AC ACD63054;
XX
DT 24-SEP-2003 (first entry)
XX
DE HCV minus strand DNAzyme substrate sequence #861.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virocid; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
PD
XX 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.
PF
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blact L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 290; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zincymes, ambeizymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 1 A; 2 C; 11 G; 0 T; 3 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1413 GGTGCTGAGCGGC 1426
DB 1 GUGUGUGAGCGGC 14

RESULT 457
AAL51462/C
ID AAL51462 standard; DNA; 17 BP.
XX
XX AAL51462;
AC
XX
DT 03-APR-2003 (first entry)
XX
DE Oligodendrocyte development disability animal model oligonucleotide - P4.
XX
XX Oligodendrocyte development disability; ds; non-human animal model;
KW DAPI2; DNA activation protein 12; psychoneurotic disorder;
KW Nasu-Hokora disease; dementia; schizophrenia; Huntington's chorea;

KW schizophrenic personality disorder; compulsive syndrome;
KW Tourette's syndrome; primer; probe.
XX
XX Unidentified.
XX
XX WO200291820-A1.
XX
XX 21-NOV-2002.
XX
XX
PF 02-MAY-2002; 2002WO-JP004405.
XX
XX 16-MAY-2001; 2001JP-00146338.
XX
XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PI Takai T, Aso H, Fujiwara M;
XX
DR WPI; 2003-129201/12.
XX
PT Non-human model animals of oligodendrocyte development disability,
PT applicable in studying onset mechanism of psychoneurotic disorders e.g.
PT Nasu-Hokora disease and schizophrenia, and in screening drugs.
XX
PS Disclosure; Page 12; 37pp; Japanese.
XX
XX The invention comprises a non-human animal model of oligodendrocyte
CC development disability. The animal model is constructed by deleting the
CC DAPI2 (DNA activation protein 12) gene function to cause the disability.
CC The animal model is useful for studying the onset of psychoneurotic
CC disorders (e.g. Nasu-Hokora disease, dementia, schizophrenia,
CC schizophrenia personality disorder, compulsive syndrome, Huntington's
CC chorea and Tourette's syndrome). The animal model is also useful in
CC screening drugs for use in treating the psychoneurotic disorders listed
CC above. The present DNA sequence represents an oligonucleotide that was
CC used in the invention
XX
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1266 CTGGAAGAGGCTGA 1279
DB 14 CTGGCAGAGGCTGA 1

RESULT 458
ADB43574/C
ID ADB43574 standard; DNA; 17 BP.
XX
XX ADB43574;
AC
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #3897.
XX
XX cytosolic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
XX Homo sapiens.
OS
XX
XX WO2003040369-A2.
XX
XX 15-MAY-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004219.
PF
XX
XX 17-SEP-2001; 2001FR-00011981.
PR
XX

PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Teleman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.
DR
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 487; 771pp; French.
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
OY
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1257 CAGCAGAGCTGGA 1270
Db 16 CAGTAAACGCTGGA 3
RESULT 459
ADB45562
ID ADB45562 standard; DNA; 17 BP.
XX
AC ADB45562;
XX
DT 18-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #5885.
XX
XX cytosstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
XX Homo sapiens.
OS
XX MO2003040369-A2.
PN
XX 15-MAY-2003.
PD
XX 17-SEP-2002; 2002WO-1B004219.
PF
XX 17-SEP-2001; 2001FR-00011981.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX Teleman A, Amson R, Tuijnder M;
PI
XX

DR WPI; 2003-441574/41.
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 720; 771pp; French.
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 4 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
OY
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1264 AGCTGGAAGAGGCT 1277
Db 2 ATCTGGAAGAGGCT 15
RESULT 460
ADC66185
ID ADC66185 standard; DNA; 17 BP.
XX
AC ADC66185;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human CFTR related oligonucleotide.
XX
XX typing; variable site; cystic fibrosis; human;
KW cystic fibrosis transmembrane conductance regulator; CFTR; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
PN
XX MO2003074737-A1.
PF
XX 12-SEP-2003.
PD
XX 07-MAR-2003; 2003WO-SE000394.
PF
XX 07-MAR-2002; 2002SE-0000695.
PR
XX (PYRO-) PYROSEQUENCING AB.
PA
XX Schiller A, Dunker J;
PI
XX WPI; 2003-731684/69.
DR
XX Typing at least two variable sites of at least one nucleic acid molecule
PT related to cystic fibrosis by simultaneously or sequentially performing
PT primer extension reactions and determining the pattern of nucleotide
PT

PT incorporation.
 XX
 XX Example 6; Fig 4; 69pp; English.
 PS
 XX The present invention describes a method for typing at least two variable
 CC sites of at least one nucleic acid molecule related to cystic fibrosis.
 CC The method comprises: (a) providing at least one nucleic acid molecule of
 CC a gene related to cystic fibrosis; (b) providing at least one extension
 CC primer, which binds to different predetermined sites in the nucleic acid
 CC molecules, where at least one extension primer is designed to extend over
 CC at least two potential variable sites in the nucleic acid molecule, and
 CC nucleotide; (c) simultaneously or sequentially performing primer
 CC extension reactions; and (d) determining the pattern of nucleotide
 CC incorporation to obtain a test pattern; optionally (e) comparing the test
 CC pattern of step (c) with one or more reference patterns, in order to type
 CC the variable sites of the nucleic acid molecule. Also described: (1)
 CC diagnosing the genetic predisposition of states, diseases and drug
 CC response related to the human cystic fibrosis transmembrane conductance
 CC regulator (CFTR) gene; and (2) a kit for use in the method for typing
 CC comprising at least one extension primer. The method is useful for typing
 CC at least two variable sites of at least one nucleic acid molecule related
 CC to cystic fibrosis. The present sequence represents an oligonucleotide
 CC which is used in the exemplification of the present invention.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 3 G; 6 T; 0 U; 2 Other;
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2.8e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1301 CATGTCATCTGTG 1314
 Db 3 CATGTCATCTGTG 16
 RESULT 461
 ADF62509
 ID ADF62509 standard; DNA; 17 BP.
 AC ADF62509;
 XX
 DT 12-FEB-2004 (first entry)
 DT
 XX Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 413.
 DE
 XX chromatin organisation modifier; CHROMO domain; cytoskeletal; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX
 OS Homo sapiens.
 OS
 XX WO2003050284-A1.
 PN
 XX 19-JUN-2003.
 PD
 XX 22-NOV-2002; 2002WO-US037506.
 PF
 XX 10-DEC-2001; 2001US-0339764P.
 PR
 XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 PA
 XX Guo J;
 PI
 XX WPI; 2003-532916/50.
 DR
 XX
 XX Example 2; SEQ ID NO 413; 164pp; English.
 PS
 XX The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current

CC sites of at least one nucleic acid molecule related to cystic fibrosis.
 CC The method comprises: (a) providing at least one nucleic acid molecule of
 CC a gene related to cystic fibrosis; (b) providing at least one extension
 CC primer, which binds to different predetermined sites in the nucleic acid
 CC molecules, where at least one extension primer is designed to extend over
 CC at least two potential variable sites in the nucleic acid molecule, and
 CC nucleotide; (c) simultaneously or sequentially performing primer
 CC extension reactions; and (d) determining the pattern of nucleotide
 CC incorporation to obtain a test pattern; optionally (e) comparing the test
 CC pattern of step (c) with one or more reference patterns, in order to type
 CC the variable sites of the nucleic acid molecule. Also described: (1)
 CC diagnosing the genetic predisposition of states, diseases and drug
 CC response related to the human cystic fibrosis transmembrane conductance
 CC regulator (CFTR) gene; and (2) a kit for use in the method for typing
 CC comprising at least one extension primer. The method is useful for typing
 CC at least two variable sites of at least one nucleic acid molecule related
 CC to cystic fibrosis. The present sequence represents an oligonucleotide
 CC which is used in the exemplification of the present invention.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 3 G; 6 T; 0 U; 2 Other;
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2.8e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1301 CATGTCATCTGTG 1314
 Db 3 CATGTCATCTGTG 16
 RESULT 462
 ADF62509
 ID ADF62509 standard; DNA; 17 BP.
 AC ADF62509;
 XX
 DT 12-FEB-2004 (first entry)
 DT
 XX Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 413.
 DE
 XX chromatin organisation modifier; CHROMO domain; cytoskeletal; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX
 OS Homo sapiens.
 OS
 XX WO2003050284-A1.
 PN
 XX 19-JUN-2003.
 PD
 XX 22-NOV-2002; 2002WO-US037506.
 PF
 XX 10-DEC-2001; 2001US-0339764P.
 PR
 XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 PA
 XX Guo J;
 PI
 XX WPI; 2003-532916/50.
 DR
 XX
 XX Example 2; SEQ ID NO 413; 164pp; English.
 PS
 XX The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current

CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.

XX Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1318 AGCTAGGGGACCTC 1331
||| |||||
Db 1 AGCAAGGGGACCTC 14

RESULT 463

ADP62506
ID ADF62506 standard; DNA; 17 BP.

AC ADF62506;

XX 12-FEB-2004 (first entry)

DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 410.

XX chromatin organisation modifier; CHROMO domain; cytosolic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.

OS Homo sapiens.

XX WO2003050284-A1.

XX 19-JUN-2003.

XX 22-NOV-2002; 2002WO-US037506.

XX 10-DEC-2001; 2001US-0339764P.

XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX Guo J;

XX WPI; 2003-532916/50.

XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.

XX Example 2; SEQ ID NO 410; 164pp; English.

XX The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.

XX Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1318 AGCTAGGGGACCTC 1331
||| |||||
Db 4 AGCAAGGGGACCTC 17

RESULT 464

ADP62508
ID ADF62508 standard; DNA; 17 BP.

AC ADF62508;

DT 12-FEB-2004 (first entry)

DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 412.

XX chromatin organisation modifier; CHROMO domain; cytosolic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.

OS Homo sapiens.

XX WO2003050284-A1.

XX 19-JUN-2003.

XX 22-NOV-2002; 2002WO-US037506.

XX 10-DEC-2001; 2001US-0339764P.

XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX Guo J;

XX WPI; 2003-532916/50.

XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.

XX Example 2; SEQ ID NO 412; 164pp; English.

XX The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.

XX Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1318 AGCTAGGGGACCTC 1331
||| |||||
Db 2 AGCAAGGGGACCTC 15

RESULT 465

ADP62507
ID ADF62507 standard; DNA; 17 BP.

AC ADF62507;

DT 12-FEB-2004 (first entry)

DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 411.

XX chromatin organisation modifier; CHROMO domain; cytosolic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;

KM human; ss; probe.
XX
OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
DR WPI; 2003-532916/50.
XX
PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS Example 2; SEQ ID NO 411; 164bp; English.
XX
CC The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation demonstrates cytoskeletal activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipokeb
CC database.
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1318 AGCTAGGGGACCTC 1331
Db 3 AGCAAGGGGACCTC 16
XX
RESULT 466
ACCS1715
ID ACCS1715 standard; DNA; 17 BP.
XX
AC ACCS1715;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #482.
XX
KM ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KM tumour regression; apoptosis; virus resistance; diagnosis;
KM cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX

PI Tuijinder M, Telerman A, Amson R;
XX
DR WPI; 2003-250496/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 151; 798bp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1292 TCAGGTGCGCATGG 1305
Db 3 TCAGGTGCGCATGG 16
XX
RESULT 467
ACCS4358/C
ID ACCS4358 standard; DNA; 17 BP.
XX
AC ACCS4358;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #3125.
XX
KM ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KM tumour regression; apoptosis; virus resistance; diagnosis;
KM cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijinder M, Telerman A, Amson R;
XX
DR WPI; 2003-250496/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 761; 798bp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX

SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2.8e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1366 AGGCTTACGAG 1379
 |||||
 17 ATGCTTACGAG 4

Db

RESULT 468
 ADL48289
 ID ADL48289 standard; RNA; 17 BP.
 XX
 AC ADL48289;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human IKK-gamma substrate sequence #799.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW reterososis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002MO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowitra B, Haeblerli P, Mcswiggen J, Fornaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1822; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC reterososis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 CC
 XX

SQ Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 4.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 85.7%; Pred. No. 2.8e+02;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAACAC 1266
 |||||
 3 GCUGCAGCAGCAGC 16

Db

RESULT 469
 ADL47853
 ID ADL47853 standard; RNA; 17 BP.
 XX
 AC ADL47853;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human IKK-gamma substrate sequence #363.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW reterososis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002MO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowitra B, Haeblerli P, Mcswiggen J, Fornaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1386; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC reterososis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 CC
 XX

Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 2.8e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

1253 GCTGCAGCAGCAGC 1266
||:|||||
4 GCTGCAGCAGCAGC 17

RESULT 470

ADL47854

ID ADL47854 standard; RNA; 17 BP.

AC ADL47854;

DT 20-MAY-2004 (first entry)

DE Human IKK-gamma substrate sequence #364.

XX antiSense oligonucleotide; neurite growth inhibitor; NOGO;

KM prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;

KM protein kinase PKR; cerebrovascular accident;

KM central nervous system injury; CNS injury; spinal cord injury; cancer;

KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KM osteoarthritis; asthma; Crohn's disease; diabetes; obesity;

KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KM graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;

KM allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KM substrate; de.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

PD 03-APR-2002; 2002WO-US010512.

PF 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Chowrira B, Haeblerli P, McSwiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

PT Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1367; 317pp; English.

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC resectosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 2.8e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

1253 GCTGCAGCAGCAGC 1266
||:|||||
1 GCTGCAGCAGCAGC 14

RESULT 471

ADK13157

ID ADK13157 standard; DNA; 17 BP.

AC ADK13157;

DT 20-MAY-2004 (first entry)

DE Human glioma endothelial marker (GEM) long tag SEQ ID NO:335.

XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;

KM anticancer; anti-glioma; immune response; cytostatic;

KM multi-drug sensitive glioma; human; long tag; ss.

OS Homo sapiens.

OS Synthetic.

PN WO2004016758-A2.

PD 26-FEB-2004.

PF 15-AUG-2003; 2003WO-US025614.

PR 15-AUG-2002; 2002US-0403390P.

PR 01-APR-2003; 2003US-0458978P.

XX (GENZ) GENZYME CORP.

PA (UNIV) UNIV JOHNS HOPKINS.

DR WPI; 2004-247973/23.

PT Diagnosing glioma by detecting expression product of any one of 255 genes, glioma endothelial markers, in brain tissue sample suspected of

PT being neoplastic, and comparing the expression with expression in normal brain tissue sample.

XX

PS Example 2; SEQ ID NO 335; 114pp; English.

CC The present invention describes a method (M1) for aiding in the diagnosis of glioma. (M1) involves detecting an expression product of at least one gene (I) in a first brain tissue sample (T) suspected of being

CC neoplastic, where (I) is chosen from any one of 255 genes (glioma endothelial markers (GEMs)) as given in specification, and comparing the

CC expression of (I) in (T) with expression of (I) in a second normal brain tissue sample (R), where increased expression of (I) in (T) relative to

CC (R), identifies (T) as likely to be neoplastic. Also described: (1) treating (M2) glioma involves contacting cells of the glioma with an

CC antibody that specifically binds to a extracellular epitope; (2) identifying (M3) a test compound as potential anticancer or anti-glioma

CC drug involves contacting a test compound with the cell which expresses (I), monitoring an expression product of the at least one gene and

CC identifying test compound as a potential anticancer drug if it decreases the expression of at least one gene; (3) identifying (M4) a test compound

CC as potential anticancer or anti-glioma drug involves contacting a test compound with the cell which expresses mRNA of at least one gene

CC identified by a tag as described above, monitoring mRNA of the gene, and

CC identifying the test compound as a potential anticancer drug if it decreases the expression of at least one gene; and (4) inducing (M5) an

CC immune response to glioma involves administering to a mammal, a protein or (I). (I) have cytoskeletal activities, and can be used to trigger immune

CC

CC destruction of glioma cells, and as immune response inducers. (M1) is
CC useful for aiding in diagnosing glioma. (M2) is useful for treating multi-
CC drug sensitive glioma in a human. (M5) is useful for inducing an immune
CC response to a glioma in a mammal having glioma or in a mammal who has had
CC a glioma surgically removed. The present sequence represents a human GBM
CC long tag oligonucleotide, which is used in the exemplification of the
CC present invention.

XX
SQ Sequence 17 BP; 2 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1414 GTGCTGAGCGGCGC 1427
Db 1 GTGCTAAGCGGCGC 14

RESULT 472
AD185892
ID AD185892 standard; RNA; 17 BP.
XX
AC AD185892;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNAzyme substrate sequence #3138.
XX
KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNAzyme.
XX
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PS (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswigen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
DR WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 3138; 198bp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNAzyme substrate
CC sequence.

XX
SQ Sequence 17 BP; 1 A; 2 C; 11 G; 0 T; 3 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1413 GTGCTGAGCGGCGC 1426
Db 1 GGUGUGAGCGGCGC 14

RESULT 473
AD185891
ID AD185891 standard; RNA; 17 BP.
XX
AC AD185891;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNAzyme substrate sequence #3137.
XX
KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNAzyme.
XX
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PS (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswigen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
DR WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 3137; 198bp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNAzyme substrate
CC sequence.

XX
SQ Sequence 17 BP; 1 A; 1 C; 10 G; 0 T; 5 U; 0 Other;

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.8e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1412 GGGTGTGACGGCG 1425
Db 4 GGUGUGAGCGGCG 17

RESULT 474
ABN08656/C
ID ABN08656 standard; DNA; 17 BP.
XX
AC ABN08656;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8648.

XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX (AECOM-) AECOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX Disclosure; SEQ ID NO 8648; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pcc_sequence
XX
XX Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1249 TCCGGCTGCGACGACG 1265
Db 17 TCCAGCTGCGAGCTGAG 1

XX RESULT 475
XX ID AAV97648 standard; RNA; 17 BP.
XX AAV97648;
XX AAV97648;
XX 17-MAR-1999 (first entry)
XX Human EGF-R target sequence nucleotide position 3716.
XX Human; epidermal growth factor receptor; EGF-R; target sequence;
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.
XX Homo sapiens.
XX WO9833893-A2.
XX 06-AUG-1998.
XX 14-JAN-1998; 98WO-US000730.
XX 31-JAN-1997; 97US-0036476P.
XX 04-DEC-1997; 97US-00985162.
XX (RIBO-) RIBOZYME PHARM INC.
XX (UVAS-) UNIV ASTON.
XX Akhtar S, Fell P, Mcawiggen JA;
XX WPI; 1998-437449/37.
XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal
XX growth factor receptor, useful for inhibiting cell proliferation and for
XX treating cancers.
XX Claim 5; Page 77; 109pp; English.
XX The present invention describes enzymatic nucleic acid molecules (NAMEs)
XX which specifically cleave RNA derived from an epidermal growth factor
XX receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
XX represent specifically claimed target sequence from human EGF-R. AAV98044
XX to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
XX hairpin ribozymes respectively for human EGF-R. The NAMEs are useful for
XX cleaving EGF-R RNA in the treatment of a condition associated with EGF-R
XX expression levels e.g. to inhibit cell proliferation in the prevention or
XX treatment of cancers. The NAME can also be used as diagnostic tools to
XX examine genetic drift and mutations within diseased cells or to detect
XX the presence of EGF-R RNA in a cell.
XX
XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
Qy 1325 GGACCTCTTCTCAAGG 1341
Db 1 GGACUUCUUCUCCAAGG 17
XX
XX RESULT 476
XX AAV16349/C
XX ID AAV16349 standard; DNA; 17 BP.
XX AAV16349;
XX 03-JUN-1998 (first entry)
XX Primer used to clone additional sequences from human netrin.
XX

KW Human; netrin; hNET; treatment; trapping; modulation; expression;
KW antibody; identification; binding; chemoattractant; axon growth;
KW spinal commissural axon; neural regeneration; orientation;
KW substrate specificity; ligand; exon trap; PCR primer; amplify; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9748797-A1.
XX
XX
PD 24-DEC-1997.
XX
PF 16-JAN-1997; 97WO-US000785.
XX
PR 17-JUN-1996; 96US-00665259.
PR 01-OCT-1996; 96US-00702614.
PR 09-DEC-1996; 96US-00762500.
XX
PA (GEN2) GENZYME CORP.
XX
XX Landes GM, Burn TC, Connors TD, Dackowski WR, Van Raay TJ;
PI Klinger KW,
XX
DR WPI; 1998-063138/06.
XX
XX Human chromosome 16 genes encoding netrin, ATP binding cassette
PT transporter, ribosomal L3 and augmenter of liver regeneration proteins -
PT useful for, e.g. treatment of liver disease and cystic fibrosis.
XX
PS Claim 17; Page 26; 220pp; English.
XX
XX Oligonucleotides AAV16347-50 are used to clone additional sequences from
CC nucleic acids encoding human netrin (hNET). Partial DNA sequences from
CC the gene was isolated using exon traps AAW4753-57. Netrins define a
CC family of chemotropic factors which have been shown to play a central
CC role in axon guidance. GRAL12 analysis predicts 6 exons within the
CC genomic DNA sequence, with 5 exons encoding sequences with homology to
CC chicken netrins. Chicken netrins have been shown to function as
CC chemoattractants for developing spinal commissural axons. Human netrins
CC may therefore have a significant role in neural regeneration. Though
CC netrins do not by themselves promote axon growth, they do play a role in
CC the orientation of axon growth. The sequence was isolated using an exon
CC trap. Sequences encoding human ATP binding cassette transporter (hABC3),
CC human ribosomal L3 (RPL3L), and human augmenter of liver regeneration
CC (hALR) were also isolated. The antisense oligonucleotides of the hNET
CC sequence are used to modulate expression of hNET prevent its translation.
CC Antibodies against hNET can be used to block binding of its naturally
CC occurring ligands. Host cells containing vectors with DNA inserts
CC encoding the protein can be used in a method for identifying compounds
CC which bind to hNET
XX
SQ Sequence 17 BP; 6 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1243 CAGTGTCCGCGTCGAG 1259
Db 17 CTGTGCTCTGGTTCAG 1

RESULT 477
AAV94867/C
ID AAV94867 standard; RNA; 17 BP.
XX
AC AAV94867;
XX
XX 24-FEB-1999 (first entry)
XX
XX Mouse IL-2 receptor g-chain substrate position 58.
DE
XX Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW

KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
KW autoimmune disease; psoriasis; allergy; inflammatory disease;
KW graft rejection; ss.
XX
XX Mus sp.
OS
XX
PN WO9824913-A2.
XX
PD 11-JUN-1998.
XX
XX
PF 02-DEC-1997; 97WO-US021748.
XX
PR 03-DEC-1996; 96US-00758306.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcswiggen JA;
XX
XX WPI; 1998-333332/29.
XX
XX
XX Ribozymes targeted to interleukin 2 - useful for treating e.g. cancer,
PT autoimmune disease and allergies.
XX
XX
PS Claim 4; Page 40; 61pp; English.
XX
XX The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.
CC CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC from the present invention. The ribozymes can be used for the treatment
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy
CC and other inflammatory conditions. The ribozymes are also used to induce
CC tolerance in a recipient to alloantigen from a donor
XX
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1369 CTTACGAGAGCGCTG 1385
Db 17 CTCGACGAGGACGACTG 1

RESULT 478
AAV71807
ID AAV71807 standard; DNA; 17 BP.
XX
AC AAV71807;
XX
XX
DT 15-MAR-1999 (first entry)
XX
XX
DE Murine IgG1 heavy chain degenerate primer.
KW
KW Humanised antibody; monoclonal antibody; Mab; antibody engineering;
KW mouse; human; vitronectin; alpha-v beta-3; receptor; reticulos; cancer;
KW metastasis; rheumatoid arthritis; atherosclerosis; angiogenesis;
KW diabetic retinopathy; inflammation; macular degeneration; osteoporosis;
KW Paget's disease; hyperparathyroidism; hypercalcaemia; therapy;
KW immunotherapy; PCR; primer; ss.
XX
XX Synthetic.
OS Mus sp.
XX
PN WO9840488-A1.
XX
PD 17-SEP-1998.
XX
XX 12-MAR-1998; 98WO-US004987.
PF
XX 12-MAR-1997; 97US-0039609P.
PR
XX

PA	(SMK) SMITHKLINE BEECHAM CORP.
XX	
PI	Jonak ZL, Johanson KO, Taylor AH;
DR	WPI, 1999-034590/03.
PT	New anti alpha_v beta_3 vitronectin receptor antibodies - used for
XX	
PT	immunotherapeutic treatment of e.g. diabetic retinopathy, inflammatory
XX	
PT	disorders, atherosclerosis, restenosis, cancers or osteoporosis.
XX	
PS	Example 13; Page 45; 97pp; English.
XX	
CC	This is the nucleotide sequence of a mouse IgG1 heavy chain degenerate
CC	primer that was used with a IgG1 hinge primer (see AAU71806) for the PCR
CC	amplification of cDNA (see AAV17197) encoding the heavy chain variable
CC	region (VH, see AAM84093) of anti-human alpha-v beta-3 vitronectin
CC	receptor murine monoclonal antibody D12. Humanised VH (see AAM84097) and
CC	VL (see AAM84098) regions were constructed that are specifically reactive
CC	with the human alpha-v beta-3 protein receptor and are capable of
CC	neutralising the receptor. They can be used for passive immunotherapy of
CC	a disorder mediated by the alpha-v beta-3 receptor, e.g. restenosis or an
CC	angiogenic associated disease
XX	
SQ	Sequence 17 BP; 3 A; 4 C; 1 G; 2 T; 0 U; 7 Other;
Query Match	4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity	52.9%; Pred. No. 3.1e+02;
Matches 9; Conservative	7; Mismatches 1; Indels 0; Gaps 0
OY	1245 GTGTCGGCGCTGCAGCA 1261 ::: : : : : :
Dn	1 SWRGTYCARCTBCARCA 17
RESULT 479	
AAA36507/C	
ID	AAA36507 standard; DNA; 17 BP.
XX	
AC	AAA36507;
XX	
DT	26-JUL-2000 (first entry)
XX	
DE	Human genomic SNP allele specific oligonucleotide SEQ ID NO:572.
XX	
KW	Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW	allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW	genomic classification; identification; DNA fingerprinting;
XX	tumour characterisation; hybridisation; ss.
OS	Homo sapiens.
XX	
PN	WO200018960-A2.
DD	06-APR-2000.
XX	
PF	24-SEP-1999; 99WO-US022283.
XX	
PR	25-SEP-1998; 98US-0101757P.
XX	
PA	(MASI) MASSACHUSETTS INST TECHNOLOGY.
XX	
PI	Landere JE, Jordan B, Housman DE, Charest A;
XX	
DR	WPI, 2000-293181/25.
XX	
PT	Detection of single nucleotide polymorphisms in genomes by preparation
XX	
PT	and analysis of reduced complexity genomes, useful for genotyping,
XX	fingerprinting and determining allele frequency of SNPs.
XX	
PS	Disclosure; Page 70; 11pp; English.
XX	
CC	A method has been developed for detecting the presence or absence of a
CC	single nucleotide polymorphism (SNP) allele in a genomic sample. The

CC	method comprises preparing a reduced complexity genome (RCG) from the SNP
CC	genomic sample and analysing the RCG for the presence or absence of a SNP
CC	allele. The method can be used to characterise a tumour, to generate a
CC	genomic pattern for an individual genome or to generate a genomic
CC	classification code for a genome. The method can be used to assess
CC	whether a subject is at risk for developing a disease or to identify a
CC	set of SNP alleles associated with a disease. The method can also be used
CC	to perform linkage analysis. AAG35944 to AAG35947 represent sequences
CC	used in the exemplification of the present invention. AAG35948 to
CC	AAG36632 represent nucleotide sequences containing SNPs
XX	
SQ	Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
OY	
Db	1377 AACGACGTGCCTTTTGC 1393 17 ATGCAGCTGCATCTTGTC 1
RESULT 480	
ID	AAA25058/C
AA	AAA25058 standard; DNA; 17 BP.
AC	AAA25058;
XX	
DT	19-UUU-2000 (first entry)
XX	
DE	Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1556.
XX	
KM	Oestrogen receptor; c-rafi; k-ras; bcl-2; ribozyme; cleavage;
KW	hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KX	gene expression modification; cancer; phosphorothioate; endonucleases;
KX	anticancer; breast cancer; endometrium cancer; ss.
XX	
OS	Homo sapiens.
PN	MO9954459-A2.
PD	28-OCT-1999.
PF	19-APR-1999; 99WO-US008547.
PR	20-APR-1998; 98US-0082404P.
PR	23-JUN-1998; 98US-00103636.
PA	(RIBO-) RIBOZYME PHARM INC.
PI	Thompson JD, Beigelman L, McSwiggan JA, Karpeisky A, Bellon L;
PI	Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P;
PI	Matulic-Adamic J;
DR	WPI; 2000-013248/01.
PT	New nucleic acids that interact, and optionally cleave, target sequences,
PT	used to treat cancer.
PS	Claim 77; Page 67; 148pp; English.
XX	
CC	The present invention describes nucleic acids (A) that interact stably
CC	with a target sequence and contain at least one phosphorodithiolate
CC	link, having endonuclease activity. (A), and more generally any catalytic
CC	nucleic acid (A') that modulates expression of the oestrogen receptor
CC	gene, are used to treat cancer (particularly of breast or endometrium),
CC	in vivo or by transforming cells ex vivo and implanting treated cells, or
CC	for other conditions associated with levels of oestrogen receptor.
CC	Because of the high selectivity for targeted RNA, (A) can also be used to
CC	correlate inhibition of gene expression with alterations in phenotype,
CC	particularly for identification of therapeutic targets, and as research
CC	reagents (for RNA, in the same way that restriction endonucleases are
CC	used with DNA). The combination of modifications in (A) improves

CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
SQ Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1306 TCATCTGTGAGAGCTA 1332
DB 17 TCAGCTGTGAAGAGCTA 1

RESULT 481
AAFO1894
ID AAFO1894 standard; DNA; 17 BP.
XX
AC AAFO1894;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #189.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM interferon alpha; ss.
XX
OS Homo sapiens.
XX
FN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PE 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 60; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
CC
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1323 GGGGACCTTCTTCGAA 1339
DB 1 GTGGACGTCTTCTTCAA 17

RESULT 482
AAFO7235
ID AAFO7235 standard; DNA; 17 BP.
XX
AC AAFO7235;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #3492.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM interferon alpha; ss.
XX
OS Homo sapiens.
XX
FN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PE 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 54; Page 136; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
CC
SQ Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1345 GAGACTTCCGAGGCA 1361
DB 1 GGGCCTGTCCGAGGCA 17

RESULT 483
ABK00540/C
ID ABK00540 standard; RNA; 17 BP.
XX
AC ABK00540;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Hammerhead Ribozyme #540.
XX
KW Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;

KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KM inflammatory arthropathy; central nervous system injury;
KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KM Parkinson's disease; ataxia; Huntington's disease;
KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
PD 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
XX (CHOW/) CHOWRIRA B M.
XX
PI Blact L, Mcswigen J, Chowrira BM;
XX WPI, 2001-607195/69.
DR
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 74; 200P; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOCO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a tRNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with an NGN motif) or
CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOCO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOCO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOCO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOCO expression. The present
CC sequence is a hammerhead ribozyme of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3, 1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1261 AACAGCTGGAAGAGCT 1277
DB 17 AGCAGCAGGAATAGCT 1
RESULT 484
ABK02521/C
ID ABK02521 standard; RNA; 17 BP.
XX
XX ABK02521;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOCO Amberzyme #193.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KM cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KM muscular; CD20; neurite growth inhibitor gene; NOCO; hammerhead ribozyme;
KM DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukemia;
KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KM inflammatory arthropathy; central nervous system injury;
KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KM Parkinson's disease; ataxia; Huntington's disease;
KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
PD 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
XX (CHOW/) CHOWRIRA B M.
XX
PI Blact L, Mcswigen J, Chowrira BM;
XX WPI, 2001-607195/69.
DR
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 135; 200P; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOCO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a tRNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with an NGN motif) or
CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention

XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1189 CCCGAGACCTGTGCTG 1205
DB 17 CTCGAAATCTGTGCTG 1

RESULT 485
ABK01652/C
ID ABK01652 standard; RNA, 17 BP.

XX ABK01652;
DT 12-MAR-2002 (first entry)
DE Human NOGO G-Cleaver #108.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neuroprotective; neuroproliferator gene; NOGO; hammerhead ribozyme;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX Homo sapiens.
OS Synthetic.

XX WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US004273.

XX 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT) BLATT L.

PA (MCSW) MCSWIGGEN J.

PI (CHOW) CHOWRIRA B M.

XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI, 2001-607195/69.

PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.

PS Claim 88; Page 93; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acid may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a G-cleaver molecule of the invention

XX Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1393 CTCGAGCTGTGACAGA 1409
DB 17 CTGTGCTGCAGATAGA 1

RESULT 486
ABK01790
ID ABK01790 standard; RNA, 17 BP.

XX ABK01790;

DT 12-MAR-2002 (first entry)

DE Human NOGO Zinczyme #112.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neuroprotective; antiParkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT-) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX
XX Blact L, Mcswiggen J, Chowrira BM,
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
XX Claim 88; Page 97; 200P; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOCO). The
XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX the cell and treat a patient having a condition associated with the level
XX of CD20. The treatment may further comprise the use of one or more
XX therapies. In particular, the CD20 targeting nucleic acid may be used to
XX treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
XX targeting nucleic acid is used to cleave RNA of the NOCO gene in the
XX presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
XX nucleic acid may be contacted with a cell to reduce NOCO activity of the
XX cell and treat a patient having a condition associated with the level of
XX NOCO. The treatment may further comprise the use of one or more
XX therapies. In particular, the NOCO-targeting nucleic acid may be used to
XX treat central nervous system (CNS) injury and cerebrovascular accident
XX (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOCO expression. The present
XX sequence is a zinzyme molecule of the invention
XX
XX Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 3.1e+02;
XX Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
XX
XX 1251 CGGCTGCAGCAGCAGCT 1267
XX |||||
XX Db 1 CGGCGCGCGCAGCAGCT 17

ABK01793
ID ABK01793 standard; RNA; 17 BP.
XX
XX AC ABK01793;
XX
XX DT 12-MAR-2002 (first entry)
XX
XX DE Human NOCO zinzyme #115.
XX
XX Human; 88; antisense therapy; cyrostatic; antiinflammatory; haemostatic;
XX cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOCO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT-) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX
XX Blact L, Mcswiggen J, Chowrira BM,
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
XX Claim 88; Page 97; 200P; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOCO). The
XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX the cell and treat a patient having a condition associated with the level
XX of CD20. The treatment may further comprise the use of one or more
XX therapies. In particular, the CD20 targeting nucleic acid may be used to
XX treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
XX targeting nucleic acid is used to cleave RNA of the NOCO gene in the
XX presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
XX nucleic acid may be contacted with a cell to reduce NOCO activity of the
XX cell and treat a patient having a condition associated with the level of

CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke). Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a zizyme molecule of the invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
QY 1251 CGGCTGCAGCAACAGCT 1267
Db 1 CAGCTGCAGCAACACUCU 17
RESULT 489
ID ABA80520/C
XX ABA80520 standard; DNA, 17 BP.
AC ABA80520;
XX
DT 24-JAN-2002 (first entry)
XX
DE MSH6 mutation correcting oligonucleotide SEQ ID NO: 3366.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CPTA; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presentin-1;
KW Alzheimer's disease; cytoskeletal; antislacking; antihaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
PS Claim 7; Page 229; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CPTA, cyclin-dependent kinase inhibitor 2A

CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presentin-1 (PSEN1) and
CC presentin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1346 AGACTTCCCGGCGCAG 1362
Db 17 AAACCTTCCAGTGAG 1
RESULT 489
ID ABA80521
XX ABA80521 standard; DNA, 17 BP.
AC ABA80521;
XX
DT 24-JAN-2002 (first entry)
XX
DE MSH6 mutation correcting oligonucleotide SEQ ID NO: 3367.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CPTA; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presentin-1;
KW Alzheimer's disease; cytoskeletal; antislacking; antihaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
PS Claim 7; Page 229; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,

```
CC retinoblastoma, BRCA1, BRCA2, CPTP, cyclin-dependent kinase inhibitor 2A
CC (CKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MSH1, MSH2, MSH6,
CC apolipoprotein B (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

Query March 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1346 AGACTTCCAGCGCAG 1362
Db 1 AAACCTTCCAGTGAAG 17

RESULT 490
ABL46727
ID ABL46727 standard; RNA; 17 BP.
XX
AC ABL46727;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID NCH ribozyme substrate oligonucleotide #181.
XX
KW Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
FN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (GLAXO) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswigen JA, Hamblin PA, Ellis JH;
XX
DR WPI; 2001-550088/61.
XX
PT New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
PS Claim 4; Page 66; 108pp; English.
XX
CC The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 0 T; 1 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1252 GGCTGCAGCAACAGCTG 1268
Db 17 GGCTGCAGCAACAGCTG 1

RESULT 492
ABL46750/C
ID ABL46750 standard; RNA; 17 BP.
XX
AC ABL46750;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID NCH ribozyme substrate oligonucleotide #204.
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1250 CCGGCTGCAGCAACAGC 1266
Db 1 CCUGCAGCAGCAGCCAGC 17

RESULT 491
ABL46891/C
ID ABL46891 standard; RNA; 17 BP.
XX
AC ABL46891;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID G-clavner ribozyme substrate oligonucleotide #32.
XX
KW Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
FN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (GLAXO) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswigen JA, Hamblin PA, Ellis JH;
XX
DR WPI; 2001-550088/61.
XX
PT New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
PS Claim 4; Page 69; 108pp; English.
XX
CC The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

XX Human; Grb2-related with Insert Domain; GRID; T-cell;
KM co-stimulatory adaptor protein; tissue rejection; graft rejection;
KM Leukaemia; Cytostatic; ss.
XX Homo sapiens.
XX WO200162911-A2.
XX
XX 30-AUG-2001.
XX
XX 23-FEB-2001; 2001WO-US005957.
XX
XX 24-FEB-2000; 2000US-0184594P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, Mcswigen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 66; 108pp; English.
XX
XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAGCTGG 1269
Db |||||
17 GCTGCTGCAGCTGCTGG 1

RESULT 493
ABN07803
ID ABN07803 standard; DNA; 17 BP.
XX
AC ABN07803;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7795.
XX
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 7795; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the protein. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1250 CCGGCTGCAGCAGC 1266
Db |||||
1 CCAGCTTCAGCAGCAGC 17

RESULT 494
ABN08659
ID ABN08659 standard; DNA; 17 BP.
XX
AC ABN08659;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8651.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX

OS Homo sapiens.
XX AC WO200192524-A2.
XX PD 06-DEC-2001.
XX PE 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AECOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX DR WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 8651; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1257 CAGCAACAGCTGGAGA 1273
Db 1 CAGCTGACAGCTGAGGA 17

RESULT 495
ABN01468/C
ID ABN01468 standard; DNA; 17 BP.

XX AC ABN01468;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mex scanning SEQ ID NO:4 sequence SEQ ID NO:1460.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PV WO200192524-A2.
XX PD 06-DEC-2001.
XX PE 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AECOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX DR WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 1460; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1369 CTTACGACGAGCTG 1385
Db 17 CTTCCGAGAGCTGCTG 1

RESULT 496

ABN07848

ID ABN07848 standard; DNA; 17 BP.

AC ABN07848;

DT 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7840.

XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

PN WO200192524-A2.

PD 06-DEC-2001.

PF 25-MAY-2001; 2001WO-US016981.

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

(AEOM-) AEOMICA INC.

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
PS Disclosure; SEQ ID NO 7840; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.1e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGACGACGAGCTGG 1269

Db 1 GCTGACGACGAGCTGG 17

RESULT 497

ABN07928/c

ID ABN07928 standard; DNA; 17 BP.

AC ABN07928;

DT 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7920.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

PN WO200192524-A2.

PD 06-DEC-2001.

PF 25-MAY-2001; 2001WO-US016981.

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

(AEOM-) AEOMICA INC.

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
PS Disclosure; SEQ ID NO 7920; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC XX

SO Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Gy 1328 CCTCTTCCAGGCG 1344
Db 17 CCTCTTCAAGCCG 1

RESULT 498
ABN07807
ID ABN07807 standard; DNA; 17 BP.
XX AC ABN07807;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7799.
XX XX
KW Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (ABOM-) ABOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI, 2002-179446/23.
DR

XX XX
PT New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionisation, comprises human myosin-like protein hGDMLP-1.
PT

PS Disclosure; SEQ ID NO 7799; 214pp; English.

XX XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC XX

SO Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Gy 1254 CTGCGACAGCTGGA 1270
Db 1 CTTACGACGACGCTGAA 17

RESULT 499
ABN08514
ID ABN08514 standard; DNA; 17 BP.
XX AC ABN08514;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8506.
XX XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (ABOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 8506; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP-
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1394 TGAGCTGCTGACAGAC 1410
Db 1 TGAGCAGCTGTACAGGC 17
RESULT 500
ABN08658
ID ABN08658 standard; DNA; 17 BP.
XX
AC ABN08658;
XX
XX 29-MAY-2002 (first entry)
DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8650.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX MO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US016981.
PF

XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 8650; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP-
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1256 GCAGCAGCTGTGAGG 1272
Db 1 GCAGCTGCAGCTGTGAGG 17
RESULT 501
ABN02596
ID ABN02596 standard; DNA; 17 BP.
XX
AC ABN02596;
XX
XX 29-MAY-2002 (first entry)
DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2588.
DE
XX

KW Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024253.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
XX Disclosure: SEQ ID NO 2588; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1288 ACCCTCAGGCGCCATG 1304
DB 1 AGCTCCAGGCGCCATG 17

RESULT 502
ABN09241-
ID ABN09241 standard; DNA; 17 BP.
XX
XX ABN09241;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9233.
DE
KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024253.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
XX Disclosure: SEQ ID NO 9233; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence

XX	Seq	Sequence	17 BP; 3 A; 5 C; 7 G; 2 T; 0 U; 0 Other;	
	Query Match		4.8%; Score 12.2; DB 1; Length 17;	
	Best Local Similarity		82.4%; Pred. No. 3.1e+02;	
	Matches	14; Conservative	0; Mismatches 3; Indels 0; Gaps 0	
QY		1205 GAGGCGAGCCATCTGTC	1221	
DB		1 GAGGCGAGCCTGCATGTC	17	
	RESULT 503			
ABN09239				
ID	ABN09239	standard; DNA; 17 BP.		
XX	AC	ABN09239;		
XX	DT	29-MAY-2002 (first entry)		
XX	DE	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9231.		
XX	KW	Human; genome-derived myosin-like protein 1; GDMLP-1; heart;		
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;			
KM	skeletal muscle disorder; amplicon; screening; ss.			
XX	OS	Homo sapiens.		
XX	PN	WO200192524-A2.		
XX	PD	06-DEC-2001.		
XX	PF	25-MAY-2001; 2001WO-US016981.		
XX	PR	26-MAY-2000; 2000US-0207456P.		
PR	21-SEP-2000; 2000US-0234687P.			
PR	27-SEP-2000; 2000US-0236359P.			
PR	04-OCT-2000; 2000GB-00024263.			
PR	30-JAN-2001; 2001WO-US000661.			
PR	30-JAN-2001; 2001WO-US000662.			
PR	30-JAN-2001; 2001WO-US000663.			
PR	30-JAN-2001; 2001WO-US000664.			
PR	30-JAN-2001; 2001WO-US000665.			
PR	30-JAN-2001; 2001WO-US000666.			
PR	30-JAN-2001; 2001WO-US000667.			
PR	30-JAN-2001; 2001WO-US000668.			
PR	30-JAN-2001; 2001WO-US000669.			
PR	30-JAN-2001; 2001WO-US000670.			
PR	05-FEB-2001; 2001US-0266860P.			
XX	PA	(ABOM-) ABOmica INC.		
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;			
XX	WPI; 2002-179446/23.			
DR				
XX	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,			
PT	or as specific biomolecule capture probes for surface-enhanced laser			
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.			
XX	Disclosure; SEQ ID NO 9231; 214pp; English.			
XX				
XX	The present invention describes a human genome-derived myosin-like			
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-1			
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1			
CC	nucleic acids can be used as probes to detect, characterise and quantify			
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to			
CC	provide initial substrates for the recombinant engineering of hGDMLP-1			
CC	protein variants having desired phenotypic improvements, and for			
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be			
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP-			
CC	-1 proteins, as standards in assays used to determine the concentration			
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule			

CC	captureprobes for surface-enhanced laser desorption ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGDMLP-1, in particular heart
CC	skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
XX	
XX	
SQ	Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
Gy	Query Match 4.8%; Score 12.2; DB 1; Length 17; Best Local Similarity 82.4%; Pred. No. 3.1e+02; Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Dn	1203 CAGAGGGCAGCATCTG 1219 1 CAGAGGGCAGCATCTGAG 17
RESULT 504	
ID	ABNO7533 standard; DNA; 17 BP.
AC	ABNO7533;
XX	
DT	29-MAY-2002 (first entry)
DE	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7525.
XX	
KM	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	skeletal muscle disorder; amplicon; screening; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200192524-A2.
PD	06-DEC-2001.
PF	25-MAY-2001; 2001WO-US016981.
XX	
PR	26-MAY-2000; 2000US-0207456P.
PR	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000681.
PR	30-JAN-2001; 2001WO-US000681.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000666.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000669.
PR	30-JAN-2001; 2001WO-US000670.
PR	05-FEB-2001; 2001US-0268660P.
XX	
PA	(AEOM-) AEOMICA INC.
XX	
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
DR	WPI; 2002-179446/23.
XX	
PT	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT	or as specific biomolecule capture probes for surface-enhanced laser
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.
PS	Disclosure; SEQ ID NO 7525; 214bp; English.
XX	

CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1253 GCTGCGAGCAGCAGCTGG 1269
Db 1 GCTGAGCAAAAGCTTG 17
RESULT 505
ABN07804
ID ABN07804 standard; DNA; 17 BP.
XX
AC ABN07804;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7796.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.

XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PR or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 7796; 214bp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1251 CGGCTGCGAGCAGCAGCT 1267
Db 1 CAGCTTCAGCAGCAGCT 17
RESULT 506
ABN08441/C
ID ABN08441 standard; DNA; 17 BP.
XX
AC ABN08441;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8433.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PA (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI, 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMRP-1.
XX
XX
XX Disclosure; SEQ ID NO 8433; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMRP-1). The protein and polynucleotide sequences of hGDMRP-
XX 1 can be used in gene therapy and vaccine production. The hGDMRP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMRP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMRP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMRP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMRP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMRP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMRP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMRP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMRP-1, in particular heart
XX and skeletal muscle disorders. hGDMRP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMRP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1305 GTCATCTGTGAGCAGCT 1321
DB 17 GTCCGCTGTGAGCAGCT 1
RESULT 507
ABN09551/C
ID ABN09551 standard; DNA; 17 BP.
XX
XX ABN09551;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMRP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9543.
XX
XX Human; genome-derived myosin-like protein 1; GDMRP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX

XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI, 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMRP-1.
XX
XX
XX Disclosure; SEQ ID NO 9543; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMRP-1). The protein and polynucleotide sequences of hGDMRP-
XX 1 can be used in gene therapy and vaccine production. The hGDMRP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMRP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMRP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMRP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMRP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMRP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMRP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMRP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMRP-1, in particular heart
XX and skeletal muscle disorders. hGDMRP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMRP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 0 A; 9 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1192 AGAAGCTGTGAGAGG 1208
DB 17 AGAAGCCAGGGAGAGG 1
RESULT 508
ABN07849
ID ABN07849 standard; DNA; 17 BP.
XX
XX ABN07849;
XX

DT 29-MAY-2002 (first entry)
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7841.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX WO200192524-A2.
PN
XX
PD 06-DEC-2001.
XX
PP 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) AEOMICA INC.
PA
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI, 2002-179446/23.
DR
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 7841; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_gct_sequence
XX
XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTGCAGCAGCAGCTGGA 1270
44
44
DB 1 CTGAAGCAGCAGCTGGA 17
RESULT 509
ABN09240
ID ABN09240 standard; DNA; 17 BP.
XX
XX
AC ABN09240;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9232.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
XX WO200192524-A2.
PN
XX
PD 06-DEC-2001.
XX
PP 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) AEOMICA INC.
PA
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI, 2002-179446/23.
DR
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 9232; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the

CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1204 AGAGGGCAGCCATCTGT 1220
Db 1 AGAGGGCAGCCTGCAGT 17
RESULT 510
ABN08512
ID ABN08512 standard; DNA; 17 BP.
AC ABN08512;
XX
XX 29-MAY-2002 (first entry)
DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8504.
DE
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US016981.
PF
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI
XX WPI, 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 8504; 214pp; English.
PS
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1392 GCTGAGCTGCTGCAG 1408
Db 1 GATGAGCAGCTGTACAG 17
RESULT 511
ABN08442/C
ID ABN08442 standard; DNA; 17 BP.
AC ABN08442;
XX
XX 29-MAY-2002 (first entry)
DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8434.
DE
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US016981.
PF
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI
XX WPI, 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser

PT description ionization, comprises human myosin-like protein hGDMLP-1.
XX Disclosure; SEQ ID NO 8434; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1304 GGTGATCTGTAGCAGC 1320
Db 17 GGTGCGCTGTGAGCACC 1
RESULT 512
ABN01967/c
ID ABN01967 standard; DNA; 17 BP.
XX
AC ABN01967;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1959.
XX
KM Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
FT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 1959; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1376 GAACGAGCTGCGTTTG 1392
Db 17 GCAACGAGCTGAGCTTG 1
RESULT 513
ABQ64028/c
ID ABQ64028 standard; DNA; 17 BP.
XX
AC ABQ64028;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 741.
XX
KM Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytosolatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.

```
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
XX Example 2; Page 254; 418bp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX invention has cytoskeletal activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
Gy Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Db 1287 GACCCCTGAGGTCAT 1303
17 GCCCCTGAGGTCAT 1
RESULT 514
ABQ64029/c
ID ABQ64029 standard; DNA; 17 BP.
XX
XX ABQ64029;
XX
XX 20-AUG-2002 (first entry)
XX
XX Human KTOM1a portion (ABQ63232) probe # 742.
XX
XX Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytoskeletal;
XX gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
XX kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200224750-A2.
XX
XX 28-MAR-2002.
XX
XX 21-SEP-2001; 2001WO-US029656.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
```

```
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
XX Example 2; Page 255; 418bp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX invention has cytoskeletal activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
Gy Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Db 1286 AGACCTTCAGGTCCTCA 1302
17 AGCCCTGAGGTCCTCA 1
RESULT 515
ABK25804
ID ABK25804 standard; DNA; 17 BP.
XX
XX ABK25804;
XX
XX 09-APR-2002 (first entry)
XX
XX Stress tolerance conferring genome altering oligonucleotide #272.
XX
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
XX o-methyl modification; DNA modification; phosphorothioate linkage;
XX DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
XX abiotic stress tolerance; improved nutritional value; hygromycin-B;
XX amino acid over production; herbicide resistance; glyphosate resistance;
XX imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
XX porphyrin herbicide resistance; triazine resistance; disease resistance;
XX modified oil production; modified starch production; waxy starch;
XX altered floral morphology; male-sterile plant; albino mutant;
XX modified fatty acid content; reduced palmitate production; albino plant;
XX increased stearate production; reduced linolenic acid production;
XX photosynthetic process.
XX
```

XX Cucurbita sp.
OS Synthetic.
XX WO200192512-A2.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-US017672.
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX (UNDE) UNIV DELAWARE.
XX Kmlec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX Claim 7; Page 112; 220pp; English.
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1191 CAGAAAGCTGTGCAGAG 1207
Db 1 CACAAACTATGCAGAG 17
RESULT 516
ABK25783/c
ID ABK25783 standard; DNA; 17 BP.
XX
AC ABK25783;
XX
XX 09-APR-2002 (first entry)
DE Stress tolerance conferring genome altering oligonucleotide #251.
XX
KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;

KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; modified fatty acid content; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX
XX Cucumis sativus.
OS Synthetic.
XX WO200192512-A2.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-US017672.
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX (UNDE) UNIV DELAWARE.
XX Kmlec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX Claim 7; Page 111; 220pp; English.
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1191 CAGAAAGCTGTGCAGAG 1207
Db 17 CACAAACTATGCAGAG 1
RESULT 517
ABK25803/c

XX	DE	Stress tolerance conferring genome altering oligonucleotide #271.
XX	XX	
XX	XX	
XX	XX	
XX	XX	
XX	XX	Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
XX	KM	o-methyl modification; LNA modification; phosphorothioate linkage;
XX	KM	DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
XX	KM	abiotic stress tolerance; improved nutritional value; hygromycin; primer;
XX	KM	amino acid over production; herbicide resistance; glyphosate resistance;
XX	KM	imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
XX	KM	porphyric herbicide resistance; triazine resistance; disease resistance;
XX	KM	modified oil production; modified starch production; waxy starch;
XX	KM	altered floral morphology; male-sterile plant; albino mutant;
XX	KM	modified fatty acid content; reduced palmitate production; albino plant;
XX	KM	increased stearate production; reduced linolenic acid production;
XX	KM	photosynthetic process.
XX	XX	
XX	OS	Cucurbita sp.
XX	OS	Synthetic.
XX	XX	
XX	PM	WO200192512-A2.
XX	XX	
XX	XX	
XX	PD	
XX	XX	06-DEC-2001.
XX	XX	
XX	PF	01-JUN-2001; 2001WO-US017672.
XX	XX	
XX	PR	01-JUN-2000; 2000US-0208538P.
XX	PR	30-OCT-2000; 2000US-024489P.
XX	PR	27-MAR-2001; 2001US-00818875.
XX	XX	
XX	PA	(UYDE) UNITV DELAWARE.
XX	XX	
XX	PI	Kmiec BB, Gamber HB, Rice MC, Kim J;
XX	XX	WPI, 2002-106307/14.
XX	XX	
XX	PT	New oligonucleotides with modified nuclease-resistant termini, useful for
XX	PT	creating plants with desired phenotypes, e.g. stress tolerance, improved
XX	PT	nutritional value, herbicide or disease resistance, or modified oil
XX	PT	production.
XX	PS	
XX	XX	Claim 7; Page 112; 220pp; English.
XX	XX	
XX	CC	The invention relates to an oligonucleotide for targeted alteration of a
XX	CC	genetic sequence, which comprises a single-stranded oligonucleotide
XX	CC	having a DNA domain. The DNA domain has at least one mismatch with
XX	CC	respect to the genetic sequence to be altered and further comprises
XX	CC	chemical modifications of the oligonucleotide. The chemical modifications
XX	CC	consist of o-methyl modification, an LNA modification, two or more
XX	CC	phosphorothioate linkages on a terminus, or a combination of any two or
XX	CC	more of these modifications. The oligonucleotides are useful for
XX	CC	directing repair or alteration of plant genetic information. The
XX	CC	oligonucleotides are particularly useful for creating plants with desired
XX	CC	phenotypes, e.g. environmental or abiotic stress tolerance, improved
XX	CC	nutritional value (e.g. altering amino acid content of plants or
XX	CC	confering amino acid over production), herbicide resistance (e.g.
XX	CC	glyphosate resistance, imidazolinone and sulphonylurea herbicide
XX	CC	resistance), porphyric herbicide resistance or triazine resistance),
XX	CC	disease resistance, modified oil production, modified starch production
XX	CC	(e.g. increased starch or production of waxy starch), altered floral
XX	CC	morphology (e.g. male-sterile plants) or modified fatty acid content
XX	CC	(e.g. reduced palmitate, increased stearate or reduced linolenic acid).
XX	CC	The oligonucleotides are also useful for producing albino mutants for the
XX	CC	analysis of photosynthetic processes. This sequence represents a genome
XX	CC	altering oligonucleotide of the invention
XX	XX	
XX	SO	Sequence 17 BP; 2 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;

	Best Local Similarity	82.4%	Pred. No. 3.1e+02	Matches	14	Conservative	0	Mismatches	3	Indels	0	Gaps	0
OY	1191	CAGAGCCTGTGCAGAG	1207										
DB	17	CACAAACCTATGCAGAG	1										
RESULT 518													
ABK25784													
ID	ABK25784	standard; DNA; 17 BP.											
XX	ABK25784;												
XX	09-APR-2002	(first entry)											
DE	Stress tolerance	conferring genome altering oligonucleotide #252.											
XX	Chromosomal genomic alteration;	genome altering oligonucleotide; PCR; ss;											
KM	o-methyl modification;	LNA modification; phosphorothioate linkage;											
KM	DNA repair; DNA alteration;	environmental tolerance; hygromycin-B;											
KM	abiotic stress tolerance;	improved nutritional value; hygromycin; primer;											
KM	amino acid over production;	herbicide resistance; glyphosate resistance;											
KM	imidazolinone herbicide resistance;	sulphonylurea herbicide resistance;											
KM	porphyric herbicide resistance;	triazine resistance; disease resistance;											
KM	modified oil production;	modified starch production; waxy starch;											
KM	altered floral morphology;	male-sterile plant; albino mutant;											
KM	modified fatty acid content;	reduced palmitate production; albino plant;											
KM	increased stearate production;	reduced linoleic acid production;											
KM	photosynthetic process.												
XX	Cucumis sativus.												
OS	Synthetic.												
OS	WO200192512-A2.												
XX	06-DEC-2001.												
PD	01-JUN-2001;	2001WO-US017672.											
XX	01-JUN-2000;	2000US-0208538P.											
XX	30-OCT-2000;	2000US-0244989P.											
PR	27-MAR-2001;	2001US-00818875.											
FR	(UYDE)	UNIV DELAMARE.											
XX	Kmiec EB,	Gamper HB, Rice WC, Kim J;											
XX	WPI; 2002-106307/14.												
DR	New oligonucleotides	with modified nuclease-resistant termini, useful for											
PT	creating plants	with desired phenotypes, e.g. stress tolerance, improved											
PT	nutritional value,	herbicide or disease resistance, or modified oil											
PT	production.												
XX	Claim 7,	Page 111; 220pp; English.											
PS	The invention	relates to an oligonucleotide for targeted alteration of a											
XX	genetic sequence,	which comprises a single-stranded oligonucleotide											
CC	having a DNA domain.	The DNA domain has at least one mismatch with											
CC	respect to the genetic	sequence to be altered and further comprises											
CC	chemical modifications	of the oligonucleotide. The chemical modifications											
CC	consist of o-methyl	modification, an LNA modification, two or more											
CC	phosphorothioate	linkages on a terminus, or a combination of any two or											
CC	more of these	modifications. The oligonucleotides are useful for											
CC	directing repair	or alteration of plant genetic information. The											
CC	oligonucleotides	are particularly useful for creating plants with desired											
CC	phenotypes, e.g.	environmental or abiotic stress tolerance, improved											
CC	nutritional value	(e.g. altering amino acid content of plants or											
CC	conferring amino	acid over production), herbicide resistance (e.g.											
CC	glyphosate	resistance, imidazolinone and sulphonylurea herbicide											

CC mapped to human chromosome 10p12.1. HTPPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1298 TGCCTGGTCACTCTGTG 1314
Db 17 TTCATGTTCACTCTGGG 1

RESULT 521

ABV79528
ID ABV79528 standard; DNA; 17 BP.

AC ABV79528;

DT 03-JAN-2003 (first entry)

DE Human HTPPL scanning oligonucleotide SEQ ID 774.

XX Human; gene therapy; tumour suppressor; HTPPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.

XX Homo sapiens.

XX EP1229046-A2.

XX PD 07-AUG-2002.

XX PF 28-JAN-2002; 2002EP-00001167.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 23-MAY-2001; 2001US-00864761.

XX PR 09-OCT-2001; 2001US-0327898P.

XX PA (ABOM-) AEOMITCA INC.

XX PI Zhan J;

XX DR WPI; 2002-676582/73.

XX PT Novel isolated human testis expressed Patched like protein (HTPL), useful
XX for identifying agonist and antagonist and specific binding partners, and
XX PT for treating subjects having defects in HTPPL.

XX PS Example 2; Page 165; 718pp; English.

XX The present invention relates to human testis expressed Patched like
XX protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPPL-S (S for short) compared to HTPPL-L (L for long). HTPPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPPL plays a role similar

CC to that of Patched, and is a potential tumour suppressor. HTPPL is
CC important in regulating male germ cell development, and the HTPPL gene was
CC mapped to human chromosome 10p12.1. HTPPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1197 CCTGTGCAGAGGCAGC 1213
Db 1 CCTTGCAGAGTCAGC 17

RESULT 522

ABK19390
ID ABK19390 standard; RNA; 17 BP.

AC ABK19390;

DT 09-APR-2002 (first entry)

DE Human ERG Amberzyme target sequence Seq ID No 2037.

XX Human; hammerhead ribozyme; cytosolic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antiproliferative; vinorelbine; osteoporosis;
KW vulnervary; cancer; lymphoma; Bwing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Ogler-Weber-rendu syndrome; leukaemia; osteoporosis; DNzyme; inozyme;
KW amberzyme.

XX Homo sapiens.

XX WO200188124-A2.

XX PD 22-NOV-2001.

XX PF 16-MAY-2001; 2001WO-US015866.

XX PR 16-MAY-2000; 2000US-00572021.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI (GLAXO) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
XX WPI; 2002-082995/11.

XX Novel polynucleotide which down regulates expression of Ets-related gene,
XX useful for treating cancer, diabetic retinopathy, macular degeneration,
XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.

XX PS Claim 4; Page 127; 149pp; English.

XX The invention relates to a nucleic acid molecule (I) which down regulates
XX expression of an Ets-related gene (ERG). (I) is useful for treating
XX conditions selected from cancer, lymphoma, Bwing's sarcoma, melanoma,
XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
XX vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge

CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (1) is useful for
CC treating a patient having a condition associated with the level of ERG.
CC by contacting cells of the patient with (1) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (1) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (1) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (1). (1) is useful for cleaving RNA of
CC ERG gene, by contacting (1) with RNA, in the presence of a divalent
CC cation such as Mg2+. (1) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (1) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK2719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention

CC SQ Sequence 17 BP; 7 A; 1 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1264 AGCTGAGAGGCTGAG 1260

Db 1 AGGAGGAGAGGCGAGAG 17

RESULT 523
ABK18938
ID ABK18938 standard; RNA; 17 BP.

AC ABK18938;

DT 09-APR-2002 (first entry)

DE Human ERG DNAzyme target sequence Seq ID No 1585.

XX Human; hammerhead ribozyme; cytosolic; antitumour; antidiabetic;
XX ophthalmological; antiarthritic; antipsoriatic; vitruicide; osteopathic;
XX vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
XX Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;
XX amberzyme.

OS Homo sapiens.

PN WO200188124-A2.

PD 22-NOV-2001.

PF 16-MAY-2001; 2001WO-US015866.

PR 16-MAY-2000; 2000US-00572021.

PA (RIBO-) RIBOZYME PHARM INC.
(GLAX) GLAXO GROUP LTD.

PI Jarvis T, Von Carlowitz I, Mcawigen JA, McLaughlin F, Randi AM;
XX

DR WPI; 2002-082995/11.

PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.

PS Claim 4; Page 105; 149pp; English.

XX The invention relates to a nucleic acid molecule (1) which down regulates
CC expression of an Ets-related gene (ERG). (1) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (1) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (1) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (1) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (1) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (1). (1) is useful for cleaving RNA of
CC ERG gene, by contacting (1) with RNA, in the presence of a divalent
CC cation such as Mg2+. (1) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (1) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK2719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention

SQ Sequence 17 BP; 3 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 70.6%; Pred. No. 3.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1217 CTGTCAGAACTCCAGC 1233

Db 1 CUGGUCACACCCCGAGC 17

RESULT 524
ABV89776
ID ABV89776 standard; DNA; 17 BP.

AC ABV89776;

DT 23-DEC-2002 (first entry)

DE Human POSHL scanning oligonucleotide SEQ ID NO 489.

XX Human; POSHL 1; SH3 domain; POSHL-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.

OS Homo sapiens.

PN EP1239051-A2.

PD 11-SEP-2002.

PF 28-JAN-2002; 2002EP-00001165.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 23-MAY-2001; 2001US-00864761.

PR 10-OCT-2001; 2001US-0328205P.

PA (AEOM-) AEOMICA INC.

Pt	Shannon M;
Dx	
Dx	WPI; 2002-684061/74.
Pt	
Pt	Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
Pt	-1, useful for treating disorders associated with decreased expression or
Pt	activity of human POSHL.
Xx	
Px	Example 2; SEQ ID NO 489; 60pp + Sequence Listing; English.
Cc	The invention relates to an isolated SH3 domain (POSH)-like signalling
Cc	protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
Cc	acids (SI, ABR83999), a sequence having 65% sequence identity to (SI),
Cc	(SI) having 95% deviations, especially conservative substitutions or a
Cc	fragment of the sequences comprising at least 8 contiguous amino acids.
Cc	Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
Cc	adaptor protein that interacts with Rho family small GTPases as well as
Cc	downstream components of the signal transduction pathway. (I) is useful
Cc	for identifying a specific binding partner. (I) and nucleic acids (II)
Cc	encoding (I) are useful for diagnosing, monitoring disease and treating
Cc	caused by altered expression of human POSHL1 including diagnosing and
Cc	treating cancer, they useful in the development of vaccines and (II) is
Cc	useful in gene therapy. (II) is useful for constructing microarrays which
Cc	are useful for measuring and for surveying gene expression and creating
Cc	transgenic non-human animals capable of producing the proteins. The
Cc	present sequence is that of a scanning oligonucleotide useful in examples
Cc	of the invention. Note: The present sequence did not form part of the
Cc	printed specification, but is based on sequence information supplied to
Cc	Derwent by the European Patent Office
Sq	
Sq	Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
Oy	
Oy	Query Match 4.8%; Score 12.2; DB 1; Length 17;
Oy	Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Oy	Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0.
Oy	
Oy	1275 GCTGAGGGCAGACGCC 1291
Oy	
Oy	1 GCTCAGGCAGAGACTCC 17
Db	
Db	
Result 525	
ABKS5867/c	
ID	ABKS5867 standard; RNA; 17 BP.
XX	
AC	ABKS5867;
DT	02-JUL--2002 (first entry)
DE	
DE	Human CLCA1 gene enzymatic nucleic acid #238.
KW	Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW	antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW	chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW	oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW	acetyllysine.
OS	
OS	Homo sapiens.
PN	
PN	WO200211674-A2.
PD	
PD	14-FEB--2002.
PF	
PF	09-AUG--2001; 2001WO-US024970.
XX	
XX	09-AUG--2000; 2000US-0224383P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(SYNT) SYNTEX USA LLC.
PA	(THOM/) THOMPSON J.
Pt	Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
Pt	Gruppe A;

XX	WPI; 2002-217145/27.
DR	
XX	
PT	Enzymatic polynucleotide that down regulates expression of chloride
PT	channel calcium activated gene, useful for treating Chronic obstructive
PT	pulmonary disease (COPD), chronic bronchitis and asthma.
XX	
PS	Claim 4; Page 57; 152pp; English.
XX	
CC	The invention relates to enzymatic nucleic acid molecules that down
CC	regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC	by cleaving RNA derived from the genes. The nucleic acid sequences are
CC	useful as pharmaceutical agents for treating conditions such as chronic
CC	obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC	fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC	that are related to or will respond to the levels of CLCA1 in a cell or
CC	tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC	hence, are useful for treatment of a patient having a condition
CC	associated with the level of CLCA1, where the invention further comprises
CC	the use of one or more therapies under conditions suitable for the
CC	treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC	antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC	nucleic acids of the invention are also used as diagnostic tools to
CC	examine genetic drift and mutations within diseased cells or to detect
CC	the presence of CLCA1 RNA in a cell. This sequence represents an
CC	enzymatic nucleic acid molecule of the invention
XX	
SQ	Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
Query Match	4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No.3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0.	
QY	1253 GCTGACGACACAGCTGG 1269
DB	17 GCAGCAGGAAAGCTCG 1
RESULT 526	
ID	ABK56469
XX	ABK56469 standard; RNA; 17 BP.
XX	
AC	ABK56469;
XX	
DT	02-JUL-2002 (first entry)
XX	
DE	Human CLCA1 gene enzymatic nucleic acid #840.
XX	
KM	Human; chloride channel calcium activated 1; CLCA1; ss; antischematic;
KM	antitumorigenic; chronic obstructive pulmonary disease, COPD; asthma;
KM	chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KM	oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
XX	acetylcysteine.
XX	
OS	Homo sapiens.
XX	
PN	WO200211674-A2.
XX	
PD	14-FEB-2002.
XX	
PF	09-AUG-2001; 2001WO-US024970.
XX	
PR	09-AUG-2000; 2000US-0224383P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
XX	(SYNT) SYNTX USA LLC.
PA	(THOM) THOMPSON J.
XX	
PI	Thompson J, Mcawiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX	Grube A;
XX	
DR	WPI; 2002-217145/27.
XX	

PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
PS Claim 4, Page 71, 152pp; English.
XX
XX The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for creating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
CC
SQ Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
Oy 1370 TTACCAAGAGCAGCTGC 1386
Db 1 UUACCCGACGACGCUUC 17
RESULT 527
ABK56914
ID ABK56914 standard; RNA; 17 BP.
AC ABK56914;
XX
XX
XX 02-JUL-2002 (first entry)
XX
XX Human CLCA1 gene enzymatic nucleic acid #1285.
XX
XX Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
XX Homo sapiens.
OS
XX
XX MO200211674-A2.
XX
XX 14-FEB-2002.
XX
XX 09-AUG-2001; 2001WO-US024970.
XX
XX 09-AUG-2000; 2000US-024383P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTX USA LLC.
PA (THOM) THOMPSON J.
XX
XX Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI Grape A;
XX
XX WPI; 2002-217145/27.
XX
XX Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.

XX
XX Claim 4, Page 86, 152pp; English.
PS
XX The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
CC
SQ Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
Oy 1368 GCTTACCAAGAGCAGCT 1384
Db 1 GAUUACCCGACGACGCU 17
RESULT 528
ACN02632/C
ID ACN02632 standard; RNA; 17 BP.
AC ACN02632;
XX
XX
XX 22-APR-2004 (first entry)
XX
XX MNV Inozyme substrate SEQ ID NO 2635.
XX
XX MNV; West Nile Virus; antiinflammatory; cyrostatic; hepatotropic;
KW viruslike; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX
XX MO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-024241P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT) BLATT L.
PA (MCSW) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 2635; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication

of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Ambazyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2',O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3',3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;

Query Match	4.8%;	Score 12.2;	DB 1;	length 17;
Best Local Similarity	82.4%;	Pred. No. 3.1e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

QY	1214	CATCTGTCAGAACCTCC	1230
Db	17	CATCTGGCAGTTCCTCC	1

RESULT 529
ACN05722/0

ID ACN05723 standard; RNA; 17 BP.

AC ACN05723;

DT 22-APR-2004 (first entry)

WNV Amberzyme substrate SEQ ID NO 5726.

KW MWNT; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KX virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.

OS West Nile Virus.

PN WO200268637-A2.

PD 06-SEP-2002.

19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-024241P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

PI Blatt L, Mcswigen JA;

DR WPI; 2002-706994/76.

PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 5726; 495pp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at

least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention.

Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

Query Match	4.8%;	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 3.1e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

QY	1329	CTCTTCTCCAAGGCAGG	1345
Db	17	CACTGCTCCAAGGAGG	1

RESULT 530
ACN08403/C

ID ACN08403 standard; RNA; 17 BP.

AC ACN08403;

DT 22-APR-2004 (first entry)

WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8406.

KM MNV, West Nile Virus; antinflammatory; cyrostatic; hepatotropic;
 KM virecid; neuroprotective; antibacterial; replication; pancreatitis;
 KM encephalitis; myocarditis; meningitis; infection; hepatitis;
 KM liver failure; cancer; cirrhosis; Hammerhead; Imozyme; DNAzyme;
 KM Amberzyme; Zinzyme; ss.

OS West Nile Virus.

PN WO200268637-A2.

06-SEP-2002
PD

19-OCT-2001; 2001WO-US048350.

20-OCT-2000; 2000US-024241P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

Blatt L, Mcswiggen JA;

DR WPI; 2002-706994/76.

PT New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 8406; 495bp; English.

The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myelocauditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNAzyme, Abzyme and Zinkzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification 3',-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 3780 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

SEQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1262 ACAGCTGGAAGAGCTG 1278
17 ACAGCTGGAAGAGCTG 1
DB 17 ACAGCTGGAAGAGCTG 1
RESULT 531
ACN10812/C
ID ACN10812 standard; RNA; 17 BP.
XX ACN10812;
AC ACN10812;
XX 22-APR-2004 (first entry)
DT 22-APR-2004 (first entry)
DE MNV minus strand Inozyme substrate SEQ ID NO 10815.
XX MNV, West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX West Nile Virus.
OS West Nile Virus.
XX WO200268637-A2.
PN WO200268637-A2.
XX 06-SEP-2002.
PD 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
PF 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
PR 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J A.
XX Blact L, Mcswigen JA;
PI Blact L, Mcswigen JA;
XX WPI; 2002-706994/76.
DR WPI; 2002-706994/76.
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX Claim 23; SEQ ID NO 10815; 495bp; English.
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1263 CAGCTGGAAGAGCTG 1279
17 CAGCTGGAAGAGCTG 1

DB 17 CAGCTGGAAGAGCTG 1
RESULT 532
ACN13459/C
ID ACN13459 standard; RNA; 17 BP.
XX ACN13459;
AC ACN13459;
XX 22-APR-2004 (first entry)
DT 22-APR-2004 (first entry)
DE MNV minus strand Zinzyme substrate SEQ ID NO 13462.
XX MNV, West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX West Nile Virus.
OS West Nile Virus.
XX WO200268637-A2.
PN WO200268637-A2.
XX 06-SEP-2002.
PD 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
PF 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
PR 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J A.
XX Blact L, Mcswigen JA;
PI Blact L, Mcswigen JA;
XX WPI; 2002-706994/76.
DR WPI; 2002-706994/76.
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX Claim 23; SEQ ID NO 13462; 495bp; English.
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;
SQ Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1252 GGCTGCAAGACAGCTG 1268
17 GGCTGCAAGACAGCTG 1
DB 17 GGCTGCAAGACAGCTG 1
RESULT 533
ACN05182/C
ID ACN05182 standard; RNA; 17 BP.

```
XX ACN05182;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV DNAzyme substrate SEQ ID NO 5185.
XX
XX MNV, West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX MO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 5185; 495bp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX treating a condition related to MNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 1216 TCTGTGAGAACTCCAG 1232
XX ||||| ||||| |||||
XX 17 TCTGGCAGTTCCTCCAG 1
XX
XX RESULT 534
XX ACN10625
XX ID ACN10625 standard; RNA; 17 BP.
XX
XX ACN10625;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV minus strand Inozyme substrate SEQ ID NO 10628.
XX
XX
```

```
KW MNV, West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
KW
KW West Nile Virus.
KW
KW MO200268637-A2.
KW
KW 06-SEP-2002.
KW
KW 19-OCT-2001; 2001WO-US048350.
KW
KW 20-OCT-2000; 2000US-0242411P.
KW
KW (RIBO-) RIBOZYME PHARM INC.
KW (BLAT/) BLATT L.
KW (MCSW/) MCSWIGEN J A.
KW
KW Blatt L, Mcswiggen JA;
KW
KW WPI; 2002-706994/76.
KW
KW New nucleic acid molecule that modulates replication of West Nile Virus
KW (MNV), useful for treating a condition related to MNV infection e.g.
KW pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
KW
KW Claim 23; SEQ ID NO 10628; 495bp; English.
KW
KW The invention relates to nucleic acid molecules that modulate replication
KW of the West Nile Virus (MNV). The nucleic acid molecules are useful for
KW treating a condition related to MNV infection e.g. pancreatitis,
KW encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
KW liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
KW molecule is selected from the group of ribozymes consisting of
KW Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
KW nucleic acid molecules further comprise at least five ribose residues, at
KW least ten 2'-O-methyl modifications, phosphorothioate linkages on at
KW least three of the 5' terminal nucleotides and a 3' end modification of a
KW 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
KW are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
KW in the specification. The present sequence is that of a nucleic acid
KW molecule of the invention
KW
KW Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
KW
KW Query Match 4.8%; Score 12.2; DB 1; Length 17;
KW Best Local Similarity 64.7%; Pred. No. 3.1e+02;
KW Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
KW
KW 1214 CATCTGTGAGAACTCC 1230
KW ||:|:| ||||| ||:|:|
KW 1 CAUUCGGCAGUUCUCC 17
KW
KW RESULT 535
KW ACN11869
KW ID ACN11869 standard; RNA; 17 BP.
KW
KW ACN11869;
KW
KW 22-APR-2004 (first entry)
KW
KW MNV minus strand Inozyme substrate SEQ ID NO 11872.
KW
KW MNV, West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
KW
KW West Nile Virus.
KW
KW
```

XX XX WO200268637-A2.
XX XX
XX XX 06-SEP-2002.
XX XX
XX XX 19-OCT-2001; 2001WO-US048350.
XX XX
XX XX 20-OCT-2000; 2000US-0242411P.
XX XX
XX XX (RIBO-) RIBOZYME PHARM INC.
XX XX (BLAT/) BLATT L.
XX XX (MCSW/) MCSWIGGEN J A.
XX XX
XX XX Blatt L, Mcswiggen JA;
XX XX WPI, 2002-706994/76.
XX XX
XX XX New nucleic acid molecule that modulates replication of West Nile Virus
XX XX (MNV), useful for treating a condition related to MNV infection e.g.
XX XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX XX
XX XX Claim 23; SEQ ID NO 11872; 495bp; English.
XX XX
XX XX The invention relates to nucleic acid molecules that modulate replication
XX XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX XX treating a condition related to MNV infection e.g. pancreatitis,
XX XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX XX molecule is selected from the group of ribozymes consisting of
XX XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
XX XX nucleic acid molecules further comprise at least five ribose residues, at
XX XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX XX in the specification. The present sequence is that of a nucleic acid
XX XX molecule of the invention
XX XX
XX XX Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
XX XX
XX XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX XX Best Local Similarity 70.6%; Pred. No. 3.1e+02;
XX XX Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
XX XX
XX XX 1329 CTCCTTCACAGGCGG 1345
XX XX
XX XX 1 CACUGCUCCAAGGAGG 17
XX XX
XX XX
XX XX RESULT 536
XX XX ACN13498
XX XX ID ACN13498 standard; RNA, 17 BP.
XX XX
XX XX ACN13498;
XX XX
XX XX 22-APR-2004 (first entry)
XX XX
XX XX MNV minus strand Zinzyne substrate SEQ ID NO 13501.
XX XX
XX XX MNV; West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX XX Amberzyme; Zinzyne; ss.
XX XX
XX XX West Nile Virus.
XX XX OS
XX XX WO200268637-A2.
XX XX
XX XX 06-SEP-2002.
XX XX
XX XX 19-OCT-2001; 2001WO-US048350.
XX XX

PR 20-OCT-2000; 2000US-0242411P.
XX XX
XX XX (RIBO-) RIBOZYME PHARM INC.
XX XX (BLAT/) BLATT L.
XX XX (MCSW/) MCSWIGGEN J A.
XX XX
XX XX Blatt L, Mcswiggen JA;
XX XX WPI, 2002-706994/76.
XX XX
XX XX New nucleic acid molecule that modulates replication of West Nile Virus
XX XX (MNV), useful for treating a condition related to MNV infection e.g.
XX XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX XX
XX XX Claim 23; SEQ ID NO 13501; 495bp; English.
XX XX
XX XX The invention relates to nucleic acid molecules that modulate replication
XX XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX XX treating a condition related to MNV infection e.g. pancreatitis,
XX XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX XX molecule is selected from the group of ribozymes consisting of
XX XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
XX XX nucleic acid molecules further comprise at least five ribose residues, at
XX XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX XX in the specification. The present sequence is that of a nucleic acid
XX XX molecule of the invention
XX XX
XX XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
XX XX
XX XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX XX Best Local Similarity 70.6%; Pred. No. 3.1e+02;
XX XX Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
XX XX
XX XX 1354 CCAGGCGACGTGAGCT 1370
XX XX
XX XX 1 CCAAGGCAUGUAGAGCU 17
XX XX
XX XX
XX XX RESULT 537
XX XX ACN12792
XX XX ID ACN12792 standard; RNA, 17 BP.
XX XX
XX XX ACN12792;
XX XX
XX XX 22-APR-2004 (first entry)
XX XX
XX XX MNV minus strand Zinzyne substrate SEQ ID NO 12795.
XX XX
XX XX MNV; West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX XX Amberzyme; Zinzyne; ss.
XX XX
XX XX West Nile Virus.
XX XX OS
XX XX WO200268637-A2.
XX XX
XX XX 06-SEP-2002.
XX XX
XX XX 19-OCT-2001; 2001WO-US048350.
XX XX
XX XX 20-OCT-2000; 2000US-0242411P.
XX XX
XX XX (RIBO-) RIBOZYME PHARM INC.
XX XX (BLAT/) BLATT L.
XX XX (MCSW/) MCSWIGGEN J A.
XX XX
XX XX Blatt L, Mcswiggen JA;
XX XX

XX WPI; 2002-706994/76.
XX
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreaticitis, meningitis, hepatocellular carcinoma or cirrhosis.
PS
XX Claim 23; SEQ ID NO 12795; 495bp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreaticitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2',-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3',-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
XX
OY 1215 ATCTGTCAGAACTCCA 1231
DB 1 AUCUGGACAGUCCUCCA 17
XX
RESULT 538
ACA99693
ID ACA99693 standard; DNA; 17 BP.
XX
XX ACA99693;
AC
XX 28-JUN-2003 (first entry)
DT
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #186.
XX
XX Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX
XX WO2003031621-A2.
PN
XX 17-APR-2003.
PD
XX
XX 11-OCT-2002; 2002WO-US032599.
PF
XX 12-OCT-2001; 2001US-0329000P.
PR
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
PA
XX Zhang J;
PI
XX WPI; 2003-381720/36.
DR
XX
XX New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
XX Example 2; SEQ ID NO 210; 156bp; English.
PS
XX The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a

CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
OY 1313 TGAGCAGTAGGGGACC 1329
DB 1 TAACTGTAGGGGACC 17
XX
RESULT 539
ACA06589
ID ACA06589 standard; RNA; 17 BP.
XX
XX ACA06589;
AC
XX 03-JUN-2003 (first entry)
DT
XX
DE NFkB sub-unit modulating inozyme substrate #408.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; RBL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; RBL-A-specific inhibitor;
KW chemotherap; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; resenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS Homo sapiens.
XX
XX US2002177568-A1.
PN
XX 28-NOV-2002.
PD
XX
XX 23-MAY-2001; 2001US-00864785.
PF
XX
XX 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-00245466.
PR 15-AUG-1994; 94US-00291932.
PR 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCOMB D T.
PA (MCSW/) MCSWIGEN J.
PA (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
PI
XX WPI; 2003-340953/32.
DR
XX
XX Novel enzymatic nucleic acid molecules which down regulate expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 33; 72pp; English.
PS
XX The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor

CC kappa B (NFkB), where (1) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (1) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapeutics such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
CC
XX
SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
QY 1379 GCAGCTGCTTTGCTG 1395
Db 1 GCAGCTGCAGUUGAUG 17
ACAA07774
ID ACA07774 standard; RNA; 17 BP.
XX
XX ACA07774;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFkB sub-unit modulating zinzyme substrate #173.
XX
KM Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
XX Homo sapiens.
XX OS
PN US200217568-A1.
XX
PD 28-NOV-2002.
XX
PF 23-MAY-2001; 2001US-00864785.
XX
XX 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-0025456.
PR 15-AUG-1994; 94US-00281932.
PR 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCHOMB D T.
PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX " ";
DR WPI: 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS Claim 3; Page 40; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (1) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFkB), where (1) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (1) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapeutics such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
CC
XX
SQ Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
QY 1380 CAGCTGCTTTGCTGA 1396
Db 1 CAGCTGCAGUUGAUGA 17
ACA06584
ID ACA06584 standard; RNA; 17 BP.
XX
XX ACA06584;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFkB sub-unit modulating inozyme substrate #403.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
XX Homo sapiens.
XX OS

Db 1 AGAGGCCCGCUGCAGAC 17

RESULT 543

ADBO2361

XX ADBO2361 standard; DNA; 17 BP.

XX AC ADBO2361;

XX DT 20-NOV-2003 (first entry)

XX DE Human MD24 scanning oligonucleotide SEQ ID 3347.

XX KM Cytostatic; immunostimulant; gene therapy; vaccine; human; zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1; chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer; developmental disorder; ss.

XX KM Homo sapiens.

XX OS

XX PN EP1281758-A2.

XX PD 05-FEB-2003.

XX PF 30-JUL-2002; 2002EP-00016874.

XX PR 02-AUG-2001; 2001US-00922181.

XX PA (AEOM-) AEOMICA INC.

XX PI Shannon M, Gu Y, Nguyen C;

XX PS WPI; 2003-423107/40.

XX DR

XX PT New zinc finger-containing proteins and nucleic acids, useful in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MD23, MD24, MD27 or MD212, e.g. cancer.

XX PT MD24, MD27 or MD212, e.g. cancer.

XX PS Example 8; SEQ ID NO 3347; 103bp; English.

XX PS

XX CC The present invention relates to novel human zinc finger-containing proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2, MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy, or in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MD23, MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic acids and proteins are also useful for diagnosing or monitoring a disease caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic acids can also be used as probes to detect and characterize gross alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are useful in constructing microarrays for measuring gene expression. The proteins are useful as therapeutic agents for gene therapy or as vaccines. The present sequence was used to illustrate the invention.

XX CC

XX SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

XX

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.1e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1271 AGAGGCTGAGGCGAGAG 1287

DB 1 AGTGCGTGAACCAAG 17

RESULT 544

ADA99492/C

XX ADA99492 standard; DNA; 17 BP.

XX AC ADA99492;

XX XX 20-NOV-2003 (first entry)

XX DT

XX DE Human MD23 scanning oligonucleotide SEQ ID 481.

XX KM Cytostatic; immunostimulant; gene therapy; vaccine; human; zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1; chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer; developmental disorder; ss.

XX KM

XX OS Homo sapiens.

XX PN EP1281758-A2.

XX PD 05-FEB-2003.

XX PF 30-JUL-2002; 2002EP-00016874.

XX PR 02-AUG-2001; 2001US-00922181.

XX PA (AEOM-) AEOMICA INC.

XX PI Shannon M, Gu Y, Nguyen C;

XX PS WPI; 2003-423107/40.

XX DR

XX PT New zinc finger-containing proteins and nucleic acids, useful in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MD23, MD24, MD27 or MD212, e.g. cancer.

XX PT MD24, MD27 or MD212, e.g. cancer.

XX PS Example 8; SEQ ID NO 481; 103bp; English.

XX PS

XX CC The present invention relates to novel human zinc finger-containing proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2, MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy, or in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MD23, MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic acids and proteins are also useful for diagnosing or monitoring a disease caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic acids can also be used as probes to detect and characterize gross alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are useful in constructing microarrays for measuring gene expression. The proteins are useful as therapeutic agents for gene therapy or as vaccines. The present sequence was used to illustrate the invention.

XX CC

XX SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

XX

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.1e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1218 TGTCAAGCTTCACCA 1234

DB 17 TGTCAAGCTTCACCA 1

RESULT 545

ADA99490/C

XX ADA99490 standard; DNA; 17 BP.

XX AC ADA99490;

XX DT 20-NOV-2003 (first entry)

XX DE Human MD23 scanning oligonucleotide SEQ ID 479.

XX KM Cytostatic; immunostimulant; gene therapy; vaccine; human; zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1; chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer; chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;

XX	developmental disorder; ss.
XX	
OS	Homo sapiens.
XX	
PN	EP1281758-A2.
XX	
PD	05-FEB-2003.
XX	
PF	30-JUL-2002; 2002EP-00016874.
XX	
PR	02-AUG-2001; 2001US-00922181.
XX	
PA	(ABOM-) ABOMICA INC.
XX	
PI	Shannon M, Gu Y, Nguyen C;
XX	
DR	WPI; 2003-423107/40.
XX	
PT	New zinc finger-containing proteins and nucleic acids, useful in
PT	manufacturing a medicament for treating or preventing a disorder
PT	associated with decreased or increased expression or activity of MD23,
PT	MD24, MD27 or MD212, e.g. cancer.
XX	
PS	Example 8; SEQ ID NO 479; 103pp; English.
XX	
CC	The present invention relates to novel human zinc finger-containing
CC	proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC	encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC	MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC	15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC	in manufacturing a medicament for treating or preventing a disorder
CC	associated with decreased or increased expression or activity of MD23,
CC	MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC	acids and proteins are also useful for diagnosing or monitoring a disease
CC	caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC	acids can also be used as probes to detect and characterize gross
CC	alterations in MD23, MD24, MD27, or MD212 genetic loci. The probes are
CC	useful in constructing microarrays for measuring gene expression. The
CC	proteins are useful as therapeutic agents for gene therapy or as
CC	vaccines. The present sequence was used to illustrate the invention.
XX	
SQ	Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
XX	
Query Match	4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
QY	1220 TCAGAACCTCCGCGATG 1236
DB	17 TCAGGCTCTCCACCATG 1
AC	ADB05268
AC	ADB05268 standard; DNA; 17 BP.
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Human MD212 scanning oligonucleotide SEQ ID 6254.
XX	
KW	Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW	zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW	chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW	developmental disorder; ss.
XX	
OS	Homo sapiens.
XX	
PN	EP1281758-A2.
XX	
PD	05-FEB-2003.
XX	

```

PF 30-JUL-2002; 2002EP-00016874.
XX
XX 02-AUG-2001; 2001US-00922181.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M, Gu Y, Nguyen C;
XX
XX WP1; 2003-423107/40.
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
XX manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 6254; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX acids can also be used as probes to detect and characterize gross
XX alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.
XX
XX Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 1285 GAGACCTCAGGAGGCC 1301
XX ||||| |||||
XX 1 GAGACCTCATGAGTGCC 17
XX
XX Db
XX
XX RESULT 547
XX ADA93493/C
XX ID ADA93493 standard; DNA; 17 BP.
XX
XX ADA93493;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human MD23 scanning oligonucleotide SEQ ID 482.
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.
XX
XX Homo sapiens.
XX
XX Homo sapiens.
XX
XX EPI281758-A2.
XX
XX 05-FEB-2003.
XX
XX 30-JUL-2002; 2002EP-00016874.
XX
XX 02-AUG-2001; 2001US-00922181.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M, Gu Y, Nguyen C;
XX
XX
XX

```

DR WPI, 2003-423107/40.
XX
XX The present invention relates to novel human zinc finger-containing
PT proteins and their coding sequences: MD23, MD24, MD27, or MD212. MD23 is
PT encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
PT MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
PT 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
PS MD24, MD27 or MD212, e.g. cancer.
XX Example 8; SEQ ID NO 482; 103bp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, or MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic loci. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1217 CTGTCAGAACCTCCAGC 1233
Db 17 CTGTCAGCTCTCCACC 1
RESULT 548
ADB02362
ID ADB02362 standard; DNA; 17 BP.
AC ADB02362;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human MD24 scanning oligonucleotide SEQ ID 3348.
DE
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX
XX EPI281758-A2.
PN
XX
XX 05-FEB-2003.
PD
XX
XX 30-JUL-2002; 2002EP-00016874.
PF
XX
XX 02-AUG-2001; 2001US-00922181.
PR
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Shannon M, Gu Y, Nguyen C;
PI
XX
XX WPI, 2003-423107/40.
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 3348; 103bp; English.

XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, or MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic loci. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Gy 1272 GAGGCTGAGGCGACAGAGA 1288
Db 1 GTGCTGAGACCAAGAGA 17
RESULT 549
ADA99491/C
ID ADA99491 standard; DNA; 17 BP.
AC ADA99491;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human MD23 scanning oligonucleotide SEQ ID 480.
DE
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX
XX EPI281758-A2.
PN
XX
XX 05-FEB-2003.
PD
XX
XX 30-JUL-2002; 2002EP-00016874.
PF
XX
XX 02-AUG-2001; 2001US-00922181.
PR
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Shannon M, Gu Y, Nguyen C;
PI
XX
XX WPI, 2003-423107/40.
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 480; 103bp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, or MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27 or MD212, e.g. cancer.

CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1219 GTCAGAGCTCCAGCAT 1235
Db 17 GTCAGGTCCTCCACCAT 1

RESULT 550
ADB00169/C
ID ADB00169 standard; DNA; 17 BP.
XX
AC ADB00169;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MD23 scanning oligonucleotide SEQ ID 1155.
XX
KM Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
XX EPI281758-A2.
PN
XX
XX 05-FEB-2003.
PD
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
PI
PI WPI; 2003-423107/40.
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
PT
XX
PS Example 8; SEQ ID NO 1155; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
CC

XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1371 TACCAGAGCAGCTGCG 1387
Db 17 TTCCAGAGGAGGCTGTG 1

RESULT 551
ADB05267
ID ADB05267 standard; DNA; 17 BP.
XX
AC ADB05267;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MD212 scanning oligonucleotide SEQ ID 6253.
XX
KM Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
XX EPI281758-A2.
PN
XX
XX 05-FEB-2003.
PD
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
PI
PI WPI; 2003-423107/40.
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
PT
XX
PS Example 8; SEQ ID NO 6253; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
CC
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1284 AGAGACCTCAGGCTGC 1300

Db 1 AGAGACCCTATGAGTGC 17

RESULT 552
ADB02346/c
ID ADB02346 standard; DNA; 17 BP.

AC ADB02346;

DT 20-NOV-2003 (first entry)

DE Human MD24 scanning oligonucleotide SEQ ID 3332.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.

OS Homo sapiens.

PI EP1281758-A2.

PN 05-FEB-2003.

PF 30-JUL-2002; 2002EP-00016874.

PR 02-AUG-2001; 2001US-00922181.

PA (AEOM-) AEOMICA INC.

PI Shannon M, Gu Y, Nguyen C;

DR WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in
XX manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MD212, e.g. cancer.

XX Example 8; SEQ ID NO 3332; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX acids can also be used as probes to detect and characterize gross
XX alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

XX 1276 CTGAGGCGAGACCT 1292

XX 17 CTGATGCGAGGCTCTCT 1

RESULT 553

ADB00361
ID ADB00361 standard; DNA; 17 BP.

AC ADB00361;
XX 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 1347.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.

OS Homo sapiens.

PI EP1281758-A2.

PN 05-FEB-2003.

PF 30-JUL-2002; 2002EP-00016874.

PR 02-AUG-2001; 2001US-00922181.

PA (AEOM-) AEOMICA INC.

PI Shannon M, Gu Y, Nguyen C;

DR WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in
XX manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MD212, e.g. cancer.

XX Example 8; SEQ ID NO 1347; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX acids can also be used as probes to detect and characterize gross
XX alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

XX 1255 TGCAGCAACGCTGGAA 1271

XX 1 TGCAGCGAGTGTGGAA 17

RESULT 554

ACD63387
ID ACD63387 standard; RNA; 17 BP.

AC ACD63387;

DT 30-SEP-2003 (first entry)

DE HCV minus strand DNAzyme substrate sequence #1026.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;

KW enzymatic nucleic acid; hammerhead ribozyme; DNase; inosine; zinkine;
KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; anti-inflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002MO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
XX (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P,
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 293; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNases,
CC inozymes, zinkines, amberyne, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNase or minus strand DNase sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
QY 1321 TAGGAGACTTCTCC 1337
Db :|||||: :|||:
1 TAGGAGAGGUTUUC 17
RESULT 555

ACC6444/c
ID ACC6444 standard; DNA; 17 BP.
XX
AC ACC6444;
XX
DT 01-JUL-2003 (first entry)
XX
XX Murine oligonucleotide associated with tumour suppression, SEQ ID 1691.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002MO-IB04210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumours and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; Page 228; 738pp; French.
XX
PS The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1406 CAGACCGGCTGAC 1422
Db :|||||: :|||:
1 CAAACTGGGCTGATC 1
RESULT 556
ACC63082
ID ACC63082 standard; DNA; 17 BP.
XX
AC ACC63082;
XX
DT 01-JUL-2003 (first entry)
XX
XX Murine oligonucleotide associated with tumour suppression, SEQ ID 329.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX

OS Mus musculus.
XX WO2003025176-A2.
XX 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004210.
XX 17-SEP-2001; 2001FR-00011979.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Tejerman A, Amson R, Tuijnder M;
XX WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; Page 69; 738pp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX recombinant polypeptides. The oligonucleotides are useful for preparation
XX of pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia
XX
XX Sequence 17 BP; 1 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
DY 1223 GACCTCCAGCATGTC 1239
Db 1 GATCCTCTGCTTGTC 17
RESULT 557
ACC67926
ID ACC67926 standard; DNA; 17 BP.
XX
XX ACC67926;
XX
XX 01-JUL-2003 (first entry)
XX
XX Murine oligonucleotide associated with tumour suppression, SEQ ID 5173.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; ss.
XX
XX Mus musculus.
XX
XX WO2003025176-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004210.
XX
XX 17-SEP-2001; 2001FR-00011979.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Tejerman A, Amson R, Tuijnder M;
XX

DR WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; Page 635; 738pp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX recombinant polypeptides. The oligonucleotides are useful for preparation
XX of pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia
XX
XX Sequence 17 BP; 3 A; 4 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
DY 1326 GACCTCTTCAGGTC 1342
Db 1 GATCTTTTTCAGGTC 17
RESULT 558
ACC68650
ID ACC68650 standard; DNA; 17 BP.
XX
XX ACC68650;
XX
XX 01-JUL-2003 (first entry)
XX
XX Murine oligonucleotide associated with tumour suppression, SEQ ID 5897.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; ss.
XX
XX Mus musculus.
XX
XX WO2003025176-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004210.
XX
XX 17-SEP-2001; 2001FR-00011979.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Tejerman A, Amson R, Tuijnder M;
XX WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; Page 720; 738pp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of a

CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match	4.8%	Score 12.2	DB 1	Length 17
Best Local Similarity	82.4%	Pred. No. 3.1e+02		
Matches 14, Conservative	0	Mismatches 3	Indels 0	Gaps 0

Qy 1387 GTTTGCTGAGCTGCTG 1403
| | | | | | | | | |
Db 1 GATCTGCCGAGCTGCTG 17

RESULT 559
ACC63303/c
ID ACC63303 standard; DNA; 17 BP.

AC ACC63303;

DT 01-JUL-2003 (First entry)

DE Murine oligonucleotide associated with tumour supression, SEQ ID 550.

KM Cyrostatic; virucide; neuroprotective; nootropic; neuroleptic; murine
KM Tumour suppression; tumour reversion; apoptosis; virus resistance;
KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; ss.

Mus musculus.

PN W02003025176-A2.

PD 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004210.

PR 17-SEP-2001; 2001FR-00011979.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-333167/31.

PT New isolated nucleic acid, useful for treating viral diseases associated with tumors and cell degeneration, also related polypeptides, antibodies and transfected cells.

PS Disclosure; Page 95; 738pp; French.

The present invention relates to murine oligonucleotides (ACCG2754-ACCG8986), which are associated with tumour suppression, tumour reversion, apoptosis and virus resistance. The oligonucleotides are useful as (1) as probes and primers for detecting, identifying, quantifying and/or amplifying nucleic acid, e.g. as one component of a gene chip; in vitro as (anti)sense reagents; and (2) for production of recombinant polypeptides. The oligonucleotides are useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrenia.

SQ Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

Query Match	4.8%	Score 12.2	DB 1	Length 17
Best Local Similarity	82.48%	Pred. No. 3.1e+02		
Matches 14; Conservative	0	Mismatches 3	Indels 0	Gaps 0

QY 1358 GGCAGCTGAGGCTTACC 1374

Db 17 GGTAGCTGAGGCTGATC 1

```

RESULT 560
ADB41888
ID ADB41888 standard; DNA; 17 BP.

```

AC ADB41888;

DT	18-DEC-2003	(revised)
DT	04-DEC-2003	(first entry)

DE Tumour suppression/reversion associated nucleotide #2211.

KM cytosstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KM primer; probe; tumour suppression; tumour reversion; apoptosis;
KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KM diagnosis.

Homo sapiens.

PN WO2003040369-A2.

PD 15-MAY-2003.

PF 17-SEP-2002; 2002WO-IB004219.

PR 17-SEP-2001; 2001FR-00011981.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-441574/41.

PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.

PS Disclosure; Page 290; 771pp; French.

CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and/or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.

Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match	4.8%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 3.1e+01;		
Matches 14; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

QY 1186 GCTCCCGAGAAGCCTGTG 1202

Db 1 GATCCAAGTAGCCTGTG 17

RESULT 561

ADC04891/C
ID ADC04891 standard; DNA; 17 BP.
XX
AC ADC04891;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1338.
XX
KM ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
NM NHEPL1; passive replacement therapy; vaccine; diagnosis.
XX
OS Homo sapiens.
XX
PN Epi273660-A2.
XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
XX New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHEPL1.
XX
XX Example 2; SEQ ID NO 1378; 468bp; English.
XX
PS The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
CC exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHEPL1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHEPL1 gene (ADC05114).
XX
SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1230 CAGCATGTGCTGCAAGT 1246
Db 17 CATCATGTGTGAAGT 1
XX
RESULT 562
ADC37824
ID ADC37824 standard; DNA; 17 BP.
XX
AC ADC37824;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:173.
XX
KM human; angiotensin-like protein 1; AMLP1; cytotostatic; gene therapy;

KM AMLP1a; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
XX New isolated nucleic acid molecule encoding a human angiotensin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
XX Example 2; SEQ ID NO 173; 172bp; English.
XX
PS The present invention describes the human angiotensin-like protein 1
CC (AMLP1). human AMLP1 has cytotostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1256 GCAGCAACAGCTGGAAG 1272
Db 1 GCAGCAACAGCAGCAGG 17
XX
RESULT 563
ADC37822
ID ADC37822 standard; DNA; 17 BP.
XX
AC ADC37822;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:171.
XX
KM human; angiotensin-like protein 1; AMLP1; cytotostatic; gene therapy;
NM AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;

DR WPI; 2003-430501/40.
XX
XX New isolated nucleic acid molecule encoding a human angiometin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
XX Example 2; SEQ ID NO 171; 172pp; English.
XX
CC The present invention describes the human angiometin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 7 A; 6 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1254 CTGCAGCAACAGCTGGA 1270
Db 1 CAGCAGCAACAGCAGCA 17
RESULT 564
ADD21021
ID ADD21021 standard; DNA; 17 BP.
XX
XX ADD21021;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human GAP_N DNA 17-mer oligo #253.
XX
XX gene therapy; antibody therapy; modulator of GAPN;
XX GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
XX
XX Homo sapiens.
XX
XX WO2003033703-A2.
XX
XX 24-APR-2003.
XX
XX 11-OCT-2002; 2002WO-US032597.
XX
XX 15-OCT-2001; 2001US-0330323P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Zhang J;
XX
XX WPI; 2003-403224/38.
XX
XX Novel human GTP-activator protein for Rab-like GTPase and polynucleotide
PT encoding the protein, useful for diagnosing, treating or preventing
PT disorders associated with increased expression or activity of the
PT protein.
XX
XX Example 2; SEQ ID NO 277; 149pp; English.
XX
XX The invention relates to an isolated human GTP-activator protein for Rab-
CC like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to
CC (I), a sequence in which at least 95% of deviations from (I) are
CC conservative substitutions, or a fragment of at least 8 contiguous amino
CC acids of (I). The polypeptide is useful for identifying a specific
CC binding partner for itself, by contacting the polypeptide in vivo to a
CC potential binding partner and determining if the polypeptide binding
CC partner binds to the polypeptide. (I) and a nucleic acid encoding the
CC polypeptide (II) are useful for diagnosing or monitoring a disease caused

CC by altered expression of GAPN, by determining the level of expression of
CC GAPN in a sample of nucleic acids or proteins that derives from a subject
CC suspected to have the disease, alterations from a normal level of
CC expression providing diagnostic and/or monitoring information. (I), (II)
CC or agonist of (I) is useful for treating or preventing a disorder
CC associated with decreased expression or activity of GAPN, and an
CC antagonist of (I) is useful for treating or preventing a disorder
CC associated with increased expression or activity of GAPN (all claimed).
CC (I) is useful as immunogen to raise antibodies that specifically
CC recognize GAPN proteins. (II) is useful to drive in vivo expression of
CC GAPN proteins, and as hybridization probes to detect, characterize and
CC quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both
CC genomic and transcript-derived nucleic acid samples. This sequence
CC represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1244 AGTGTCTCCGCTGACG 1260
Db 1 AGGAGTCTCCGCTGAGC 17
RESULT 565
ADD21022
ID ADD21022 standard; DNA; 17 BP.
XX
XX ADD21022;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human GAP_N DNA 17-mer oligo #254.
XX
XX gene therapy; antibody therapy; modulator of GAPN;
XX GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
XX
XX Homo sapiens.
XX
XX WO2003033703-A2.
XX
XX 24-APR-2003.
XX
XX 11-OCT-2002; 2002WO-US032597.
XX
XX 15-OCT-2001; 2001US-0330323P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Zhang J;
XX
XX WPI; 2003-403224/38.
XX
XX Novel human GTP-activator protein for Rab-like GTPase and polynucleotide
PT encoding the protein, useful for diagnosing, treating or preventing
PT disorders associated with increased expression or activity of the
PT protein.
XX
XX Example 2; SEQ ID NO 278; 149pp; English.
XX
XX The invention relates to an isolated human GTP-activator protein for Rab-
CC like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to
CC (I), a sequence in which at least 95% of deviations from (I) are
CC conservative substitutions, or a fragment of at least 8 contiguous amino
CC acids of (I). The polypeptide is useful for identifying a specific
CC binding partner for itself, by contacting the polypeptide in vivo to a
CC potential binding partner and determining if the polypeptide binding
CC partner binds to the polypeptide. (I) and a nucleic acid encoding the
CC polypeptide (II) are useful for diagnosing or monitoring a disease caused
CC by altered expression of GAPN, by determining the level of expression of
CC GAPN in a sample of nucleic acids or proteins that derives from a subject

CC suspected to have the disease, alterations from a normal level of
CC expression providing diagnostic and/or monitoring information. (I), (II)
CC or agonist of (I) is useful for treating or preventing a disorder
CC associated with decreased expression or activity of GAPN, and an
CC antagonist of (I) is useful for treating or preventing a disorder
CC associated with increased expression or activity of GAPN (all claimed).
CC (I) is useful as immunogen to raise antibodies that specifically
CC recognize GAPN proteins. (II) is useful to drive in vivo expression of
CC GAPN proteins, and as hybridization probes to detect, characterize and
CC quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both
CC genomic and transcript-derived nucleic acid samples. This sequence
CC represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.
XX

SO Sequence 17 BP; 2 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1245 GTGCTCGGCTGCAGCA 1261
DB 1 GGGGTCCTGGAGCA 17

RESULT 566
ADD21024
ID ADD21024 standard; DNA; 17 BP.

XX AC ADD21024;
XX DT 15-JAN-2004 (first entry)
XX DE Human GAP_N DNA 17-mer oligo #256.

XX KW gene therapy; antibody therapy; modulator of GAPN;
XX KW GTP-activator for Rab-like GTPase; GAP_N; immunogen; ss.
XX OS Homo sapiens.

XX PN WO200303703-A2.
XX PD 24-APR-2003.

XX PF 11-OCT-2002; 2002MO-US032597.
XX PR 15-OCT-2001; 2001US-0330323P.

XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX PI Zhang J;
XX DR WPI; 2003-403224/38.

XX PT Novel human GTP-activator protein for Rab-like GTPase and polynucleotide
XX PT encoding the protein, useful for diagnosing, treating or preventing
XX PT disorders associated with increased expression or activity of the
XX PT protein.
XX PS Example 2; SEQ ID NO 280; 149bp; English.

XX CC The invention relates to an isolated human GTP-activator protein for Rab-
XX CC like GTPase (GAPN) polypeptide (I), a sequence having 65% identity to
XX CC (I), a sequence in which at least 95% of deviations from (I) are
XX CC conservative substitutions, or a fragment of at least 8 contiguous amino
XX CC acids of (I). The polypeptide is useful for identifying a specific
XX CC binding partner for itself, by contacting the polypeptide in vivo to a
XX CC potential binding partner and determining if the polypeptide binding
XX CC partner binds to the polypeptide. (I) and a nucleic acid encoding the
XX CC polypeptide (II) are useful for diagnosing or monitoring a disease caused
XX CC by altered expression of GAPN, by determining the level of expression of
XX CC GAPN in a sample of nucleic acids or proteins that derives from a subject
XX CC suspected to have the disease, alterations from a normal level of
XX CC expression providing diagnostic and/or monitoring information. (I), (II)

CC or agonist of (I) is useful for treating or preventing a disorder
CC associated with decreased expression or activity of GAPN, and an
CC antagonist of (I) is useful for treating or preventing a disorder
CC associated with increased expression or activity of GAPN (all claimed).
CC (I) is useful as immunogen to raise antibodies that specifically
CC recognize GAPN proteins. (II) is useful to drive in vivo expression of
CC GAPN proteins, and as hybridization probes to detect, characterize and
CC quantify GAPN nucleic acids in and isolate GAPN nucleic acids from both
CC genomic and transcript-derived nucleic acid samples. This sequence
CC represents a 17-mer oligonucleotide spanning the GAP_N DNA sequence.
XX

SO Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1247 GGTCTCGGCTGCAGCAC 1263
DB 1 GTCTCCGCTGGAGCAC 17

RESULT 567
AD151595/C
ID AD151595 standard; DNA; 17 BP.

XX AC AD151595;
XX DT 15-APR-2004 (first entry)

XX DE Human tumour suppression/reversion-related DNA sequence SegID4098.
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW cytoskeletal; virocidic; neuroprotective; neuroleptic; probe;
XX KW primer; PCR; gene chip; antisense; viral disease; tumour;
XX KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX OS Homo sapiens.
XX PN WO2003025177-A2.
XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002MO-IB004523.
XX PR 17-SEP-2001; 2001FR-00011980.

XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Teلمان A, Amson R, Tuijnder M;
XX DR WPI; 2003-313354/30.

XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumours and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; SEQ ID NO 4098; 30pp; French.

XX CC This invention relates to novel isolated nucleic acid sequences involved
XX CC in the phenomena of tumour suppression, tumour reversion, apoptosis
XX CC and/or resistance to viruses. The invention may be useful for the
XX CC development of compounds with a cytostatic, virocidic, neuroprotective,
XX CC neuroleptic or neuroleptic activity. The DNA sequences may be useful as
XX CC probes and primers for detecting, identifying, quantifying and/or
XX CC amplifying nucleic acid, for example as one component of a gene chip, in
XX CC vitro as antisense reagents and for production of recombinant
XX CC polypeptides. The invention may therefore be useful for preparation of
XX CC pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia. The
XX CC present sequence is that of a nucleic acid sequence of the invention.
XX CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1210 CAGCATCTGCAGAAC 1226
DB 17 CTGCATCTGCAGATC 1

RESULT 568

ADM09584/C
ID ADM09584 standard; RNA; 17 BP.

AC ADM09584;

DT 20-MAY-2004 (first entry)

XX Human NOGO receptor amberzyme substrate sequence #139.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor amberzyme; substrate; ss.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PF 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeblerl P, Mcswigen J, Fossnaugh K;

XX WPI; 2003-058513/05.

DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 979; 317bp; English.

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor amberzyme substrate sequence.

XX
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1283 CAGAGCCCTCAGGATG 1299
DB 17 CAGAGTCCCAAGGATG 1

RESULT 569

ADM09561
ID ADM09561 standard; RNA; 17 BP.

AC ADM09561;

DT 20-MAY-2004 (first entry)

XX Human NOGO receptor amberzyme substrate sequence #116.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor amberzyme; substrate; ss.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PF 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeblerl P, Mcswigen J, Fossnaugh K;

XX WPI; 2003-058513/05.

DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 956; 317bp; English.

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor amberzyme substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 7 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
QY 1359 GCAGCTGAGGCTTACCA 1375
Db 1 GCCGCTGGGCGCUCCCA 17
RESULT: 570
ADL49613
ID ADL49613 standard; RNA; 17 BP.
XX
AC ADL49613;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #727.
XX
KM antisense oligonucleotide; neurite growth inhibitor; NOGO;
KM prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KM protein kinase PKR; cerebrovascular accident;
KM central nervous system injury; CNS injury; spinal cord injury; cancer;
KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KM resectosis; asthma; Crohn's disease; diabetes; obesity;
KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KM graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KM allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KM substrate; ds.
XX
OS Unidentified.
XX
PN W0200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blact L, Chowitra B, Haebertl P, Mcswiggen J, Fornaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 3146; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC resectosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 3 C; 5 G; 0 T; 6 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
QY 1303 TGTTCATCTGTGACGAG 1319
Db 1 UGUGAUCUCUUCACACAG 17
RESULT: 571
ADL46693/C
ID ADL46693 standard; RNA; 17 BP.
XX
AC ADL46693;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor inozyme substrate sequence #126.
XX
KM antisense oligonucleotide; neurite growth inhibitor; NOGO;
KM prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KM protein kinase PKR; cerebrovascular accident;
KM central nervous system injury; CNS injury; spinal cord injury; cancer;
KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KM resectosis; asthma; Crohn's disease; diabetes; obesity;
KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KM graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KM allergy; asthma; allergic rhinitis; atopic dermatitis;
KM NOGO receptor inozyme; substrate; ds.
XX
OS Unidentified.
XX
PN W0200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blact L, Chowitra B, Haebertl P, Mcswiggen J, Fornaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 226; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC resectosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1244 AGTGTCCGCTGCAGC 1260
DB 17 AGCGTCCAGGTGCAGC 1
RESULT 572
ADL49927/c
ID ADL49927 standard; RNA; 17 BP.
XX
AC ADL49927;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1041.
XX
KM antisense oligonucleotide; neurite growth inhibitor; NOGO;
KM prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
KM protein kinase PKR; cerebrovascular accident;
KM central nervous system injury; CNS injury; spinal cord injury; cancer;
KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KM restenosis; asthma; Crohn's disease; diabetes; obesity;
KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KM graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KM allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KM substrate; ds.
XX
OS Unidentified.
XX
XX MO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002MO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerl P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor; prostaglandin D2 receptor; Ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 3460; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 9 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1272 GAGGCTGAGGCGAGGA 1288
DB 17 GAGGCTGAGGCGAGGA 1
RESULT 573
ADL50179/c
ID ADL50179 standard; RNA; 17 BP.
XX
AC ADL50179;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1293.
XX
KM antisense oligonucleotide; neurite growth inhibitor; NOGO;
KM prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
KM protein kinase PKR; cerebrovascular accident;
KM central nervous system injury; CNS injury; spinal cord injury; cancer;
KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KM restenosis; asthma; Crohn's disease; diabetes; obesity;
KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KM graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KM allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KM substrate; ds.
XX
OS Unidentified.
XX
XX MO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002MO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerl P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor; prostaglandin D2 receptor; Ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 3742; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
SQ Sequence 17 BP; 6 A; 4 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1341 GCAGAGACTTCCAG 1357
DB 17 GCAGACTACTTTCAG 1

RESULT 574
ADM09496/C
ID ADM09496 standard; RNA; 17 BP.

AC ADM09496;

DT 20-MAY-2004 (first entry)

DE Human NOGO receptor amberzyme substrate sequence #51.

XX antiense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaalandin D2 receptor; PTGDR; Ikappab kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor amberzyme; substrate; ss.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

PF 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Chowrita B, Haeblerl P, Mcswiggen J, Fornaugh K;

DR WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
PS Claim 9; SEQ ID NO 891; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor amberzyme substrate sequence.

SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1242 GCAGTGTCCCGCTGCA 1258
DB 17 GCAGCGTCCAGTGTCA 1

RESULT 575
ADM09585/C
ID ADM09585 standard; RNA; 17 BP.

AC ADM09585;

DT 20-MAY-2004 (first entry)

DE Human NOGO receptor amberzyme substrate sequence #140.

XX antiense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaalandin D2 receptor; PTGDR; Ikappab kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor amberzyme; substrate; ss.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

PF 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Chowrita B, Haeblerl P, Mcswiggen J, Fornaugh K;

DR WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
PS Claim 9; SEQ ID NO 980; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor amberzyme substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1282 GCAGAGACCTCAGGCT 1298
DB 17 GCAGAGTCCCAAGGCT 1
RESULT 576
ADM09586/C
ID ADM09586 standard; RNA; 17 BP.
XX
AC ADM09586;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor amberzyme substrate sequence #141.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostatic androgen receptor; PTGDR; Ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor amberzyme; substrate; ss.
XX
OS unidentified.
XX
PN MO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002MO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blact L, Chowrira B, Haeblerl P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
BS Claim 9; SEQ ID NO 981; 317bp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor amberzyme substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1281 GGCAGAGACCTCAGG 1297
DB 17 GCAGAGTCCCAAGGCT 1
RESULT 577
ADM55922/C
ID ADM55922 standard; mRNA; 17 BP.
XX
AC ADM55922;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human GRID mRNA substrate sequence #524.
XX
XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
KW NCH ribozyme; G-cleaver ribozyme; zinczyme; DNAzyme; inozyme;
KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX
OS Homo sapiens.
XX
PN US2003134806-A1.
XX
PD 17-JUN-2003.
XX
PF 23-FEB-2001; 2001US-00792818.
XX
PR 10-FEB-2000; 2000US-0181594P.
XX
PA (JARV/) JARVIS T.
PA (CARL/) CARLOWITZ I V.
PA (MCSW/) MCSWIGGEN J.
PA (HAMB/) HAMBLIN P A.
PA (ELLIS/) ELLIS J H.
XX
PI Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
XX
DR WPI; 2003-829646/77.
XX
XX New nucleic acid molecule that down-regulates expression of Grb2-related
PT with insert domain (GRID) gene, useful for treating a condition
PT associated with the level of GRID, e.g. tissue/graft rejection and
PT leukemia.
XX
BS Claim 4; SEQ ID NO 524; 74bp; English.
XX
XX The invention relates to a nucleic acid molecule that down-regulates
CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, zinczyme, DNAzyme,
CC amberzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell
CC including the novel nucleic acid molecule, reducing GRID activity in a
CC cell by contacting the cell with the novel nucleic acid molecule,
CC treating a patient having a condition associated with the level of GRID
CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
CC contacting the cell with the novel nucleic acid molecule, an expression
CC vector comprising a nucleic acid sequence (encoding at least the novel
CC nucleic acid molecule in a manner that allows its expression), a
CC mammalian cell including the expression vector and an enzymatic nucleic
CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
CC molecule is useful for treating a condition associated with the level of
CC GRID, e.g. tissue/graft rejection and leukemia. The present sequence is
CC a target region for the enzymatic nucleic acids of the invention.
XX

SQL Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1252 GGCTGACGACGACGCTG 1268
17 GGCTGCTGCGACTGCTG 1
DB
RESULT 578
ADM54085
ID ADM54085 standard; mRNA; 17 BP.
AC ADM54085;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human GRID mRNA substrate sequence #360.
XX
KW Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
KW NCH ribozyme; G-cleaver ribozyme; Zinzyne; DNazyme; amberzyme; Inozyme;
KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX
OS Homo sapiens.
XX
PN US2003134806-A1.
XX
PD 17-JUL-2003.
XX
PR 23-FEB-2001; 2001US-00792818.
XX
PR 10-FEB-2000; 2000US-0181594P.
XX
PA (JARV/) JARVIS T.
PA (CARL/) CARLOWITZ I V.
PA (MCSW/) MCSWIGEN J.
PA (HAMB/) HAMBLIN P A.
PA (ELLI/) ELLIS J H.
PI Jarvis T, Carlowitz IV, Mcswigen J, Hamblin PA, Ellis JH;
XX
DR WPI; 2003-829646/77.
XX
PT New nucleic acid molecule that down-regulates expression of Grb2-related
PT with insert domain (GRID) gene, useful for treating a condition
PT associated with the level of GRID, e.g. tissue/graft rejection and
PT leukemia.
XX
PS Claim 4; SEQ ID NO 360; 74pp; English.
XX
CC The invention relates to a nucleic acid molecule that down-regulates
CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyne, DNazyme,
CC amberzyme, Inozyme or hairpin ribozyme. Also include are a mammalian cell
CC including the novel nucleic acid molecule, reducing GRID activity in a
CC cell by contacting the cell with the novel nucleic acid molecule,
CC treating a patient having a condition associated with the level of GRID
CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
CC contacting the cell with the novel nucleic acid molecule, an expression
CC vector comprising a nucleic acid sequences (encoding at least the novel
CC nucleic acid molecule in a manner that allows its expression), a
CC mammalian cell including the expression vector and an enzymatic nucleic
CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
CC molecule is useful for treating a condition associated with the level of
CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
CC a target region for the enzymatic nucleic acids of the invention.
XX
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 0 T; 1 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1250 CCGCTGACGACGACGAC 1266
1 CCUGCAGCAGCACGACG 17
DB
RESULT 579
ADM54108/C
ID ADM54108 standard; mRNA; 17 BP.
AC ADM54108;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human GRID mRNA substrate sequence #383.
XX
KW Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
KW NCH ribozyme; G-cleaver ribozyme; Zinzyne; DNazyme; amberzyme; Inozyme;
KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX
OS Homo sapiens.
XX
PN US2003134806-A1.
XX
PD 17-JUL-2003.
XX
PR 23-FEB-2001; 2001US-00792818.
XX
PR 10-FEB-2000; 2000US-0181594P.
XX
PA (JARV/) JARVIS T.
PA (CARL/) CARLOWITZ I V.
PA (MCSW/) MCSWIGEN J.
PA (HAMB/) HAMBLIN P A.
PA (ELLI/) ELLIS J H.
PI Jarvis T, Carlowitz IV, Mcswigen J, Hamblin PA, Ellis JH;
XX
DR WPI; 2003-829646/77.
XX
PT New nucleic acid molecule that down-regulates expression of Grb2-related
PT with insert domain (GRID) gene, useful for treating a condition
PT associated with the level of GRID, e.g. tissue/graft rejection and
PT leukemia.
XX
PS Claim 4; SEQ ID NO 383; 74pp; English.
XX
CC The invention relates to a nucleic acid molecule that down-regulates
CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyne, DNazyme,
CC amberzyme, Inozyme or hairpin ribozyme. Also include are a mammalian cell
CC including the novel nucleic acid molecule, reducing GRID activity in a
CC cell by contacting the cell with the novel nucleic acid molecule,
CC treating a patient having a condition associated with the level of GRID
CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
CC contacting the cell with the novel nucleic acid molecule, an expression
CC vector comprising a nucleic acid sequences (encoding at least the novel
CC nucleic acid molecule in a manner that allows its expression), a
CC mammalian cell including the expression vector and an enzymatic nucleic
CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
CC molecule is useful for treating a condition associated with the level of
CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
CC a target region for the enzymatic nucleic acids of the invention.
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OS Cucurbita.
OS Synthetic.
XX
XX MO2004033708-A2.
XX
XX PD 22-APR-2004.
XX
XX PF 07-OCT-2003; 2003WO-US031862.
XX
XX PR 07-OCT-2002; 2002US-0416983P.
XX
XX PR 07-MAR-2003; 2003US-0453360P.
XX
XX PA (UYDE) UNIV DELAWARE.
XX
XX PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
XX PI Kmiec EB, Van Brabant A;
XX
XX DR WPI, 2004-340941/31.
XX
XX PT Identifying a cell with a desired oligonucleotide-directed sequence
XX alteration at a nucleic acid target site within the cell by identifying
XX the desired sequence alteration in cells selected for the presence of a
XX selectable phenotype.
XX
XX PS Example 25; SEQ ID NO 1163; 303pp; English.
XX
XX CC This invention relates to a novel method of identifying a cell having a
XX desired oligonucleotide-directed sequence alteration at a first nucleic
XX acid target site within the cell. The method comprises identifying the
XX desired sequence alteration in cells that have been selected for the
XX presence of a selectable phenotype conferred by a concurrent
XX oligonucleotide-directed sequence alteration at a second nucleic acid
XX target site within the cells. The method is useful in identifying a cell
XX having a desired oligonucleotide-directed sequence alteration at a first
XX nucleic acid target site within the cell. The method may be useful for
XX the production of plants with herbicide resistance, male or female
XX sterile plants, abiotic stress tolerance, albino plants or plants with
XX altered amino acid production as well as for use in mammalian cell lines.
XX The present sequence is that of a mutagenic oligonucleotide which was
XX used in the exemplification of the invention.
XX
XX SQ Sequence 17 BP; 2 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 1191 CAGAAGCCTGTGCAGAG 1207
XX DB 17 CACAACTATGCAGAG 1
XX
XX RESULT 583
XX ADN44474/C
XX ID ADN44474 standard; DNA; 17 BP.
XX
XX AC ADN44474;
XX
XX DT 15-JUL-2004 (first entry)
XX
XX DE Mutant cell identification-related mutagenic oligonucleotide SeqID1143.
XX
XX KW cell identification; oligonucleotide-directed sequence alteration;
XX selectable phenotype; transgenic plant; herbicide resistance;
XX sterile plant; abiotic stress tolerance; albino plant;
XX amino acid production; ss.
XX
XX OS Cucumis sativus.
XX OS Synthetic.
XX
XX PN WO2004033708-A2.
XX
XX PR 07-MAR-2003; 2003US-0453360P.
XX
XX PR 22-APR-2004.

XX
XX PF 07-OCT-2003; 2003WO-US031862.
XX
XX PR 07-OCT-2002; 2002US-0416983P.
XX
XX PR 07-MAR-2003; 2003US-0453360P.
XX
XX PA (UYDE) UNIV DELAWARE.
XX
XX PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
XX PI Kmiec EB, Van Brabant A;
XX
XX DR WPI, 2004-340941/31.
XX
XX PT Identifying a cell with a desired oligonucleotide-directed sequence
XX alteration at a nucleic acid target site within the cell by identifying
XX the desired sequence alteration in cells selected for the presence of a
XX selectable phenotype.
XX
XX PS Example 25; SEQ ID NO 1143; 303pp; English.
XX
XX CC This invention relates to a novel method of identifying a cell having a
XX desired oligonucleotide-directed sequence alteration at a first nucleic
XX acid target site within the cell. The method comprises identifying the
XX desired sequence alteration in cells that have been selected for the
XX presence of a selectable phenotype conferred by a concurrent
XX oligonucleotide-directed sequence alteration at a second nucleic acid
XX target site within the cells. The method is useful in identifying a cell
XX having a desired oligonucleotide-directed sequence alteration at a first
XX nucleic acid target site within the cell. The method may be useful for
XX the production of plants with herbicide resistance, male or female
XX sterile plants, abiotic stress tolerance, albino plants or plants with
XX altered amino acid production as well as for use in mammalian cell lines.
XX The present sequence is that of a mutagenic oligonucleotide which was
XX used in the exemplification of the invention.
XX
XX SQ Sequence 17 BP; 2 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 4.8%; Score 12.2; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 3.1e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 1191 CAGAAGCCTGTGCAGAG 1207
XX DB 17 CACAACTATGCAGAG 1
XX
XX RESULT 584
XX ADN44495
XX ID ADN44495 standard; DNA; 17 BP.
XX
XX AC ADN44495;
XX
XX DT 15-JUL-2004 (first entry)
XX
XX DE Mutant cell identification-related mutagenic oligonucleotide SeqID1164.
XX
XX KW cell identification; oligonucleotide-directed sequence alteration;
XX selectable phenotype; transgenic plant; herbicide resistance;
XX sterile plant; abiotic stress tolerance; albino plant;
XX amino acid production; ss.
XX
XX OS Cucurbita.
XX OS Synthetic.
XX
XX PN WO2004033708-A2.
XX
XX PR 22-APR-2004.
XX
XX PF 07-OCT-2003; 2003WO-US031862.
XX
XX PR 07-OCT-2002; 2002US-0416983P.
XX
XX PR 07-MAR-2003; 2003US-0453360P.
XX
XX PR 22-APR-2004.

PA (UYDE) UNIV DELAWARE.
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
PI Kmiec EB, Van Brabant A;
XX
DR WPI; 2004-340941/31.
XX
PT Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
PS Example 25; SEQ ID NO 1164; 303pp; English.
CC This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.
SQ Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1191 CAGAGCCTGTGCAGAG 1207
DB 1 CACAAACCTATGCAGAG 17
RESULT 585
AADD61809/C
ID AADD61809 standard; DNA; 14 BP.
XX
AC AAD61809;
XX
DT 15-JAN-2004 (first entry)
XX
DE Rat IGFBP-3 gene IRE palindromic DNA.
XX
KW Insulin-responsive DNA binding protein-1; IRDBP-1; diabetes; obesity;
KW insulin-resistant syndrome; cell proliferative disorder; gene therapy;
KW cancer; insulin-like growth factor binding protein; IGFBP; IRE; rat;
KW insulin responsive element; ds.
XX
OS Rattus norvegicus.
XX
PN US2003125296-A1.
XX
PD 03-JUL-2003.
XX
PF 04-DEC-2002; 2002US-00310002.
XX
PR 01-NOV-2000; 2000US-00703559.
PR 04-DEC-2001; 2001US-033585P.
PR 18-JUN-2002; 2002US-0390000P.
XX
PA (VILL/) VILLAFUERTE B C.
XX
PI Villafuerte BC;
XX
DR WPI; 2003-811002/76.
XX

PT New nucleic acids encoding an insulin-responsive DNA binding protein-1
PT (IRDBP-1), useful for treating diabetes, obesity, insulin-resistant
PT syndrome, cell proliferative disorders, e.g. cancer of the lungs, colon,
PT breast or kidney.
PS Example 1; Page 26; 178pp; English.
XX
CC The present invention relates to novel insulin-responsive DNA binding
CC protein-1 (IRDBP-1) and to nucleic acid molecule encoding such protein.
CC Nucleic acids, polypeptides and methods of the invention are useful for
CC treating diabetes, obesity, insulin-resistant syndrome and cell
CC proliferative disorders e.g. cancer of the lungs, colon, breast and
CC kidneys. The invention is also useful in gene therapy. The present
CC sequence is rat insulin-like growth factor binding protein (IGFBP)-3 gene
CC insulin responsive element (IRE) palindromic DNA. This sequence is used
CC in the invention
XX
SQ Sequence 14 BP; 4 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1343 AGGAGACTTTC 1354
DB 13 AGGAGACTTTC 2
RESULT 586
AAT54816/C
ID AAT54816 standard; RNA; 15 BP.
XX
AC AAT54816;
XX
DT 25-MAR-2003 (revised)
DT 07-APR-1997 (first entry)
XX
DE Mouse re1a hammerhead ribozyme target sequence (nt. position 129).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW Philadelphia chromosome; myelogenous leukaemia; CML; cancer;
KW atherosclerosis; myocardial infarction; autoimmune disease;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW 89.
XX
OS Mus musculus.
XX
PN W09523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.
XX
PR 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
XX

PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpelisky A, Kisch K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Traetz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX
XX
XX Claim 2; Page 225; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves rRNA at the
XX nucleoside base position indicated in the DE line. The rRNA gene product
XX is a subunit of the transcriptional regulator NF-kappaB and is implicated
XX specifically in the induction of inflammatory responses. Regions of the
XX mRNA that do not form secondary folding structures and that contain
XX potential hammerhead and hairpin ribozyme cleavage sites were identified
XX by computer analysis. Ribozymes directed against these mRNA sequences
XX were designed and synthesised with modifications that improve the target
XX cleavage resistance. The ribozymes are designed to cleave the target
XX sequences and thereby inhibit rRNA expression, making them potentially
XX useful for treating rheumatoid arthritis, restenosis and asthma as well
XX as for increasing tolerance to transplanted tissues. The potential
XX immunosuppressive properties of a ribozyme that cleaves rRNA means
XX that uses are limited to local delivery, acute indications or ex vivo
XX treatment. (Updated on 25-MAR-2003 to correct PI field.)
XX
XX
XX Sequence 15 BP; 1 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1189 CCCGAGAGCCTG 1200
DB 12 CCCGAGAGCCTG 1
RESULT 587
AAC69826
ID AAC69826 standard; RNA; 15 BP.
XX
XX AAC69826;
XX
XX 30-JAN-2001 (first entry)
XX
XX B. coli mred RNAMOT-identified MS2 CP binding site, SEQ ID NO:21.
XX
XX SELEX; systematic evolution of ligands by exponential enrichment;
XX nucleic acid ligand; aptamer; in vitro evolution; iterative selection;
XX MS2 CP binding site; bacteriophage MS2 replicase fragment;
XX RNAMOT program; ss.
XX Escherichia coli.
XX
XX
XX WO200056930-A1.
XX
XX

XX
XX 28-SEP-2000.
PD
XX
XX 20-MAR-2000; 2000MO-US007486.
PF
XX
XX 24-MAR-1999; 99US-00275850.
PR
XX
XX (NEXS-) NEXSTAR PHARM INC.
PA
XX
XX Pagratia N, Gold L, Shtatland T, Javornik B;
PI
XX
XX WPI; 2000-594583/56.
XX
XX
XX Identifying nucleic acid ligands of a target molecule comprises annealing
XX complementary oligonucleotides, partitioning the nucleic acids and
XX amplifying the nucleic acids exhibiting increased affinity.
XX
XX Example 2; Page 76; 264pp; English.
XX
XX The invention relates to a method of identifying nucleic acid ligands of
XX a target molecule from a candidate mixture composed of single stranded
XX nucleic acids, each having a region of randomised sequence and a region
XX of fixed sequence. The method uses modified versions of the SELEX
XX (systematic evolution of ligands by exponential enrichment) method in
XX which the participation of fixed sequences is minimised or eliminated.
XX This method comprises annealing complementary oligonucleotides to the
XX fixed sequences of the candidate mixture, contacting the
XX candidate mixture with the target molecule, partitioning the nucleic
XX acids which have increased affinity relative to the candidate mixture, a
XX and amplifying the nucleic acids exhibiting increased affinity to yield a
XX ligand enriched mixture of nucleic acids. In one embodiment of the
XX invention, one or more regions of fixed sequences is replaced with
XX different fixed sequences, and the binding, partitioning and
XX amplification steps are repeated. In another embodiment, the partitioned
XX nucleic acids are hybridised with a library of single stranded
XX complementary nucleic acids, are then amplified, and the fixed regions of
XX the increased affinity nucleic acids cleaved. In the exemplifications of
XX the invention, a consensus binding site for MS2 CP (bacteriophage MS2
XX replicase fragment was identified by SELEX. MS2 CP binding sites were
XX then identified in the Escherichia coli genomic library by SELEX or by
XX the RNAMOT program. The present sequence represents an E. coli MS2 CP
XX binding site identified by the RNAMOT program
XX
XX
XX Sequence 15 BP; 5 A; 5 C; 4 G; 0 T; 1 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.4e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1255 TGCAGCAACAGC 1266
DB 1 TGCAGCAACAGC 12
RESULT 588
AAF52825
ID AAF52825 standard; DNA; 15 BP.
XX
XX AAF52825;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #3785.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; rubea;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX
XX

OS Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 PD 21-JUN-2000; 2000WO-AU000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA Wraight CJ, Werther GA, Edmondson SR;
 PI WPI; 2001-041421/05.
 DR WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 8; Page 85; 201pp; English.
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SQ Sequence 15 BP; 3 A; 2 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 4.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1235 TGTGCTGGCAGT 1246
 Db 1 TGTGCTGGCAGT 12
 RESULT 589
 AAF50721
 ID AAF50721 standard; DNA; 15 BP.
 XX AAF50721;
 AC AAF50721;
 XX 30-MAR-2001 (first entry)
 DT IGF-I oligonucleotide #1681.
 DE IGF-I oligonucleotide #1681.
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 PD 21-JUN-2000; 2000WO-AU000693.

PD 28-DEC-2000.
 XX 21-JUN-2000; 2000WO-AU000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA Wraight CJ, Werther GA, Edmondson SR;
 PI WPI; 2001-041421/05.
 DR WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 8; Page 71; 201pp; English.
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SQ Sequence 15 BP; 5 A; 5 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 4.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1260 CAAACGCTGGAA 1271
 Db 3 CAAACGCTGGAA 14
 RESULT 590
 AAF50720
 ID AAF50720 standard; DNA; 15 BP.
 XX AAF50720;
 AC AAF50720;
 XX 30-MAR-2001 (first entry)
 DT IGF-I oligonucleotide #1680.
 DE IGF-I oligonucleotide #1680.
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 PD 21-JUN-2000; 2000WO-AU000693.

PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
DR
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenese nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
PS Example 8; Page 71; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenese oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenese
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
SQ Sequence 15 BP; 5 A; 5 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX
Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1260 CACAGCTGGAA 1271
DB 4 CACAGCTGGAA 15
XX
XX
RESULT 591
AAF52819
ID AAF52819 standard; DNA; 15 BP.
XX
AC AAF52819;
XX
XX 30-MAR-2001 (first entry)
DT
XX IGF-I oligonucleotide #3779.
DE
XX
XX Antisenese therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrheoa; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000MO-AU000653.
PF
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX

PI Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenese nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
PS Example 8; Page 85; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenese oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenese
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
SQ Sequence 15 BP; 1 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX
Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1232 GCATGTGCTGCG 1243
DB 4 GCATGTGCTGCG 15
XX
XX
RESULT 592
AAS18274
ID AAS18274 standard; DNA; 15 BP.
XX
AC AAS18274;
XX
XX 25-FEB-2002 (first entry)
DT
XX
XX ASO primer #21 to detect IMPDH2 gene polymorphisms.
DE
XX
XX Human; single nucleotide polymorphism; SNP; IMPDH2; chromosome 3p21.2;
KW IMP dehydrogenase 2; haplotyping; genotyping; cancer; cytoskeletal;
KW allele-specific oligonucleotide; ASO; primer; ss.
XX
XX Homo sapiens.
OS
XX WO200177363-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 11-APR-2001; 2001WO-US011851.
PF
XX 11-APR-2000; 2000US-0196248P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Chew A, Choi JY, Koshy B, Lee HH, Stephens JC;
PI WPI; 2002-041297/05.
DR
XX
XX New isolated polymnucleotide having polymorphic variant of IMP2
PT dehydrogenase gene, useful for studying expression of the gene in vivo,
PT and for testing efficacy of therapeutic agents for cancer in biological
PT system.
XX

```
PS Claim 15; Page 13; 70pp; English.
XX
CC The present invention relates to novel single nucleotide polymorphisms
CC (SNPs) in the human IMP dehydrogenase 2 (IMPDH2) gene located on
CC chromosome 3p21.2, and methods for haplotyping and/or genotyping the
CC IMPDH2 gene in an individual. The methods of the invention make use of
CC allele-specific oligonucleotides (ASOs) as probes and primers and/or
CC primer-extension oligonucleotides for detecting the IMPDH2 gene
CC polymorphisms. The polymorphisms and screened compounds are useful for
CC (developing) treatment of diseases associated with IMPDH2 activity, such
CC as cancer. AAS18254-AAS18279 represent ASO primers for detecting IMPDH2
CC gene polymorphisms
XX
SQ Sequence 15 BP; 2 A; 2 C; 5 G; 5 T; 0 U; 1 Other;

Query Match          4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy      1389 TTTGCTGAGCTGCT 1402
        |||||
        1 TTTGCTGAGCTGCT 14

Db
RESULT 593
AAL41773
ID AAL41773 standard; DNA; 15 BP.
XX
AC AAL41773;
XX
DT 25-APR-2002 (first entry)
XX
DE Human MC2R gene ASO primer SEQ ID NO: 22.
XX
KM Human; melanocortin 2 receptor (adrenocorticotrophic hormone); MC2R;
KW primer; haplotype; familial glucocorticoid deficiency; FGD; cancer;
OS chromosome 18q11.2; SNP; single nucleotide polymorphism; ss.
XX
OS Homo sapiens.
XX
PN WO200202821-A1.
XX
PD 10-JAN-2002.
XX
PF 29-JUN-2001; 2001WO-US021064.
XX
PR 30-JUN-2000; 2000US-0215330P.
XX
PA (GENA-) GENA1SSANCE PHARM INC.
XX
PI Kazemi A, Koshiy B, Lee HH, Sauker EA;
XX
DR WPI; 2002-171650/22.
XX
PT Melanocortin 2 receptor (MC2R) gene polymorphic variants, useful e.g. in
PT studying the expression and function of MC2R and screening candidate
PT drugs for treating familial glucocorticoid deficiency and cancer.
XX
PS Claim 16; Page 14; 79pp; English.
XX
CC The present invention provides the gene, protein and cDNA sequences of
CC the human melanocortin 2 receptor (adrenocorticotrophic hormone) (MC2R).
CC Also identified are a number of single nucleotide polymorphisms (SNPs)
CC found within the sequences. The sequences can be used to find the
CC haplotype of the MC2R gene in an individual and to identify drugs for the
CC treatment of cancer and familial glucocorticoid deficiency. The present
CC sequence is an allele specific primer for the gene of the invention,
CC which is found on chromosome 18q11.2
XX
SQ Sequence 15 BP; 4 A; 5 C; 3 G; 2 T; 0 U; 1 Other;

Query Match          4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy      1227 CTCGACATGNGCT 1240
        |||||
        1 CTCGACGAGAGTCT 14

Db
RESULT 594
ABK34186
ID ABK34186 standard; DNA; 15 BP.
XX
AC ABK34186;
XX
DT 08-MAY-2002 (first entry)
XX
DE Human interleukin 12B (IL12B) gene, allele-specific oligonucleotide #10.
XX
KM Human; interleukin 12B, IL12B, haplotype; SNP; primer; ss;
KW single nucleotide polymorphism; allele-specific oligonucleotide.
XX
OS Homo sapiens.
XX
PN WO200210190-A2.
XX
PD 07-FEB-2002.
XX
PF 30-JUL-2001; 2001WO-US023927.
XX
PR 29-JUL-2000; 2000US-0221436P.
XX
PA (GENA-) GENA1SSANCE PHARM INC.
XX
PI Messer C, Sanchis A;
XX
DR WPI; 2002-188721/24.
XX
PT New genetic variants having polymorphisms in the human interleukin 12B
PT (IL12B) gene, useful for studying the function of IL12B, and for treating
PT disorders affected by expression or function of the IL12B isogene.
XX
PS Claim 16; Page 13; 95pp; English.
XX
CC The invention relates to an isolated polymucleotide, comprising genes and
CC haplotypes of the interleukin 12B (IL12B) gene. The polymucleotide
CC comprises polymorphic sites in the IL12B gene, referred to as PSI-11. The
CC observed and identified haplotypes, isogenes and polymorphisms of the
CC IL12B gene, as well as the locations of these polymorphisms, are fully
CC defined in a table in the specification. Also described is an isolated
CC polypeptide comprising an amino acid sequence which is a polymorphic
CC variant of a reference sequence for the IL12B protein or its fragment.
CC Polynucleotides comprising a polymorphic gene variant or fragment may be
CC used for therapeutic purposes, where a patient could benefit from
CC expression or increased expression of a particular IL12B protein isoform,
CC or an expression vector encoding the isoform may be administered to the
CC patient. IL12B peptide variants may be used to as antigens to generate
CC antibodies specific for the IL12B isoforms, and in drug screening assays.
CC Compositions comprising the polymucleotide of the isogenes may be used to
CC treat disorders affected by expression or function of the IL12B isogene.
CC ABK34177-ABK34231 represent human interleukin 12B gene, allele-specific
CC oligonucleotides of the invention
XX
SQ Sequence 15 BP; 3 A; 5 C; 3 G; 3 T; 0 U; 1 Other;

Query Match          4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy      1299 GCCATGTCATCTCG 1312
        |||||
        2 GCCACGKTCATCTG 15

Db
RESULT 595
```

ABT05303/C
 ID ABT05303 standard; DNA; 15 BP.
 XX
 AC ABT05303;
 XX
 DT 24-OCT-2002 (first entry)
 XX
 DE Human N-acetylglucosaminidase (NAGA) alpha gene ASO probe 11.
 XX
 KW Human; probe; ss; gene therapy; N-acetylglucosaminidase alpha; NAGA;
 KW chromosome 22q13.2-q13.31; lysosomal glycosidase; screening; SNP;
 KW NAGA-related disease; single nucleotide polymorphism; haplotyping;
 KW genotyping.
 XX
 OS Homo sapiens.
 XX
 PN WO200194637-A1.
 XX
 PD 13-DEC-2001.
 XX
 PF 07-JUN-2001; 2001WO-US018456.
 XX
 PR 07-JUN-2000; 2000US-0210110P.
 XX
 PS (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Duda A, Kazemi A, Koshy B, Parks KE;
 XX
 DR WPI; 2002-566449/60.
 XX
 PT New genetic variants of isolated N-acetylglucosaminidase (NAGA), Alpha
 PT gene, useful for therapeutic purposes, for studying the expression and
 PT function of the polynucleotide, and for expressing NAGA protein.
 XX
 PS Claim 16; Page 13; 91pp; English.
 XX
 CC The invention comprises the amino acid and coding sequence of the human N
 CC -acetylglucosaminidase (NAGA) alpha protein. The invention specifically
 CC comprises novel polymorphic sites identified within the NAGA gene. The
 CC NAGA gene is located on chromosome 22q13.2-q13.31, and encodes a
 CC lysosomal glycosidase that cleaves alpha-N-acetylglucosaminyl
 CC moieties in glycoconjugates. The NAGA DNA and protein sequences of the
 CC invention are useful for studying the expression and function of NAGA and
 CC for screening candidate drugs to treat diseases related to NAGA activity.
 CC The NAGA gene polymorphisms identified in the present invention are
 CC useful for haplotyping and genotyping the NAGA gene of an individual. The
 CC present DNA sequence represents an N-acetylglucosaminidase gene allele-
 CC specific oligonucleotide probe
 CC
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 2 G; 4 T; 0 U; 1 Other;
 Query Match 4.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 2.4e+02;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Oy 1275 GCTGGGCGCAGAGA 1288
 Db 15 GCTGGGCGCAGAGA 2
 RESULT 596
 ABT05330
 ID ABT05330 standard; DNA; 15 BP.
 XX
 AC ABT05330;
 XX
 DT 24-OCT-2002 (first entry)
 XX
 DE Human N-acetylglucosaminidase (NAGA) alpha gene ASO primer 22.
 XX
 KW Human; PCR; primer; ss; gene therapy; N-acetylglucosaminidase alpha;
 KW chromosome 22q13.2-q13.31; lysosomal glycosidase; screening; SNP;
 KW NAGA-related disease; single nucleotide polymorphism; haplotyping; NAGA;

KW genotyping.
 XX
 OS Homo sapiens.
 XX
 PN WO200194637-A1.
 XX
 PD 13-DEC-2001.
 XX
 PF 07-JUN-2001; 2001WO-US018456.
 XX
 PR 07-JUN-2000; 2000US-0210110P.
 XX
 PS (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Duda A, Kazemi A, Koshy B, Parks KE;
 XX
 DR WPI; 2002-566449/60.
 XX
 PT New genetic variants of isolated N-acetylglucosaminidase (NAGA), Alpha
 PT gene, useful for therapeutic purposes, for studying the expression and
 PT function of the polynucleotide, and for expressing NAGA protein.
 XX
 PS Claim 16; Page 13; 91pp; English.
 XX
 CC The invention comprises the amino acid and coding sequence of the human N
 CC -acetylglucosaminidase (NAGA) alpha protein. The invention specifically
 CC comprises novel polymorphic sites identified within the NAGA gene. The
 CC NAGA gene is located on chromosome 22q13.2-q13.31, and encodes a
 CC lysosomal glycosidase that cleaves alpha-N-acetylglucosaminyl
 CC moieties in glycoconjugates. The NAGA DNA and protein sequences of the
 CC invention are useful for studying the expression and function of NAGA and
 CC for screening candidate drugs to treat diseases related to NAGA activity.
 CC The NAGA gene polymorphisms identified in the present invention are
 CC useful for haplotyping and genotyping the NAGA gene of an individual. The
 CC present DNA sequence represents an N-acetylglucosaminidase gene allele-
 CC specific oligonucleotide primer
 CC
 XX
 SQ Sequence 15 BP; 2 A; 3 C; 7 G; 2 T; 0 U; 1 Other;
 Query Match 4.8%; Score 12; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 2.4e+02;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Oy 1313 TGAGCAGCTGAGG 1326
 Db 1 TGAGCAGCTGAGG 14
 RESULT 597
 ABS64223/C
 ID ABS64223 standard; DNA; 15 BP.
 XX
 AC ABS64223;
 XX
 DT 15-NOV-2002 (first entry)
 XX
 DE Tachykinin receptor gene TACR2, allele-specific primer #33.
 XX
 KW Human; single nucleotide polymorphism; SNP; TACR2; primer; probe; ss;
 KW tachykinin receptor.
 XX
 OS Homo sapiens.
 XX
 PN WO200263046-A1.
 XX
 PD 15-AUG-2002.
 XX
 PF 09-NOV-2001; 2001WO-US047394.
 XX
 PR 09-NOV-2000; 2000US-0247649P.
 XX
 PS (GENA-) GENAISSANCE PHARM INC.
 XX

PI Cappola G, Chew A, Gilson CR, Koshy B;
XX WPI; 2002-636600/68.
XX
XX
XX New genetic variants having polymorphisms in the Tachykinin receptor
PT (TRCR2) protein, useful for studying the function of TRCR2, and for
PT treating disorders associated with abnormal expression or function of
PT TRCR2 isogene.
XX
XX
XX Claim 14, Page 15; 139pp; English.
XX
XX The invention relates to an isolated polypeptide comprising a polymeric
CC variant of a reference sequence for the Tachykinin receptor (TRCR2)
CC protein. Also described is a method for: (1) haplotyping or genotyping
CC the TRCR2 gene of an individual; (2) predicting a haplotype pair for the
CC TRCR2 gene of an individual; (3) identifying an association between a
CC trait and at least one haplotype or haplotype pair of the TRCR2 gene; and
CC (4) isolated oligonucleotide for detecting a single nucleotide
CC polymorphism in the TRCR2 gene. Polymorphic variants of the TRCR2 gene
CC are useful in studying the expression and biological function of TRCR2,
CC and in identifying drugs targeting TRCR2 protein for treating disorders
CC associated with abnormal expression or function of TRCR2, e.g. asthma or
CC breast cancer. Polynucleotides comprising a polymorphic gene variant or
CC fragment may be used for therapeutic purposes, where a patient could
CC benefit from expression or increased expression of a particular TRCR2
CC protein isoform, or an expression vector encoding the isoform may be
CC administered to the patient. Haplotype information is useful in improving
CC the efficiency and output of several steps in drug discovery and
CC development process, including target validation, identifying lead
CC compounds, and early phase clinical trials. Information on polymorphisms
CC may be applied in studying biological functions of TRCR2 as well as in
CC identifying drugs targeting this protein for the treatment of disorders
CC related to its abnormal expression or function. ABS64163-ABS64302
CC represent human TRCR2 gene allele-specific oligonucleotide probes and
CC primers used to detect haplotypes of the TRCR2 gene of the invention
XX
XX
SQ Sequence 15 BP; 0 A; 5 C; 4 G; 5 T; 0 U; 1 Other;
Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
OY 1276 CTGAGGCGACAGAC 1289
|:|||||||
DB 15 CTGAGGCGACAGAC 2
RESULT 598
ACD82535/C
ID ACD82535 standard; DNA; 15 BP.
XX
XX
AC ACD82535;
XX
DT 19-SEP-2003 (first entry)
XX
DE Nucleic acid cloning associated adaptor molecule #236.
XX
KM Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KM internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
XX Synthetic.
OS
XX US2003044791-A1.
XX
XX
PD 06-MAR-2003.
XX
XX
PF 13-JUN-2001; 2001US-00880313.
XX
XX 13-JUN-2001; 2001US-00880313.
XX
XX (FLEM/) FLEMINGTON B K.
PA
XX
PI Flemington EK;

XX
XX WPI; 2003-521745/49.
DR
XX
XX New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
XX
XX Claim 12; Fig 5; 100pp; English.
XX
XX
XX The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
XX
SQ Sequence 15 BP; 2 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1251 CGGCTGCAGCANA 1262
|:|||||||
DB 15 CGGCTGCAGCANA 4
RESULT 599
AAQ97769/C
ID AAQ97769 standard; DNA; 16 BP.
XX
XX
AC AAQ97769;
XX
DT 12-MAR-1996 (first entry)
XX
DE Bovine prostaglandin F2 alpha receptor antisense primer VIA.
XX
XX Bovine; prostaglandin; F2 alpha receptor; corpus luteum; involute;
KM progesterone; production inhibition; degenerate; antisense primer VIA;
KM ss.
XX
XX Synthetic.
OS
XX JP07135979-A.
XX
XX
PD 30-MAY-1995.
XX
XX
PF 22-NOV-1993; 93JP-00291796.
XX
XX
PR 22-NOV-1993; 93JP-00291796.
XX
XX (OSAB-) ZH OSAKA BIOSCIENCE KENKYUSHO.
PA
XX
XX WPI; 1995-227400/30.
XX
XX
XX Bovine prostaglandin (PG) F2 alpha receptor - reacts directly with corpus
PT luteum to inhibit progesterone production.
XX
XX
XX Example 1; Page 3; 9pp; Japanese.
XX
XX
CC AAQ97767-097772 are degenerate primers for the bovine prostaglandin F2
CC alpha receptor cDNA. The receptor reacts directly with the corpus luteum
CC to inhibit progesterone prodn., and to involve the corpus luteum
XX
XX
SQ Sequence 16 BP; 4 A; 2 C; 2 G; 2 T; 0 U; 6 Other;

Query Match 4.8%; Score 12; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 2.8e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1390 TTGCTGAGCTGCTGA 1405
DB 16 KYGYSATCTGCTSSA 1

RESULT 600
AAV43468
ID AAV43468 standard; RNA; 16 BP.
XX
AC AAV43468;
XX
DT 17-OCT-2003 (revised)
DT 14-SEP-1998 (first entry)
XX
DE HIV-1 beta-chemokine receptor (CCR)-5 target sequence 13.
XX
KM Endo-ribonuclease; ribozyme; cleave; co-receptor RNA; HIV infection;
KM chemokine receptor; CCR; fusion; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9817308-A1.
XX
PD 30-APR-1998.
XX
PF 24-OCT-1997; 97WO-US019923.
XX
PR 25-OCT-1996; 96US-0027875P.
PR 19-DEC-1996; 96US-00770235.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Leavitt MC, Trlez R, Feng Y, Barber J, Yu M;
XX WPI; 1998-261188/23.
XX
XX Endo-ribonuclease nucleic acids - which encode ribozymes which cleave co-
PT receptor RNA expressed in cells, used particularly for inhibiting HIV
PT infection of cells.
XX
PS Claim 3; Page 27; 83pp; English.
XX
CC This represents a target sequence of HIV-1 co-receptor beta-chemokine
CC receptor (CCR)-5. The invention provides endo-ribonuclease nucleic acid
CC that encodes a ribozyme which cleaves a co-receptor RNA expressed in a
CC cell. The co-receptor RNA is a member of the seven trans-membrane protein
CC receptor family. This can be used in a method of inhibiting HIV infection
CC of a cell which comprises cleaving a co-receptor mRNA expressed in the
CC cell. The co-receptor mRNA encodes an HIV co-receptor protein selected
CC from fusion, beta-chemokine receptor-5 (CCR-5), CCR-3 and CCR-2b. The
CC cleavage of the co-receptor mRNA inhibits the production of the selected
CC co-receptor protein, thereby inhibiting HIV infection of the cell. The
CC endo-ribonuclease can be used to specifically cleave RNAs. The method
CC can be used for inhibiting HIV infection of cells by inhibiting
CC expression of HIV co-receptor on the surface of cells. Because the level
CC of co-receptor on the surface of the cell is reduced, HIV entry into the
CC cells is inhibited. Cleavage of HIV co-receptor mRNA using targeted
CC ribozymes is not cytotoxic to cells expressing the co-receptor and the
CC cells retain normal immune function. (Updated on 17-OCT-2003 to
CC standardise OS field)
XX
SQ Sequence 16 BP; 3 A; 4 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 4.8%; Score 12; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 2.8e+02;
Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1301 CATGCTCATCTG 1312
||:||||:|

DB 2 CAUGGUCAUUG 13
AA73460
ID AAF73460 standard; DNA; 16 BP.
XX
AC AAF73460;
XX
DT 08-MAY-2001 (first entry)
XX
DE HGF nucleic acid ligand SEQ ID NO: 10.
XX
KM Hepatocyte growth factor/ scatter factor; HGF; c-met; integrin; stroke;
KM cell adhesion; cell migration; nucleic acid ligand; thrombosis; cancer;
KM hypertension; arteriosclerosis; myocardial infarction; restenosis;
KM rheumatoid arthritis; macular degeneration; endometriosis; psoriasis;
KM osteoporosis; DNA-RNA hybrid; ss.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..16
FT /tag= b
FT /mod_base= OTHER
FT /note= "all bases are 2' Ome"
FT misc_RNA 5..16
FT /*tag= a
XX
PN WO200109159-A1.
XX
PD 08-FEB-2001.
XX
PF 24-JUL-2000; 2000WO-US020139.
XX
PR 29-JUL-1999; 99US-00364539.
PR 29-JUL-1999; 99US-00364543.
XX
PA (NEXS-) NEXSTAR PHARM INC.
XX
XX Ruckman J, Gold L, Stephens A, Janjic N, Rabin R, Lochrie M;
XX WPI; 2001-103180/11.
XX
DR WPI; 2001-103180/11.
XX
PT Isolation of nucleic acid ligands to hepatocyte growth factor, its
PT receptor c-met and integrins, useful for treating tumors, deep vein
PT thrombosis and diabetic retinopathy.
XX
PS Example 1; Fig 2; 226pp; English.
XX
CC The present invention provides nucleic acid ligands to hepatocyte growth
CC factor/scatter factor (HGF), its receptor c-met and integrins. Integrins
CC are involved in cell adhesion and migration. The ligands of the
CC involved in cell proliferation and migration. The ligands of the
CC invention are useful in the treatment of diseases such as cancer,
CC thrombosis, hypertension, arteriosclerosis, myocardial infarction,
CC rheumatoid arthritis, macular degeneration, endometriosis, psoriasis,
CC stroke, osteoporosis and restenosis. The present sequence is an example
CC of a ligand of the invention
XX
SQ Sequence 16 BP; 1 A; 4 C; 7 G; 2 T; 2 U; 0 Other;

Query Match 4.8%; Score 12; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1415 TGCTGAGCGGCG 1426
DB 4 TGCTGAGCGGCG 15

RESULT 602
AA790963

```
ID AAT90963 standard; cDNA, 17 BP.
XX
XX AAT90963;
XX
XX
XX 25-MAR-2003 (revised)
XX 19-JAN-1998 (first entry)
XX
XX Gene-specific inside primer GSI for PDE IV-C coding sequence.
XX
XX Phosphodiesterase IV isoenzyme; hPDE IV-C; human; PDB; enzyme; therapy;
XX cyclic nucleotide degradation; intracellular; second messenger; asthma;
XX inflammation; primer; amplify; PCR; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX US5672509-A.
XX
XX 30-SEP-1997.
XX
XX 05-AUG-1994; 94US-00286856.
XX
XX 25-AUG-1993; 93US-00112815.
XX
XX (PFIZ ) PFIZER INC.
XX
XX Fisher DA;
XX
XX WPI; 1997-488862/45.
XX
XX DNA encoding human phosphodiesterase IV isoenzyme - useful for producing
XX recombinant isoenzyme, for screening for therapeutics for asthma and
XX inflammation.
XX
XX Disclosure; Col 10; 15pp; English.
XX
XX AAT90958-T90963 represent amplification primers used to isolate the human
XX phosphodiesterase IV isoenzyme C (hPDE IV-C) coding sequence (see
XX AAT90951) from a human testis cDNA library. Cyclic phosphodiesterase
XX enzymes (PDEs) are a family of enzymes that catalyse the degradation of
XX cyclic nucleotides. Cyclic nucleotides are important intracellular second
XX messengers. The hPDE IV-C coding sequence can be used to produce the
XX recombinant isoenzyme, which may be useful in PDE IV activity assays. The
XX recombinant isoenzyme may also be used in screening assays for drugs that
XX may be improved therapeutics in the areas of asthma and inflammation.
XX Primers determined from the hPDE IV-C sequence, that are specific for
XX hPDE IV-C (such as AAT90952 and AAT90953), can be used in a RT-PCR
XX amplification, in an assay for detecting hPDE IV-C in human cells.
XX (Updated on 25-MAR-2003 to correct PF field.)
XX
XX Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
XX
XX
XX Query Match 4.8%; Score 12; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 3.3e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1204 AGAGGCGAGCCA 1215
XX |||||
XX DB 2 AGAGGCGAGCCA 13
XX
XX
XX RESULT 603
XX AAT93233
XX ID AAT93233 standard; DNA; 17 BP.
XX
XX
XX AAT93233;
XX
XX
XX 25-MAR-2003 (revised)
XX 26-FEB-1998 (first entry)
XX
XX Primer GSI for human phosphodiesterase IV isoenzyme.
XX
XX Human; cyclic nucleotide phosphodiesterase IV-C; isoenzyme; therapy;
```

```
KW asthma; inflammation; hPDE IV-C; PCR primer; amplify; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX US5686286-A.
XX
XX 11-NOV-1997.
XX
XX 07-JUN-1995; 95US-00472831.
XX
XX 25-AUG-1993; 93US-00112815.
XX
XX 05-AUG-1994; 94US-00286856.
XX
XX (PFIZ ) PFIZER INC.
XX
XX Fisher DA;
XX
XX WPI; 1997-558143/51.
XX
XX Human phosphodiesterase IV isoenzyme hPDE IV-C - used to identify PDE
XX inhibitors that may be used for treating asthma and inflammation.
XX
XX Disclosure; Col 10; 13pp; English.
XX
XX AAT93222-T93233 represent primers for human cyclic nucleotide
XX phosphodiesterase IV (hPDE IV) isoenzymes. These sequences can be used to
XX identify and isolate the hPDE IV-C isoenzyme coding sequence of the
XX invention, shown in AAT93221. The amplified DNA sequence was isolated
XX from a human testis cDNA library. The amplified sequence when expressed
XX by a host cell, can be used to determine the sequences of hPDE IV-C
XX specific primers. These primers can be used for detecting the presence of
XX hPDE IV-C in human cells. The host cell line can be used to identify
XX compounds or other substances that inhibit or modify the activity of hPDE
XX IV-C. The screening can identify drugs that may be improved therapeutics
XX for treating asthma and inflammation. (Updated on 25-MAR-2003 to correct
XX PF field.)
XX
XX Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
XX
XX
XX Query Match 4.8%; Score 12; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 3.3e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1204 AGAGGCGAGCCA 1215
XX |||||
XX DB 2 AGAGGCGAGCCA 13
XX
XX
XX RESULT 604
XX ABN10742
XX ID ABN10742 standard; DNA; 17 BP.
XX
XX
XX ABN10742;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPL-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10734.
XX
XX Human; genome-derived myosin-like protein 1; GDMPL-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
```

PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX description ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 10734; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser description ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 1 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1182 CTGGGCTCCAG 1193
DB 2 CTGGGCTCCAG 13
RESULT 605
ABN09237
ID ABN09237 standard; DNA; 17 BP.
XX
XX AC ABN09237;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9229.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
KW

XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX description ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 9229; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser description ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 6 C; 7 G; 1 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1203 CAGAGGCGGCC 1214
DB 3 CAGAGGCGGCC 14
RESULT 606
ABN10739

ID ABN10739 standard; DNA; 17 BP.
XX
AC ABN10739;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10731.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI, 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 10731; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Gy 1182 CTGGGCTCCAG 1193
Db 5 CTGGGCTCCAG 16
RESULT 607
ID ABN10738 standard; DNA; 17 BP.
XX
AC ABN10738;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10730.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI, 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 10730; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the protein. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1182 CTGGGCTCCCG 1193
Db 6 CTGGGCTCCCG 17
RESULT 608
ABN10740
ID ABN10740 standard; DNA; 17 BP.
AC ABN10740;
XX
XX 29-MAY-2002 (first entry)
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10732.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 10732; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the protein. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1182 CTGGGCTCCCG 1193
Db 4 CTGGGCTCCCG 15
RESULT 609
ABN08783
ID ABN08783 standard; DNA; 17 BP.
AC ABN08783;
XX
XX 29-MAY-2002 (first entry)
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8775.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX

DR WP1; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 8775; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1304 GGTCTATCTGTGA 1315
DB 5 GGTCTATCTGTGA 16
RESULT 610
ABN09234
ID ABN09234 standard; DNA; 17 BP.
XX
XX ABN09234;
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9226.
DE
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
PN
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
PF
XX
XX 26-MAY-2000; 2000US-0207455P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WP1; 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 9226; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 4 A; 7 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1203 CAGAGGCGCAGCC 1214
DB 6 CAGAGGCGCAGCC 17
RESULT 611
ABN09235
ID ABN09235 standard; DNA; 17 BP.
XX
XX ABN09235;
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9227.
DE
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
PN
XX
XX 06-DEC-2001.
PD
XX

PF 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
DR WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 9227; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
DR WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 8774; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 613
ABN09236
ID ABN09236 standard; DNA; 17 BP.
XX
AC ABN09236;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9228.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 9228; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0;
XX
DY 1203 CAGAGGCGAGCC 1214
|||
DB 4 CAGAGGCGAGCC 15
XX
RESULT 614
ABN09238
ID ABN09238 standard; DNA; 17 BP.
XX
AC ABN09238;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9230.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 9230; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionization, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The hGDMLP-1
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Gy 1203 CAGAGGCGAGCC 1214
Db 2 CAGAGGCGAGCC 13

RESULT 615
ABN10741
ID ABN10741 standard; DNA; 17 BP.
AC ABN10741;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10733.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (ABOM-) ABOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 10733; 214pp; English.

XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionization, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC
SQ Sequence 17 BP; 1 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Gy 1182 CTGGGCTCCAG 1193
Db 3 CTGGGCTCCAG 14

RESULT 616
ABN10743
ID ABN10743 standard; DNA; 17 BP.
AC ABN10743;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10735.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX

PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 10735; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 1 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1182 CTGGGCTCCGAG 1193
DB 1 CTGGGCTCCGAG 12
XX
RESULT 617
ABT39571
ID ABT39571 standard; DNA; 17 BP.
XX
AC ABT39571;
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 5208.
DE
XX Cytostatic; virocid; neuroprotective; nootropic; neuropathic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX Homo sapiens.
OS
XX WO2003025175-A2.
PN
XX 27-MAR-2003.
PD
XX 17-SEP-2002; 2002WO-IB004208.
PF
XX 17-SEP-2001; 2001FR-00011978.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX

PI Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX
PS Disclosure; Page 642; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 7 A; 5 C; 2 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1220 TCAGAACTCCA 1231
DB 3 TCAGAACTCCA 14
XX
RESULT 618
ABZ65158
ID ABZ65158 standard; RNA; 17 BP.
XX
AC ABZ65158;
XX
XX 21-MAR-2003 (first entry)
XX
XX Human HER2 DNAzyme substrate #615.
DE
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX Homo sapiens.
OS
XX WO200297114-A2.
PN
XX 05-DEC-2002.
PD
XX 29-MAY-2002; 2002WO-US016840.
PF
XX 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcawiggen J;
PI

XX DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
XX HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 4; Page 144; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosinatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265511, AB265520 - AB265524,
CC AB265530 - AB265585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
XX
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 83.3%; Pred. No. 3.3e+02;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1182 CTGGGCTCCGAG 1193
DB 5 CUGGCGUCCGAC 16
XX
RESULT 619
ADB98935
XX ID ADB98935 standard; DNA; 17 BP.
XX AC ADB98935;
XX
XX 04-DEC-2003 (first entry)
XX
XX LRP5 mutagenic PCR primer #54.
XX
XX Osteopontin; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
XX bone mass modulation; osteoporosis; PCR; primer; ss.
XX
XX Synthetic.
XX
XX WO200292000-A2.
XX
XX
XX 21-NOV-2002.
XX
XX 13-MAY-2002; 2002WO-US014877.
XX
XX 11-MAY-2001; 2001US-0290073P.
XX 17-MAY-2001; 2001US-0291311P.
XX 01-FEB-2002; 2002US-0353038P.
XX 04-MAR-2002; 2002US-0361293P.
XX
XX (GENO-) GENOME THERAPEUTICS CORP.
XX (AMNP) WYETH.
XX
XX Allen K, Antkowiak A, Graham JR, Morales A, Yaworsky PJ, Liu W,
XX
XX WPI; 2003-129214/12.
XX
XX New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
XX diagnosing a HBM-like phenotype in a subject and for preparing a
XX composition for modulating bone mass and/or lipid levels in a subject
XX suffering from e.g. osteoporosis.
XX
XX Disclosure; Page 53; 629pp; English.
XX

CC The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC level modulation. The invention is useful for diagnosing a HBM-like
CC phenotype in a subject and for preparing a composition for modulating
CC bone mass and/or lipid levels in a subject suffering from e.g.
CC osteoporosis. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1235 TGTGCTGCGAGT 1246
DB 1 TGTGCTGCGAGT 12
XX
RESULT 620
AD151186
XX ID AD151186 standard; DNA; 17 BP.
XX AC AD151186;
XX
XX 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID3689.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytosinatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
XX primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX
XX Disclosure; SEQ ID NO 3689; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytosinatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX

```
SQ Sequence 17 BP; 7 A; 5 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1220 TCAGAACTCCA 1231
Db 3 TCAGAACTCCA 14

RESULT 621
ACCS1667
ID ACCS1667 standard; DNA; 17 BP.
XX
XX
AC ACS1667;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #434.
XX
KM ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KM tumour regression; apoptosis; virus resistance; diagnosis;
KM cellular degeneration.
XX
XX OS Homo sapiens.
XX
XX FR2826373-A1.
XX
XX PD 27-DEC-2002.
XX
XX PF 20-JUN-2001; 2001FR-00008139.
XX
XX PR 20-JUN-2001; 2001FR-00008139.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
XX PI Tuijnder M, Telerman A, Amson R;
XX
XX DR WPI; 2003-250498/25.
XX
XX PT New nucleic acid sequences associated with tumor suppression, regression,
XX apoptosis or virus resistance are useful to diagnose and treat viral
XX disease, development of tumor cells and cell degeneration.
XX
XX PS Claim 1; Page 140; 798pp; French.
XX
XX CC This sequence represents an isolated nucleic acid sequence associated
XX with tumour suppression or regression, apoptosis or virus resistance. The
XX invention relates to these sequences or sequences having at least 80%
XX identity to them, and polypeptides encoded by the sequences or
XX polypeptides having 80% identity to the polypeptide sequences. The
XX invention is used to diagnose or treat viral disease or disease
XX characterized by development of tumour cells or cellular degeneration
XX
XX SQ Sequence 17 BP; 7 A; 5 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1220 TCAGAACTCCA 1231
Db 3 TCAGAACTCCA 14

RESULT 622
ADF92299/c
ID ADF92299 standard; DNA; 17 BP.
XX
XX
AC ADF92299;
XX
DT 26-FEB-2004 (first entry)
XX
```

```
XX
XX DE Human cytokeraatin 19-related loop F PCR primer - SEQ ID 387.
XX
XX KM human; cytokeraatin; CK; LAMP; loop mediated isothermal amplification;
XX KM tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
XX KM PCR; loop F.
XX
XX OS Homo sapiens.
XX
XX PN WO2003097878-A1.
XX
XX PD 27-NOV-2003.
XX
XX PF 20-MAY-2003; 2003WO-JP006256.
XX
XX PR 21-MAY-2002; 2002JP-00145689.
XX PR 17-JUN-2002; 2002JP-00175271.
XX PR 09-JUL-2002; 2002JP-00197959.
XX
XX PA (SYSM-) SYSMEX CORP.
XX
XX PI Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
XX
XX DR WPI; 2004-012543/01.
XX
XX PT LAMP nucleic acid amplification primers for detection of cytokeraatin
XX expression as indicator in diagnosis of tumour metastasis.
XX
XX PS Claim 19; SEQ ID NO 387; 266pp; Japanese.
XX
XX CC The invention relates to novel nucleic acid amplification primers for the
XX detection of human cytokeraatin (CK) 18, 19 or 20 expression by the LAMP
XX (loop mediated isothermal amplification) method. The primers of the
XX invention may be useful for the detecting cytokeraatin 18-20 expression as
XX an indicator for the diagnosis of tumour metastasis, particularly
XX prostate cancer and lymphoma. The amplification using the primers is
XX highly efficient and allows very sensitive detection of tumour
XX metastasis. The current sequence is that of the human CK19-related PCR
XX primer of the invention.
XX
XX SQ Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1371 TACCGAAGCAG 1382
Db 15 TACCGAAGCAG 4

RESULT 623
ADL82354
ID ADL82354 standard; DNA; 17 BP.
XX
XX
AC ADL82354;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Human ER+ breast cancer differentially expressed sequence #324.
XX
XX KM gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX
XX OS Homo sapiens.
XX
XX PN US2003166026-A1.
XX
XX PD 04-SEP-2003.
XX
XX PF 08-JAN-2003; 2003US-00339782.
XX
XX PR 09-JAN-2002; 2002US-0348053P.
XX
```

PA (LYNX-) LYNX THERAPEUTICS INC.
XX
XX Goodman LJ, Bowen BA;
XX
XX WPI; 2004-069003/07.
XX
XX Vector containing nucleic acid associated with breast cancer, useful for
PT treating, diagnosing and characterizing breast cancer, also related
PT polypeptides and antibodies.
XX
XX Claim 1; SEQ ID NO 325; 61pp; English.
XX
XX The invention relates to a composition which contains at least one vector
CC (B) containing a nucleic acid (I) associated with breast cancer. The
CC vector (B), also polypeptides (II) encoded by (I), are used for treatment
CC of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
CC -specific antibodies (Ab) are used to predict characteristics (e.g.
CC invasiveness or stage) of breast cancer, and (I), or its fragments, are
CC used to modulate characteristics of such cells; to identify breast cancer
CC genes and to detect breast cancer (by detecting polymorphic nucleic acid
CC or its products). The present sequence represents a human ER+ breast
CC cancer differentially expressed sequence.
XX
XX Sequence 17 BP; 7 A; 5 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1220 TCAGAACTCCA 1231
Db 3 TCAGAACTCCA 14
|||||
ID AAL61584 standard; DNA; 20 BP.
XX
XX AAL61584;
AC
XX
XX 22-SEP-2003 (first entry)
DT
XX
XX Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130509.
DE
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKK α ; I-kappa-B-related; NFKB1L2;
KW ikappaB γ ; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
XX Homo sapiens.
OS
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH 1. .20
FT modified_base
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1. .5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16. .20
FT modified_base
FT /*tag= C
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX

XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Monia BP, Matt AT;
XX
XX WPI; 2003-468635/44.
XX
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX Claim 3; Page 75; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKK α , I-kappa-B-related, ikappaB γ , nuclear factor of kappa light
CC polypeptide gene enhancer in B-cells inhibitor-like 2 and NFKB1L2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
XX
XX Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.8%; Score 12; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1359 GCAGCTGAGCT 1370
Db 19 GCAGCTGAGCT 8
|||||
ID AAT54830 standard; RNA; 15 BP.
XX
XX AAT54830;
AC
XX
XX 25-MAR-2003 (revised)
DT
XX
XX 07-APR-1997 (first entry)
DT
XX
XX Mouse rela hammerhead ribozyme target sequence (nt. position 204).
DE
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF- α ; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; testostosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
XX Mub musculus.
OS
XX
XX WO9523225-A2.
XX
XX 31-AUG-1995.
XX
XX 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX
XX 29-MAR-1994; 94US-00218934.
XX
XX

PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321934.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LM;
PI Grimm S, Karpelsky A, Kisich K, Matulic-Adamic J, Mewisigen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI, 1995-351090/45.
XX
PR Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 225; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves relA mRNA at the
CC nucleotide base position indicated in the DE line. The relA gene product
CC is a subunit of the transcriptional regulator NF-kappaB and is implicated
CC specifically in the induction of inflammatory responses. Regions of the
CC mRNA that do not form secondary folding structures and that contain
CC potential hammerhead and hairpin ribozyme cleavage sites were identified
CC by computer analysis. Ribozymes directed against these mRNA sequences
CC were designed and synthesised with modifications that improve their
CC nuclease resistance. The ribozymes are designed to cleave the target
CC sequences and thereby inhibit relA expression, making them potentially
CC useful for treating rheumatoid arthritis, restenosis and asthma as well
CC as for increasing tolerance to transplanted tissues. The potential
CC immunosuppressive properties of a ribozyme that cleaves relA mRNA means
CC that uses are limited to local delivery, acute indications or ex vivo
CC treatment. (Updated on 25-MAR-2003 to correct PI field.)
XX
XX Sequence 15 BP; 1 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
SQ

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1412 GGGTGTGAGCGGCGC 1426
DB 1 GGGCGCCGCGCGGC 15

RESULT 626
AAT54967/C
ID AAT54967 standard; RNA; 15 BP.
XX
AC AAT54967;
XX

DT 25-MAR-2003 (revised)
DT 07-APR-1997 (first entry)
XX
XX Mouse relA hammerhead ribozyme target sequence (nt. position 1660).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KM gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KM intercellular adhesion molecule; rel A; tumour necrosis factor;
KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KM translocation; chronic myelogenous leukemia; CML; cancer;
KM Philadelphia chromosome; inflammation; autoimmune disease;
KM atherosclerosis; myocardial infarction; stroke; restenosis;
KM transplant rejection; rheumatoid arthritis; psoriasis;
KM myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KM ss.
XX
XX Mus musculus.
XX
PN W09523225-A2.
XX
XX 31-AUG-1995.
XX
PD 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX 23-FEB-1994; 94US-00218934.
PR 29-MAR-1994; 94US-00222795.
PR 04-APR-1994; 94US-00227958.
PR 07-APR-1994; 94US-00228043.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321933.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LM;
PI Grimm S, Karpelsky A, Kisich K, Matulic-Adamic J, Mewisigen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI, 1995-351090/45.
XX
PR Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 226; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves relA mRNA at the
CC nucleotide base position indicated in the DE line. The relA gene product
CC is a subunit of the transcriptional regulator NF-kappaB and is implicated
CC specifically in the induction of inflammatory responses. Regions of the
CC mRNA that do not form secondary folding structures and that contain
CC potential hammerhead and hairpin ribozyme cleavage sites were identified

CC by computer analysis. Ribozymes directed against these mRNA sequences
 CC were designed and synthesized with modifications that improve their
 CC nuclease resistance. The ribozymes are designed to cleave the target
 CC sequences and thereby inhibit relA expression, making them potentially
 CC useful for treating rheumatoid arthritis, restenosis and asthma as well
 CC as for increasing tolerance to transplanted tissues. The potential
 CC immunosuppressive properties of a ribozyme that cleaves relA mRNA means
 CC that uses are limited to local delivery, acute indications or ex vivo
 CC treatment. (Updated on 25-MAR-2003 to correct PI field.)

CC Sequence 15 BP; 2 A; 7 C; 3 G; 0 T; 3 U; 0 Other;

CC Query Match 4.7%; Score 11.8; DB 1; Length 15;

CC Best Local Similarity 86.7%; Pred. No. 2.6e+02;

CC Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC 1198 CTGTCAGAGGCGCAG 1212

CC 15 CTGGCAGAGGTCAG 1

CC Db

CC AAT54864/C

CC ID AAT54864 standard; RNA; 15 BP.

CC AC AAT54864;

CC XX 25-MAR-2003 (revised)

CC DT 07-APR-1997 (first entry)

CC DE Mouse relA hammerhead ribozyme target sequence (nt. position 391).

CC Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 CC gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 CC intercellular adhesion molecule; rel A; tumor necrosis factor;
 CC TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 CC translocation; chronic myelogenous leukaemia; CML; cancer;
 CC Philadelphia chromosome; inflammation; autoimmune disease;
 CC atherosclerosis; myocardial infarction; stroke; restenosis;
 CC transplant rejection; rheumatoid arthritis; psoriasis;
 CC myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 CC human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 CC 88.

CC OS Mus musculus.

CC PN W09523225-A2.

CC PD 31-AUG-1995.

CC PF 23-FEB-1995; 95WO-1B000156.

CC XX 23-FEB-1994; 94US-00201109.

CC PR 29-MAR-1994; 94US-00218934.

CC PR 04-APR-1994; 94US-00222795.

CC PR 07-APR-1994; 94US-00224483.

CC PR 15-APR-1994; 94US-00227958.

CC PR 15-APR-1994; 94US-00228041.

CC PR 18-MAY-1994; 94US-00245736.

CC PR 06-JUL-1994; 94US-00271280.

CC PR 15-AUG-1994; 94US-00291932.

CC PR 16-AUG-1994; 94US-00291433.

CC PR 17-AUG-1994; 94US-00282620.

CC PR 19-AUG-1994; 94US-00293520.

CC PR 02-SEP-1994; 94US-00300000.

CC PR 08-SEP-1994; 94US-00303039.

CC PR 23-SEP-1994; 94US-00311466.

CC PR 23-SEP-1994; 94US-00311749.

CC PR 28-SEP-1994; 94US-00314397.

CC PR 03-OCT-1994; 94US-00316771.

CC PR 07-OCT-1994; 94US-00319492.

CC PR 11-OCT-1994; 94US-00321993.

CC PR 04-NOV-1994; 94US-00334847.

PR 10-NOV-1994; 94US-00337608.
 PR 28-NOV-1994; 94US-00345516.
 PR 16-DEC-1994; 94US-00357577.
 PR 23-DEC-1994; 94US-00363233.
 PR 30-JAN-1995; 95US-00380734.

PR (RIBO-) RIBOZYME PHARM INC.

PI Stinchcomb DT, Chovvira B, Dizenzo A, Draper KG, Dudycz LW;

PI Grimm S, Karpelsky A, Ksiech K, Natulic-Adamic U, Mcswiggen JA;

PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;

PI Tracz D, Usman N, Wincott FE, Wolff T;

DR WPI; 1995-351090/45.

PT Ribozymes having modified bases and methods for producing them - for use

PT in inhibiting disease related genes.

PS Claim 2; Page 225; 407pp; English.

CC The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves relA mRNA at the
 CC nucleotide base position indicated in the DE line. The relA gene product
 CC is a subunit of the transcriptional regulator NF-kappaB and is implicated
 CC specifically in the induction of inflammatory responses. Regions of the
 CC mRNA that do not form secondary folding structures and that contain
 CC potential hammerhead and hairpin ribozyme cleavage sites were identified
 CC by computer analysis. Ribozymes directed against these mRNA sequences
 CC were designed and synthesised with modifications that improve their
 CC nuclease resistance. The ribozymes are designed to cleave the target
 CC sequences and thereby inhibit relA expression, making them potentially
 CC useful for treating rheumatoid arthritis, restenosis and asthma as well
 CC as for increasing tolerance to transplanted tissues. The potential
 CC immunosuppressive properties of a ribozyme that cleaves relA mRNA means
 CC that uses are limited to local delivery, acute indications or ex vivo
 CC treatment. (Updated on 25-MAR-2003 to correct PI field.)

CC Sequence 15 BP; 2 A; 7 C; 3 G; 0 T; 3 U; 0 Other;

CC Query Match 4.7%; Score 11.8; DB 1; Length 15;

CC Best Local Similarity 86.7%; Pred. No. 2.6e+02;

CC Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC 1198 CTGTCAGAGGCGCAG 1212

CC 15 CTGGCAGAGGTCAG 1

CC Db

CC AAX66552 standard; RNA; 15 BP.

CC AC AAX66552;

CC XX 20-JUL-1999 (first entry)

CC DE Human CD40 hammerhead ribozyme target SEQ ID NO:3184.

CC Arthritic condition; graft tolerance; immune response; target; cleavage;
 CC hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 CC stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 CC rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 CC diagnosis; 88.

CC OS Homo sapiens.

CC PN W09618736-A2.

CC PD 20-JUN-1996.

CC PR 22-NOV-1995; 95WO-US015516.

CC PR 13-DEC-1994; 94US-00354920.

PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0000951P.
PR 07-JUL-1995; 95US-0000974P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P,
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Kapelsky A, Thompson JD, Modak A, Burgin A;
DR WPI; 1996-300653/30.
XX
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX
XX Claim 10; Page 204; 307pp; English.
XX
XX The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX
XX SQ Sequence 15 BP; 1 A; 6 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.6e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 1243 CAGTGTCCGCGCTGC 1257
DB 1 CAGUGGUCUCCGCCG 15
RESULT 629
ID AAV48561 standard; DNA; 15 BP.
XX
XX AAV48561;
AC
XX
XX 15-OCT-1998 (first entry)
DT
XX
XX p53 gene antisense oligonucleotide p53-T-26.
DE
XX
XX p53; antisense oligonucleotide; modulate; gene expression; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX EP856579-A1.
XX
XX PD 05-AUG-1998.

XX
XX 31-JAN-1997; 97EP-00101531.
XX
XX 31-JAN-1997; 97EP-00101531.
XX
XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
XX Schlingensiepen K, Brysch W;
PI WPI; 1998-400910/35.
XX
XX
XX Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of residues
PT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
PT culture.
XX
XX Example 2; Fig 4b; 286pp; English.
XX
XX AAV48485-564 represent antisense oligonucleotides directed against the
CC p53 gene. Of these, only oligonucleotides AAV48485-517 resulted in
CC effective downregulation of negative growth by p53 and increased cell
CC proliferation, while AAV48518-64 had little effect. The oligonucleotides
CC exemplify the invention. The specification describes oligonucleotides
CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC can each form three hydrogen bonds to cytosine; do not contain four
CC consecutive nucleotides able to form three H-bonds each to four
CC consecutive cytosines; do not contain two sequences of three consecutive
CC nucleotides each able to form three H-bonds to three consecutive
CC cytosines; and the ratio between residues able to form two H-bonds each
CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC oligonucleotides are used to modulate expression of genes, particularly
CC the genes for p53, ErbB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC oligonucleotides can also be used to analyse function of proteins (by
CC altering their expression or activity) and therapeutically, e.g. in cases
CC of cancer or (targeting TGF) for stimulating the immune system
XX
XX SQ Sequence 15 BP; 0 A; 4 C; 10 G; 1 T; 0 U; 0 Other;
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1411 CCGGTGCTGAGCGCG 1425
DB 1 CCGGTGCTGAGCGCG 15
RESULT 630
ID AA64417 standard; RNA; 15 BP.
XX
XX AA64417;
AC
XX
XX 28-MAR-2000 (first entry)
DT
XX
XX Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 8915.
DE
XX
XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
XX cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
XX autoimmune disease; ss.
XX
XX Hepatitis C virus.
XX
XX WO9955847-A2.
XX
XX 04-NOV-1999.
XX
XX 26-APR-1999; 99MO-US009027.
XX
XX 27-APR-1998; 98US-0083217P.
XX

PR 18-SEP-1998; 98US-0100842P.
PR 25-FEB-1999; 98US-00257608.
PR 23-MAR-1999; 99US-00274553.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blact L, Mcawiggen JA, Roberts E, Pavco PA, Macejak D;
XX
XX WPI; 2000-062023/05.
PT Novel ribozymes for the treatment of diseases and conditions related to
XX hepatitis C infection.
XX
PS Claim 1; Page 91; 123pp; English.
XX
CC The present sequence represents the preferred target sequence of an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC the descriptor line. The HCV sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm and regions of the mRNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC target these sites and their activities optimised by either varying the
CC length of the binding arms or by modification to prevent degradation by
CC nucleases. The ribozymes of the invention inhibit gene expression and/or
CC viral replication, and are used to treat diseases associated with
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC hepatocellular carcinoma. The ribozymes may be used in combination with
CC interferon to treat HCV infection, other infectious diseases, autoimmune
CC diseases, and cancer
XX
SQ Sequence 15 BP; 7 A; 2 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1261 AACAGCTGAGAGCG 1275
DB 1 AACAGCTGAGAGCG 15

RESULT 631
AAZ64174/C
ID AAZ64174 standard; RNA; 15 BP.
XX
XX AAZ64174;
XX
XX 28-MAR-2000 (first entry)
XX
DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 5744.
XX
XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KW cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KW autoimmune disease; ss.
XX
XX Hepatitis C virus.
OS
XX
XX W09955847-A2.
PN
XX 04-NOV-1999.
PD
XX 26-APR-1999; 99WO-US009027.
PF
XX 27-APR-1998; 98US-0083217P.
PR 18-SEP-1998; 98US-0100842P.
PR 25-FEB-1999; 99US-00257608.
PR 23-MAR-1999; 99US-00274553.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blact L, Mcawiggen JA, Roberts E, Pavco PA, Macejak D;
PI
XX

DR WPI; 2000-062023/05.
XX
XX Novel ribozymes for the treatment of diseases and conditions related to
PT hepatitis C infection.
XX
XX Claim 1; Page 83; 123pp; English.
XX
CC The present sequence represents the preferred target sequence of an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC the descriptor line. The HCV sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm and regions of the mRNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC target these sites and their activities optimised by either varying the
CC length of the binding arms or by modification to prevent degradation by
CC nucleases. The ribozymes of the invention inhibit gene expression and/or
CC viral replication, and are used to treat diseases associated with
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC hepatocellular carcinoma. The ribozymes may be used in combination with
CC interferon to treat HCV infection, other infectious diseases, autoimmune
CC diseases, and cancer
XX
SQ Sequence 15 BP; 2 A; 9 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1412 GGGTGTGAGCGGC 1426
DB 15 GGGTGTGAGCGGC 1

RESULT 632
AAZ64292/C
ID AAZ64292 standard; RNA; 15 BP.
XX
XX AAZ64292;
XX
XX 28-MAR-2000 (first entry)
XX
DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 7344.
XX
XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KW cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KW autoimmune disease; ss.
XX
XX Hepatitis C virus.
OS
XX
XX W09955847-A2.
PN
XX 04-NOV-1999.
PD
XX 26-APR-1999; 99WO-US009027.
PF
XX 27-APR-1998; 98US-0083217P.
PR 18-SEP-1998; 98US-0100842P.
PR 25-FEB-1999; 99US-00257608.
PR 23-MAR-1999; 99US-00274553.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blact L, Mcawiggen JA, Roberts E, Pavco PA, Macejak D;
PI
XX WPI; 2000-062023/05.
PT Novel ribozymes for the treatment of diseases and conditions related to
XX hepatitis C infection.
XX
PS Claim 1; Page 87; 123pp; English.
XX
XX The present sequence represents the preferred target sequence of an

CC enzymatic, nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC the descriptor line. The HCV sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm and regions of the RNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesized to
CC target these sites and their activities optimised by either varying the
CC length of the binding arms or by modification to prevent degradation by
CC nucleases. The ribozymes of the invention inhibit gene expression and/or
CC viral replication, and are used to treat diseases associated with
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC hepatocellular carcinoma. The ribozymes may be used in combination with
CC interferon to treat HCV infection, other infectious diseases, autoimmune
CC diseases, and cancer

CC Sequence 15 BP; 3 A; 2 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1216 TCTGTGAGACCTCC 1230
Db 15 TCTGTGAGACCAAC 1
|||||
15 TCTGTGAGACCAAC 1

RESULT 633
AAF45848
ID AAF45848 standard; DNA; 15 BP.
XX AAF45848;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
DE IGFBP2 oligonucleotide #687.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX Homo sapiens.
OS
XX
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURDOCH CHILDRENS RES INST.
PA
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 6; Page 38; 201pp; English.
PS
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX inhibiting or reducing growth factor mediated cell proliferation,

CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, ptyriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia

CC Sequence 15 BP; 0 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1238 GCTGGCGTGTCTCG 1252
Db 1 GCTGGCGGTGTCTCG 15
|||||
1 GCTGGCGGTGTCTCG 15

RESULT 634
AAF49371
ID AAF49371 standard; DNA; 15 BP.
XX AAF49371;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
DE IGF-I oligonucleotide #331.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX Homo sapiens.
OS
XX
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURDOCH CHILDRENS RES INST.
PA
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 63; 201pp; English.
PS
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,

CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
SQ Sequence 15 BP; 2 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1320 CTAGGAGACCTCTTC 1334
DB 1 CTCGAGACCTCTTC 15

RESULT 635
AAF49374
ID AAF49374 standard; DNA; 15 BP.
AC AAF49374;
XX 30-MAR-2001 (first entry)
DT IGF-I oligonucleotide #334.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 63; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
SQ Sequence 15 BP; 1 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
SQ Sequence 15 BP; 2 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1323 GCGAGCCTCTCTCC 1337
DB 1 GGAGACCTCTCTCCC 15

RESULT 636
AAF52764
ID AAF52764 standard; DNA; 15 BP.
AC AAF52764;
XX 30-MAR-2001 (first entry)
DT IGF-I oligonucleotide #3724.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 85; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
SQ Sequence 15 BP; 1 A; 4 C; 7 G; 3 T; 0 U; 0 Other;


```
RESULT 639
AAFA8295/C
ID AAF48295 standard; DNA; 15 BP.
XX
XX
AC AAF48295;
XX
XX 30-MAR-2001 (first entry)
DT
DE IGFBP3 oligonucleotide #1715.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; vitruide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX MO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000MO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI, 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 7; Page 55; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 0 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1252 GGCTGCAGACACG 1266
DB 15 GGCCGACGAAAGC 1
RESULT 640
AAFS0719
XX
XX AAF50719 standard; DNA; 15 BP.
XX
XX
AC AAF50719;
XX
XX 30-MAR-2001 (first entry)
DT
DE IGF-I oligonucleotide #1679.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; vitruide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX MO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000MO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI, 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 71; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCACCAACGCTGGA 1270
DB 1 GCTCCACACGCTGGA 15
```

```
RESULT 641
AAFA5849
ID AAF45849 standard; DNA; 15 BP.
XX
XX
AC AAF45849;
XX
XX 30-MAR-2001 (first entry)
DT
DE IGF-I oligonucleotide #1679.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; vitruide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX MO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000MO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI, 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 71; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCACCAACGCTGGA 1270
DB 1 GCTCCACACGCTGGA 15
```

DT 30-MAR-2001 (first entry)
XX IGFBP2 oligonucleotide #688.
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
OS Homo sapiens.
XX WO200078341-A1.
XX 28-DEC-2000.
XX 21-JUN-2000; 2000WO-AU000693.
XX 21-JUN-1999; 99US-0140345P.
XX 21-JUN-1999; 99US-0140345P.
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX Example 6; Page 38; 201pp; English.
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX Sequence 15 BP; 0 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1239 CTGGCAGTGTCCGG 1253
DB 1 CTGGCCGTGTCCGG 15
RESULT 642
AAF49273
ID AAF49273 standard; DNA; 15 BP.
XX AAF49273;
XX 30-MAR-2001 (first entry)
XX IGF-I oligonucleotide #233.
XX

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX Homo sapiens.
XX WO200078341-A1.
XX 28-DEC-2000.
XX 21-JUN-2000; 2000WO-AU000693.
XX 21-JUN-1999; 99US-0140345P.
XX 21-JUN-1999; 99US-0140345P.
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX Example 8; Page 62; 201pp; English.
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1330 TCTTCTCCAGGCG 1344
DB 1 TCATCTCCAGGCG 15
RESULT 643
AAF49375
ID AAF49375 standard; DNA; 15 BP.
XX AAF49375;
XX 30-MAR-2001 (first entry)
XX IGF-I oligonucleotide #335.
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX Homo sapiens.
OS
XX MO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000MO-AU000693.
PF
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURDO-) MURDOCH CHILDRENS RES INST.
PA
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
DR
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 63; 201pp; English.
PS
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAP45151 and AAP45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1324 GGGACCTCTTCGA 1338
DB 1 GAGACCTCTCCCA 15
AAH46697
ID AAH46697 standard; DNA; 15 BP.
XX
XX AAH46697;
AC
XX
XX 19-SEP-2001 (first entry)
DT
XX Target virus detection probe #18.
DE
XX Target virus detection probe; FRET; labelled probe;
KW fluorescence resonance energy transfer; ss.
XX
XX Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 11
FT 1
FT /*tag= a

FT /mod base= OTHER
FT /note= "modified by Cys"
XX
XX JP2000312589-A.
PN
XX 14-NOV-2000.
PD
XX 16-JUL-1999; 99JP-00203474.
PF
XX 04-MAR-1999; 99JP-00057132.
PR
XX (BUNSHI BIOTONICS KENKYUSHO KK.
PA
XX WPI; 2001-400707/43.
DR
XX
XX Detecting a virus comprises a probe formed between at least two same
PT energy donor fluorescent pigments (dip) and an energy acceptor
PT fluorescent pigment (afp) in which the energy from (dip) is relayed to
PT (afp) successively and transferred.
XX
XX Disclosure; Page 10; 40pp; Japanese.
PS
XX The present invention describes a method of detecting a target virus
CC using fluorescence resonance energy transfer (FRET), involving reacting
CC with a labelled probe formed between at least two same energy donor
CC fluorescent pigments and an energy acceptor fluorescent pigment in which
CC the energy from the former is relayed to the latter successively and
CC transferred. The probe can be used for the detection of a target virus.
CC The present sequence is a probe described in the exemplification of the
CC invention
XX
XX Sequence 15 BP; 5 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1192 AGAGCCTTTCAGA 1206
DB 1 AGAGCCTTTCAGA 15
AAD20690/C
ID AAD20690 standard; DNA; 15 BP.
XX
XX AAD20690;
AC
XX
XX 03-JAN-2002 (first entry)
DT
XX
XX ASO probe #9 used to detect human GPIIb gene polymorphism.
DE
XX Human; haplotyping; glycoprotein Ib (platelet) alpha protein; GPIIb;
KW Bernard-Soulier syndrome; platelet-type von Willebrand disease; HIV;
KW Alzheimer's disease; allele-specific oligonucleotide; polymorphism;
KW probe; human immunodeficiency virus; ASO; ss.
XX
XX Homo sapiens.
OS
XX MO200175065-A2.
PN
XX 11-OCT-2001.
PD
XX 03-APR-2001; 2001WO-US010671.
PF
XX 03-APR-2000; 2000US-0194341P.
PR
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX Bentivegna SC, Choi JY, Klem SE, Koshy B, Parks KE;
PI WPI; 2001-626427/72.
DR
XX

PT New haplotypes of the glycoprotein Ib platelet alpha polypeptide gene are
PT useful for diagnosis and drug discovery for treating Bernard Soulier
PT syndrome, platelet-type von Willebrand disease, HIV and Alzheimer's
PT disease.
XX
XX PS Claim 16; Page 14; 66pp; English.
XX
CC The invention relates to methods for haplotyping glycoprotein Ib
CC (platelet) alpha polypeptide (GP1BA) gene of an individual. The method
CC involves determining if the individual has one of the GP1BA haplotypes or
CC haplotype pairs. The methods of the invention are useful for disease
CC diagnosis and in the discovery and development of drugs for treating
CC diseases associated with GP1BA activity e.g. Bernard-Soulier syndrome,
CC platelet-type von Willebrand disease, HIV and Alzheimer's disease. The
CC present sequence is allele-specific oligonucleotide (ASO) probe used for
CC detecting human GP1BA gene polymorphisms
XX
SQ Sequence 15 BP; 1 A; 7 C; 3 G; 3 T; 0 U; 1 Other;
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1272 GAGGCTGAGGCGACA 1286
Db 15 GAGGCTGYGCCACA 1
RESULT 646
AAL16939
ID AAL16939 standard; DNA; 15 BP.
XX
XX AC AAL16939;
XX
XX DT 28-NOV-2001 (first entry)
XX
XX DE Probing nucleobase sequence of PNA probe #10.
XX
XX KW Peptide nucleic acid; PNA probe; probing nucleobase sequence; detection;
KW identification; pharmaceutical product; therapy; personal care product;
KW clinical specimen; environmental sample; water; dairy product; beverage;
KW food; ss.
XX
XX OS Eukaryota.
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT modified_base 1..15
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This sequence is a peptide nucleic acid i.e. it
FT contains a polyamide backbone instead of a deoxyribose-
FT phosphate backbone"
FT modified_base 1
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Thymine is modified with Flu-OE", where Flu =
FT 5(6)-carboxy-fluorescein, O = 8-amino-3,6-dioxactanoic
FT acid and E is defined in the specification"
FT modified_base 15
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Adenine is modified with EE-NH2"
XX
XX FN US2001010910-A1.
XX
XX PD 02-AUG-2001.
XX
XX PP 03-AUG-1999; 99US-00368089.
XX
XX PR 07-AUG-1998; 98US-0095628P.
XX
XX PA (BOST-) BOSTON PROBES INC.

XX
XX PI Hybrid-Nielsen JJ, O'Keefe HP;
XX WPI; 2001-496165/54.
XX
XX DR WPI; 2001-496165/54.
XX
XX PT New peptide nucleic acid probes comprising a probing nucleobase sequence,
XX useful for detecting, identifying or enumerating bacteria or eucarya in
XX food, beverages, water, pharmaceutical, personal care or dairy products.
XX
XX PS Example 10; Page 14; 30pp; English.
XX
XX CC The invention relates to novel peptide nucleic acid (PNA) probes, which
XX comprise a probing nucleobase sequence suitable for the universal yet
XX specific detection, identification or enumeration of bacteria or eucarya
XX in a sample. PNA probes and the kit comprising the probes are useful for
XX distinguishing, identifying, detecting or quantifying bacteria and
XX eucarya in food, beverages, water, pharmaceutical products, personal care
XX products, dairy products, clinical or environmental samples, and for the
XX analysis of raw materials, equipment, products or processes used to
XX manufacture or store food, beverages, water, pharmaceutical products,
XX personal care products, dairy products or environmental samples. The
XX probes are also useful for the detection of bacteria and eucarya in
XX clinical specimens, equipment, fixtures or products used to treat humans
XX and animals. The present sequence is a probing nucleobase sequence of PNA
XX probe. This sequence is designed to hybridise to eukaryote target
XX sequence to enable its detection
XX
SQ Sequence 15 BP; 6 A; 4 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1201 TGCAGAGGCGACCA 1215
Db 1 TACAAGGCGACCA 15
RESULT 647
AAL45923/c
ID AAL45923 standard; DNA; 15 BP.
XX
XX AC AAL45923;
XX
XX DT 08-JUL-2002 (first entry)
XX
XX DE Murine dystrophin-specific antisense oligonucleotide mAO#5.
XX
XX KW Antisense oligonucleotide; exon skipping; exon inclusion signal;
KW disease treatment; splice-modulation; gene therapy; dystrophin;
KW haemostatic; antithyroid; muscular; mouse; ss.
XX
XX OS Mus sp.
XX
XX PN EP1191097-A1.
XX
XX PD 27-MAR-2002.
XX
XX PF 21-SEP-2000; 2000EP-00203283.
XX
XX PR 21-SEP-2000; 2000EP-00203283.
XX
XX PA (UTLE-) UNIV LEIDS MEDISCH CENT.
XX
XX PI Van Ommen GB, Van Deutekom JCT, Den Dunnen JT, Dauwerse JG;
XX Datsen NA;
XX WPI; 2002-354071/39.
XX
XX PT Decreasing the production of an aberrant protein in a cell, for treatment
XX of inherited diseases such as Duchenne Muscular Dystrophy or Hemophilia,
XX comprises a splice modulation therapy of exons.

PS Example 1, Page 6, 18pp, English.

XX The present invention relates to a method of decreasing the production of
CC an aberrant protein in a cell containing pre-mRNA of exons coding for the
CC protein, involving providing the cell with an agent capable of
CC specifically inhibiting an exon inclusion signal of one of the exons, and
CC allowing translation of mRNA produced from splicing of pre-mRNA. The new
CC method decreases the production of an aberrant protein in a cell by using
CC a process known as exon-skipping. The process is carried out by providing
CC an agent such as a nucleic acid to inhibit the exon inclusion signal. The
CC nucleic acid agent can therefore be used as a preparation of a medicament
CC for treatment of inherited diseases such as haemophilia A, clotting
CC factor VIII deficiency, some forms of congenital hypothyroidism, Duchenne
CC Muscular Dystrophy, and Becker Muscular Dystrophy. The present sequence
CC is an antisense oligonucleotide directed at the murine dystrophin pre-
CC mRNA

XX Sequence 15 BP; 1 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1265 GCTGGAGAGGCTGA 1279
DB 15 GCTGGAGAGGCTGA 1

RESULT 648
ABL52290
ID ABL52290 standard; DNA; 15 BP.

XX ABL52290;

DT 15-JUN-2002 (first entry)

XX Human CCR6 allele specific oligonucleotide primer SEQ ID NO:14.

XX Human, chemokine (C-C motif) receptor 6; chemokine receptor 6; CCR6;
KW receptor; polymorphic; single nucleotide polymorphism; SNP; genotyping;
KW haplotyping; antipsoriatic; gene therapy; antisense gene therapy;
KW psoriasis; allele specific oligonucleotide; ASO; primer; ss.

XX Homo sapiens.

OS Key Location/Qualifiers
FH misc_feature 14
FT /*tag= a
FT /note= "polymorphic base indicated by an ambiguity base"

XX W0200226764-A2.

PN 04-APR-2002.

XX 24-SEP-2001; 2001WO-US029823.

PF 26-SEP-2000; 2000US-0235705P.

XX (GENA-) GENAISSANCE PHARM INC.

PA (GENA-) GENAISSANCE PHARM INC.

PI Chew A, Choi JY, Koshy B;

XX WPI; 2002-394235/42.

DR New genetic variants of chemokine (C-C) motif receptor 6, useful for
XX therapeutic purposes and for expressing CCR6 protein useful in
PT identifying drugs to treat psoriasis.

XX Claim 16, Page 13, 73pp, English.

XX The present invention describes an isolated polynucleotide (I) comprising
CC a nucleotide sequence which is a polymorphic variant of a reference
CC sequence for chemokine (C-C motif) receptor 6 (CCR6) gene (see ABL52278)

CC or its fragment, or a polymorphic variant of a reference sequence for a
CC CCR6 cDNA (see ABL52279) or its fragment. Also described is are methods
CC for haplotyping and genotyping the CCR6 gene of an individual, and a
CC method for identifying (iii) an association between a trait and a
CC haplotype or haplotype pair of CCR6 gene, by comparing the frequency of
CC the haplotypes 1-13 or haplotype pair in a population exhibiting the
CC trait with the frequency of the haplotype or haplotype pair in a
CC reference population. (ii) has antipsoriatic activity, and can be used in
CC gene therapy and antisense gene therapy. (ii) is useful for identifying
CC an association between a trait such as a clinical response to a drug
CC targeting CCR6 and a haplotype or haplotype pair of CCR6 gene. Methods
CC from the present invention have applicability in developing diagnostic
CC tests and therapeutic treatments for psoriasis. (i) is useful for
CC studying the expression and function of CCR6 and expressing CCR6 proteins
CC for use in screening for candidate drugs to treat diseases related to
CC CCR6 activity. Establishing the CCR6 haplotype or haplotype pair of an
CC individual is useful for improving the efficiency and reliability of
CC several steps in the discovery and development of drugs for treating
CC diseases associated with CCR6 activity, such as psoriasis. The present
CC sequence represents an allele specific oligonucleotide (ASO) primer for
CC human CCR6, which is used in the exemplification of the present invention

XX Sequence 15 BP; 3 A; 5 C; 5 G; 1 T; 0 U; 1 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1279 AGGCGAGAGCCCTC 1293
DB 1 AGGCGAGAGCCCTC 15

RESULT 649
ABX01470
ID ABX01470 standard; RNA; 15 BP.

XX ABX01470;

DT 23-DEC-2002 (first entry)

XX Hepatitis C virus substrate #1252 for HCV hammerhead ribozyme #1252.

XX Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytostatic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.

XX Hepatitis C virus.

OS US2002082225-A1.

PN 27-JUN-2002.

XX 23-MAR-1999; 99US-00274553.

PF 23-MAR-1999; 99US-00274553.

XX 23-MAR-1999; 99US-00274553.

XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.

PI Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;

XX WPI; 2002-617759/66.

DR New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
XX replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.

XX Claim 1; Page 57; 80pp; English.
PS
XX
CC The present invention relates to enzymatic nucleic acids which
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC (HP) motif where the binding arms comprise sequences complementary to one
CC of the substrate sequences defined in the specification. The HCV
CC ribozymes are useful for modulating the expression and/or replication of
CC HCV. They can be used to treat cirrhosis, liver failure and/or
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC a condition associated with HCV infection in conjunction with one or more
CC other drug therapies, particularly type I interferon, especially
CC interferon alpha, beta or gamma or consensus interferon. The present
CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC Some of the sequence data for this patent did not form part of the
CC printed specification. The complete sequence data for this patent was
CC obtained in electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/patseq/entry.html
XX
SQ Sequence 15 BP; 7 A; 2 C; 4 G; 0 T; 2 U; 0 Other;
XX
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
OY 1261 AACAGCTGGAAGAGG 1275
Db |||||:|||||
1 AACAGCTUGAAAGG 15
DE
RESULT 650
ABX01227/C
ID ABX01227 standard; RNA; 15 BP.
XX
AC ABX01227;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #1009 for HCV hammerhead ribozyme #1009.
XX
KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytosolic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
KW Hepatitis C virus.
OS
XX
FN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blact L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
PS
XX Claim 1; Page 50; 80pp; English.

XX
CC The present invention relates to enzymatic nucleic acids which
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC (HP) motif where the binding arms comprise sequences complementary to one
CC of the substrate sequences defined in the specification. The HCV
CC ribozymes are useful for modulating the expression and/or replication of
CC HCV. They can be used to treat cirrhosis, liver failure and/or
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC a condition associated with HCV infection in conjunction with one or more
CC other drug therapies, particularly type I interferon, especially
CC interferon alpha, beta or gamma or consensus interferon. The present
CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC Some of the sequence data for this patent did not form part of the
CC printed specification. The complete sequence data for this patent was
CC obtained in electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/patseq/entry.html
XX
SQ Sequence 15 BP; 2 A; 9 C; 2 G; 0 T; 2 U; 0 Other;
XX
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1412 GGGTGTGAGCGGC 1426
Db |||||:|||||
15 GGGTGTGAGCGGAC 1
DE
RESULT 651
ABX01345/C
ID ABX01345 standard; RNA; 15 BP.
XX
AC ABX01345;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #1127 for HCV hammerhead ribozyme #1127.
XX
KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytosolic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
KW Hepatitis C virus.
OS
XX
FN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blact L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
PS
XX Claim 1; Page 53; 80pp; English.
XX
CC The present invention relates to enzymatic nucleic acids which

Db 15 CAGCAGCGCTGCA 1

RESULT 654
ACD66351/C
ID ACD66351 standard; RNA, 15 BP.
XX
AC ACD66351;
XX
DT 23-SEP-2003 (first entry)
XX
DE Anti-HCV nucleic acid molecule target sequence #234.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; anti-HCV;
KW viral replication; degenerative; disease state; HBV infection;
KW HCV infection; cirrhosis; liver failure; hepatocellular carcinoma;
KW hepatotropic; cytostatic; virucide; antiinflammatory; target; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PE 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 322; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC diseases states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a target for one of the anti-

CC HCV nucleic acid molecules disclosed in the present invention
XX
SQ Sequence 15 BP; 2 A; 5 C; 3 G; 0 T; 5 U; 0 Other;
XX
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1265 GCTGGAGAGCGCTGA 1279
DB 15 GCTGGAGAGACACTGA 1
XX
RESULT 655
ACD66421/C
ID ACD66421 standard; RNA, 15 BP.
XX
AC ACD66421;
XX
DT 23-SEP-2003 (first entry)
XX
DE Anti-HCV enzymatic nucleic acid substrate sequence #7.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; anti-HCV;
KW viral replication; degenerative; disease state; HBV infection;
KW HCV infection; cirrhosis; liver failure; hepatocellular carcinoma;
KW hepatotropic; cytostatic; virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PE 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 326; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse


```
XX Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1247 GGTCCGGCTGCAGCA 1261
DB 1 GATCCGCTGCAGCA 15

RESULT 658
ACD82304
ID ACD82304 standard; DNA; 15 BP.
XX
AC ACD82304;
XX
AC ACD82304;
XX
DT 19-SEP-2003 (first entry)
XX
DE Nucleic acid cloning associated adaptor molecule #5.
XX
KM Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KM internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
DR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 1; 100pp; English.
XX
CC The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
SQ Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
QY
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
DB 1247 GGTCCGGCTGCAGCA 1261
DB 1 GATCCGCTGCAGCA 15

RESULT 659
```

```
ACD82546
ID ACD82546 standard; DNA; 15 BP.
XX
AC ACD82546;
XX
DT 19-SEP-2003 (first entry)
XX
DE Nucleic acid cloning associated adaptor molecule #247.
XX
KM Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KM internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
DR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 5; 100pp; English.
XX
CC The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
SQ Sequence 15 BP; 3 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
QY
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1247 GGTCCGGCTGCAGCA 1261
DB 1 GATCCGCTGCAGCA 15

RESULT 660
ABX08696/C
ID ABX08696 standard; DNA; 15 BP.
XX
AC ABX08696;
XX
DT 20-JAN-2003 (first entry)
XX
DE Pathogenic organism detection method associated PCR primer #26.
XX
KM PCR; primer; ss; hepatitis C virus; human; pathogenic microorganism;
KM influenza; AIDS; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
```

XX WO200277281-A1.
XX
XX 03-OCT-2002.
XX
XX
XX 05-MAR-2002; 2002WO-JP002030.
XX
XX 27-MAR-2001; 2001JP-00090053.
XX 18-SEP-2001; 2001JP-00284112.
XX (TOKE) TOSHIBA KK.
XX
XX Hashimoto K, Hashimoto M, Mishiho S, Oota Y;
XX WPI; 2003-040593/03.
XX
XX
XX Detecting nucleic acids relating diseases particularly due to pathogenic
XX microorganisms e.g. hepatitis, influenza and AIDS in individuals from
XX their data using immobilized probes on substrate, also for therapeutic
XX evaluation.
XX
XX Example 3; Page 92; 125pp; Japanese.
XX
XX This invention relates to a method for obtaining first data on a nucleic
XX acid from an individual exposed to a specific disease and second data on
XX a nucleic acid from a pathogenic microorganism occurring in the
XX individual in order to relate the specific disease to such pathogenic
XX microorganism. The method of the invention comprises the reaction of a
XX nucleic acid extract from the individual with a probe-immobilization
XX substrate containing first and second probes for detection of the
XX pathogenic microorganism with the first probe for detecting a specific
XX microbe-caused disease, and the second probe for detecting a specific
XX nucleic acid in the individual and obtaining first data from the reaction
XX results as well as the detected binding of a nucleic acid with the first
XX probe and/or second data from the detected binding of a nucleic acid with
XX the second probe. The method of the invention is useful for detecting
XX nucleic acids relating diseases particularly due to pathogenic
XX microorganisms e.g. hepatitis C, influenza and AIDS in individuals, and
XX also for therapeutic evaluation. Such a method is convenient and accurate
XX and may be used to design specific therapy for effective treatment even
XX for individual patients in a tailor-made manner. The present sequence
XX represents a PCR primer used in the method of the invention
XX
XX Sequence 15 BP; 2 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 4.7%; Score 11.8; DB 1; Length 15;
XX Best Local Similarity 86.7%; Pred. No. 2.6e+02;
XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX
XX 1249 TCCGGCTGCAGCAAC 1263
XX
XX 15 TCCGGGTGCAGAAC 1
XX
XX
XX RESULT 661
XX ADF92298/C
XX ID ADF92298 standard; DNA; 15 BP.
XX
XX ADF92298;
XX
XX 26-FEB-2004 (first entry)
XX
XX Human cytokeratin 19-related loop F PCR primer - SEQ ID 386.
XX
XX human, cytokeratin; CK; LAMP; loop mediated isothermal amplification;
XX tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
XX PCR; loop F.
XX
XX Homo sapiens.
XX
XX WO2003097878-A1.
XX
XX 27-NOV-2003.
XX
XX

XX 20-MAY-2003; 2003WO-JP006256.
XX
XX
XX 21-MAY-2002; 2002JP-00145689.
XX 17-JUN-2002; 2002JP-00195271.
XX 09-JUL-2002; 2002JP-00197579.
XX
XX (SYSM-) SYSMEX CORP.
XX
XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
XX WPI; 2004-012543/01.
XX
XX
XX LAMP nucleic acid amplification primers for detection of cytokeratin
XX expression as indicator in diagnosis of tumour metastasis.
XX
XX Claim 19; SEQ ID NO 386; 266pp; Japanese.
XX
XX
XX The invention relates to novel nucleic acid amplification primers for the
XX detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
XX (loop mediated isothermal amplification) method. The primers of the
XX invention may be useful for the detection of tumour metastasis, particularly
XX an indicator for the diagnosis of tumour metastasis, particularly
XX prostate cancer and lymphoma. The amplification using the primers is
XX highly efficient and allows very sensitive detection of tumour
XX metastasis. The current sequence is that of the human CK19-related PCR
XX primer of the invention.
XX
XX Sequence 15 BP; 0 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX
XX Query Match 4.7%; Score 11.8; DB 1; Length 15;
XX Best Local Similarity 86.7%; Pred. No. 2.6e+02;
XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX
XX 1372 ACCAGAGCCAGCTGC 1386
XX
XX 15 ACCAGAACAGAGGGC 1
XX
XX
XX RESULT 662
XX ADH50189
XX ID ADH50189 standard; DNA; 15 BP.
XX
XX ADH50189;
XX
XX 25-MAR-2004 (first entry)
XX
XX Bacterial DNA hybridization probe, SEQ ID No 40.
XX
XX
XX non-viral organism; detection; purulent infection; bacteraemia;
XX meningitis; endocarditis; neonatal meningitis; respiratory diphtheria;
XX inflammatory intestinal disease; endocarditis; respiratory diphtheria;
XX pneumonia; abscess; oral infection; festering nasopharyngitis; mouth;
XX urinary track; deep infection; arthritis; enteritis; diarrhoea; brain;
XX respiratory; male reproductive; bite wound; otitis media;
XX acute appendicitis; aphtha; mycosis; probe; ss.
XX
XX Unidentified.
XX
XX WO2003095677-A1.
XX
XX 20-NOV-2003.
XX
XX 09-MAY-2003; 2003WO-KR000923.
XX
XX
XX 09-MAY-2002; 2002KR-00025561.
XX 09-MAY-2002; 2002KR-00025562.
XX 09-MAY-2002; 2002KR-00025566.
XX 09-MAY-2002; 2002KR-00025567.
XX 09-MAY-2002; 2002KR-00025569.
XX 09-MAY-2002; 2002KR-00025579.
XX 09-MAY-2002; 2002KR-00025580.
XX 09-MAY-2002; 2002KR-00025582.
XX
XX

```

PR 09-MAY-2002; 2002KR-00025583.
PR 09-MAY-2002; 2002KR-00025634.
PR 09-MAY-2002; 2002KR-00025687.
PR 28-AUG-2002; 2002KR-00051054.
PR 25-JAN-2003; 2003KR-00005082.
PR 27-JAN-2003; 2003KR-00005341.
PR 27-JAN-2003; 2003KR-00005342.
PR 27-JAN-2003; 2003KR-00005344.
XX
XX (MEDI-) MEDIGENES.
XX
XX Lee S, Chang K, Yoo S, Yoo S, Keum K, Yoo N, Yoo W, Lee G,
XX Kim J;
XX WPI, 2004-012140/01.
XX
XX New nucleic acid molecule, useful for preparing a composition for
XX diagnosing diseases caused by non-viral organisms, e.g., Acinetobacter
XX baumannii, Bacteroides fragilis, Cardiobacterium hominis or Clostridium
XX ramosum.
XX
XX Example 7; SEQ ID NO 40; 135bp; English.
XX
XX The invention relates to a novel detection method of non-viral organisms.
XX The invention further relates to a novel isolated nucleic acid molecule
XX which has a fully defined sequence comprising 1830-5502 bp. The detection
XX method comprises a kit, which contains: a composition comprising the
XX nucleic acid probe; a pair of forward and reverse primers used for
XX amplifying the polynucleic acids in the biological sample; a buffer
XX enabling hybridization reaction between the probes contained in the
XX composition and the polynucleic acids present in the biological sample or
XX their amplified products or components necessary for producing the buffer
XX ; a solution for washing hybrids; and optionally means for detection of
XX the hybrids. The novel nucleic acid is useful for preparing a composition
XX for diagnosing diseases caused by non-viral organisms, e.g.,
XX Acinetobacter baumannii, Acinetobacterium hominis, Chryseobacterium,
XX Bacteroides fragilis, Cardiobacterium hominis, Chryseobacterium,
XX meningosepticum, Clostridium ramosum, Corynebacterium diphtheriae,
XX Klebsiella oxytoca, Ochrobactrum anthropi, Peptostreptococcus prevotii,
XX Porphyromonas gingivalis, Peptostreptococcus anaerobius,
XX Peptostreptococcus magnus, Fusobacterium necrophorum, Proteus vulgaris,
XX Enterobacter aerogenes, Streptococcus mutans, Kingella kingae,
XX Bacteroides ovatus, Bacteroides thetaiotaomicron, Clostridium difficile,
XX Hemophilus aphrophilus, Neisseria gonorrhoea, Elkella corrodens,
XX Bacteroides vulgatus, Branhamella catarrhalis, Sutterella wadsworthensis,
XX Actinomyces israelii, Streptococcus epidermidis, Burkholderia cepacia,
XX Salmonella enteritidis, Escherichia coli, Klebsiella pneumoniae, Proteus
XX mirabilis, Streptococcus pneumoniae, Vibrio vulnificus, Pseudomonas
XX aeruginosa, Aeromonas hydrophila, Listeria monocytogenes, Enterococcus
XX faecium, Staphylococcus aureus, Neisseria meningitidis, Legionella
XX pneumophila, Candida albicans or Candida glabrata. These non-viral
XX organisms can cause, but are not limited to, disorders such as: purulent
XX infection, bacteraemia, meningitis, endocarditis, neonatal meningitis,
XX inflammatory intestinal diseases, endocarditis, respiratory diphteria,
XX pneumonia, abscesses, oral infection, febrile nasopharyngitis, mouth
XX infection, urinary tract infection, deep infection, arthritis, enteritis,
XX diarrhoea, localised brain or respiratory infection, male reproductive
XX disorder, bite wounds, otitis media, acute appendicitis, aphtha, and
XX mycosis. This polynucleotide sequence represents a probe used in the
XX exemplification of the invention.
XX
XX Sequence 15 BP; 4 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 4.7%; Score 11.8; DB 1; Length 15;
XX Best Local Similarity 86.7%; Pred. No. 2.6e+02;
XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1374 CAGAAGCAGCTGCGT 1388
XX |||||
XX 1 CAGAAGTACCTCCT 15

```

```

ADK67644/C
ID ADK67644 standard; DNA; 15 BP.
XX
XX ADK67644;
AC
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide HD3S/15, decreases Huntingtin aggregation.
XX
XX Huntington's disease; huntingtin; protein aggregation; phosphorothioate;
XX gene therapy; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..3
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= phosphorothioate nucleotides"
XX modified_base 13..15
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "OTHER= phosphorothioate nucleotides"
XX
XX WO2004014306-A2.
XX
XX 19-FEB-2004.
XX
XX 07-AUG-2003; 2003WO-US024868.
XX
XX 07-AUG-2002; 2002US-0402198P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Parekh-Olmedo H;
XX WPI; 2004-180536/17.
XX
XX Identifying the oligonucleotide species that disrupts aggregation of a
XX protein aggregant in a cell by introducing the oligonucleotide species or
XX composition separately into cells that have or are likely to develop
XX aggregation.
XX
XX Example 3; SEQ ID NO 14; 59bp; English.
XX
XX The present sequence is that of oligonucleotide HD3S/15, a 15-mer
XX containing 3 phosphorothioate linkages at each terminus that is
XX complementary to the non-transcribed strand of the Huntington's disease
XX (HD) gene. In an example from the invention, the oligonucleotide was
XX shown to be capable of reducing aggregate formation in PC12 cell lines
XX containing integrated copies of a poly(103)Q-enhanced green fluorescent
XX protein fusion gene. The invention is based on the discovery that
XX oligonucleotides unrelated in sequence to that of a nucleic acid which
XX encodes a protein aggregant can be effective in disrupting or preventing
XX aggregation in disorders of protein assembly. A claimed method for
XX identifying, from a plurality of oligonucleotides differing in sequence
XX and/or composition, those oligonucleotide species that disrupt
XX aggregation of a protein aggregant in a cell, comprises introducing the
XX oligonucleotides separately into cells that have or are likely to develop
XX protein aggregates, and identifying those that are effective at
XX preventing, reducing or disrupting aggregation. The oligonucleotides are
XX useful for treating a disorder of protein assembly such as HD,
XX Alzheimer's disease, cystic fibrosis, amyotrophic lateral sclerosis,
XX Parkinson's disease, spinobulbar muscular atrophy, spinocerebellar ataxia
XX types 1, 2, 3, 6 and 7, dentatorubral-pallidoluysian atrophy, prion
XX diseases, scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jacob
XX disease, new variant CJD, Pick's disease, diabetes type II, multiple
XX myeloma-plasma cell dyscrasia, medullary carcinoma of the thyroid,
XX chronic renal failure, congestive heart failure, chronic inflammation,
XX atherosclerosis (apoA1) or familial amyloidosis.
XX
XX Sequence 15 BP; 1 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
XX

```

```
Query Match          4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1260 CAACAGCTGGAAGAG 1274
      |||||
      15 CAACAGCTGCAACAG 1

Db

RESULT 664
ADL72196/C
ID      ADL72196 standard; DNA; 15 BP.
XX
XX
AC      ADL72196;
XX
XX      20-MAY-2004 (first entry)
XX
XX      Human nucleotide sequence, SEQ ID 3.
XX
XX      Base-sequencing; sensing electrode; genetic engineering; gene analysis;
XX      disease diagnosis; human; ss.
XX
XX      Homo sapiens.
XX
XX      WO2004019024-A1.
XX
XX      04-MAR-2004.
XX
XX      28-AUG-2002; 2002WO-JP008671.
XX
XX      23-AUG-2002; 2002JP-00244018.
XX
XX      (TOKE ) TOSHIBA KK.
XX
XX      Okada J, Hashimoto K, Takahashi M;
XX      WPI; 2004-248114/23.
XX
XX      Nucleic acid probe-immobilized sensing electrodes in devices for base
XX      sequencing, applicable in genetic engineering and medicine e.g. in gene
XX      analysis, disease diagnosis and species identification.
XX
XX      Example 1; SEQ ID NO 3; 55pp; Japanese.
XX
XX      The invention relates to a base-sequencing electrode that comprises: a
XX      conductive sensing electrode; first blocking molecules coated onto
XX      surface of such sensing electrode; a target complementary nucleic acid
XX      probe which is immobilized onto the sensing electrode; a conductive
XX      reference electrode; and second blocking molecules coated onto surface of
XX      the reference electrode to reduce adsorption of an inserting agent by the
XX      surface. The target complementary probe is immobilized onto the sensing
XX      electrode via a first spacer member made from a linear organic molecule
XX      which has a base sequence complementary to a target base sequence to be
XX      determined. The reference electrode is immobilized through a second
XX      spacer member formed of a linear organic molecule to provide a dummy
XX      probe with a base sequence non-complementary to the target base
XX      sequence. The electrodes and devices are for base sequencing, which are
XX      applicable in genetic engineering and medicine e.g. in gene analysis,
XX      disease diagnosis and species identification. Such electrodes and devices
XX      are easily and cheaply constructed for accurate base sequencing with ease
XX      in operation and result judgment. Sequences ADL72195-ADL72197 represent
XX      human derived nucleotide sequences used in the method of the invention.
XX
XX      Sequence 15 BP; 2 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX      Query Match          4.7%; Score 11.8; DB 1; Length 15;
XX      Best Local Similarity 86.7%; Pred. No. 2.6e+02;
XX      Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX      1249 TCCGGCTGCAGCAAC 1263
XX      |||||
XX      15 TCCGGCTGCAGCAAC 1
XX
XX      Db
```

```
RESULT 665
ADM88705/C
ID      ADM88705 standard; DNA; 15 BP.
XX
XX      ADM88705;
XX
XX      03-JUN-2004 (first entry)
XX
XX      Eukaryote 18S RNA probe #1.
XX
XX      multiplex peptide nucleic acid in situ hybridisation; PNA-ISH assay;
XX      bacteria detection; eucarya detection; bacteria identification;
XX      eucarya identification; PNA probe; peptide nucleic acid probe;
XX      quantitating hybridisation; food; beverage; water; pharmaceutical;
XX      personal care product; dairy product; environmental sample; 18S RNA;
XX      probe; ss; eukaryote; PNA; peptide nucleic acid.
XX
XX      Eukaryota.
XX
XX      OS
XX      FH      Key
XX      FT      modified_base
XX
XX      Location/Qualifiers
XX      1
XX      /*tag= a
XX      /mod_base= OTHER
XX      /note= "OTHER= (5 (6) -carboxyfluorescein) - (8amino-3,6-
XX      dioxoacetic acid) - (N,N'-
XX      (methoxyethyl)amino)carbonyl(methoxymethyl)carbonyl)2"
XX      15
XX      /mod_base= b
XX      /*tag= b
XX      /mod_base= OTHER
XX      /note= "OTHER= C-terminal amide"
XX
XX      US6656687-B1.
XX
XX      02-DEC-2003.
XX
XX      30-MAR-2001; 2001US-00822763.
XX
XX      07-AUG-1998; 98US-0095628P.
XX      03-AUG-1999; 99US-00368089.
XX
XX      (BOST-) BOSTON PROBS INC.
XX
XX      Hybrid-Nielsen JJ;
XX
XX      WPI; 2004-088236/09.
XX
XX      Multiplex peptide nucleic acid in-situ hybridization assay for detection,
XX      identification or quantitation of organisms in sample, comprises
XX      contacting sample with peptide nucleic acid probes comprising probing
XX      nucleobase sequence.
XX
XX      Example 10; Col 25-26; 28pp; English.
XX
XX      The invention describes a multiplex peptide nucleic acid in situ
XX      hybridisation (PNA-ISH) assay for the detection, identification or
XX      quantitation of two or more organisms in a sample. The assay comprises
XX      contacting the sample with two or more independently detectable PNA
XX      probes, each comprising a probing nucleobase sequence that hybridises to
XX      a different target sequence. At least one detectable PNA probe hybridises
XX      to the target sequence in at least one bacteria and at least one other
XX      independently detectable PNA probe hybridises to the target sequence in
XX      at least one eucarya. It also includes detecting, identifying or
XX      quantitating hybridisation of the probing nucleobase sequence of the
XX      individual PNA probes to the target sequence of each of the different
XX      organisms and correlating the result for each of the two or more
XX      independently detectable PNA probes with the presence, absence or number
XX      of the different organisms in the sample. The invention is for the
XX      detection, identification or quantitation of two or more organisms in a
XX      sample. The sample is a food, a beverage, water, a pharmaceutical
XX      product, a personal care product, a dairy product or an environmental
XX      sample. It can be a raw material, a piece of equipment, a fixture, a
XX      product or a clinical environment. It can also be a human or animal
```

CC origin. The invention provides for the rapid, reliable and sensitive
CC multiplex analysis of samples for the presence or absence of
CC microorganisms and particularly bacteria and/or eucarya. The probes and
CC assays are useful for the detecting, identifying and quantifying only
CC colony forming units (viable organisms) in a sample. This sequence
CC represents a 18s RNA probe used for detecting eukaryotes in a sample.

XX Sequence 15 BP; 6 A; 4 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1201 TGCAGAGGCGACCA 1215
Db 1 TACAAAGCGACCA 15

RESULT 666
AD187738/C
ID AD187738 standard; RNA; 15 BP.

XX AD187738;

XX 03-JUN-2004 (first entry)

XX Anti-HCV molecule target sequence #230.

XX 8s; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNazyme.

XX Hepatitis C virus.

XX US2003125270-A1.

XX 03-JUL-2003.

XX 18-DEC-2000; 2000US-00740332.

XX 18-DEC-2000; 2000US-00740332.

XX (BLATT/) BLATT L.

XX (MCSW/) MCSWIGGEN J.

XX (ROBE/) ROBERTS E.

XX (PAVC/) PAVCO P A.

XX (MACE/) MACEJACK D.

XX Blact L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;

XX WPI; 2004-031273/03.

XX Enzymatic nucleic acid molecules which specifically cleave RNA derived

XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,

XX especially in combination with type I interferon therapy.

XX Claim 1; SEQ ID NO 4784; 198bp; English.

XX The invention relates to an enzymatic nucleic acid molecule which

XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which

XX the binding arms of the enzymatic nucleic acid molecule comprises

XX sequences complementary to any of the defined substrate sequences given

XX in the specification. The nucleic acid molecule may be administered for

XX the treatment of HCV infections, especially in combination with type I

XX interferons. The present sequence represents an anti-HCV molecule target

XX sequence.

Db 15 GCTGAGAGCACTGA 1

RESULT 667

ADO49528/C

ID ADO49528 standard; DNA; 15 BP.

XX ADO49528;

XX 29-JUL-2004 (first entry)

XX H. pylori strain J99 genome fragment SEQ ID NO:151.

XX ds; stroke; phosphodiesterase 4D; PDE4D.

XX Helicobacter pylori.

XX US2004091865-A1.

XX 13-MAY-2004.

XX 25-SEP-2002; 2002US-00255120.

XX 19-MAR-2001; 2001US-00813352.

XX 04-FEB-2002; 2002US-00067514.

XX (DECO-) DECODE GENETICS BHF.

XX Gtetrastodttr S, Jonadottr S, Reynisdottir ST, Thorleifsson G;

XX WPI; 2004-374932/35.

XX Diagnosing susceptibility to a stroke in an individual comprising

XX screening for an at-risk haplotype in the phosphodiesterase 4D gene.

XX Disclosure; SEQ ID NO 151; 574bp; English.

XX The invention relates to a method of diagnosing susceptibility to a

XX stroke in an individual comprising screening for an at-risk haplotype in

XX the phosphodiesterase 4D (PDE4D) gene that is more frequently present in

XX an individual susceptible to stroke (affected) compared to a healthy

XX individual (control), where the at-risk haplotype increases risk of

XX stroke significantly. The composition, methods and kit are useful for

XX diagnosing, predicting of clinical course and treating stroke using

XX polymorphisms in the PDE4D gene. These may also be used in identifying

XX agents that enhance or inhibit PDE4D polypeptide expression or activity.

XX The present sequence represents a fragment of H. pylori strain J99 genome

XX which is not referred to at all in the main body of the specification.

XX Sequence 15 BP; 6 A; 4 C; 2 G; 3 T; 0 U; 0 Other;

XX Query Match 4.7%; Score 11.8; DB 1; Length 15;

XX Best Local Similarity 86.7%; Pred. No. 2.6e+02;

XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1303 TGGTCATCTGTGAGC 1317

Db 15 TGGTATCTTTGAGC 1

RESULT 668

ADO49413/C

ID ADO49413 standard; DNA; 15 BP.

XX ADO49413;

XX 29-JUL-2004 (first entry)

XX H. pylori strain J99 genome fragment SEQ ID NO:36.

XX ds; stroke; phosphodiesterase 4D; PDE4D.

XX

```
OS Helicobacter pylori.
XX
XX US2004091865-A1.
XX
XX 13-MAY-2004.
XX
XX 25-SEP-2002; 2002US-00255120.
XX
XX 19-MAR-2001; 2001US-00811352.
XX
XX 04-FEB-2002; 2002US-00067514.
XX
XX (DECO-) DECODE GENETICS EHF.
XX
XX Grestatodottr S, Jonsdottr S, Reynisdottr ST, Thorleifsson G;
XX
XX WPI; 2004-374932/35.
XX
XX Diagnosing susceptibility to a stroke in an individual comprising
XX screening for an at-risk haplotype in the phosphodiesterase 4D gene.
XX
XX Disclosure; SEQ ID NO 36; 574pp; English.
XX
XX The invention relates to a method of diagnosing susceptibility to a
XX stroke in an individual comprising screening for an at-risk haplotype in
XX the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
XX an individual susceptible to stroke (affected) compared to a healthy
XX individual (control), where the at-risk haplotype increases risk of
XX stroke significantly. The composition, methods and kit are useful for
XX diagnosing, predicting of clinical course and treating stroke using
XX polymorphisms in the PDE4D gene. These may also be used in identifying
XX agents that enhance or inhibit PDE4D polypeptide expression or activity.
XX The present sequence represents a fragment of H. pylori strain J99 genome
XX which is not referred to at all in the main body of the specification.
XX
XX Sequence 15 BP; 6 A; 4 C; 2 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 4.7%; Score 11.8; DB 1; Length 15;
XX Best Local Similarity 86.7%; Pred. No. 2.6e+02;
XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1303 TGGTCATCTGTGAGC 1317
XX |||||
XX 15 TGGTATCTTTGAGC 1
XX
XX RESULT 669
XX AAT55606/C
XX ID AAT55606 standard; RNA; 16 BP.
XX
XX AAT55606;
XX
XX 25-MAR-2003 (revised)
XX DT 15-APR-1997 (first entry)
XX
XX Mouse relA hairpin ribozyme target sequence (nt. position 366).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
XX gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
XX intercellular adhesion molecule; rel A; tumor necrosis factor;
XX TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
XX translocation; chronic myelogenous leukaemia; CML; cancer;
XX Philadelphia chromosome; inflammation; autoimmune disease;
XX atherosclerosis; myocardial infarction; stroke; restenosis;
XX transplant rejection; rheumatoid arthritis; psoriasis;
XX myocardial ischaemia; Kawasaki disease; septic shock; HIV;
XX human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
XX
XX 88.
XX
XX Mus musculus.
XX
XX OS
XX
XX W09523225-A2.
XX
XX 31-AUG-1995.
XX
```

```
XX
XX 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX
XX 29-MAR-1994; 94US-00218934.
XX
XX 04-APR-1994; 94US-00222795.
XX
XX 07-APR-1994; 94US-00224483.
XX
XX 15-APR-1994; 94US-00227958.
XX
XX 18-MAY-1994; 94US-00228041.
XX
XX 18-MAY-1994; 94US-00245736.
XX
XX 06-JUL-1994; 94US-00271280.
XX
XX 15-AUG-1994; 94US-00291932.
XX
XX 16-AUG-1994; 94US-00291933.
XX
XX 17-AUG-1994; 94US-00292620.
XX
XX 19-AUG-1994; 94US-00293520.
XX
XX 02-SEP-1994; 94US-00300000.
XX
XX 08-SEP-1994; 94US-00303039.
XX
XX 23-SEP-1994; 94US-00311486.
XX
XX 23-SEP-1994; 94US-00311749.
XX
XX 28-SEP-1994; 94US-00314397.
XX
XX 03-OCT-1994; 94US-00316771.
XX
XX 07-OCT-1994; 94US-00319492.
XX
XX 11-OCT-1994; 94US-00321993.
XX
XX 04-NOV-1994; 94US-00334647.
XX
XX 10-NOV-1994; 94US-00337608.
XX
XX 28-NOV-1994; 94US-00345516.
XX
XX 16-DEC-1994; 94US-00357577.
XX
XX 23-DEC-1994; 94US-00363533.
XX
XX 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
XX Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mewawigen JA;
XX Modak A, Pavco P, Belgiman L, Sullivan SM, Sweedler D, Thompson JD,
XX Tracz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX
XX Claim 2; Page 240; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves relA mRNA at the
XX nucleotide base position indicated in the DE line. The relA gene product
XX is a subunit of the transcriptional regulator NF-kappaB and is implicated
XX specifically in the induction of inflammatory responses. Regions of the
XX mRNA that do not form secondary folding structures and that contain
XX potential hammerhead and hairpin ribozyme cleavage sites were identified
XX by computer analysis. Ribozymes directed against these mRNA sequences
XX were designed and synthesised with modifications that improve their
XX nuclease resistance. The ribozymes are designed to cleave the target
XX sequences and thereby inhibit relA expression, making them potentially
XX useful for treating rheumatoid arthritis, restenosis and asthma as well
XX as for increasing tolerance to transplanted tissues. The potential
XX immunosuppressive properties of a ribozyme that cleaves relA mRNA means
XX that uses are limited to local delivery, acute indications or ex vivo
XX treatment. (Updated on 25-MAR-2003 to correct PI field.)
XX
XX Sequence 16 BP; 2 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 4.7%; Score 11.8; DB 1; Length 16;
XX Best Local Similarity 86.7%; Pred. No. 3.1e+02;
XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1200 GTGCAGAGGCGCAGCC 1214
XX |||||
XX 16 GGGCAGAGGTCAGCC 2
XX
XX RESULT 670
XX
```

AA	F24333/C
ID	AAF24333 standard; DNA; 16 BP.
XX	
AC	AAF24333;
XX	
DT	09-APR-2001 (first entry)
XX	
DE	Human NFAR-1/NFAR-2 intron/exon junction sequence #33.
XX	
KW	Human; nuclear factor associated with dsRNA; NFAR-1; NFAR-2;
KM	transcription regulator; chromosome 19p13.1-13.2; apoptosis;
KW	tumorigenesis; ds.
XX	
OS	Homo sapiens.
XX	
PN	WO200077205-A1.
XX	
PD	21-DEC-2000.
XX	
PF	09-JUN-2000; 2000MO-US015767.
XX	
PR	11-JUN-1999; 99US-0138612P.
XX	
PA	(BARB/) BARBER G N.
XX	(SAUN/) SAUNDERS L.
PA	(PERK/) PERKINS D J.
XX	
PI	Barber GN, Saunders L, Perkins DJ;
XX	
DR	WPI; 2001-080688/09.
XX	
PT	Novel isolated human nuclear factor associated with dsRNA polypeptide
XX	useful for determining structure-function relationships and as affinity
PT	tag to identify and isolate interacting proteins that bind to the factor.
XX	
PS	Disclosure; Page 62; 73pp; English.
XX	
CC	The present invention provides the protein and coding sequences of two
CC	human nuclear factors associated with dsRNA (NFAR-1 and NFAR-2). These
CC	are transcriptional regulators and are thought to play a role in
CC	apoptosis and tumourigenesis. The coding sequence (found on chromosome
CC	19p13.1-13.2) is useful as a probe to detect rearrangements in tumour
CC	cells and the protein is useful for determining structure-function
CC	relationships
XX	
SQ	Sequence 16 BP; 2 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
XX	
Query Match	4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity	86.7%; Pred.No.3.1e+02;
Matches 13; Conservative	0; Mismatches 2; Indels 0; Gaps 0.
OY	1261 AACAGCTGGAAGAGG 1275
DB	15 AACACTCGCAGAGG 1
XXXX	
RESULT 671	
ABAO2928	
ID	ABAO2928 standard; DNA; 16 BP.
XX	
AC	ABAO2928;
XX	
DT	15-FEB-2002 (first entry)
XX	
DE	Human cyclophilin B RT-PCR primer 2.
XX	
KW	Human; acute transplant rejection; gene expression;
KW	pro-apoptotic gene cluster; cytoprotective; IL-7/17; IL-8; IL-10; IL-15;
KW	T cell; urinary system; renal graft; antimicrobial; antiviral;
KW	antifungal; competitive template RT-PCR; PCR primer; ss.
XX	
OS	Synthetic.
XX	

PM WO200181916-A2.

PD 01-NOV-2001.

XX 23-APR-2001; 2001WO-US013014.

XX 24-APR-2000; 2000US-0199327P.

PR 06-OCT-2000; 2000US-0238718P.

PR 12-OCT-2000; 2000US-0239635P.

PR 16-OCT-2000; 2000US-0240735P.

PR 06-FEB-2001; 2001US-00778013.

XX (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.

PA Ma N, Strom T, Soares MC, Ferran C, Suthanthiran M;

PI Vaseconcellos L, Avithingsanon Y;

XX WPI, 2002-034457/04.

XX

XX Evaluating acute transplant rejection in a host especially in a recipient

PT of a urinary system graft, by determining a heightened magnitude of

PR expression of genes in rejection-associated gene clusters.

XX

XX Disclosure: Fig 3; 101pp; English.

XX

XX The invention relates to evaluating acute transplant rejection in a host,

CC comprising obtaining a sample, determining the magnitude of gene

CC expression of at least two genes from one or more rejection associated-

CC gene clusters, where the genes were selected from the pro-apoptotic

CC cluster, the cytoprotective cluster, the IL-7/17, IL-8, IL-10, IL-15 and

CC T cell clusters, comparing the results to a baseline magnitude of gene

CC expression of the two genes and detecting upregulation of the two genes.

CC The method is useful for evaluating acute transplant rejection in a host

CC especially in a recipient of a urinary system (renal) graft, where gene

CC expression in the urine sample of at least two genes of a pro-apoptotic

CC gene cluster is determined. The method is further useful for treating a

CC transplant-related condition in a host. The method comprises

CC choosing a therapy comprising adding to the host a baseline therapeutic

CC regimen an effective dose of an anti-rejection agent appropriate, for

CC treating rejection state. The anti-rejection agent is selected from

CC azathioprine, cyclosporine, FK506, mycophenolate mofetil, anti-CD25

CC antibody, antithymocyte globulin, rapamycin, ACE inhibitors, perillyl

CC alcohol, anti-CTLA4 antibody, anti-CD40L antibody, anti-thrombin III,

CC tissue plasminogen activator, antioxidants, anti-CD154, anti-CD3

CC antibody. The regimen may further comprise modifying the host's baseline

CC therapeutic regimen by adding pharmacological agent selected from

CC antimicrobial agents, antiviral agents and antifungal agents or by

CC reducing a dose of a baseline anti-rejection agent. The method accurately

CC quantitate marker gene expression in biopsy tissue, urine, urine

CC sediment, peripheral blood mononuclear and other body fluids and

CC correlates the magnitude of expression of these genes with rejection of

CC allografts. Moreover, the evaluation of the expression of marker genes in

CC a post-transplant sample, along with the evaluation of the expression of

CC an infectious agent gene also accurately detects allografts rejection.

CC The is rapid and reliable for diagnosing acute rejection, even in cases

CC where allograft biopsies show only mild cellular infiltrates. The present

CC sequence is that of a PCR primer used for quantitation of gene expression

CC by competitive template RT-PCR in a method of the invention

XX

SQ Sequence 16 BP; 4 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

XX

XX Query Match 4.7%; Score 11.8; DB 1; Length 16;

XX Best Local Similarity 86.7%; Pred. No. 3,1e+02;

XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX

XX 1345 GAGACTTCCACGCG 1359

XX ||||| |||||

XX ||||| |||||

XX ||||| |||||

DB 1 GAGACTTCACACGCG 15

XX

RESULT 672

ABK48424 standard; DNA; 16 BP.

XX ABK48424;
AC
XX 02-JUL-2002 (first entry)
XX
XX Human MEGF/Fibrillin-like protein NOV8 forward primer Ag192.
XX
XX Human; MEGF/Fibrillin-like protein; NOVX; NOV8; primer; ss; vaccine;
XX cancer; tumour; bone disorder; avascular necrosis; allergy;
XX haematopoietic disorder; immune disorder; endometriosis; renal disease;
XX infection; inflammatory disease; lung disease; scleroderma; ataxia;
XX bowel disease; appendicitis; blood disorder; cardiovascular disorder;
XX graft versus host disease; GVHD; lymphedema; brain disorder;
XX ocular disorder; hepatitis C virus infection; cardiac disorder;
XX autosomal dominant deafness; DFNA-2.
XX
XX Homo sapiens.
XX
XX WO200214368-A2.
XX
XX 21-FEB-2002.
XX
XX 16-AUG-2001; 2001WO-US025624.
XX
XX 16-AUG-2000; 2000US-0225692P.
XX 16-AUG-2000; 2000US-0225693P.
XX 16-AUG-2000; 2000US-0225837P.
XX 18-AUG-2000; 2000US-0226236P.
XX 18-AUG-2000; 2000US-0226353P.
XX 22-AUG-2000; 2000US-0227085P.
XX 23-AUG-2000; 2000US-0227395P.
XX 24-AUG-2000; 2000US-0227492P.
XX 24-AUG-2000; 2000US-0227600P.
XX 14-MAR-2001; 2001US-0275952P.
XX 15-AUG-2001; 2001US-00930512.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Zethusen BD, Padigaru M, Spytek KA, Spaderna SK, Gangoli EA;
XX Raetelli L, Burgess CE, Majumder K, Shimkete R, Mishra V;
XX Vernet CAM, Szekeres BG, Grose WM, Alsobrook JP, Liu X, Gerlach VL;
XX Ellerman K, Smithson G, Peyman J, Stone D, Macdougall J;
XX
XX WPI; 2002-329571/36.
XX
XX Novel cytoplasmic, nuclear membrane bound and secreted NOVX polypeptides,
XX useful for treating cancers and tumors, bone disorders, Paget's disease,
XX hematopoietic disorders, spinal diseases and immune disorders.
XX
XX Example 1; Page 208; 234pp; English.
XX
XX The present invention relates to new isolated NOVX polypeptides named
XX NOV1-NOV9. The invention can be used for identifying an agent (a cellular
XX receptor or downstream effector) that binds to the polypeptide. The
XX molecules of the invention are useful for treating or preventing NOVX-
XX associated disorders in humans. The antibody of the invention is useful
XX for determining the presence or amount of NOVX in a sample, and for
XX treating a pathological state in a mammal. The method of the invention is
XX useful for determining the presence of an amount of NOVX in a sample
XX which is used as a marker for cancerous cell or tissue type. The
XX molecules of the invention are useful in the manufacture of a medicament
XX for treating or preventing cancer, tumour, bone disorders, avascular
XX necrosis, allergy, haematopoietic disorders, immune disorders,
XX endometriosis, renal diseases, infections, inflammatory diseases, lung
XX diseases, scleroderma, ataxia, bowel diseases, appendicitis, blood
XX disorders, cardiovascular disorders, graft versus host disease (GVHD),
XX lymphedema, brain disorders, ocular disorders, hepatitis C virus
XX infection, cardiac disorders and autosomal dominant deafness (DFNA-2).
XX The present nucleic acid sequence represents the human MEGF/Fibrillin-
XX like protein NOV8 forward primer Ag192 that was used in the methods of
XX the invention to assess the expression of gene NOV8
XX
XX Sequence 16 BP; 3 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1199 TGTGCGAGGCGCAC 1213
Db 1 TGTGCGAGGCGCAC 15
RESULT 673
ID ABL30914/c
ID ABL30914 standard; DNA; 16 BP.
XX
XX ABL30914;
XX
XX 21-MAR-2002 (first entry)
XX
XX Human HLA genotyping oligonucleotide SEQ ID NO 403.
XX
XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX
XX Homo sapiens.
XX
XX WO200192572-A1.
XX
XX 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-JP004662.
XX
XX 01-JUN-2000; 2000JP-00164798.
XX
XX (NITSN) NISSHINO IND INC.
XX (SYST-) SYSTEM RES INC.
XX
XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
XX WPI; 2002-122074/16.
XX
XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
XX individuals e.g. by determining immunogenetic differences when
XX transplanting between them.
XX
XX Claim 21; Page 169; 345pp; Japanese.
XX
XX The invention relates to a typing kit for judging human leukocyte antigen
XX (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
XX oligonucleotides (ABL30512-ABL31809) originating in the sequences of
XX genes e.g. belonging to HLA class I antigens on human genome and
XX containing gene polymorphisms as alloantigens have been immobilised as
XX primers for amplification of cleaved nucleic acids relating to gene
XX polymorphisms. The method is useful for judging HLA genotypes of
XX individuals by determining immunogenetic differences before transplanting
XX organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
XX pancreas, Langerhans islet in pancreas and cornea, susceptibility
XX diagnosis of genetic diseases and identifying individuals
XX
XX Sequence 16 BP; 1 A; 10 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 4.7%; Score 11.8; DB 1; Length 16;
XX Best Local Similarity 86.7%; Pred. No. 3.1e+02;
XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1403 GGACGACCGGGTGC 1417
Db 15 GGACGACCGGGTGC 1
RESULT 674
ABX56490
ID ABX56490 standard; DNA; 16 BP.

XX ABX56490;
 AC
 XX 17-FEB-2003 (first entry)
 DT
 XX Human epidermal growth factor-like protein forward PCR primer #1.
 DE
 XX Gamma-aminobutyric acid receptor-like protein; depression; stroke;
 KW GABA receptor-like protein; Parkinson's disease; Huntington's disease;
 KW Tourette's syndrome; amphotrophic lateral sclerosis; head trauma;
 KW Alzheimer's disease; alcoholism; vigilance; anxiety; muscle tension;
 KW erythropoietic activity; memory; cardiomyopathy; cancer; angiogenesis;
 KW epitheliogenic right ventricular dysplasia; renal disease; diabetes;
 KW Epidermal growth factor like protein; leukaemia; lupus; anaemia; ulcer;
 KW haematopoietic stem and progenitor cell like protein; cirrhosis;
 KW sulfotransferase-like protein; cholangitis; hepatitis; hyperthyroidism;
 KW developmental disorder; Syntaxin-like protein; myxoid liposarcoma;
 KW asthma; Lambert-Eaton myasthenic syndrome; acute myeloidleukaemia;
 KW transgenic animal; PCR; primer; ss.
 XX
 OS Homo sapiens.
 OS
 XX US2002123612-A1.
 PN
 XX 05-SEP-2002.
 PD
 XX 03-JUL-2001; 2001US-00898570.
 PF
 XX 19-APR-2000; 2000US-0198293P.
 PR 20-APR-2000; 2000US-0198645P.
 PR 25-APR-2000; 2000US-0199476P.
 PR 26-APR-2000; 2000US-0199880P.
 PR 26-APR-2000; 2000US-0200024P.
 PR 26-APR-2000; 2000US-0200025P.
 PR 09-JUN-2000; 2000US-0210809P.
 PR 03-JUL-2000; 2000US-0215855P.
 PR 17-JUL-2000; 2000US-0218591P.
 PR 11-AUG-2000; 2000US-0224610P.
 PR 27-FEB-2001; 2001US-0271814P.
 XX
 PA (GERL/) GERLACH V. L.
 PA (ELER/) ELLERMAN K.
 PA (MACD/) MACDOUGALL J R.
 PA (SMIT/) SMITHSON G.
 PA
 PI Gerlach VL, Ellerman K, Macdougall JR, Smithson G;
 XX
 DR WPI; 2003-066815/06.
 XX
 PT Novel polypeptides and nucleic acids which are members of epidermal
 PT growth factor, complement receptor families for diagnosing and treating
 PT psychiatric conditions, depression, stroke, Alzheimer's and Parkinson's
 PT disease.
 PT
 XX
 XX Example 5A; Page 74; 91pp; English.
 PS
 XX
 CC The invention describes an isolated POLYX (POLY1-17) polypeptide and its
 CC variant. POLYX polypeptides (especially POLY5, POLY6 and POLY7), the
 CC polynucleotides encoding them (I) and an anti-POLYX-antibody (III) are
 CC useful for treating or preventing a pathology associated with POLYX
 CC polypeptide in humans and for treating a syndrome associated with human
 CC disease. POLYX polypeptide is also useful for identifying an agent that
 CC binds to POLYX and a cell expressing POLYX is useful for identifying a
 CC therapeutic agent for use in treatment of a pathology related to aberrant
 CC expression or physiological interactions of the polypeptide. (III) is
 CC useful for treating a pathological state in a mammal and for determining
 CC the presence or amount of POLYX in a sample. POLY1-4 (GABA receptor-like
 CC proteins) are useful for the treatment of psychiatric and medical
 CC conditions, depression, stroke, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amphotrophic lateral sclerosis, head trauma,
 CC Alzheimer's disease, alcoholism, vigilance, anxiety, muscle tension,
 CC epileptogenic activity and memory functions, cardiomyopathy and
 CC arrhythmogenic right ventricular dysplasia. POLY5-8 (Epidermal growth

CC factor like proteins) may be useful for treating cancer, aberrant
 CC angiogenesis, renal disease and diabetes. POLY12 (haematopoietic stem and
 CC progenitor cell like protein) may be useful for treatment of leukaemia,
 CC lupus and anaemia. POLY13 (sulfotransferase-like protein) may be useful
 CC for treating cirrhosis, cholangitis, hepatitis, ulcers, hyperthyroidism
 CC and developmental disorders. POLY14-16 (Syntaxin-like proteins) may be
 CC useful in treatment of Lambert-Eaton myasthenic syndrome, asthma, myxoid
 CC liposarcoma and acute myeloid leukaemia, and POLY 18 may be useful in
 CC treatment of cancers. Cells comprising (I) are useful for producing non-
 CC human transgenic animals which are useful for studying the function
 CC and/or activity of POLYX protein and for identifying and/or evaluating
 CC modulators of POLYX protein activity. This sequence represents a PCR
 CC primer used to isolate DNA encoding novel human proteins characterised in
 CC the invention.
 XX
 SQ Sequence 16 BP; 3 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
 GY 1199 TGTGCGAGGCGCAGC 1213
 DB 1 TGTGCGAGGCGCAGC 15
 DB
 RESULT 675
 ADF92303/C
 ID ADF92303 standard; DNA, 16 BP.
 AC ADF92303;
 XX 26-FEB-2004 (first entry)
 DT
 XX Human cyokeratin 19-related loop F PCR primer - SEQ ID 391.
 DE
 XX human; cyokeratin; CK; LAMP; loop mediated isothermal amplification;
 KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
 KW PCR; loop F.
 KW
 XX Homo sapiens.
 OS
 XX WO2003097878-A1.
 PN
 XX 27-NOV-2003.
 PD
 XX 20-MAY-2003; 2003WO-JP006256.
 PF
 XX 21-MAY-2002; 2002JP-00145689.
 PR 17-JUN-2002; 2002JP-00175271.
 PR 09-JUL-2002; 2002JP-00199759.
 PR
 XX (SYSM-) SYSMEX CORP.
 PA
 XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
 PI WPI; 2004-012543/01.
 DR
 XX LAMP nucleic acid amplification primers for detection of cyokeratin
 PT expression as indicator in diagnosis of tumour metastasis.
 PT
 XX Claim 19; SEQ ID NO 391; 266pp; Japanese.
 PS
 XX The invention relates to novel nucleic acid amplification primers for the
 CC detection of human cyokeratin (CK) 18, 19 or 20 expression by the LAMP
 CC (loop mediated isothermal amplification) method. The primers of the
 CC invention may be useful for the detecting cyokeratin 18-20 expression as
 CC an indicator for the diagnosis of tumour metastasis, particularly
 CC prostate cancer and lymphoma. The amplification using the primers is
 CC highly efficient and allows very sensitive detection of tumour
 CC metastasis. The current sequence is that of the human CK19-related PCR
 CC primer of the invention.
 CC

SQ Sequence 16 BP; 0 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1372 ACCAGAGCAGCTGC 1386
16 ACCAGAGCAGCGGC 2
DB 16 ACCAGAGCAGCGGC 2
RESULT 676
AD192405/C
ID AD192405 standard; RNA; 16 BP.
XX
AC AD192405;
XX
DT 03-JUN-2004 (first entry)
XX
DE Anti-HCV enzymatic nucleic acid substrate sequence #7.
XX
KM 89; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNazyme.
XX
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUN-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blact L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX
DR WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Disclosure; SEQ ID NO 9642; 198pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents an anti-HCV enzymatic
CC nucleic acid substrate sequence.
XX
SQ Sequence 16 BP; 2 A; 5 C; 3 G; 0 T; 5 U; 1 Other;
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1265 GCTGAGAGGCTGA 1279
15 GCTGAGAGCACTGA 1
DB 15 GCTGAGAGCACTGA 1
RESULT 677
ABK99821/C
ID ABK99821 standard; DNA; 20 BP.

XX
AC ABK99821;
XX
DT 21-OCT-2002 (first entry)
XX
DE Mouse RAID antisense oligonucleotide #75.
XX
KM Antisense gene therapy; RAID; death domain; caspase recruitment domain;
KM CARD; hyperproliferative disorder; cancer; growth disorder; mouse;
KM metabolic disorder; infection; inflammation; tumour formation;
KM RIP associated ICH-1/CED-3-homologous protein with death domain;
KM receptor interacting protein; antisense oligonucleotide; ss.
XX
OS Mus musculus.
XX
PN W0200248314-A2.
XX
PD 20-JUN-2002.
XX
PF 29-OCT-2001; 2001WO-US050914.
XX
PR 01-NOV-2000; 2000US-00705267.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Zhang H, Freier SM, Watt AT;
XX
DR WPI; 2002-583496/62.
XX
PT Novel antisense compound that hybridizes and inhibits nucleic acid
PT encoding RAID which is an adaptor molecule containing both death domain
PT and caspase recruitment domains, for treating hyperproliferative
PT disorder.
XX
PS Example 16; Page 96; 144pp; English.
XX
CC The invention describes a compound (I) 8-50 nucleobases in length
CC targeted to a nucleic acid molecule (II) encoding RAID which is an
CC adaptor molecule containing both death domain (DD) and caspase
CC recruitment domains (CARD), where (I) specifically hybridizes with and
CC inhibits expression of RAID, or specifically hybridizes with at least an
CC 8-nucleobase portion of an active site on (II). (I) is useful for
CC inhibiting the expression of RAID (Receptor interacting protein (RIP)
CC associated ICH-1/CED-3-homologous protein with death domain) in cells or
CC tissues, and for treating an animal having a disease or condition
CC associated with RAID, where the disease or condition is a
CC hyperproliferative disorder such as cancer, or a growth or metabolic
CC disorder. (I) is also useful for diagnostics, therapeutics, prophylaxis,
CC as research reagents and kits, for distinguishing functions of various
CC members of a biological pathway, and in antisense gene therapy. (I) is
CC also useful prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. This sequence represents a mouse RAID
CC antisense oligonucleotide used to control expression of the RAID protein
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 4.7%; Score 11.8; DB 1; Length 20;
Best Local Similarity 86.7%; Pred. No. 5.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1228 TCCAGCATGTGCTGG 1242
20 TCCAGCATGTCTGG 6
DB 20 TCCAGCATGTCTGG 6
RESULT 678
ABL52157
ID ABL52157 standard; DNA; 15 BP.
XX
AC ABL52157;
XX
DT 12-JUN-2002 (first entry)
XX

DE Human PER1 allele specific oligonucleotide primer SEQ ID NO:82.
XX
XX Human; period (Drosophila) homologue 1; PER1; polymorphic variant;
KW polymorphic site; genotyping; haplotyping; circadian rhythm regulation;
KM single nucleotide polymorphism; SNP; gene; primer; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH misc_feature 14
FT /*tag= a
FT /note= "polymorphic site indicated by an ambiguity base"
XX
XX WO200222650-A2.
XX
XX PD 21-MAR-2002.
XX
XX PF 13-SEP-2001; 2001WO-US028780.
XX
XX PR 13-SEP-2000; 2000US-0232468P.
XX
XX PA (GENA-) GENAISSANCE PHARM INC.
XX
XX PI Duda A, Kliem SE, Koshy B;
XX
XX DR WPI; 2002-393941/42.
XX
XX PT Novel isolated human period Drosophila homolog 1 polynucleotide, useful
PT for therapeutic purposes, for studying the expression and function of the
PT polynucleotide, and for expressing the homolog.
XX
XX PS Claim 17; Page 15; 162pp; English.
XX
XX CC The present invention describes an isolated human period (Drosophila)
CC homologue 1, (PER1) polynucleotide (1) comprising a sequence which is a
CC polymorphic variant for a reference sequence (ABL52077) for the PER1 gene
CC or its fragment, or a polymorphic variant of a reference sequence
CC (ABL52078) for a PER1 cDNA or its fragment. The present invention also
CC describes methods for genotyping and haplotyping the PER1 gene of an
CC individual. (1) is useful in studying the expression and function of
CC PER1, and in expressing PER1 protein for use in screening for candidate
CC drugs to treat diseases related to PER1 activity. (1) is useful for
CC therapeutic purposes. A recombinant non-human organism transformed or
CC transfected with (1) can be used for studying expression of the PER1
CC isogenes in vivo, for in vivo screening and testing of drugs targeted
CC against PER1 protein, and for testing the efficacy of therapeutic agents
CC and compounds for disorders associated with circadian rhythm regulation.
CC The present sequence represents an allele specific oligonucleotide primer
CC for human PER1, which is used in the exemplification of the present
CC invention
XX
XX SQ Sequence 15 BP; 0 A; 6 C; 6 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 4.6%; Score 11.6; DB 1; Length 15;
XX Best Local Similarity 91.7%; Pred. No. 2.8e+02;
XX Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1182 CTGGGCTCCAG 1193
DB 4 CTGGGCTCCAG 15

RESULT 679
ABN80547/C
ID ABN80547 standard; DNA; 15 BP.
XX
XX ABRN80547;
XX
XX AC
XX
XX DT 19-JUL-2002 (first entry)
XX
XX DE Human P450(cytochrome) oxidoreductase allele specific probe #13.
XX
XX KW Human; P450(cytochrome) oxidoreductase; POR; cancer; haplotype; SNP;

KW single nucleotide polymorphism; flavoprotein; enzyme; probe; ss.
XX
XX OS Homo sapiens.
XX
XX KM WO200226768-A2.
XX
XX PD 04-APR-2002.
XX
XX PF 01-OCT-2001; 2001WO-US030877.
XX
XX PR 29-SEP-2000; 2000US-0236449P.
XX
XX PA (GENA-) GENAISSANCE PHARM INC.
XX
XX PI Kazemi A, Kliem SE, Lanz EM, Messer C, Tanguey DA;
XX
XX DR WPI; 2002-394236/42.
XX
XX PT New genetic variants comprising haplotypes of the P450 (cytochrome)
PT oxidoreductase (POR) isogene, useful in improving the efficiency of drug
PT screening protocols for compounds targeting POR.
XX
XX PS Claim 14; Page 14; 141pp; English.
XX
XX CC The present invention provides the protein, gene and cDNA sequences of
CC human P450(cytochrome) oxidoreductase POR, and single nucleotide
CC polymorphisms (SNPs) identified therein. The sequences can be used to
CC haplotype the POR gene of an individual, and to establish whether POR is
CC a suitable target for drugs to treat cancer and disorders associated with
CC impaired protein synthesis in cells. The present sequence is an allele
CC specific probe for the coding sequences of the invention
XX
XX SQ Sequence 15 BP; 2 A; 4 C; 5 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 4.6%; Score 11.6; DB 1; Length 15;
XX Best Local Similarity 91.7%; Pred. No. 2.8e+02;
XX Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1254 CTGCAGCAACG 1265
DB 12 CTGCAGCAACG 1

RESULT 680
AAL39498
ID AAL39498 standard; DNA; 15 BP.
XX
XX AC AAL39498;
XX
XX DT 05-SEP-2002 (first entry)
XX
XX DE CCBP2 detecting ASO primer SEQ ID No 25.
XX
XX KM Chemokine binding protein 2; CCBP2; CCBP2 protein isoform; gene therapy;
KW polymorphic gene variant; single nucleotide polymorphism; human; primer;
KW PCR; ss.
XX
XX OS Homo sapiens.
XX
XX PF WO200232926-A2.
XX
XX PD 25-APR-2002.
XX
XX PP 12-OCT-2001; 2001WO-US042685.
XX
XX PR 12-OCT-2000; 2000US-0239638P.
XX
XX PA (GENA-) GENAISSANCE PHARM INC.
XX
XX PI Armstrong B, Kazemi A, Koshy B;
XX
XX DR WPI; 2002-435524/46.
XX

PT New genetic variants having polymorphisms in the chemokine binding
PT protein 2 (CCBP2) gene, useful for studying CCBP2 functions, and for
PT treating disorders affected by expression or function of the CCBP2
PT isogene.
XX
PS Claim 14, Page 13, 84pp; English.
XX
CC The invention relates to an isolated polynucleotide comprising genes and
CC haplotypes of the chemokine binding protein 2 (CCBP2) gene. Polymorphic
CC variants of the CCBP2 gene are useful in studying the expression and
CC function of CCBP2, and in expressing CCBP2 proteins for use in screening
CC candidate drugs for treating diseases associated with CCBP2 activity.
CC Polynucleotides comprising a polymorphic gene variant or fragment may be
CC used for therapeutic purposes, where a patient could benefit from
CC expression or increased expression of a particular CCBP2 protein isoform,
CC or an expression vector encoding the isoform may be administered to the
CC patient. Haplotype information is useful in improving the efficiency and
CC output of several steps in drug discovery and development process,
CC including target validation, identifying lead compounds, and early phase
CC clinical trials. The polynucleotides of the invention can be used to
CC treat disorders related to the CCBP2 gene by gene therapy. This
CC polynucleotide sequence represents a preferred ASO primer for detecting
CC CCBP2 gene polymorphisms relating to the invention
CC
SQ Sequence 15 BP; 4 A; 5 C; 4 G; 1 T; 0 U; 1 Other;
XX
Query Match 4.6%; Score 11.6; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1352 TCCGAGGCGAGC 1363
DB 3 TCCGAGGCGAGC 14
XX
RESULT 681
ABZ81780/C
ID ABZ81780 standard; DNA; 18 BP.
XX
AC ABZ81780;
XX
DT 11-JUN-2003 (first entry)
XX
DE Huntington's disease gene mutated exon 1 region.
XX
KM Huntington's disease; noctropic; anticonvulsant; huntingtin; human;
KM gene therapy; mutant; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT mutation replace(5,A)
FT /*tag= a
XX
PN WO2003013437-A2.
XX
PD 20-FEB-2003.
XX
PF 07-AUG-2002; 2002WO-US025352.
XX
PR 07-AUG-2001; 2001US-0310757P.
PR 08-AUG-2001; 2001US-0310770P.
PR 08-AUG-2001; 2001US-0310889P.
PR 04-DEC-2001; 2001US-0337219P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Parekh-Olmedo H;
XX
DR WPI; 2003-256478/25.
XX
PT New single stranded oligonucleotides comprising a DNA domain having at

PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
PS Example 7, Fig 20, 133pp; English.
XX
CC The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also ABZ81760). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD3S/52 (see ABZ81756). The second glutamine
CC (CAG) repeat triplet is converted to CTC, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD3S/25 is an
CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
CC
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 4.6%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 1251 CGGCTGCGAGCAACAGCTG 1268
DB 18 CTGCTGCTGCTGCGAGCTG 1
XX
RESULT 682
ABZ81779/C
ID ABZ81779 standard; DNA; 18 BP.
XX
AC ABZ81779;
XX
DT 11-JUN-2003 (first entry)
XX
DE Huntington's disease gene mutated exon 1 region.
XX
KM Huntington's disease; noctropic; anticonvulsant; huntingtin; human;
KM gene therapy; mutant; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT mutation replace(5,A)
FT /*tag= a
XX
PN WO2003013437-A2.
XX
PD 20-FEB-2003.
XX
PF 07-AUG-2002; 2002WO-US025352.
XX
PR 07-AUG-2001; 2001US-0310757P.
PR 08-AUG-2001; 2001US-0310770P.
PR 08-AUG-2001; 2001US-0310889P.
PR 04-DEC-2001; 2001US-0337219P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Parekh-Olmedo H;
XX
DR WPI; 2003-256478/25.
XX
PT New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
PS Example 7, Fig 20, 133pp; English.
XX
PT The present sequence is that of a portion of a mutated glutamine (CAG)

CC triplet repeat region of exon 1 of the human Huntington's disease (HD) gene (see also AB281760). The triplet repeat region is mutated following treatment with single-stranded phosphorothioate-containing HD gene-targeted oligonucleotide HD3S/25 (see AB281755). The second glutamine (CA8) repeat triplet is converted to CTG, creating a restriction fragment length polymorphism site that enables cleavage by PvuII. HD3S/25 is an example of oligonucleotides of the invention for targeted alteration of the HD gene. Such oligonucleotides can be used for the treatment or prevention of HD

SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 4.6%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1251 CCGCTGCAGCAACACTG 1268
DB 18 CTGCTGCTGCTGCAGCTG 1

RESULT 683

AA161555
ID AA161555 standard; DNA; 20 BP.
AC AA161555;
XX
XX 22-SEP-2003 (first entry)
DT
XX Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130480.
DE
XX Human; inhibitor-kappa B-R; I-kappaB; IKK; I-kappa-B-related; NFKB1L2; IKKAPB; I-kappaB; immune response; infection; inflammation; therapy; tumor; prophylaxis; phosphorothioate; ss.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues are 5-methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Watt AT;
XX
XX WPI; 2003-468635/44.
XX
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding inhibitor-kappa B-R, useful for diagnosing or treating diseases associated with expression of inhibitor-kappa B-R, e.g., a heightened immune response or infection.
XX
XX Claim 3; Page 74; 108BP; English.

XX The invention relates to antisense compounds targeted to a nucleic acid molecule encoding human inhibitor-kappa B-R (also known as I-kappaB, IKK, I-kappa-B-related, ikkappab r, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 2 and NFKB1L2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with the expression of inhibitor-kappa B-R such as a heightened immune response involving increased cytokine expression, or a result of infection (e.g. bacterial, viral or parasitic). They are useful for diagnostics, therapeutics, prophylaxis e.g. to prevent or delay infection, inflammation or tumor formation, as research reagents and kits and in distinguishing between functions of various members of a biological pathway. They are also useful in antisense therapy. The present sequence is an oligonucleotide targeted to human inhibitor-kappa B-R DNA

SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 4.6%; Score 11.6; DB 1; Length 20;
Best Local Similarity 77.8%; Pred. No. 5.7e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1229 CCAGCATGCTGCGCACT 1246
DB 1 CCAGCATGCTGCGAGGT 18

RESULT 684

AA11036
ID AA11036 standard; RNA; 13 BP.
AC AA11036;
XX
XX 25-MAR-2003 (revised)
DT
DT 14-JUL-1998 (first entry)
XX
XX Human ribozyme target sequence from HLA-DPB 09DPB #1.
DE
XX Ribozyme; target; human lymphocyte antigen; HLA-DPB; MHC allele; major histocompatibility complex; cleavage; suppression; transplant; incompatibility; autoimmune disease; juvenile diabetes;
XX
XX Rheumatoid arthritis; ss.
XX
XX Homo sapiens.
OS
OS
XX WO9704087-A1.
XX
XX 06-FEB-1997.
XX
XX 18-JUL-1996; 96WO-EP003173.
XX
XX 18-JUL-1995; 95EP-0011256.
XX
XX (KRUPP/) KRUPP G.
XX (MARG/) MARGET M.
XX (WEST/) WESTPHAL E.
XX (MUELLER/) MUELLER-RUCHHOLTZ W.
XX
XX Krupp G, Marget M, Westphal E, Mueller-Ruchholtz W;
XX
XX WPI; 1997-132628/12.
XX
XX Ribozyme that cleaves specific MHC allele(s) - used to inhibit graft versus host reactions, to overcome blood incompatibility and to treat auto-immune disease.
XX
XX Claim 5; Fig 1; 76pp; German.
XX
XX AA110915-111123 are target sequences for a novel ribozyme which cleaves specific alleles from the major histocompatibility complex (MHC). This ribozyme contains a catalytic region and a hybridisation region which is complementary to all mRNA transcribed from vertebrate genes of a specific family of closely related MHC alleles or to mRNA from a single MHC

CC allele, and is able to cleave such mRNA. The mRNA has a target region
CC which in case is essentially conserved in all genes of the family but
CC differs from genes of all other MHC alleles to such a degree that no
CC cleavage of mRNA transcribed from these other alleles occurs. This allows
CC the selective reduction or inhibition of expression of all genes of a
CC family or of a single gene. This ribozyme can be used for permanent or
CC transient suppression of expression of MHC alleles, in vivo or in vitro.
CC Specific applications are to prevent guest vs. host or host vs. guest
CC reactions, to prevent blood incompatibilities (partic. of the ABO, rhesus
CC and Kell systems) and to treat autoimmune diseases such as juvenile
CC diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
CC need for immunosuppressants in transplant patients. It provides very
CC specific reduction of particular HLA molecules that cause incompatibility
CC between donor and recipient. (Updated on 25-MAR-2003 to correct PA
CC field.) (Updated on 25-MAR-2003 to correct PI field.)

CC Sequence 13 BP; 3 A; 3 C; 6 G; 0 T; 1 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1264 AGCTGAGAGAGC 1276
|||:|||||
Db 1 AGCUGACGAGC 13

RESULT 685
ABZ72854
ID ABZ72854 standard; RNA; 13 BP.
XX ABZ72854;
XX
DT 09-APR-2003 (first entry)
XX
XX VEGFR2 R21 ribozyme target sequence SEQ ID NO:110.
XX

KM Hairpin ribozyme; hammerhead ribozyme; ribozyme; retinal disease; target;
KM ophthalmological; gene therapy; eye; retinal dysfunction; AAV;
KM diabetic retinopathy; macular degeneration; autosomal dominant retinitis;
KM blood-retinal barrier dysfunction; adeno-associated virus; blindness; ss.
XX
XX OS Mus sp.
XX
XX WO200288320-A2.

XX
XX 07-NOV-2002.
XX
XX 01-MAY-2002; 2002MO-US013679.
XX
XX 01-MAY-2001; 2001US-00847601.
XX
XX (UYFL) UNIV FLORIDA.
XX

XX PI Lewin AS, Shaw LC, Grant MB;
XX
XX WPI; 2003-111880/10.
XX
XX

PT A recombinant adeno-associated virus-vectored ribozyme composition,
PT useful for treating a disease or dysfunction of the mammalian eye e.g.
PT retinal disease, e.g. diabetic retinopathy or age-related macular
PT degeneration.
XX
XX

PS Claim 1; Page 80; 115pp; English.

CC The present invention describes a recombinant adeno-associated virus
CC (AAV) vectored ribozyme composition (I). (I) comprises: (a) at least a
CC first ribozyme that specifically cleaves an mRNA encoding a protein,
CC polypeptide, or peptide selected from the group of rod opsin, INOS,
CC RDS/peripherin, VEGFR1, VEGFR2, adenosine A-2B receptor, IGF-1, integrin
CC alpha 1, integrin alpha 3, integrin alpha 5, or integrin alpha V; (b) a
CC vector comprising a polynucleotide encoding the ribozyme, where the
CC polynucleotide operably positioned downstream of at least a first

CC promoter that directs expression of the polynucleotide in a selected
CC mammalian cell transformed with the vector; (c) a viral particle
CC comprising the ribozyme or the polynucleotide; (d) an AAV vector
CC comprising the ribozyme or the polynucleotide; or (e) a host cell
CC comprising the ribozyme or the polynucleotide. Also described is a method
CC for decreasing the amount of mRNA encoding a selected polypeptide in a
CC retinal cell of a mammalian eye, comprising providing to the eye the
CC composition described above, and for a time effective to specifically
CC cleave the mRNA in the cell. (I) has ophthalmological activity, and can
CC be used in gene therapy. (I) can be used for treating a disease or
CC dysfunction of the mammalian eye, such as a retinal disease or retinal
CC degeneration, (diabetic) retinopathy, or (age-related) macular
CC degeneration. (I) is also useful for manufacturing a medicament for
CC treating the diseases mentioned above, including autosomal dominant
CC retinitis or a blood-retinal barrier dysfunction. (I) can also be useful
CC for treating, decreasing the severity, or ameliorating the symptoms of a
CC pathological condition, e.g. atrophic or pigmented lesions of the eye,
CC blindness, a reduction in central or peripheral vision, or a reduction in
CC total vision. ABZ72763 to ABZ72953 represent sequences used in the
CC exemplification of the present invention

CC Sequence 13 BP; 1 A; 3 C; 3 G; 0 T; 6 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 53.8%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1301 CATGCTCATCTCT 1313
|||:|||||
Db 1 CATGUCUCUCUG 13

RESULT 686
AAV95593
ID AAV95593 standard; RNA; 14 BP.
XX AAV95593;
XX

XX 24-FEB-1999 (first entry)
XX
XX

DE Human c-fos target sequence nucleotide position 201.

XX Human; c-fos; hammerhead ribozyme; hairpin ribozyme; target site; cancer;
XX oncogene; leukemia; neuroblastoma; diagnosis; genetic drift; mutation;
XX diseased cell; se.
XX
XX OS Homo sapiens.

XX
XX WO9832846-A2.
XX
XX 30-JUL-1998.
XX
XX

XX 20-JAN-1998; 98WO-US001017.
XX
XX 23-JAN-1997; 97US-0037658P.
XX
XX 24-DEC-1997; 97US-00998099.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX

XX Javris T, Mcswiggen JA, Stinchcomb DT;
XX
XX WPI; 1998-427942/36.
XX
XX

PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from a c-fos gene - useful for treating conditions related to levels of c
PT -fos, especially cancer.
XX
XX

PS Claim 5; Page 53; 72pp; English.

XX The present invention describes an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from a c-fos gene. AAV95401 to AAV95540
XX and AAV95541 to AAV95584 represent hammerhead ribozymes and hairpin
XX ribozymes, respectively, which specifically cleave human c-fos. AAV95261

```
CC to AAV95400 and AAV95585 to AAV95628 represent human c-fos target
CC sequences. The enzymatic nucleic acid molecules can be used for treating
CC cancer associated with elevated levels of c-fos oncogene, especially
CC leukaemias, neuroblastomas and lung, breast and colon cancers. The
CC ribozymes may also be used as diagnostic tools to examine genetic drift
CC and mutations within diseased cells, or to detect the presence of c-fos
CC RNA in a cell
XX
SQ Sequence 14 BP; 2 A; 7 C; 3 G; 0 T; 2 U; 0 Other;

Query Match          4.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 76.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY      1249 TCCTGGCTGCAGCA 1261
      :|||:|||
      2 UCCCGCUGCAGCA 14

RESULT 687
AAQ75046
ID AAQ75046 strand; DNA; 15 BP.
XX
XX AAQ75046;
AC
XX 25-MAR-2003 (revised)
DT 18-AUG-1995 (first entry)
XX
XX Human bFGF antisense oligomer.
DE
XX Human b fibroblast growth factor; bFGF; antisense therapy;
KM restenosis prevention; cardiovascular angioplasty; ss.
XX
OS Synthetic.
XX
XX WO9426888-A1.
XX
XX 24-NOV-1994.
XX
XX 18-MAY-1994; 94WO-US005566.
XX
XX 19-MAY-1993; 93US-00063980.
XX 20-AUG-1993; 93US-00110294.
XX
XX (STRD ) UNIV LELAND STANFORD JUNIOR.
XX
XX DzaU VJ;
XX
XX WPI; 1995-006785/01.
XX
XX Inhibiting cellular activity associated with vascular lesions - with
XX anti:sense oligomers against cyclin or cyclin dependent kinase genes,
XX partic. for preventing restenosis after cardiovascular angioplasty.
XX
XX Disclosure; Page 8; 77pp; English.
XX
XX AAQ75046 is a human bFGF antisense oligomer, which inhibits the
XX expression of bFGF. When administered to a site of lesion formation the
XX antisense oligomer helps prevent restenosis, after cardiovascular
XX angioplasty. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX
SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match          4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1295 GGGTGCATGCTC 1307
      ||| ||| ||| |||
      1 GGCTGCATGCTC 13

RESULT 688
```

```
AAQ75047/C
ID AAQ75047 standard; DNA; 15 BP.
XX
XX AAQ75047;
AC
XX 25-MAR-2003 (revised)
DT 15-AUG-1995 (first entry)
XX
XX Human bFGF PCR primer.
DE
XX Human b fibroblast growth factor; bFGF; antisense therapy;
KM restenosis prevention; cardiovascular angioplasty; PCR primer; ss.
XX
XX Synthetic.
XX
XX WO9426888-A1.
XX
XX 24-NOV-1994.
XX
XX 18-MAY-1994; 94WO-US005566.
XX
XX 19-MAY-1993; 93US-00063980.
XX 20-AUG-1993; 93US-00110294.
XX
XX (STRD ) UNIV LELAND STANFORD JUNIOR.
XX
XX DzaU VJ;
XX
XX WPI; 1995-006785/01.
XX
XX Inhibiting cellular activity associated with vascular lesions - with
XX anti:sense oligomers against cyclin or cyclin dependent kinase genes,
XX partic. for preventing restenosis after cardiovascular angioplasty.
XX
XX Disclosure; Page 8; 77pp; English.
XX
XX AAQ75047 and AAQ75048 are a pair of primers for the PCR amplification of
XX human bFGF. These were used in the development of an antisense oligomer
XX which inhibits the expression of bFGF. When administered to a site of
XX lesion formation the oligomer helps prevent restenosis, after
XX cardiovascular angioplasty. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX
SQ Sequence 15 BP; 3 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match          4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1295 GGGTGCATGCTC 1307
      ||| ||| ||| |||
      15 GGCTGCATGCTC 3

RESULT 689
AAQ75414
ID AAQ75414 standard; cDNA; 15 BP.
XX
XX AAQ75414;
AC
XX 14-JUN-1996 (first entry)
DT
XX
XX AS-FGF (antisense fibroblast growth factor).
DE
XX Fibroblast growth factor; FGF; antisense; AS-FGF; inhibitor; therapy;
KM Wistar-Kyoto rat aortic smooth muscle cell; RASM; liposome; stroke;
KM haemagglutinin-neuramidase; HN; Sendai virus; SV; hypertension; LFL;
KM liposome forming lipid; restenosis; hyperplasia atherosclerosis;
KM angiogenesis; myocardial hypertrophy; aneurysm; ss.
XX
XX Synthetic.
XX
XX WO9530330-A1.
XX
```

PD 16-NOV-1995.
XX
XX 28-APR-1995; 95WO-US005420.
XX
XX 10-MAY-1994; 94US-00241372.
XX
XX (DZAU/) DZAU V J.
XX
XX DZau VJ, Yaeufumt K;
XX
XX WPI; 1995-403876/51.
XX
XX Prodn. of liposome(s) for fusion with cells - used esp. for delivery of
XX anti:sense nucleic acids to inhibit cellular proliferation.
XX
XX Example 3; Page 65; 98pp; English.
XX
XX This sequence represents the antisense sequence of a fragment of
XX fibroblast growth factor (FGF). The sequence inhibits FGF synthesis in
XX Wistar-Kyoto rat aortic smooth muscle (RASW) cells under basal
XX conditions. This sequence and the sequences represented by AAT05420,
XX AAT05422, AAT05424, AAT05426, AAT05428-9, AAT05431, AAT05433 and AAT05435
XX are used in the liposomes of the invention. The liposomes of the
XX invention are produced by combining two liposomes to produce a liposome
XX for fusion with cells. The first liposome is produced by agitating
XX purified haemagglutinin-neuraminidase (HN) and fusion proteins of Sendai
XX virus (SV) with liposome forming lipids (Lipids) in an aqueous medium. The
XX second liposome is produced by agitating an agent of interest with Lipids
XX (where at least 25% of the lipids are cationic), in an aqueous solution.
XX The agents are preferably antisense oligonucleotides, such as this
XX sequence, AAT05420, AAT05422, AAT05424, AAT05426, AAT05428-9, AAT05431,
XX AAT05433 and AAT05435. The antisense sequences inhibit the expression of
XX a protein associated with cellular proliferation. They can be used for
XX treating diseases such as hypertension, restenosis, hyperplasia
XX atherosclerosis, angiogenesis, myocardial hypertrophy, strokes and
XX aneurysms
XX
XX Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1295 GGGTGCATGGTC 1307
DB 1 GGGTGCATGGTC 13
RESULT 690
AA088737
ID AA088737 standard; DNA; 15 BP.
XX
XX AA088737;
XX
XX 27-FEB-1996 (first entry)
XX
XX Human bFGF translation start site modified antisense oligonucleotide.
DE
XX antisense; analogue; non-terminal pyrimidine; phosphorothioate; backbone;
XX treatment; HIV; human immunodeficiency virus; HSV; herpes simplex virus;
XX cancer; integrin; cell adhesion receptor; infection; diagnosis;
XX nuclease resistance; ss.
XX
XX Homo sapiens.
XX
XX BP653439-A2.
XX
XX 17-MAY-1995.
XX
XX 07-NOV-1994; 94EP-00117513.
XX
XX 12-NOV-1993; 93DE-04338704.
XX

PA (FARH) HOECHST AG.
XX
XX P&ymann A, Uhlmann E, Mag M, Kretzschmar G, Helsenberg M, Winkler I;
XX
XX WPI; 1995-180677/24.
XX
XX New anti:sense oligo:nucleotide analogues - with modified non-terminal
XX pyrimidine nucleotide units, useful for treating viral infections,
XX cancer, etc.
XX
XX Claim 1; Page 30; 36pp; German.
XX
XX The antisense oligonucleotide (ON) shown is a derivative of an equivalent
XX wild type Human bFGF translation start site ON, in which at least one,
XX esp. 2-10, non-terminal pyrimidine nucleotide(s) is/are modified. The
XX modification may be: (a) replacement of a phosphodiester linkage by: a
XX phosphoro-thioate (PS), -dithioate, -aramidate; borano-, alkyl-, aralkyl-
XX phosphate; 2,2-trichloro-1,1-dimethyl-, alkyl- or aryl- phosphonate
XX linkage; or (3')-thioformacetal, methylhydroxylamine, oxime,
XX methylenedimethylhydrazo, dimethylene sulphone or silyl linkage; (b)
XX replacement of a sugar phosphate backbone by a 'morpholinonucleoside'
XX oligomer; (c) replacement of beta-D-2-deoxyribose by another sugar or
XX carbocyclic, open-chain or bicyclic sugar analogue; or (c) replacement of
XX the natural nucleoside base by an analogue, e.g. 5-hydroxymethyl-uridine.
XX The 5' and/or 3' terminus may also be modified with a lipophilic gp., eg.
XX a fattyacyl. The modifications increase nuclease resistance and thus
XX improve stability and activity
XX
XX Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1295 GGGTGCATGGTC 1307
DB 1 GGGTGCATGGTC 13
RESULT 691
AAT52000/C
ID AAT52000 standard; RNA; 15 BP.
XX
XX AAT52000;
XX
XX 25-MAR-2003 (revised)
XX
XX 18-MAR-1997 (first entry)
XX
XX Human ICAM hammerhead ribozyme target sequence (nt. position 2226).
DE
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
XX gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
XX intercellular adhesion molecule; rel A; tumour necrosis factor;
XX TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
XX translocation; chronic myelogenous leukaemia; CML; cancer;
XX Philadelphia chromosome; inflammation; autoimmune disease;
XX atherosclerosis; myocardial infarction; stroke; restenosis;
XX transplant rejection; rheumatoid arthritis; psoriasis;
XX myocardial ischemia; Kawasaki disease; septic shock; HIV;
XX human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
XX ss.
XX
XX Homo sapiens.
XX
XX MO9523225-A2.
XX
XX 31-AUG-1995.
XX
XX 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX
XX 29-MAR-1994; 94US-00218934.
XX
XX 04-APR-1994; 94US-00222795.
XX

```
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00211280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudyecz LM;
PI Grimm S, Karpeisky A, Kisch K, Matulic-Adamic J, Mcawiggen JA;
PI Modak A, Pavoic P, Beiselman L, Sullivan SM, Sweedler D, Thompson JD;
PI Trazz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
XX Claim 2; Page 174; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICM-1 mRNA at the
XX nucleotide base position indicated in the DE line. Regions of the mRNA
XX that do not form secondary folding structures and that contain potential
XX hammerhead and hairpin ribozyme cleavage sites were identified by
XX computer analysis. Ribozymes directed against these mRNA sequences were
XX designed and synthesised with modifications that improve their nuclease
XX resistance. The ribozymes cleave the ICM-1 target sequences and thereby
XX inhibit ICM-1 expression, making them useful for reducing transplant
XX rejection and alleviating symptoms in patients with rheumatoid arthritis,
XX asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
XX correct PI field.)
XX
XX Sequence 15 BP; 1 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1278 GAGGCGCAGAGACC 1290
DB 15 GAGGCCAGAGACC 3
RESULT 692
AAQ97684
ID AAQ97684 standard; DNA; 15 BP.
XX
XX AAQ97684;
AC
XX
XX 22-MAR-1996 (first entry)
DT
XX
XX Biotinylated antisense oligonucleotide against bFGF.
DE
XX
XX antisense; bFGF; basic fibroblast growth factor; biotinylated;
```

```
KW monoclonal antibody; avidin; complex; non-viral vector; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FT modified_base 1
FT /*tag= a
FT /mod_base= 5'-biotin-G
XX
XX MO9521195-A1.
XX
XX 10-AUG-1995.
XX
XX 06-FEB-1995; 95WO-US001161.
XX
XX 07-FEB-1994; 94US-00192655.
XX
XX (RERE-) RES DEV FOUND.
PA
XX
XX Rosenblum MG, Donato NJ;
PI
XX
XX WPI; 1995-283733/37.
XX
XX A non-viral vector having a cell binding component - used to introduce
PT genetic material into, or to deliver a cytotoxic moiety to a specific
PT cell.
XX
XX Example 13; Page 18; 35pp; English.
XX
XX A non-viral vector comprising a cell binding component having a biotin-
XX binding element (eg. avidin or streptavidin) conjugated to a biotinylated
XX moiety is claimed. The cell binding element is a monoclonal antibody
XX (Mab) or a ligand which binds a cell surface receptor or a nucleic acid,
XX pref. a triplex forming oligonucleotide or an antisense oligonucleotide.
XX An anti-epidermal growth factor (EGF) receptor monoclonal antibody (A108)
XX was chemically conjugated to avidin. AAQ97684 represents the
XX complementary sequence to the basic fibroblast growth factor (bFGF) mRNA
XX translation start site, it was synthesised with a biotinylated guanosine
XX at the 5' terminal position. The biotinylated oligonucleotide was
XX incubated with the A108-avidin complexes of A108-avidin:antisense bFGF
XX (19) which express EGF receptor and are critically dependent on the cells
XX own synthesis of bFGF to promote their own growth. The SNB cell growth
XX was measured to determine the extent of growth suppression by preventing
XX expression of bFGF in these target cells
XX
XX Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1295 GCGTGCATGCTC 1307
DB 1 GCGTGCATGCTC 13
RESULT 693
AAT44260
ID AAT44260 standard; DNA; 15 BP.
XX
XX AAT44260;
AC
XX
XX 22-JUL-1997 (first entry)
DT
XX
XX bFGF antisense component of capped oligonucleotide.
DE
XX
XX Antisense therapy; basic fibroblast growth factor; bFGF; guanosine;
KW nuclease resistance; stability; ss.
XX
XX Synthetic.
XX
XX DE19502912-A1.
```

[illegible]

Claim 3, Page 21, 37pp; English.

A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a) (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms complementary to the present sequence (nucleotide position 12310). The ribozyme blocks to some extent apo(a) expression, and can therefore be used to diagnose or treat conditions related to lipoprotein (a) levels, e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart disease. PCR was used to generate a substrate for T7 RNA polymerase transcription from monkey apo(a) cDNA clones. Labelled transcripts were synthesised in vitro to form 2 templates. The oligonucleotides and labelled transcripts were annealed, RNaseH added and the mixts. incubated. After a designated time the reactions were stopped, and RNA sepd. on sequencing polyacrylamide gels. The percentage of substrate cleaved was determined by autoradiographic quantification, and the most accessible ribozyme target sites chosen

Sequence 15 BP; 4 A; 2 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 53.8%; Pred. No. 3e+02;
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0

1303 TGGTCATCTGTCA 1315
 :||:|:|:|:|:|:
 1 UGUCACUACUAGA 13

RESULT 695
 AAX33920
 ID AAX33920 standard; DNA; 15 BP.
 XX
 AC AAX33920;
 XX
 DT 30-JUN-1999 (first entry)
 XX
 DE bGCF expression inhibitor.
 XX
 XX bGCF expression inhibitor.
 KW Gene expression inhibitor; probe; nucleic acid detection; growth factor;
 KW viral infection; therapy; HSV-1; cancer; restenosis; integrin;
 KM cell-cell adhesion receptor; bGCF; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN A09648028-A.
 XX
 XX 26-SEP-1996.
 PD
 XX
 XX 12-MAR-1996; 96AU-00048028.
 PF
 XX
 PR 13-MAR-1995; 95DE-01008923.
 PR 24-NOV-1995; 95DE-01043865.
 XX
 PA (FARM) HOECHST AG.
 XX
 PI Peyman A, Uhlmann E, Breipohl G, Wallmeier H;
 XX
 DR WPI; 1996-455932/46.
 PT
 XX
 XX New phosphono:mono:ester oligo:nucleotide analogues - inhibitors of gene
 expression for treating viral infections, cancer, restenosis, etc.
 XX
 PS Disclosure, Page 42; 129pp; English.

This sequence represents an inhibitor of bGCF, and is an example of an oligonucleotide analogue of the invention. The oligonucleotide analogues of the invention are used as inhibitors of gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detection of nucleic acids, and as auxiliaries in molecular biology. As gene expression inhibitors they may be used for treating viral infections (especially where the virus is HSV-

CC 1, HSV-2, an influenza virus, VSV, hepatitis B or papilloma virus),
CC cancer, restenosis, medical conditions mediated by integrins or cell-cell
CC adhesion receptors, and medical conditions induced by growth factors
CC (especially TNF-alpha)

XX SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1295 GGGTCCCATGGTC 1307
DB 1 GGCTGCCATGGTC 13

RESULT 696
AAT89133
ID AAT89133 standard; RNA; 15 BP.

AC AAT89133;

DT 04-MAR-1998 (first entry)

XX Lutetium texaphyrin RNA conjugate for light induced cleavage of DNA.

XX Photosensitive; texaphyrin; DNA cleavage; light induced; photocleavage;
KW lutetium; ss.

OS Synthetic.

XX Key Location/Qualifiers

XX Key misc_binding 1..15

FT /tag= b

FT /note= "this region binds to AAT89134"

FT misc_feature 1

FT /tag= a

FT /mod_base

FT /note= "Cytosine is modified by lutetium(III) texaphyrin
compound"

FT misc_feature 15

FT /tag= C

FT /note= "Guanine is modified by a methoxy group"

XX MO9609315-A1.

XX PD 28-MAR-1996.

XX PF 21-SEP-1995; 95WO-US012312.

XX PR 21-SEP-1994; 94US-00310501.

XX PR 06-JUN-1995; 95US-00469177.

XX PA (TEKA) UNITV TEXAS SYSTEM.

XX PA (PHAR-) PHARMACYCLICS INC.

XX PI Megda D, Sessler JL, Iverson BL, Sansom PI, Wright M, Mody TD;

XX PI Hemmi GW;

XX DR WPI; 1996-200644/20.

XX Use of photosensitive texaphyrin cpds. - for light-induced cleavage of
XX polymers of deoxyribonucleic acid in analyses or therapy.

XX Example 8; Fig 3; 81pp; English.

XX The present sequence represents RNA coupled to a photosensitive

XX texaphyrin molecule, which was used in a new method for photocleavage of

XX DNA. Targeted intracellular light-induced cleavage of a selected DNA

XX comprises introducing into a cell a photosensitive texaphyrin (PT)

XX coupled to an oligonucleotide which is complementary to the selected DNA

XX and exposing the cell to light to cleave the DNA. Modulating the activity

XX of a selected DNA comprises contacting the DNA with a PT coupled to an

CC oligonucleotide which binds to the DNA and exposing the DNA-PT mixture to
CC light to cleave the DNA. These methods can be used e.g. in cleavage of
CC DNA in footprinting analysis, DNA sequencing, chromosome analyses, gene
CC isolation, recombinant DNA manipulations, mapping of large genomes and
CC chromosomes and for site-directed mutagenesis. They can also be used in
CC anti-viral therapy and for the treatment of cancers, inflammatory
CC responses that are caused by over expression of certain proteins,
CC infectious diseases and genetically-based disorders

XX SQ Sequence 15 BP; 2 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 1307 CATCTGTAGCAG 1319
DB 1 CAUCUGGAGCCG 13

RESULT 697
AAT34531/C
ID AAT34531 standard; DNA; 15 BP.

XX AAT34531;

DT 10-OCT-1996 (first entry)

XX Human Fas antigen 5' PCR primer.

XX Fas antigen; autoimmune disease; systemic lupus erythematosus; SLE;
KW angioimmunoblastic lymphadenopathy; AILD; PCR; primer;

XX polymerase chain reaction; ss.

XX OS Synthetic.

XX MO9620206-A1.

XX PD 04-JUL-1996.

XX PF 22-DEC-1995; 95WO-US017083.

XX PR 23-DEC-1994; 94US-00371263.

XX PA (UABR-) UAB RES FOUND.

XX PI Mountz JD, Liu C, Zhou T, Cheng J;

XX PI WPI; 1996-321796/32.

XX Natural, soluble form of Fas antigen secreted by human cells is result of
XX alternative mRNA processing - used to diagnose Fas-associated disease,
XX e.g. systemic lupus erythematosus.

XX Example 1; Page 74; 152pp; English.

XX A PCR primer (AAT34531) is based on nucleotides 1-22 of human Fas antigen

XX cDNA (see also AAT34526). It was used with a primer (AAT34532)

XX complementary to nucleotides 1316-1336 of the cDNA to amplify human fas

XX mRNA from nucleotides 170-1336. The template mRNA was obtained from the

XX peripheral blood mononuclear cells of healthy subjects and from systemic

XX lupus erythematosus (SLE) and angioimmunoblastic lymphadenopathy

XX patients. PCR products were cloned into a PCR vector, expressed in E.

XX coli, and sequenced (see also AAT34533-34). 4 Distinct mRNA variants (see

XX also AAT34527-30) were identified

XX SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1247 GGTCCGGCTGCAG 1259

DB 15 GGTCCGGGTGCAG 3

RESULT 698
AAT34533/C

ID AAT34533 standard; DNA; 15 BP.

AC AAT34533;

DT 10-OCT-1996 (first entry)

DE Human Fas antigen primer.

XX Fas antigen; autoimmune disease; systemic lupus erythematosus; SLE;

KW angioimmunoblastic lymphadenopathy; AILD; PCR; primer;

KW polymerase chain reaction; ss.

OS Synthetic.

PN W09620206-A1.

PD 04-JUL-1996.

PF 22-DEC-1995; 95MO-US017083.

PR 23-DEC-1994; 94US-00371263.

PA (UABR-) UAB RES FOUND.

PI Mountz JD, Liu C, Zhou T, Cheng J;

DR WPI; 1996-321796/32.

PT Natural, soluble form of Fas antigen secreted by human cells is result of

PT alternative mRNA processing - used to diagnose Fas-associated disease,

PT e.g. systemic lupus erythematosus.

PS Example 1; Page 75; 152pp; English.

XX A primer (AAT34533) is based on nucleotides 377-3912 of human Fas antigen

CC CDNA (see also AAT34526). It was used with a primer (AAT34534)

CC complementary to nucleotides 1059-1076 of the cDNA to sequence PCR

CC products amplified (see also AAT34531-32) from fas mRNA derived from the

CC peripheral blood mononuclear cells of healthy subjects and from systemic

CC lupus erythematosus (SLE) and angioimmunoblastic lymphadenopathy

CC patients. 4 Distinct mRNA variants (see also AAT34527-30) were identified

XX Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1247 GGTCCGGGTGCAG 1259

DB 15 GGTCCGGGTGCAG 3

RESULT 699
AAX24214

ID AAX24214 standard; DNA; 15 BP.

AC AAX24214;

DT 01-JUL-1999 (first entry)

DE Phosphonomonoester oligonucleotide analogue 30.

XX Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;

KW ribozyme; diagnostic agent; detection; treatment; disease; virus;

KW integrin; cell-cell adhesion receptor; TNF-alpha; ss.

PI

XX

OS Synthetic.

PN DE19508923-A1.

PD 19-SEP-1996.

PF 13-MAR-1995; 95DE-01008923.

PR 13-MAR-1995; 95DE-01008923.

PA (FARH) HOECHST AG.

PI Anuschirwan P, Uhlmann E, Breipohl G, Wallmeier H;

DR WPI; 1996-425893/43.

PT New oligo:nucleotide analogues contg. phospho:mono:ester bridges - for

PT therapeutic inhibition of gene expression, e.g. in cancer or viral

PT infection, with good specificity and in vivo stability.

PS Disclosure; Page 23; 36pp; German.

XX This invention describes novel phosphonomonoester oligonucleotide

CC analogues which act as inhibitors of gene expression (as sense/antisense,

CC ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e.

CC probes for detecting nucleic acid) or for treatment of diseases caused by

CC viruses, influenced by integrins or cell-cell adhesion receptors, induced

CC by factors such as TNF-alpha, or cancer or restenosis. The products of

CC the invention satisfy the requirements of good in-vivo stability; ability

CC to cross cellular and nuclear membranes, and specific binding to target

CC nucleic acid better than known oligonucleotides

XX Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1295 GGTGCCCATGCTC 1307

DB 1 GGTGCCCATGCTC 13

RESULT 700
AAT63296

ID AAT63296 standard; CDNA; 15 BP.

AC AAT63296;

DT 25-MAR-2003 (revised)

DT 21-MAY-1997 (first entry)

DE Human basic fibroblast growth factor antisense primer to start site.

XX primer; inhibition; growth; malignant behaviour; glioma; mitogen; tumour;

KW basic fibroblast growth factor; angiogenesis; vascularisation; intron;

KW splice site; donor; acceptor; antisense; ss.

OS Synthetic.

PN US5583116-A.

PD 10-DEC-1996.

PF 21-DEC-1994; 94US-00382521.

PR 10-JAN-1992; 92US-00818898.

PR 20-SEP-1993; 93US-00124354.

PA (GOOD-) GOOD SAMARITAN HOSPITAL & MEDICAL CENT.

PI Morrison RS;

XX

DR WPI; 1997-050634/05.
 XX Inhibiting growth and malignancy behaviour of glioma cells - using basic
 PT fibroblast growth factor-specific anti-sense primers.
 XX
 XX Claim 3; Col 3-4; 7pp; English.
 XX
 XX Primers AAT63294-97 were used in a method of inhibiting growth or
 CC malignant behaviour of glioma cells. Basic fibroblast growth factor
 CC (bFGF) is a known mitogen active in angiogenesis which can stimulate
 CC tumour growth or tumour vascularisation. This antisense oligonucleotide
 CC is targeted to the translation initiation site of the bFGF coding
 CC sequence. (Updated on 25-MAR-2003 to correct PF field.)
 XX
 XX Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 4.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3e+02; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1;
 Oy 1295 GGGTGCATGGTC 1307
 Db 1 GGCTGCCATGGTC 13
 RESULT 701
 AAV07304
 ID AAV07304 standard; DNA; 15 BP.
 AC AAV07304;
 XX
 XX 14-AUG-1998 (first entry)
 DE Metallohexaphyrin-oligonucleotide conjugate #18.
 XX
 XX Metallohexaphyrin; dysprosium; europium; conjugate; Rhase H;
 KM antisense therapy; ss.
 XX
 XX Synthetic.
 OS
 XX
 FT Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base
 FT /note= "DyTxNH-(CH2)6-PSO3-Cytosine, where DyTx is
 FT dysprosium (III) texaphyrin"
 FT
 XX
 XX US5763172-A.
 FN
 XX
 XX 09-JUN-1998.
 PD
 XX
 XX 07-JUN-1995; 95US-00486962.
 PF
 XX
 XX 21-JAN-1992; 92US-00822964.
 PR 09-JUN-1993; 93US-00075123.
 PR 14-APR-1994; 94US-00227370.
 PR 09-JUN-1994; 94WO-US006284.
 PR 26-MAY-1995; 95US-00452261.
 PR 07-JUN-1995; 95US-00485581.
 PR
 XX
 XX (PHAR-) PHARMACYCLICS INC.
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 XX
 PI Seesler JL, Wright M, Miller RA, Dow WC, Magda D;
 DR WPI; 1998-347306/30.
 XX
 XX
 XX Enhancing therapeutic activity of oligo-nucleotides in cells - using
 PT conjugate comprising metallohexaphyrin, which hydrolyses phosphate ester
 PT bonds of RNA, and oligo-nucleotide, which binds to targeted RNA.
 XX
 XX Example 8; Col 29-30; 34pp; English.
 PS
 XX

CC The invention relates to a method of enhancing the therapeutic activity
 CC of oligonucleotides in cells. It comprises contacting a targeted
 CC intracellular RNA in a cell with a metallohexaphyrin-oligonucleotide
 CC conjugate. The contact is carried out under physiological conditions for
 CC a time sufficient to hydrolyse the phosphate ester bond of the targeted
 CC RNA. The metallohexaphyrin of the conjugate has catalytic activity for
 CC phosphate ester bond hydrolysis. The oligonucleotide of the conjugate has
 CC complementary binding affinity to the targeted RNA. The conjugate may be
 CC used in antisense therapies for treating, e.g. cancer, viral infections,
 CC autoimmune diseases and restenosis. The conjugate may also be used as
 CC hydrolysis reagents for the detoxification of di- and trialkyl phosphate
 CC esters, which are used in solvents, insecticides and chemical nerve
 CC gases. The metallohexaphyrin complex enhances the therapeutic activity of
 CC the oligonucleotide, not only by facilitating cellular uptake of the
 CC oligonucleotide but also by hydrolysing target RNA within the cell,
 CC independent of RNase H. Attachment to the complex may also cause the
 CC oligonucleotide to take on some of the pharmacodynamic and biotransformation
 CC properties of the texaphyrin, such as selective localisation in tumours.
 CC The present sequence represents a metallo- texaphyrin-oligonucleotide
 CC conjugate
 CC
 XX
 XX Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 4.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3e+02; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1;
 Oy 1307 CATCTGTGAGCAG 1319
 Db 1 CATCTGTGAGCCG 13
 RESULT 702
 AAX61949
 ID AAX61949 standard; DNA; 15 BP.
 AC AAX61949;
 XX
 XX 31-AUG-1999 (first entry)
 DE Type-specific HPV probe SGP34.
 XX
 XX PCR primer; probe; human papillomavirus; HPV; A region; B region;
 KM C region; D region; detection; HPV genotype; cervical cancer; ss.
 XX
 XX Synthetic.
 OS
 XX Human papillomavirus.
 FN
 XX
 XX WO9914377-A2.
 FN
 XX
 XX 25-MAR-1999.
 PD
 XX
 XX 14-SEP-1998; 98WO-EP005829.
 PF
 XX
 XX 16-SEP-1997; 97EP-00870136.
 PR
 XX
 XX (INNO-) INNOGENETICS NV.
 PA (DELF-) DELFTS DIAGNOSTIC LAB BV.
 XX
 XX
 PI Van Doorn L, Quint W, Kleter B, Ter Schegget J;
 DR WPI; 1999-244048/20.
 XX
 XX
 XX Detection and identification of human papillomavirus.
 PT
 XX
 XX Claim 8; Page 32; 78pp; English.
 PS
 XX
 XX AAX61849-X61982 and AAX62002-X62093 represent PCR primers and probes used
 CC for detecting and/or identifying human papillomavirus (HPV) present in a
 CC biological sample. The method comprises amplification of a polynucleic
 CC acid fragment of HPV using a 5'-primer specifically hybridizing to the A
 CC region or B region of the genome of at least one HPV type, and a 3'-
 CC primer specifically hybridizing to the C region of at least one HPV type,

CC and hybridisation of the amplified fragments with at least one probe
CC capable of specific hybridization with the D region of at least one HPV
CC type. The primers individually or as a combination of 5'-primer and 3'-
CC primer, and the probes are used in the detection and/or identification of
CC HPV present in a biological sample. An isolated HPV polynucleotide, or
CC fragment, can also be used as a primer in a method for detection and/or
CC identification of HPV present in a sample. Identification of the
CC different HPV genotypes may have great clinical and epidemiological
CC importance. The presence of high-risk HPV types is a prognostic marker
CC for development and detection of cervical cancer

XX Sequence 15 BP; 3 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;

Oy 1232 GCATGTCTGCGCA 1244
||| |||||
Db 1 GCATTGCTGCGCA 13

RESULT 703

AAx89353
ID AAX89353 standard; DNA; 15 BP.

XX AC AAX89353;

XX DT 24-SEP-1999 (first entry)

DE Human basic fibroblast growth factor specific antisense primer AS-2.

KW Angiogenicity; glioma cell; basic fibroblast growth factor; bFGF;

KM neutral tissue; tumour vascularisation; human; PCR primer; ss.

OS Synthetic.

OS Homo sapiens.

XX PN US5935856-A.

XX PD 10-AUG-1999.

XX PF 09-DEC-1996; 96US-00760870.

XX PR 10-JAN-1992; 93US-00818898.

XX PR 20-SEP-1993; 93US-00124354.

XX PR 21-DEC-1994; 94US-00382521.

PA (LEGA-) LEGACY GOOD SAMARITAN HOSPITAL & MEDICAL.

XX PI Morrison RS;

XX DR WPI; 1999-457607/38.

PT Modulating the expression of basic fibroblast growth factor using

XX PT antisense primers.

XX PS Claim 3; Col 3-4; 9pp; English.

CC The invention provides a method for inhibiting angiogenicity of glioma

CC cells or altering the expression of basic fibroblast growth factor (bFGF)

CC in the developing glial cells of neural tissues that uses bFGF-specific

CC antisense primers. The methods and primers may be useful for the

CC modulation of bFGF and control of tumour vascularisation. Sequences

XX AAX89352-353 represent human bFGF (h-bFGF) specific antisense primers

XX SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;

Oy 1295 GGGTGCCATGCTC 1307

Db ||| |||||
1 GCGTGCCATGCTC 13

RESULT 704

AAZ64295/C
ID AAZ64295 standard; RNA; 15 BP.

XX AC AAZ64295;

XX DT 28-MAR-2000 (first entry)

DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 7366.

KM Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;

KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;

XX KM autoimmune disease; ss.

XX OS Hepatitis C virus.

XX PN WO955847-A2.

XX PD 04-NOV-1999.

XX PF 26-APR-1999; 99WO-US009027.

XX PR 27-APR-1998; 98US-0083217P.

XX PR 18-SEP-1998; 98US-0100842P.

XX PR 25-FEB-1999; 99US-00257608.

XX PR 23-MAR-1999; 99US-00274553.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Mcwiggan JA, Roberts E, Pavco PA, Macejak D;

XX DR WPI; 2000-062023/05.

PT Novel ribozymes for the treatment of diseases and conditions related to

XX PT hepatitis C infection.

XX PS Claim 1; Page 87; 123pp; English.

CC The present sequence represents the preferred target sequence of an

CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves

CC the Hepatitis C virus (HCV) RNA sequence at the base position given in

CC the descriptor line. The HCV sequence was screened for optimal ribozyme

CC target sites using a computer folding algorithm and regions of the RNA

CC which did not form secondary folding structures and contained potential

CC ribozyme cleavage sites were identified. Ribozymes were synthesised to

CC target these sites and their activities optimised by either varying the

CC length of the binding arms or by modification to prevent degradation by

CC nucleases. The ribozymes of the invention inhibit gene expression and/or

CC viral replication, and are used to treat diseases associated with

CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and

CC hepatocellular carcinoma. The ribozymes may be used in combination with

CC interferon to treat HCV infection, other infectious diseases, autoimmune

XX diseases, and cancer

XX SQ Sequence 15 BP; 0 A; 4 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;

Oy 1337 CAAGCGAGAGAC 1349
||| |||||
Db 15 CAAGCGAGAGAC 3

RESULT 705

AAc69824
ID AAC69824 standard; RNA; 15 BP.

AC AAC69824;
XX
DT 30-JAN-2001 (first entry)
XX
DE E. coli yfca RNAMOT-identified MS2 CP binding site, SEQ ID NO:19.
XX
DB
XX SELEX; systematic evolution of ligands by exponential enrichment;
KW nucleic acid ligand; aptamer; in vitro evolution; iterative selection;
KW MS2 CP binding site; bacteriophage MS2 replicase fragment;
KW RNAMOT program; ss.
XX
OS Escherichia coli.
XX
PN WO200056930-A1.
XX
PD 28-SEP-2000.
XX
PF 20-MAR-2000; 2000WO-US007486.
XX
PR 24-MAR-1999; 99US-00275850.
XX
PA (NEXS-) NEXSTAR PHARM INC.
XX
PI Pagratia N, Gold L, Shtatland T, Javornik B;
DR WPI; 2000-594583/56.
XX
PT Identifying nucleic acid ligands of a target molecule comprises annealing
PT complementary oligonucleotides, partitioning the nucleic acids and
XX amplifying the nucleic acids exhibiting increased affinity.
XX
PS Example 2; Page 76; 264pp; English.
XX
CC The invention relates to a method of identifying nucleic acid ligands of
CC a target molecule from a candidate mixture composed of single stranded
CC nucleic acids, each having a region of randomized sequence and a region
CC of fixed sequence. The method uses modified versions of the SELEX
CC (systematic evolution of ligands by exponential enrichment) method in
CC which the participation of fixed sequences is minimised or eliminated.
CC This method comprises annealing complementary oligonucleotides to the
CC fixed sequences of the candidate molecule mixture, contacting the
CC candidate mixture with the target molecule, partitioning the nucleic
CC acids which have increased affinity relative to the candidate mixture,
CC and amplifying the nucleic acids exhibiting increased affinity to yield a
CC ligand enriched mixture of nucleic acids. In one embodiment of the
CC invention, one or more regions of fixed sequences is replaced with
CC different fixed sequences, and the binding, partitioning and
CC amplification steps are repeated. In another embodiment, the partitioned
CC nucleic acids are hybridised with a library of single stranded
CC complementary nucleic acids, are then amplified, and the fixed regions of
CC the increased affinity nucleic acids cleaved. In the exemplifications of
CC the invention, a consensus binding site for MS2 CP (bacteriophage MS2
CC replicase fragment was identified by SELEX. MS2 CP binding sites were
CC then identified in the Escherichia coli genomic library by SELEX or by
CC the RNAMOT program. The present sequence represents an E. coli MS2 CP
CC binding site identified by the RNAMOT program
XX
SQ Sequence 15 BP; 4 A; 6 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX
DT 29-AUG-2001 (first entry)
XX
DE Human CHMR1 allele specific oligonucleotide probe #15.
XX
DB
XX Human; m1 acetylcholine receptor; CHRM1; immunogen; antibody;
KW Alzheimer's disease; dementia with Lewy bodies; DLB;
KW allele specific oligonucleotide probe; ss.
XX
OS Homo sapiens.
XX
PN WO200127312-A2.
XX
PD 19-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US028211.
XX
PR 13-OCT-1999; 99US-0159269P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
DR WPI; 2001-282046/29.
XX
PT New variants of the m1 muscarinic acetylcholine receptor gene, useful to
PT find treatment for Alzheimer's and dementia, have single nucleotide
XX variations at one or more of five polymorphic sites.
XX
PS Claim 15; Page 19; 52pp; English.
XX
CC The sequence represents an allele specific oligonucleotide probe for
CC genotyping individuals using the Human gene encoding the m1 muscarinic
CC acetylcholine receptor, CHMR1. CHMR1 is one subtype of a family of 5
CC genetically distinct muscarinic acetylcholine receptors, mAChR, that play
CC important roles in higher brain function such as learning and memory. The
CC protein is a possible drug target for treatments for Alzheimer's disease
CC and dementia with Lewy bodies (DLB). The gene, polypeptide, haplotypes
CC and antibodies raised against the protein are useful for diagnosing and
CC developing treatments for diseases associated with the abnormal
CC expression of the gene or activity of the protein, e.g. Alzheimer's
CC disease and dementia with Lewy bodies
XX
SQ Sequence 15 BP; 2 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1271 AGAGCTGAGGGC 1283
DB 3 AGGGCTGAGGGC 15

RESULT 707
AAAF60910
ID AAAF60910 standard; DNA; 15 BP.
XX
AC AAAF60910;
XX
DT 15-MAY-2001 (first entry)
XX
DE Anti-DFGF oligonucleotide SEQ ID 19.
XX
KW Transport; membrane; cytosolic; virocidic; vasotropic; dermatological;
KW antiproliferative; antitumor; antitumor; gene therapy; tumor cell; antisense;
KW tumor therapy; drug; ss.
XX
OS Unidentified.
XX
PN DE19935302-A1.
XX
PD 08-FEB-2001.

XX 28-JUL-1999; 99DE-01035302.
XX
XX 28-JUL-1999; 99DE-01035302.
XX
XX (AVET) AVENTIS PHARMA DEUT GMBH.
XX
XX Uhlmann E, Greiner B, Unger E, Gothe G, Schwerdel M;
XX WPI, 2001-203679/21.
XX
XX New substituted aryl conjugates of parent molecules, especially
XX oligonucleotides, having improved transmembrane and intracellular
XX transport properties, useful as medicaments or diagnostic agents.
XX
XX Disclosure: Page 6; 28pp; German.
XX
XX This invention describes a novel conjugate (I) which consists of (A) a
XX molecule to be transported and (B) at least one aryl residue of formula -
XX Ar-(X-C(Y)-R₁)_n (II). Ar = group containing at least one aromatic ring;
XX X = O or N (Bic); Y = O, S or NH-R₂ (Sic); R₁ = optionally substituted
XX 1-22C alkyl (optionally containing double and/or triple bonds); R₂ =
XX optionally substituted 1-18C alkyl (optionally containing double and/or
XX triple bonds); n = integer of 1 or more. (A) is bonded to (B) directly or
XX via a chemical group, provided that the chemical group is other than CH₂
XX -S if the bond is via a phosphodiester linkage of (A). The invention also
XX describes (i) the preparation of a conjugate (I') of (A') a molecule to
XX be transported and (B') at least one aryl residue (not restricted to
XX (II)), by preparing (A') containing a reactive function at the position
XX at which (B') is to be bonded, preparing (B') and reacting (A') and (B');
XX and (ii) the use of aryl groups (ii) (optionally bonded via a chemical
XX group) for transporting (A) across biological membranes. The products of
XX the invention have cytostatic, virucide, vasotropic, dermatological,
XX antiparasitic and antineoplastic activity and can be used for gene
XX therapy. Conjugation of (A) with (B) is useful for transporting (A)
XX across biological membranes or into eukaryotic or prokaryotic cells
XX (specifically bacterial, yeast or mammalian cells, including human cells,
XX particularly tumor cells). Medicaments, diagnostic agents and test kits
XX containing (I) are also claimed. Typically (I) are antisense
XX oligonucleotide derivatives for tumor therapy; oligonucleotide drugs for
XX treating viral infections or diseases associated with integrins or cell-
XX cell interactions (e.g. resectosis, vitiligo, psoriasis or asthma); or
XX labeled oligonucleotides for in vivo diagnostic use, e.g. by in situ
XX hybridization. Conjugation with (B) markedly improves the cellular uptake
XX of (A), e.g. in tumor cells. (B) include fluorescein derivative residues,
XX in which case the conjugates (I) are fluorescently labeled, allowing
XX microscopic monitoring of cellular uptake etc. The cellular uptake of (I)
XX is superior to that obtained using other conjugated groups related to
XX (II); e.g. oligonucleotides conjugated with fluorescein diacetate (within
XX the scope of (B)) have superior uptake to corresponding fluorescein
XX conjugates
XX
SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1295 GGGTGCATGCTC 1307
DB 1 GGGTGCATGCTC 13
XX
XX
RESULT 708
AAF49429
ID AAF49429 standard; DNA; 15 BP.
XX
XX AAF49429;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #389.
XX

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; rube;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI, 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 63; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, rube, pilaris, serborrhea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX diseases, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1299 GCCATGCTCATCT 1311
DB 3 GCCATGCTCATCT 15
XX
XX
RESULT 709
AAF49270
ID AAF49270 standard; DNA; 15 BP.
XX
XX AAF49270;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #230.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW

KM	growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM	hyperneovascular condition; hyperplasia; kidney disease;
XX	neovascular condition of the retina; ss.
XX	
OS	Homo sapiens.
XX	
FN	WO20078341-A1.
PD	28-DEC-2000.
XX	
PF	21-JUN-2000; 2000WO-AU000693.
XX	
PR	21-JUN-1999; 99US-0140345P.
XX	
PA	(MURD-) MURDOCH CHILDRENS RES INST.
XX	
PI	Wraight CJ, Werther GA, Edmondson SR;
XX	
DR	WPI, 2001-041421/05.
PT	
PT	Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT	UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT	inhibits or reduces growth factor mediated cell proliferation and/or
PT	inflammation.
XX	
PS	Example 8; Page 62; 201pp; English.
XX	
CC	The present invention relates to a method for ameliorating the effects of
CC	skin disorders. The method comprises contacting the skin with an
CC	antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC	receptor, IGF binding protein (IGFBP)-2 or IGFBP3), which is capable of
CC	inhibiting or reducing growth factor mediated cell proliferation,
CC	inflammation and/or other disorders. The present sequence is an
CC	oligonucleotide which can be used to design the antisense
CC	oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC	P45161). The method is useful for ameliorating the effects of psoriasis,
CC	ichthyosis, pityriasis, warts, pilaris, seborrhea, keloids, keratosis,
CC	neoplasias, scleroderma, ruba, benign growths, cancers of the skin, a
CC	hyperneovascular condition such as a neovascular condition of the retina,
CC	brain or skin, growth factor-mediated malignancies, other sclerotic
CC	disease, kidney disease, hyperproliferation of the inside of blood
CC	vessels or any other hyperplasia
XX	
SQ	Sequence 15 BP; 3 A; 5 C; 3 G; 4 T; 0 U; 0 Other;
Query Match	
Best Local Similarity 4.5%; Score 11.4; DB 1; Length 15;	
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0	
QY	1329 CTCTTCTCCAAGG 1341
Db	3 CTCATCTCCAAG 15
RESULT 710	
AAF50261/c	
ID	AAF50261 standard; DNA; 15 BP.
XX	
AC	AAF50261;
XX	
DT	30-MAR-2001 (first entry)
XX	
DE	IGF-I oligonucleotide #1221.
XX	
XX	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM	cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KM	skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM	growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM	hyperneovascular condition; hyperplasia; kidney disease;
KM	neovascular condition of the retina; ss.

XX XX Homo sapiens.
OS
XX
PN WO20078341-A1.
PD
XX 28-DEC-2000.
PP
XX 21-JUN-2000; 2000WO-AU000693.
PR
XX 21-JUN-1999; 99US-014034SP.
PA (MURD-) MURDOCH CHILDRENS RES INST.
PI Wraight CJ, Werther GA, Edmondson SR;
DR MPI; 2001-041421/05.
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.
PS Example 8; Page 68; 201dp; English.
XX The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAF45151 and AAF45153-P45161). This method is useful for ameliorating the effects of psoriasis, ichthyosis, pityriasis, rubra, pilaris, seborrheoa, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic diseases, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

SQ Sequence 15 BP; 1 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0.

CY 1336 CCAGGCGACGAGA 1348
DB 14 CCAGGCGATGGAGA 2
|||||||
|||

RESULT 71
AAF50262/C
ID AAF50262 standard; DNA; 15 BP.
AC AAF50262;
XX
DT 30-MAR-2001 (first entry)
DE IGF-I oligonucleotide #1222.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; rubra;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hypervascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
OS Homo sapiens.
PN WO20078341-A1.

```
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
PS
XX Example 8; Page 68; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
SQ Sequence 15 BP; 1 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1336 CCAAGCGACGAGA 1348
DB 13 CCAAGCGACGAGA 1

RESULT 712
AAF49378
ID AAF49378 standard; DNA; 15 BP.
AC AAF49378;
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGF-I oligonucleotide #338.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
```

```
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
PS
XX Example 8; Page 63; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
SQ Sequence 15 BP; 3 A; 9 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1337 ACCCTTCTCCCA 1339
DB 1 ACCCTTCTCCCA 13

RESULT 713
AAF49431
ID AAF49431 standard; DNA; 15 BP.
AC AAF49431;
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGF-I oligonucleotide #391.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
```

XX Wraight CJ, Werther GA, Edmondson SR;
PI
DR WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional), and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 63; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein (IGBP)-2 or IGFBR3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC P45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
SQ Sequence 15 BP; 1 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

```

XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional), and an antisen nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX PS
XX PS Example 8; Page 63; 201pp; English.
CC CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth factor [IGF]-1
CC receptor, IGF binding protein [IGBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, scleroderma, rubea, pilaris, seborrheoa, keloids, keratosis,
CC neoplasias, pterygia, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX XX
SQ Sequence 15 BP; 1 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Fred. NO. 3e+02; Indels 0; Gaps 0
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

```

Query Match	4.5%	Score 11.4	DB 1	Length 15
Best Local Similarity	92.3%	Pred. No.3e+02		
Matches 12	Conservative	0	Mismatches 1	Indels 0
OY	1299 GCCATGTCATCT	1311		
Db	1 GCCCTGGTCATCT	13		
RESULT 714				
AAF49430				
ID	AAF49430	standard; DNA; 15 BP.		
XX				
AC	AAF49430;			
DT	30-MAR-2001	(first entry)		
XX				
DE	IGF-I oligonucleotide #390.			
XX				
KW	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cyclostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; insulin-like growth factor 1 receptor; IGF-1; pityriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hypervascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.			
KW				
XX				
OS	Homo sapiens.			
XX				
FN	WO20078341-A1.			
XX				
PD	28-DEC-2000.			
XX				
PF	21-JUN-2000; 2000WO-AU000693.			
XX				
PR	21-JUN-1999; 99US-0140345P.			
XX				
PA	(MURD-) MURDOCH CHILDRENS RES INST.			
PI	Wraight CJ, Werther GA, Edmondson SR;			
XX				
DR	WPI; 2001-041421/05.			

QY	1299	GCATGCGTCATCT	1311
Db	2	GCCCTGTCATCT	14
RESULT 715			
	AAAF47495/C		
ID	AAAF47495	standard; DNA; 15 BP.	
XX	AAAF47495;		
AC			
XX			
DT	30-MAR-2001	(first entry)	
XX			
DE	IGFBP3 oligonucleotide #915.		
XX			
KW	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;		
KW	cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;		
KW	skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;		
KW	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;		
KW	growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;		
KW	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;		
KW	hypertrovascular condition; hyperplasia; kidney disease;		
KW	neovascular condition of the retina; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	MO200078341-AL.		
XX			
PD	28-DEC-2000.		
XX			
PF	21-JUN-2000; 2000WO-AU000693.		
XX			
PR	21-JUN-1999; 99US-0140345P.		
XX			
PA	(MURDOCH CHILDRENS RES INST.		
XX			
PI	Wraight CJ, Werther GA, Edmondson SR;		
XX			
DR	WPI; 2001-041421/05.		
XX			
PT	Ameliorating the effects of a disorder, e.g. psoriasis, by administering		
UV	UV (ultra-violet) treatment (optional) and an antisense nucleic acid that		
PT	inhibits or reduces growth factor mediated cell proliferation and/or		

Ameliorating the effects of a disorder, e.g. psoriasis, by administering PT UV (ultra-violet) treatment (optional) and an antisenesc nucleic acid that PT inhibits or reduces growth factor mediated cell proliferation and/or

CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia

CC Sequence 15 BP; 2 A; 8 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1266 CTGGAGAGGCTG 1278

Db 13 CTGGAGAGGCTG 1

RESULT 718

AAH28575/C

ID AAH28575 standard; DNA; 15 BP.

AC AAH28575;

DT 17-JUN-2001 (first entry)

DE Human interleukin-13 allele specific oligonucleotide #61.

KW Human; interleukin-13; IL13; single nucleotide polymorphism; SNP; cancer;
KW inflammation; immune disorder; cytokine; asthma; chromosome 5q31;
KW fibrosis; forensic; disease susceptibility; drug screening; probe; ss.

OS Homo sapiens.

PN WO200123410-A2.

PD 05-APR-2001.

PF 27-SEP-2000; 2000WO-US026556.

PR 28-SEP-1999; 99US-0156489P.

PA (GENA-) GENA1SSANCE PHARM INC.

PI Chew A, Denton RR, Nandabalan K, Stephens JC;

DR WPI; 2001-343160/36.

PT Novel polynucleotide comprising single nucleotide polymorphisms in human
PT interleukin-13 gene is useful for studying expression and function of
PT interleukin-13, as well as diagnosing and treating cancer, inflammatory,
PT and immune disorders.

PS Claim 15; Page 20; 85pp; English.

CC The present invention provides the protein, cDNA and genomic sequences of
CC human interleukin-13 (IL13), and describes the single nucleotide
CC polymorphisms (SNPs) found within the gene, which is found on chromosome
CC 5q31. IL13 is a pro-inflammatory cytokine thought to be involved in the
CC pathogenesis of asthma and other immune and inflammatory diseases. The
CC IL13 sequences and the SNPs identified can be used in drug screening, to
CC determine an individual's susceptibility to disease, in forensic and
CC paternity testing, and to identify treatments for cancer, immune and
CC inflammatory diseases, including asthma and diseases characterised by
CC fibrosis. The present sequence is an IL13 allele-specific oligonucleotide
XX Sequence 15 BP; 4 A; 8 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1237 TGCTGCGAGTGT 1249

Db 15 TGCTGCGAGGCT 3

RESULT 719

AAF26653 standard; DNA; 15 BP.

AC AAF26653;

DT 02-APR-2001 (first entry)

DE Dekkera bruxellensis (Brettanomyces) detection probe SEQ ID NO:10.

KW Dekkera bruxellensis; Brettanomyces; detection; identification;
KW quantitation; yeast; probe; winery; brewery; food; dairy product;
KW pharmaceutical product; personal care product; environmental sample;
KW clinical sample; beverage; wine; beer; ss.

OS Dekkera bruxellensis.

PN WO200077259-A1.

PD 21-DEC-2000.

PF 14-JUN-2000; 2000WO-US016273.

PR 15-JUN-1999; 99US-0139212P.

PA (BOST-) BOSTON PROBES INC.

PI Hyldig-Nielsen J, O'Keefe HP, Stender H;

DR WPI; 2001-071284/08.

PT Probe and probe sets suitable for detecting, identifying or quantifying
PT the presence of Dekkera/Brettanomyces yeast, particularly Dekkera
PT bruxellensis (Brettanomyces) in wineries and breweries.

PS Claim 10; Page 37; 53pp; English.

CC AAF26654 to AAF26654 represents probes for detecting, identifying or
CC quantitating the presence of Dekkera/Brettanomyces yeast, particularly
CC Dekkera bruxellensis (Brettanomyces) in a sample of interest. The probes
CC and probe sets from the present invention are useful for the detection of
CC Dekkera/Brettanomyces Yeast in particularly Dekkera bruxellensis
CC (Brettanomyces) in wineries and breweries. The probes and probe sets are
CC also useful for detection of yeast in food, pharmaceutical products,
CC personal care products, dairy products, environmental samples, clinical
CC samples and/or beverages

CC Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1185 GGCTCCGAGAC 1197

Db 3 GGCTCCGAGACC 15

RESULT 720

AAH18764/C

ID AAH18764 standard; DNA; 15 BP.

AC AAH18764;

XX

DT	25-JUN-2001	(first entry)
XX		
DE	Human IL4 allele-specific primer SEQ ID NO: 23.	
XX		
KW	Human; interleukin-4; IL4; single nucleotide polymorphism; SNP; atopy;	
KW	inflammatory disorder; immune disorder; population diversity;	
KW	paternity test; forensic test; cytokine; chromosome 5q31.1; probe;	
KW	PCR primer; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	MO200123404-A1.	
XX		
PD	05-APR-2001.	
XX		
PF	28-SEP-2000; 2000WO-US026608.	
XX		
PR	30-SEP-1999; 99US-0156825P.	
XX		
PA	(GENA-) GENAISSANCE PHARM INC.	
PI	Chew A, Choi JY, Denton RR, Nandabalan K, Stephens JC;	
XX		
DR	WPI, 2001-316132/33.	
XX		
PT	Polynucleotide comprising novel single nucleotide polymorphisms in human	
PT	interleukin-4 gene for use in studying expression, function of	
PT	interleukin-4, in developing drugs, diagnosis and treatment of immune	
XX	disorders.	
XX		
PS	Claim 12; Page 16; 71pp; English.	
XX		
CC	The present invention provides the protein, cDNA and gene of human	
CC	interleukin-4 (IL4). The coding sequences for this protein contain single	
CC	nucleotide polymorphisms (SNPs) which may be associated with differences	
CC	in susceptibility to atopy, inflammatory and immune diseases and	
CC	different drug responses. They may also be used in applications such as	
CC	forensic and paternity testing and studying population diversity and	
CC	anthropological lineage. The IL4 gene is found on human chromosome 5q31.1	
XX		
SO	Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 U; 0 Other;	
	Query Match	4.5%; Score 11.4; DB 1; Length 15;
	Best Local Similarity	92.3%; Pred. No. 3e+02;
	Matches 12; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	1232 GCATGTGCTGGCA 1244	
DB	13 GCATGTGCTGGCA 1	
	RESULT 721	
	AAF69368/c	
ID	AAF69368 standard; DNA; 15 BP.	
XX		
AC	AAF69368;	
XX		
DT	18-APR-2001 (first entry)	
XX		
DB	Human IL4alpha gene probe #8.	
XX		
KW	Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;	
KW	allergic disease; probe; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200104270-A1.	
XX		
PD	18-JAN-2001.	
XX		
PF	13-JUL-2000; 2000WO-US019094.	
XX		
PR	13-JUL-1999; 99US-0143435P.	

XX	(GENA-)	GEMATSSANCE PHARM INC.
PA		
PI	Chew A,	Denton RR, Duda A, Nandabalan K, Stephens JC;
PI	Windemuth AK;	
XX		
XX	WPI; 2001-103078/11.	
XX		
PT	New isolated polynucleotide useful for the identification of therapeutics	
PT	in allergic diseases is new.	
PS	Claim 15; Page 41; 188pp; English.	
XX		
CC	The present invention relates to polymorphisms of the human interleukin 4	
CC	receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference	
CC	sequence). Polynucleotides comprising polymorphic gene variants are	
CC	useful for therapeutic purposes. For example, where a patient may benefit	
CC	from expression of a particular IL4Ralpha protein isoform, an expression	
CC	vector encoding the isoform may be administered to the patient. It may	
CC	desirable to decrease or block expression of a particular IL4Ralpha	
CC	isogene, which may be done by turning off by transforming a targeted	
CC	organ, tissue or cell population with an expression vector that expresses	
CC	high levels of untranslatable mRNA for the isogene. Specific therapeutics	
CC	identified by these methods may be useful for allergic diseases. The	
CC	present sequence is a probe for human IL4R-alpha	
SO		
Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;		
Query Match	4.5%; Score 11.4; DB 1; Length 15;	
Best Local Similarity	92.3%; Pred. No. 3e+02;	
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0.		
Oy	1360 CAGCTGAGCCTTA 1372	
Db	13 CAGCGAGGCTTA 1	
RESULT 722		
AAH49215		
ID	AAH49215 standard; DNA; 15 BP.	
XX		
AC	AAH49215;	
DT		
XX	26-NOV-2001 (first entry)	
DE		
XX	Anti-BFGF oligonucleotide XXX.	
XX		
KM	Polyamide-oligonucleotide derivative; anticancer; antiproliferative;	
KM	antiviral; hepatotropic; vasotropic; antisense inhibition; ribozyme;	
KM	integrin; cell-cell adhesion; cancer; restenosis; stability; PNA;	
XX	peptide nucleic acid; ss.	
OS	Synthetic.	
PN	EP113021-A2.	
PD		
XX	04-JUL-2001.	
PF		
PR	08-MAR-1995; 2001EP-00104012.	
PR	14-MAR-1994; 94DE-04408528.	
XX	08-MAR-1995; 95EP-00103312.	
PA	(AVET) AVENTIS PHARMA DEUT GMBH.	
FI	Uhlmann E, Breipohl G;	
DR		
XX	WPI; 2001-591267/67.	
PT	New DNA-peptide nucleic acid chimerae, useful e.g. as antisense agents	
PT	for treating e.g. cancer, also as diagnostic probes and primers.	
PS	Disclosure; Page 23; 54pp; German.	

XX This invention describes novel polyamide-oligonucleotide derivatives (I)
CC and their physiologically acceptable salts of formula F((DNA)-Li) q(PNA-
CC Li)_x(DNA-Li)_s(PNA-Li)_{x'} where q, r, s, t = 0 or 1, with the sum of
CC two or more adjacent letters at least 2; x = 1-20; DNA = nucleic acid
CC (such as DNA or RNA or their known derivatives); Li = covalent linkage
CC between DNA and PNA, i.e. a bond or a residue containing at least one
CC atom of carbon, nitrogen, oxygen or sulfur; PNA = polyamide structure
CC containing at least one nucleobase different from thymine; and F, F' =
CC end groups and/or are connected through a covalent bond. The products of
CC the invention have anticancer, antiproliferative, antiviral, hepatotropic
CC and vasoactive activity and can be used for the inhibition of gene
CC expression by antisense, ribozyme, sense, or triple-helix methods, or by
CC binding to proteins (aptamers). (I) are used for treating diseases caused
CC by viruses (human immune deficiency, herpes simplex, influenza, vesicular
CC stomatitis, hepatitis B or papilloma), or mediated by integrating or cell-
CC cell adhesion reactions, for treating cancer, or for inhibiting
CC resection, particularly as antisense reagents. They are also useful in
CC heterogeneous or homogeneous assays, as primers or probes, particularly
CC where the target is amplified before being detected by hybridization, for
CC the diagnosis of genetic, malignant or pathogen-related diseases. (I) retain
CC the increased affinity for complementary strands and better stability in
CC serum, associated with conventional peptide nucleic acids (PNA), but lack
CC the disadvantages, i.e. have improved cellular uptake, do not aggregate
CC in aqueous solution, and have reduced affinity for purification
CC materials, reduced cytotoxicity, better sequence specificity. They are
CC more active than either DNA or PNA oligomers. When used as probes, (I)
CC show different responses to base-pair mismatches in the DNA and RNA
CC segments, allowing better discrimination between pathogenic and non-
CC pathogenic conditions such as the transition from proto-oncogene to
CC oncogene, also, when used as primers, with the PNA segment at the 5'-end,
CC they produce amplicons resistant to 5'-exonuclease, allowing this enzyme
CC to be used to eliminate RNA or DNA primers. The DNA component allows
CC additional reactions not possible with PNA alone, e.g. 3'-tailing and (I)
CC may be incorporated into a gene. AHA9208-AHA9264 represent
CC oligonucleotides used to illustrate the method of the invention
XX
SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1;

QY 1295 GGGTGCATGCTC 1307
1 GGCTCCATGCTC 13

RESULT 723
AAF25088
ID AAF25088 standard; DNA; 15 BP.
XX
AC AAF25088;
XX
DT 30-APR-2001 (first entry)
XX
DE PCR primer for M. vaccae immunogenic epitope DNA9.
XX
KW Epitope; antigen; cytokine production; immune disorder; tuberculosis;
KW cancer; mycobacterial infection; TH1 immune response; vaccine;
XX PCR primer; ss.
XX
OS Mycobacterium vaccae.
XX
PN WO200104140-A1.
XX
PD 18-JAN-2001.
XX
PE 10-JUL-2000; 2000WO-NZ000121.
XX
PR 12-JUL-1999; 99US-00351348.
PR 29-NOV-1999; 99US-00450072.
XX

PA (GENE-) GENESIS RES & DEV CORP LTD.
XX
PI Delcayre A;
XX
DR WPI; 2001-168411/17.
XX
PT Novel polypeptides comprising immunogenic epitopes of Mycobacterium
PT vaccae, useful for treating mycobacterial infections, immune disorders
PT and cancers.
XX
PS Example 2; Page 60; 80pp; English.
XX
XX The specification describes an immunogenic epitope of a Mycobacterium
XX vaccae antigen. The epitope is a stimulator of cytokine production. The
XX epitopes are useful for the treatment of immune disorders, infectious
XX diseases, especially tuberculosis, and cancer. They are also useful for
XX treatment of other mycobacterial infections such as those caused by
XX Mycobacterium avium. The epitopes are especially useful for inducing TH1
XX immune responses, and for producing vaccines. PCR primers AAF25088-89
XX were used to amplify DNA encoding a M. vaccae epitope of the invention
XX
SQ Sequence 15 BP; 1 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1;

QY 1359 GCAGCTGAGGCTT 1371
|||||
|||||
2 GCAGCTGAGGCTT 14

RESULT 724
ABL01602
ID ABL01602 standard; DNA; 15 BP.
XX
AC ABL01602;
XX
DT 15-MAR-2002 (first entry)
XX
DE bFGF targeted antisense peptide nucleic acid SEQ ID NO: 8.
XX
KW Peptide nucleic acid; PNA; cytostatic; virucide; dermatological;
KW antiaesthetic; overexpression; viral infection; vitiligo; antisense;
KW pigmentation disorder; asthma; polyamide backbone; ss.
XX
OS Unidentified.
XX
XX
XX Key Location/Qualifiers
XX modified_base 1..15
FT /*tag= a
FT /note= "This sequence is a peptide nucleic acid, i.e. it
FT contains a polyamide backbone instead of a deoxyribose
FT backbone"
FT 1
FT /*tag= b
FT /mod_base= OTHER
FT /note= "linked to one of the peptides shown in ABB04517
FT and ABB04518 to form a PNA-peptide conjugate"
XX
XX WO200179216-A2.
XX
XX 25-OCT-2001.
XX
XX PD 07-APR-2001; 2001WO-EP004030.
XX
XX PR 18-APR-2000; 2000DE-01019135.
XX
XX (AVET) AVENTIS PHARMA DEUT GMBH.
XX Uhlmann E, Breipohl G, Will DW;
XX WPI; 2002-075055/10.
XX

XX New peptide nucleic acid derivatives, useful e.g. for tumor treatment and
PT diagnosis, contain terminal, deprotonizable phosphoryl groups for e.g.
PT improved solubility.
XX
XX Disclosure; Page 19; 93pp; German.
XX
XX The present invention relates to peptide nucleic acid (PNA) derivatives
CC having at the C-, and optionally N-, terminus one or more phosphoryl
CC groups, at least one of which contains one or more deprotonizable groups,
CC preferably hydroxy or mercapto. These PNAs are useful in the treatment of
CC tumours or any disease associated with (over)expression of particular
CC genes, including viral infections, vitiligo or other pigmentary
CC disorders, and asthma. The present sequence is a peptide nucleic acid
CC described in the exemplification of the invention
XX
SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1295 GGGTGCATGGTC 1307
DB 1 GGTGCGCATGGTC 13
RESULT 725
ABK97488/C
ID ABK97488 standard; DNA; 15 BP.
XX
XX ABK97488;
AC
XX 07-OCT-2002 (first entry)
DT
XX
XX Human LCAT gene polymorphism detection ASO probe #11.
DE
XX
XX Lecithin:cholesterol acyltransferase; LCAT; Norum disease; gene therapy;
KM fish-eye disease; atherosclerotic cardiovascular disease; forensic;
KM population diversity; anthropological lineage; paternity testing; human;
KM polymorphism; allele-specific oligonucleotide; ASO; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200253575-A1.
PN
XX
XX 11-JUL-2002.
PD
XX
XX 03-JAN-2001; 2001WO-US000092.
PF
XX
XX 03-JAN-2001; 2001WO-US000092.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Chew A, Denton RR, Nandabalan K, Stephens JC,
PI
XX
XX WPI; 2002-557737/59.
DR
XX
XX Novel isolated polymorphic variant polynucleotide of lecithin-cholesterol
PT acyltransferase gene, useful for studying expression and biological
PT function of the gene, and for therapeutic, diagnostic or forensic
PT purposes.
XX
XX Claim 16; Page 17; 72pp; English.
PS
XX
XX The present invention relates to a new polynucleotide comprising a
CC nucleotide sequence which is a polymorphic variant of a reference
CC sequence for lecithin-cholesterol acyltransferase (LCAT). The invention
CC is useful for identifying an association between a trait (preferably a
CC clinical response to drug targeting LCAT) and at least one genotype or
CC haplotype of LCAT gene. The method of the invention has applicability in
CC developing diagnostic tests and therapeutic treatments for Norum disease,
CC fish-eye disease and atherosclerotic cardiovascular disease. The

CC haplotyping and genotyping methods are useful for studying population
CC diversity, anthropological lineage, the significance of diversity and
CC lineage at the phenotypological level, paternity testing, forensic applications
CC and for identifying association between the LCAT genetic variation and a
CC trait such as level of drug response or susceptibility to disease. In
CC addition, the methods for identifying the LCAT haplotypes present in
CC individuals are useful in the development of drugs targeting LCAT. For
CC example, determining the frequency of individual LCAT haplotypes in a
CC population with a specific disease, e.g. Norum disease, will facilitate
CC the development of drugs targeting the LCAT isoform(s) that are most
CC frequent in that disease population. The present nucleic acid sequence
CC represents one of a collection (ABK97478-ABK97491) of allele-specific
CC oligonucleotide (ASO) probes that were used in the invention to detect
CC polymorphisms in the human LCAT gene
XX
SQ Sequence 15 BP; 1 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1282 GCAGAGACCTCA 1294
DB 13 GCAGAGACACTCA 1
RESULT 726
AAL38345/C
ID AAL38345 standard; DNA; 15 BP.
XX
XX AAL38345;
AC
XX
XX 15-AUG-2002 (first entry)
DT
XX
XX ASO probe for detecting SCYA7 gene polymorphism SEQ ID 7.
DE
XX
XX Small inducible cytokine A7; SCYA7; polymorphic variant; haplotyping;
KM inflammatory disorder; cancer; haplotype; single nucleotide polymorphism;
KM genotype; human; ASO; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200226771-A2.
PN
XX
XX 04-APR-2002.
PD
XX
XX 01-OCT-2001; 2001WO-US030880.
PF
XX
XX 29-SEP-2000; 2000US-0236989P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Chew A, Choi JY, Koshy B,
PI
XX
XX WPI; 2002-426009/45.
DR
XX
XX Novel small inducible cytokine A7 gene useful for therapeutic purposes,
PT for studying the expression and function of the polynucleotide, and for
PT expressing the cytokine protein.
XX
XX Claim 14; Page 12; 54pp; English.
PS
XX
XX The invention relates to an isolated small inducible cytokine A7 (SCYA7)
CC polynucleotide comprising a nucleotide sequence which is a polymorphic
CC variant of a reference sequence for the SCYA7 CDNA or its fragment. The
CC polymorphic variant SCYA7 gene is useful in screening for drugs
CC targeting, which comprises contacting the SCYA7 gene with a candidate
CC agent and assaying for binding activity. The SCYA7 gene and a recombinant
CC nonhuman organism are useful in studying the expression and function of
CC SCYA7, and in expressing SCYA7 protein for use in screening for candidate
CC drugs to treat diseases related to SCYA7 activity such as inflammatory
CC disorders, and cancer. Haplotyping the SCYA7 gene of an individual and
CC identifying the association between a trait and at least one haplotype/

CC haplotype pair are useful in developing diagnostic tests and therapeutic treatments for diseases associated with SCYA7 activity. Haplotyping the CC SCYA7 gene of an individual is also useful in the design of clinical trials of candidate drugs for treating specific conditions or diseases associated with SCYA7 activity. Genotyping the SCYA7 gene of an individual is useful in determining whether an individual has one of the haplotypes or one of the haplotype pairs. An isolated oligonucleotide probe of SCYA7 and the kit for haplotyping/genotyping the SCYA7 gene are useful in genotyping and/or haplotyping the SCYA7 gene in an individual. This polynucleotide sequence represents an ASO probe used for detecting polymorphisms in the SCYA7 gene of the invention

CC Sequence 15 BP; 1 A; 9 C; 0 G; 4 T; 0 U; 1 Other;

XX

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1268 GGAAGAGGCTGAGGG 1282
|||
15 GGAAGAGRTGAGGG 1

Db

RESULT 727
ABL60175
ID ABL60175 standard; DNA; 15 BP.
XX
AC ABL60175;
XX
DT 22-JUN-2002 (first entry)
XX
DE Human MUC1 PCR primer SEQ ID NO 19.
XX
DE Human, mucin 1; MUC1; transmembrane protein; SNP; cancer; cytostatic; single nucleotide polymorphism; haplotyping; genotyping; drug; antiinflammatory; PCR; primer; ss.
KW
XX
OS Homo sapiens.
XX
PN WO200226765-A2.
XX
PD 04-APR-2002.
XX
PF 25-SEP-2001; 2001WO-US030151.
XX
PR 28-SEP-2000; 2000US-0236113P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Koshy B;
XX
DR WPI; 2002-405042/43.
XX
PT New genetic variants of mucin 1, Transmembrane gene, useful in studying expression and function of protein encoded by the gene and for screening drugs to treat diseases e.g. cancer.
XX
PS Claim 14; Page 13; 75pp; English.

CC The invention relates to a polynucleotide (ABL60158, ABL60159) encoding mucin 1/MUC1 (AB077476), Transmembrane isogene. The invention describes novel genetic variants of the MUC1 gene. The invention is useful for haplotyping/genotyping the MUC1 gene in an individual and identifying an association between a trait and at least one of the haplotypes or haplotype pairs of MUC1 gene. MUC1 is useful for studying the expression and function of MUC1 and expressing MUC1 protein for use in screening for candidate drugs to treat diseases related to MUC1 activity and in studying the effect of the variation on the biological activity of MUC1 as well as on the binding affinity of candidate drugs targeting MUC1 for the treatment of e.g. cancer. MUC1 is further used by the pharmaceutical research scientist to validate MUC1 as a candidate target for and in design of clinical trials of candidate drugs for, treating a specific condition drugs or disease predicted to be associated with MUC1 activity.

CC MUC1 antibodies are useful in a variety of diagnostic and prognostic CC formats and therapeutic methods. The present sequence is that of a PCR CC primer for detecting MUC1 polymorphisms, useful to the invention

XX

XX Sequence 15 BP; 1 A; 4 C; 6 G; 3 T; 0 U; 1 Other;

XX

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1198 CTGTGCAGAGGCAG 1212
|||
1 CTGTGCTAGGCGG 15

Db

RESULT 728
ABA97515
ID ABA97515 standard; DNA; 15 BP.
XX
AC ABA97515;
XX
DT 16-APR-2002 (first entry)
XX
DE BFGF targeted antisense peptide nucleic acid SEQ ID NO: 63.
XX
DE Peptide nucleic acid; PNA; polyamide backbone; phosphoryl radical; cytostatic; virucide; dermatological; antiasthmatic; cancer; antisense; viral infection; vitiligo; pigmentation disorder; asthma; ss.
KW
XX
OS Unidentified.
XX
OS Synthetic.
XX
PN WO200179249-A2.
XX
PD 25-OCT-2001.
XX
PF 07-APR-2001; 2001WO-EP004027.
XX
PR 18-APR-2000; 2000DE-01019136.
XX
PA (AVET) AVENTIS PHARMA DEUT GMBH.
XX
PI Uhmann E, Breipohl G, Will DW;
XX
DR WPI; 2002-089643/12.
XX
PT New peptide nucleic acid derivatives, useful e.g. for treating tumors and diagnosis, have N-terminal phosphoryl residue for improving e.g. solubility in water.
XX
PS Disclosure; Page 96; 96pp; German.

CC The present invention relates to peptide nucleic acid (PNA) derivatives. CC These can be used in the treatment of cancer, viral infections, vitiligo CC or other pigmentation disorders, and asthma. The present sequence is an CC oligonucleotide fragment of a PNA described in the exemplification of the CC invention

XX

XX Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

XX

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCCTATGCTC 1307
|||
1 GGGTGCCTATGCTC 13

Db

RESULT 729
AAD32452/C
ID AAD32452 standard; DNA; 15 BP.
XX

AC AAD32452;
XX
DT 18-JUN-2002 (first entry)
XX
DE Human ORIG1 gene polymorphism detecting ASO probe #9.
XX
KW Human; olfactory receptor family 1 subfamily G member 1; ORIG1; therapy;
XX polymorphism; drug screening; olfactory sensory deficit; gene therapy;
KW chromosome 17p13.3; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200212561-A2.
XX
PD 14-FEB-2002.
XX
PF 03-AUG-2001; 2001WO-US024478.
XX
PR 03-AUG-2000; 2000US-0222755P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Kazemi A, Messer C, Tanguay DA;
XX
DR WPI; 2002-269097/31.
XX
PT Novel isolated human olfactory receptor, family 1, subfamily G, member 1
FT polynucleotide, for therapeutic purposes, for studying expression and
XX function of the polynucleotide and for expressing receptor protein.
XX
PS Claim 16; Page 13; 96pp; English.
XX
CC The present invention relates to an isolated human olfactory receptor,
CC family 1, subfamily G, member 1, (ORIG1) polynucleotide comprising a
CC sequence which is a polymorphic variant for a reference sequence for the
CC ORIG1 gene or its fragment, or a polymorphic variant of a reference
CC sequence for a ORIG1 cDNA or its fragment. ORIG1 is useful in studying
CC the expression and function of ORIG1 and in expressing ORIG1 protein for
CC use in screening for candidate drugs to treat diseases related to ORIG1
CC activity. ORIG1 is useful for therapeutic purposes. The invention is
CC useful for studying expression of the ORIG1 isogenes in vivo, for in vivo
CC screening and testing of drugs targeted against ORIG1 protein, and for
CC testing the efficacy of therapeutic agents and compounds for olfactory
CC sensory deficits, in a biological system. The invention is useful in gene
CC therapy and is located on the . The present sequence is human ORIG1 gene
CC polymorphism detecting ASO (allele specific oligonucleotide) probe
XX
SQ Sequence 15 BP; 4 A; 4 C; 3 G; 3 T; 0 U; 1 Other;
XX
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1393 CTGAGCTGCTGACA 1407
DB 15 CTGAGATCTCTGCTCA 1
XX
RESULT 730
ABL52248
ID ABL52248 standard; DNA; 15 BP.
XX
AC ABL52248;
XX
DT 15-JUN-2002 (first entry)
XX
DE Human PHK2 allele specific oligonucleotide primer SEQ ID NO:35.
XX
KW Human; phosphorilase kinase gamma 2 (testis); PHK2; enzyme; SNF;
KW phosphorilase kinase gamma 2; single nucleotide polymorphism;
KW polymorphic; hepatocytic; gene therapy; glycogen storage disease;
KW liver cirrhosis; allele specific oligonucleotide; ASO; primer; ss.
XX

OS Homo sapiens.
XX
FH Key: Location/Qualifiers
FT misc_feature 14
FT /tag= a
FT /note= "polymorphic site indicated by an ambiguity base"
XX
PN WO200194365-A2.
XX
PD 13-DEC-2001.
XX
PF 11-JUN-2001; 2001WO-US018814.
XX
PR 09-JUN-2000; 2000US-0210568P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Choi YJ, Koshiy B, Sanchis A, Sausker EA;
XX
DR WPI; 2002-404359/43.
XX
PT New variants of phosphorilase kinase gamma 2 isogenes, useful for
FT improving efficiency and reliability in the development of drugs for
XX treating diseases e.g. liver cirrhosis.
XX
PS Claim 16; Page 13; 76pp; English.
XX
CC The present invention describes an isolated polynucleotide (I) comprising
CC a nucleotide sequence which is a polymorphic variant of a reference
CC sequence for human phosphorilase kinase gamma2 (testis) (PHK2) gene or
CC its fragment, or a polymorphic variant of a reference sequence for a
CC PHK2 cDNA or its fragment. Also described is an isolated polypeptide
CC (II) comprising an amino acid sequence which is a polymorphic variant of
CC a reference sequence for PHK2 protein or its fragment, where the
CC reference sequence comprises a sequence (see ABB09290) of 406 amino
CC acids, and the polymorphic variant comprises one or more variant amino
CC acids, selected from glutamic acid at a position corresponding to amino
CC acid position 153 and tryptophan at position corresponding to amino acid
CC position 329. (I) has hepatocytic activity and can be used in gene
CC therapy. (II) is useful in screening for drugs targeting (II), by
CC contacting a PHK2 polymorphic variant with a candidate agent and
CC assaying for binding activity. The identified candidate agents targeting
CC PHK2, are useful for treating liver cirrhosis and glycogen storage
CC diseases. The present sequence represents an allele specific
CC oligonucleotide (ASO) primer for the PHK2 gene, which is used in the
CC exemplification of the present invention
XX
SQ Sequence 15 BP; 3 A; 6 C; 4 G; 1 T; 0 U; 1 Other;
XX
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1280 GGGGAGAGACCCCTCA 1294
DB 1 GGGCCAGACCCCTSA 15
XX
RESULT 731
ABN80600/C
ID ABN80600 standard; DNA; 15 BP.
XX
AC ABN80600;
XX
DT 19-JUN-2002 (first entry)
XX
DE Human P450(cytochrome) oxidoreductase allele specific PCR primer #40.
XX
KW Human; P450(cytochrome) oxidoreductase; POR; cancer; haplotype; SNF;
KW single nucleotide polymorphism; flavoprotein; enzyme; PCR; primer; ss.
XX
OS Homo sapiens.
XX

PN WO200226768-A2.
XX
PD 04-APR-2002.
XX
XX 01-OCT-2001; 2001WO-US030877.
PP
PR 29-SEP-2000; 2000US-0236449P.
XX
PA (GENA-) GENA1SSANCE PHARM INC.
XX
PI Kazemi A, Kijem SE, Lanz EM, Messer C, Tanguay DA;
XX WPI; 2002-394236/42.
DR
PT New genetic variants comprising haplotypes of the P450 (cytochrome)
PT oxidoreductase (POR) isogene, useful in improving the efficiency of drug
PT screening protocols for compounds targeting POR.
XX
PS Claim 14; Page 15; 141pp; English.
XX
CC The present invention provides the protein, gene and cDNA sequences of
CC human P450(cytochrome) oxidoreductase POR, and single nucleotide
CC polymorphisms (SNPs) identified therein. The sequences can be used to
CC haplotype the POR gene of an individual, and to establish whether POR is
CC a suitable target for drugs to treat cancer and disorders associated with
CC impaired protein synthesis in cells. The present sequence is an allele
CC specific primer for the coding sequences of the invention
XX
SQ Sequence 15 BP; 1 A; 3 C; 6 G; 4 T; 0 U; 1 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1250 CCGGCTGCAGCACA 1264
Db 15 CYGGCCGCATCACACA 1
RESULT 732
ABK12186/c
ID ABK12188 standard; DNA; 15 BP.
XX
AC ABK12188;
XX
DT 18-JUN-2002 (first entry)
XX
DE Human Tachykinin Receptor 1 allele specific oligonucleotide primer #9.
XX
KW Human; ss; primer; TACR1; Tachykinin receptor 1; chromosome 2; PCR; SNP;
KW single nucleotide polymorphism; gene therapy; haplotype; genotype; pain;
KW depression; vomiting; acute inflammatory diarrhoea; ASO;
KW opiate addiction; drug screening; allele specific oligonucleotide.
XX
OS Homo sapiens.
XX
PN WO200216399-A2.
XX
PD 28-FEB-2002.
XX
PP 27-AUG-2001; 2001WO-US026663.
XX
PR 25-AUG-2000; 2000US-0227815P.
XX
PA (GENA-) GENA1SSANCE PHARM INC.
XX
PI Anastasio AE, Kazemi A;
XX WPI; 2002-280907/32.
DR
XX
PT Novel isolated polynucleotide which is a polymorphic variant of
PT tachykinin receptor 1 (TACR1) gene useful for expressing TACR1 protein
PT isoform used in screening drug candidates to treat pain, depression,

PT vomiting.
XX
XX Claim 17; Page 14; 89pp; English.
XX
CC The invention relates to an isolated polynucleotide sequence which
CC comprises a tachykinin receptor 1 (TACR1) isogene (SQ) that is any one of
CC 16 SG as given in specification, where each SG comprises specific regions
CC of the TACR1 genomic DNA appearing as ABK12169, and is defined by
CC polymorphisms at positions (P) 3164, 3319, 3906, 4339, 4444, 92915,
CC 94601, 94821, 94892, 94960. Also included are fragments of the TACR1,
CC isogenes and TACR1 cDNA, a transgenic non-human animal transformed with
CC the TACR1 isogene or coding region, haplotyping (or genotyping) the TACR1
CC of an individual by determining either the haplotype of one or both
CC copies of the TACR1 gene, predicting the haplotype pair for the TACR1
CC gene of an individual, identifying an association between a trait and a
CC haplotype pair, an isolated oligonucleotide for detecting the
CC polymorphisms, a computer system for storing and analysing polymorphism
CC data and a genome anthology for TACR1 gene. The TACR1 isogene is useful
CC for studying expression and function of TACR1 and expressing TACR1
CC protein for use in screening for candidate drugs to treat diseases
CC related to TACR1 activity. The polymorphism and haplotype data is useful
CC for validating whether TACR1 is a suitable target for drugs to treat
CC pain, depression, vomiting, acute inflammatory diarrhoea and opiate
CC addiction, screening for such drugs and reducing bias in clinical trials
CC of such drugs. The genotyping method is useful for determining whether an
CC individual has one of the haplotype pairs. The haplotyping method is
CC useful for improving efficiency and outcome of several steps in discovery
CC and development of drugs for treating the diseases. The haplotyping
CC method is also useful for validating TACR1 as a candidate target for
CC treating a specific condition or disease predicted to be associated with
CC TACR1 activity. The method is also useful for screening compounds to
CC treat a specific condition or disease predicted to be associated with
CC TACR1 activity. The methods are useful for identifying an association
CC between susceptibility to a disease, staging of a disease, or response to
CC a drug. The gene for TACR1 is located on human chromosome 2. The present
CC sequence is an allele specific oligonucleotide (ASO) PCR primer used to
CC detect polymorphisms in the TACR1 gene
XX
SQ Sequence 15 BP; 5 A; 3 C; 4 G; 2 T; 0 U; 1 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1301 CATGTCATCTGTGA 1315
Db 15 CRTGTCCTCATCA 1
RESULT 733
ABL45861
ID ABL45861 standard; DNA; 15 BP.
XX
AC ABL45861;
XX
DT 26-APR-2002 (first entry)
XX
DE Human EDG6 gene allele specific primer SEQ ID NO: 55.
XX
KW Human; endothelial differentiation, G-protein coupled receptor 6; EDG6;
KW haplotype; cancer; angiogenesis; inflammation; chromosome 19p13.3;
KW cycostatic; antiinflammatory; gene therapy; SNP;
KW single nucleotide polymorphism; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200206446-A2.
XX
PD 24-JAN-2002.
XX
PP 17-JUN-2001; 2001WO-US02523.
XX
PR 17-JUN-2000; 2000US-0218727P.

XX (GENA-) GENAISSANCE PHARM INC.
 XX Kliehm SE, Koehn B;
 XX WPI; 2002-171804/22.
 XX
 PT New genetic variants of endothelial differentiation, G-protein coupled
 PT receptor-6 gene for studying expression, function of the gene and
 PT expressing EDC6 protein for use in screening drugs to treat cancer,
 PT inflammation.
 PS Claim 16; Page 14; 11pp; English.
 XX
 CC The present invention provides the gene, protein and cDNA sequences of
 CC the human endothelial differentiation, G-protein coupled receptor 6
 CC (EDG6). Also identified are single nucleotide polymorphisms (SNPs) found
 CC within the sequences. The sequences can be used in the identification of
 CC the haplotype of an individual, and in the treatment of cancer,
 CC angiogenesis and inflammation. The present sequence is an allele specific
 CC primer for the EDC6 gene, which is found on chromosome 19p13.3
 XX
 SQ Sequence 15 BP; 3 A; 6 C; 2 G; 3 T; 0 U; 1 Other;
 Query Match 4.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 Oy 1221 CAGAACCTCCAGCAT 1235
 Db 1 CAGCATCTCCAGCAT 15
 RESULT 734
 ABL91823
 ID ABL91823 standard; DNA; 15 BP.
 XX
 AC ABL91823;
 XX
 DT 11-JUL-2002 (first entry)
 XX
 DE Human LIPG gene allele specific oligonucleotide primer 2.
 XX
 KW Human; ss; allele specific oligonucleotide; primer;
 KW single nucleotide polymorphism; SNP; lipase endothelial isogene; LIPG;
 KW drug screening; atherosclerosis; cardiovascular disorder;
 KW LIPG haplotyping; LIPG genotyping.
 XX
 OS Homo sapiens.
 OS
 PN WO200216397-A2.
 XX
 PD 28-FEB-2002.
 XX
 PF 17-AUG-2001; 2001WO-US026639.
 XX
 PR 25-AUG-2000; 2000US-0227825P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Duda A, Kazemi A, Kliehm SE, Messer C;
 XX
 DR WPI; 2002-292055/33.
 XX
 PT Novel genetic variants of lipase, Endothelial isogene, useful for
 PT improving efficiency and reliability in drug development for treating
 PT diseases associated with LIPG activity, e.g. atherosclerosis.
 XX
 PS Claim 16; Page 13; 134pp; English.
 XX
 CC The invention comprises the DNA and amino acid sequence of the human
 CC lipase, endothelial (LIPG) isogene. Specifically, the invention relates
 CC to the discovery of 20 novel polymorphic sites within the LIPG gene. The

CC LIPG coding sequence and protein are useful for screening drugs that can
 CC be used to treat atherosclerosis and other cardiovascular disorders. The
 CC LIPG coding sequence can also be used to haplotype and genotype the LIPG
 CC gene of an individual. The DNA sequences ABL91822 - ABL91861 represent
 CC LIPG gene allele specific oligonucleotide primers
 XX
 SQ Sequence 15 BP; 2 A; 7 C; 2 G; 3 T; 0 U; 1 Other;
 Query Match 4.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1330 TCTTCTCCAGGC 1342
 Db 1 TCTTCTCCAGGC 13
 RESULT 735
 AAL46751
 ID AAL46751 standard; DNA; 15 BP.
 XX
 AC AAL46751;
 XX
 DT 08-AUG-2002 (first entry)
 XX
 DE BFGF antisense oligonucleotide #1.
 XX
 KW Modified antisense oligonucleotide; antisense; HIV; cancer; infection;
 KW cytosstatic; virucide; anti-HIV; hepatotropic; antiinflammatory;
 KW phosphorothioate backbone; integrin; cell-cell adhesion receptor; ss.
 XX
 OS Unidentified.
 OS
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..3
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 1
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "optionally modified by farnesyl, phytlyl,
 FT hexadecyl, cholesterol or hexamethylentetraamine"
 FT modified_base 6
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 8
 FT /*tag= d
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 12..14
 FT /*tag= e
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 15
 FT /*tag= f
 FT /mod_base= OTHER
 FT /note= "optionally modified by hexadecyl, cholesterol or
 FT Vitamin B"
 FT
 PN EP1182206-A2.
 XX
 XX 27-FEB-2002.
 XX
 PD 07-NOV-1994; 2001EP-00124078.
 XX
 PF 12-NOV-1993; 93DE-04338704.
 XX
 PR 07-NOV-1994; 94EP-00117513.
 XX
 PA (FARH) HOECHST AG.
 XX
 PI Peymann A, Uhlmann E, Mag M, Kretechnar G, Heilsberg M, Winkler I;

XX WPI; 2002-353922/39.
XX
XX New nucleoside-resistant oligonucleotides having modified non-terminal
PT pyrimidine nucleoside(s), useful e.g. for treating cancer or viral
PT diseases or as diagnostic reagents.
XX
XX Example 3; Page 16; 19pp; German.
XX
XX The present invention relates to oligonucleotides having at least one non-
CC -terminal pyrimidine nucleoside modified and additionally having the 5'-
CC and/or 3'-terminal modified. These can be used in the treatment of viral
CC infections, such as HIV, HSV-1, HSV-2, influenza virus, VSV, hepatitis B
CC and papilloma viruses, cancer and diseases involving integrins and cell-
CC cell adhesion receptors. The present sequence is an antisense
CC oligonucleotide of the invention
XX
SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1295 GGGTGCATGCTC 1307
DB 1 GGCTGCATGCTC 13
RESULT 736
AAK98549/C
ID AAK98549 standard; DNA; 15 BP.
XX
XX AAK98549;
AC
XX
XX 16-APR-2002 (first entry)
DT
XX
XX Human enolase 3 gene allele specific primer SEQ ID NO: 20.
DE
XX
XX Human; enolase 3(beta, muscle); ENO3; single nucleotide polymorphism;
KW SNP; haplotype analysis; isogene; primer; ss.
XX
OS Homo sapiens.
OS
XX
XX WO200202579-A2.
PN
XX
XX 10-JAN-2002.
PD
XX
XX 02-JUL-2001; 2001WO-US020952.
PF
XX
XX 30-JUN-2000; 2000US-0215236P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Duda A, Finkel K, Koshy B, Parks KE;
PI
XX
XX WPI; 2002-154721/20.
DR
XX
XX Novel genetic variants of enolase 3, (beta, muscle) gene useful in
PT studying expression and function of the protein, and for screening drugs
PT to treat disorders of glycolytic pathway.
PT
XX
XX Claim 16; Page 13; 90pp; English.
XX
XX The present invention provides the protein, cDNA and genomic sequences of
CC a human enolase 3 (beta, muscle) isogene containing a number of single
CC nucleotide polymorphisms (SNPs). The sequences can be used to identify
CC the haplotype of an individual and identify whether particular haplotypes
CC are linked to certain diseases. The present sequence is a primer for the
CC ENO3 gene described in the exemplification of the invention
XX
XX Sequence 15 BP; 1 A; 8 C; 2 G; 3 T; 0 U; 1 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1198 CTGTGAGAGGCGAG 1212
DB 15 CTGTGAGAGGCGAG 1
RESULT 737
ABK72626/C
ID ABK72626 standard; DNA; 15 BP.
XX
XX ABK72626;
AC
XX
XX 30-JUN-2002 (first entry)
DT
XX
XX Leukotriene B4 receptor allele specific oligonucleotide primer #16.
DE
XX
XX Human; leukotriene B4; receptor; chemokine receptor-like 1; LTB4R;
KW Chemoattractant; inflammation; immune response; infection;
KW inflammatory disorder; recombinant non-human animal;
KW allele specific oligonucleotide; PCR; primer; ss.
XX
XX
OS Homo sapiens.
OS
XX
XX WO200230949-A2.
PN
XX
XX 18-APR-2002.
PD
XX
XX 12-OCT-2001; 2001WO-US032002.
PF
XX
XX 13-OCT-2000; 2000US-0240223P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Bieganski KM, Chew A, Koshy B, Sanchis A, Sausker EA;
PI
XX
XX WPI; 2002-416857/44.
DR
XX
XX Novel isolated human leukotriene B4 receptor polynucleotide, useful for
PT therapeutic purposes, for studying expression and function of the
PT polynucleotide, and for expressing the receptor.
PT
XX
XX Claim 15; Page 13; 69pp; English.
XX
XX The invention describes an isolated human leukotriene B4 receptor
CC (chemokine receptor-like 1) (LTB4R) polynucleotide (1) comprising a
CC sequence which is a polymorphic variant for a reference sequence for the
CC LTB4R gene or its fragment, or a polymorphic variant of a reference
CC sequence for a LTB4R cDNA or its fragment. LTB4R is a potent
CC chemoattractant that is primarily involved in inflammation, immune
CC responses and host defense against infection. (1) is useful in studying
CC the expression and function of LTB4R, and in expressing LTB4R protein for
CC use in screening for candidate drugs to treat diseases related to LTB4R
CC activity, e.g. inflammatory disorders. A recombinant non-human animal is
CC useful for studying expression of the LTB4R isogenes in vivo, for in vivo
CC screening and testing of drugs targeted against LTB4R protein, and for
CC testing the efficacy of therapeutic agents and compounds for diseases
CC associated with LTB4R activity, e.g. inflammatory disorders, in a
CC biological system. This sequence represents an allele specific
CC oligonucleotide primer used for detecting polymorphisms in the
CC leukotriene B4 receptor (LTB4R) gene
XX
SQ Sequence 15 BP; 1 A; 8 C; 2 G; 3 T; 0 U; 1 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1268 GGAAGAGGCTGAG 1280
DB 13 GGAAGAGGCTGAG 1

RESULT 738

ABX01348/C

ID ABX01348 standard; RNA; 15 BP.

AC ABX01348;

DT 23-DEC-2002 (first entry)

XX Hepatitis C virus substrate #1130 for HCV hammerhead ribozyme #1130.

XX Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;

XX HCV ribozyme; HCV expression; HCV replication; cirrhosis; virocidic;

XX liver failure; hepatocellular carcinoma; HCV infection; drug therapy;

XX type I interferon; interferon alpha; interferon beta; cytosolitic;

XX interferon gamma; consensus interferon; hepatotropic; antiinflammatory;

XX substrate; hammerhead ribozyme; HH ribozyme; ss.

XX Hepatitis C virus.

XX US2002082225-A1.

XX 27-JUN-2002.

XX 23-MAR-1999; 99US-00274553.

XX 23-MAR-1999; 99US-00274553.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGEN J A.

XX (ROBE/) ROBERTS B.

XX (PAVC/) PAVCO P A.

XX (MACE/) MACEJACK D.

XX Blact L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;

XX MPI; 2002-617759/66.

XX New ribozymes targeting RNA derived from hepatitis C virus inhibit viral

XX replication and are useful to treat hepatitis C virus infections and

XX cirrhosis, liver failure or hepatocellular carcinoma.

XX Claim 1; Page 53; 80pp; English.

XX The present invention relates to enzymatic nucleic acids which

XX specifically cleave RNA derived from Hepatitis C virus (HCV). The

XX enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin

XX (HP) motif where the binding arms comprise sequences complementary to one

XX of the substrate sequences defined in the specification. The HCV

XX ribozymes are useful for modulating the expression and/or replication of

XX HCV. They can be used to treat cirrhosis, liver failure and/or

XX hepatocellular carcinoma. The HCV ribozymes are also useful for treating

XX a condition associated with HCV infection in conjunction with one or more

XX other drug therapies, particularly type I interferon, especially

XX interferon alpha, beta or gamma or consensus interferon. The present

XX sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:

XX Some of the sequence data for this patent did not form part of the

XX printed specification. The complete sequence data for this patent was

XX obtained in electronic format directly from the USPTO web site at

XX seqdata.uspto.gov/psipdsidentry.html

XX Sequence 15 BP; 0 A; 4 C; 4 G; 0 T; 7 U; 0 Other;

XX Query Match 4.5%; Score 11.4; DB 1; Length 15;

XX Best Local Similarity 92.3%; Pred. No. 3e+02;

XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX QY 1337 CAAGCAGAGAGC 1349

XX DB 15 CAAGCAGAGAGC 3

XX RESULT 739

ACN15299

ID ACN15299 standard; RNA; 15 BP.

AC ACN15299;

DT 22-APR-2004 (first entry)

XX MNV minus enzymatic nucleic acid substrate SEQ ID NO 15302.

XX MNV, West Nile Virus; antiinflammatory; cytosolitic; hepatotropic;

XX virocidic; neuroprotective; antibacterial; replication; pancreatitis;

XX encephalitis; myocarditis; meningitis; infection; hepatitis;

XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

XX Ambezyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-024241P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGEN J A.

XX Blact L, Mcswiggen JA;

XX MPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (MNV), useful for treating a condition related to MNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 15302; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication

XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for

XX treating a condition related to MNV infection e.g. pancreatitis,

XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

XX molecule is selected from the group of ribozymes consisting of

XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Ambezyme and Zinzyme. The

XX nucleic acid molecules further comprise at least five ribose residues, at

XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at

XX least three of the 5' terminal nucleotides and a 3' end modification of a

XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

XX in the specification. The present sequence is that of a nucleic acid

XX molecule of the invention

XX Sequence 15 BP; 2 A; 3 C; 5 G; 0 T; 5 U; 0 Other;

XX Query Match 4.5%; Score 11.4; DB 1; Length 15;

XX Best Local Similarity 76.9%; Pred. No. 3e+02;

XX Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

XX QY 1397 GGTGCTGAGAGA 1409

XX DB 2 GTGCTGAGAGAGA 14

XX RESULT 740

XX ACDB2528 standard; DNA; 15 BP.

XX ACDB2528;

XX DT 19-SEP-2003 (first entry)

XX XX

DE Nucleic acid cloning associated adaptor molecule #229.
XX
XX Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KW internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
DR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 5; 100pp; English.
XX
CC The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
SQ Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1247 GGTCCGCTGCAG 1259
DB 1 GATCCGCTGCAG 13
XX
RESULT 741
ACD82516
ID ACD82516 standard; DNA; 15 BP.
XX
AC ACD82516;
XX
DT 19-SEP-2003 (first entry)
XX
DE Nucleic acid cloning associated adaptor molecule #217.
XX
KW Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KW internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX

PR 13-JUN-2001; 2001US-00880313.
XX
XX (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
DR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 5; 100pp; English.
XX
CC The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
SQ Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1247 GGTCCGCTGCAG 1259
DB 1 GATCCGCTGCAG 13
XX
RESULT 742
ACD82570
ID ACD82570 standard; DNA; 15 BP.
XX
AC ACD82570;
XX
DT 19-SEP-2003 (first entry)
XX
DE Nucleic acid cloning associated adaptor molecule #271.
XX
KW Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KW internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
DR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 5; 100pp; English.
XX

XX The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule

XX
SQ Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1247 GGTCCGGCTGCAG 1259
DB 1 GATCCGGCTGCAG 13
|||||

RESULT 743
ACD82510
ID ACD82510 standard; DNA, 15 BP.
XX
AC ACD82510;
XX
DT 19-SEP-2003 (first entry)
DE Nucleic acid cloning associated adaptor molecule #211.
XX
XX Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KW internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
DR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 5; 100pp; English.
XX
CC The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated

CC adaptor molecule

XX
SQ Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1247 GGTCCGGCTGCAG 1259
DB 1 GATCCGGCTGCAG 13
|||||

RESULT 744
ACD82522
ID ACD82522 standard; DNA, 15 BP.
XX
AC ACD82522;
XX
DT 19-SEP-2003 (first entry)
DE Nucleic acid cloning associated adaptor molecule #223.
XX
XX Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KW internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
DR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 5; 100pp; English.
XX
CC The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule

XX
SQ Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1247 GGTCCGGCTGCAG 1259
DB 1 GATCCGGCTGCAG 13
|||||

RESULT 745

ID	AD66131/C	ADC66131 standard; DNA; 15 BP.
XX	AC	ADC66131;
XX	D7	18-DEC-2003 (first entry)
XX	DE	Human CFTR exon 19B PCR primer #2.
XX	KW	cyping; variable site; cystic fibrosis; human;
XX	KM	cystic fibrosis transmembrane conductance regulator; CFTR; PCR primer; ss.
OS	Synthetic.	
OS	Homo sapiens.	
PN	M02003074737-A1.	
PD	12-SEP-2003.	
PX	07-MAR-2003; 2003WO-SER000394.	
PF	07-MAR-2002; 2002SE-00000695.	
PR	(PYRO-) PYROSEQUENCING AB.	
PA	Schiller A, Dunker J;	
PI	WPJ, 2003-731684/69.	
DR		
PT	Typing at least two variable sites of at least one nucleic acid molecule related to cystic fibrosis by simultaneously or sequentially performing primer extension reactions and determining the pattern of nucleotide incorporation.	
PS	Example 2; Page 28; 69pp; English.	
XX	The present invention describes a method for typing at least two variable sites of at least one nucleic acid molecule related to cystic fibrosis. The method comprises:	
CC	(a) providing at least one nucleic acid molecule of a gene related to cystic fibrosis;	
CC	(b) providing at least one extension primer, which binds to different predetermined sites in the nucleic acid molecules,	
CC	where at least one extension primer is designed to extend over at least two potential variable sites in the nucleic acid molecule, and nucleotides;	
CC	(c) simultaneously or sequentially performing primer extension reactions; and	
CC	(d) determining the pattern of nucleotide incorporation to obtain a test pattern; optionally	
CC	(e) comparing the test pattern of step (c) with one or more reference patterns, in order to type the variable sites of the nucleic acid molecules. Also described: (1) diagnosing the genetic predisposition of states, diseases and drug response related to the human cystic fibrosis transmembrane conductance regulator (CFTR) gene; and (2) a kit for use in the method for typing comprising at least one extension primer. The method is useful for typing at least two variable sites of at least one nucleic acid molecule related to cystic fibrosis. The present sequence represents a PCR primer for human CFTR, which is used in the exemplification of the present invention.	
SO	Sequence 15 BP; 3 A; 3 C; 5 G; 4 T; 0 U; 0 Other;	
Query Match	4.5%; Score 11.4; DB 1; Length 15;	
Best Local Similarity	92.3%; Pred. No. 3e+02;	
Matches	Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
OY	1188 TCCTCAGAACGCGTG 1200	
DB	TTCCTCAGTGGCGGTG 1	
DF74540	ADF74540 standard; DNA; 15 BP.	

XX	ADP74540;
AC	
XX	26-FEB-2004 (first entry)
DT	
XX	
DE	Allele-specific oligo primer for detecting CERP haplotypes (SeqID 21).
XX	
KM	ss; cholesterol] ester transfer protein; CERP; ASO; haplotypes;
KW	statin-specific variation; high density lipoprotein cholesterol; HDLC;
KV	cardiovascular disease; dyslipidemia; hyperlipidaemia;
KW	hypercholesterolaemia; allele specific oligonucleotide; primer; PCR;
KW	human.
XX	
OS	Homo sapiens.
XX	
PN	WO2003091698-A2.
PD	
XX	06-NOV-2003.
PF	
PR	28-APR-2003; 2003WO-US013346.
PR	
PA	26-APR-2002; 2002US-0375791P.
XX	(GENA-) GENAISANCE PHARM INC.
P1	
PI	Brain CD, Dain BJ, Judson RS, Messer C, Reed CR;
DR	
XX	WP1; 2003-865625/80.
PT	
PT	New kit for determining whether an individual has a statin response
PT	marker I or II comprising a set of oligonucleotides for identifying an
PT	allele at a polymorphic site, useful in diagnosing or treating e.g.,
PT	hypercholesterolemia.
PS	
PS	Disclosure; SEQ ID NO 21; 72pp; English.
XX	
CC	This invention relates to novel genetic markers and variants of the gene
CC	encoding the cholesterol] ester transfer protein (CERP) located on
CC	chromosome 1qg13. Specifically, it refers to a set of haplotypes in the
CC	CERP gene that are associated with statin-specific variation in high
CC	density lipoprotein cholesterol (HDLc) response. The present invention
CC	describes a kit for determining whether an individual has a statin
CC	response marker I or II, which comprises a set of oligonucleotides
CC	designed for identifying at least one of the alleles at each of the
CC	polymorphic sites of CERP. Accordingly, the method of the invention can
CC	be used in preparing a composition for diagnosing or treating
CC	cardiovascular disease caused by elevated LDLc or HDLc, and more
CC	particularly for the treatment of dyslipidemia, hyperlipidaemia or
CC	hypercholesterolaemia. This oligonucleotide sequence is a human allele-
CC	-specific oligo (ASO) primer used for detecting the CERP haplotypes of the
CC	invention.
CC	
XX	
SQ	Sequence 15 BP; 2 A; 2 C; 7 G; 3 T; 0 U; 1 Other;
Query Match	4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity	80.0%; Pred. No. 3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;	
OY	1313 TGAGGACTAGGGGA 1327 1 TGGGCTGCTAGGGR 15
DB	
RESULT 747	
ADG98502	
ID	ADG98502 standard; DNA; 15 BP.
XX	
AC	ADG98502;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Human CERP gene allele specific oligonucleotide PCR primer #75.
XX	

KW human; cholesterol ester transfer protein; CETP;
KW single nucleotide polymorphism; SNP; drug screening; atherosclerosis;
KW cardiovascular disease; hypercholesterolemia;
KW allele specific oligonucleotide; ss; PCR; primer.
XX
XX Homo sapiens.
OS
XX MO2003091277-A2.
PN
XX
XX 06-NOV-2003.
PD
XX
XX 28-APR-2003; 2003WO-US013288.
PF
XX
XX 26-APR-2002; 2002US-0375791P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX Anastasio AE, Chew A, Kazemi A, Lachowicz M, Lee HH, Parks KE,
PI Petersen N, Rounds E, Sausker EA, Tirrell C;
XX
XX WPI; 2003-865576/80.
DR
XX
XX New isolated polynucleotide useful for haplotyping and/or genotyping
PT cholesterol ester transfer protein (CETP) gene in an individual or in
PT screening for drugs useful in treating diseases associated with CETP
PT activity.
XX
XX Claim 43; SEQ ID NO 134; 250bp; English.
PS
XX
XX The invention comprises the amino acid and coding sequences of the human
CC cholesterol ester transfer protein (CETP), the invention also comprises
CC polymorphisms identified within the CETP gene. The DNA and protein
CC sequences of the invention are useful in haplotyping and/or genotyping
CC the CETP gene in an individual. The DNA and protein sequences may also be
CC used to screen drugs or compounds targeting the CETP or its variant to
CC treat a condition or disease associated with CETP (e.g. atherosclerosis,
CC cardiovascular disease or hypercholesterolemia). The present DNA
CC sequence represents an allele specific oligonucleotide PCR primer for the
CC human CETP gene.
XX
XX
SQ Sequence 15 BP; 2 A; 2 C; 7 G; 3 T; 0 U; 1 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 12; Conservative 1; Mismatches 2;
QY 1313 TGAGCAGCTAGGGA 1327
Db 1 TGGGCTGCTAGGGA 15
RESULT 748
ACF57607
ID ACF57607 standard; DNA; 15 BP.
XX
XX ACF57607;
AC
XX
XX 22-APR-2004 (first entry)
DT
XX
XX Human ALDOB gene allele-specific primer SEQ ID NO: 58.
DE
XX
XX Human; ALDOB; fructose-bisphosphate aldolase B; SNP;
KM single nucleotide polymorphism; primer; probe; ss.
XX
XX Homo sapiens.
OS
XX MO2003091454-A1.
PN
XX
XX 06-NOV-2003.
PD
XX
XX 26-APR-2002; 2002WO-US013328.
PF
XX
XX 26-APR-2002; 2002WO-US013328.
PR

XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX Chew A, Kazemi A, Koshy B;
PI WPI; 2003-877338/81.
XX
XX WPI; 2003-877338/81.
DR
XX
XX Claim 39; Page 15; 0pp; English.
PS
XX
XX The present invention provides the protein and coding sequences of human
CC fructose-bisphosphate aldolase B (ALDOB) and single nucleotide
CC polymorphisms (SNPs) which have been identified in each sequence. The
CC method of haplotyping the sequences is useful for haplotyping the
CC fructose-bisphosphate aldolase B (ALDOB) gene of an individual or for
CC validating the ALDOB protein as a candidate target for treating a medical
CC condition predicted to be associated with ALDOB activity. The present
CC sequence is an allele-specific primer/probe used to identify the
CC haplotype of the human ALDOB gene in the exemplification of the invention
XX
XX
SQ Sequence 15 BP; 4 A; 3 C; 5 G; 2 T; 0 U; 1 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 12; Conservative 1; Mismatches 2;
QY 1278 GAGGCGAGACCCCT 1292
Db 1 GAGGCGTAGACCTT 15
RESULT 749
AAK62014
ID AAK62014 standard; DNA; 16 BP.
XX
XX AAK62014;
AC
XX
XX 31-AUG-1999 (first entry)
DT
XX
XX HPV type-specific probe HPV34 P1.
DE
XX
XX PCR primer; probe; human papillomavirus; HPV; A region; B region;
KM C region; D region; detection; HPV genotype; cervical cancer; ss.
XX
XX Synthetic.
OS Human papillomavirus.
XX
XX WO9914377-A2.
PN
XX
XX 25-MAR-1999.
PD
XX
XX 14-SEP-1998; 98WO-EP005829.
PF
XX
XX 16-SEP-1997; 97EP-00870136.
PR
XX
XX (INNO-) INNOGENETICS NV.
PA (DELTA-) DELFTS DIAGNOSTIC LAB BV.
XX
XX Van Doorn L, Quint W, Kleter B, Ter Schegget J;
PI WPI; 1999-244048/20.
DR
XX
XX Detection and identification of human papillomavirus.
PT
XX
XX Claim 8; Page 38; 78pp; English.
PS
XX
XX AAK61849-X61982 and AAK62002-X62093 represent PCR primers and probes used
CC for detecting and/or identifying human papillomavirus (HPV) present in a
CC biological sample. The method comprises amplification of a polynucleic
CC acid fragment of HPV using a 5'-primer specifically hybridizing to the A
CC region or B region of the genome of at least one HPV type, and a 3'-
CC primer specifically hybridizing to the C region of at least one HPV type,
CC and hybridisation of the amplified fragments with at least one probe
CC capable of specific hybridization with the D region of at least one HPV

CC type. The primers individually or as a combination of 5'-primer and 3'-
CC primer, and the probes are used in the detection and/or identification of
CC HPV present in a biological sample. An isolated HPV polynucleotide, or
CC fragment, can also be used as a primer in a method for detection and/or
CC identification of HPV present in a sample. Identification of the
CC different HPV genotypes may have great clinical and epidemiological
CC importance. The presence of high-risk HPV types is a prognostic marker
CC for development and detection of cervical cancer
XX
SQ Sequence 16 BP; 3 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1232 GCATGCTCTGCA 1244
Db 2 GCATTGCTGCGCA 14
RESULT 750
AAZ60885/c
ID AAZ60885 standard; DNA; 16 BP.
XX
AC AAZ60885;
XX
DT 16-MAY-2000 (first entry)
XX
DE PCR primer used to amplify a human 7 transmembrane receptor sequence.
XX
KW Human; seven transmembrane receptor; quantitative analysis;
KW gene expression; fluorescent reporter signal; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200005409-A1.
XX
PD 03-FEB-2000.
XX
PP 21-JUL-1999; 99WO-GB002359.
XX
PR 21-JUL-1998; 98GB-00015799.
XX
PA (PHAR-) PHARMAGENE LAB LTD.
XX
PI Carey JE;
XX
XX WPI; 2000-182722/16.
XX
PT Quantitative analysis of the expression of two target genes in a
PT simultaneous PCR.
XX
PS Example 2; Page 16; 33pp; English.
XX
CC PCR primers AAZ60885-86 were used to amplify nucleic acids encoding a
CC human seven transmembrane receptor, in the course of the invention. The
CC specification describes a method for quantitative analysis of gene
CC expression. The method uses a respective fluorescent reporter signal for
CC at least a first and second target gene within a single replication
CC reaction vessel. The method of the invention is used across multiple
CC analysis of gene expression. The method may be used across multiple RNA
CC samples derived from different tissues to generate maps of transcript
CC expression or to profile the expression of many different transcripts in
CC the same RNA sample. The method is particularly suited for use in
CC automated systems involving fluorescent dyes
XX
SQ Sequence 16 BP; 1 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1375 AGAAGCAGCTGCG 1387

Db ||||| |||||
15 AGAAGCGCTGCG 3
RESULT 751
AA14189
ID AA14189 standard; DNA; 16 BP.
XX
AC AA14189;
XX
DT 21-JUL-2000 (first entry)
XX
DE B. pertussis 16S-23S rRNA spacer probe BP2, SEQ ID NO:29.
XX
KW Acute respiratory tract infection; multiplex reverse transcriptase-PCR;
KW paediatric; detection; identification; human respiratory syncytial virus;
KW parainfluenza virus type 1; parainfluenza virus type 3;
KW Mycoplasma pneumoniae; Chlamydia pneumoniae; human enterovirus;
KW influenza virus type A; influenza virus type B; adenovirus;
KW Bordetella pertussis; Bordetella parapertussis; hybridisation probe; ss.
XX
OS Bordetella pertussis.
XX
PN WO200017391-A1.
XX
PD 30-MAR-2000.
XX
PP 22-SEP-1999; 99WO-EP007065.
XX
PR 24-SEP-1998; 98EP-00870203.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Janne G, Schmitt H;
XX
DR WPI; 2000-283612/24.
XX
PT Identifying organisms causing acute respiratory tract infections via a
PT reverse transcription-polymerase chain reactions.
XX
PS Claim 7; Page 24; 45pp; English.
XX
CC The invention relates to a novel method for the detection of acute
CC respiratory tract infection via multiplex reverse transcriptase-PCR (RT-
CC PCR). The method comprises the simultaneous amplification of several
CC target nucleotide sequences of different species origin present in a
CC biological sample, and uses primer sets designed to amplify gene regions
CC of a variety of organisms implicated in causing acute respiratory tract
CC infection. The amplified DNA is then detected via the use of a species-
CC and gene-specific probe. The gene regions that are amplified and detected
CC in the method of the invention are the human respiratory syncytial virus
CC (RSV) fusion glycoprotein F1 subunit gene; the parainfluenza virus type 1
CC (PIV-1) haemagglutinin neuraminidase gene; the parainfluenza virus type 3
CC (PIV-3) fusion protein gene 5' non-coding region; the 16S rRNA sequences
CC from Mycoplasma pneumoniae and Chlamydia pneumoniae; the human
CC enterovirus 5' non-coding region; the non-structural protein genes from
CC influenza virus type A (InfA) and type B (InfB); and the hexon gene from
CC adenoviruses. The spacer region between the 16S and 23S rRNA sequences of
CC M. pneumoniae, C. pneumoniae, Bordetella pertussis and Bordetella
CC parapertussis may also be amplified and detected. The method of the
CC invention makes it possible to detect the presence of a range of
CC microorganisms which infect the respiratory tract, particularly in
CC children, using one amplification step. The different microorganisms can
CC be detected simultaneously within one day. The precise identification of
CC the causative organism(s) of acute respiratory tract infection in a
CC patient should result in more tailored antibiotic therapies, and reduced
CC usage of antibiotics. This would in turn help to delay the emergence of
CC antibiotic resistant bacteria, and would reduce side-effects and
CC healthcare costs. Sequences AA14161-A14176, AA14184-A14194 and AA14213
CC - AA14217 represent gene-specific hybridisation probes used in the
CC practice and exemplifications of the invention
XX
SQ Sequence 16 BP; 3 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

KM Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KM internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PE 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
PR WPI; 2003-521745/49.
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Example 10; Page 38; 100pp; English.
XX
CC The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
SQ Sequence 16 BP; 3 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1247 GGTCCGGCTGCAG 1259
DB 1 GATCCGGCTGCAG 13
XX
RESULT 755
ACD82537/C
ID ACD82537 standard; DNA; 16 BP.
XX
AC ACD82537;
XX
DT 19-SEP-2003 (first entry)
XX
DE Nucleic acid cloning associated adaptor molecule #238.
XX
KW Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KW internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS Synthetic.
XX
PN US2003044791-A1.
XX
PD 06-MAR-2003.
XX
PE 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX

PA (FLEM/) FLEMINGTON E K.
XX
PI Flemington EK;
XX
XX WPI; 2003-521745/49.
XX
DR New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 5; 100pp; English.
XX
XX The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
SQ Sequence 16 BP; 2 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1250 CCGGCTGCAGCAA 1262
DB 16 CCGGCTGCAGCAA 4
XX
RESULT 756
ADD36337
ID ADD36337 standard; DNA; 16 BP.
XX
AC ADD36337;
XX
DT 15-JAN-2004 (first entry)
XX
DE DNA binding site Seq ID145 related to human THAP6.
XX
KW THAP; Thantos (death) Associated Protein; THAP family;
KW cell proliferation; cell death; tissue homeostasis; tumorigenesis;
KW THAP1; pro-apoptotic protein; cytosstatic; gene therapy; cancer;
KW THAP domain; THAP1; ds.
XX
OS Synthetic.
XX
PN WO2003051917-A2.
XX
PD 26-JUN-2003.
XX
PE 10-DEC-2002; 2002WO-EP014027.
XX
PR 18-DEC-2001; 2001US-0341997P.
XX
PA (ENDO-) ENDOCUBE SAS.
XX
PA (CNRS) CNRS CENT NAT RECH SCI.
XX
PI Girard J, Rousaigne M, Kossida S, Amalric F;
XX
DR WPI; 2003-532998/50.
XX
PT Identifying a test compound that modulates THAP-mediated activities for
PT treating cancer by determining whether the test compound selectively
PT modulates the activity of the THAP-family polypeptide.
XX

PS	Disclosure; SEQ ID NO 145; 303bp; English.
XX	
CC	This invention relates to a method of identifying a compound which
CC	modulates THAP (Thanos (death) Associated Protein)-mediated activities.
CC	The invention also relates to genes and proteins of the THAP family and
CC	uses thereof. Coordination of cell proliferation and cell death is
CC	required for normal development and tissue homeostasis in multicellular
CC	organisms. A defect in these two processes is a fundamental requirement
CC	for tumorigenesis. THAP1 is a pro-apoptotic protein and therapeutics
CC	which modulate THAP1 activity may be cytostatic. The sequences of the
CC	invention may prove useful for gene therapy. The method is useful for
CC	preparing a composition for treating cancer. The present sequence is that
CC	of a DNA binding site recognised by human THAP1 which is related to the
CC	invention.
XX	
SO	Sequence 16 BP; 4 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
QY	
Db	1232 GCATGTGCTGGCA 1244 3 GCATGTACTGGCA 15
RESULT 757	
ADP19704/C	
ID	ADP19704 standard; DNA; 16 BP.
AC	
XX	ADP19704;
XX	
DT	12-AUG-2004 (first entry)
XX	
DE	Human GH1 gene PCR primer GHBFR.
XX	
KW	human; growth hormone; growth hormone variant; GH; GH1;
KW	receptor-mediated cell signalling pathway activator;
KW	growth hormone dysfunction; growth hormone irregularity; chromosome 17;
KW	PCR; primer; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	WO2004044002-A1.
PD	
XX	27-MAY-2004.
PF	
XX	04-NOV-2003; 2003WO-GB004775.
XX	
PR	12-NOV-2002; 2002GB-00026441.
PR	12-NOV-2002; 2002WO-GB005112.
PR	10-APR-2003; 2003GB-00008242.
XX	
PA	(UYWA-) UNIV WALES COLLEGE OF MEDICINE.
P1	
XX	Cooper DN, Procter AM, Gregory J, Millar DS, Lewis M, Uied A;
XX	WPI; 2004-411699/38.
XX	
PT	Isolated variant of human growth hormone nucleic acid molecule, GH1
PT	useful for diagnosing growth hormone dysfunction or development of
XX	suitable therapies, comprises altered nitrogenous bases.
XX	
PS	Example 2; Page 25; 66pp; English.
XX	
CC	The present invention describes an isolated variant of a human growth
CC	hormone (GH) nucleic acid molecule (1), GH1, comprising the substitution:
CC	+1491 cytosine substituted by guanine, wherein 1491 refers to the
CC	position of the nucleotide with respect to this transcription initiation
CC	site which is designated 1 or comprises a nucleic acid molecule that
CC	encodes a protein, i.e. a GH protein, including the substitution
CC	11e179et. Also described: (1) a transcript of (1); (2) an isolated

```

CC polypeptide encoded by (I); (3) an isolated polypeptide which is a
CC variant of the growth hormone protein, GH, and which includes the
CC substitution Ile179Met; (4) screening (M1) an individual suspected of
CC having dysfunction GH, involving: (a) obtaining a test sample
CC comprising a nucleic acid molecule of human GH1 gene from an individual,
CC sequencing the molecule, examining the sequence for a1491 cytosine
CC substituted by guanine, and where the substitution exists concluding
CC there is GH dysfunction; (b) obtaining a test sample comprising a growth
CC hormone, GH, polypeptide from the individual, sequencing the polypeptide,
CC examining the sequence for a Ile179Met substitution, and where the
CC substitution exists concluding there is a GH dysfunction; or (c)
CC obtaining a test sample from the individual comprising the individual's
CC endogenous growth mitogen-activated protein kinases (MAPK) hormone,
CC examining the growth hormone to determine whether and to what extent it
CC will activate the receptor-mediated cell signaling pathway, and where
CC there is a reduction in MAPK cell signaling, with respect to wild-type
CC GH, concluding there is a GH dysfunction; (5) a kit suitable for carrying
CC out M1; (6) an oligonucleotide suitable for use in (M1) and optionally,
CC provided in the kit; (7) an isolated growth hormone polypeptide or
CC protein (II), containing an Ile179Met substitution and which further
CC provides for differential activation of receptor-mediated cell signaling
CC pathways or possessing a reduced ability to activate the MAP kinase
CC pathway; (8) an antibody specific for (II); (9) pharmaceutical
CC composition comprising (I) or (II) with a carrier; (10) vector (III)
CC comprising (I); (11) host cell (IV) comprising (III); and (12) a
CC polypeptide or protein produced by using (IV). (I) activates receptor-
CC mediated cell signaling pathway. (I) and (II) are useful for the
CC diagnosis of growth hormone dysfunction or the development of suitable
CC therapies. (I) or (II) is useful as a pharmaceutical composition for
CC treating growth hormone irregularities. (IV) is useful for preparing
CC (II), by culturing (IV) and recovering from the culture medium the
CC polypeptide or protein produced by the cell. The present sequence
CC represents a PCR primer for human GH1, which is used in an example from
CC the present invention. Human GH1 is located on chromosome 17q23.
SQ
XX
XX Sequence 16 BP; 0 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
GY 1203 CAGAGGGCAGCCA 1215
DB 13 CAGAGGGCAGCCA 1

```

XX Fryklund L, Lewis M, Cooper D;
XX WPI; 2004-420339/39.
XX Determining the significance of a polymorphism or mutation on the
XX structural properties of a protein comprises exposing the protein to at
XX least one protease.
XX Disclosure; Page 11; 29pp; English.
XX The invention relates to a novel method for determining the significance
XX of a given nucleic acid polymorphism or mutation, in a nucleic acid
XX molecule, on the structural properties of a protein encoded by the
XX nucleic acid molecule. The method comprises exposing the protein encoded
XX by the nucleic acid molecule to at least one protease. The method of the
XX invention may be useful for determining the significance of a given
XX nucleic acid polymorphism or mutation, in a nucleic acid molecule, on the
XX structural properties of a protein encoded by the nucleic acid molecule.
XX The current sequence is that of the PCR primer 1 of the invention which
XX was used to amplify human growth hormone 1 (GH1) gDNA.
XX
XX Sequence 16 BP; 0 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1203 CAGAGGCGACCCA 1215
Db |||||
13 CAGAGGCGACCCA 1
RESULT 759
ADQ08960
ID ADQ08960 standard; DNA; 16 BP.
XX
XX ADQ08960;
XX
XX 23-SEP-2004 (first entry)
XX
XX THAP responsive element SEQ ID NO:145.
XX
XX
XX Thnatos-associated protein; THAP; THAP responsive gene; THAP family;
XX THAP responsive element; angiogenesis; inflammation; metastasis; cancer;
XX apoptosis; cardiovascular disease; neurodegenerative disease; chemokine;
XX antiangiogenic; antiinflammatory; cardiovascular; cytosolic;
XX neuroprotective; osteopathic; THAP modulator; THAP synthesis modulator;
XX 88.
XX
XX Synthetic.
XX
XX WO200405050-A2.
XX
XX 01-JUL-2004.
XX
XX 10-DEC-2003; 2003WO-IB006434.
XX
XX 10-DEC-2002; 2002US-0432699P.
XX
XX 03-JUL-2003; 2003US-0485027P.
XX
XX (ENDO-) ENDOCUBE SAS.
XX
XX (CNRS) CNRS CENT NAT RECH SCI.
XX
XX Girard J, Amalric F, Rousigne M, Clouaire T;
XX
XX WPI; 2004-525034/50.
XX
XX
XX Modulating expression of a Thnatos (death)-Associated Protein (THAP)
XX responsive gene for preventing or treating e.g. cancer or inflammation,
XX comprises modulating the interaction of a THAP polypeptide with a nucleic
XX acid.

PS Claim 124; SEQ ID NO 145; 612pp; English.
XX
XX The present invention describes a method for modulating the expression of
XX a thnatos (death)-associated protein (THAP) responsive gene. The method
XX comprises modulating the interaction of a THAP-family polypeptide or its
XX biological fragment with a nucleic acid, and so enhancing or repressing
XX the expression of the THAP responsive gene. Also described: (1) a method
XX of modulating the expression of a gene responsive to a THAP/chemokine
XX complex; (2) a pharmaceutical composition comprising a THAP responsive
XX element in a pharmaceutical carrier; (3) a transcription factor decoy
XX consisting essentially of a THAP responsive element; (4) a cell
XX comprising a transcription factor decoy described above; (5) methods of
XX modulating the interaction between a nucleic acid and a THAP-family
XX polypeptide or its biological fragment, or a nucleic acid and a
XX THAP/chemokine complex; (6) a vector packaging cell line comprising a
XX cell comprising a viral vector which comprises a promoter operably linked
XX to a nucleic acid encoding a THAP-family polypeptide or its biological
XX fragment; (7) a method of constructing a cell which expresses a
XX recombinant THAP-family polypeptide; (8) a method of ameliorating
XX symptoms associated with a condition mediated by a THAP/chemokine complex
XX ; (9) methods of identifying a test compound that modulates transcription
XX at a THAP responsive element or that modulates the transport of a
XX chemokine into the nucleus; (10) methods for reducing the symptoms
XX associated with a condition selected from excessive or insufficient
XX angiogenesis, inflammation, metastasis of a cancerous tissue, excessive
XX or insufficient apoptosis, cardiovascular disease and neurodegenerative
XX diseases; symptoms associated with a condition resulting from the
XX activity of a chemokine or a THAP-family polypeptide in an individual; or
XX symptoms associated with transcriptional repression or activation
XX mediated by a THAP-family polypeptide in an individual; (11) a vector
XX comprising a THAP responsive promoter operably linked to a nucleic acid
XX encoding a detectable product; (12) a genetically engineered cell
XX comprising the vector described above or that expresses a THAP-family
XX polypeptide or its biological fragment; (13) an in vitro transcription
XX reaction comprising a nucleic acid comprising a THAP responsive promoter,
XX ribonucleotides and an RNA polymerase; and (14) an isolated mutant THAP
XX family polypeptide that does not bind to a chemokine. The pharmaceutical
XX composition has antiangiogenic, antiinflammatory, cardiovascular,
XX cytosolic, neuroprotective and osteopathic activities, and can be used
XX as a THAP and THAP synthesis modulator. The composition can be used for
XX modulating the expression of a THAP responsive gene. Modulation is useful
XX for reducing symptoms of conditions such as excessive or insufficient
XX angiogenesis, inflammation, metastasis of a cancerous tissue, excessive
XX or insufficient apoptosis, cardiovascular disease or neurodegenerative
XX diseases. The present sequence is used in the exemplification of the
XX present invention.
XX
XX Sequence 16 BP; 4 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1232 GCATGCTCTGCA 1244
Db |||||
3 GCATGCTCTGCA 15

Search completed: December 6, 2004, 18:15:46
Job time : 6 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model1

Run on: December 6, 2004, 18:20:30 ; Search time 2 Seconds
(without alignments)
2.976 Million cell updates/sec

Title: us-09-993-731-10

Perfect score: 252
Sequence: 1 ctggctccccaagaacctgt.....gtctgagcgsgccatc 252

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 676 seqs, 11808 residues

Total number of hits satisfying chosen parameters: 1352

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 646 summaries

Database : rnpbdb.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20	7.9	20	1 US-09-993-731-50	Sequence 50, App1
2	20	7.9	20	1 US-09-993-731-51	Sequence 51, App1
3	20	7.9	20	1 US-09-993-731-52	Sequence 52, App1
4	20	7.9	20	1 US-09-993-731-53	Sequence 53, App1
5	20	7.9	20	1 US-09-993-731-54	Sequence 54, App1
6	20	7.9	20	1 US-09-993-731-55	Sequence 55, App1
7	20	7.9	20	1 US-09-993-731-56	Sequence 56, App1
8	20	7.9	20	1 US-09-993-731-57	Sequence 57, App1
9	20	7.9	20	1 US-09-993-731-58	Sequence 58, App1
10	20	7.9	20	1 US-09-993-731-59	Sequence 59, App1
11	20	7.9	20	1 US-09-993-731-60	Sequence 60, App1
12	20	7.9	20	1 US-09-993-731-61	Sequence 61, App1
13	20	7.9	20	1 US-09-993-731-62	Sequence 62, App1
14	20	7.9	20	1 US-09-993-731-63	Sequence 63, App1
15	20	7.9	20	1 US-09-993-731-64	Sequence 64, App1
16	20	7.9	20	1 US-09-993-731-65	Sequence 65, App1
17	20	7.9	20	1 US-09-993-731-66	Sequence 66, App1
18	20	7.9	20	1 US-09-993-731-67	Sequence 67, App1
19	18.6	7.4	25	1 US-10-098-263B-36118	Sequence 36118, A
20	18.4	7.3	23	1 US-09-935-998A-70	Sequence 70, App1
21	18.4	7.3	23	1 US-10-005-626A-70	Sequence 70, App1
22	16.4	6.5	20	1 US-10-199-199-70	Sequence 70, App1
23	16.4	6.5	20	1 US-10-199-199-135	Sequence 135, App1
24	16.2	6.4	21	1 US-10-005-956-417	Sequence 417, App1
25	16.2	6.4	21	1 US-10-005-956-418	Sequence 418, App1
26	16.2	6.4	21	1 US-10-005-956-419	Sequence 419, App1
27	16.2	6.4	21	1 US-10-005-956-420	Sequence 420, App1
28	16.2	6.4	22	1 US-10-188-186-217	Sequence 217, App1
29	15.8	6.3	21	1 US-09-935-464-38	Sequence 38, App1
30	15.8	6.3	21	1 US-10-125-835-38	Sequence 38, App1
31	15.4	6.1	17	1 US-09-866-108-929	Sequence 929, App1
32	15.4	6.1	17	1 US-10-723-361-929	Sequence 929, App1
33	15.4	6.1	20	1 US-09-854-883-313	Sequence 313, App1

C 107	14.8	5.9	20	1	US-10-145-092A-21	Sequence 21, App1	C 180	14.2	5.6	20	1	US-10-292-849-28	Sequence 28, App1
C 108	14.8	5.9	20	1	US-10-145-129A-21	Sequence 21, App1	C 181	14.2	5.6	20	1	US-10-292-849-100	Sequence 100, App
C 109	14.8	5.9	20	1	US-10-165-038A-21	Sequence 21, App1	C 182	14.2	5.6	20	1	US-10-300-263-69	Sequence 69, App1
C 110	14.8	5.9	20	1	US-10-165-353A-21	Sequence 21, App1	C 183	14.2	5.6	20	1	US-10-300-263-135	Sequence 135, App
C 111	14.8	5.9	20	1	US-10-167-600-21	Sequence 21, App1	C 184	14	5.6	20	1	US-10-117-586C-132	Sequence 32, App1
C 112	14.8	5.9	20	1	US-10-170-481A-21	Sequence 21, App1	C 185	14	5.6	20	1	US-10-665-216-162	Sequence 162, App
C 113	14.8	5.9	20	1	US-10-172-039A-21	Sequence 21, App1	C 186	13.8	5.5	17	1	US-09-666-108-927	Sequence 927, App
C 114	14.8	5.9	20	1	US-10-210-028-21	Sequence 21, App1	C 187	13.8	5.5	17	1	US-09-666-108-253	Sequence 2593, App
C 115	14.8	5.9	20	1	US-10-017-085A-21	Sequence 21, App1	C 188	13.8	5.5	17	1	US-09-666-108-6611	Sequence 6611, App
C 116	14.8	5.9	20	1	US-10-013-916A-21	Sequence 21, App1	C 189	13.8	5.5	17	1	US-09-666-108-6612	Sequence 6612, App
C 117	14.8	5.9	20	1	US-10-143-026B-21	Sequence 21, App1	C 190	13.8	5.5	17	1	US-09-866-108-8648	Sequence 8648, App
C 118	14.8	5.9	20	1	US-10-013-918A-21	Sequence 21, App1	C 191	13.8	5.5	17	1	US-09-825-805-667	Sequence 667, App
C 119	14.8	5.9	20	1	US-10-162-521A-21	Sequence 21, App1	C 192	13.8	5.5	17	1	US-09-818-875-927	Sequence 927, App
C 120	14.8	5.9	20	1	US-10-013-928A-21	Sequence 21, App1	C 193	13.8	5.5	17	1	US-09-818-875-928	Sequence 928, App
C 121	14.8	5.9	20	1	US-10-162-522A-21	Sequence 21, App1	C 194	13.8	5.5	17	1	US-09-930-423-795	Sequence 795, App
C 122	14.8	5.9	20	1	US-10-013-923A-21	Sequence 21, App1	C 195	13.8	5.5	17	1	US-09-745-237A-795	Sequence 795, App
C 123	14.8	5.9	20	1	US-10-013-925A-21	Sequence 21, App1	C 196	13.8	5.5	17	1	US-10-163-552-337	Sequence 337, App
C 124	14.8	5.9	20	1	US-10-013-927A-21	Sequence 21, App1	C 197	13.8	5.5	17	1	US-10-156-306-5922	Sequence 5922, App
C 125	14.8	5.9	20	1	US-10-145-093A-21	Sequence 21, App1	C 198	13.8	5.5	17	1	US-10-209-787-927	Sequence 927, App
C 126	14.8	5.9	20	1	US-10-013-919A-21	Sequence 21, App1	C 199	13.8	5.5	17	1	US-10-209-787-928	Sequence 928, App
C 127	14.8	5.9	20	1	US-10-013-920A-21	Sequence 21, App1	C 200	13.8	5.5	17	1	US-10-261-185-927	Sequence 927, App
C 128	14.8	5.9	20	1	US-10-164-749A-21	Sequence 21, App1	C 201	13.8	5.5	17	1	US-10-261-185-928	Sequence 928, App
C 129	14.8	5.9	20	1	US-10-013-917A-21	Sequence 21, App1	C 202	13.8	5.5	17	1	US-10-138-674-1607	Sequence 1607, App
C 130	14.8	5.9	20	1	US-10-317-500-171	Sequence 21, App	C 203	13.8	5.5	17	1	US-10-723-361-927	Sequence 927, App
C 131	14.8	5.9	20	1	US-10-317-500-272	Sequence 21, App	C 204	13.8	5.5	17	1	US-10-723-361-2593	Sequence 2593, App
C 132	14.8	5.9	20	1	US-10-152-388B-21	Sequence 21, App1	C 205	13.8	5.5	17	1	US-10-723-361-6611	Sequence 6611, App
C 133	14.8	5.9	21	1	US-10-786-720-1125B	Sequence 1125B, A	C 206	13.8	5.5	17	1	US-10-723-361-6612	Sequence 6612, App
C 134	14.4	5.7	17	1	US-09-866-108-928	Sequence 928, App	C 207	13.8	5.5	17	1	US-10-723-361-8648	Sequence 8648, App
C 135	14.4	5.7	17	1	US-09-866-108-930	Sequence 930, App	C 208	13.8	5.5	17	1	US-10-681-074-927	Sequence 927, App
C 136	14.4	5.7	17	1	US-09-825-805-668	Sequence 668, App	C 209	13.8	5.5	17	1	US-10-681-074-928	Sequence 928, App
C 137	14.4	5.7	17	1	US-09-818-875-915	Sequence 915, App	C 210	13.8	5.5	17	1	US-10-440-850-1062	Sequence 1062, App
C 138	14.4	5.7	17	1	US-09-818-875-916	Sequence 916, App	C 211	13.8	5.5	18	1	US-10-440-850-2186	Sequence 2186, App
C 139	14.4	5.7	17	1	US-09-818-875-923	Sequence 923, App	C 212	13.8	5.5	18	1	US-10-138-674-2186	Sequence 2186, App
C 140	14.4	5.7	17	1	US-09-818-875-924	Sequence 924, App	C 213	13.8	5.5	18	1	US-10-287-949A-2186	Sequence 2186, App
C 141	14.4	5.7	17	1	US-10-163-552-338	Sequence 338, App	C 214	13.8	5.5	19	1	US-10-205-309-103	Sequence 103, App
C 142	14.4	5.7	17	1	US-10-209-787-915	Sequence 915, App	C 215	13.8	5.5	19	1	US-10-205-309-169	Sequence 169, App
C 143	14.4	5.7	17	1	US-10-209-787-916	Sequence 916, App	C 216	13.8	5.5	19	1	US-10-205-309-428	Sequence 428, App
C 144	14.4	5.7	17	1	US-10-209-787-923	Sequence 923, App	C 217	13.8	5.5	19	1	US-10-205-309-494	Sequence 494, App
C 145	14.4	5.7	17	1	US-10-209-787-924	Sequence 924, App	C 218	13.4	5.3	15	1	US-09-880-313A-235	Sequence 235, App
C 146	14.4	5.7	17	1	US-10-261-185-915	Sequence 915, App	C 219	13.4	5.3	15	1	US-10-163-552-1980	Sequence 1980, App
C 147	14.4	5.7	17	1	US-10-261-185-916	Sequence 916, App	C 220	13.4	5.3	17	1	US-09-866-108-931	Sequence 931, App
C 148	14.4	5.7	17	1	US-10-261-185-923	Sequence 923, App	C 221	13.4	5.3	17	1	US-09-930-423-1074	Sequence 1074, App
C 149	14.4	5.7	17	1	US-10-261-185-924	Sequence 924, App	C 222	13.4	5.3	17	1	US-09-930-423-1221	Sequence 1221, App
C 150	14.4	5.7	17	1	US-10-138-674-2336	Sequence 2336, App	C 223	13.4	5.3	17	1	US-09-930-423-1575	Sequence 1575, App
C 151	14.4	5.7	17	1	US-10-287-949A-2336	Sequence 2336, App	C 224	13.4	5.3	17	1	US-09-740-332-1418	Sequence 1418, App
C 152	14.4	5.7	17	1	US-10-723-361-928	Sequence 928, App	C 225	13.4	5.3	17	1	US-09-745-237A-1074	Sequence 1074, App
C 153	14.4	5.7	17	1	US-10-723-361-930	Sequence 930, App	C 226	13.4	5.3	17	1	US-09-745-237A-1221	Sequence 1221, App
C 154	14.4	5.7	17	1	US-10-681-074-915	Sequence 915, App	C 227	13.4	5.3	17	1	US-09-745-237A-1575	Sequence 1575, App
C 155	14.4	5.7	17	1	US-10-681-074-916	Sequence 916, App	C 228	13.4	5.3	17	1	US-09-817-879-1418	Sequence 1418, App
C 156	14.4	5.7	17	1	US-10-681-074-923	Sequence 923, App	C 229	13.4	5.3	17	1	US-10-138-674-1608	Sequence 1608, App
C 157	14.4	5.7	17	1	US-10-681-074-924	Sequence 924, App	C 230	13.4	5.3	17	1	US-10-138-674-2337	Sequence 2337, App
C 158	14.4	5.7	19	1	US-10-224-005-63	Sequence 63, App1	C 231	13.4	5.3	17	1	US-10-138-674-6233	Sequence 6233, App
C 159	14.4	5.7	19	1	US-10-224-005-224	Sequence 224, App	C 232	13.4	5.3	17	1	US-10-138-674-6233	Sequence 6233, App
C 160	14.4	5.7	20	1	US-09-280-030-45	Sequence 45, App1	C 233	13.4	5.3	17	1	US-10-287-949A-1237	Sequence 1237, App
C 161	14.4	5.7	20	1	US-09-956-279-5	Sequence 5, App1	C 234	13.4	5.3	17	1	US-10-287-949A-6233	Sequence 2406, App
C 162	14.4	5.7	20	1	US-10-161-996-142	Sequence 142, App	C 235	13.4	5.3	17	1	US-10-712-672-2406	Sequence 4011, App
C 163	14.4	5.7	20	1	US-10-380-127A-60	Sequence 60, App1	C 236	13.4	5.3	17	1	US-10-669-841-4011	Sequence 4011, App
C 164	14.4	5.7	20	1	US-10-293-864-25	Sequence 25, App1	C 237	13.4	5.3	17	1	US-10-723-361-931	Sequence 931, App
C 165	14.4	5.7	20	1	US-10-293-864-103	Sequence 103, App	C 238	13.4	5.3	19	1	US-09-853-688-34	Sequence 34, App1
C 166	14.4	5.7	20	1	US-10-303-635-130	Sequence 130, App	C 239	13.4	5.3	19	1	US-09-853-688-61	Sequence 61, App1
C 167	14.4	5.7	20	1	US-10-737-576-5	Sequence 5, App1	C 240	13.4	5.3	19	1	US-09-823-549-44	Sequence 44, App1
C 168	14.2	5.6	19	1	US-10-251-117-603	Sequence 603, App	C 241	13.4	5.3	19	1	US-10-361-028-30	Sequence 30, App1
C 169	14.2	5.6	19	1	US-10-251-117-910	Sequence 910, App	C 242	13.4	5.3	19	1	US-10-361-028-34	Sequence 34, App1
C 170	14.2	5.6	19	1	US-10-205-309-151	Sequence 151, App	C 243	13.4	5.3	19	1	US-10-788-318-34	Sequence 34, App1
C 171	14.2	5.6	19	1	US-10-205-309-476	Sequence 476, App	C 244	13.4	5.3	19	1	US-10-788-318-61	Sequence 61, App1
C 172	14.2	5.6	19	1	US-10-430-011-139	Sequence 139, App	C 245	13.2	5.2	18	1	US-09-685-992-44	Sequence 44, App1
C 173	14.2	5.6	20	1	US-09-780-172-71	Sequence 71, App1	C 246	13.2	5.2	18	1	US-09-685-992-76	Sequence 76, App1
C 174	14.2	5.6	20	1	US-09-993-731-82	Sequence 82, App1	C 247	13.2	5.2	18	1	US-10-116-325-76	Sequence 76, App1
C 175	14.2	5.6	20	1	US-10-178-331-1	Sequence 1, App1	C 248	13.2	5.2	18	1	US-10-440-850-1007	Sequence 1007, App
C 176	14.2	5.6	20	1	US-10-024-369-22	Sequence 22, App1	C 249	13.2	5.2	18	1	US-10-388-263-76	Sequence 76, App1
C 177	14.2	5.6	20	1	US-10-161-996-93	Sequence 93, App1	C 250	13.2	5.2	18	1	US-10-108-260A-5412	Sequence 5412, App
C 178	14.2	5.6	20	1	US-10-161-996-222	Sequence 222, App	C 251	13.2	5.2	18	1	US-10-698-689-76	Sequence 76, App1
C 179	14.2	5.6	20	1	US-10-136-728-111	Sequence 111, App	C 252	13.2	5.2	18	1	US-10-698-689-240	Sequence 240, App

C 253	13.2	5.2	18	1	US-10-830-475-76	Sequence 76, Appl	C 326	12.8	5.1	17	1	US-10-669-841-4931	Sequence 4931, Ap
254	13	5.2	17	1	US-09-866-108-2589	Sequence 2589, Ap	327	12.8	5.1	17	1	US-10-669-841-5348	Sequence 5348, Ap
255	13	5.2	17	1	US-09-866-108-2590	Sequence 2590, Ap	328	12.8	5.1	17	1	US-10-723-361-926	Sequence 926, Appl
256	13	5.2	17	1	US-09-866-108-3591	Sequence 2591, Ap	329	12.8	5.1	17	1	US-10-723-361-1962	Sequence 1962, Ap
257	13	5.2	17	1	US-09-866-108-2592	Sequence 2592, Ap	330	12.8	5.1	17	1	US-10-723-361-1963	Sequence 1963, Ap
258	13	5.2	17	1	US-10-723-361-2589	Sequence 2589, Ap	331	12.8	5.1	17	1	US-10-723-361-1964	Sequence 1964, Ap
259	13	5.2	17	1	US-10-723-361-2590	Sequence 2590, Ap	332	12.8	5.1	17	1	US-10-723-361-6610	Sequence 6610, Ap
260	13	5.2	17	1	US-10-723-361-2591	Sequence 2591, Ap	333	12.8	5.1	17	1	US-10-723-361-6613	Sequence 6613, Ap
261	13	5.2	17	1	US-10-723-361-2592	Sequence 2592, Ap	334	12.8	5.1	17	1	US-10-723-361-7346	Sequence 7346, Ap
262	13	5.2	18	1	US-10-368-263-258	Sequence 258, Appl	335	12.8	5.1	17	1	US-10-723-361-7347	Sequence 7347, Ap
C 263	13	5.2	18	1	US-10-349-143-4727	Sequence 4727, Ap	336	12.8	5.1	17	1	US-10-723-361-7797	Sequence 7797, Ap
C 264	13	5.2	18	1	US-10-628-109-176	Sequence 176, Appl	337	12.8	5.1	17	1	US-10-723-361-7798	Sequence 7798, Ap
265	13	5.2	18	1	US-10-608-436-36	Sequence 36, Appl	338	12.8	5.1	17	1	US-10-723-361-8647	Sequence 8647, Ap
266	12.8	5.1	16	1	US-10-339-674-122	Sequence 122, Appl	339	12.8	5.1	17	1	US-10-723-361-9346	Sequence 9346, Ap
267	12.8	5.1	16	1	US-09-866-108-2867	Sequence 2867, Appl	340	12.8	5.1	17	1	US-10-723-361-9347	Sequence 9347, Ap
268	12.8	5.1	17	1	US-09-866-108-526	Sequence 926, Appl	341	12.8	5.1	17	1	US-10-712-633-3610	Sequence 3610, Ap
269	12.8	5.1	17	1	US-09-866-108-1962	Sequence 1962, Ap	342	12.8	5.1	17	1	US-10-712-633-3877	Sequence 3877, Ap
270	12.8	5.1	17	1	US-09-866-108-1963	Sequence 1963, Ap	343	12.8	5.1	17	1	US-09-969-373-4044	Sequence 4044, Ap
271	12.8	5.1	17	1	US-09-866-108-2594	Sequence 2594, Ap	344	12.8	5.1	18	1	US-10-179-940-535	Sequence 535, Appl
C 272	12.8	5.1	17	1	US-09-866-108-6610	Sequence 6610, Ap	C 345	12.6	5.0	18	1	US-10-355-820-15	Sequence 15, Appl
C 273	12.8	5.1	17	1	US-09-866-108-6613	Sequence 6613, Ap	346	12.6	5.0	20	1	US-10-136-728-111	Sequence 111, Appl
274	12.8	5.1	17	1	US-09-866-108-7346	Sequence 7346, Ap	C 347	12.6	5.0	14	1	US-10-401-8308-1	Sequence 1, Appl1
275	12.8	5.1	17	1	US-09-866-108-7347	Sequence 7347, Ap	348	12.4	4.9	14	1	US-10-402-689-1	Sequence 29, Appl1
276	12.8	5.1	17	1	US-09-866-108-7797	Sequence 7797, Ap	349	12.4	4.9	16	1	US-09-866-108-9232	Sequence 932, Appl
277	12.8	5.1	17	1	US-09-866-108-7798	Sequence 7798, Ap	350	12.4	4.9	17	1	US-09-866-108-8308	Sequence 8308, Ap
278	12.8	5.1	17	1	US-09-866-108-8647	Sequence 8647, Ap	351	12.4	4.9	17	1	US-09-866-108-8309	Sequence 8309, Ap
279	12.8	5.1	17	1	US-09-866-108-8649	Sequence 8649, Ap	C 352	12.4	4.9	17	1	US-09-866-108-8310	Sequence 8310, Ap
280	12.8	5.1	17	1	US-09-866-108-9346	Sequence 9346, Ap	C 353	12.4	4.9	17	1	US-09-866-108-8311	Sequence 8311, Ap
281	12.8	5.1	17	1	US-09-866-108-9347	Sequence 9347, Ap	C 354	12.4	4.9	17	1	US-09-866-108-8312	Sequence 8312, Ap
282	12.8	5.1	17	1	US-09-825-805-448	Sequence 448, Appl	C 355	12.4	4.9	17	1	US-09-866-108-8776	Sequence 8776, Ap
283	12.8	5.1	17	1	US-09-825-805-502	Sequence 502, Appl	356	12.4	4.9	17	1	US-09-866-108-8777	Sequence 8777, Ap
C 284	12.8	5.1	17	1	US-09-780-533A-539	Sequence 539, Appl	357	12.4	4.9	17	1	US-09-866-108-8778	Sequence 8778, Ap
C 285	12.8	5.1	17	1	US-09-780-533A-2178	Sequence 2178, Appl	358	12.4	4.9	17	1	US-09-866-108-8779	Sequence 8779, Ap
C 286	12.8	5.1	17	1	US-09-848-754A-2157	Sequence 2157, Appl	359	12.4	4.9	17	1	US-09-827-998-1717	Sequence 1717, Ap
C 287	12.8	5.1	17	1	US-09-848-754A-2158	Sequence 2158, Appl	C 360	12.4	4.9	17	1	US-09-961-077-175	Sequence 175, Appl
C 288	12.8	5.1	17	1	US-09-930-423-796	Sequence 796, Appl	C 361	12.4	4.9	17	1	US-09-827-998-1718	Sequence 1718, Ap
C 289	12.8	5.1	17	1	US-09-930-423-984	Sequence 984, Appl	C 362	12.4	4.9	17	1	US-09-827-998-1719	Sequence 1719, Ap
C 290	12.8	5.1	17	1	US-09-827-395A-515	Sequence 515, Appl	C 363	12.4	4.9	17	1	US-09-827-998-1720	Sequence 1720, Ap
C 291	12.8	5.1	17	1	US-09-827-395A-1014	Sequence 1014, Appl	C 364	12.4	4.9	17	1	US-09-864-785-1547	Sequence 1547, Appl
C 292	12.8	5.1	17	1	US-09-740-332-1800	Sequence 1800, Appl	C 365	12.4	4.9	17	1	US-09-961-077-176	Sequence 176, Appl
C 293	12.8	5.1	17	1	US-09-740-332-1944	Sequence 1944, Appl	C 366	12.4	4.9	17	1	US-09-930-423-794	Sequence 794, Appl
294	12.8	5.1	17	1	US-09-740-332-2217	Sequence 2217, Appl	C 367	12.4	4.9	17	1	US-09-930-423-1574	Sequence 1574, Appl
C 295	12.8	5.1	17	1	US-09-740-332-2338	Sequence 2338, Appl	368	12.4	4.9	17	1	US-09-817-879-3138	Sequence 3138, Appl
C 296	12.8	5.1	17	1	US-09-740-332-2755	Sequence 2755, Appl	369	12.4	4.9	17	1	US-09-817-879-3139	Sequence 3139, Appl
C 297	12.8	5.1	17	1	US-09-745-237A-796	Sequence 796, Appl	370	12.4	4.9	17	1	US-09-745-237A-794	Sequence 794, Appl
C 298	12.8	5.1	17	1	US-09-745-237A-984	Sequence 984, Appl	C 371	12.4	4.9	17	1	US-09-745-237A-1574	Sequence 1574, Appl
C 299	12.8	5.1	17	1	US-09-817-879-1800	Sequence 1800, Appl	372	12.4	4.9	17	1	US-09-817-879-3137	Sequence 3137, Appl
C 300	12.8	5.1	17	1	US-09-817-879-1944	Sequence 1944, Appl	373	12.4	4.9	17	1	US-09-817-879-3138	Sequence 3138, Appl
C 301	12.8	5.1	17	1	US-09-817-879-2217	Sequence 2217, Appl	374	12.4	4.9	17	1	US-10-156-306-4918	Sequence 4918, Appl
C 302	12.8	5.1	17	1	US-09-817-879-2338	Sequence 2338, Appl	375	12.4	4.9	17	1	US-10-156-306-4919	Sequence 4919, Appl
C 303	12.8	5.1	17	1	US-09-817-879-2755	Sequence 2755, Appl	376	12.4	4.9	17	1	US-10-156-306-5857	Sequence 5857, Appl
C 304	12.8	5.1	17	1	US-10-060-756A-1817	Sequence 1817, Appl	377	12.4	4.9	17	1	US-10-156-306-5858	Sequence 5858, Appl
C 305	12.8	5.1	17	1	US-10-060-756A-1818	Sequence 1818, Appl	378	12.4	4.9	17	1	US-10-675-685-1717	Sequence 1717, Appl
C 306	12.8	5.1	17	1	US-10-060-756A-1820	Sequence 1820, Appl	C 379	12.4	4.9	17	1	US-10-675-685-1718	Sequence 1718, Appl
C 307	12.8	5.1	17	1	US-10-060-756A-1821	Sequence 1821, Appl	C 380	12.4	4.9	17	1	US-10-675-685-1719	Sequence 1719, Appl
C 308	12.8	5.1	17	1	US-10-163-552-222	Sequence 222, Appl	C 381	12.4	4.9	17	1	US-10-675-685-1720	Sequence 1720, Appl
309	12.8	5.1	17	1	US-10-163-552-652	Sequence 652, Appl	C 382	12.4	4.9	17	1	US-10-723-361-8308	Sequence 8308, Appl
C 310	12.8	5.1	17	1	US-10-430-882-515	Sequence 515, Appl	383	12.4	4.9	17	1	US-10-138-674-1609	Sequence 1609, Appl
C 311	12.8	5.1	17	1	US-10-430-882-1014	Sequence 1014, Appl	384	12.4	4.9	17	1	US-10-287-949A-1609	Sequence 1609, Appl
C 312	12.8	5.1	17	1	US-10-138-674-3061	Sequence 3061, Appl	385	12.4	4.9	17	1	US-10-669-841-5731	Sequence 5731, Appl
C 313	12.8	5.1	17	1	US-10-138-674-6458	Sequence 6458, Appl	386	12.4	4.9	17	1	US-10-669-841-5731	Sequence 5731, Appl
C 314	12.8	5.1	17	1	US-10-138-674-8537	Sequence 8537, Appl	387	12.4	4.9	17	1	US-10-723-361-8308	Sequence 8308, Appl
C 315	12.8	5.1	17	1	US-10-138-674-8734	Sequence 8734, Appl	C 388	12.4	4.9	17	1	US-10-723-361-8309	Sequence 8309, Appl
C 316	12.8	5.1	17	1	US-10-287-949A-3061	Sequence 3061, Appl	C 389	12.4	4.9	17	1	US-10-723-361-8310	Sequence 8310, Appl
C 317	12.8	5.1	17	1	US-10-287-949A-6458	Sequence 6458, Appl	C 390	12.4	4.9	17	1	US-10-723-361-8311	Sequence 8311, Appl
C 318	12.8	5.1	17	1	US-10-287-949A-8537	Sequence 8537, Appl	C 391	12.4	4.9	17	1	US-10-723-361-8312	Sequence 8312, Appl
C 319	12.8	5.1	17	1	US-10-287-949A-8734	Sequence 8734, Appl	392	12.4	4.9	17	1	US-10-723-361-8776	Sequence 8776, Appl
C 320	12.8	5.1	17	1	US-10-712-672-369	Sequence 369, Appl	393	12.4	4.9	17	1	US-10-723-361-8777	Sequence 8777, Appl
321	12.8	5.1	17	1	US-10-712-672-1263	Sequence 1263, Appl	394	12.4	4.9	17	1	US-10-723-361-8778	Sequence 8778, Appl
C 322	12.8	5.1	17	1	US-10-712-672-1980	Sequence 1980, Appl	395	12.4	4.9	17	1	US-10-723-361-8779	Sequence 8779, Appl
C 323	12.8	5.1	17	1	US-10-669-841-4393	Sequence 4393, Appl	C 396	12.2	4.8	17	1	US-09-866-108-8648	Sequence 8648, Appl
C 324	12.8	5.1	17	1	US-10-669-841-4537	Sequence 4537, Appl	C 397	12.2	4.8	17	1	US-10-723-361-8648	Sequence 8648, Appl
325	12.8	5.1	17	1	US-10-669-841-4810	Sequence 4810, Appl	C 398	12.2	4.8	17	1	US-09-866-108-1460	Sequence 1460, Appl

C 399	12.2	4.8	17	1	US-09-866-108-1959	Sequence 1959, Ap	472	12.2	4.8	17	1	US-10-084-839-952	Sequence 952, App
400	12.2	4.8	17	1	US-09-866-108-2588	Sequence 2588, Ap	C 473	12.2	4.8	17	1	US-10-430-882-226	Sequence 226, App
401	12.2	4.8	17	1	US-09-866-108-7525	Sequence 7525, Ap	C 474	12.2	4.8	17	1	US-10-430-882-890	Sequence 890, App
402	12.2	4.8	17	1	US-09-866-108-7795	Sequence 7795, Ap	C 475	12.2	4.8	17	1	US-10-430-882-891	Sequence 891, App
403	12.2	4.8	17	1	US-09-866-108-7796	Sequence 7796, Ap	C 476	12.2	4.8	17	1	US-10-430-882-956	Sequence 956, App
404	12.2	4.8	17	1	US-09-866-108-7799	Sequence 7799, Ap	C 477	12.2	4.8	17	1	US-10-430-882-979	Sequence 979, App
405	12.2	4.8	17	1	US-09-866-108-7840	Sequence 7840, Ap	C 478	12.2	4.8	17	1	US-10-430-882-980	Sequence 980, App
406	12.2	4.8	17	1	US-09-866-108-7841	Sequence 7841, Ap	C 479	12.2	4.8	17	1	US-10-430-882-981	Sequence 981, App
C 407	12.2	4.8	17	1	US-09-866-108-7920	Sequence 7920, Ap	C 480	12.2	4.8	17	1	US-10-209-787-3366	Sequence 3366, Ap
C 408	12.2	4.8	17	1	US-09-866-108-8433	Sequence 8433, Ap	C 481	12.2	4.8	17	1	US-10-209-787-3367	Sequence 3367, Ap
C 409	12.2	4.8	17	1	US-09-866-108-8434	Sequence 8434, Ap	C 482	12.2	4.8	17	1	US-10-307-005-1143	Sequence 1144, Ap
410	12.2	4.8	17	1	US-09-866-108-8504	Sequence 8504, Ap	C 483	12.2	4.8	17	1	US-10-307-005-1144	Sequence 1144, Ap
411	12.2	4.8	17	1	US-09-866-108-8506	Sequence 8506, Ap	C 484	12.2	4.8	17	1	US-10-307-005-1153	Sequence 1164, Ap
412	12.2	4.8	17	1	US-09-866-108-8650	Sequence 8650, Ap	C 485	12.2	4.8	17	1	US-10-307-005-1154	Sequence 1164, Ap
413	12.2	4.8	17	1	US-09-866-108-8651	Sequence 8651, Ap	C 486	12.2	4.8	17	1	US-10-261-185-3366	Sequence 3366, Ap
414	12.2	4.8	17	1	US-09-866-108-9231	Sequence 9231, Ap	C 487	12.2	4.8	17	1	US-10-261-185-3367	Sequence 3367, Ap
415	12.2	4.8	17	1	US-09-866-108-9232	Sequence 9232, Ap	C 488	12.2	4.8	17	1	US-10-138-674-5055	Sequence 5055, Ap
416	12.2	4.8	17	1	US-09-866-108-9233	Sequence 9233, Ap	C 489	12.2	4.8	17	1	US-10-138-674-6456	Sequence 6456, Ap
C 417	12.2	4.8	17	1	US-09-866-108-9543	Sequence 9543, Ap	C 490	12.2	4.8	17	1	US-10-138-674-6784	Sequence 6784, Ap
418	12.2	4.8	17	1	US-09-864-785-403	Sequence 403, App	C 491	12.2	4.8	17	1	US-10-138-674-7221	Sequence 7221, Ap
419	12.2	4.8	17	1	US-09-864-785-404	Sequence 404, App	C 492	12.2	4.8	17	1	US-10-138-674-9271	Sequence 9271, Ap
420	12.2	4.8	17	1	US-09-864-785-408	Sequence 408, App	C 493	12.2	4.8	17	1	US-10-676-154-5565	Sequence 5565, App
421	12.2	4.8	17	1	US-09-864-785-1593	Sequence 1593, App	C 494	12.2	4.8	17	1	US-10-287-949A-5955	Sequence 5955, Ap
C 422	12.2	4.8	17	1	US-09-818-875-5366	Sequence 3366, Ap	C 495	12.2	4.8	17	1	US-10-287-949A-6456	Sequence 6456, Ap
C 423	12.2	4.8	17	1	US-09-818-875-5367	Sequence 3367, Ap	C 496	12.2	4.8	17	1	US-10-287-949A-6784	Sequence 6784, Ap
C 424	12.2	4.8	17	1	US-09-780-533A-540	Sequence 540, App	C 497	12.2	4.8	17	1	US-10-287-949A-7221	Sequence 7221, Ap
C 425	12.2	4.8	17	1	US-09-780-533A-1652	Sequence 1652, App	C 498	12.2	4.8	17	1	US-10-287-949A-9271	Sequence 9271, Ap
426	12.2	4.8	17	1	US-09-780-533A-1790	Sequence 1790, Ap	C 499	12.2	4.8	17	1	US-10-712-672-1109	Sequence 1109, App
427	12.2	4.8	17	1	US-09-780-533A-1793	Sequence 1793, Ap	C 500	12.2	4.8	17	1	US-10-712-672-1110	Sequence 110, App
C 428	12.2	4.8	17	1	US-09-780-533A-2521	Sequence 2521, Ap	C 501	12.2	4.8	17	1	US-10-712-672-1144	Sequence 144, App
C 429	12.2	4.8	17	1	US-09-927-046-238	Sequence 238, App	C 502	12.2	4.8	17	1	US-10-712-672-838	Sequence 838, App
C 430	12.2	4.8	17	1	US-09-927-046-240	Sequence 240, App	C 503	12.2	4.8	17	1	US-10-712-672-881	Sequence 881, App
431	12.2	4.8	17	1	US-09-848-754A-1285	Sequence 1285, Ap	C 504	12.2	4.8	17	1	US-10-712-672-1211	Sequence 1281, Ap
432	12.2	4.8	17	1	US-09-848-754A-428	Sequence 428, App	C 505	12.2	4.8	17	1	US-10-712-672-2106	Sequence 2106, Ap
C 433	12.2	4.8	17	1	US-09-848-754A-885	Sequence 885, App	C 506	12.2	4.8	17	1	US-10-659-841-5896	Sequence 5896, Ap
C 434	12.2	4.8	17	1	US-09-848-754A-886	Sequence 886, App	C 507	12.2	4.8	17	1	US-10-723-361-1460	Sequence 1460, Ap
C 435	12.2	4.8	17	1	US-09-848-754A-1033	Sequence 1033, App	C 508	12.2	4.8	17	1	US-10-723-361-1959	Sequence 1959, Ap
C 436	12.2	4.8	17	1	US-09-848-754A-1036	Sequence 1036, App	C 509	12.2	4.8	17	1	US-10-723-361-2588	Sequence 2588, Ap
437	12.2	4.8	17	1	US-09-848-754A-1214	Sequence 1214, Ap	C 510	12.2	4.8	17	1	US-10-723-361-7525	Sequence 7525, Ap
C 438	12.2	4.8	17	1	US-09-848-754A-2032	Sequence 2032, Ap	C 511	12.2	4.8	17	1	US-10-723-361-7795	Sequence 7795, Ap
C 439	12.2	4.8	17	1	US-09-848-754A-2244	Sequence 2244, Ap	C 512	12.2	4.8	17	1	US-10-723-361-7796	Sequence 7796, Ap
C 440	12.2	4.8	17	1	US-09-930-423-825	Sequence 825, App	C 513	12.2	4.8	17	1	US-10-723-361-7799	Sequence 7799, Ap
C 441	12.2	4.8	17	1	US-09-930-423-1271	Sequence 1271, Ap	C 514	12.2	4.8	17	1	US-10-723-361-7840	Sequence 7840, Ap
442	12.2	4.8	17	1	US-09-864-636A-209	Sequence 209, App	C 515	12.2	4.8	17	1	US-10-723-361-7841	Sequence 7841, Ap
443	12.2	4.8	17	1	US-09-864-636A-952	Sequence 952, App	C 516	12.2	4.8	17	1	US-10-723-361-7930	Sequence 7930, Ap
444	12.2	4.8	17	1	US-09-864-636A-952	Sequence 952, App	C 517	12.2	4.8	17	1	US-10-723-361-8433	Sequence 8433, Ap
C 445	12.2	4.8	17	1	US-09-827-395A-226	Sequence 226, App	C 518	12.2	4.8	17	1	US-10-723-361-8434	Sequence 8434, Ap
C 446	12.2	4.8	17	1	US-09-827-395A-890	Sequence 890, App	C 519	12.2	4.8	17	1	US-10-723-361-8504	Sequence 8504, Ap
C 447	12.2	4.8	17	1	US-09-827-395A-891	Sequence 891, App	C 520	12.2	4.8	17	1	US-10-723-361-8506	Sequence 8506, Ap
448	12.2	4.8	17	1	US-09-827-395A-956	Sequence 956, App	C 521	12.2	4.8	17	1	US-10-723-361-8650	Sequence 8650, Ap
C 449	12.2	4.8	17	1	US-09-827-395A-979	Sequence 979, App	C 522	12.2	4.8	17	1	US-10-723-361-8651	Sequence 8651, Ap
C 450	12.2	4.8	17	1	US-09-827-395A-980	Sequence 980, App	C 523	12.2	4.8	17	1	US-10-723-361-9231	Sequence 9231, Ap
C 451	12.2	4.8	17	1	US-09-827-395A-981	Sequence 981, App	C 524	12.2	4.8	17	1	US-10-723-361-9232	Sequence 9232, Ap
452	12.2	4.8	17	1	US-09-740-332-5303	Sequence 3303, App	C 525	12.2	4.8	17	1	US-10-723-361-9233	Sequence 9233, Ap
453	12.2	4.8	17	1	US-09-792-818-360	Sequence 360, App	C 526	12.2	4.8	17	1	US-10-723-361-9543	Sequence 9543, Ap
C 454	12.2	4.8	17	1	US-09-792-818-383	Sequence 383, App	C 527	12.2	4.8	17	1	US-10-681-074-3366	Sequence 3366, Ap
C 455	12.2	4.8	17	1	US-09-792-818-524	Sequence 524, App	C 528	12.2	4.8	17	1	US-10-681-074-3367	Sequence 3367, Ap
C 456	12.2	4.8	17	1	US-09-745-237A-225	Sequence 225, App	C 529	12.2	4.8	17	1	US-10-712-633-92	Sequence 92, App1
C 457	12.2	4.8	17	1	US-09-745-237A-1271	Sequence 1271, Ap	C 530	12.2	4.8	17	1	US-10-712-633-3876	Sequence 3876, Ap
458	12.2	4.8	17	1	US-09-817-879-5303	Sequence 5303, App	C 531	12.2	4.8	17	1	US-10-712-633-4542	Sequence 4542, Ap
459	12.2	4.8	17	1	US-09-864-426A-209	Sequence 209, App	C 532	12	4.8	15	1	US-09-907-111-21	Sequence 21, App1
460	12.2	4.8	17	1	US-09-864-426A-926	Sequence 926, App	C 533	12	4.8	15	1	US-09-880-313A-236	Sequence 236, App1
461	12.2	4.8	17	1	US-10-060-756A-774	Sequence 774, App	C 534	12	4.8	15	1	US-10-056-414-16	Sequence 16, App1
462	12.2	4.8	17	1	US-10-060-756A-916	Sequence 916, App	C 535	12	4.8	15	1	US-10-160-358-61	Sequence 61, App1
C 463	12.2	4.8	17	1	US-10-060-756A-1819	Sequence 1819, App	C 536	12	4.8	16	1	US-10-339-674-149	Sequence 149, App
C 464	12.2	4.8	17	1	US-10-060-998-1378	Sequence 1378, App	C 537	12	4.8	16	1	US-10-339-674-296	Sequence 2906, Ap
C 465	12.2	4.8	17	1	US-10-156-306-1358	Sequence 1358, Ap	C 538	12	4.8	17	1	US-09-866-108-8774	Sequence 8774, Ap
466	12.2	4.8	17	1	US-10-156-306-1672	Sequence 1672, Ap	C 539	12	4.8	17	1	US-09-866-108-8775	Sequence 8775, Ap
C 467	12.2	4.8	17	1	US-10-156-306-1672	Sequence 1672, Ap	C 540	12	4.8	17	1	US-09-866-108-9226	Sequence 9226, Ap
C 468	12.2	4.8	17	1	US-10-061-201-489	Sequence 489, App	C 541	12	4.8	17	1	US-09-866-108-9227	Sequence 9227, Ap
469	12.2	4.8	17	1	US-10-084-839-209	Sequence 209, App	C 542	12	4.8	17	1	US-09-866-108-9228	Sequence 9228, Ap
470	12.2	4.8	17	1	US-10-084-839-209	Sequence 209, App	C 543	12	4.8	17	1	US-09-866-108-9229	Sequence 9229, Ap
471	12.2	4.8	17	1	US-10-084-839-926	Sequence 926, App	C 544	12	4.8	17	1	US-09-866-108-9230	Sequence 9230, Ap

545	12	4.8	17	1	US-09-866-108-10730
546	12	4.8	17	1	US-09-866-108-10731
547	12	4.8	17	1	US-09-866-108-10732
548	12	4.8	17	1	US-09-866-108-10733
549	12	4.8	17	1	US-09-866-108-10734
550	12	4.8	17	1	US-09-866-108-10735
551	12	4.8	17	1	US-09-825-805-762
552	12	4.8	17	1	US-10-163-552-615
553	12	4.8	17	1	US-10-339-782-325
554	12	4.8	17	1	US-10-712-672-2703
555	12	4.8	17	1	US-10-723-361-8774
556	12	4.8	17	1	US-10-723-361-8775
557	12	4.8	17	1	US-10-723-361-9226
558	12	4.8	17	1	US-10-723-361-9227
559	12	4.8	17	1	US-10-723-361-9228
560	12	4.8	17	1	US-10-723-361-9229
561	12	4.8	17	1	US-10-723-361-9230
562	12	4.8	17	1	US-10-723-361-10730
563	12	4.8	17	1	US-10-723-361-10731
564	12	4.8	17	1	US-10-723-361-10732
565	12	4.8	17	1	US-10-723-361-10733
566	12	4.8	17	1	US-10-723-361-10734
567	12	4.8	20	1	US-09-993-731-82
568	12	4.8	20	1	US-09-504-231A-1009
569	12	4.7	15	1	US-09-504-231A-1127
570	11.8	4.7	15	1	US-09-813-289-13
571	11.8	4.7	15	1	US-09-813-289-13
572	11.8	4.7	15	1	US-09-274-553D-1127
573	11.8	4.7	15	1	US-09-274-553D-1127
574	11.8	4.7	15	1	US-09-274-553D-1127
575	11.8	4.7	15	1	US-09-825-805-164
576	11.8	4.7	15	1	US-09-825-805-164
577	11.8	4.7	15	1	US-09-825-805-164
578	11.8	4.7	15	1	US-09-825-805-164
579	11.8	4.7	15	1	US-09-880-313A-5
580	11.8	4.7	15	1	US-09-880-313A-247
581	11.8	4.7	15	1	US-09-740-332-4784
582	11.8	4.7	15	1	US-09-817-879-4784
583	11.8	4.7	15	1	US-10-056-414-23
584	11.8	4.7	15	1	US-10-056-414-40
585	11.8	4.7	15	1	US-10-056-414-192
586	11.8	4.7	15	1	US-10-215-432-12
587	11.8	4.7	15	1	US-10-440-850-822
588	11.8	4.7	15	1	US-10-418-182-198
589	11.8	4.7	15	1	US-10-395-031-4
590	11.8	4.7	15	1	US-10-255-120-36
591	11.8	4.7	15	1	US-10-255-120-151
592	11.8	4.7	15	1	US-10-669-841-7381
593	11.8	4.7	15	1	US-09-898-570-50
594	11.8	4.7	15	1	US-09-778-013-47
595	11.8	4.7	15	1	US-09-740-332-9646
596	11.8	4.7	15	1	US-09-817-879-9646
597	11.8	4.7	15	1	US-09-930-512-110
598	11.8	4.7	15	1	US-10-056-414-815
599	11.8	4.7	15	1	US-10-297-068-403
600	11.8	4.7	15	1	US-10-138-674-5669
601	11.8	4.7	15	1	US-10-138-674-7077
602	11.8	4.7	15	1	US-10-138-674-7112
603	11.8	4.7	15	1	US-10-287-949A-5669
604	11.8	4.7	15	1	US-10-287-949A-7077
605	11.8	4.7	15	1	US-10-287-949A-7112
606	11.8	4.7	15	1	US-10-668-841-7397
607	11.8	4.7	15	1	US-10-793-677-27
608	11.6	4.6	15	1	US-10-604-944-53
609	11.4	4.5	15	1	US-09-993-731-53
610	11.4	4.5	15	1	US-09-504-231A-1130
611	11.4	4.5	15	1	US-09-274-553D-1130
612	11.4	4.5	15	1	US-09-866-784-31
613	11.4	4.5	15	1	US-09-835-371-8
614	11.4	4.5	15	1	US-09-907-111-19
615	11.4	4.5	15	1	US-09-835-370-8
616	11.4	4.5	15	1	US-09-880-313A-211
617	11.4	4.5	15	1	US-09-880-313A-217
			15	1	US-09-880-313A-223

Sequence 10730, A
Sequence 10731, A
Sequence 10732, A
Sequence 10733, A
Sequence 10734, A
Sequence 10735, A
Sequence 762, App
Sequence 615, App
Sequence 325, App
Sequence 2703, App
Sequence 8775, App
Sequence 9226, App
Sequence 9227, App
Sequence 9228, App
Sequence 9229, App
Sequence 9230, App
Sequence 10730, A
Sequence 10731, A
Sequence 10732, A
Sequence 10733, A
Sequence 10734, A
Sequence 10735, A
Sequence 82, App1
Sequence 1009, App
Sequence 1127, App
Sequence 1252, App
Sequence 164, App
Sequence 21, App1
Sequence 247, App
Sequence 4784, App
Sequence 4784, App
Sequence 23, App1
Sequence 40, App1
Sequence 192, App
Sequence 12, App1
Sequence 822, App
Sequence 199, App
Sequence 36, App1
Sequence 47, App1
Sequence 9646, App
Sequence 9646, App
Sequence 110, App
Sequence 815, App
Sequence 403, App
Sequence 5669, App
Sequence 7077, App
Sequence 7397, App
Sequence 27, App1
Sequence 63, App1
Sequence 53, App1
Sequence 1130, App
Sequence 1130, App
Sequence 8, App1
Sequence 19, App1
Sequence 8, App1
Sequence 21, App
Sequence 217, App
Sequence 223, App

618. 11.4 4.5 15 1 US-09-880-313A-229
619 11.4 4.5 15 1 US-09-880-313A-271
620 11.4 4.5 15 1 US-10-100-679-22
621 11.4 4.5 15 1 US-10-010-802-11
622 11.4 4.5 15 1 US-10-241-780-101
623 11.4 4.5 15 1 US-10-607-752-22
624 11.4 4.5 15 1 US-09-880-313A-238
625 11.4 4.5 15 1 US-09-880-313A-267
626 11.4 4.5 15 1 US-10-241-780-166
627 11.4 4.5 15 1 US-10-317-832-145
628 11.4 4.5 15 1 US-10-712-672-1580
629 11.4 4.5 15 1 US-10-741-601-26228
630 11.4 4.5 15 1 US-10-723-878-145
631 11.2 4.4 15 1 US-09-811-045A-3
632 11.2 4.4 15 1 US-09-829-855-47
633 11.2 4.4 15 1 US-09-829-855-131
634 11.2 4.4 15 1 US-09-726-084-89
635 11.2 4.4 15 1 US-09-823-947-31
636 11.2 4.4 15 1 US-10-146-058-39
637 11.2 4.4 15 1 US-10-043-875-125
638 11.2 4.4 15 1 US-10-043-875-217
639 11.2 4.4 15 1 US-10-331-907-443
640 11.2 4.4 15 1 US-10-339-674-1755
641 11.2 4.4 15 1 US-10-307-928A-36
642 11.2 4.4 15 1 US-10-407-807-5
643 11.2 4.4 15 1 US-10-712-672-1454
644 11.2 4.4 15 1 US-10-607-077A-47
645 11.2 4.4 15 1 US-10-607-077A-131
646 11.2 4.4 15 1 US-10-730-488-89

ALIGNMENTS

RESULT 1
US-09-993-731-50/c
Sequence 50, Application US/09993731
Publication No. US20030105040A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
FILE REFERENCE: RFS-0302
CURRENT APPLICATION NUMBER: US/09/993,731
CURRENT FILING DATE: 2001-11-13
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 50
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-50

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Db 20 CTGGGCTCCGAGACCTGT 1201
CTGGGCTCCGAGACCTGT 1201
RESULT 2
US-09-993-731-51/c
Sequence 51, Application US/09993731
Publication No. US20030105040A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
FILE REFERENCE: RFS-0302
CURRENT APPLICATION NUMBER: US/09/993,731

```
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-51
```

```
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1194 AAGCTGTGACGAGGCGAGC 1213
Db 20 AAGCTGTGACGAGGCGAGC 1
```

```
RESULT 3
US-09-993-731-52/C
; Sequence 52, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-52
```

```
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1213 CCATCTGTGACGAGCTCCAG 1232
Db 20 CCATCTGTGACGAGCTCCAG 1
```

```
RESULT 4
US-09-993-731-53/C
; Sequence 53, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-53
```

```
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1223 GAACCTCCAGCATGTGCTGG 1242
```

```
Db 20 GAACCTCCAGCATGTGCTGG 1
```

```
RESULT 5
US-09-993-731-54/C
; Sequence 54, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-54
```

```
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1234 ATGTGCTGGCAGTGTCCGG 1253
Db 20 ATGTGCTGGCAGTGTCCGG 1
```

```
RESULT 6
US-09-993-731-55/C
; Sequence 55, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-55
```

```
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1238 GCTGCGAGTGTCCGGCTGC 1257
Db 20 GCTGCGAGTGTCCGGCTGC 1
```

```
RESULT 7
US-09-993-731-56/C
; Sequence 56, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
```

; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-56

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1258 AGCAACAGCTGGAGAGGCT 1277
|||
Db 20 AGCAACAGCTGGAGAGGCT 1

RESULT 8
US-09-993-731-57/c

; Sequence 57, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION

; FILE REFERENCE: RTS-0302

; CURRENT APPLICATION NUMBER: US/09/993,731

; CURRENT FILING DATE: 2001-11-13

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 57

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-57

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1289 CCCTCAGGTCGTCATGTCA 1308
|||
Db 20 CCCTCAGGTCGTCATGTCA 1

RESULT 9
US-09-993-731-58/c

; Sequence 58, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION

; FILE REFERENCE: RTS-0302

; CURRENT APPLICATION NUMBER: US/09/993,731

; CURRENT FILING DATE: 2001-11-13

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 58

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-58

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1297 GTGCCATGTCATCTGTGAG 1316
|||

Db 20 GTGCCATGTCATCTGTGAG 1

RESULT 10
US-09-993-731-59/c

; Sequence 59, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION

; FILE REFERENCE: RTS-0302

; CURRENT APPLICATION NUMBER: US/09/993,731

; CURRENT FILING DATE: 2001-11-13

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 59

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-59

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1300 CCATGTCATCTGTGAGCAG 1319
|||
Db 20 CCATGTCATCTGTGAGCAG 1

RESULT 11
US-09-993-731-60/c

; Sequence 60, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION

; FILE REFERENCE: RTS-0302

; CURRENT APPLICATION NUMBER: US/09/993,731

; CURRENT FILING DATE: 2001-11-13

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 60

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-60

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1310 CTGTGACGACTGGGAGCC 1329
|||
Db 20 CTGTGACGACTGGGAGCC 1

RESULT 12
US-09-993-731-61/c

; Sequence 61, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION

; FILE REFERENCE: RTS-0302

; CURRENT APPLICATION NUMBER: US/09/993,731

; CURRENT FILING DATE: 2001-11-13

; NUMBER OF SEQ ID NOS: 89

```
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-61
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1323 GGGGACCTCTTCCAGGC 1342
Db 20 GGGGACCTCTTCCAGGC 1
```

```
RESULT 13
US-09-993-731-62/c
; Sequence 62, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-62
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1328 CCTCTTCTCCAGGCAGAG 1347
Db 20 CCTCTTCTCCAGGCAGAG 1
```

```
RESULT 14
US-09-993-731-63/c
; Sequence 63, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-63
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1342 CAGGAGCTTTCCAGGCA 1361
Db 20 CAGGAGCTTTCCAGGCA 1
```

```
RESULT 15
US-09-993-731-64/c
; Sequence 64, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-64
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1347 GACTTCCAGGCGAGCTGA 1366
Db 20 GACTTCCAGGCGAGCTGA 1
```

```
RESULT 16
US-09-993-731-65/c
; Sequence 65, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-65
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1373 CCAGAGCAGCTGCGTTTG 1392
Db 20 CCAGAGCAGCTGCGTTTG 1
```

```
RESULT 17
US-09-993-731-66/c
; Sequence 66, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 66
```

LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-66

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGACAGACC 1411
DB 20 GCTGAGCTGCTGACAGACC 1

RESULT 18
US-09-993-731-67/c
Sequence 67, Application US/09993731
Publication No. US20030105040A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Andrew T. Walt
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
FILE REFERENCE: RTS-0302
CURRENT APPLICATION NUMBER: US/09/993,731
CURRENT FILING DATE: 2001-11-13
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 67
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-67

Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1414 GTGCTGAGCGGGCCATCATC 1433
DB 20 GTGCTGAGCGGGCCATCATC 1

RESULT 19
US-10-098-263B-36118
Sequence 36118, Application US/10098263B
Publication No. US20030104410A1
GENERAL INFORMATION:
APPLICANT: Miltman, Michael
TITLE OF INVENTION: Human Microarray
FILE REFERENCE: 3118.1
CURRENT APPLICATION NUMBER: US/10/098,263B
CURRENT FILING DATE: 2003-01-08
PRIOR APPLICATION NUMBER: 60/276,759
PRIOR FILING DATE: 2001-03-16
NUMBER OF SEQ ID NOS: 131066
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 36118
LENGTH: 25
TYPE: DNA
ORGANISM: Homo sapiens
US-10-098-263B-36118

Query Match 7.4%; Score 18.6; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 71;
Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1393 CTGAGCTGCTGACAGACCGGGTGC 1417
DB 1 CGGAGCTCTAGACAGACCGGGTGC 25

RESULT 20
US-09-935-998A-70
Sequence 70, Application US/09935998A
Publication No. US20040197775A1
GENERAL INFORMATION:
APPLICANT: Genetic Technologies
APPLICANT: Simons, Malcolm J.
TITLE OF INVENTION: Intron Sequence Analysis Method for Detection of Adjacent and Remote
FILE REFERENCE: 005493.P001
CURRENT APPLICATION NUMBER: US/09/935,998A
CURRENT FILING DATE: 2001-08-23
PRIOR APPLICATION NUMBER: US 07/949,652
PRIOR FILING DATE: 1992-09-23
PRIOR APPLICATION NUMBER: US 07/551,239
PRIOR FILING DATE: 1990-07-11
PRIOR APPLICATION NUMBER: US 07/465,863
PRIOR FILING DATE: 1990-01-16
PRIOR APPLICATION NUMBER: US 07/405,499
PRIOR FILING DATE: 1989-09-11
PRIOR APPLICATION NUMBER: US 07/398,217
PRIOR FILING DATE: 1989-08-25
SOFTWARE: PatentIn version 3.1
SEQ ID NO 70
LENGTH: 23
TYPE: DNA
ORGANISM: Homo sapiens
US-09-935-998A-70

Query Match 7.3%; Score 18.4; DB 1; Length 23;
Best Local Similarity 95.0%; Pred. No. 60;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1274 GGCTGAGCGCAGACCCCTC 1293
DB 2 GGCTGAGCGCAGACCCCTC 21

RESULT 21
US-10-005-626A-70
Sequence 70, Application US/10005626A
Publication No. US20030119003A1
GENERAL INFORMATION:
APPLICANT: Genentype A.G.
APPLICANT: Michael, Simons J.
TITLE OF INVENTION: Intron Sequence Analysis Method for Detection of Adjacent and Remote
FILE REFERENCE: 21401-7002
CURRENT APPLICATION NUMBER: US/10/005,626A
CURRENT FILING DATE: 2001-12-03
PRIOR APPLICATION NUMBER: US 10/005,626
PRIOR FILING DATE: 2001-12-03
PRIOR APPLICATION NUMBER: US 09/070,497
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: US 08/682,054
PRIOR FILING DATE: 1996-07-16
PRIOR APPLICATION NUMBER: US 07/949,652
PRIOR FILING DATE: 1992-09-23
PRIOR APPLICATION NUMBER: US 07/551,239
PRIOR FILING DATE: 1990-07-11
PRIOR APPLICATION NUMBER: US 07/465,863
PRIOR FILING DATE: 1990-01-16
PRIOR APPLICATION NUMBER: US 07/405,499
PRIOR FILING DATE: 1989-09-11
PRIOR APPLICATION NUMBER: US 07/398,217
PRIOR FILING DATE: 1989-08-25
NUMBER OF SEQ ID NOS: 78
SOFTWARE: PatentIn version 3.1
SEQ ID NO 70
LENGTH: 23
TYPE: DNA

```
; ORGANISM: Homo sapiens
; US-10-005-626A-70

Query Match
Best Local Similarity 7.3%; Score 18.4; DB 1; Length 23;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1274 GCGTGAAGGAGAGAGCCCTC 1293
Db 2 GCGTGAAGGAGAGAGACTCTC 21

RESULT 22
US-10-199-199-70/c
; Sequence 70, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0375
; CURRENT APPLICATION NUMBER: US/10/199,199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-199-199-70

Query Match
Best Local Similarity 6.5%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1251 CGGCTGAGAGAGAGCTG 1268
Db 19 CGGCTGAGAGAGAGCTG 2

RESULT 23
US-10-199-199-135
; Sequence 135, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0375
; CURRENT APPLICATION NUMBER: US/10/199,199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; US-10-199-199-135

Query Match
Best Local Similarity 6.5%; Score 16.4; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1251 CGGCTGAGAGAGAGCTG 1268
Db 2 CGGCTGAGAGAGAGCTG 19

RESULT 24
US-10-005-956-417
; Sequence 417, Application US/10005956
; Publication No. US20030113726A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 417
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-005-956-417

Query Match
Best Local Similarity 6.4%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1186 GCTCCAGAGAGCTGTGACGA 1206
Db 1 GCTCCAGAGAGCTGTGACGA 21

RESULT 25
US-10-005-956-418
; Sequence 418, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 418
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-005-956-418

Query Match
Best Local Similarity 6.4%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1186 GCTCCAGAGAGCTGTGACGA 1206
Db 1 GCTCCAGAGAGCTGTGACGA 21

RESULT 26
US-10-005-956-419
; Sequence 419, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
```

;; PRIOR FILING DATE: 2000-12-04
;; PRIOR APPLICATION NUMBER: 60/263,678
;; PRIOR FILING DATE: 2001-01-23
;; PRIOR APPLICATION NUMBER: 60/273,037
;; PRIOR FILING DATE: 2001-03-02
;; NUMBER OF SEQ ID NOS: 1579
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 419
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: homo sapiens
US-10-005-956-419

Query Match 6.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1186 GCTCCAGAGCCGTGCGAGA 1206
DB 1 GCTCTCAGAGCCAGTTCAGA 21

RESULT 27
US-10-005-956-420
;; Sequence 420, Application US/10005956
;; Publication No. US20030113726A1
;; GENERAL INFORMATION:
;; APPLICANT: Bristol-Myers Squibb Company
;; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
;; FILE REFERENCE: D0053NP
;; CURRENT APPLICATION NUMBER: US/10/005,956
;; PRIOR FILING DATE: 2001-12-03
;; PRIOR APPLICATION NUMBER: 60/251,015
;; PRIOR FILING DATE: 2000-12-04
;; PRIOR APPLICATION NUMBER: 60/263,678
;; PRIOR FILING DATE: 2001-01-23
;; PRIOR APPLICATION NUMBER: 60/273,037
;; PRIOR FILING DATE: 2001-03-02
;; NUMBER OF SEQ ID NOS: 1579
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 420
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: homo sapiens
US-10-005-956-420

Query Match 6.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1186 GCTCCAGAGCCGTGCGAGA 1206
DB 1 GCTCTCAGAGCCAGTTCAGA 21

RESULT 28
US-10-188-186-217/c
;; Sequence 217, Application US/10188186
;; Publication No. US20040029789A1
;; GENERAL INFORMATION:
;; APPLICANT: Anderson et al.
;; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
;; FILE REFERENCE: 21402-397C
;; CURRENT APPLICATION NUMBER: US/10/188,186
;; PRIOR FILING DATE: 2002-07-02
;; PRIOR APPLICATION NUMBER: 60/303046
;; PRIOR FILING DATE: 2001-07-05
;; PRIOR APPLICATION NUMBER: 60/360814
;; PRIOR FILING DATE: 2002-03-01
;; PRIOR APPLICATION NUMBER: 60/303828
;; PRIOR FILING DATE: 2001-09-07
;; PRIOR APPLICATION NUMBER: 60/323380
;; PRIOR FILING DATE: 2001-09-19

;; PRIOR APPLICATION NUMBER: 60/361133
;; PRIOR FILING DATE: 2002-03-01
;; PRIOR APPLICATION NUMBER: 60/304016
;; PRIOR FILING DATE: 2001-07-09
;; PRIOR APPLICATION NUMBER: 60/304502
;; PRIOR FILING DATE: 2001-07-11
;; PRIOR APPLICATION NUMBER: 60/305262
;; PRIOR FILING DATE: 2001-07-13
;; PRIOR APPLICATION NUMBER: 60/373881
;; PRIOR FILING DATE: 2002-04-19
;; PRIOR APPLICATION NUMBER: 60/305673
;; PRIOR FILING DATE: 2001-07-16
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 368
;; SOFTWARE: Cuscom
;; SEQ ID NO: 217
;; LENGTH: 22
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-188-186-217

Query Match 6.4%; Score 16.2; DB 1; Length 22;
Best Local Similarity 85.7%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1192 AGAAGCTGTGCGAGGCGAG 1212
DB 22 AGAAGCTGTGCGAGGCGAG 2

RESULT 29
US-09-935-464-38
;; Sequence 38, Application US/09935464
;; Publication No. US20030027153A1
;; GENERAL INFORMATION:
;; APPLICANT: Meyer, Joanne
;; APPLICANT: Barrington-Martin, Rory
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING NEUROPSYCHIA
;; FILE REFERENCE: 3322/1H702 US1
;; CURRENT APPLICATION NUMBER: US/09/935,464
;; PRIOR FILING DATE: 2001-08-23
;; PRIOR APPLICATION NUMBER: US 09/757,300
;; PRIOR FILING DATE: 2001-01-09
;; NUMBER OF SEQ ID NOS: 90
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 38
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-935-464-38

Query Match 6.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1327 ACCCTTCTCCAGGCGAG 1345
DB 1 ACCCTTCTCCAGGCGCTGG 19

RESULT 30
US-10-125-835-38
;; Sequence 38, Application US/10125835
;; Publication No. US20030092019A1
;; GENERAL INFORMATION:
;; APPLICANT: Meyer, Joanne
;; APPLICANT: Barrington-Martin, Rory
;; APPLICANT: Parker, Alexander
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING

```
; TITLE OF INVENTION: NEUROPSYCHIATRIC
; TITLE OF INVENTION: DISORDERS SUCH AS SCHIZOPHRENIA
; FILE REFERENCE: 3322/0H702 US0
; CURRENT APPLICATION NUMBER: US/10/125,835
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: US/09/757,300
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 38
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-125-835-38

Query Match
Best Local Similarity 6.3%; Score 15.8; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1327 ACCTCTTCTCCAGGCGAG 1345
Db 1 ACCTCTTCTCCAGGCGG 19

RESULT 31
US-09-866-108-929
; Sequence 929, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 929
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-929

Query Match
Best Local Similarity 6.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1264 AGCTGAAGAGGCTGAG 1280
Db 1 AGCTGAAGAGGCTGAG 17

RESULT 32
US-10-723-361-929
; Sequence 929, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 929
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-929

Query Match
Best Local Similarity 6.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1264 AGCTGAAGAGGCTGAG 1280
Db 1 AGCTGAAGAGGCTGAG 17

RESULT 33
US-09-854-883-313
; Sequence 313, Application US/09854883
; Patent No. US20020055479A1
; GENERAL INFORMATION:
```

APPLICANT: Lex M. Cowser
APPLICANT: Jacqueline Wyatt
APPLICANT: Susan M. Freier
APPLICANT: Brett P. Monia
APPLICANT: Madeline M. Butler
APPLICANT: Robert McKay
TITLE OF INVENTION: ANTISENSE MODULATION OF PTPIB EXPRESSION
FILE REFERENCE: ISPH-0576
CURRENT APPLICATION NUMBER: US/09/854,883
CURRENT FILING DATE: 2001-05-14
PRIOR APPLICATION NUMBER: US 09/629,644
PRIOR FILING DATE: 2000-07-31
PRIOR APPLICATION NUMBER: US 09/487,368
PRIOR FILING DATE: 2000-01-18
NUMBER OF SEQ ID NOS: 389
SEQ ID NO 313
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-854-883-313

Query Match 6.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1328 CCTCTTCTCCAGGAG 1344
DB 2 CCTCTTCTCCAGGAG 18

RESULT 34
US-10-360-510-313
Sequence 313, Application US/10360510
Publication No. US20030220282A1
GENERAL INFORMATION:
APPLICANT: Lex M. Cowser
APPLICANT: Jacqueline Wyatt
APPLICANT: Susan M. Freier
APPLICANT: Brett P. Monia
APPLICANT: Madeline M. Butler
APPLICANT: Robert McKay
TITLE OF INVENTION: ANTISENSE MODULATION OF PTPIB EXPRESSION
FILE REFERENCE: ISPH-0576
CURRENT APPLICATION NUMBER: US/10/360,510
CURRENT FILING DATE: 2003-02-07
PRIOR APPLICATION NUMBER: US/09/854,883
PRIOR FILING DATE: 2001-05-14
PRIOR APPLICATION NUMBER: US 09/629,644
PRIOR FILING DATE: 2000-07-31
PRIOR APPLICATION NUMBER: US 09/487,368
PRIOR FILING DATE: 2000-01-18
NUMBER OF SEQ ID NOS: 389
SEQ ID NO 313
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-313

Query Match 6.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1328 CCTCTTCTCCAGGAG 1344
DB 2 CCTCTTCTCCAGGAG 18

RESULT 35
US-10-470-673-34/C

Sequence 34, Application US/10470673
Publication No. US20040137556A1
GENERAL INFORMATION:
APPLICANT: Spagnoli, Roberto
APPLICANT: Achstetter, Tilmann
APPLICANT: Calet, Gilles
APPLICANT: Degryse, Eric
APPLICANT: Dumas, Bruno
APPLICANT: Bompou, Denis
APPLICANT: Winter, Jacques
TITLE OF INVENTION: Yeast strains autonomously producing steroids
FILE REFERENCE: 2544-US-PCT
CURRENT APPLICATION NUMBER: US/10/470,673
CURRENT FILING DATE: 2003-07-28
PRIOR APPLICATION NUMBER: FR 0101294
PRIOR FILING DATE: 2001-01-31
NUMBER OF SEQ ID NOS: 49
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 34
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide C17-5
US-10-470-673-34

Query Match 6.1%; Score 15.4; DB 1; Length 22;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1220 TCAGACCTCCAGATG 1236
DB 21 TCAGACCTCCAGATG 5

RESULT 36
US-09-969-852-11
Sequence 11, Application US/09969852
Patent No. US2002013721A1
GENERAL INFORMATION:
APPLICANT: Liu, Tianyan
APPLICANT: Liu, Huifen
APPLICANT: Li, Wei
APPLICANT: Zhao, Lipin
TITLE OF INVENTION: A METHOD FOR ESTABLISHING AN EXPRESSION SYSTEM OF SPIDER DRAGLINE
FILE REFERENCE: LIU=65
CURRENT APPLICATION NUMBER: US/09/969,852
CURRENT FILING DATE: 2001-10-04
PRIOR APPLICATION NUMBER: CN01106406.4
PRIOR FILING DATE: 2001-01-02
NUMBER OF SEQ ID NOS: 14
SOFTWARE: PatentIn version 3.1
SEQ ID NO 11
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-969-852-11

Query Match 6.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1253 GCTGACGACACGCTGAG 1272
DB 1 GCAGCAGCAGCAGCTGAG 20

RESULT 37
US-09-915-814-70/C
Sequence 70, Application US/09915814

```
; Publication No. US20030096771A1
; GENERAL INFORMATION:
; APPLICANT: Madeline M. Butler
; APPLICANT: Andrew T. Matc
; APPLICANT: Susan M. Freter
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF HORMONE-SENSITIVE LIPASE EXPRESSION
; FILE REFERENCE: ISPH-0587
; CURRENT APPLICATION NUMBER: US/09/915,814
; CURRENT FILING DATE: 2001-07-26
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-915-814-70

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1269 GAAGAGGCTGAGGCGCAGAGA 1288
Db 20 GAAGAGGCTGAGGCGCAAAA 1

RESULT 38
US-10-021-707-36/c
; Sequence 36, Application US/10021707
; Publication No. US20030186903A1
; GENERAL INFORMATION:
; APPLICANT: James Karas
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF MYD88 EXPRESSION
; FILE REFERENCE: RTS-0330
; CURRENT APPLICATION NUMBER: US/10/021,707
; CURRENT FILING DATE: 2001-11-23
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-021-707-36

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1258 AGCAGCGCTGGAGAGGCT 1277
Db 20 AGCAGCGCGAGGAGGCT 1

RESULT 39
US-10-673-063-36/c
; Sequence 36, Application US/10673063
; Publication No. US20040038926A1
; GENERAL INFORMATION:
; APPLICANT: James Karas
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF MYD88 EXPRESSION
; FILE REFERENCE: RTS-0330
; CURRENT APPLICATION NUMBER: US/10/673,063
; CURRENT FILING DATE: 2003-09-26
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-673-063-36

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1258 AGCAGCGCTGGAGAGGCT 1277
Db 20 AGCAGCGCGAGGAGGCT 1

RESULT 40
US-10-182-230-156
; Sequence 156, Application US/10182230
; Publication No. US20030215817A1
; GENERAL INFORMATION:
; APPLICANT: Leonardi, Amedeo
; APPLICANT: Sartani, Abraham
; APPLICANT: Glass, James R.
; APPLICANT: Sutcliffe, J. Gregor
; APPLICANT: Hasei, Karl W.
; TITLE OF INVENTION: Modulation of Gene Expression in Formation of Faty Atheroscleroti
; FILE REFERENCE: Lesions
; CURRENT APPLICATION NUMBER: US/10/182,230
; CURRENT FILING DATE: 2003-02-03
; PRIOR APPLICATION NUMBER: 60/177,963
; PRIOR FILING DATE: 2000-01-25
; NUMBER OF SEQ ID NOS: 197
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 156
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: RT-PCR 3' PCR primer for REG1
; US-10-182-230-156

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1256 GCAGCAAGCTGAGAGAGG 1275
Db 1 GCAGCAAGAGGAGAGAGG 20

RESULT 41
US-10-178-325-107/c
; Sequence 107, Application US/10178325
; Publication No. US2003019467A1
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsert, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; FILE REFERENCE: Expression
; CURRENT APPLICATION NUMBER: US/10/178,325
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/387,341
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 09/156,424
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,979
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,807
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/161,015
; PRIOR FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
```

```

; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 107
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-178-325-107

Query Match      5.9%; Score 14.8; DB 1; Length 18;
Best Local Similarly 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1251 CGGCTGACGACGACGCTG 1268
Db      18 CGGCTGACGACGCTG 1

RESULT 42
US-09-978-295A-21/C
; Sequence 21, Application US/0978295A
; Patent No. US20020156006A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Bacon, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Flavaro, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertlisen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C11
; CURRENT APPLICATION NUMBER: US/09/978,295A
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
```

```

; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080327
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080328
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080333
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080334
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/081070
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081049
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081071
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081195
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081952
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081838
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082568
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/082569
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/082704
```

;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15

;; PRIOR APPLICATION NUMBER: 60/085697
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCAACGCTGGAGA 1273
Db 18 GCAGCAACGCTGGATGA 1
RESULT 43
US-09-978-697-21/c
; Sequence 21, Application US/09978697
; Patent No. US20020169284A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Balton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630PIC27
; CURRENT APPLICATION NUMBER: US/09/978, 697
;; CURRENT FILING DATE: 2001-10-16
;; PRIOR APPLICATION NUMBER: 09/918585
;; PRIOR FILING DATE: 2001-07-30
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/064249
;; PRIOR FILING DATE: 1997-11-03
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/077450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/07791
;; PRIOR FILING DATE: 1998-03-12
;; PRIOR APPLICATION NUMBER: 60/078004
;; PRIOR FILING DATE: 1998-03-13
;; PRIOR APPLICATION NUMBER: 60/078886
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078936

PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22

PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCAACGCTGGAAGA 1273

Db 18 GCAGCACCAGCTGATGA 1

RESULT 44
US-09-978-192A-21/c

; Sequence 21, Application US/09978192A
; Patent No. US2002017553A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Baker Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Deenoyers, Luc

; APPLICANT: Eaton, Dan

; APPLICANT: Ferrara, Napoleon

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerltsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Kijavini, Ivar J.

; APPLICANT: Kuo, Sophia S.

; APPLICANT: Nadier, Mary A.

; APPLICANT: Pahl, James

; APPLICANT: Pahl, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Shelton, David L.

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2630P1c9

; CURRENT APPLICATION NUMBER: US/09/978,192A

; PRIOR APPLICATION NUMBER: 09/918585

; PRIOR FILING DATE: 2001-07-30

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/064249

; PRIOR FILING DATE: 1997-11-03

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066364

; PRIOR FILING DATE: 1997-11-21

; PRIOR APPLICATION NUMBER: 60/077450

; PRIOR FILING DATE: 1998-03-10

; PRIOR APPLICATION NUMBER: 60/077632

; PRIOR FILING DATE: 1998-03-11

; PRIOR APPLICATION NUMBER: 60/077641

; PRIOR FILING DATE: 1998-03-11

; PRIOR APPLICATION NUMBER: 60/077649

; PRIOR FILING DATE: 1998-03-11

; PRIOR APPLICATION NUMBER: 60/077791

; PRIOR FILING DATE: 1998-03-12

; PRIOR APPLICATION NUMBER: 60/078004

; PRIOR FILING DATE: 1998-03-13

; PRIOR APPLICATION NUMBER: 60/078886

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/078936

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/078939

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/079294

; PRIOR FILING DATE: 1998-03-25

; PRIOR APPLICATION NUMBER: 60/079656

; PRIOR FILING DATE: 1998-03-26

; PRIOR APPLICATION NUMBER: 60/079664

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/079689

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/079663

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/079728

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/079786

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/079920

; PRIOR FILING DATE: 1998-03-30

; PRIOR APPLICATION NUMBER: 60/079923

; PRIOR FILING DATE: 1998-03-30

; PRIOR APPLICATION NUMBER: 60/080105

; PRIOR FILING DATE: 1998-03-31

; PRIOR APPLICATION NUMBER: 60/080107

; PRIOR FILING DATE: 1998-03-31

; PRIOR APPLICATION NUMBER: 60/080165

; PRIOR FILING DATE: 1998-03-31

; PRIOR APPLICATION NUMBER: 60/080194

; PRIOR FILING DATE: 1998-03-31

; PRIOR APPLICATION NUMBER: 60/080327

; PRIOR FILING DATE: 1998-04-01

; PRIOR APPLICATION NUMBER: 60/080328

; PRIOR FILING DATE: 1998-04-01

; PRIOR APPLICATION NUMBER: 60/080333

; PRIOR FILING DATE: 1998-04-01

; PRIOR APPLICATION NUMBER: 60/080334

; PRIOR FILING DATE: 1998-04-01

; PRIOR APPLICATION NUMBER: 60/081070

; PRIOR FILING DATE: 1998-04-08

; PRIOR APPLICATION NUMBER: 60/081049

; PRIOR FILING DATE: 1998-04-08

; PRIOR APPLICATION NUMBER: 60/081071

; PRIOR FILING DATE: 1998-04-08

; PRIOR APPLICATION NUMBER: 60/081195

; PRIOR FILING DATE: 1998-04-08

; PRIOR APPLICATION NUMBER: 60/081203

; PRIOR FILING DATE: 1998-04-08

; PRIOR APPLICATION NUMBER: 60/081229

; PRIOR FILING DATE: 1998-04-09

; PRIOR APPLICATION NUMBER: 60/081955

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/081817

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/081819

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/081952

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/081838

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/082568

; PRIOR FILING DATE: 1998-04-21

; PRIOR APPLICATION NUMBER: 60/082569

; PRIOR FILING DATE: 1998-04-21

; PRIOR APPLICATION NUMBER: 60/082704

; PRIOR FILING DATE: 1998-04-22

; PRIOR APPLICATION NUMBER: 60/082804

; PRIOR FILING DATE: 1998-04-22

; PRIOR APPLICATION NUMBER: 60/082700

; PRIOR FILING DATE: 1998-04-22

; PRIOR APPLICATION NUMBER: 60/082797

; PRIOR FILING DATE: 1998-04-22

; PRIOR APPLICATION NUMBER: 60/082796

; PRIOR FILING DATE: 1998-04-23

; PRIOR APPLICATION NUMBER: 60/083336

; PRIOR FILING DATE: 1998-04-27

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/083392

PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CY 1256 GCACGACAGCTGAGAG 1273
DB 18 GCACGACAGCTGATGA 1

RESULT 45
US-09-999-832A-21/C
Sequence 21, Application US/09999832A

Publication No. US20020192706A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gertschen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gueney, Austen L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tuma, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630PIC63
CURRENT APPLICATION NUMBER: US/09/999, 832A
CURRENT FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663

;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079786
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079920
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/079923
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/080105
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080107
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29

;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACGCTGGAGA 1273
DB 18 GCAGCAACGCTGGATGA 1

RESULT 46
US-09-978-189-21/C
Sequence 21, Application US/09978189
Publication No. US20030004102A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan

APPLICANT: Ferrate, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerltsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Klyavin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C7
CURRENT APPLICATION NUMBER: US/09/978,189
PRIOR FILING DATE: 2001-10-15
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30

PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559

```

; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083500
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083742
; PRIOR FILING DATE: 1998-04-30
; PRIOR APPLICATION NUMBER: 60/084366
; PRIOR FILING DATE: 1998-05-05
; PRIOR APPLICATION NUMBER: 60/084414
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084639
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084640
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084598
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084643
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085582
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085700
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085689
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085580
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085573
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697

```

```

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1256 GCAGCAACAGCTGGAAGA 1273
DB      18 GCAGCACACGCTGATGA 1

```

RESULT 47

```

; Sequence 21, Application US/09978608A
; Publication No. US20030045462A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey

```

```

; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630PIC22
; CURRENT APPLICATION NUMBER: US/09/978,608A
; NUMBER OF SEQ ID NOS: 624
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-09-978-608A-21

```

```

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1256 GCAGCAACAGCTGGAAGA 1273
DB      18 GCAGCACACGCTGATGA 1

```

RESULT 48

```

; Sequence 21, Application US/09978585A
; Publication No. US20030049633A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same

```

```

; FILE REFERENCE: P2630P1C15
; CURRENT APPLICATION NUMBER: US/09/978,585A
; CURRENT FILING DATE: 2001-10-16
; NUMBER OF SEQ ID NOS: 624
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-09-978-585A-21

Query March 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCACAAGCTGGAGAG 1273
Db 18 GCAGCACCAGCTGGATGA 1

RESULT 49
US-09-978-191A-21/c
; Sequence 21, Application US/0978191A
; Publication No. US2003050239A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Batton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvarolf, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gettleisen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tuma, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C4
; CURRENT APPLICATION NUMBER: US/09/978,191A
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
```

```

; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080327
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080328
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080333
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080334
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/081070
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081049
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081071
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081195
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081952
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081838
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082568
```

;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15

;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGAGAGA 1273
Db 18 GCAGCAACAGCTGAGAGA 1

RESULT 50
US-09-978-403A-21/C
Sequence 21, Application US/09978403A
Publication No. US2003050240A1

GENERAL INFORMATION:

;; APPLICANT: Ashkenazi, Avi
;; APPLICANT: Baker Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan
;; APPLICANT: Ferrara, Napoleon
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerber, Hanspeter
;; APPLICANT: Gerltsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, J. Christopher
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Kijavlin, Ivar J.
;; APPLICANT: Kuo, Sophia S.
;; APPLICANT: Napier, Mary A.
;; APPLICANT: Pan, James;
;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Shelton, David L.
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2630PIC17
;; CURRENT APPLICATION NUMBER: US/09/978,403A
;; CURRENT FILING DATE: 2002-03-19
;; PRIOR APPLICATION NUMBER: 09/918585
;; PRIOR FILING DATE: 2001-07-30
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/064249
;; PRIOR FILING DATE: 1997-11-03
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/077450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; PRIOR FILING DATE: 1998-03-12
;; PRIOR APPLICATION NUMBER: 60/078004

PRIOR FILING DATE:	1998-03-13
PRIOR APPLICATION NUMBER:	60/0788866
PRIOR FILING DATE:	1998-03-20
PRIOR APPLICATION NUMBER:	60/0789366
PRIOR FILING DATE:	1998-03-20
PRIOR APPLICATION NUMBER:	60/0789100
PRIOR FILING DATE:	1998-03-20
PRIOR APPLICATION NUMBER:	60/0789339
PRIOR FILING DATE:	1998-03-20
PRIOR APPLICATION NUMBER:	60/0792994
PRIOR FILING DATE:	1998-03-25
PRIOR APPLICATION NUMBER:	60/0796555
PRIOR FILING DATE:	1998-03-26
PRIOR APPLICATION NUMBER:	60/0796666
PRIOR FILING DATE:	1998-03-27
PRIOR APPLICATION NUMBER:	60/0797282
PRIOR FILING DATE:	1998-03-27
PRIOR APPLICATION NUMBER:	60/0797866
PRIOR FILING DATE:	1998-03-27
PRIOR APPLICATION NUMBER:	60/0799200
PRIOR FILING DATE:	1998-03-30
PRIOR APPLICATION NUMBER:	60/0799222
PRIOR FILING DATE:	1998-03-30
PRIOR APPLICATION NUMBER:	60/0801050
PRIOR FILING DATE:	1998-03-31
PRIOR APPLICATION NUMBER:	60/0801340
PRIOR FILING DATE:	1998-03-31
PRIOR APPLICATION NUMBER:	60/0801655
PRIOR FILING DATE:	1998-03-31
PRIOR APPLICATION NUMBER:	60/0801940
PRIOR FILING DATE:	1998-03-31
PRIOR APPLICATION NUMBER:	60/0803270
PRIOR FILING DATE:	1998-04-01
PRIOR APPLICATION NUMBER:	60/0803280
PRIOR FILING DATE:	1998-04-01
PRIOR APPLICATION NUMBER:	60/0803330
PRIOR FILING DATE:	1998-04-01
PRIOR APPLICATION NUMBER:	60/0803340
PRIOR FILING DATE:	1998-04-01
PRIOR APPLICATION NUMBER:	60/0810700
PRIOR FILING DATE:	1998-04-08
PRIOR APPLICATION NUMBER:	60/0810450
PRIOR FILING DATE:	1998-04-08
PRIOR APPLICATION NUMBER:	60/0810710
PRIOR FILING DATE:	1998-04-08
PRIOR APPLICATION NUMBER:	60/0811950
PRIOR FILING DATE:	1998-04-08
PRIOR APPLICATION NUMBER:	60/0812030
PRIOR FILING DATE:	1998-04-09
PRIOR APPLICATION NUMBER:	60/0812280
PRIOR FILING DATE:	1998-04-09
PRIOR APPLICATION NUMBER:	60/0819555
PRIOR FILING DATE:	1998-04-15
PRIOR APPLICATION NUMBER:	60/0818170
PRIOR FILING DATE:	1998-04-15
PRIOR APPLICATION NUMBER:	60/0818190
PRIOR FILING DATE:	1998-04-15
PRIOR APPLICATION NUMBER:	60/0819555
PRIOR FILING DATE:	1998-04-15
PRIOR APPLICATION NUMBER:	60/0818380
PRIOR FILING DATE:	1998-04-15
PRIOR APPLICATION NUMBER:	60/0825686
PRIOR FILING DATE:	1998-04-21
PRIOR APPLICATION NUMBER:	60/0825656
PRIOR FILING DATE:	1998-04-21
PRIOR APPLICATION NUMBER:	60/0827040
PRIOR FILING DATE:	1998-04-22
PRIOR APPLICATION NUMBER:	60/0828040
PRIOR FILING DATE:	1998-04-22

PRIOR APPLICATION NUMBER:	60/082700
PRIOR FILING DATE:	1998-04-22
PRIOR APPLICATION NUMBER:	60/082797
PRIOR FILING DATE:	1998-04-22
PRIOR APPLICATION NUMBER:	60/082796
PRIOR FILING DATE:	1998-04-23
PRIOR APPLICATION NUMBER:	60/083336
PRIOR FILING DATE:	1998-04-27
PRIOR APPLICATION NUMBER:	60/083322
PRIOR FILING DATE:	1998-04-28
PRIOR APPLICATION NUMBER:	60/083392
PRIOR FILING DATE:	1998-04-29
PRIOR APPLICATION NUMBER:	60/083495
PRIOR FILING DATE:	1998-04-29
PRIOR APPLICATION NUMBER:	60/083455
PRIOR FILING DATE:	1998-04-29
PRIOR APPLICATION NUMBER:	60/083554
PRIOR FILING DATE:	1998-04-29
PRIOR APPLICATION NUMBER:	60/083558
PRIOR FILING DATE:	1998-04-29
PRIOR APPLICATION NUMBER:	60/083559
PRIOR FILING DATE:	1998-04-29
PRIOR APPLICATION NUMBER:	60/083500
PRIOR FILING DATE:	1998-04-29
PRIOR APPLICATION NUMBER:	60/083742
PRIOR FILING DATE:	1998-04-30
PRIOR APPLICATION NUMBER:	60/084366
PRIOR FILING DATE:	1998-05-05
PRIOR APPLICATION NUMBER:	60/084414
PRIOR FILING DATE:	1998-05-06
PRIOR APPLICATION NUMBER:	60/084441
PRIOR FILING DATE:	1998-05-06
PRIOR APPLICATION NUMBER:	60/084637
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084639
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084640
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084644
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084598
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084600
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084627
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084643
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/084643
PRIOR FILING DATE:	1998-05-13
PRIOR APPLICATION NUMBER:	60/085323
PRIOR FILING DATE:	1998-05-13
PRIOR APPLICATION NUMBER:	60/085382
PRIOR FILING DATE:	1998-05-15
PRIOR APPLICATION NUMBER:	60/085700
PRIOR FILING DATE:	1998-05-15
PRIOR APPLICATION NUMBER:	60/085669
PRIOR FILING DATE:	1998-05-15
PRIOR APPLICATION NUMBER:	60/085719
PRIOR FILING DATE:	1998-05-15
PRIOR APPLICATION NUMBER:	60/085860
PRIOR FILING DATE:	1998-05-15
PRIOR APPLICATION NUMBER:	60/085573
PRIOR FILING DATE:	1998-05-15
PRIOR APPLICATION NUMBER:	60/085704
PRIOR FILING DATE:	1998-05-15
PRIOR APPLICATION NUMBER:	60/085697

Query Match

5.98; Score 14.8; DB 1; Length 20;

```
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1256 GCAGCAGCAGCTGCAGAGA 1273
Db      18 GCAGCAGCAGCTGCATCA 1

RESULT 51
US-09-978-564A-21/C
; Sequence 21, Application US/09978564A
; Publication No. US20030050241A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gottlieb, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gruney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavich, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C25
; CURRENT APPLICATION NUMBER: US/09/978,564A
; CURRENT FILING DATE: 2001-10-16
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078866
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080327
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080328
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080333
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080334
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/081070
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081049
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081071
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081195
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081952
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081838
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082568
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/082569
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/082704
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082700
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082797
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082796
; PRIOR FILING DATE: 1998-04-23
; PRIOR APPLICATION NUMBER: 60/083336
```

;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query March 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAGAGA 1273
DB 18 GCAGCAACAGCTGATGA 1

RESULT 52
US-09-999-833A-21/c
Sequence 21, Application US/09999833A
Publication No. US20030054405A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Denoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerlitsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630PIC65
CURRENT APPLICATION NUMBER: US/09/999,833A
CURRENT FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664

;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079689
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079663
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079786
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079920
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/079923
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/080105
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080107
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29

;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCAACAGCTGAGAGA 1273
|||||
Db 18 GCAGCAACAGCTGATGA 1

RESULT 53
US-09-981-915A-21/c
; Sequence 21, Application US/09981915A
; Publication No. US20030054986A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi

APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gertlisen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gutney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C12
CURRENT APPLICATION NUMBER: US/09/981,915A
CURRENT FILING DATE: 2001-10-16
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27

PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083332
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554

```

; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083558
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083559
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083500
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083742
; PRIOR FILING DATE: 1998-04-30
; PRIOR APPLICATION NUMBER: 60/084366
; PRIOR FILING DATE: 1998-05-05
; PRIOR APPLICATION NUMBER: 60/084414
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084639
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084640
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084598
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084643
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085582
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085700
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085689
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085580
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085573
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1256 GCAGCACGCTGAGAGA 1273
Db      18 GCAGCACGCTGATGA 1

RESULT 54
US-09-978-824-21/c
; Sequence 21, Application US/09978824
; Publication No. US20030055216A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austen L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C14
; CURRENT APPLICATION NUMBER: US/09/978,824
; PRIOR FILING DATE: 2001-10-17
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/07450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
```

;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080107
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29

;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCAACAGCTGGAAGA 1273
Db 18 GCAGCACAGCTGATGA 1

RESULT 55
US-09-918-585A-21/c
Publication No. US20030060406A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Denoyers, Luc
APPLICANT: Baton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Bilen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gottlieb, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.

APPLICANT: Hillan, Kenneth J
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C1
CURRENT APPLICATION NUMBER: US/09/918,585A
CURRENT FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637

PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/086023

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 8.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAGCAGCTGGAAGA 1273
Db 18 GCAGCAGCAGCTGATGA 1

RESULT 56
US-09-999-834A-21/c
Sequence 21: Application US/0999834A
Publication NO. US20030064407A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Bortstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gruney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann

APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumes, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C75
CURRENT APPLICATION NUMBER: US/09/999, 834A
CURRENT FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334

;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07

;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGGANGA 1273
Db 18 GCAGCAGCAGCTGGATGA 1

RESULT 57
US-09-978-423A-21/C
; Sequence 21, Application US/09978423A
; Publication No. US2003069178A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gunney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Nadler, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same

FILE REFERENCE: P2630PIC21
CURRENT APPLICATION NUMBER: US/09/978,423A
CURRENT FILING DATE: 2002-05-16
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08

PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643

;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCACGCTGAGAG 1273
DB 18 GCAGCACGCTGAGTA 1

RESULT 58

US-09-978-193A-21/C

;; Sequence 21, Application US/09978193A
;; Publication No. US20030073624A1
;; GENERAL INFORMATION:
;; APPLICANT: Ashkenazi, Avi
;; APPLICANT: Baker Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan
;; APPLICANT: Ferrara, Napoleon
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerber, Hanspeter
;; APPLICANT: Gottlsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, J. Christopher
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Kljavin, Ivar J.
;; APPLICANT: Kuo, Sophia S.
;; APPLICANT: Napier, Mary A.
;; APPLICANT: Pan, James;
;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Shelton, David L.
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2630P1G
;; CURRENT APPLICATION NUMBER: US/09/978, 193A
;; PRIOR FILING DATE: 2002-02-21
;; PRIOR APPLICATION NUMBER: 09/918585
;; PRIOR FILING DATE: 2001-07-30
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17

;; PRIOR APPLICATION NUMBER: 60/064249
;; PRIOR FILING DATE: 1997-11-03
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/077450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; PRIOR FILING DATE: 1998-03-12
;; PRIOR APPLICATION NUMBER: 60/078004
;; PRIOR FILING DATE: 1998-03-13
;; PRIOR APPLICATION NUMBER: 60/078886
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078936
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078939
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/079294
;; PRIOR FILING DATE: 1998-03-25
;; PRIOR APPLICATION NUMBER: 60/079656
;; PRIOR FILING DATE: 1998-03-26
;; PRIOR APPLICATION NUMBER: 60/079664
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079689
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079663
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079786
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079920
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/079923
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/080105
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080107
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955

PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13

PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.3%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.3%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCACGCTGGAGCA 1273
Db 18 GCAGCACGCTGGATGA 1

RESULT 59
US-09-999-830A-21/c
Sequence 21, Application US/09999830A
Publication No. US2003007700A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerlitsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Nadier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paonl, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OR INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630PIC70
CURRENT APPLICATION NUMBER: US/09/999,830A
CURRENT FILING DATE: 2001-08-31
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450

[illegible]

PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGAGAG 1273
DB 18 GCAGCAGCAGCTGAGAG 1

RESULT 60
US-09-978-757A-21/C
Sequence 21, Application US/09978757A
Publication No. US20030083248A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gertlisen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C26
CURRENT APPLICATION NUMBER: US/09/978, 757A
CURRENT FILING DATE: 2002-03-19
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11

PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704

```

; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082700
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082797
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082796
; PRIOR FILING DATE: 1998-04-23
; PRIOR APPLICATION NUMBER: 60/083336
; PRIOR FILING DATE: 1998-04-27
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/083392
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083495
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083496
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083499
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083545
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083554
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083558
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083559
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083500
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083742
; PRIOR FILING DATE: 1998-04-30
; PRIOR APPLICATION NUMBER: 60/084366
; PRIOR FILING DATE: 1998-05-05
; PRIOR APPLICATION NUMBER: 60/084414
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084639
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084640
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084598
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084643
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085582
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085700
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085689
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085580
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085573
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15

; PRIOR APPLICATION NUMBER: 60/085697
; Query Match 5.9%; Score 14.8; DB 1; Length 20;
; Best Local Similarity 88.9%; Pred. No. 1.8e+02;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGANGA 1273
Db 18 GCAGCACAGCTGATGA 1

RESULT 61
US-09-978-187B-21/c
; Sequence 21, Application US/09978187B
; Publication No. US20030096744A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Bolstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Nepier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630PIC5
; CURRENT APPLICATION NUMBER: US/09/978,187B
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/06364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
```

PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22

PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
G 1256 GCAGCAAGCTGGAAGA 1273

Db 18 GCAGCACCACTGATGA 1

RESULT 62

US-09-978-643A-21/c
; Sequence 21, Application US/09978643A
; Publication No. US20030104998A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltzen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C16
; CURRENT APPLICATION NUMBER: US/09/978,643A
; CURRENT FILING DATE: 2001-10-16
; NUMBER OF SEQ ID NOS: 624
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-09-978-643A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAAGA 1273

Db 18 GCAGCACCACTGATGA 1

RESULT 63
US-09-978-375A-21/c
; Sequence 21, Application US/09978375A
; Publication No. US20030130181A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltzen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C24
; CURRENT APPLICATION NUMBER: US/09/978,375A
; CURRENT FILING DATE: 2002-04-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-09-978-375A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAAGA 1273

Db 18 GCAGCACCACTGATGA 1

RESULT 64
US-09-978-298A-21/c
; Sequence 21, Application US/09978298A
; Publication No. US20030134785A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltzen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel

APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2630PIC2
CURRENT FILING DATE: 2001-10-15
CURRENT FILING DATE: 2001-10-15
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08

PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600

;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1256 GCACGACAGCTGAGAG 1273
Db 18 GCACGACAGCTGATGA 1

RESULT 65
US-09-978-188A-21/c

;; Sequence 21, Application US/0978188A
;; Publication No. US20030139328A1

;; GENERAL INFORMATION:

;; APPLICANT: Ashkenazi, Avi

;; APPLICANT: Baker Kevin P.

;; APPLICANT: Bolstein, David

;; APPLICANT: Desnoyers, Luc

;; APPLICANT: Eaton, Dan

;; APPLICANT: Ferrara, Napoleon

;; APPLICANT: Filvaroff, Ellen

;; APPLICANT: Fong, Sherman

;; APPLICANT: Gao, Wei-Qiang

;; APPLICANT: Gerber, Hanspeter

;; APPLICANT: Gottlieb, Mary E.

;; APPLICANT: Godowski, Paul J.

;; APPLICANT: Grimaldi, J. Christopher

;; APPLICANT: Gurney, Austin L.

;; APPLICANT: Hillan, Kenneth J

;; APPLICANT: Kijavlin, Ivar J.

;; APPLICANT: Kuo, Sophia S.

;; APPLICANT: Napier, Mary A.

;; APPLICANT: Pan, James;

;; APPLICANT: Paoni, Nicholas F.

;; APPLICANT: Roy, Margaret Ann

;; APPLICANT: Shelton, David L.

;; APPLICANT: Stewart, Timothy A.

;; APPLICANT: Tumas, Daniel

;; APPLICANT: Williams, P. Mickey

;; APPLICANT: Wood, William I.

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

;; FILE REFERENCE: P2630P18

;; CURRENT APPLICATION NUMBER: US/09/978,188A

;; CURRENT FILING DATE: 2001-10-15

;;

;; PRIOR APPLICATION NUMBER: 09/918585
;; PRIOR FILING DATE: 2001-07-30
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/064249
;; PRIOR FILING DATE: 1997-11-03
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/07450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; PRIOR FILING DATE: 1998-03-12
;; PRIOR APPLICATION NUMBER: 60/078004
;; PRIOR FILING DATE: 1998-03-13
;; PRIOR APPLICATION NUMBER: 60/078886
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078936
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078939
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/079294
;; PRIOR FILING DATE: 1998-03-25
;; PRIOR APPLICATION NUMBER: 60/079656
;; PRIOR FILING DATE: 1998-03-26
;; PRIOR APPLICATION NUMBER: 60/079664
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079689
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079663
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079786
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079920
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/079923
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/080105
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080107
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203

PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13

PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.3%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCAACAGCTGGAAGA 1273
DB 18 GCAGCACAGCTGATCA 1

RESULT 66
US-09-978-681A-21/c
Sequence 21, Application US/09978681A
Publication No. US20030195148A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerltzen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630PIC18
CURRENT APPLICATION NUMBER: US/09/978, 681A
CURRENT FILING DATE: 2002-03-19
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311

PRIOR APPLICATION NUMBER: 60/081819-19	PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952-22	PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838-38	PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082556-66	PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082569-69	PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569-69	PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704-44	PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804-44	PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082706-66	PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336-36	PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083495-95	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083455-55	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083456-56	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083354-54	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558-58	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559-59	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083544-44	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500-00	PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742-42	PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366-66	PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414-14	PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084411-11	PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637-37	PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639-39	PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640-40	PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084538-38	PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600-00	PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627-27	PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084633-33	PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085339-39	PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338-38	PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323-23	PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582-82	PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700-00	PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700-00	PRIOR FILING DATE: 1998-05-15

;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCACACGCTGGAGA 1273
Db 18 GCAGCACACGCTGGATGA 1

RESULT 67
US-09-978-194A-21/c
; Sequence 21, Application US/09978194A
; Publication No. US2003019533A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertschen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Paul J.
; APPLICANT: Gruney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secured and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C10
; CURRENT APPLICATION NUMBER: US/09/978, 194A
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11

;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; PRIOR FILING DATE: 1998-03-12
;; PRIOR APPLICATION NUMBER: 60/078004
;; PRIOR FILING DATE: 1998-03-13
;; PRIOR APPLICATION NUMBER: 60/078886
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078936
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078939
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/079294
;; PRIOR FILING DATE: 1998-03-25
;; PRIOR APPLICATION NUMBER: 60/079656
;; PRIOR FILING DATE: 1998-03-26
;; PRIOR APPLICATION NUMBER: 60/079664
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079689
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079663
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079786
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079920
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/079923
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/080105
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080107
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568

PRIOR FILING DATE: 1998-04-21
 PRIOR APPLICATION NUMBER: 60/082569
 PRIOR FILING DATE: 1998-04-21
 PRIOR APPLICATION NUMBER: 60/082704
 PRIOR FILING DATE: 1998-04-22
 PRIOR APPLICATION NUMBER: 60/082804
 PRIOR FILING DATE: 1998-04-22
 PRIOR APPLICATION NUMBER: 60/082700
 PRIOR FILING DATE: 1998-04-22
 PRIOR APPLICATION NUMBER: 60/082797
 PRIOR FILING DATE: 1998-04-22
 PRIOR APPLICATION NUMBER: 60/082796
 PRIOR FILING DATE: 1998-04-23
 PRIOR APPLICATION NUMBER: 60/083336
 PRIOR FILING DATE: 1998-04-27
 PRIOR APPLICATION NUMBER: 60/083322
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/083392
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083495
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083496
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083499
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083445
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083554
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083558
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083559
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083500
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083742
 PRIOR FILING DATE: 1998-04-30
 PRIOR APPLICATION NUMBER: 60/084366
 PRIOR FILING DATE: 1998-05-05
 PRIOR APPLICATION NUMBER: 60/084414
 PRIOR FILING DATE: 1998-05-06
 PRIOR APPLICATION NUMBER: 60/084441
 PRIOR FILING DATE: 1998-05-06
 PRIOR APPLICATION NUMBER: 60/084637
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084639
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084640
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084598
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084600
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084627
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084643
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/085339
 PRIOR FILING DATE: 1998-05-13
 PRIOR APPLICATION NUMBER: 60/085338
 PRIOR FILING DATE: 1998-05-13
 PRIOR APPLICATION NUMBER: 60/085323
 PRIOR FILING DATE: 1998-05-13
 PRIOR APPLICATION NUMBER: 60/085582
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085700
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085689
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085579
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085580
 PRIOR FILING DATE: 1998-05-15

PRIOR APPLICATION NUMBER: 60/085573
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085704
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAAGA 1273
 Db 18 GCAGCAACAGCTGATGA 1

RESULT 68
 US-09-999-829A-21/c
 Sequence 21, Application US/09999829A
 Publication No. US20030195344A1
 GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi
 APPLICANT: Baker Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Desnoyers, Luc
 APPLICANT: Eaton, Dan
 APPLICANT: Ferrara, Napoleon
 APPLICANT: Filvaroff, Ellen
 APPLICANT: Fong, Sherman
 APPLICANT: Gao, Wei-Qiang
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerltisen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, J. Christopher
 APPLICANT: Gurney, Austin L.
 APPLICANT: Hillan, Kenneth J.
 APPLICANT: Kijawin, Ivar J.
 APPLICANT: Kuo, Sophia S.
 APPLICANT: Napier, Mary A.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann
 APPLICANT: Shelton, David L.
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William I.
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 FILE REFERENCE: P2630P1C61
 CURRENT APPLICATION NUMBER: US/09/999,829A
 CURRENT FILING DATE: 2002-03-19
 NUMBER OF SEQ. ID NOS: 624
 Prior Application removed - See File Wrapper or Palm
 SEQ ID NO 21
 LENGTH: 20
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic oligonucleotide probe
 US-09-999-829A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAAGA 1273
 Db 18 GCAGCAACAGCTGATGA 1

RESULT 69
 US-09-978-299A-21/c

Sequence 21, Application US/09978239A
Publication No. US2003019435A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gertlisen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tuma, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
Acids Encoding the Same
FILE REFERENCE: P2630P1C3
CURRENT APPLICATION NUMBER: US/09/978,299A
CURRENT FILING DATE: 2001-10-15
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27

PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499

```
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083545
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083554
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083558
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083559
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083500
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083742
/ PRIOR FILING DATE: 1998-04-30
/ PRIOR APPLICATION NUMBER: 60/084366
/ PRIOR FILING DATE: 1998-05-05
/ PRIOR APPLICATION NUMBER: 60/084414
/ PRIOR FILING DATE: 1998-05-06
/ PRIOR APPLICATION NUMBER: 60/084441
/ PRIOR FILING DATE: 1998-05-06
/ PRIOR APPLICATION NUMBER: 60/084637
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084639
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084640
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084598
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084600
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084627
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084643
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/085339
/ PRIOR FILING DATE: 1998-05-13
/ PRIOR APPLICATION NUMBER: 60/085338
/ PRIOR FILING DATE: 1998-05-13
/ PRIOR APPLICATION NUMBER: 60/085323
/ PRIOR FILING DATE: 1998-05-13
/ PRIOR APPLICATION NUMBER: 60/085582
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085700
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085689
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085579
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085580
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085573
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085704
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085697

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGCAGACA 1273
Db      18 GCAGCACACAGCTGCATGCA 1

RESULT 70
US-09-978-544A-21/c
/ Sequence 21, Application US/09978544A
/ Publication No. US20030199436A1
/ GENERAL INFORMATION:
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Baker Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc

/ APPLICANT: Eaton, Dan
/ APPLICANT: Ferreira, Napoleon
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, J. Christopher
/ APPLICANT: Gurney, Auelin L.
/ APPLICANT: Hillen, Kenneth J.
/ APPLICANT: Kijavlin, Ivar J.
/ APPLICANT: Kuo, Sophia S.
/ APPLICANT: Napier, Mary A.
/ APPLICANT: Pan, James;
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Shelton, David L.
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2630P1C13
/ CURRENT APPLICATION NUMBER: US/09/978,544A
/ PRIOR FILING DATE: 2002-03-19
/ PRIOR APPLICATION NUMBER: 09/918585
/ PRIOR FILING DATE: 2001-07-30
/ PRIOR APPLICATION NUMBER: 60/062250
/ PRIOR FILING DATE: 1997-10-17
/ PRIOR APPLICATION NUMBER: 60/064249
/ PRIOR FILING DATE: 1997-11-03
/ PRIOR APPLICATION NUMBER: 60/065311
/ PRIOR FILING DATE: 1997-11-13
/ PRIOR APPLICATION NUMBER: 60/066364
/ PRIOR FILING DATE: 1997-11-21
/ PRIOR APPLICATION NUMBER: 60/077450
/ PRIOR FILING DATE: 1998-03-10
/ PRIOR APPLICATION NUMBER: 60/077632
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077641
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077649
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077791
/ PRIOR FILING DATE: 1998-03-12
/ PRIOR APPLICATION NUMBER: 60/078004
/ PRIOR FILING DATE: 1998-03-13
/ PRIOR APPLICATION NUMBER: 60/078886
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078936
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078910
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078939
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/079294
/ PRIOR FILING DATE: 1998-03-25
/ PRIOR APPLICATION NUMBER: 60/079656
/ PRIOR FILING DATE: 1998-03-26
/ PRIOR APPLICATION NUMBER: 60/079664
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079689
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079663
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079728
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079786
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079920
```

; PRIOR FILING DATE: 1998-03-30
 ; PRIOR APPLICATION NUMBER: 60/079923
 ; PRIOR FILING DATE: 1998-03-30
 ; PRIOR APPLICATION NUMBER: 60/080105
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080107
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080165
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080194
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080327
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/080328
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/080333
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/080334
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/081070
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081049
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081071
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081195
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081203
 ; PRIOR FILING DATE: 1998-04-09
 ; PRIOR APPLICATION NUMBER: 60/081229
 ; PRIOR FILING DATE: 1998-04-09
 ; PRIOR APPLICATION NUMBER: 60/081955
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081817
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081819
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081952
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081838
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/082568
 ; PRIOR FILING DATE: 1998-04-21
 ; PRIOR APPLICATION NUMBER: 60/082569
 ; PRIOR FILING DATE: 1998-04-21
 ; PRIOR APPLICATION NUMBER: 60/082704
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082804
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082700
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082797
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082796
 ; PRIOR FILING DATE: 1998-04-23
 ; PRIOR APPLICATION NUMBER: 60/083336
 ; PRIOR FILING DATE: 1998-04-27
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/083392
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083495
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083496
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083499
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083545
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083554
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083558
 ; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: 60/083559
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083500
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083742
 ; PRIOR FILING DATE: 1998-04-30
 ; PRIOR APPLICATION NUMBER: 60/084366
 ; PRIOR FILING DATE: 1998-05-05
 ; PRIOR APPLICATION NUMBER: 60/084414
 ; PRIOR FILING DATE: 1998-05-06
 ; PRIOR APPLICATION NUMBER: 60/084441
 ; PRIOR FILING DATE: 1998-05-06
 ; PRIOR APPLICATION NUMBER: 60/084637
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084639
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084640
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084598
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084627
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084643
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/085339
 ; PRIOR FILING DATE: 1998-05-13
 ; PRIOR APPLICATION NUMBER: 60/085338
 ; PRIOR FILING DATE: 1998-05-13
 ; PRIOR APPLICATION NUMBER: 60/085323
 ; PRIOR FILING DATE: 1998-05-13
 ; PRIOR APPLICATION NUMBER: 60/085582
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085700
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085689
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085579
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085580
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085573
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085704
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAAGA 1273
 Db 18 GCAGCAACAGCTGGAATGA 1

RESULT 71
 US-09-978-665A-21/c
 ; Sequence 21, Application US/09978665A
 ; Publication No. US20030199437A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Baker Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Batton, Dan
 ; APPLICANT: Ferrara, Napoleon
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerltsen, Mary E.

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OR INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C19
CURRENT APPLICATION NUMBER: US/09/978,665A
CURRENT FILING DATE: 2001-10-16
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366

```

; PRIOR FILING DATE: 1998-05-05
; PRIOR APPLICATION NUMBER: 60/084414
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084639
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084640
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084598
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084643
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085582
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085700
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085689
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085580
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085573
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR APPLICATION NUMBER: 60/085697

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGCAGAGA 1273
Db      18 GCAGCAACAGCTGCATGA 1

RESULT 72
US-09-978-802A-21/c
; Sequence 21, Application US/09978802A
; Publication No. US2003019674A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavrin, Ivar J.
; APPLICANT: Kuo, Sophia S.
```

```

; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Pao, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OR INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630PIC20
; CURRENT APPLICATION NUMBER: US/09/978,802A
; PRIOR FILING DATE: 2001-10-16
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080327
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080328
```

;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07

;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCAACAGCTGGAGAGA 1273
Db 18 GCAGCAACAGCTGGAGATGA 1

RESULT 73
US-09-999-831A-21/c
; Sequence 21, Application US/09999831A
; Publication No. US20040048332A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowsky, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumaes, Daniel

```

; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC68
; CURRENT APPLICATION NUMBER: US/09/999,831A
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 624
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-09-999-831A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCACACGCTGGAGCA 1273
Db      18 GCAGCACACGCTGGATGA 1

RESULT 74
US-10-017-081A-21/c
; Sequence 21, Application US/10017081A
; Publication No. US20030049684A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James I.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC69
; CURRENT APPLICATION NUMBER: US/10/017,081A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-081A-21
```

```

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCACACGCTGGAGCA 1273
Db      18 GCAGCACACGCTGGATGA 1

RESULT 75
US-10-167-749-21/c
; Sequence 21, Application US/10167749
; Publication No. US20030056137A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James I.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC60
; CURRENT APPLICATION NUMBER: US/10/167,749
; CURRENT FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-167-749-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAGA 1273
DB 18 GCAGCACCTGATGA 1

RESULT 76

US-10-013-921A-21/c
Sequence 21, Application US/10013921A
Publication No. US2003068648A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2630P1C84
CURRENT APPLICATION NUMBER: US/10/013,921A
CURRENT FILING DATE: 2002-03-19
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20

PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797

PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAGA 1273
Db 18 GCAGCAACAGCTGGATGA 1
RESULT 77
US-10-013-929A-21/c
Sequence 21, Application US/10013929A
Publication No. US20030072745A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Deenoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Flivaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austen L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P26301C89
CURRENT APPLICATION NUMBER: US/10/013.929A
CURRENT FILING DATE: 2002-03-19
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294

; PRIOR FILING DATE: 1998-03-25
 ; PRIOR APPLICATION NUMBER: 60/079656
 ; PRIOR FILING DATE: 1998-03-26
 ; PRIOR APPLICATION NUMBER: 60/079664
 ; PRIOR FILING DATE: 1998-03-27
 ; PRIOR APPLICATION NUMBER: 60/079689
 ; PRIOR FILING DATE: 1998-03-27
 ; PRIOR APPLICATION NUMBER: 60/079663
 ; PRIOR FILING DATE: 1998-03-27
 ; PRIOR APPLICATION NUMBER: 60/079728
 ; PRIOR FILING DATE: 1998-03-27
 ; PRIOR APPLICATION NUMBER: 60/079786
 ; PRIOR FILING DATE: 1998-03-27
 ; PRIOR APPLICATION NUMBER: 60/079920
 ; PRIOR FILING DATE: 1998-03-30
 ; PRIOR APPLICATION NUMBER: 60/079923
 ; PRIOR FILING DATE: 1998-03-30
 ; PRIOR APPLICATION NUMBER: 60/080105
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080107
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080165
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080194
 ; PRIOR FILING DATE: 1998-03-31
 ; PRIOR APPLICATION NUMBER: 60/080327
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/080328
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/080333
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/080334
 ; PRIOR FILING DATE: 1998-04-01
 ; PRIOR APPLICATION NUMBER: 60/081070
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081049
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081071
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081195
 ; PRIOR FILING DATE: 1998-04-08
 ; PRIOR APPLICATION NUMBER: 60/081203
 ; PRIOR FILING DATE: 1998-04-09
 ; PRIOR APPLICATION NUMBER: 60/081229
 ; PRIOR FILING DATE: 1998-04-09
 ; PRIOR APPLICATION NUMBER: 60/081955
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081817
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081819
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081952
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/081838
 ; PRIOR FILING DATE: 1998-04-15
 ; PRIOR APPLICATION NUMBER: 60/082568
 ; PRIOR FILING DATE: 1998-04-21
 ; PRIOR APPLICATION NUMBER: 60/082569
 ; PRIOR FILING DATE: 1998-04-21
 ; PRIOR APPLICATION NUMBER: 60/082704
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082804
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082700
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082797
 ; PRIOR FILING DATE: 1998-04-22
 ; PRIOR APPLICATION NUMBER: 60/082796
 ; PRIOR FILING DATE: 1998-04-23
 ; PRIOR APPLICATION NUMBER: 60/083336
 ; PRIOR FILING DATE: 1998-04-27
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/083392
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083495
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083496
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083499
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083545
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083554
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083558
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083559
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083500
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/083742
 ; PRIOR FILING DATE: 1998-04-30
 ; PRIOR APPLICATION NUMBER: 60/08366
 ; PRIOR FILING DATE: 1998-05-05
 ; PRIOR APPLICATION NUMBER: 60/084414
 ; PRIOR FILING DATE: 1998-05-06
 ; PRIOR APPLICATION NUMBER: 60/08441
 ; PRIOR FILING DATE: 1998-05-06
 ; PRIOR APPLICATION NUMBER: 60/084637
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084639
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084640
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084598
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084627
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/084643
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/085339
 ; PRIOR FILING DATE: 1998-05-13
 ; PRIOR APPLICATION NUMBER: 60/085338
 ; PRIOR FILING DATE: 1998-05-13
 ; PRIOR APPLICATION NUMBER: 60/085323
 ; PRIOR FILING DATE: 1998-05-13
 ; PRIOR APPLICATION NUMBER: 60/085582
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085700
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085689
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085579
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085580
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085573
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085704
 ; PRIOR FILING DATE: 1998-05-15
 ; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred.No.1.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACGCTGGAAGA 1273
 |||||
 Db 18 GCAGCAACGCTGATGA 1

RESULT 78
 US-10-016-177A-21/c

```
; Sequence 21, Application US/10016177A
; Publication No. US20030073131A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C90
; CURRENT APPLICATION NUMBER: US/10/016,177A
; PRIOR FILING DATE: 2002-04-30
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-016-177A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACAGCTGGATGA 1

RESULT 79
US-10-166-709A-21/c
; Sequence 21, Application US/10166709A
; Publication No. US20030104536A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
```

```
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C90
; CURRENT APPLICATION NUMBER: US/10/166,709A
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079254
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
```

;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06

;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGGAGCA 1273
Db 18 GCAGCAGCAGCTGGATGA 1
|||||
RESULT 80
US-10-143-031A-21/c
; Sequence 21, Application US/10143031A
; Publication No. US20030138439A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavyn, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.

```

; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C39
; CURRENT APPLICATION NUMBER: US/10/143,031A
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-143-031A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACACGCTGGATGA 1

RESULT 81
US-10-006-972A-70
; Sequence 70, Application US/10006972A
; Publication No. US2003013359A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE 3 EXPRESSION
; FILE REFERENCE: RTS-0335
; CURRENT APPLICATION NUMBER: US/10/006,972A
; CURRENT FILING DATE: 2001-12-04
; NUMBER OF SEQ ID NOS: 94
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
; US-10-006-972A-70

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      1290 CCTCAGGTCCTCATGTC 1307
Db      1 CCTCAAGTCCTCATGTC 18

RESULT 82
US-10-143-030A-21/c
; Sequence 21, Application US/10143030A
; Publication No. US20030147901A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Denoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertlisen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C33
; CURRENT APPLICATION NUMBER: US/10/143,030A
; CURRENT FILING DATE: 2002-08-27
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-143-030A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
```

Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGGAGA 1273
Db 18 GCAGCAGCAGCTGGATGA 1

RESULT 83
US-10-002-967A-21/C

; Sequence 21, Application US/10002967A
; Publication No. US20030148373A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Denoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertlisen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OR INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OR INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C72
; CURRENT APPLICATION NUMBER: US/10/002,967A
; CURRENT FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080327
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080328
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080333
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080334
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/081070
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081049
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081071
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081195
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081952
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081838
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082568
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/082569
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/082704
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082700
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082797
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082796
; PRIOR FILING DATE: 1998-04-23
; PRIOR APPLICATION NUMBER: 60/083336

PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAGAG 1273
Db 18 GCAGCAACAGCTGATGA 1

RESULT 84

US-10-017-083A-21/C

Sequence 21, Application US/10017083A

Publication No. US20030148376A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi

APPLICANT: Baker Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan

APPLICANT: Ferrara, Napoleon

APPLICANT: Filvaroff, Ellen

APPLICANT: Fong, Sherman

APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, J. Christopher

APPLICANT: Gurney, Austin L.

APPLICANT: Hillan, Kenneth J.

APPLICANT: Kijavlin, Ivar J.

APPLICANT: Kuo, Sophia S.

APPLICANT: Napier, Mary A.

APPLICANT: Pan, James;

APPLICANT: Paoni, Nicholas F.

APPLICANT: Roy, Margaret Ann

APPLICANT: Shelton, David L.

APPLICANT: Stewart, Timothy A.

APPLICANT: Tumas, Daniel

APPLICANT: Williams, P. Mickey

APPLICANT: Wood, William I.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

FILE REFERENCE: P2630PIC67

CURRENT FILING DATE: 2001-10-24

Prior Application removed - See File Wrapper or Palm

NUMBER OF SEQ ID NOS: 624

SEQ ID NO 21

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-017-083A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAGAG 1273
Db 18 GCAGCAACAGCTGATGA 1

RESULT 85

US-10-145-128A-21/C

Sequence 21, Application US/10145128A

Publication No. US20030157615A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi

APPLICANT: Baker Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan

APPLICANT: Ferrara, Napoleon

APPLICANT: Filvaroff, Ellen

APPLICANT: Fong, Sherman

APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.

```

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C46
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-145-128A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACACAGCTGATGA 1

RESULT 86
US-10-017-191A-21/C
; Sequence 21. Application US/10017191A
; Publication No. US20030170254A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
```

```

; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertlsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James;
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C62
; CURRENT FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/07450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
```

PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29

PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCAACGCTGGAAGA 1273
Db 18 GCAGCACCGCTGGAATGA 1

RESULT 87
US-10-143-028A-21/c
Publication No. US20030180310A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Batou, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerltsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.

```
/ APPLICANT: Hillan, Kenneth J
/ APPLICANT: Kijavini, Ivar J.
/ APPLICANT: Kuo, Sophia S.
/ APPLICANT: Napier, Mary A.
/ APPLICANT: Pan, James;
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Shelton, David L.
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Thomas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2630P1C37
/ CURRENT APPLICATION NUMBER: US/10/143,028A
/ PRIOR APPLICATION NUMBER: 2001-10-19
/ PRIOR APPLICATION NUMBER: 09/918585
/ PRIOR FILING DATE: 2001-07-30
/ PRIOR APPLICATION NUMBER: 60/062250
/ PRIOR FILING DATE: 1997-10-17
/ PRIOR APPLICATION NUMBER: 60/064249
/ PRIOR FILING DATE: 1997-11-03
/ PRIOR APPLICATION NUMBER: 60/065311
/ PRIOR FILING DATE: 1997-11-13
/ PRIOR APPLICATION NUMBER: 60/066364
/ PRIOR FILING DATE: 1997-11-21
/ PRIOR APPLICATION NUMBER: 60/077450
/ PRIOR FILING DATE: 1998-03-10
/ PRIOR APPLICATION NUMBER: 60/077632
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077641
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077649
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077791
/ PRIOR FILING DATE: 1998-03-12
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 624
/ SEQ ID NO 21
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-143-028A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAGCAGCTGGAGA 1273
Db       18 GCAGCAGCAGCTGGATGA 1

RESULT 88
US-10-143-029A-21/C
/ Sequence 21, Application US/10143029A
/ Publication No. US20030180311A1
/ GENERAL INFORMATION:
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Baker Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyer, Luc
/ APPLICANT: Eaton, Dan
/ APPLICANT: Ferrara, Napoleon
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
```

```
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, J. Christopher
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J
/ APPLICANT: Kijavini, Ivar J.
/ APPLICANT: Kuo, Sophia S.
/ APPLICANT: Napier, Mary A.
/ APPLICANT: Pan, James;
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Shelton, David L.
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Thomas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2630P1C54
/ CURRENT APPLICATION NUMBER: US/10/143,029A
/ PRIOR APPLICATION NUMBER: 2001-10-19
/ PRIOR APPLICATION NUMBER: 09/918585
/ PRIOR FILING DATE: 2001-07-30
/ PRIOR APPLICATION NUMBER: 60/062250
/ PRIOR FILING DATE: 1997-10-17
/ PRIOR APPLICATION NUMBER: 60/064249
/ PRIOR FILING DATE: 1997-11-03
/ PRIOR APPLICATION NUMBER: 60/065311
/ PRIOR FILING DATE: 1997-11-13
/ PRIOR APPLICATION NUMBER: 60/066364
/ PRIOR FILING DATE: 1997-11-21
/ PRIOR APPLICATION NUMBER: 60/077450
/ PRIOR FILING DATE: 1998-03-10
/ PRIOR APPLICATION NUMBER: 60/077632
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077641
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077649
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077791
/ PRIOR FILING DATE: 1998-03-12
/ PRIOR APPLICATION NUMBER: 60/078004
/ PRIOR FILING DATE: 1998-03-13
/ PRIOR APPLICATION NUMBER: 60/078886
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078936
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078910
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078939
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/079294
/ PRIOR FILING DATE: 1998-03-25
/ PRIOR APPLICATION NUMBER: 60/079656
/ PRIOR FILING DATE: 1998-03-26
/ PRIOR APPLICATION NUMBER: 60/079664
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079689
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079663
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079728
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079786
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079920
/ PRIOR FILING DATE: 1998-03-30
/ PRIOR APPLICATION NUMBER: 60/079923
/ PRIOR FILING DATE: 1998-03-30
/ PRIOR APPLICATION NUMBER: 60/080105
/ PRIOR FILING DATE: 1998-03-31
/ PRIOR APPLICATION NUMBER: 60/080107
/ PRIOR FILING DATE: 1998-03-31
/ PRIOR APPLICATION NUMBER: 60/080165
```

;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05

;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1256 GCAGCACACGCTGGAGAA 1273
Db 18 GCAGCACACGCTGGATGA 1

RESULT 89
US-10-145-089A-21/c
; Sequence 21, Application US/10145089A
; Publication No. US20030180867A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.

```
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C31
; CURRENT APPLICATION NUMBER: US/10/145,089A
; PRIOR FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-145-089A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACCAAGCTGGATGA 1

RESULT 90
US-10-165-067A-21/c
; Sequence 21, Application US/10165067A
; Publication No. US20030185841A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
```

```
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C42
; CURRENT APPLICATION NUMBER: US/10/165,067A
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-165-067A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACCAAGCTGGATGA 1

RESULT 91
US-10-145-017A-21/c
; Sequence 21, Application US/10145017A
; Publication No. US20030186365A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey J.
; APPLICANT: Godowski, Paul J.
```

```

: APPLICANT: Grimaldi, J. Christopher
: APPLICANT: Gurney, Austin L.
: APPLICANT: Hillan, Kenneth J.
: APPLICANT: Kljavin, Ivar J.
: APPLICANT: Kuo, Sophia S.
: APPLICANT: Napier, Mary A.
: APPLICANT: Pan, James;
: APPLICANT: Paoni, Nicholas F.
: APPLICANT: Roy, Margaret Ann
: APPLICANT: Shelton, David L.
: APPLICANT: Stewart, Timothy A.
: APPLICANT: Tumas, Daniel
: APPLICANT: Williams, P. Mickey
: APPLICANT: Wood, William I.
: TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
: TITLE OF INVENTION: Acids Encoding the Same
: FILE REFERENCE: P2630PIC32
: CURRENT FILING DATE: 2001-10-19
: PRIOR APPLICATION NUMBER: 09/918585
: PRIOR FILING DATE: 2001-07-30
: PRIOR APPLICATION NUMBER: 60/062250
: PRIOR FILING DATE: 1997-10-17
: PRIOR APPLICATION NUMBER: 60/064249
: PRIOR FILING DATE: 1997-11-03
: PRIOR APPLICATION NUMBER: 60/065311
: PRIOR FILING DATE: 1997-11-13
: PRIOR APPLICATION NUMBER: 60/066364
: PRIOR FILING DATE: 1997-11-21
: PRIOR APPLICATION NUMBER: 60/077450
: PRIOR FILING DATE: 1998-03-10
: PRIOR APPLICATION NUMBER: 60/077632
: PRIOR FILING DATE: 1998-03-11
: PRIOR APPLICATION NUMBER: 60/077641
: PRIOR FILING DATE: 1998-03-11
: PRIOR APPLICATION NUMBER: 60/077649
: PRIOR FILING DATE: 1998-03-11
: PRIOR APPLICATION NUMBER: 60/077791
: PRIOR FILING DATE: 1998-03-12
: Remaining Prior Application data removed - See File Wrapper or PALM.
: NUMBER OF SEQ ID NOS: 624
: SEQ ID NO 21
: LENGTH: 20
: TYPE: DNA
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: Synthetic oligonucleotide probe
: US-10-145-017A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACACGCTGATGA 1

RESULT 92
US-10-164-728A-21/c
: Sequence 21, Application US/10164728A
: Publication No. US20030186368A1
: GENERAL INFORMATION:
: APPLICANT: Ashkenazi, Avi
: APPLICANT: Baker Kevin P.
: APPLICANT: Botstein, David
: APPLICANT: Desnoyers, Luc
: APPLICANT: Eaton, Dan
: APPLICANT: Ferrara, Napoleon
: APPLICANT: Filvaroff, Ellen
: APPLICANT: Fong, Sherman
: APPLICANT: Gao, Wei-Qiang
: APPLICANT: Gerber, Hanspeter
```

```

: APPLICANT: Gerritsen, Mary E.
: APPLICANT: Goddard, Audrey
: APPLICANT: Godowski, Paul J.
: APPLICANT: Grimaldi, J. Christopher
: APPLICANT: Gurney, Austin L.
: APPLICANT: Hillan, Kenneth J.
: APPLICANT: Kljavin, Ivar J.
: APPLICANT: Kuo, Sophia S.
: APPLICANT: Napier, Mary A.
: APPLICANT: Pan, James;
: APPLICANT: Paoni, Nicholas F.
: APPLICANT: Roy, Margaret Ann
: APPLICANT: Shelton, David L.
: APPLICANT: Stewart, Timothy A.
: APPLICANT: Tumas, Daniel
: APPLICANT: Williams, P. Mickey
: APPLICANT: Wood, William I.
: TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
: TITLE OF INVENTION: Acids Encoding the Same
: FILE REFERENCE: P2630PIC43
: CURRENT FILING DATE: 2001-10-19
: PRIOR APPLICATION NUMBER: 09/918585
: PRIOR FILING DATE: 2001-07-30
: PRIOR APPLICATION NUMBER: 60/062250
: PRIOR FILING DATE: 1997-10-17
: PRIOR APPLICATION NUMBER: 60/064249
: PRIOR FILING DATE: 1997-11-03
: PRIOR APPLICATION NUMBER: 60/065311
: PRIOR FILING DATE: 1997-11-13
: PRIOR APPLICATION NUMBER: 60/066364
: PRIOR FILING DATE: 1997-11-21
: PRIOR APPLICATION NUMBER: 60/077450
: PRIOR FILING DATE: 1998-03-10
: PRIOR APPLICATION NUMBER: 60/077632
: PRIOR FILING DATE: 1998-03-11
: PRIOR APPLICATION NUMBER: 60/077641
: PRIOR FILING DATE: 1998-03-11
: PRIOR APPLICATION NUMBER: 60/077649
: PRIOR FILING DATE: 1998-03-11
: PRIOR APPLICATION NUMBER: 60/077791
: PRIOR FILING DATE: 1998-03-12
: Remaining Prior Application data removed - See File Wrapper or PALM.
: NUMBER OF SEQ ID NOS: 624
: SEQ ID NO 21
: LENGTH: 20
: TYPE: DNA
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: Synthetic oligonucleotide probe
: US-10-164-728A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACACGCTGATGA 1

RESULT 93
US-10-013-926A-21/c
: Sequence 21, Application US/10013926A
: Publication No. US20030187241A1
: GENERAL INFORMATION:
: APPLICANT: Ashkenazi, Avi
: APPLICANT: Baker Kevin P.
: APPLICANT: Botstein, David
: APPLICANT: Desnoyers, Luc
: APPLICANT: Eaton, Dan
: APPLICANT: Ferrara, Napoleon
: APPLICANT: Filvaroff, Ellen
```

```
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C80
; CURRENT APPLICATION NUMBER: US/10/013,926A
; CURRENT FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-013-926A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
      ||||| ||||| ||||| |||||
Db      18 GCAGCACACGCTGGATGA 1

RESULT 94
US-10-165-247A-21/c
; Sequence 21, Application US/10165247A
; Publication No. US20030190321A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
```

```
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C41
; CURRENT APPLICATION NUMBER: US/10/165,247A
; CURRENT FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-165-247A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
      ||||| ||||| ||||| |||||
Db      18 GCAGCACACGCTGGATGA 1

RESULT 95
US-10-145-124A-21/c
; Sequence 21, Application US/10145124A
; Publication No. US20030190701A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Ashkenazi, Avi
```

```

; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltzen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austen L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C44
; CURRENT APPLICATION NUMBER: US/10/145,124A
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-145-124A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1256 GCAGCAACAGCTGGAGCA 1273
DB      18 GCAGCACCACTGATGA 1

RESULT 96
US-10-160-502A-21/c
; Sequence 21, Application US/10160502A
```

```

; Publication No. US20030190703A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltzen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austen L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C57
; CURRENT APPLICATION NUMBER: US/10/160,502A
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-160-502A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1256 GCAGCAACAGCTGGAGCA 1273
DB      18 GCAGCACCACTGATGA 1
```

```
RESULT 97
US-10-145-087A-21/c
; Sequence 21, Application US/10145087A
; Publication No. US20030194410A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertlisen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumaas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C47
; CURRENT APPLICATION NUMBER: US/10/145,087A
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-145-087A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Db          18 GCAGCACGACGTGATGA 1

RESULT 98
US-10-017-086A-21/c
; Sequence 21, Application US/10017086A
; Publication No. US20030194744A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertlisen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumaas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C64
; CURRENT APPLICATION NUMBER: US/10/017,086A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-086A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY          1256 GCAGCAACAGCTGGAAGA 1273
|||||
Db          18 GCAGCACGACGTGATGA 1

RESULT 99
US-10-164-829A-21/c
; Sequence 21, Application US/10164829A
; Publication No. US20030194780A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
```

```

; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C36
; CURRENT APPLICATION NUMBER: US/10/164,829A
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-164-829A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1256 GCAGCAACAGCTGAGAGA 1273
Db      18 GCAGCACACGCTGATGA 1

RESULT 100
US-10-164-929A-21/c
; Sequence 21, Application US/10164929A
; Publication No. US20030194781A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
```

```

; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C36
; CURRENT APPLICATION NUMBER: US/10/164,929A
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-164-929A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1256 GCAGCAACAGCTGAGAGA 1273
Db      18 GCAGCACACGCTGATGA 1

RESULT 101
US-10-013-922A-21/c
; Sequence 21, Application US/10013922A
; Publication No. US20030195345A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
```

APPLICANT: Deenoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerltsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gunney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C81
CURRENT APPLICATION NUMBER: US/10/013,922A
CURRENT FILING DATE: 2001-10-25
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27

PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558

```
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083559
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083500
/ PRIOR FILING DATE: 1998-04-29
/ PRIOR APPLICATION NUMBER: 60/083742
/ PRIOR FILING DATE: 1998-04-30
/ PRIOR APPLICATION NUMBER: 60/084366
/ PRIOR FILING DATE: 1998-05-05
/ PRIOR APPLICATION NUMBER: 60/084414
/ PRIOR FILING DATE: 1998-05-06
/ PRIOR APPLICATION NUMBER: 60/084441
/ PRIOR FILING DATE: 1998-05-06
/ PRIOR APPLICATION NUMBER: 60/084637
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084639
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084640
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084598
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084600
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084627
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/084643
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/085339
/ PRIOR FILING DATE: 1998-05-13
/ PRIOR APPLICATION NUMBER: 60/085338
/ PRIOR FILING DATE: 1998-05-13
/ PRIOR APPLICATION NUMBER: 60/085323
/ PRIOR FILING DATE: 1998-05-13
/ PRIOR APPLICATION NUMBER: 60/085582
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085700
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085689
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085579
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085580
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085573
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085704
/ PRIOR FILING DATE: 1998-05-15
/ PRIOR APPLICATION NUMBER: 60/085697
/ PRIOR APPLICATION NUMBER: 60/085697

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pared. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAGCAGCTGGAGAGA 1273
Db      18 GCAGCAGCAGCTGGATGA 1

RESULT 102
US-10-020-445A-21/c
; Sequence 21, Application US/10020445A
; Publication No. US20030198994A1
; GENERAL INFORMATION:
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Baker Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Deenoyers, Luc
/ APPLICANT: Eaton, Dan
/ APPLICANT: Ferrara, Napoleon
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, J. Christopher
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Kijavrin, Ivar J.
/ APPLICANT: Kuo, Sophia S.
/ APPLICANT: Napier, Mary A.
/ APPLICANT: Pan, James;
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Shelton, David L.
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2610P1C74
/ CURRENT APPLICATION NUMBER: US/10/020,445A
/ PRIOR FILING DATE: 2001-10-24
/ PRIOR APPLICATION NUMBER: 09/918585
/ PRIOR FILING DATE: 2001-07-30
/ PRIOR APPLICATION NUMBER: 60/062250
/ PRIOR FILING DATE: 1997-10-17
/ PRIOR APPLICATION NUMBER: 60/064249
/ PRIOR FILING DATE: 1997-11-03
/ PRIOR APPLICATION NUMBER: 60/065311
/ PRIOR FILING DATE: 1997-11-13
/ PRIOR APPLICATION NUMBER: 60/066364
/ PRIOR FILING DATE: 1997-11-21
/ PRIOR APPLICATION NUMBER: 60/077450
/ PRIOR FILING DATE: 1998-03-10
/ PRIOR APPLICATION NUMBER: 60/077632
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077641
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077649
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077921
/ PRIOR FILING DATE: 1998-03-12
/ PRIOR APPLICATION NUMBER: 60/078004
/ PRIOR FILING DATE: 1998-03-13
/ PRIOR APPLICATION NUMBER: 60/078886
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078936
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078910
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/078939
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/079294
/ PRIOR FILING DATE: 1998-03-25
/ PRIOR APPLICATION NUMBER: 60/079656
/ PRIOR FILING DATE: 1998-03-26
/ PRIOR APPLICATION NUMBER: 60/079664
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079689
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079663
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079728
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079786
/ PRIOR FILING DATE: 1998-03-27
/ PRIOR APPLICATION NUMBER: 60/079920
/ PRIOR FILING DATE: 1998-03-30
/ PRIOR APPLICATION NUMBER: 60/079923
/ PRIOR FILING DATE: 1998-03-30
/ PRIOR APPLICATION NUMBER: 60/080105
/ PRIOR FILING DATE: 1998-03-31
/ PRIOR APPLICATION NUMBER: 60/080107
```

;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30

;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCACACGCTGGAGGA 1273
Db 18 GCAGCACACGCTGGATGA 1

RESULT 103
US-10-013-924A-21/c
; Sequence 21, Application US/10013924A
; Publication No. US20030199021A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.

```

; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C76
; CURRENT APPLICATION NUMBER: US/10/013,924A
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-924A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGCA 1273
DB      18 GCAGCAACAGCTGGATGA 1

RESULT 104
US-10-017-084A-21/C
; Sequence 21, Application US/10017084A
; Publication No. US20030203402A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
```

```

; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C52
; CURRENT APPLICATION NUMBER: US/10/145,016A
US-10-145-016A-21/C
; Sequence 21, Application US/10145016A
; Publication No. US20030203433A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C52
; CURRENT APPLICATION NUMBER: US/10/145,016A

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGCA 1273
DB      18 GCAGCAACAGCTGGATGA 1

RESULT 105
US-10-145-016A-21/C
; Sequence 21, Application US/10145016A
; Publication No. US20030203433A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C52
; CURRENT APPLICATION NUMBER: US/10/145,016A
```

```
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-145-016A-21
```

```
Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1256 GCAGCAACAGCTGTGAGA 1273
          ||||| ||||| ||||| ||
Db       18 GCAGCACACAGCTGTGATGA 1
```

```
RESULT 106
US-10-145-088A-21/c
; Sequence 21, Application US/10145088A
; Publication No. US20030203434A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

```
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C49
; CURRENT APPLICATION NUMBER: US/10/145,088A
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-145-088A-21
```

```
Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1256 GCAGCAACAGCTGTGAGA 1273
          ||||| ||||| ||||| ||
Db       18 GCAGCACACAGCTGTGATGA 1
```

```
RESULT 107
US-10-145-092A-21/c
; Sequence 21, Application US/10145092A
; Publication No. US20030203435A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
```

```

; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC45
; CURRENT APPLICATION NUMBER: US/10/145, 092A
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-145-092A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACCACTGGATGA 1

RESULT 108
US-10-145-129A-21/C
; Sequence 21, Application US/10145129A
; Publication No. US20030203436A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey J.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavrin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
```

```

; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tuma, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC51
; CURRENT APPLICATION NUMBER: US/10/145, 129A
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-145-129A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCACCACTGGATGA 1

RESULT 109
US-10-165-038A-21/C
; Sequence 21, Application US/10165038A
; Publication No. US20030203441A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey J.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavrin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
```

```

; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630PIC9
; CURRENT APPLICATION NUMBER: US/10/165,038A
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-165-038A-21

```

```

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1256 GCAGCAACAGCTGGAAGA 1273
          ||||| ||||| ||||| ||
Db       18 GCAGCACACGCTGGATGA 1

```

```

RESULT 110
US-10-165-353A-21/c
; Sequence 21, Application US/10165353A
; Publication No. US20030203442A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.

```

```

; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630PIC40
; CURRENT APPLICATION NUMBER: US/10/165,353A
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-165-353A-21

```

```

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1256 GCAGCAACAGCTGGAAGA 1273
          ||||| ||||| ||||| ||
Db       18 GCAGCACACGCTGGATGA 1

```

```

RESULT 111
US-10-167-600-21/c
; Sequence 21, Application US/10167600
; Publication No. US20030203443A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.

```

```
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumaas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC35
; CURRENT APPLICATION NUMBER: US/10/167,600
; CURRENT FILING DATE: 2002-12-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-167-600-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1256 GCAGCACAGCTGGAGAGA 1273
Db      18 GCAGCACAGCTGGATGA 1
```

```
RESULT 112
US-10-170-481A-21/c
; Sequence 21, Application US/10170481A
; Publication No. US20030203444A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
```

```
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumaas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC53
; CURRENT APPLICATION NUMBER: US/10/170,481A
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-170-481A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1256 GCAGCACAGCTGGAGAGA 1273
Db      18 GCAGCACAGCTGGATGA 1
```

```
RESULT 113
US-10-172-039A-21/c
; Sequence 21, Application US/10172039A
; Publication No. US20030203445A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
```

```
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Geritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, J. Christopher
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Kijavlin, Ivar J.
/ APPLICANT: Kuo, Sophia S.
/ APPLICANT: Napier, Mary A.
/ APPLICANT: Pan, James;
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Shelton, David L.
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2630P1C30
/ CURRENT APPLICATION NUMBER: US/10/172,039A
/ CURRENT FILING DATE: 2002-10-10
/ PRIOR APPLICATION NUMBER: 09/918585
/ PRIOR FILING DATE: 2001-07-30
/ PRIOR APPLICATION NUMBER: 60/062250
/ PRIOR FILING DATE: 1997-10-17
/ PRIOR APPLICATION NUMBER: 60/064249
/ PRIOR FILING DATE: 1997-11-03
/ PRIOR APPLICATION NUMBER: 60/065311
/ PRIOR FILING DATE: 1997-11-13
/ PRIOR APPLICATION NUMBER: 60/066364
/ PRIOR FILING DATE: 1997-11-21
/ PRIOR APPLICATION NUMBER: 60/077450
/ PRIOR FILING DATE: 1998-03-10
/ PRIOR APPLICATION NUMBER: 60/077632
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077641
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077649
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077791
/ PRIOR FILING DATE: 1998-03-12
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 624
/ SEQ ID NO 21
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-172-039A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1256 GCAGCAACGCTGGAAGA 1273
Db      18 GCAGCACCACTGATGA 1

RESULT 114
US-10-210-028-21/c
/ Sequence 21, Application US/10210028
/ Publication No. US2003020346A1
/ GENERAL INFORMATION:
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Baker Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Deenoyers, Luc
```

```
/ APPLICANT: Eaton, Dan
/ APPLICANT: Ferrara, Napoleon
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Geritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, J. Christopher
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Kijavlin, Ivar J.
/ APPLICANT: Kuo, Sophia S.
/ APPLICANT: Napier, Mary A.
/ APPLICANT: Pan, James;
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Shelton, David L.
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2630P1C52
/ CURRENT APPLICATION NUMBER: US/10/210,028
/ CURRENT FILING DATE: 2001-10-18
/ PRIOR APPLICATION NUMBER: 09/918585
/ PRIOR FILING DATE: 2001-07-30
/ PRIOR APPLICATION NUMBER: 60/062250
/ PRIOR FILING DATE: 1997-10-17
/ PRIOR APPLICATION NUMBER: 60/064249
/ PRIOR FILING DATE: 1997-11-03
/ PRIOR APPLICATION NUMBER: 60/065311
/ PRIOR FILING DATE: 1997-11-13
/ PRIOR APPLICATION NUMBER: 60/066364
/ PRIOR FILING DATE: 1997-11-21
/ PRIOR APPLICATION NUMBER: 60/077450
/ PRIOR FILING DATE: 1998-03-10
/ PRIOR APPLICATION NUMBER: 60/077632
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077641
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077649
/ PRIOR FILING DATE: 1998-03-11
/ PRIOR APPLICATION NUMBER: 60/077791
/ PRIOR FILING DATE: 1998-03-12
/ Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 624
/ SEQ ID NO 21
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-210-028-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1256 GCAGCAACGCTGGAAGA 1273
Db      18 GCAGCACCACTGATGA 1

RESULT 115
US-10-017-085A-21/c
/ Sequence 21, Application US/10017085A
/ Publication No. US20030204055A1
/ GENERAL INFORMATION:
/ APPLICANT: Ashkenazi, Avi
```

```

; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C73
; CURRENT APPLICATION NUMBER: US/10/017,085A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-017-085A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
DB      18 GCAGCAACAGCTGGATGA 1

RESULT 116
US-10-013-916A-21/C
; Sequence 21, Application US/10013916A
; Publication No. US20030206915A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
```

```

; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C79
; CURRENT APPLICATION NUMBER: US/10/013,916A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-013-916A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGGAGA 1273
DB      18 GCAGCAACAGCTGGATGA 1

RESULT 117
US-10-143-026B-21/C
; Sequence 21, Application US/10143026B
; Publication No. US20030207803A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C58
; CURRENT APPLICATION NUMBER: US/10/143,026B
; CURRENT FILING DATE: 2003-05-09
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
```

;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/064249
;; PRIOR FILING DATE: 1997-11-03
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/077450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 624
;; SEQ ID NO 21
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-143-0268-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.88+0.0;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCACAGCTGGAGAGA 1273
Db 18 GCAGCACAGCTGGATGA 1

RESULT 118
US-10-013-918A-21/c
; Sequence 21, Application US/10013918A
; Publication No. US20030211091A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Flivaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavan, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secured and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C77
; CURRENT APPLICATION NUMBER: US/10/013.918A
; CURRENT FILING DATE: 2002-03-25

;; PRIOR APPLICATION NUMBER: 09/918585
;; PRIOR FILING DATE: 2001-07-30
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/064249
;; PRIOR FILING DATE: 1997-11-03
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/077450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; PRIOR FILING DATE: 1998-03-12
;; PRIOR APPLICATION NUMBER: 60/078004
;; PRIOR FILING DATE: 1998-03-13
;; PRIOR APPLICATION NUMBER: 60/078886
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078936
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/078939
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/079294
;; PRIOR FILING DATE: 1998-03-25
;; PRIOR APPLICATION NUMBER: 60/079656
;; PRIOR FILING DATE: 1998-03-26
;; PRIOR APPLICATION NUMBER: 60/079664
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079689
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079663
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079786
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/079920
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/079923
;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: 60/080105
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080107
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080165
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080194
;; PRIOR FILING DATE: 1998-03-31
;; PRIOR APPLICATION NUMBER: 60/080327
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080328
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080333
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/080334
;; PRIOR FILING DATE: 1998-04-01
;; PRIOR APPLICATION NUMBER: 60/081070
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203

PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083556
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13

PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085682
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.3%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACGCTGGAAGA 1273
Db 18 GCAGCACACGCTGATGA 1

RESULT 119
US-10-162-521A-21/c
Publication No. US20030211092A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Geritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James;
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tuma, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630PIC55
CURRENT APPLICATION NUMBER: US/10/162,521A
CURRENT FILING DATE: 2002-11-29
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311

;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/077450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; PRIOR FILING DATE: 1998-03-12
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 624
;; SEQ ID NO 21
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-162-521A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGGAGGA 1273
Db 18 GCAGCAGCAGCTGGATGA 1

RESULT 120
US-10-013-928A-21/c
;; Sequence 21, Application US/10013928A
;; Publication No. US20030215905A1
;; GENERAL INFORMATION:
;; APPLICANT: Ashkenazi, Avi
;; APPLICANT: Baker Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan
;; APPLICANT: Ferrara, Napoleon
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerber, Hanspeter
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, J. Christopher
;; APPLICANT: Gunney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Kijavlin, Ivar J.
;; APPLICANT: Kuo, Sophia S.
;; APPLICANT: Napier, Mary A.
;; APPLICANT: Pan, James;
;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Shelton, David L.
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2630P1C6
;; CURRENT APPLICATION NUMBER: US/10/013,928A
;; CURRENT FILING DATE: 2001-10-25
;; PRIOR APPLICATION NUMBER: 09/918585
;; PRIOR FILING DATE: 2001-07-30
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17

;; PRIOR APPLICATION NUMBER: 60/064249
;; PRIOR FILING DATE: 1997-11-03
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066364
;; PRIOR FILING DATE: 1997-11-21
;; PRIOR APPLICATION NUMBER: 60/077450
;; PRIOR FILING DATE: 1998-03-10
;; PRIOR APPLICATION NUMBER: 60/077632
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077641
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077649
;; PRIOR FILING DATE: 1998-03-11
;; PRIOR APPLICATION NUMBER: 60/077791
;; PRIOR FILING DATE: 1998-03-12
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 624
;; SEQ ID NO 21
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-928A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGGAGGA 1273
Db 18 GCAGCAGCAGCTGGATGA 1

RESULT 121
US-10-162-522A-21/c
;; Sequence 21, Application US/10162522A
;; Publication No. US20030215908A1
;; GENERAL INFORMATION:
;; APPLICANT: Ashkenazi, Avi
;; APPLICANT: Baker Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan
;; APPLICANT: Ferrara, Napoleon
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerber, Hanspeter
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, J. Christopher
;; APPLICANT: Gunney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Kijavlin, Ivar J.
;; APPLICANT: Kuo, Sophia S.
;; APPLICANT: Napier, Mary A.
;; APPLICANT: Pan, James;
;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Shelton, David L.
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2630P1C6
;; CURRENT APPLICATION NUMBER: US/10/162,522A
;; CURRENT FILING DATE: 2002-10-10
;; PRIOR APPLICATION NUMBER: 09/918585

```

; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-162-522A-21
```

```

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCAACAGCTGGATGA 1
```

```

RESULT 122
US-10-013-923A-21/c
; Sequence 21, Application US/10013923A
; Publication No. US20030216305A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavrin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C87
```

```

; CURRENT APPLICATION NUMBER: US/10/013, 923A
; CURRENT FILING DATE: 2001-10-25
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-923A-21
```

```

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1256 GCAGCAACAGCTGGAGA 1273
Db      18 GCAGCAACAGCTGGATGA 1
```

```

RESULT 123
US-10-013-925A-21/c
; Sequence 21, Application US/10013925A
; Publication No. US20030216560A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerlitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J
; APPLICANT: Kijavrin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C83
; CURRENT APPLICATION NUMBER: US/10/013, 925A
; CURRENT FILING DATE: 2002-05-03
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-925A-21

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Db 18 GCAGCACACGCTGGATGA 1

RESULT 124

US-10-013-927A-21/c
; Sequence 21, Application US/10013927A
; Publication No. US20030216561A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C48
; CURRENT APPLICATION NUMBER: US/10/013,927A
; CURRENT FILING DATE: 2001-10-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-927A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCACACGCTGGAGA 1273

Db 18 GCAGCACACGCTGGATGA 1

RESULT 125

US-10-145-093A-21/c
; Sequence 21, Application US/10145093A
; Publication No. US20040005312A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerltsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Kijavlin, Ivar J.

; APPLICANT: Kuo, Sophia S.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Shelton, David L.

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2630P1C48

; CURRENT APPLICATION NUMBER: US/10/145,093A

; CURRENT FILING DATE: 2001-10-18

; PRIOR APPLICATION NUMBER: 09/918585

; PRIOR FILING DATE: 2001-07-30

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/064249

; PRIOR FILING DATE: 1997-11-03

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066364

; PRIOR FILING DATE: 1997-11-21

; PRIOR APPLICATION NUMBER: 60/07450

; PRIOR FILING DATE: 1998-03-10

; PRIOR APPLICATION NUMBER: 60/07632

; PRIOR FILING DATE: 1998-03-11

; PRIOR APPLICATION NUMBER: 60/07641

; PRIOR FILING DATE: 1998-03-11

; PRIOR APPLICATION NUMBER: 60/077649

; PRIOR FILING DATE: 1998-03-11

; PRIOR APPLICATION NUMBER: 60/07791

; PRIOR FILING DATE: 1998-03-12

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 624

; SEQ ID NO 21

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-145-093A-21

Query Match 5.9%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCACACGCTGGAGA 1273

Db 18 GCAGCACACGCTGGATGA 1

RESULT 126

US-10-013-919A-21/c
; Sequence 21, Application US/10013919A
; Publication No. US20040005657A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan

```

; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geriltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C85
; CURRENT APPLICATION NUMBER: US/10/013,919A
; PRIOR FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-919A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCACAGCTGGAGA 1273
DB      18 GCAGCACAGCTGGATGA 1

RESULT 127
US-10-013-920A-21/C
; Sequence 21, Application US/10013920A
; Publication No. US20040006219A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
```

```

; APPLICANT: Botstein, David
; APPLICANT: Denoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geriltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C78
; CURRENT APPLICATION NUMBER: US/10/013,920A
; PRIOR FILING DATE: 2001-10-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-920A-21

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1256 GCAGCACAGCTGGAGA 1273
DB      18 GCAGCACAGCTGGATGA 1

RESULT 128
US-10-164-749A-21/C
; Sequence 21, Application US/10164749A
; Publication No. US20040029218A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Denoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geriltsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
```

```

; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C60
; CURRENT APPLICATION NUMBER: US/10/164,749A
; CURRENT FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-164-749A-21

```

```

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1256 GCAGCAACAGCTGGAAGA 1273
Db      18 GCAGCACACAGCTGGATGA 1

```

```

RESULT 129
US-10-013-917A-21/c
; Sequence 21, Application US/10013917A
; Publication No. US2004006392A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertsens, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J

```

```

; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C82
; CURRENT APPLICATION NUMBER: US/10/013,917A
; CURRENT FILING DATE: 2001-10-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-917A-21

```

```

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1256 GCAGCAACAGCTGGAAGA 1273
Db      18 GCAGCACACAGCTGGATGA 1

```

```

RESULT 130
US-10-317-500-171
; Sequence 171, Application US/10317500
; Publication No. US20040115637A1
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PPAR-ALPHA EXPRESSION
; FILE REFERENCE: RTS-0380
; CURRENT APPLICATION NUMBER: US/10/317,500
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 276
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-500-171

```

```

Query Match          5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1353 CCCAGGCGACGCTGAGGCT 1370
Db      1 CCCTGGGCGACCTGAGGCT 18

```

```

RESULT 131
US-10-317-500-272/c
; Sequence 272, Application US/10317500
; Publication No. US20040115637A1
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PPAR-ALPHA EXPRESSION
; FILE REFERENCE: RTS-0380

```

FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-152-388B-21

Query Match
Best Local Similarity 88.9%; Score 14.8; DB 1; Length 20;
Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-10-317-500-272

ORGANISM: M. musculus
FEATURE:

US-10-317-500-272

Query Match
Best Local Similarity 88.9%; Score 14.8; DB 1; Length 20;
Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-10-152-388B-21/C

Sequence 21, Application US/10152388B
Publication No. US20040223964A1

GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerltsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 39780-P2630P1C50
CURRENT APPLICATION NUMBER: US/10/152,388B
CURRENT FILING DATE: 2001-10-18
PRIOR APPLICATION NUMBER: US 09/918,585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: PCT/US00/04341
PRIOR FILING DATE: 2000-02-18
PRIOR APPLICATION NUMBER: US 60/131,445
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: US 09/380,138
PRIOR FILING DATE: 1999-08-25
PRIOR APPLICATION NUMBER: PCT/US99/05028
PRIOR FILING DATE: 1999-03-08
PRIOR APPLICATION NUMBER: US 60/085,689
PRIOR FILING DATE: 1998-05-15
NUMBER OF SEQ ID NOS: 624
SEQ ID NO 21
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-152-388B-21

Query Match
Best Local Similarity 88.9%; Score 14.8; DB 1; Length 20;
Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-10-152-388B-21

ORGANISM: M. musculus
FEATURE:

US-10-152-388B-21

Query Match
Best Local Similarity 88.9%; Score 14.8; DB 1; Length 20;
Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-10-152-388B-21/C

Sequence 11258, Application US/10786720
Publication No. US2004019181A1

GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: O'Toole, Margot
APPLICANT: Liu, Wei
APPLICANT: TITL OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
FILE REFERENCE: 031896-023000 (AM101311L)
CURRENT APPLICATION NUMBER: US/10/786,720
CURRENT FILING DATE: 2004-02-26
NUMBER OF SEQ ID NOS: 21135
SOFTWARE: PatentIn version 3.2
SEQ ID NO 11258
LENGTH: 21
TYPE: RNA
ORGANISM: RNAi-sense strand
US-10-786-720-11258

Query Match
Best Local Similarity 88.9%; Score 14.8; DB 1; Length 21;
Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-10-786-720-11258

Query Match
Best Local Similarity 88.9%; Score 14.8; DB 1; Length 21;
Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-10-786-720-11258

Sequence 928, Application US/09866108
Patent No. US2002004880A1

GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: ABOWICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-928
```

```

Query Match      5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1264 AGCTGAAGAGGCTGA 1279
Db       2 AGCTGAAGAGGCTGA 17
```

```

RESULT 135
US-09-866-108-930
; Sequence 930, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 930
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-930
```

```

Query Match      5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1265 GCTGAAGAGGCTGAG 1280
Db       1 GCTGAAGAGGCTGAG 16
```

```

RESULT 136
US-09-825-805-668/c
; Sequence 668, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Swedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot;
; FILE REFERENCE: MEB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 668
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-668
```

```

Query Match      5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1266 CTGAAGAGGCTGAGG 1281
Db       17 CTGAAGAGGCTGAGG 2
```

```

RESULT 137
US-09-818-875-915
; Sequence 915, Application US/09818875
```

```
Publication No. US20030051270A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/09/818,875
CURRENT FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 915
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-818-875-915
```

```
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY 1256 GCAGCAACAGCTGGA 1271
Db 2 GCAGCAACAGCTGGA 17
```

```
RESULT 138
US-09-818-875-916/c
Sequence 916, Application US/09818875
Publication No. US20030051270A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/09/818,875
CURRENT FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 916
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-818-875-916
```

```
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY 1256 GCAGCAACAGCTGGA 1271
Db 16 GCAGCAACAGCTGGA 1
```

```
RESULT 139
US-09-818-875-923
Sequence 923, Application US/09818875
Publication No. US20030051270A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/09/818,875
CURRENT FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 923
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-818-875-923
```

```
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY 1256 GCAGCAACAGCTGGA 1271
Db 2 GCAGCAACAGCTGGA 17
```

```
RESULT 140
US-09-818-875-924/c
Sequence 924, Application US/09818875
Publication No. US20030051270A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US/09/818,875
CURRENT FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 924
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-818-875-924
```

```
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY 1256 GCAGCAACAGCTGGA 1271
Db 16 GCAGCAACAGCTGGA 1
```

Db 16 GGAGCAACAGCTGGAA 1

RESULT 141

```
US-10-163-552-338/C
; Sequence 338, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 338
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-338
```

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1266 CTGGAAGAGGCTGAG 1261

Db 17 CTGGAAGAGGCTGAGG 2

RESULT 142

```
US-10-209-787-915
; Sequence 915, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 915
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-915
```

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAA 1271

Db 2 GGAGCAACAGCTGGAA 17

RESULT 143

```
US-10-209-787-916/C
; Sequence 916, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 916
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-916
```

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAA 1271

Db 16 GGAGCAACAGCTGGAA 1

RESULT 144

```
US-10-209-787-923
; Sequence 923, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 923
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-923
```

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAA 1271
| | | | | | | | | |
Db 2 GGAGCAACAGCTGAA 17

RESULT 145

US-10-209-787-924/C
; Sequence 924, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO: 924
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-924

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAA 1271
| | | | | | | | | |
Db 16 GGAGCAACAGCTGAA 1

RESULT 146

US-10-261-185-915
; Sequence 915, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO: 915
; LENGTH: 17

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-915

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAA 1271
| | | | | | | | | |
Db 2 GGAGCAACAGCTGAA 17

RESULT 147

US-10-261-185-916/C
; Sequence 916, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO: 916
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-916

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAA 1271
| | | | | | | | | |
Db 16 GGAGCAACAGCTGAA 1

RESULT 148

US-10-261-185-923
; Sequence 923, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO: 923
; LENGTH: 17

;; PRIOR FILING DATE: 2000-06-01
;; PRIOR APPLICATION NUMBER: US 60/244,989
;; PRIOR FILING DATE: 2000-10-10
;; NUMBER OF SEQ ID NOS: 4385
;; SOFTWARE: Friedman macro Napro4
;; SEQ ID NO 923
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-261-185-923

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGA 1271
Db 2 GGAGCAACAGCTGGA 17

RESULT 149

US-10-261-185-924/C
;; Sequence 924, Application US/10261185
;; Publication No. US20040014057A1
;; GENERAL INFORMATION:
;; APPLICANT: Kmiec, Eric B.
;; APPLICANT: Gamper, Howard B.
;; APPLICANT: Rice, Michael C.
;; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;; TITLE OF INVENTION: Stranded Oligonucleotides
;; FILE REFERENCE: Napro-4CON
;; CURRENT APPLICATION NUMBER: US/10/261,185
;; CURRENT FILING DATE: 2002-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/09761
;; PRIOR FILING DATE: 2001-03-27
;; PRIOR APPLICATION NUMBER: US 60/192,176
;; PRIOR FILING DATE: 2000-03-27
;; PRIOR APPLICATION NUMBER: US 60/192,179
;; PRIOR FILING DATE: 2000-03-27
;; PRIOR APPLICATION NUMBER: US 60/208,538
;; PRIOR FILING DATE: 2000-06-01
;; PRIOR APPLICATION NUMBER: US 60/244,989
;; PRIOR FILING DATE: 2000-10-10
;; NUMBER OF SEQ ID NOS: 4385
;; SOFTWARE: Friedman macro Napro4
;; SEQ ID NO 924
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-261-185-924

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGA 1271
Db 16 GGAGCAACAGCTGGA 1

RESULT 150

US-10-138-674-2336
;; Sequence 924, Application US/10138674
;; Publication No. US20040077565A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyne Pharmaceuticals, Inc.
;; APPLICANT: Pavco, Pam
;; APPLICANT: McSwiggen, Jim
;; APPLICANT: Stinchcomb, Dan
;; APPLICANT: Escobedo, Jaime
;; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
;; FILE REFERENCE: MH800-876-N (400/049)

;; CURRENT APPLICATION NUMBER: US/10/138,674
;; CURRENT FILING DATE: 2002-05-03
;; NUMBER OF SEQ ID NOS: 20822
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2336
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Mus musculus
US-10-138-674-2336

Query Match
Best Local Similarity 62.5%; Score 14.4; DB 1; Length 17;
Pred. No. 1.4e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1301 CATGTCATCTGTGAG 1316
Db 1 CAUGGUCUUCUGUGAG 16

RESULT 151

US-10-287-949A-2336
;; Sequence 2336, Application US/10287949A
;; Publication No. US20040102389A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyne Pharmaceuticals, Inc.
;; APPLICANT: Pavco, Pam
;; APPLICANT: McSwiggen, Jim
;; APPLICANT: Stinchcomb, Dan
;; APPLICANT: Escobedo, Jaime
;; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
;; FILE REFERENCE: MH800-876-N (400/049)
;; CURRENT APPLICATION NUMBER: US/10/287,949A
;; CURRENT FILING DATE: 2003-04-11
;; NUMBER OF SEQ ID NOS: 20822
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2336
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Mus musculus
US-10-287-949A-2336

Query Match
Best Local Similarity 62.5%; Score 14.4; DB 1; Length 17;
Pred. No. 1.4e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1301 CATGTCATCTGTGAG 1316
Db 1 CAUGGUCUUCUGUGAG 16

RESULT 152

US-10-723-361-928
;; Sequence 928, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; CURRENT FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-928

Query Match      5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1264 AGCTGAAGAGGCTGA 1279
Db      2 AGCTGAAGAGGCTGA 17

RESULT 153
US-10-723-361-930
; Sequence 930, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Menheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 930
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-930

Query Match      5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1265 GCTGAAGAGGCTGAG 1280
Db      1 GCTGAAGAGGCTGAG 16

RESULT 154
US-10-681-074-915
; Sequence 915, Application US/10681074
; Publication No. US2004015722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NAPIRO-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 915
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-915

Query Match      5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1256 GCAGCAACAGCTGAA 1271
Db      2 GCAGCAACAGCTGAA 17

RESULT 155
US-10-681-074-916/c
; Sequence 916, Application US/10681074
; Publication No. US2004015722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NAPIRO-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 916
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-916

Query Match      5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 1256 GCAGCAACAGCTGGAA 1271
| | | | | | | | | |
Db 16 GGAGCAACAGCTGGAA 1

RESULT 156
US-10-681-074-923
; Sequence 923, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KITEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NABro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; PRIOR FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 923
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-923

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAA 1271
| | | | | | | | | |
Db 2 GGAGCAACAGCTGGAA 17

RESULT 157
US-10-681-074-924/c
; Sequence 924, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KITEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NABro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; PRIOR FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 924
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-924

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAA 1271
| | | | | | | | | |
Db 16 GGAGCAACAGCTGGAA 1

RESULT 158

US-10-224-005-63/c
; Sequence 63, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Fossnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADK
; FILE REFERENCE: 900/041 (MBH01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; PRIOR FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 63
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-224-005-63

Query Match 5.7%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1268 GGAAAGGCTGAGGCG 1283
| | | | | | | | | |
Db 16 GGAAAGGATGAGGCG 1

RESULT 159
US-10-224-005-224
; Sequence 224, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Fossnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADK
; FILE REFERENCE: 900/041 (MBH01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; PRIOR FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 224
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-224-005-224

Query Match 5.7%; Score 14.4; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1268 GGAAAGGCTGAGGCG 1283
| | | | | | | | | |
Db 4 GGAAAGGATGAGGCG 19

RESULT 160
US-09-280-030-45/c
; Sequence 45, Application US/09280030A
; Patent No. US20010021515A1
; GENERAL INFORMATION:
; APPLICANT: Sato, Seiji

```
; APPLICANT: Higashikuni, Naohiko
; APPLICANT: Kudo, Toshiyuki
; TITLE OF INVENTION: DNAS ENCODING NEW FUSION PROTEINS AND PROCESSES FOR
; TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE
; FILE REFERENCE: 382.1026
; CURRENT APPLICATION NUMBER: US/09/280,030A
; CURRENT FILING DATE: 1999-03-26
; EARLIER APPLICATION NUMBER: JP10-87339/1998
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; PUBLICATION INFORMATION:
; JOURNAL: Science
; VOLUME: 205
; PAGES: 602-607
; DATE: 1979
; US-09-280-030-45

Query Match          5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1356 AGGCGAGCTGAGGCTT 1371
Db      20 AGGCGAGCTGAGGCTT 5

RESULT 161
US-09-279-5
; Sequence 5, Application US/09956279
; Publication No. US20020086422A1
; GENERAL INFORMATION:
; APPLICANT: Weismann, Irving L.
; APPLICANT: Traver, David Jeffrey
; APPLICANT: Akashi, Koichi
; TITLE OF INVENTION: MAMMALIAN MYELOID PROGENITOR CELL
; TITLE OF INVENTION: SUBSETS
; FILE REFERENCE: STAN126C1P
; CURRENT APPLICATION NUMBER: US/09/956,279
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: 09/607,529
; PRIOR FILING DATE: 2000-06-29
; PRIOR APPLICATION NUMBER: 60/141,421
; PRIOR FILING DATE: 1999-06-29
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-956-279-5

Query Match          5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1389 TTTCGTGAGCTGCTGG 1404
Db      5 TTTCGTGAGCTGCTGG 20

RESULT 162
US-10-161-996-142
; Sequence 142, Application US/10161996
; Publication No. US20030224515A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freiler
```

```
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-161-996-142

Query Match          5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1231 AGCATGCTGCTGCAGCT 1246
Db      5 AGCATGCTGCTGCAGCT 20

RESULT 163
US-10-380-127A-60
; Sequence 60, Application US/10380127A
; Publication No. US20040033976A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Donna T. Ward
; APPLICANT: William A. Garde
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline R. Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEK3 EXPRESSION
; FILE REFERENCE: RTP-0174
; CURRENT APPLICATION NUMBER: US/10/380,127A
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: 09/658,688
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-380-127A-60

Query Match          5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1356 AGGCGAGCTGAGGCTT 1371
Db      2 AGGCGAGCTGAGGCTT 17

RESULT 164
US-10-293-864-25/C
; Sequence 25, Application US/10293864
; Publication No. US20040092465A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HUNTINGTIN INTERACTING PROTEIN 1 EXPRESSION
; FILE REFERENCE: RTS-0432
; CURRENT APPLICATION NUMBER: US/10/293,864
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
```

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-293-864-25

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1263 CAGCTGAGAGGCTG 1278
DB 18 CAGCTGAGAGGCTG 3

RESULT 165
US-10-293-864-103
Sequence 103, Application US/10293864
Publication No. US20040092465A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF HUNTINGTIN INTERACTING PROTEIN 1 EXPRESSION
FILE REFERENCE: RTS-0432
CURRENT APPLICATION NUMBER: US/10/293,864
CURRENT FILING DATE: 2002-11-11
NUMBER OF SEQ ID NOS: 165
SEQ ID NO 103
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-293-864-103

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1263 CAGCTGAGAGGCTG 1278
DB 3 CAGCTGAGAGGCTG 18

RESULT 166
US-10-303-635-130
Sequence 130, Application US/10303635
Publication No. US20040102621A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF FORKHEAD BOX C2 EXPRESSION
FILE REFERENCE: RTS-0418
CURRENT APPLICATION NUMBER: US/10/303,635
CURRENT FILING DATE: 2002-11-21
NUMBER OF SEQ ID NOS: 257
SEQ ID NO 130
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-635-130

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1386 CGTTTGCTGAGCTGC 1401
DB 2 CGTTTGCTGAGCTGC 17

RESULT 167
US-10-737-576-5
Sequence 5, Application US/10737576
Publication No. US20040132186A1

GENERAL INFORMATION:
APPLICANT: Weisman, Irving L.
APPLICANT: Traver, David Jeffrey
APPLICANT: Akashi, Koichi
TITLE OF INVENTION: MAMMALIAN MYELOID PROGENITOR CELL
FILE REFERENCE: STAN126CIP
CURRENT APPLICATION NUMBER: US/10/737,576
CURRENT FILING DATE: 2003-12-15
PRIOR APPLICATION NUMBER: US/09/956,279
PRIOR FILING DATE: 2001-09-17
PRIOR APPLICATION NUMBER: 09/607,529
PRIOR FILING DATE: 2000-06-29
PRIOR APPLICATION NUMBER: 60/141,421
PRIOR FILING DATE: 1999-06-29
NUMBER OF SEQ ID NOS: 6
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 5
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-737-576-5

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1389 TTGCTGAGCTGCTGG 1404
DB 5 TTGCTGAGCTGCTGG 20

RESULT 168
US-10-251-117-603/C
Sequence 603, Application US/10251117
Publication No. US20030170891A1
GENERAL INFORMATION:
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Receptor
FILE REFERENCE: 900/042 (MBH02-468-A)
CURRENT APPLICATION NUMBER: US/10/251,117
CURRENT FILING DATE: 2003-02-24
PRIOR APPLICATION NUMBER: US 60/393,924
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 10/163,552
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 09/916,466
PRIOR FILING DATE: 2001-07-25
PRIOR APPLICATION NUMBER: US 60/296,249
PRIOR FILING DATE: 2001-06-06
NUMBER OF SEQ ID NOS: 1213
SOFTWARE: PatentIn version 3.0
SEQ ID NO 603
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-251-117-603

Query Match 5.6%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1187 CTCGAGAGGCTGTGAG 1205
DB 19 CTCGAGAGGCTGTGAG 1

RESULT 169
US-10-251-117-910
; Sequence 910, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MEH02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 910
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-910

Query Match
Best Local Similarity 68.4%; Pred. No. 2e+02; Length 19;
Matches 13; Conservative 3; Mismatches 0; Gaps 0;
QY 1187 CTCGCAGAGCGCTGTGCAG 1205
DB 1 CUCCCGGGGGCCUUGCAG 19
RESULT 170
US-10-205-309-151/C
; Sequence 151, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; TITLE OF INVENTION: Interfering RNA
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 151
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-205-309-151

Query Match
Best Local Similarity 84.2%; Pred. No. 2e+02; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1246 TGGTCGGGCTGCAGCAACA 1264
DB 1 TGGTCAGGCTGCAGCAACA 1
RESULT 171

US-10-205-309-476
; Sequence 476, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; TITLE OF INVENTION: Interfering RNA
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 476
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-205-309-476

Query Match
Best Local Similarity 68.4%; Pred. No. 2e+02; Length 19;
Matches 13; Conservative 3; Mismatches 0; Gaps 0;
QY 1246 TGGTCGGGCTGCAGCAACA 1264
DB 1 UGGUCAGGCTGCAGCAACA 19

RESULT 172
US-10-430-011-139
; Sequence 139, Application US/10430011
; Publication No. US20030213010A1
; GENERAL INFORMATION:
; APPLICANT: Monsanto Technology, LLC
; APPLICANT: Weaver, Lisa
; APPLICANT: Oulmasov, Tim
; APPLICANT: Vaduva, Gabriela
; APPLICANT: Liang, Jihong
; APPLICANT: Varagona, Rita
; APPLICANT: Venkatesh, Tyamagondlu
; TITLE OF INVENTION: Transgenic High Tryptophan Plants
; FILE REFERENCE: 51857R
; CURRENT APPLICATION NUMBER: US/10/430,011
; CURRENT FILING DATE: 2003-05-05
; NUMBER OF SEQ ID NOS: 143
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 139
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: A primer.
US-10-430-011-139

Query Match
Best Local Similarity 84.2%; Pred. No. 2e+02; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1292 TCAGGCGCATGTCATC 1310
DB 1 TCAGGCTGCTGTGCTTC 19

RESULT 173
US-09-780-172-71/C
; Sequence 71, Application US/09780172
; Patent No. US20020147163A1
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASEIN KINASE 2-ALPHA EXPRESSION
; FILE REFERENCE: RTS-0159
; CURRENT APPLICATION NUMBER: US/09/780,172
; CURRENT FILING DATE: 2001-02-08
; NUMBER OF SEQ ID NOS: 96
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-780-172-71
```

```
Query Match          5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1190 CCAGAGCCTGTGCAGAG 1208
Db      19  CCTGATGCTGCAGCAGAG 1
```

```
RESULT 174
US-09-993-731-82
; Sequence 82, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Matt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-82
```

```
Query Match          5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1252 GGCTGCAGCAACGCTGGA 1270
Db      2  GGCTGCAGCCTCAGCTGCA 20
```

```
RESULT 175
US-10-178-331-1/c
; Sequence 1, Application US/10178331
; Publication No. US2003002221A1
; GENERAL INFORMATION:
; APPLICANT: Ellingson, Jay L.E.
; APPLICANT: Veeva, Dirk N.
; TITLE OF INVENTION: METHODS AND OLIGONUCLEOTIDES FOR THE DETECTION OF
; TITLE OF INVENTION: SALMONELLA SP., E. COLI O157:H7, AND LISTERIA
; TITLE OF INVENTION: MONOCYTOGENES.
; FILE REFERENCE: 630699.90011
; CURRENT APPLICATION NUMBER: US/10/178,331
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: 60/300,199
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: 60/373,588
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: 60/373,589
; PRIOR FILING DATE: 2002-04-18
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:PCR primer for
; OTHER INFORMATION: Salmonella sp.
US-10-178-331-1
```

```
Query Match          5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1377 AACGACCTGCGTTTCTG 1395
Db      20  AACGATCCGCAATTTCCTG 2
```

```
RESULT 176
US-10-024-369-22
; Sequence 22, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-22
```

```
Query Match          5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1344 GGAGACTTTCCTCCAGGCGAG 1362
Db      2  GGAGACTTCCCGCAGTGCGAG 20
```

```
RESULT 177
US-10-161-996-93/c
; Sequence 93, Application US/10161996
; Publication No. US20030224515A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-161-996-93
```

```
Query Match          5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```

1  PRIOR FILING DATE: 2001-05-09
2  PRIOR APPLICATION NUMBER: 60/290,194
3  PRIOR FILING DATE: 2001-05-11
4  PRIOR APPLICATION NUMBER: 60/290,753
5  PRIOR FILING DATE: 2001-05-14
6  PRIOR APPLICATION NUMBER: 60/291,189
7  PRIOR FILING DATE: 2001-05-15
8  PRIOR APPLICATION NUMBER: 60/292,374
9  PRIOR FILING DATE: 2001-05-21
10 PRIOR APPLICATION NUMBER: 60/293,107
11 PRIOR FILING DATE: 2001-05-23
12 Remaining Prior Application data removed - See File Wrapper or PALM.
13 NUMBER OF SEQ ID NOS: 132
14 SEQ ID NO 111
15 LENGTH: 20
16 TYPE: DNA
17 ORGANISM: Artificial Sequence
18 FEATURE:
19 OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
20 US-10-136-728-111
21
22 Query Match
23 Best Local Similarity 84.2%; Score 14.2; DB 1; Length 20;
24 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
25
26 QY 1219 GTCGAACTTCGACATGT 1237
27 |||||
28 Db 1 GTCAGCAGATCCAGATGT 19
29
30 RESULT 180
31 US-10-292-849-28/c
32 Sequence 28, Application US/10292849
33 Publication No. US20040092463A1
34 GENERAL INFORMATION:
35 APPLICANT: Andrew T. Watt
36 TITLE OF INVENTION: MODULATION OF P1M-1 EXPRESSION
37 FILE REFERENCE: RTS-0170
38 CURRENT APPLICATION NUMBER: US/10/292,849
39 CURRENT FILING DATE: 2002-11-11
40 NUMBER OF SEQ ID NOS: 138
41 SEQ ID NO 28
42 LENGTH: 20
43 TYPE: DNA
44 ORGANISM: Artificial Sequence
45 FEATURE:
46 OTHER INFORMATION: Antisense Oligonucleotide
47 US-10-292-849-28
48
49 Query Match
50 Best Local Similarity 84.2%; Score 14.2; DB 1; Length 20;
51 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
52
53 QY 1240 TGGCAGTCGTCGCGCTGCA 1258
54 |||||
55 Db 19 TGGAAAGTCGTCCTGCTGAA 1
56
57 RESULT 181
58 US-10-292-849-100
59 Sequence 100, Application US/10292849
60 Publication No. US20040092463A1
61 GENERAL INFORMATION:
62 APPLICANT: Andrew T. Watt
63 TITLE OF INVENTION: MODULATION OF P1M-1 EXPRESSION
64 FILE REFERENCE: RTS-0170
65 CURRENT APPLICATION NUMBER: US/10/292,849
66 CURRENT FILING DATE: 2002-11-11
67 NUMBER OF SEQ ID NOS: 138
68 SEQ ID NO 100
69 LENGTH: 20
70 TYPE: DNA
71 ORGANISM: H. sapiens

```

;
FEATURE:
US-10-292-849-100

Query Match	5.6%	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2%;	Pred. No. 2.3e+02;		
Matches 16;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

QY	1240	TGGCAGTGGTCCGGCTGCA	1258
Db	2	TGCAAGTGGTCCCTGCTGAA	20

RESULT 182
US-10-300-263-69/c

```

Sequence 69, Application US/10300263
Publication No. US20040096834A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Doble
TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
FILE REFERENCE: RTS-0431
CURRENT APPLICATION NUMBER: US/10/300,263
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 154
SEQ ID NO 69
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-263-69

```

Query Match	5.6%	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2%;	Pred. No. 2.3e+02;		
Matches 16;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

QY	1339	AGCGAGGAGACTTTCCAG	1357
Db	20	AGCGAGGATCTTCCAAG	2

```

RESULT 183
US-10-300-263-135
: Sequence 135, Application US/10300263
: Publication No. US20040096834A1
: GENERAL INFORMATION:
: APPLICANT: Kenneth W. Dobie
: TITLE OF INVENTION: MODULATION OF HIP-1 PROTEIN INTERACTOR EXPRESSION
: FILE REFERENCE: RTS-0431
: CURRENT APPLICATION NUMBER: US/10/300,263
: CURRENT FILING DATE: 2002-11-19
: NUMBER OF SEQ ID NOS: 154
: SEQ ID NO 135
: LENGTH: 20
: TYPE: DNA
: ORGANISM: H. sapiens
: FEATURE:
: US-10-300-263-135

```

Query Match	5.6%	Score 14.2	DB 1	Length 20
Best Local Similarity	84.2%	Pred. No. 2.3e+02		
Matches 16	Conservative 0	Mismatches 3	Indels 0	Gaps 0

```

QY      1339 AGCAGAGACTTCCAG 1357
          |||||  |||||  ||
Db      1 AGCAGATTCTTCCAAG 19

```

RESULT 184
US-10-117-586C-32/C
; Sequence 32, Application US/10117586C
; Publication No. US20030152938A1
; GENERAL INFORMATION:
; APPLICANT: NATIONAL CANCER CENTER

```

: TITLE OF INVENTION: RET OLGONUCLEOTIDE MICROCHIP AND METHOD FOR DETECTING HEREDITARY
: TITLE OF INVENTION: CANCER
: FILE REFERENCE: P0A11254/PUG
: CURRENT APPLICATION NUMBER: US/10/117,586C
: CURRENT FILING DATE: 2002-04-05
: NUMBER OF SEQ. ID NOS.: 77
: SOFTWARE: KopatentIn 1.71
: SEQ. ID NO. 32
: LENGTH: 20
: TYPE: DNA
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: 620M-(W)
US-10-117-586C-32

```

Query Match	5.6%	Score 14;	DB 1;	Length 20;
Best Local Similarity	100.0%	Pred. No. 2.5e+02;		
Matches 14;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

```

QY      1184 GGGCTCCAGAAC 1197
          |||||
Db      18 GGGCTCCAGAAC 5

```

RESULT 185
US-10-665-216-162/c
: Sequence 162. Apr

Sequence 162, Application US/10665216
Publication No. US20040043957A1
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker
APPLICANT: Susan M. Freier
APPLICANT: Andrew T. Watt
TITLE OF INVENTION: ANTISENSE MODULATION OF UROKINASE PLASMINOGEN ACTIVATOR EXPRESSION
FILE REFERENCE: R1S-0188
CURRENT APPLICATION NUMBER: US/10/665,216
CURRENT FILING DATE: 2003-09-19
PRIOR APPLICATION NUMBER: US/09/821,972
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 168
SEQ ID NO 162
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-665-216-162

Query Match	5.6%;	Score 14;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 2.5e+02;		
Matches 14;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	1351	TTCCACGGGACGCT	1364
Db	17	TTCCACGGGACGCT	4

RESULT 186
US-09-866-108-927

```

Sequence 927, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOmica-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456

```

PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 927
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-927

Query Match 5.5% Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1262 ACAGCTGAAGAGGCTG 1278
Db 1 AGAGCTGAAGAGGCTG 17
RESULT 187
US-09-866-108-2593
Sequence 2593, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2593
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2593

Query Match 5.5% Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1293 CAGGTCGATGATGAT 1309
Db 1 CAGGTCGATGATGAT 17
RESULT 188
US-09-866-108-6611/c
Sequence 6611, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6611
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6611
```

```

Query Match      5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1222 AGAACCTCCAGCATGTG 1238
Db      17  AGAGCTCTCAGAGATGTG 1
```

```

RESULT 189
US-09-866-108-6612/C
```

```

; Sequence 6612, Application US/09866108
; Patent No. US20020048800A1
```

```

; GENERAL INFORMATION:
```

```

; APPLICANT: GU, Yizhong
```

```

; APPLICANT: JI, Yonggang
```

```

; APPLICANT: PENN, Sharron G.
```

```

; APPLICANT: HANZEL, David K.
```

```

; APPLICANT: RANK, David R.
```

```

; APPLICANT: CHEN, Wensheng
```

```

; APPLICANT: SHANNON, Mark
```

```

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
```

```

; FILE REFERENCE: AEOMICA-7
```

```

; CURRENT APPLICATION NUMBER: US/09/866,108
```

```

; CURRENT FILING DATE: 2001-05-25
```

```

; PRIOR APPLICATION NUMBER: US 60/207,456
```

```

; PRIOR FILING DATE: 2000-05-26
```

```

; PRIOR APPLICATION NUMBER: GB 24263,6
```

```

; PRIOR FILING DATE: 2000-10-04
```

```

; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00662
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00661
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: US 60/234,687
```

```

; PRIOR FILING DATE: 2000-09-21
```

```

; PRIOR APPLICATION NUMBER: US 60/266,860
```

```

; PRIOR FILING DATE: 2001-02-05
```

```

; NUMBER OF SEQ ID NOS: 15752
```

```

; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6612
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6612
```

```

Query Match      5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1221 CAGACCTCCAGCATGT 1237
Db      17  CAGAGCTCTCAGAGATGT 1
```

```

RESULT 190
```

```

US-09-866-108-8648
```

```

; Sequence 8648, Application US/09866108
```

```

; Patent No. US20020048800A1
```

```

; GENERAL INFORMATION:
```

```

; APPLICANT: GU, Yizhong
```

```

; APPLICANT: JI, Yonggang
```

```

; APPLICANT: PENN, Sharron G.
```

```

; APPLICANT: HANZEL, David K.
```

```

; APPLICANT: RANK, David R.
```

```

; APPLICANT: CHEN, Wensheng
```

```

; APPLICANT: SHANNON, Mark
```

```

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
```

```

; FILE REFERENCE: AEOMICA-7
```

```

; CURRENT APPLICATION NUMBER: US/09/866,108
```

```

; CURRENT FILING DATE: 2001-05-25
```

```

; PRIOR APPLICATION NUMBER: US 60/207,456
```

```

; PRIOR FILING DATE: 2000-05-26
```

```

; PRIOR APPLICATION NUMBER: GB 24263,6
```

```

; PRIOR FILING DATE: 2000-10-04
```

```

; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00662
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00661
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```

; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```

; PRIOR FILING DATE: 2000-09-21
```

```

; PRIOR APPLICATION NUMBER: US 60/266,860
```

```

; PRIOR FILING DATE: 2001-02-05
```

```

; NUMBER OF SEQ ID NOS: 15752
```

```

; SOFTWARE: Aeomica Sequence Listing Engine
```

```

; SEQ ID NO 8648
```

```

; LENGTH: 17
```

```

; TYPE: DNA
```

```

; ORGANISM: Homo sapiens
```

```

US-09-866-108-8648
```

```

Query Match      5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 1254 CTGCAGCAAGCTGGA 1270
|||||
Db 1 CTGCAGCTGCAGCTGGA 17

RESULT 191

US-09-825-805-667/c
; Sequence 667, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Karpelesky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Zimen, Shawn
; APPLICANT: Sweedler, Dave
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleo
; FILE REFERENCE: MHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; PRIOR FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 667
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-667

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1268 GGAAGAGGCTGAGGCA 1284
|||||
Db 17 GGAAGAGGCTGAGGTCA 1

RESULT 192

US-09-818-875-927
; Sequence 927, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989

; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 927
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-927

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1264 AGCTGGAAGAGGCTGAG 1280
|||||
Db 1 AGCTGGAAGAGTCTGGG 17

RESULT 193

US-09-818-875-928/c
; Sequence 928, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-928

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1264 AGCTGGAAGAGGCTGAG 1280
|||||
Db 17 AGCTGGAAGAGTCTGGG 1

RESULT 194

US-09-930-423-795/c
; Sequence 795, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; PRIOR FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 795
; LENGTH: 17
; TYPE: RNA

```
; ORGANISM: Homo sapiens
US-09-930-423-795

Query Match
Best Local Similarity 5.5%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1200 GTGCAGAGGCGAGCCAT 1216
DB 17 GCGCAGATGGCAGCCAT 1

RESULT 195
US-09-745-237A-795/C
; Sequence 795, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 795
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-795

Query Match
Best Local Similarity 5.5%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1200 GTGCAGAGGCGAGCCAT 1216
DB 17 GCGCAGATGGCAGCCAT 1

RESULT 196
US-10-163-552-337/C
; Sequence 337, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MEHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 337
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-337

Query Match
Best Local Similarity 5.5%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1268 GGAAGAGGCTGAGGCGCA 1284
DB 17 GGAAGAGGCTGAGGCTCA 1

RESULT 197
US-10-156-306-5922
; Sequence 5922, Application US/10156306
```

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IκK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5922
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5922

Query Match
Best Local Similarity 5.5%; Score 13.8; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1254 CTGCAGACAGCTGGA 1270
DB 1 CUGCAGAGCGCTGGA 17

RESULT 198
US-10-209-787-927
; Sequence 927, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 927
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-927

Query Match
Best Local Similarity 5.5%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1264 AGCTGGAAGAGCTGAG 1280
DB 1 AGCTGGAAGAGCTGGG 17

RESULT 199
US-10-209-787-928/C
; Sequence 928, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
```

APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 10/209,787
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedmann macro Napro4
SEQ ID NO 928
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-928

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1264 AGCTGGAAGAGGCTGAG 1280
DB 17 AGCTGGAAGAGTCTGGG 1

RESULT 200

US-10-261-185-927
Sequence 927, Application US/10261185
Publication No. US20040014057A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4CON
CURRENT FILING DATE: 2002-09-27
PRIOR APPLICATION NUMBER: US/10/261,185
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: PCT/US01/09761
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedmann macro Napro4
SEQ ID NO 927
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-261-185-927

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1264 AGCTGGAAGAGGCTGAG 1280
DB 1 AGCTGGAAGAGTCTGGG 17

RESULT 201
US-10-261-185-928/C
Sequence 928, Application US/10261185
Publication No. US20040014057A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
FILE REFERENCE: Napro-4CON
CURRENT FILING DATE: 2002-09-27
PRIOR APPLICATION NUMBER: US/10/261,185
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedmann macro Napro4
SEQ ID NO 928
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-261-185-928

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1264 AGCTGGAAGAGGCTGAG 1280
DB 17 AGCTGGAAGAGTCTGGG 1

RESULT 202

US-10-138-674-1607
Sequence 1607, Application US/10138674
Publication No. US20040077565A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
FILE REFERENCE: MBH00-876-N (400/049)
CURRENT FILING DATE: 2002-05-03
PRIOR APPLICATION NUMBER: US/10/138,674
PRIOR FILING DATE: 2002-05-03
NUMBER OF SEQ ID NOS: 20822
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1607
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-138-674-1607

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1299 GCCATGTCATCTGTGA 1315
DB 1 GCCAUGGUCUCUGUGA 17

RESULT 203

```
US-10-287-949A-1607
; Sequence 1607, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Scinchomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1607
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1607

Query Match          5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      1299 GCCATGTCATCTGTGA 1315
Db      1 GCGAUGGUCUUCUGUA 17

RESULT 204
US-10-723-361-927
; Sequence 927, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 927
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-10-723-361-927

Query Match          5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1262 ACAGCTGAAGAGGCTG 1278
Db      1 AGAGCTGAAGAGGCTG 17

RESULT 205
US-10-723-361-2593
; Sequence 2593, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 2593
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2593

Query Match          5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1293 CAGGTCGATGTCAT 1309
Db      1 CAGGTCGATGTCAT 17

RESULT 206
US-10-723-361-6611/c
; Sequence 6611, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6611
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-6611

Query Match      5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1222 AGAAGCTCCAGCATGTG 1238
Db      17 AGAGCTCCAGCATGTG 1

RESULT 207
US-10-723-361-6612/c
; Sequence 6612, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6612
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-6612
```

```

Query Match      5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1221 CAGAGCTCCAGCATGT 1237
Db      17 CAGAGCTCCAGCATGT 1
```

```

RESULT 208
US-10-723-361-8648
; Sequence 8648, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8648
```

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1254 CTGCAGCAAGCTGGA 1270
|||||
Db 1 CTGCAGCTGCAGCTGGA 17

RESULT 209
US-10-681-074-927
; Sequence 927, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NABro-18 US
; CURRENT FILING DATE: 2003-10-07
; CURRENT APPLICATION NUMBER: US/10/681,074
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 927
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-927

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1264 AGCTGAAGAGGCTGAG 1280
|||||
Db 1 AGCTGAAGAGCTGTGG 17

RESULT 210
US-10-681-074-928/c
; Sequence 928, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NABro-18 US
; CURRENT FILING DATE: 2003-10-07
; CURRENT APPLICATION NUMBER: US/10/681,074
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-928

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1264 AGCTGAAGAGGCTGAG 1280
|||||
Db 17 AGCTGAAGAGCTGTGG 1

RESULT 211
US-10-440-850-1062/c

; Sequence 1062, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revers
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MEB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1062
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-1062

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1266 CTGAAGAGGCTGAGG 1282
|||||
Db 18 CTGGGGGAGGCTGAGG 2

RESULT 212
US-10-138-674-2186/c
; Sequence 2186, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Recobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2186
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2186

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1267 TGAAGAGGCTGAGGC 1283
|||||
Db 17 TGACAGAGGCTGTGGC 1

```
RESULT 213
US-10-287-949A-2186/c
; Sequence 2186, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHBOO-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2186
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2186

Query Match          5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1267 TGGAGAGGCTGAGGCGC 1283
DB      17  TGGCAGAGGCTGTGGCC 1

RESULT 214
US-10-205-309-103/c
; Sequence 103, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 103
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-205-309-103

Query Match          5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1200 GTGCAGAGGCGAGCCAT 1216
DB      18  GCGCAGATGGCAGCCAT 2

RESULT 215
US-10-205-309-169
; Sequence 169, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; FILE REFERENCE: 900/033
```

```
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 169
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-205-309-169

Query Match          5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 2.4e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1318 AGCTAGGAGGACCTCTTC 1334
DB      3  AGGAGAGAGACCTCCTTC 19

RESULT 216
US-10-205-309-428
; Sequence 428, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 428
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-205-309-428

Query Match          5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1200 GTGCAGAGGCGAGCCAT 1216
DB      2  GCGCAGATGGCAGCCAU 18

RESULT 217
US-10-205-309-494/c
; Sequence 494, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 494
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-205-309-494
```

Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1318 AGTAGGAGCCTCTTC 1334
Db 17 AGTAGGAGCCTCTTC 1

RESULT 218
US-09-880-313A-235
; Sequence 235, Application US/09880313A
; Publication No. US20030044791A1
; GENERAL INFORMATION:
; APPLICANT: Flemington, Eric K
; TITLE OF INVENTION: Adaptors and Methods of Use
; FILE REFERENCE: 9397/1000
; CURRENT APPLICATION NUMBER: US/09/880,313A
; CURRENT FILING DATE: 2001-06-13
; NUMBER OF SEQ ID NOS: 276
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 235
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-09-880-313A-235

Query Match 5.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1247 GGTCCGCTGCAGCA 1261
Db 1 GATCCGGCTGCAGCA 15

RESULT 219
US-10-163-552-1980/C
; Sequence 1980, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1980
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-1980

Query Match 5.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1267 TCGAAGAGGCTGAGG 1281
Db 15 TCGAAGAGGCTGAGG 1

RESULT 220
US-09-866-108-931
; Sequence 931, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 931
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-931

Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1266 CTGAAGAGGCTGAG 1280
Db 1 CTGAAGAGGCTGAG 15

RESULT 221
US-09-930-423-1074/C
; Sequence 1074, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1074

LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-1074

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1202 GCAGAGGCGAGCCAT 1216
DB 17 GCAGATGCGAGCCAT 3

RESULT 222
US-09-930-423-1221
Sequence 1221, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH00,918-A 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: Patentin version 3.0
SEQ ID NO 1221
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-1221

Query Match
Best Local Similarity 80.0%; Score 13.4; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1371 TACCAGAGCAGCTG 1385
DB 1 UACCAGAGCAGCTG 15

RESULT 223
US-09-930-423-1575
Sequence 1575, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH00,918-A 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: Patentin version 3.0
SEQ ID NO 1575
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-1575

Query Match
Best Local Similarity 80.0%; Score 13.4; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1371 TACCAGAGCAGCTG 1385
DB 2 UACCAGAGCAGCTG 16

RESULT 224

US-09-740-332-1418/c
Sequence 1418, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: Patentin version 3.0
SEQ ID NO 1418
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1418

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1412 GCGTCTGAGCGGC 1426
DB 15 GCGTGTGAGCGGC 1

RESULT 225
US-09-745-237A-1074/c
Sequence 1074, Application US/09745237A
Publication No. US20030143708A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: 400/007 (MBH00-918-A)
CURRENT APPLICATION NUMBER: US/09/745,237A
CURRENT FILING DATE: 2002-04-15
NUMBER OF SEQ ID NOS: 4550
SOFTWARE: Patentin version 3.0
SEQ ID NO 1074
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-745-237A-1074

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1202 GCAGAGGCGAGCCAT 1216
DB 17 GCAGATGCGAGCCAT 3

RESULT 226
US-09-745-237A-1221
Sequence 1221, Application US/09745237A
Publication No. US20030143708A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: 400/007 (MBH00-918-A)
CURRENT APPLICATION NUMBER: US/09/745,237A
CURRENT FILING DATE: 2002-04-15
NUMBER OF SEQ ID NOS: 4550

```
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1221
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1221
```

```
Query Match          5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1371 TACCAGAGCAGCTG 1385
        :|||||:|||||:|
Db       1 UACCAGAGCAGCTG 15
```

```
RESULT 227
US-09-745-237A-1575
; Sequence 1575, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1575
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1575
```

```
Query Match          5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1371 TACCAGAGCAGCTG 1385
        :|||||:|||||:|
Db       2 UACCAGAGCAGCTG 16
```

```
RESULT 228
US-09-817-879-1418/C
; Sequence 1418, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1418
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: m1ec_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1418
```

```
Query Match          5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1412 GGGTGTGAGCGGC 1426
```

```
Db       15 GGGTGTGAGCGGC 1
```

```
RESULT 229
US-10-138-674-1608
; Sequence 1608, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1608
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1608
```

```
Query Match          5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.1e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1301 CATGTCATCTGTGA 1315
        ||:|:|:|:|:|:|
Db       1 CAUGGUCUUCUGAG 15
```

```
RESULT 230
US-10-138-674-2337
; Sequence 2337, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2337
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2337
```

```
Query Match          5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.1e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1302 ATGTCATCTGTGAG 1316
        |:|:|:|:|:|:|
Db       1 AUGGUCUUCUGAG 15
```

```
RESULT 231
US-10-138-674-6233
; Sequence 6233, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
```

```

: APPLICANT: Ribozyme Pharmaceuticals, Inc.
: APPLICANT: Pavco, Pam
: APPLICANT: McSwigen, Jim
: APPLICANT: Stinchcomb, Dan
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
: TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
: FILE REFERENCE: MBH800-876-N (400/049)
: CURRENT APPLICATION NUMBER: US/10/138,674
: CURRENT FILING DATE: 2002-05-03
: NUMBER OF SEQ ID NOS: 20822
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 6233
: LENGTH: 17
: TYPE: RNA
: ORGANISM: Homo sapiens
: OS-10-138-674-6233

```

Query Match 5.3%; Score 13.4; DB 1; Length 17;
 Query Local Similarity 60.0%; Pred. No. 2.1e+02;
 Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0.

Qy	1301	CATGTCATCTGTGA	1315
		: : : : : :	
Db	2	CAUGGUCUUCUGUA	16

```

RESULT 232
US-10-287-949A-1608
Sequence 1608, Application US/10287949A
Publication No. US20040102389A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Expression of a Gene
FILE REFERENCE: MBH00-876-N (400/049)
CURRENT APPLICATION NUMBER: US/10/287,949A
CURRENT FILING DATE: 2003-04-11
NUMBER OF SEQ ID NOS: 20822
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1608
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-287-949A-1608

```

	Query Match	5.3%	Score 13.4; DB 1	length 17;
	Best Local Similarity	60.0%	Pred. No.2,le+08	
	Matches	9;	Conservative	5; Mismatches 1; Indels 0; Gaps 0;
QY	1301 CATGCTCATCTGTGTA	1315		
	: : : : :			
Dd	1 CAUGAUCUUCUGUA	15		

RESULT 233
US-10-287-949A-2337
Sequence 2337, Application US/10287949A
Publication No. US20040102389A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggan, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OR INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Vascular Endothelial Growth Factor Receptor
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MHB00-876-N (400/049)
CURRENT APPLICATION NUMBER: US/10/287, 949A

```

: CURRENT FILING DATE: 2003-04-11
: NUMBER OF SEQ ID NOS: 20822
: SOFTWARE: Relentin version 3.0
: SEQ ID NO 2337
: LENGTH: 17
: TYPE: RNA
: ORGANISM: Mus musculus
:
: US-10-287-949A-2337

```

Query Match	5.3%	Score	13.4	DB	1	Length	17
Best Local	Similarity	60.0%	Pred. No.	2.1e+02			
Matches	9	Conservative	5	Mismatches	1	Indels	0
						Gaps	0

```
QY      1302 ATGTCATCTGTGAG 1316
          |||:|:|:|:|
Db      1 AUGGUCUUCUGUGAG 15
```

```

RESULT 234
US-10-287-949A-6233
? Sequence 6233, Application US/10287949A
? Publication No. US20040102389A1
? GENERAL INFORMATION:
? APPLICANT: Ribozyme Pharmaceuticals, Inc.
? APPLICANT: Pavco, Pam
? APPLICANT: McSwigen, Jim
? APPLICANT: Stinchcomb, Dan
? APPLICANT: Escobedo, Jaime
? TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
? TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
? FILE REFERENCE: MBH00-876-N (400/049)
? CURRENT APPLICATION NUMBER: US/10/287,949A
? CURRENT FILING DATE: 2003-04-11
? NUMBER OF SEQ ID NOS: 20822
? SOFTWARE: PatentIn version 3.0
? SEQ ID NO 6233
? LENGTH: 17
? TYPE: RNA
? ORGANISM: Homo sapiens
? US-10-287-949A-6233

```

Query Match	5.3%	Score	13.4	DB 1	Length	17			
Similarity		Pred. NO.	2.1e+02						
Best Local	60.0%								
Matches	9	Conservative	5	Mismatches	1	Indels	0	Gaps	0

QY	1301	CATGTCATCTGTGA	1315
		: : : : : :	
Db	2	CAUGGUCUUCUGUA	16

```

1 RESULT 235
2 US-10-712-672-2406
3 Sequence 2406, Application US/10712672
4 Publication No. US20040102413A1
5 GENERAL INFORMATION:
6 APPLICANT: Ribozyyme Pharmaceuticals, Inc.
7 APPLICANT: Chowrira, Bharat
8 APPLICANT: McSwiggen, Jim
9 APPLICANT: Stinchcomb, Dan
10 TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
11 FILE REFERENCE: MBH800-882-C (400/019)
12 CURRENT APPLICATION NUMBER: US/10/712,672
13 CURRENT FILING DATE: 2003-11-13
14 PRIOR APPLICATION NUMBER: US/09/653,225
15 PRIOR FILING DATE: 2000-08-31
16 PRIOR APPLICATION NUMBER: 60/197,769
17 PRIOR FILING DATE: 2000-04-14
18 PRIOR APPLICATION NUMBER: 60/150,713
19 PRIOR FILING DATE: 1999-08-31
20 NUMBER OF SEQ ID NOS: 5586
21 SOFTWARE: PatentIn version 3.0
22 SEQ ID NO 2406
23 LENGTH: 17

```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2406

Query Match      5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1218 TGTGACGACTCCAG 1232
      1 |||||:||||
Db      3 UGACGAACTCCAG 17

RESULT 236
US-10-669-841-4011/c
; Sequence 4011, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, Mcswigen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPV
; FILE REFERENCE: 400/042US (MEH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4011
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4011

Query Match      5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1412 GGGTGCTGAGCGGC 1426
      ||||| ||||| |||||
```

```
Db      15 GGGTGCTGAGCGGC 1

RESULT 237
US-10-723-361-931
; Sequence 931, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UJ, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 931
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-931

Query Match      5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1266 CTGAGAGGCTGAG 1280
      ||||| ||||| |||||
Db      1 CTGAAAGGCTGAG 15

RESULT 238
US-09-853-688-34/c
; Sequence 34, Application US/09853688
; Patent No. US20020081605A1
; GENERAL INFORMATION:
; APPLICANT: COOPER, DAVID N.
; APPLICANT: PROCTER, ANNIE M.
; APPLICANT: GREGORY, JOHN
; APPLICANT: MILLAR, DAVID S.
; TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN
; FILE REFERENCE: WCM78
; CURRENT APPLICATION NUMBER: US/09/853,688
; CURRENT FILING DATE: 2001-05-14
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.1
```

SEQ ID NO 34
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
US-09-853-688-34

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1357 GGGCAGCTGAGGCTT 1371
Db 19 GGGCAGCTGTGGCTT 5

RESULT 239
US-09-853-688-61/c
Sequence 61, Application US/09853688
Patent No. US20020081605A1
GENERAL INFORMATION:

APPLICANT: COOPER, DAVID N.
APPLICANT: PROCTER, ANNIE M.
APPLICANT: GREGORY, JOHN
APPLICANT: MILLAR, DAVID S.
TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN
FILE REFERENCE: WCM78
CURRENT APPLICATION NUMBER: US/09/853,688
CURRENT FILING DATE: 2001-05-14
NUMBER OF SEQ ID NOS: 66
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 61
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
US-09-853-688-61

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1357 GGGCAGCTGAGGCTT 1371
Db 19 GGGCAGCTGTGGCTT 5

RESULT 240
US-09-823-549-44/c
Sequence 44, Application US/09823549
Publication No. US20020147998A1
GENERAL INFORMATION:

APPLICANT: McConlogue, Lisa C
APPLICANT: Games, Kate D.
APPLICANT: Yednock, Theodore A.
APPLICANT: Hua, Tan
APPLICANT: Messersmith, Elizabeth
APPLICANT: Baird, Frederique
TITLE OF INVENTION: SCREENING MARKERS AND METHODS FOR NEURODEGENERATIVE DISORDERS
FILE REFERENCE: 015270-009110US
CURRENT APPLICATION NUMBER: US/09/823,549
CURRENT FILING DATE: 2001-03-30
PRIOR APPLICATION NUMBER: US 60/193,847
PRIOR FILING DATE: 2000-03-30
NUMBER OF SEQ ID NOS: 85
SOFTWARE: PatentIn version 3.1
SEQ ID NO 44
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: IL-10 reverse primer
US-09-823-549-44

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1286 AGACCTCAGGGTGC 1300
Db 16 AGACCTCAGGATGC 2

RESULT 241
US-10-361-028-30
Sequence 30, Application US/10361028
Publication No. US20030199471A1
GENERAL INFORMATION:

APPLICANT: TAIRA, KAZUNARI
APPLICANT: WAKASHINA, MASAKI
APPLICANT: KIMABARA, TOMOKO
APPLICANT: KAWASAKI, HIROAKI
TITLE OF INVENTION: FUNCTIONAL CHIMERIC MOLECULES CAPABLE OF SLIDING
FILE REFERENCE: 081356/0151
CURRENT APPLICATION NUMBER: US/10/361,028
CURRENT FILING DATE: 2003-02-10
PRIOR APPLICATION NUMBER: US/09/704,525
PRIOR FILING DATE: 2000-11-03
PRIOR APPLICATION NUMBER: JP 316133/1999
PRIOR FILING DATE: 1999-11-05
NUMBER OF SEQ ID NOS: 56
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 30
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-10-361-028-30

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 2.8e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1326 GACCTCTTCGCCAG 1340
Db 5 GACCTCUCUCCCAUG 19

RESULT 242
US-10-788-318-34/c
Sequence 34, Application US/10788318
Publication No. US20040137510A1
GENERAL INFORMATION:

APPLICANT: COOPER, DAVID N.
APPLICANT: GREGORY, JOHN
APPLICANT: MILLAR, DAVID S.
TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN
FILE REFERENCE: WCM78
CURRENT APPLICATION NUMBER: US/10/788,318
CURRENT FILING DATE: 2004-03-01
NUMBER OF SEQ ID NOS: 66
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 34
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
US-10-788-318-34

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1357 GGGCAGCTGAGGCTT 1371
Db 19 GGGCAGCTGTGGCTT 5

RESULT 243
US-10-788-318-61/c
; Sequence 61, Application US/10788318
; Publication No. US20040137510A1
; GENERAL INFORMATION:
; APPLICANT: COOPER, DAVID N.
; APPLICANT: PROCTER, ANNIE M.
; APPLICANT: GREGORY, JOHN
; APPLICANT: MILLAR, DAVID S.
; TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN
; FILE REFERENCE: WCM78
; CURRENT APPLICATION NUMBER: US/10/788,318
; CURRENT FILING DATE: 2004-03-01
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 61
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-788-318-61

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1357 GGGCAGCTGAGCTT 1371
DB 19 GGGCAGCTGTGGCTT 5

RESULT 244
US-10-685-992-44/c
; Sequence 44, Application US/10685992
; Publication No. US20040213739A1
; GENERAL INFORMATION:
; APPLICANT: McConlogue, Lisa C
; APPLICANT: Games, Kate D.
; APPLICANT: Yednock, Theodore A.
; APPLICANT: Hua, Tan
; APPLICANT: Messersmith, Elizabeth
; APPLICANT: Bard, Frederique
; TITLE OF INVENTION: SCREENING MARKERS AND METHODS FOR NEURODEGENERATIVE DISORDERS
; FILE REFERENCE: 015270-009110US
; CURRENT APPLICATION NUMBER: US/10/685,992
; CURRENT FILING DATE: 2003-10-14
; PRIOR APPLICATION NUMBER: US/09/823,549
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: US 60/193,847
; PRIOR FILING DATE: 2000-03-30
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IL-10 reverse primer
US-10-685-992-44

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1286 AGACCTCAGGCGC 1300
DB 16 AGACCTCAGGATGC 2

RESULT 245
US-09-067-638B-76/c
; Sequence 76, Application US/09067638B

; Patent No. US20020028923A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Brenda F. Baker
; APPLICANT: John McNeil
; APPLICANT: Susan M. Preier
; APPLICANT: Henri M. Saemor
; APPLICANT: Douglas G. Brooks
; APPLICANT: Cara Ohashi
; APPLICANT: Jacqueline R. Wyatt
; APPLICANT: Alexander Borchers
; APPLICANT: Timothy A. Vickers
; TITLE OF INVENTION: Identification of Genetic
; TITLE OF INVENTION: Targets for Modulation by Oligonucleotides and
; TITLE OF INVENTION: Generation of Oligonucleotides for Gene
; TITLE OF INVENTION: Modulation
; NUMBER OF SEQUENCES: 112
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: WOODCOCK WASHBURN KURTZ
; ADDRESSEE: MACKIEWICZ & NORRIS LLP
; STREET: 1 LIBERTY PLACE 46TH FLOOR
; CITY: PHILADELPHIA
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; COMPUTER: IBM
; OPERATING SYSTEM: PC-Windows NT
; SOFTWARE: WORD PERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/067,638B
; FILING DATE: 28-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/081,483
; FILING DATE: 13-APR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-2960
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-067-638B-76

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1337 CAAGCAGAGACTTCC 1354
DB 18 CAGTCAGAGAGACTTAC 1

RESULT 246
US-10-181-603-30/c
; Sequence 30, Application US/10181603
; Publication No. US20030049662A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RTSP-0342
; CURRENT APPLICATION NUMBER: US/10/181,603
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01165

PRIOR FILING DATE: 2001-01-12
PRIOR APPLICATION NUMBER: 09/487,444
PRIOR FILING DATE: 2000-01-19
NUMBER OF SEQ ID NOS: 49
SEQ ID NO 30
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-603-30

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1405 ACAGACCGGTGCTGAGC 1422
Db 18 ACAGACCGGTGAGCTGAGC 1

RESULT 247
US-10-116-325-76/c
Sequence 76, Application US/10116325
Publication No. US20030113739A1
GENERAL INFORMATION:
APPLICANT: Cowsett, Lex M.
APPLICANT: Baker, Brenda F.
APPLICANT: McNeill, John
APPLICANT: Freier, Susan M.
APPLICANT: Sasnor, Henri M.
APPLICANT: Brooks, Douglas G.
APPLICANT: Ohashi, Cara
APPLICANT: Wyatt, Jacqueline R.
APPLICANT: Borchers, Alexander
APPLICANT: Vickers, Timothy A.
TITLE OF INVENTION: Identification Of Genetic Targets For Modulation By Oligonucleotides
TITLE OF INVENTION: Generation Of Oligonucleotides For Gene Modulation
FILE REFERENCE: ISIS5026
CURRENT APPLICATION NUMBER: US/10/116,325
CURRENT FILING DATE: 2002-04-04
PRIOR APPLICATION NUMBER: 09/067,638
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/081,483
PRIOR FILING DATE: 1998-04-13
NUMBER OF SEQ ID NOS: 112
SOFTWARE: PatentIn version 3.1
SEQ ID NO 76
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. US20030113739A1e1 Sequence
US-10-116-325-76

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1337 CAAGCAGAGACTTCC 1354
Db 18 CAGTCAGAGACTTAC 1

RESULT 248
US-10-440-850-1007/c
Sequence 1007, Application US/10440850
Publication No. US20030207837A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Stinchcomb, Dan
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, Jim

TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reverse
TITLE OF INVENTION: Immune Responses
FILE REFERENCE: 250/130 (MHB00-900-A)
CURRENT APPLICATION NUMBER: US/10/440,850
CURRENT FILING DATE: 2003-05-19
PRIOR APPLICATION NUMBER: US/09/650,012
PRIOR FILING DATE: 2000-08-28
PRIOR APPLICATION NUMBER: US 08/585,684
PRIOR FILING DATE: 1996-01-12
PRIOR APPLICATION NUMBER: US 60/000,951
PRIOR FILING DATE: 1995-07-07
PRIOR APPLICATION NUMBER: US 09/038,073
PRIOR FILING DATE: 1998-03-11
NUMBER OF SEQ ID NOS: 2285
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1007
LENGTH: 18
TYPE: RNA
ORGANISM: Homo sapiens
US-10-440-850-1007

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1256 GCAGCAAGCTGGAAGA 1273
Db 18 GCACCAAGACTGAAGA 1

RESULT 249
US-10-388-263-76/c
Sequence 76, Application US/10388263
Publication No. US20030228597A1
GENERAL INFORMATION:
APPLICANT: Cowsett, Lex M.
APPLICANT: Baker, Brenda F.
APPLICANT: McNeill, John
APPLICANT: Freier, Susan M.
APPLICANT: Sasnor, Henri M.
APPLICANT: Brooks, Douglas G.
APPLICANT: Ohashi, Cara
APPLICANT: Wyatt, Jacqueline R.
APPLICANT: Borchers, Alexander
APPLICANT: Vickers, Timothy A.
TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
FILE REFERENCE: ISIS-4503
CURRENT APPLICATION NUMBER: US/10/388,263
CURRENT FILING DATE: 2003-03-12
NUMBER OF SEQ ID NOS: 947
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 76
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-76

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1337 CAAGCAGAGACTTCC 1354
Db 18 CAGTCAGAGACTTAC 1

RESULT 250
US-10-108-260A-5412/c
Sequence 5412, Application US/10108260A

```
/ Publication No. US20040005560A1
/ GENERAL INFORMATION:
/ APPLICANT: HELIX RESEARCH INSTITUTE
/ TITLE OF INVENTION: No. US20040005560A1el full length cDNA
/ FILE REFERENCE: HI-A0106
/ CURRENT APPLICATION NUMBER: US/10/108,260A
/ CURRENT FILING DATE: 2002-03-27
/ NUMBER OF SEQ ID NOS: 5458
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 5412
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized F
US-10-108-260A-5412

Query Match      5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1259 GCACAGCTGGAAGAGC 1276
Db      18 GCAGCAGCTGAAGAGTC 1

RESULT 251
US-10-698-689-76/c
/ Sequence 76, Application US/10698689
/ Publication No. US20040186071A1
/ GENERAL INFORMATION:
/ APPLICANT: Bennett, C. Frank
/ APPLICANT: Cowser, Lex M.
/ APPLICANT: Malik, Leila
/ APPLICANT: Siwkowski, Andrew
/ APPLICANT: Eldrup, Anne B.
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
/ FILE REFERENCE: ISIS-5315
/ CURRENT APPLICATION NUMBER: US/10/698,689
/ CURRENT FILING DATE: 2003-10-31
/ PRIOR APPLICATION NUMBER: PCT/US03/31166
/ PRIOR FILING DATE: 2003-09-30
/ PRIOR APPLICATION NUMBER: US 10/261,382
/ PRIOR FILING DATE: 2002-09-30
/ PRIOR APPLICATION NUMBER: US 09/067,638
/ PRIOR FILING DATE: 1998-04-28
/ PRIOR APPLICATION NUMBER: US 60/081,483
/ PRIOR FILING DATE: 1998-04-13
/ NUMBER OF SEQ ID NOS: 248
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 76
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Construct
US-10-698-689-76

Query Match      5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1337 CAAGCAGAGACTTCC 1354
Db      18 CAGTCAGAGACTTTAC 1

RESULT 252
US-10-698-689-240
/ Sequence 240, Application US/10698689
/ Publication No. US20040186071A1
/ GENERAL INFORMATION:
/ APPLICANT: Bennett, C. Frank
```

```
/ APPLICANT: Cowser, Lex M.
/ APPLICANT: Malik, Leila
/ APPLICANT: Siwkowski, Andrew
/ APPLICANT: Eldrup, Anne B.
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
/ FILE REFERENCE: ISIS-5315
/ CURRENT APPLICATION NUMBER: US/10/698,689
/ CURRENT FILING DATE: 2003-10-31
/ PRIOR APPLICATION NUMBER: PCT/US03/31166
/ PRIOR FILING DATE: 2003-09-30
/ PRIOR APPLICATION NUMBER: US 10/261,382
/ PRIOR FILING DATE: 2002-09-30
/ PRIOR APPLICATION NUMBER: US 09/067,638
/ PRIOR FILING DATE: 1998-04-28
/ PRIOR APPLICATION NUMBER: US 60/081,483
/ PRIOR FILING DATE: 1998-04-13
/ NUMBER OF SEQ ID NOS: 248
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 240
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Construct
US-10-698-689-240

Query Match      5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1337 CAAGCAGAGACTTCC 1354
Db      1 CAGTCAGAGACTTTAC 18

RESULT 253
US-10-830-475-76/c
/ Sequence 76, Application US/10830475
/ Publication No. US20040197814A1
/ GENERAL INFORMATION:
/ APPLICANT: Lex M. Cowser
/ APPLICANT: Brenda F. Baker
/ APPLICANT: John McNeil
/ APPLICANT: Susan M. Freier
/ APPLICANT: Henri M. Sasnor
/ APPLICANT: Douglas G. Brooks
/ APPLICANT: Cara Ohashi
/ APPLICANT: Jacqueline R. Wyatt
/ APPLICANT: Alexander Borchers
/ APPLICANT: Timothy A. Vickers
/ TITLE OF INVENTION: Identification of Genetic
/ Targets for Modulation By Oligonucleotides and
/ Generation of Oligonucleotides for Gene
/ Modulation
/ NUMBER OF SEQUENCES: 112
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: WOODCOCK WASHBURN KURTZ
/ STREET: 1 LIBERTY PLACE 46TH FLOOR
/ CITY: PHILADELPHIA
/ STATE: PA
/ COUNTRY: USA
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
/ COMPUTER: IBM
/ OPERATING SYSTEM: PC-Windows NT
/ SOFTWARE: WORD PERFECT 6.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/10/830,475
/ FILING DATE: 21-Apr-2004
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
```

APPLICATION NUMBER: US/09/067,638B
FILING DATE: 28-APR-1998
APPLICATION NUMBER: 60/081,483
FILING DATE: 13-APR-1998
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: 151S-2960
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 76:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 76:
US-10-830-475-76

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1337 CAAGCAGAGACTTCC 1354
DB 18 CAGTCAGAGACTTTAC 1

RESULT 254
US-09-866-108-2589
Sequence 2589, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21

PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2589
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2589

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1293 CAGGTCGCATGG 1305
DB 5 CAGGTCGCATGG 17

RESULT 255
US-09-866-108-2590
Sequence 2590, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2590
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2590

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTGCCATGG 1305
|||||
Db 4 CAGGTGCCATGG 16

RESULT 256
US-09-866-108-2591
; Sequence 2591, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2591
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2591

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTGCCATGG 1305
|||||
Db 3 CAGGTGCCATGG 15

RESULT 257

US-09-866-108-2592
; Sequence 2592, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2592
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2592

QY 1293 CAGGTGCCATGG 1305
|||||
Db 2 CAGGTGCCATGG 14

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 258
US-10-723-361-2589
; Sequence 2589, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng

QY 1293 CAGGTGCCATGG 1305
|||||
Db 2 CAGGTGCCATGG 14

```
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 2589
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-2589

Query Match
Best Local Similarity 100.0%; Score 13; DB 1; Length 17;
Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTCCTCATGG 1305
DB 5 CAGGTCCTCATGG 17

RESULT 259
US-10-723-361-2590
Sequence 2590, Application US/10723361
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 2591
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-2591
```

```
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 2590
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-2590

Query Match
Best Local Similarity 100.0%; Score 13; DB 1; Length 17;
Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTCCTCATGG 1305
DB 4 CAGGTCCTCATGG 16
```

```
RESULT 260
US-10-723-361-2591
Sequence 2591, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeonica Sequence Listing Engine
SEQ ID NO 2591
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-2591

Query Match
Best Local Similarity 100.0%; Score 13; DB 1; Length 17;
Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1293 CAGGTCGCATGG 1305
|||||
Db 3 CAGGTCGCATGG 15

RESULT 261

US-10-723-361-2592
; Sequence 2592, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Mensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: P0105
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1575
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2592
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-2592

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTCGCATGG 1305
|||||
Db 2 CAGGTCGCATGG 14

RESULT 262

US-10-388-263-258/c
; Sequence 258, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowser, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Freiler, Susan M.
; APPLICANT: Saemor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander

; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 258
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-388-263-258

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1375 AGAAGCAGCTGCG 1387
|||||
Db 18 AGAAGCAGCTGCG 6

RESULT 263
US-10-349-143-4727/c
; Sequence 4727, Application US/10349143
; Publication No. US200400584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/10/349,143
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4727
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-17363 for SEQ 793,
; US-10-349-143-4727

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1327 ACCTCTTCTCCA 1339
|||||
Db 13 ACCTCTTCTCCA 1

RESULT 264
US-10-628-109-176/c
; Sequence 176, Application US/10628109
; Publication No. US20040101886A1
; GENERAL INFORMATION:
; APPLICANT: Bowditch, Katherine S.
; APPLICANT: Frederickson, Shana

APPLICANT: Lin, Ying-Chi
APPLICANT: McWhirter, John
TITLE OF INVENTION: NESTED OLIGONUCLEOTIDES CONTAINING A HAIRPIN FOR NUCLEIC ACID
FILE REFERENCE: 1087-35 DIV
CURRENT APPLICATION NUMBER: US/10/628,109
CURRENT FILING DATE: 2003-07-28
PRIOR APPLICATION NUMBER: US 60/254,669
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 60/323,400
PRIOR FILING DATE: 2001-09-19
PRIOR APPLICATION NUMBER: US 10/014,012
PRIOR FILING DATE: 2001-12-10
NUMBER OF SEQ ID NOS: 231
SOFTWARE: PatentIn version 3.2
SEQ ID NO 176
LENGTH: 18
TYPE: DNA
ORGANISM: artificial sequence
FEATURE:
OTHER INFORMATION: primer
US-10-628-109-176

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1195 AGCCTGTGCAGAG 1207
DB 13 AGCCTGTGCAGAG 1

RESULT 265
US-10-608-436-36
Sequence 36, Application US/10608436
Publication No. US20040131633A1
GENERAL INFORMATION:
APPLICANT: ELLIS, JOHN TIMOTHY
APPLICANT: ATKINSON, ROBERT
APPLICANT: RYCE, CHERYL
APPLICANT: QUINN, HELEN ELIZABETH
APPLICANT: MILLER, CATHERINE MARGARET
APPLICANT: MORISON, DAVID ANDREW
TITLE OF INVENTION: PARASITE ANTIGENS
FILE REFERENCE: 47-194
CURRENT APPLICATION NUMBER: US/10/608,436
CURRENT FILING DATE: 2003-06-30
PRIOR APPLICATION NUMBER: AU PP 9928
PRIOR FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: PCT/AU00/00354
PRIOR FILING DATE: 2000-04-20
NUMBER OF SEQ ID NOS: 60
SOFTWARE: PatentIn version 3.2
SEQ ID NO 36
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR primer
US-10-608-436-36

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1336 CCAAGCAGAGAGA 1348
DB 1 CCAAGCAGAGAGA 13

RESULT 266
US-10-339-674-122

Sequence 122, Application US/10339674
Publication No. US20030204318A1
GENERAL INFORMATION:
APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
CURRENT APPLICATION NUMBER: US/10/339,674
CURRENT FILING DATE: 2003-06-06
NUMBER OF SEQ ID NOS: 3537
SOFTWARE: Proprietary
SEQ ID NO 122
LENGTH: 16
TYPE: DNA
ORGANISM: Escherichia coli K-12 MG1655 complete genome.
FEATURE:
LOCATION: (141811)..(141825)
OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectionObjectNumber = 163
US-10-339-674-122

Query Match 5.1%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1397 GCTGCTGCAGACCG 1412
DB 1 GCTGCTGCAGATTAACCG 16

RESULT 267
US-10-339-674-2867
Sequence 2867, Application US/10339674
Publication No. US20030204318A1
GENERAL INFORMATION:
APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
CURRENT APPLICATION NUMBER: US/10/339,674
CURRENT FILING DATE: 2003-06-06
NUMBER OF SEQ ID NOS: 3537
SOFTWARE: Proprietary
SEQ ID NO 2867
LENGTH: 16
TYPE: DNA
ORGANISM: Escherichia coli K-12 MG1655 complete genome.
FEATURE:
LOCATION: (3890645)..(3890660)
OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectionObjectNumber = 3801
US-10-339-674-2867

Query Match 5.1%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1397 GCTGCTGCAGACCG 1412
DB 1 GCTGCTGCAGATTAACCG 16

RESULT 268
US-09-866-108-926
Sequence 926, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Shangang G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOmica-7
CURRENT APPLICATION NUMBER: US/09/866,108

```
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/223,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeomica Sequence Listing Engine
/ SEQ ID NO 926
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-926
```

```
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1262 ACAGCTGAAGAGGCT 1277
Db 2 AGAGCTGAAGAGGCT 17
```

```
RESULT 269
US-09-866-108-1962
/ Sequence 1962, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
```

```
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeomica Sequence Listing Engine
/ SEQ ID NO 1962
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-1962
```

```
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1392 GCTGAGTGTGAGCA 1407
Db 2 GCTGAGTGTGAGCA 17
```

```
RESULT 270
US-09-866-108-1963
/ Sequence 1963, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1963
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-1963

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1392 GCTGAGCTGCTGACCA 1407
Db      1 GCTCAGCTGCTGCACCA 16

RESULT 271
US-09-866-108-2594
; Sequence 2594, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263, 6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
```

```

; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2594
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-2594

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1294 AGGATGCATGTCAT 1309
Db      1 AGGATGCATGAGAT 16

RESULT 272
US-09-866-108-6610/c
; Sequence 6610, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263, 6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6610
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-6610

Query Match          5.1%; Score 12.8; DB 1; Length 17;
```

Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1223 GAACCTCAGCATGTG 1238
DB 17 GAGCTCCAGCATGTG 2

RESULT 273

US-09-866-108-6613/C
; Sequence 6613, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6613
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6613

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 CAGAACTCGACATG 1236
DB 16 CAGAGCTCCAGCATG 1

RESULT 274
US-09-866-108-7346

; Sequence 7346, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7346
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7346

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 AACGCTGGAAGAGC 1276
DB 2 AACGCTTGAAGAGC 17

RESULT 275

US-09-866-108-7347
; Sequence 7347, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 7347
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-7347

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1261 AACGCTGGAAGAGC 1276
Db 1 AACGTTGGAAGAGC 16
|||||
|||

RESULT 276
US-09-866-108-7797
; Sequence 7797, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 7797
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-7797

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1253 GCTGACGACAGCTG 1268
Db 2 GCTTCAGCAGCAGCTG 17
|||||
|||

RESULT 277
US-09-866-108-7798
; Sequence 7798, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

US-09-866-108-8649

Query Match

5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1255 TGCAGCAACAGCTGCA 1270

DB 1 TGCAGCTGCAGCTGCA 16

RESULT 280

US-09-866-108-9346

; Sequence 9346, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: A60MCA Sequence Listing Engine
; SEQ ID NO 9346
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9346

Query Match

5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1269 GAAGAGCTGAGGCA 1284

DB 2 GAAGAGCTGAGGCA 17

RESULT 281

US-09-866-108-9347

; Sequence 9347, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: A60MCA Sequence Listing Engine
; SEQ ID NO 9347
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9347

Query Match

5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1269 GAAGAGCTGAGGCA 1284

DB 1 GAAGAGCTGAGGCA 16

RESULT 282

US-09-825-805-448

; Sequence 448, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex

APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
FILE REFERENCE: MHB00-831-F (400/009)
CURRENT APPLICATION NUMBER: US/09/825,805
CURRENT FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 09/578,223
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 09/476,387
PRIOR FILING DATE: 1999-12-30
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1558
SOFTWARE: PatentIn version 3.0
SEQ ID NO 448
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-825-805-448

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.6e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1392 GCTGAGCTGCTGACA 1407
||:||||:||||
Db 1 GCUCGCGUCGACACA 16

RESULT 283
US-09-825-805-502
Sequence 502, Application US/09825805
Publication No. US20030004122A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
FILE REFERENCE: MHB00-831-F (400/009)
CURRENT APPLICATION NUMBER: US/09/825,805
CURRENT FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 09/578,223
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 09/476,387
PRIOR FILING DATE: 1999-12-30
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1558
SOFTWARE: PatentIn version 3.0
SEQ ID NO 502
LENGTH: 17
TYPE: RNA

ORGANISM: Homo sapiens
US-09-825-805-502

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.6e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1305 GTCATCTGTAGCAGC 1320
||:||||:||||
Db 2 GCACUCGUCGAGCUGC 17

RESULT 284
US-09-780-533A-539/C
Sequence 539, Application US/09780533A
Publication No. US20030060611A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwigen, Jim
APPLICANT: Chowrira, Bharat
APPLICANT: Haeblerl, Pete
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
FILE REFERENCE: MHB00,878-A (400/011)
CURRENT APPLICATION NUMBER: US/09/780,533A
CURRENT FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: US 60/181,797
PRIOR FILING DATE: 2000-02-11
NUMBER OF SEQ ID NOS: 6679
SOFTWARE: PatentIn version 3.0
SEQ ID NO 539
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-780-533A-539

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1263 CAGCTGGAAGGCTG 1278
|||||
Db 16 CAGCAGGAATAGGCTG 1

RESULT 285
US-09-780-533A-2178/C
Sequence 2178, Application US/09780533A
Publication No. US20030060611A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
APPLICANT: McSwigen, Jim
APPLICANT: Chowrira, Bharat
APPLICANT: Haeblerl, Pete
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
FILE REFERENCE: MHB00,878-A (400/011)
CURRENT APPLICATION NUMBER: US/09/780,533A
CURRENT FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: US 60/181,797
PRIOR FILING DATE: 2000-02-11
NUMBER OF SEQ ID NOS: 6679
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2178
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-780-533A-2178

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1188 TCCGAGAGCCTGTC 1203
|||
Db 17 TCTCAGATCTCTGTC 2

RESULT 286

US-09-848-754A-2157/c
; Sequence 2157, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2157
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2157

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1202 GCAGAGGCGAGCCATC 1217
|||
Db 17 GCAGAGGCGAGCCAGC 2

RESULT 287

US-09-848-754A-2158/c
; Sequence 2158, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2158
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2158

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1200 GTGCAGAGGCGAGCCA 1215
|||
Db 17 GGCAGAGCGAGCCCA 2

RESULT 288

US-09-930-423-796/c
; Sequence 796, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15

; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 796
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-930-423-796

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1200 GTGCAGAGGCGAGCCA 1215
|||
Db 16 GCGCAGATGCGAGCCA 1

RESULT 289

US-09-930-423-984/c
; Sequence 984, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 984
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-930-423-984

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1195 AGCCTGTGCGAGAGGC 1210
|||
Db 17 AGCCTGTGCGAGCGGC 2

RESULT 290

US-09-827-395A-515/c
; Sequence 515, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence McSwigen
; APPLICANT: Bhairat Chowdhra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Nogo and Nogo Receptor Ge
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 515
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-515

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1356 AGGCGACCTGAGGCTT 1371
| | | | | | | | | |
Db 17 AGGCGACCTGAGGCTT 2

RESULT 291
US-09-827-395A-1014/C
; Sequence 1014, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C
; FILE REFERENCE: MHHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1014
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-1014

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1356 AGGCGACCTGAGGCTT 1371
| | | | | | | | | |
Db 16 AGGCGACCTGAGGCTT 1

RESULT 292
US-09-740-332-1800/C
; Sequence 1800, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Hepatic C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1800

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1334 CTCGACGACGAGAC 1349
| | | | | | | | | |
Db 17 CGCCAGGACGAGAC 2

RESULT 293
US-09-740-332-1944
; Sequence 1944, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Hepatic C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1944

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1265 GCTGAGAGGCTGAG 1280
| | | | | | | | | |
Db 1 GCTGAGAGGCTGAG 16

RESULT 294
US-09-740-332-2217
; Sequence 2217, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Hepatic C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2217
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2217

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1205 GAGGCGACCATCTGT 1220
| | | | | | | | | |
Db 2 GAGGCGCGCCACCTGU 17

RESULT 295
US-09-740-332-2338/C
; Sequence 2338, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Hepatic C Virus Infection
; FILE REFERENCE: RPI 400/003
US-09-740-332-2338

```
; CURRENT APPLICATION NUMBER: US/09/740.332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: Patent version 3.0
; SEQ ID NO 2338
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2338

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1205 GAGGCGAGCCATCTGT 1220
DB 17 GAGGCGGCGCCACTCTGT 2

RESULT 296
US-09-740-332-2755
; Sequence 2755, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740.332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: Patent version 3.0
; SEQ ID NO 2755
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2755

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1334 CTCGAGCGAGAGAC 1349
DB 2 CGCCAGCGAGAGAC 17

RESULT 297
US-09-745-237A-796/c
; Sequence 796, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745.237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: Patent version 3.0
; SEQ ID NO 796
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-745-237A-796

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1200 GTGCGAGCGGCGAGCCA 1215
DB 16 GCGCGAGTGGCAGCCA 1

RESULT 298
US-09-745-237A-984/c
; Sequence 984, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745.237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: Patent version 3.0
; SEQ ID NO 984
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-984

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1195 AGCCTGTGCGAGGCGC 1210
DB 17 AGCCTGTGCGAGGCGC 2

RESULT 299
US-09-817-879-1800/c
; Sequence 1800, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817.879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: Patent version 3.0
; SEQ ID NO 1800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1800

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1334 CTCGAGCGAGAGAC 1349
DB 17 CGCCAGCGAGAGAC 2

RESULT 300
```

```
US-09-817-879-1944
; Sequence 1944, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1944
```

```
Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1265 GCTGAGAGGCTGAG 1280
DB 1 GCTGAGAGGCTGAG 16
```

```
RESULT 301
US-09-817-879-2217
; Sequence 2217, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2217
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2217
```

```
Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1205 GAGGCGAGCCATCTGT 1220
DB 2 GAGGCGAGCCATCTGT 17
```

```
RESULT 302
US-09-817-879-2338/C
; Sequence 2338, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
```

```
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2338
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2338
```

```
Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1205 GAGGCGAGCCATCTGT 1220
DB 17 GAGGCGAGCCATCTGT 2
```

```
RESULT 303
US-09-817-879-2755
; Sequence 2755, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2755
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2755
```

```
Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1334 CTCGAGGAGGAGAC 1349
DB 2 CGCCAGGAGGAGGAGAC 17
```

```
RESULT 304
US-10-060-756A-1817/C
; Sequence 1817, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/327,898
;; PRIOR FILING DATE: 2001-10-09
;; NUMBER OF SEQ ID NOS: 4804
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 1817
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-060-756A-1817

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 CCATGTCATCTGTGA 1315
Db 17 CCATGTCATCTGTGA 2

RESULT 305
US-10-060-756A-1818/C
; Sequence 1818, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1818
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1818

US-10-060-756A-1818

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 CCATGTCATCTGTGA 1315
Db 16 CCATGTCATCTGTGA 1

RESULT 306
US-10-060-756A-1820/C
; Sequence 1820, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian

;; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;; FILE REFERENCE: PB0177
;; CURRENT APPLICATION NUMBER: US/10/060,756A
;; CURRENT FILING DATE: 2002-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/327,898
;; PRIOR FILING DATE: 2001-10-09
;; NUMBER OF SEQ ID NOS: 4804
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 1820
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-060-756A-1820

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 GTGTCATGTCATCTG 1312
Db 17 GTGTCATGTCATCTG 2

RESULT 307
US-10-060-756A-1821/C
; Sequence 1821, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1821
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1821

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1297 GTGCCATGTCATCTG 1312
|||
Db 16 GTTCATGTCATCTG 1

RESULT 308
US-10-163-552-222
; Sequence 222, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSw19gen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 222
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-222

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.6e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1305 GTCATCTGTGAGCAGC 1320
|||
Db 2 GGCAUCUGUGAGCUGC 17

RESULT 309
US-10-163-552-652
; Sequence 652, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSw19gen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 652
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-652

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.6e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1392 GCTGAGCTGCTGACCA 1407
|||
Db 1 GCUCGCGUCGUGACCA 16

RESULT 310
US-10-430-882-515/C
; Sequence 515, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James MCSw19gen

; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 515
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-515

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1356 AGGGACCTGAGGCTT 1371
|||
Db 17 AGGGACCTGAGGCTT 2

RESULT 311
US-10-430-882-1014/C
; Sequence 1014, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James MCSw19gen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1014
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-1014

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1356 AGGGACCTGAGGCTT 1371
|||
Db 16 AGGGACCTGAGGCTT 1

```
RESULT 312
US-10-138-674-3061/c
; Sequence 3061, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3061
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3061

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1280 GGGCAGAGACCTCAG 1295
Db      16 GGGCAGAGACCATGAG 1

RESULT 313
US-10-138-674-6458/c
; Sequence 6458, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6458
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6458

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1267 TGGAGAGGCTGAGCG 1282
Db      16 TGGCAGAGGCTGTGG 1

RESULT 314
US-10-138-674-8537
; Sequence 8537, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
```

```
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8537
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8537

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 2.6e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      1298 TGGCATGTCATCTGT 1313
Db      2 UGGCAUGGUCUCUCUG 17

RESULT 315
US-10-138-674-8734/c
; Sequence 8734, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8734
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8734

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1268 GGAAGAGGCTGAGGC 1283
Db      17 GGCAGAGGCTGTGGC 2

RESULT 316
US-10-287-949A-3061/c
; Sequence 3061, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
```

SEQ ID NO 3061
LENGTH: 17
TYPE: RNA
ORGANISM: Mus musculus
US-10-287-949A-3061

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1280 GGGCAGAGACCTCAG 1235
DB 16 GGGCAGAGACCTAG 1

RESULT 317
US-10-287-949A-6458/C
Sequence 6458, Application US/10287949A
Publication No. US20040102389A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00-876-N (400/049)
CURRENT APPLICATION NUMBER: US/10/287,949A
CURRENT FILING DATE: 2003-04-11
NUMBER OF SEQ ID NOS: 20822
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6458
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-287-949A-6458

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1267 TGGAGAGGCTGAGGG 1282
DB 16 TGGCAGAGGCTGTGGG 1

RESULT 318
US-10-287-949A-8537
Sequence 8537, Application US/10287949A
Publication No. US20040102389A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00-876-N (400/049)
CURRENT APPLICATION NUMBER: US/10/287,949A
CURRENT FILING DATE: 2003-04-11
NUMBER OF SEQ ID NOS: 20822
SOFTWARE: PatentIn version 3.0
SEQ ID NO 8537
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-287-949A-8537

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 2.6e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1298 TGGCATGTCTATCTGT 1313
DB 2 TGGCAGUGUCUUCUGU 17

RESULT 319
US-10-287-949A-8734/C
Sequence 8734, Application US/10287949A
Publication No. US20040102389A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00-876-N (400/049)
CURRENT APPLICATION NUMBER: US/10/287,949A
CURRENT FILING DATE: 2003-04-11
NUMBER OF SEQ ID NOS: 20822
SOFTWARE: PatentIn version 3.0
SEQ ID NO 8734
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-287-949A-8734

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1268 GGAAGAGGCTGAGGGC 1283
DB 17 GGCAGAGGCTGTGGC 2

RESULT 320
US-10-712-672-369/C
Sequence 369, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Chowitira, Bharat
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 369
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-369

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1196 GCCTGTGAGAGGCA 1211
DB 16 GCCTGTGTACAGGCA 1

RESULT 321
US-10-712-672-1263
Sequence 1263, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MBH00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1263
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-1263

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1373 CCAGAGCAGCTGCCT 1388
DB 1 CCAGAGCAGCTGCCT 16

RESULT 322
US-10-712-672-1980
Sequence 1980, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MBH00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1980
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-1980

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1360 CAGTGAAGCTTACCA 1375
DB 2 CAGTGAAGCTTACCA 17

RESULT 323
US-10-669-841-4393/C
Sequence 4393, Application US/10669841
Publication No. US20040127446A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blact
APPLICANT: Dennis, Macejak
APPLICANT: James, MCSwigen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Kenneth, Draper
APPLICANT: Elisabeth, Roberts
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
FILE REFERENCE: 400/04205 (MBH02-249-E)
CURRENT APPLICATION NUMBER: US/10/669,841
CURRENT FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: PCT/US02/09187
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/296,876
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 60/335,059
PRIOR FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: US 60/337,055
PRIOR FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 09/817,879
PRIOR FILING DATE: 2001-03-26
PRIOR APPLICATION NUMBER: US 09/740,332
PRIOR FILING DATE: 2000-12-18
PRIOR APPLICATION NUMBER: US 09/611,931
PRIOR FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: US 09/504,321
PRIOR FILING DATE: 2000-02-15
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 16207
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4393
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4393

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1334 CTCGAGGAGGAGGAG 1349
DB 17 CTCGAGGAGGAGGAG 2

RESULT 324
US-10-669-841-4537
Sequence 4537, Application US/10669841
Publication No. US20040127446A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blact
APPLICANT: Dennis, Macejak
APPLICANT: James, MCSwigen
APPLICANT: David, Morrissey

```
/ APPLICANT: Pamela, Pavco
/ APPLICANT: Patrice, Lee
/ APPLICANT: Kenneth, Draper
/ APPLICANT: Elisabeth, Roberts
/ TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPB
/ FILE REFERENCE: 400/042US (MEHB02-249-E)
/ CURRENT APPLICATION NUMBER: US/10/669,841
/ PRIOR FILING DATE: 2003-09-23
/ PRIOR APPLICATION NUMBER: PCT/US02/09187
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: US 60/296,876
/ PRIOR FILING DATE: 2001-06-08
/ PRIOR APPLICATION NUMBER: US 60/335,059
/ PRIOR FILING DATE: 2001-10-24
/ PRIOR APPLICATION NUMBER: US 60/337,055
/ PRIOR FILING DATE: 2001-12-05
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 09/817,879
/ PRIOR FILING DATE: 2001-03-26
/ PRIOR APPLICATION NUMBER: US 09/740,332
/ PRIOR FILING DATE: 2000-12-18
/ PRIOR APPLICATION NUMBER: US 09/611,931
/ PRIOR FILING DATE: 2000-07-07
/ PRIOR APPLICATION NUMBER: US 09/504,321
/ PRIOR FILING DATE: 2000-02-15
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 16207
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 4537
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
/ NAME/KEY: misc_feature
/ LOCATION:
/ OTHER INFORMATION: oligonucleotide substrate
/ US-10-669-841-4537

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      1265 GCTGGAGAGGCTGAG 1280
Db      1 GCUGAGAGACGACUGAG 16

RESULT 325
/ US-10-669-841-4810
/ Sequence 4810, Application US/10669841
/ Publication No. US20040127446A1
/ GENERAL INFORMATION:
/ APPLICANT: Sinna Therapeutics, Inc.
/ APPLICANT: Lawrence, Blatt
/ APPLICANT: Dennis, Macejak
/ APPLICANT: James, McSwigen
/ APPLICANT: David, Morrissey
/ APPLICANT: Pamela, Pavco
/ APPLICANT: Patrice, Lee
/ APPLICANT: Kenneth, Draper
/ APPLICANT: Elisabeth, Roberts
/ TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPB
/ FILE REFERENCE: 400/042US (MEHB02-249-E)
/ CURRENT APPLICATION NUMBER: US/10/669,841
/ PRIOR FILING DATE: 2003-09-23
/ PRIOR APPLICATION NUMBER: PCT/US02/09187
```

```
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: US 60/296,876
/ PRIOR FILING DATE: 2001-06-08
/ PRIOR APPLICATION NUMBER: US 60/335,059
/ PRIOR FILING DATE: 2001-10-24
/ PRIOR APPLICATION NUMBER: US 60/337,055
/ PRIOR FILING DATE: 2001-12-05
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 09/817,879
/ PRIOR FILING DATE: 2001-03-26
/ PRIOR APPLICATION NUMBER: US 09/740,332
/ PRIOR FILING DATE: 2000-12-18
/ PRIOR APPLICATION NUMBER: US 09/611,931
/ PRIOR FILING DATE: 2000-07-07
/ PRIOR APPLICATION NUMBER: US 09/504,321
/ PRIOR FILING DATE: 2000-02-15
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 16207
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 4810
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
/ NAME/KEY: misc_feature
/ LOCATION:
/ OTHER INFORMATION: oligonucleotide substrate
/ US-10-669-841-4810

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      1205 GAGGCGAGCATCTGT 1220
Db      2 GAGGCGCGCACCUGU 17

RESULT 326
/ US-10-669-841-4931/C
/ Sequence 4931, Application US/10669841
/ Publication No. US20040127446A1
/ GENERAL INFORMATION:
/ APPLICANT: Sinna Therapeutics, Inc.
/ APPLICANT: Lawrence, Blatt
/ APPLICANT: Dennis, Macejak
/ APPLICANT: James, McSwigen
/ APPLICANT: David, Morrissey
/ APPLICANT: Pamela, Pavco
/ APPLICANT: Patrice, Lee
/ APPLICANT: Kenneth, Draper
/ APPLICANT: Elisabeth, Roberts
/ TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPB
/ FILE REFERENCE: 400/042US (MEHB02-249-E)
/ CURRENT APPLICATION NUMBER: US/10/669,841
/ PRIOR FILING DATE: 2003-09-23
/ PRIOR APPLICATION NUMBER: PCT/US02/09187
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: US 60/296,876
/ PRIOR FILING DATE: 2001-06-08
/ PRIOR APPLICATION NUMBER: US 60/335,059
/ PRIOR FILING DATE: 2001-10-24
/ PRIOR APPLICATION NUMBER: US 60/337,055
/ PRIOR FILING DATE: 2001-12-05
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
```

```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-4931

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1205 GAGGCGAGCCATCTGT 1220
Db      17 GAGGCGCGCCACTGT 2

RESULT 327
US-10-669-841-5348
; Sequence 5348, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Lawrence, Blatc
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MEH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5348
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-5348

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1334 CTCGAGCGAGAGAC 1349
Db      2 CGCCAGCGAGAGAC 17

RESULT 328
US-10-723-361-926
; Sequence 926, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 926
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-926

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1262 ACAGCTGGAAGAGGCT 1277
```

Db 2 AGAGCTGAAGAGCT 17

RESULT 329

US-10-723-361-1962
; Sequence 1962, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecm1ca Sequence Listing Engine
; SEQ ID NO 1962
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1962

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGACA 1407
Db 2 GCTCAGCTGCTGACA 17

RESULT 330

US-10-723-361-1963
; Sequence 1963, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecm1ca Sequence Listing Engine
; SEQ ID NO 1963
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1963

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGACA 1407
Db 1 GCTCAGCTGCTGACA 16

RESULT 331

US-10-723-361-2594
; Sequence 2594, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 2594
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-2594

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 AGGCTGCCATGTCAT 1309
Db 1 AGGCTGCCATGTCAT 16

RESULT 332

US-10-723-361-6610/C
Sequence 6610, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 6610
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-6610

QY 1223 GAACCTCCAGCATG 1238
Db 17 GAGCCTCCAGCATG 2

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1223 GAACCTCCAGCATG 1238
Db 17 GAGCCTCCAGCATG 2

RESULT 333

US-10-723-361-6613/C
Sequence 6613, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 6613
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-6613

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 CAGACCTCCAGCATG 1236
Db 16 CAGACCTCCAGCATG 1

RESULT 334

US-10-723-361-7346
Sequence 7346, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25

```
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7346
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-7346
```

```
Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1261 AACAGCTGGAAGAGCC 1276
Db      2 AACAGTTGGAAGAGC 17
```

```
RESULT 335
US-10-723-361-7347
; Sequence 7347, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7347
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-7347
```

```
Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1261 AACAGCTGGAAGAGCC 1276
Db      1 AACAGTTGGAAGAGC 16
```

```
RESULT 336
US-10-723-361-7797
; Sequence 7797, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15735
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7797
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-7797
```

```
Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1253 GCTGACGACAGAGCTG 1268
Db      2 GCTTCAGCAGCAGCTG 17
```

```
RESULT 337
US-10-723-361-7798
```

```
; Sequence 7798, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7798
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-7798

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1253 GCTGCAGCAGCAGCTG 1268
Db      1 GCTTCAGCAGCAGCTG 16

RESULT 338
US-10-723-361-8647
; Sequence 8647, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
```

```
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8647
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8647

Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1254 CTGCAGCAGCAGCTGG 1269
Db      2 CTGCAGCTGCAGCTGG 17

RESULT 339
US-10-723-361-8649
; Sequence 8649, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8649
```

LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-8649

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1255 TGCAGCAGCTGCGA 1270
DB 1 TGCAGCTGCGAGTGA 16

RESULT 340
US-10-723-361-9346
Sequence 9346, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT FILING DATE: US/10/723,361
PRIOR FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remain Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 9346
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-9346

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1269 GAAGAGCTGAGGCA 1284
DB 2 GAAGAGCTGGGACA 17

RESULT 341
US-10-723-361-9347
Sequence 9347, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:

APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT FILING DATE: US/10/723,361
PRIOR FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remain Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 9347
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-9347

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1269 GAAGAGCTGAGGCA 1284
DB 1 GAAGAGCTGGGACA 16

RESULT 342
US-10-712-633-3610
Sequence 3610, Application US/10712633
Publication No. US20040220128A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pamela
APPLICANT: Sandberg, Jennifer
APPLICANT: Gordon, Gilad
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND (C
FILE REFERENCE: MEH802-325PCT (400/047)
CURRENT FILING DATE: US/10/712,633
CURRENT APPLICATION NUMBER: US/10/712,633
PRIOR FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 09/708,690
PRIOR FILING DATE: 2000-11-07

;; PRIOR APPLICATION NUMBER: US 09/870,161
;; PRIOR FILING DATE: 2001-05-29
;; PRIOR APPLICATION NUMBER: US 60/334,461
;; PRIOR FILING DATE: 2001-11-30
;; PRIOR APPLICATION NUMBER: US 10/138,674
;; PRIOR FILING DATE: 2002-05-03
;; NUMBER OF SEQ ID NOS: 5989
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 3610
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo Sapiens
US-10-712-633-3610

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 2.6e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1298 TGCATGTCATCTGT 1313
DB 2 UGCGAUGGUCUCUCU 17

RESULT 343
US-10-712-633-3877/c
;; Sequence 3877, Application US/10712633
;; Publication No. US20040220128A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Pavco, Pamela
;; APPLICANT: Sandberg, Jennifer
;; APPLICANT: Gordon, Glad
;; APPLICANT: McSwigen, James
;; APPLICANT: Stinchcomb, Dan
;; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
;; FILE REFERENCE: MBH02-325PCT (400/047)
;; CURRENT APPLICATION NUMBER: US/10/712,633
;; PRIOR APPLICATION NUMBER: 2003-11-13
;; PRIOR FILING DATE: 1995-10-26
;; PRIOR APPLICATION NUMBER: US 08/584,040
;; PRIOR FILING DATE: 1996-01-08
;; PRIOR APPLICATION NUMBER: US 09/371,772
;; PRIOR FILING DATE: 1999-08-10
;; PRIOR APPLICATION NUMBER: US 09/708,690
;; PRIOR FILING DATE: 2000-11-07
;; PRIOR APPLICATION NUMBER: US 09/870,161
;; PRIOR FILING DATE: 2001-05-29
;; PRIOR APPLICATION NUMBER: US 60/334,461
;; PRIOR FILING DATE: 2001-11-30
;; PRIOR APPLICATION NUMBER: US 10/138,674
;; PRIOR FILING DATE: 2002-05-03
;; NUMBER OF SEQ ID NOS: 5989
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 3877
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo Sapiens
US-10-712-633-3877

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1268 GGAAGAGCTGAGGCG 1283
DB 17 GCGAGAGGCTGTGGGC 2

RESULT 344
US-09-969-373-4044
;; Sequence 4044, Application US/09969373

;; Patent No. US20020133852A1
;; GENERAL INFORMATION:
;; APPLICANT: Effeertz, Roger J.
;; APPLICANT: Hauge, Brian M.
;; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;; FILE REFERENCE: 38-10(52679)A
;; CURRENT APPLICATION NUMBER: US/09/969,373
;; CURRENT FILING DATE: 2001-10-02
;; PRIOR APPLICATION NUMBER: US 09/754,853
;; PRIOR FILING DATE: 2001-01-05
;; PRIOR APPLICATION NUMBER: US 09/760,427
;; PRIOR FILING DATE: 2001-01-13
;; PRIOR APPLICATION NUMBER: US 09/855,768
;; PRIOR FILING DATE: 2001-05-15
;; NUMBER OF SEQ ID NOS: 4593
;; SEQ ID NO 4044
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Glycine max
US-09-969-373-4044

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 CCATGGTCATCTGGA 1315
DB 2 CCATGGTCATCTTGA 17

RESULT 345
US-10-179-940-535/c
;; Sequence 535, Application US/10179940
;; Publication No. US20040018618A1
;; GENERAL INFORMATION:
;; APPLICANT: Abrams, Mark A.
;; APPLICANT: Bauer, S. C.
;; APPLICANT: Barford-Goldberg, Sarah R.
;; APPLICANT: Caparon, Maite H.
;; APPLICANT: Easton, Alan M.
;; APPLICANT: Klein, Barbara K.
;; APPLICANT: McKearn, John P.
;; APPLICANT: Oline, Peter O.
;; APPLICANT: Paik, Kumman
;; APPLICANT: Polazzi, Joseph O.
;; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
;; NUMBER OF SEQUENCES: 549
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Carol M. Nielsen, Gardere Wynne Sewell LLP,
;; STREET: 1601 Elm Street, Suite 3000
;; CITY: Dallas
;; STATE: Texas
;; COUNTRY: USA
;; ZIP: 75201-4761
;; MEDIUM TYPE: Floppy disk
;; COMPUTER READABLE FORM:
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/10/179,940
;; FILING DATE: 19-Jun-2002
;; CLASSIFICATION: Unknown
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/981044
;; FILING DATE: 24-NOV-1992
;; APPLICATION NUMBER: PCT/US93/11198
;; FILING DATE: 22-NOV-1993
;; APPLICATION NUMBER: US 08/411796
;; FILING DATE: 09-APR-1995
;; APPLICATION NUMBER: US 08/559390
;; FILING DATE: 15-NOV-1995
;; ATTORNEY/AGENT INFORMATION:

```

; NAME: Carol M. Nielsen
; REGISTRATION NUMBER: 37,676
; REFERENCE/DOCKET NUMBER: 126181-1056 (C2713/1)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (713)276-5383
; TELEFAX: (713)276-5555
; INFORMATION FOR SEQ ID NO: 535:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 535:
US-10-179-940-535

Query Match          5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1337 CAAGCAGAGACTTT 1352
Db      17  CATGCAGAGATT 2

RESULT 346
US-10-355-820-15
; Sequence 15, Application US/10355820
; Publication No. US20030166282A1
; GENERAL INFORMATION:
; APPLICANT: BROWN, DAVID
; APPLICANT: FORD, LANCE
; APPLICANT: JARVIS, RICH
; APPLICANT: PALLOTTA, VINCE
; APPLICANT: PASLOSKE, BRITTAN
; TITLE OF INVENTION: HIGH POTENCY siRNAs FOR REDUCING THE EXPRESSION OF
; TITLE OF INVENTION: TARGET GENES
; FILE REFERENCE: AMB1:07705
; CURRENT APPLICATION NUMBER: US/10/355,820
; CURRENT FILING DATE: 2003-01-31
; PRIOR APPLICATION NUMBER: 60/353,332
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (15)..(17)
; OTHER INFORMATION: d = a, t or g
US-10-355-820-15

Query Match          5.0%; Score 12.6; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1338 AAGCAGAGACTTT 1352
Db      2   AAGCAGAGACTT 16

RESULT 347
US-10-136-728-111/c
; Sequence 111, Application US/10136728
; Publication No. US20030236188A1
; GENERAL INFORMATION:
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Li, Li

```

```

; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Stone, David J.
; APPLICANT: Guo, Xiaojia
; APPLICANT: Anderson, David W.
; APPLICANT: Patnirajan, Meera
; APPLICANT: Gerlach, Valerie L.
; APPLICANT: Taupier, Raymond J.
; APPLICANT: Pena, Carol E.A.
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Gorman, Linda
; APPLICANT: Zerhusen, Bryan D.
; APPLICANT: Smithson, Glenda
; APPLICANT: MacDougall, John R.
; APPLICANT: Mezes, Peter S.
; APPLICANT: Perman, John A.
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: No. US20030236188A1el Human Proteins, Polynucleotides Encoding The
; TITLE OF INVENTION: The Same
; FILE REFERENCE: 21402-347 D (Cura 647 Other)
; CURRENT APPLICATION NUMBER: US/10/136,728
; CURRENT FILING DATE: 2002-05-01
; PRIOR APPLICATION NUMBER: 60/288,395
; PRIOR FILING DATE: 2001-05-03
; PRIOR APPLICATION NUMBER: 60/289,087
; PRIOR FILING DATE: 2001-05-07
; PRIOR APPLICATION NUMBER: 60/289,619
; PRIOR FILING DATE: 2001-05-08
; PRIOR APPLICATION NUMBER: 60/289,818
; PRIOR FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: 60/289,817
; PRIOR FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: 60/290,194
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: 60/290,753
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: 60/291,189
; PRIOR FILING DATE: 2001-05-15
; PRIOR APPLICATION NUMBER: 60/292,374
; PRIOR FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 60/293,107
; PRIOR FILING DATE: 2001-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 132
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
US-10-136-728-111

Query Match          5.0%; Score 12.6; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1225 ACCTCCAGCATGTGCTG 1243
Db      19  ACATCCTGATGTGCTGAC 1

RESULT 348
US-10-401-830B-1
; Sequence 1, Application US/10401830B
; Publication No. US20040191779A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jie
; APPLICANT: Wei, Hsiu-ying
; APPLICANT: McEvoy, Leslie M.
; TITLE OF INVENTION: Statistical Analysis Of Regulatory
; TITLE OF INVENTION: Factor Binding Sites Of Differentially Expressed Genes
; FILE REFERENCE: 39753-0002 US
; CURRENT APPLICATION NUMBER: US/10/401,830B

```

;; CURRENT FILING DATE: 2003-03-28
;; NUMBER OF SEQ ID NOS: 4
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 1
;; LENGTH: 14
;; TYPE: DNA
;; ORGANISM: Homo Sapiens
US-10-401-830B-1

Query Match 4.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1343 AGGAGACTTCCCA 1356
Db 1 AGGGGACTTCCCA 14

RESULT 349
US-10-402-689-1
; Sequence 1, Application US/10402689
; Publication No. US20040191781A1
; GENERAL INFORMATION:
; APPLICANT: ZHANG, Jie
; APPLICANT: WEI, Hui-Ying
; APPLICANT: MCEVOY, Leslie Margaret
; TITLE OF INVENTION: GENOMIC PROFILING OF REGULATORY FACTOR
; TITLE OF INVENTION: BINDING SITES
; FILE REFERENCE: 39753-0003 US
; CURRENT APPLICATION NUMBER: US/10/402,689
; CURRENT FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: not yet assigned
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: protein bind
; LOCATION: (1)...(14)
US-10-402-689-1

Query Match 4.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1343 AGGAGACTTCCCA 1356
Db 1 AGGGGACTTCCCA 14

RESULT 350
US-09-837-992-29
; Sequence 29, Application US/09837992
; Patent No. US20020081687A1
; GENERAL INFORMATION:
; APPLICANT: Tian, Hui
; APPLICANT: Schultz, Joshua
; APPLICANT: Shan, Bei
; APPLICANT: Tularik Inc.
; TITLE OF INVENTION: Slicetoleremia Susceptibility Gene (SSG); Compositions
; TITLE OF INVENTION: and Methods of Use
; FILE REFERENCE: 018781-006020US
; CURRENT APPLICATION NUMBER: US/09/837,992
; CURRENT FILING DATE: 2001-04-18
; PRIOR APPLICATION NUMBER: US 60/198,465
; PRIOR FILING DATE: 2000-04-18
; PRIOR APPLICATION NUMBER: US 60/204,234
; PRIOR FILING DATE: 2000-05-15
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1

;; SEQ ID NO 29
;; LENGTH: 16
;; TYPE: DNA
;; ORGANISM: Homo sapiens
;; FEATURE:
;; OTHER INFORMATION: 5' splicing site for exon 6
US-09-837-992-29

Query Match 4.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1237 TGCTGCGAGTGTC 1250
Db 1 TGCTGCGAGAGCTC 14

RESULT 351
US-09-866-108-932
; Sequence 932, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine

;; SEQ ID NO 932
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-932

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1267 TGAAGAGGCTGAG 1280
Db 1 TGAAGAGGCTGAG 14

RESULT 352
US-09-866-108-8308/C

; Sequence 8308, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR FILING DATE: 2000-05-26
; PRIOR FILING DATE: 2000-05-26
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8308
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8308

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1373 CCAGAGCAGCTGC 1386
Db 17 CCAGAGCAGCTGC 4

RESULT 353
US-09-866-108-8309/C
; Sequence 8309, Application US/09866108

; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8309
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8309

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1373 CCAGAGCAGCTGC 1386
Db 16 CCAGAGCAGCTGC 3

RESULT 354
US-09-866-108-8310/C
; Sequence 8310, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

```
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8310
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8310

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8311
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8311

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1373 CCAGAGCAGCTGC 1386
DB 15 CCAGAGCAGCTGC 2

RESULT 355
US-09-866-108-8311/c
Sequence 8311, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```
QY 1373 CCAGAGCAGCTGC 1386
DB 14 CCAGAGCAGCTGC 1

RESULT 356
US-09-866-108-8776
Sequence 8776, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8776
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8776

```

```

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```
Qy      1304 GGTGATCTGTGAGC 1317
Db      4 GGTGATCTGTGACC 17

```

RESULT 357

```

US-09-866-108-8777
; Sequence 8777, Application US/09866108
; Patent No. US20020048600A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687

```

```

; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8777
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8777

```

```

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```
Qy      1304 GGTGATCTGTGAGC 1317
Db      3 GGTGATCTGTGACC 16

```

RESULT 358

```

US-09-866-108-8778
; Sequence 8778, Application US/09866108
; Patent No. US20020048600A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8778
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8778

```

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1304 GGTGATCTGTGAGC 1317
Db 2 GGTGATCTGTGAGC 15

RESULT 359
US-09-866-108-8779
; Sequence 8779, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Menheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263, 6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15732
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8779
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8779

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1304 GGTGATCTGTGAGC 1317
Db 1 GGTGATCTGTGAGC 14

RESULT 360
US-09-827-998-1717/c
; Sequence 1717, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1717
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-1717

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGG 1269
Db 17 GCAGCAACAGCTGG 4

RESULT 361
US-09-827-998-1718/c
; Sequence 1718, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1718
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-1718

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGG 1269
Db 16 GCAGCAACAGCTGG 3

RESULT 362
US-09-827-998-1719/c
; Sequence 1719, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8

;
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1719
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-1719

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGG 1269
DB 15 GCAGCAACAGCTGG 2

RESULT 363
US-09-827-998-1720/c
; Sequence 1720, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMRP-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1720
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-1720

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGG 1269
DB 14 GCAGCAACAGCTGG 1

RESULT 364
US-09-864-785-272/c
; Sequence 272, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of NF-Kappa B
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 272
; LENGTH: 17

;
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; US-09-864-785-272

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGGA 1405
DB 16 GCTGAGCTGCTGGA 3

RESULT 365
US-09-864-785-1547/c
; Sequence 1547, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of NF-Kappa B
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1547
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; US-09-864-785-1547

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGGA 1405
DB 15 GCTGAGCTGCTGGA 2

RESULT 366
US-09-961-077-175/c
; Sequence 175, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; Edgington, Brent E.
; McSwigen, James A.
; Merlo, Patricia Ann Owens
; Guo, Lining
; Skokut, Thomas A.
; Young, Scott A.
; Folkerts, Otto
; Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/961,077
FILING DATE: 21-Sep-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/679, 645
FILING DATE: July 12, 1996
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 175:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-961-077-175
SEQUENCE DESCRIPTION: SEQ ID NO: 175:

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1263 CAGCTGGAGAGGC 1276
DB 15 CAGCTGGATGAGGC 2

RESULT 367
US-09-930-423-794/C
Sequence 794, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blact, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH80,918-A 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: PatentIn version 3.0
SEQ ID NO 794
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-794

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1203 CAGAGGCGACCCAT 1216
DB 17 CAGATGCGACGCAT 4

RESULT 368
US-09-930-423-1574
Sequence 1574, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blact, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH80,918-A 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1574
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-1574

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1371 TACCAGAGCAGCT 1384
DB 4 UACCAGGCGACGU 17

RESULT 369
US-09-740-332-3137
Sequence 3137, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3137
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3137

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1412 GGGTCTGAGCGG 1425
DB 4 GGGUGGUGAGCGG 17

RESULT 370
US-09-740-332-3138
Sequence 3138, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704

```
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3138
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3138

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1413 GGTGCTGAGCGGC 1426
Db      1 GGUUGUGAGCGGC 14

RESULT 371
US-09-745-237A-794/C
; Sequence 794, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 794
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-794

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1203 CAGAGGCGAGCCAT 1216
Db      17 CAGATGGCAGCCAT 4

RESULT 372
US-09-745-237A-1574
; Sequence 1574, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1574
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1574

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1371 TACCAGAGCAGCT 1384
Db      4 UACGAGAGCAGCU 17

RESULT 373
US-09-817-879-3137
; Sequence 3137, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3137
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3137

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1412 GGGTGCTGAGCGGC 1425
Db      4 GGGUGUGAGCGGC 17

RESULT 374
US-09-817-879-3138
; Sequence 3138, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3138
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3138

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1413 GGTGCTGAGCGGC 1426
Db      1 GGUUGUGAGCGGC 14

RESULT 375
US-10-156-306-4917
; Sequence 4917, Application US/10156306
; Publication No. US20030119017A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4917
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-156-306-4917

Query Match
Best Local Similarity 4.9%; Score 12.4; DB 1; Length 17;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAACAGC 1266
DB 4 GCUGCAGCAGCAGC 17

RESULT 376
US-10-156-306-4918
; Sequence 4918, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4918
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-156-306-4918

Query Match
Best Local Similarity 4.9%; Score 12.4; DB 1; Length 17;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAACAGC 1266
DB 1 GCUGCAGCAGCAGC 14

RESULT 377
US-10-156-306-5857
; Sequence 5857, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwigen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-156-306-5857
```

```

Query Match
Best Local Similarity 4.9%; Score 12.4; DB 1; Length 17;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAACAGC 1266
DB 3 GCUGCAGCAGCAGC 16

RESULT 378
US-10-257-124-3
; Sequence 3, Application US/10257124
; Publication No. US20030148311A1
; GENERAL INFORMATION:
; APPLICANT: SHANGHAI CANCER INSTITUTE
; TITLE OF INVENTION: A NOVEL HUMAN HEPATOMA ASSOCIATED PROTEIN AND THE POLYNUCLEOTIDE I
; TITLE OF INVENTION: SAID POLYPEPTIDE
; FILE REFERENCE: 001465PCWO
; CURRENT APPLICATION NUMBER: US/10/257,124
; CURRENT FILING DATE: 2002-10-08
; PRIOR APPLICATION NUMBER: CN 00115401.X
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Synthetic primer
; US-10-257-124-3

Query Match
Best Local Similarity 4.9%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1420 AGCGGCGCATCATC 1433
DB 3 AGTGGGCGCATCATC 16
```

```

RESULT 379
US-10-675-685-1717/c
; Sequence 1717, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomca Sequence Listing Engine
; SEQ ID NO 1717
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-675-685-1717

Query Match
Best Local Similarity 4.9%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGG 1269
DB 17 GCAGCAACAGCTGG 4

RESULT 380
```

US-10-675-685-1718/c
; Sequence 1718, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1718
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-1718

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGG 1269
Db 16 GCAGCAACAGCTGG 3

RESULT 381
US-10-675-685-1719/c
; Sequence 1719, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1719
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-1719

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGG 1269
Db 15 GCAGCAACAGCTGG 2

RESULT 382
US-10-675-685-1720/c
; Sequence 1720, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685

; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1720
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-1720

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGG 1269
Db 14 GCAGCAACAGCTGG 1

RESULT 383
US-10-138-674-1609
; Sequence 1609, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1609
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1609

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1302 ATGTCATCTGTGA 1315
Db 1 AUGGUCUCUGUGA 14

RESULT 384
US-10-287-949A-1609
; Sequence 1609, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1609
; LENGTH: 17

TYPE: RNA
ORGANISM: Homo sapiens
US-10-287-949A-1609

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1302 ATGTCATCTGTGA 1315
|||||:|:|:|
DB 1 AUGGUCUCUGUGA 14

RESULT 385
US-10-669-841-5730
Sequence 5730, Application US/10669841
Publication No. US20040127446A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blact
APPLICANT: Dennis, Macejak
APPLICANT: James, McSwiggen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Patrice, Lee
APPLICANT: Kenneth, Draper
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
FILE REFERENCE: 400/042US (MBHB02-249-E)
CURRENT APPLICATION NUMBER: US/10/669,841
CURRENT FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: PCT/US02/09187
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/296,876
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 60/335,059
PRIOR FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: US 60/337,055
PRIOR FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 09/817,879
PRIOR FILING DATE: 2001-03-26
PRIOR APPLICATION NUMBER: US 09/740,332
PRIOR FILING DATE: 2000-12-18
PRIOR APPLICATION NUMBER: US 09/611,931
PRIOR FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: US 09/504,321
PRIOR FILING DATE: 2000-02-15
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 16207
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5730
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5730

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1412 GGGTGTGAGCGGC 1425
|||||:|:|:|

DB 4 GGGUGUGAGCGGC 17

RESULT 386
US-10-669-841-5731
Sequence 5731, Application US/10669841
Publication No. US20040127446A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blact
APPLICANT: Dennis, Macejak
APPLICANT: James, McSwiggen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Patrice, Lee
APPLICANT: Kenneth, Draper
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
FILE REFERENCE: 400/042US (MBHB02-249-E)
CURRENT APPLICATION NUMBER: US/10/669,841
CURRENT FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: PCT/US02/09187
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/296,876
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 60/335,059
PRIOR FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: US 60/337,055
PRIOR FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 09/817,879
PRIOR FILING DATE: 2001-03-26
PRIOR APPLICATION NUMBER: US 09/740,332
PRIOR FILING DATE: 2000-12-18
PRIOR APPLICATION NUMBER: US 09/611,931
PRIOR FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: US 09/504,321
PRIOR FILING DATE: 2000-02-15
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 16207
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5731
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5731

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1413 GGGTGTGAGCGGC 1426
|||||:|:|:|
DB 1 GGGUGUGAGCGGC 14
RESULT 387
US-10-723-361-932
Sequence 932, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: UI, Yonggang

```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 932
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-932

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1267 TGAAGAGGCTGAG 1280
Db      1 TGAAGAGGCTGAG 14

RESULT 388
US-10-723-361-8308/c
; Sequence 8308, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8308
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8308

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1373 CCAAGAGGCTGC 1386
Db      17 CCAAGAGGCTGC 4

RESULT 389
US-10-723-361-8309/c
; Sequence 8309, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8309
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8309
```

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1373 CCAGAGCAGCTGC 1386
DB 16 CCAGAGCAGCTGC 3

RESULT 390
US-10-723-361-8310/c

; Sequence 8310, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8310
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8310

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1373 CCAGAGCAGCTGC 1386
DB 15 CCAGAGCAGCTGC 2

RESULT 391
US-10-723-361-8311/c

; Sequence 8311, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8311
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-8311

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1373 CCAGAGCAGCTGC 1386
DB 14 CCAGAGCAGCTGC 1

RESULT 392
US-10-723-361-8776

; Sequence 8776, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8776
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8776

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1304 GGTGATCTGTGAGC 1317
Db      4 GGTGATCTGTGACC 17

RESULT 393
US-10-723-361-8777
; Sequence 8777, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8777
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8777

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```

Qy      1304 GGTGATCTGTGAGC 1317
Db      3 GGTGATCTGTGACC 16

RESULT 394
US-10-723-361-8778
; Sequence 8778, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8778
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8778

Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1304 GGTGATCTGTGAGC 1317
Db      2 GGTGATCTGTGACC 15

RESULT 395
US-10-723-361-8779
; Sequence 8779, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
```

```
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723.361
CURRENT FILING DATE: 2003-11-25
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8779
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-8779
```

```
Query Match 4.9% Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1304 GGTGCTGCTGAGC 1317
DB 1 GGTGCTGCTGACC 14
```

```
RESULT 396
US-09-866-108-8648/C
Sequence 8648, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: ACOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
```

```
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8648
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8648
```

```
Query Match 4.8% Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1249 TCCGCTGCGACACAG 1265
DB 17 TCCGCTGCGACAG 1
```

```
RESULT 397
US-10-723-361-8648/C
Sequence 8648, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8648
LENGTH: 17
TYPE: DNA
```

! ORGANISM: Homo sapiens
US-10-723-361-8648

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1249 TCCGGCTGCAGCAACAG 1265
DB 17 TCCAGCTGCAGCTGCAG 1

RESULT 398
US-09-866-108-1460/c
; Sequence 1460, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1460
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1460

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1369 CTTACCAAGACGAGCTG 1385
DB 17 CTTCCAGAGAGCTGCTG 1

RESULT 399
US-09-866-108-1959/c
; Sequence 1959, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1959

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1376 GAAGACGCTGCTTTG 1392
DB 17 GCAGACGCTGAGCTTG 1

RESULT 400
US-09-866-108-2588
; Sequence 2588, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.

```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2588
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-2588

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1288 ACCCTCAGGCGTGCATG 1304
Db      1  ACCTCCAGGCGTGCATG 17

RESULT 401
US-09-866-108-7525
; Sequence 7525, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```

; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-7525

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1253 GCTGAGCAACAGCTGG 1269
Db      1  GCTGAGCAACAGCTGG 17

RESULT 402
US-09-866-108-7795
; Sequence 7795, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7795
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7795

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3,4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1250 CCGGCTGCAGCAGCAGC 1266

Db 1 CCAGCTTCAGCAGCAGC 17

```

RESULT 403
US-09-866-108-7796
; Sequence 7796, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7796
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7796
```

```

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3,4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1251 CCGGCTGCAGCAGCAGCT 1267

Db 1 CAGCTTCAGCAGCAGCT 17

```

RESULT 404
US-09-866-108-7799
; Sequence 7799, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
```

SEQ ID NO 7799
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-7799

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3,4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTCGACGACAGCTGGA 1270
Db 1 CTCGACGACAGCTGGA 17

RESULT 405
US-09-866-108-7840
Sequence 7840, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 7840
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-7840

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3,4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGACGACAGCTGG 1269
Db 1 GCTGACGACAGCTGG 17

RESULT 406
US-09-866-108-7841
Sequence 7841, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 7841
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-7841

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3,4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTCGACGACAGCTGGA 1270
Db 1 CTCGACGACAGCTGGA 17

RESULT 407
US-09-866-108-7920/c
Sequence 7920, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:

```
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeomica Sequence Listing Engine
/ SEQ ID NO 7920
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-7920

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1328 CCTCTTCCAGGCAG 1344
Db      17 CCTCTCTCAAGCAG 1

RESULT 408
US-09-866-108-8433/C
/ Sequence 8433, Application US/09866108
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
```

```
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeomica Sequence Listing Engine
/ SEQ ID NO 8433
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-8433

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1305 GTCATCTGTAGCAGCT 1321
Db      17 GTCCGCTGTAGCAGCCT 1

RESULT 409
US-09-866-108-8434/C
/ Sequence 8434, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
```

;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 8434
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-8434

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1304 GGTGCTGCTGAGCACC 1320
Db 17 GGTGCTGCTGAGCACC 1

RESULT 410
US-09-866-108-8504
;; Sequence 8504, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263,6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663

;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 8504
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-8504

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1392 GGTGAGCTGCTGAGCAG 1408
Db 1 GATGAGCAGCTGTACAG 17

RESULT 411
US-09-866-108-8506
;; Sequence 8506, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263,6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860

;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO: 8506
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-8506

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1394 TGAGCTGCTGACACAG 1410
Db 1 TGAGCAGCTGTACAGC 17

RESULT 412

US-09-866-108-8650
; Sequence 8650, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 8650
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8650

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAG 1272
Db 1 GCAGCTGAGCTGGAG 17

RESULT 413

US-09-866-108-8651
; Sequence 8651, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 8651
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8651

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1257 CAGCAACAGCTGGAGA 1273
Db 1 CAGCTGAGCTGGAGA 17

RESULT 414

US-09-866-108-9231

```
; Sequence 9231, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9231
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9231

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9232
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9232

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9233
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9233
```

```

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1205 GAGGGCAGCCATCTGTC 1221
Db      1 GAGGGCAGCCCTGCAGTC 17
```

```

RESULT 417
US-09-866-108-9543/c
; Sequence 9543, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yongsang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9543
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9543
```

```

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1192 AGAAGCCTGCGCAGAGC 1208
Db      17 AGAAGCAGGGAGAGAGC 1
```

```

RESULT 418
US-09-864-785-403
; Sequence 403, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of NF-Kappa B
; CURRENT APPLICATION NUMBER: US/09/864,785
; PRIOR FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-403
```

```

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1243 CAGTGTCCGGCTGCAG 1259
Db      1 CAGAGGCCUCCUGCAG 17
```

```

RESULT 419
US-09-864-785-404
; Sequence 404, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 404
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-404

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY      1244 AGTGTCCGGCTGCAGC 1260
Db       1 AGAGCCCTCUCGUCAGC 17

RESULT 420
; Sequence 408, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 408
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-408

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.4e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1379 GCAGCTCGCTTTCCTG 1395
Db       1 GCAGCUCGAGUUCUGAUG 17

RESULT 421
; Sequence 1593, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 1593
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1593

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.4e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1380 CAGCTGCGTTCCTGCTGA 1396
Db       1 CAGCUCGAGUUCUGAUGA 17

RESULT 422
; Sequence 3366, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,589
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3366

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1346 AGACTTCCCGAGGCGAG 1362
Db       17 AAACCTTCCCACTGAAG 1

RESULT 423
; Sequence 3367, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
```

```
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-10
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3367
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3367

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1346 AGACTTCCCGAGGCGAG 1362
Db 1 AACTTCCCGAGGAG 17

RESULT 424
US-09-780-533A-540/c
; Sequence 540, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowitra, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 540
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-540

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1261 AACGCTGGAAGGCT 1277
Db 17 AGCAGCAGGAATAGGCT 1

RESULT 425
US-09-780-533A-1652/c
; Sequence 1652, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowitra, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1652
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1652

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1393 CTGAGCTGCTGCAGAGA 1409
Db 17 CTGTGCTGCAGATAGA 1

RESULT 426
US-09-780-533A-1790
; Sequence 1790, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowitra, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1790
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1790

Query Match
Best Local Similarity 76.5%; Score 12.2; DB 1; Length 17;
Pred. No. 3.4e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1251 CGGCTGCAGCAACAGCT 1267
Db 1 CGGCGGCGGAGCAGAGCU 17

RESULT 427
US-09-780-533A-1793
; Sequence 1793, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowitra, Bharat
; APPLICANT: Haeblerl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1793
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1793

Query Match
Best Local Similarity 70.6%; Score 12.2; DB 1; Length 17;
Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
```

QY 1251 CGGCTGCAGCAGCTG 1267
Db 1 CAGCUGCAGCAUCUUCU 17

RESULT 428
US-09-780-533A-2521/C
; Sequence 2521, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowitra, Bharat
; APPLICANT: Haebertli, Peter
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2521
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2521

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1189 CCCGAGAGCCTGTCAG 1205
Db 17 CTCGAGATCCTGTCCTG 1

RESULT 429
US-09-927-046-238/C
; Sequence 238, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: McSwigen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloro
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 238
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-238

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAACGCTGG 1269
Db 17 GCAGCAGAGAAAAGCTGG 1

RESULT 430
US-09-927-046-840
; Sequence 840, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: McSwigen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-840

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.4e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1370 TTACCGAGAGCAGCTGC 1386
Db 1 UTAACUGCAGCAGCAGCUUC 17

RESULT 431
US-09-927-046-1285
; Sequence 1285, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: McSwigen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1285

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.4e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1368 GCTTACCGAGAGCAGCT 1384
Db 1 GAUUAACUGCAGCAGCAGCU 17

RESULT 432
US-09-848-754A-428
; Sequence 428, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 428
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-428

Query Match
Best Local Similarity 64.7%; Score 12.2; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1325 GGACCTCTTCTCCAGG 1341
Db 1 GGACUUCUUCUCCAGG 17

RESULT 433
US-09-848-754A-885/C
; Sequence 885, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 885
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-885

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 CAGAGCGCAGCCATCTG 1219
Db 17 CAGAGCGCAGCCAGCAG 1

RESULT 434
US-09-848-754A-886/C
; Sequence 886, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 886
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-886

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1198 CTGTGCGAGGCGCAGCC 1214
Db 17 CCGGCGCAGAGCCGCGCAGC 1

RESULT 435
US-09-848-754A-1033/C
; Sequence 1033, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1033
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1033

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1196 GCCTGTGCGAGGCGCAG 1212
Db 17 GCCTGTGCGAGCCCTGCAG 1

RESULT 436
US-09-848-754A-1036/C
; Sequence 1036, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1036
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1036

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1187 CTCCGAGAGCCTGTGTC 1203
Db 17 CTCCGCGGCGCCTGTGC 1

RESULT 437
US-09-848-754A-1214
; Sequence 1214, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
```

NUMBER OF SEQ ID NOS: 9645
SOFTWARE: Patent version 3.0
SEQ ID NO 1214
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-848-754A-1214

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1353 CCCAGGCGCAGCTGAGGC 1369
Db 1 CCAGGCGCUCUGGGGC 17

RESULT 438

US-09-848-754A-2022/c
Sequence 2022, Application US/09848754A
Publication No. US20030073207A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
FILE REFERENCE: MBH00-958-1 (400/018)
CURRENT APPLICATION NUMBER: US/09/848,754A
CURRENT FILING DATE: 2001-05-03
NUMBER OF SEQ ID NOS: 9645
SOFTWARE: Patent version 3.0
SEQ ID NO 2022
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-848-754A-2022

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1276 CTGAGGCGCAGACCT 1292
Db 17 CTCAGGCGCAGACACT 1

RESULT 439

US-09-848-754A-2244/c
Sequence 2244, Application US/09848754A
Publication No. US20030073207A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
FILE REFERENCE: MBH00-958-1 (400/018)
CURRENT APPLICATION NUMBER: US/09/848,754A
CURRENT FILING DATE: 2001-05-03
NUMBER OF SEQ ID NOS: 9645
SOFTWARE: Patent version 3.0
SEQ ID NO 2244
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-848-754A-2244

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1189 CCCAGAGCCTGTGCAG 1205
Db 17 CCCGCGGCGCTGTGCAG 1

RESULT 440

US-09-930-423-225/c
Sequence 225, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH00, 918-A, 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: Patent version 3.0
SEQ ID NO 225
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-225

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1339 AGCAGAGACCTTCCC 1355
Db 17 AGCAGAGATTCCC 1

RESULT 441

US-09-930-423-1271/c
Sequence 1271, Application US/09930423
Publication No. US20030092003A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blatt, Larry
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: MBH00, 918-A, 400/027
CURRENT APPLICATION NUMBER: US/09/930,423
CURRENT FILING DATE: 2001-08-15
NUMBER OF SEQ ID NOS: 4553
SOFTWARE: Patent version 3.0
SEQ ID NO 1271
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-09-930-423-1271

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1281 GCGAGAGCCTCAGG 1297
Db 17 GCCAGAACCATCAGG 1

RESULT 442

US-09-864-636A-209
Sequence 209, Application US/09864636A
Publication No. US20030104378A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Allwal, Hatim
APPLICANT: Bartholomay, Christian
APPLICANT: Chehak, Luane
TITLE OF INVENTION: Detection of RNA Sequences
FILE REFERENCE: FORS-04944
CURRENT APPLICATION NUMBER: US/09/864,636A
CURRENT FILING DATE: 2002-10-15
NUMBER OF SEQ ID NOS: 2640
SOFTWARE: Patent version 3.0

; SEQ ID NO 209
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-209

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGGAAGAGGC 1276
Db 1 CTACAACTGGAGAGGC 17

RESULT 443
US-09-864-636A-926
; Sequence 926, Application US/09864636A
; Publication No. US20030104378A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allwai, Hatim
; APPLICANT: Bartholomay, Christian
; APPLICANT: Chehak, LuAnne
; TITLE OF INVENTION: Detection of RNA Sequences
; FILE REFERENCE: FORS-04944
; CURRENT APPLICATION NUMBER: US/09/864,636A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 926
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-926

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGGAAGAGGC 1276
Db 1 CTACAACTGGAGAGGC 17

RESULT 444
US-09-864-636A-952
; Sequence 952, Application US/09864636A
; Publication No. US20030104378A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allwai, Hatim
; APPLICANT: Bartholomay, Christian
; APPLICANT: Chehak, LuAnne
; TITLE OF INVENTION: Detection of RNA Sequences
; FILE REFERENCE: FORS-04944
; CURRENT APPLICATION NUMBER: US/09/864,636A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-952

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGGAAGAGGC 1276
Db 1 CTACAACTGGAGAGGC 17

RESULT 445
US-09-827-395A-226/c
; Sequence 226, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NCO and NCO Receptor Ge
; FILE REFERENCE: MHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 226
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-226

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1244 AGTGTCGGCTGCAGC 1260
Db 17 AGCGGTCCAGGTGCAGC 1

RESULT 446
US-09-827-395A-890/c
; Sequence 890, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NCO and NCO Receptor Ge
; FILE REFERENCE: MHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 890
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-890

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1243 CAGTGTCGGCTGCAG 1259
||| ||||| | |||||

Db 17 CAGCGTCCAGTGCAG 1

RESULT 447

US-09-827-395A-891/c

; Sequence 891, Application US/09827395A

; Publication No. US20030113891A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Lawrence Blatt

; APPLICANT: James McSwiggen

; APPLICANT: Bharat Chowhira

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G

; FILE REFERENCE: MBH00-878-C (400/017)

; CURRENT APPLICATION NUMBER: US/09/827,395A

; CURRENT FILING DATE: 2001-04-05

; PRIOR APPLICATION NUMBER: 09/780,533

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 60/181,797

; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 891

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-827-395A-891

Query Match

Best Local Similarity 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.4e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1242 GCAGTGTCCGCGTCCA 1258

Db 17 GCAGCGGTCCAGGTGCA 1

RESULT 448

US-09-827-395A-956

; Sequence 956, Application US/09827395A

; Publication No. US20030113891A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Lawrence Blatt

; APPLICANT: James McSwiggen

; APPLICANT: Bharat Chowhira

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G

; FILE REFERENCE: MBH00-878-C (400/017)

; CURRENT APPLICATION NUMBER: US/09/827,395A

; CURRENT FILING DATE: 2001-04-05

; PRIOR APPLICATION NUMBER: 09/780,533

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 60/181,797

; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 956

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-827-395A-956

Query Match

Best Local Similarity 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 64.7%; Pred. No. 3.4e+02;

Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1359 GCAGTGAAGCTTACCA 1375

Db 1 GCCCGUGGGGCUUCCCA 17

RESULT 449

US-09-827-395A-979/c

; Sequence 979, Application US/09827395A

; Publication No. US20030113891A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Lawrence Blatt

; APPLICANT: James McSwiggen

; APPLICANT: Bharat Chowhira

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G

; FILE REFERENCE: MBH00-878-C (400/017)

; CURRENT APPLICATION NUMBER: US/09/827,395A

; CURRENT FILING DATE: 2001-04-05

; PRIOR APPLICATION NUMBER: 09/780,533

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 60/181,797

; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 979

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-827-395A-979

Query Match

Best Local Similarity 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.4e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1283 CAGAGACCTCAGCGTG 1299

Db 17 CAGAGTCCCAAGGCTG 1

RESULT 450

US-09-827-395A-980/c

; Sequence 980, Application US/09827395A

; Publication No. US20030113891A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Lawrence Blatt

; APPLICANT: James McSwiggen

; APPLICANT: Bharat Chowhira

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G

; FILE REFERENCE: MBH00-878-C (400/017)

; CURRENT APPLICATION NUMBER: US/09/827,395A

; CURRENT FILING DATE: 2001-04-05

; PRIOR APPLICATION NUMBER: 09/780,533

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 60/181,797

; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 980

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-827-395A-980

Query Match

Best Local Similarity 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.4e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1282 GCAGAGCCTCAGCGT 1298

Db 17 GCAGAGTCCCAAGGCT 1

RESULT 451

US-09-827-395A-981/c

; Sequence 981, Application US/09827395A

; Publication No. US20030113891A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Lawrence Blatt

```
; APPLICANT: James McSwigen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MEHB00-878-C (400/0117)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 981
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-981

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1281 GGCAGAGACCTCAGGG 1297
Db 17 GGCAGAGCTCCCAAGGG 1

RESULT 452
US-09-740-332-3303
; Sequence 3303, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3303
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3303

Query Match
Best Local Similarity 52.9%; Score 12.2; DB 1; Length 17;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1321 TAGGGAGCTCTTCTCC 1337
Db 1 UAGGGAGGAGUUUUC 17

RESULT 453
US-09-792-818-360
; Sequence 360, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwigen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MEHB00-901-A (400/013)
```

```
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-360

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1250 CCGGCTGCAGCAACAGC 1266
Db 1 CTUGCAGCAGCACACAC 17

RESULT 454
US-09-792-818-383/C
; Sequence 383, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwigen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MEHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 383
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-383

Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGCGCAACAGCTCG 1269
Db 17 GCTGCTGCAGCTGCTCG 1

RESULT 455
US-09-792-818-524/C
; Sequence 524, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwigen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MEHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 524
; LENGTH: 17
; TYPE: RNA
```

ORGANISM: Homo sapiens
US-09-792-818-524

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1252 GGCTGCGCAACGCTG 1268
DB 17 GGCTGCTGCGCTGCTG 1

RESULT 456
US-09-745-237A-225/C
Sequence 225, Application US/09745237A
Publication No. US20030143708A1

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blact, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: 400/007 (MBHB00-918-A)
CURRENT APPLICATION NUMBER: US/09/745,237A
CURRENT FILING DATE: 2002-04-15
NUMBER OF SEQ ID NOS: 4550
SOFTWARE: PatentIn version 3.0
SEQ ID NO 225
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-745-237A-225

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1339 AGCAGAGGACTTCCC 1355
DB 17 AACGAGCAGAAATTCCC 1

RESULT 457
US-09-745-237A-1271/C
Sequence 1271, Application US/09745237A
Publication No. US20030143708A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Blact, Larry
APPLICANT: McSwiggen, Jim
TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
FILE REFERENCE: 400/007 (MBHB00-918-A)
CURRENT APPLICATION NUMBER: US/09/745,237A
CURRENT FILING DATE: 2002-04-15
NUMBER OF SEQ ID NOS: 4550
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1271
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-745-237A-1271

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1281 GGCAGAGACCTCGGG 1297
DB 17 GCCAGAAACATCGGG 1

RESULT 458
US-09-817-879-3303
Sequence 3303, Application US/09817879

Publication No. US20030171311A1

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: MBHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3303
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3303

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.4e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1321 TAGGGGACCTCTCTCC 1337
DB 1 UAGGGAGGUUUUCC 17

RESULT 459
US-09-864-426A-209
Sequence 209, Application US/09864426A
Publication No. US20040018489A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Ma, Wu Po
APPLICANT: Lyamichev, Victor
APPLICANT: Saiser, Michael
TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
FILE REFERENCE: FORS-04946
CURRENT APPLICATION NUMBER: US/09/864,426A
CURRENT FILING DATE: 2001-05-24
NUMBER OF SEQ ID NOS: 2640
SOFTWARE: PatentIn version 3.0
SEQ ID NO 209
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-09-864-426A-209

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGAGAGGC 1276
DB 1 CTCAACTGAGAGAGGC 17

RESULT 460
US-09-864-426A-926
Sequence 926, Application US/09864426A
Publication No. US20040018489A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Ma, Wu Po
APPLICANT: Lyamichev, Victor
APPLICANT: Saiser, Michael
TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
FILE REFERENCE: FORS-04946
CURRENT APPLICATION NUMBER: US/09/864,426A

; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 926
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-426A-926

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGGAAGGCGC 1276
Db 1 CTACAACTGGAGGAGGC 17

RESULT 461
US-09-864-426A-952
; Sequence 952, Application US/09864426A
; Publication No. US20040018489A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Ma, Wu Po
; APPLICANT: Lyamichev, Victor
; APPLICANT: Salsner, Michael
; TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
; FILE REFERENCE: FORS-04946
; CURRENT APPLICATION NUMBER: US/09/864,426A
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-426A-952

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGGAAGGCGC 1276
Db 1 CTACAACTGGAGGAGGC 17

RESULT 462
US-10-060-756A-774
; Sequence 774, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 774
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-774

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1197 CCTGTGACAGAGGCGCAGC 1213
Db 1 CTTTGCAGAACTCAGC 17

RESULT 463
US-10-060-756A-916/c
; Sequence 916, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 916
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-916

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1385 GCGTTTGTGACTGTC 1401
Db 17 GCGTTTGTGACTGTC 1

RESULT 464
US-10-060-756A-1819/c
; Sequence 1819, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177

```
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1819
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1819

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1298 TGGCATGTCATCTGTG 1314
DB      17  TTCCATGTTCTCTGGG 1

RESULT 465
US-10-060-998-1378/c
; Sequence 1378, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1378
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1378

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1230 CAGCATGTGCTGCAGT 1246
DB      17  CATCATGTGCTGAAGT 1

RESULT 466
US-10-156-306-1358
; Sequence 1358, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1358
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1358

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.4e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

OY      1303 TGGTCATCTGTGAGCAG 1319
DB      1  UGGUGAUCUUUCAGCAG 17

RESULT 467
US-10-156-306-1672/c
; Sequence 1672, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1672
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1672

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1272 GAGGCTGAGGAGGAGAG 1288
DB      17  GAGGCTGAGGAGGAGAG 1

RESULT 468
US-10-156-306-2376/c
; Sequence 2376, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2376
```

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1341 GCAGAGACTTCCAG 1357
Db 17 GCAGGATACCTTTTCAG 1

RESULT 469

US-10-061-201-489
Sequence 489, Application US/10061201
Publication No. US20030166229A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
FILE REFERENCE: P0178
CURRENT APPLICATION NUMBER: US/10/061,201
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/328,205
PRIOR FILING DATE: 2001-10-10
NUMBER OF SEQ ID NOS: 4162
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 489
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-489

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 GCTGAGGCGAGAGCC 1291
Db 1 GCTCAGGCGAGAGCTCC 17

RESULT 470

US-10-084-839-209
Sequence 209, Application US/10084839
Publication No. US20030186238A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Allawi, Hatim
APPLICANT: Argue, Brad T.
APPLICANT: Bartholomay, Christian T.
APPLICANT: Chenak, LuAnne
APPLICANT: Curtis, Michelle L.
APPLICANT: Eis, Peggy S.
APPLICANT: Hall, Jeff G.
APPLICANT: IP, Hon S.
APPLICANT: Ji, Lin
APPLICANT: Kaiser, Michael
APPLICANT: Kwiatkowski, Jr., Robert W.

APPLICANT: Lukowiak, Andrew A.
APPLICANT: Lyamichchev, Victor
APPLICANT: Lyamatcheva, Natalie E.
APPLICANT: Ma, Wupo
APPLICANT: Neri, Bruce P.
APPLICANT: Olson, Sarah M.
APPLICANT: Olson-Munoz, Marilyn C.
APPLICANT: Schaefer, James J.
APPLICANT: Skrzypczynski, Zbigniew
APPLICANT: Takova, Tsetska Y.
APPLICANT: Thompson, Lisa C.
APPLICANT: Vedvik, Kevin L.
TITLE OF INVENTION: RNA Detection Assays
FILE REFERENCE: FORS-06666
CURRENT APPLICATION NUMBER: US/10/084,839
CURRENT FILING DATE: 2002-02-26
NUMBER OF SEQ ID NOS: 4004
SOFTWARE: PatentIn version 3.1
SEQ ID NO 209
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-084-839-209

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGAGAGAGC 1276
Db 1 CTCACACTGAGAGAGC 17

RESULT 471

US-10-084-839-926
Sequence 926, Application US/10084839
Publication No. US20030186238A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Allawi, Hatim
APPLICANT: Argue, Brad T.
APPLICANT: Bartholomay, Christian T.
APPLICANT: Chenak, LuAnne
APPLICANT: Curtis, Michelle L.
APPLICANT: Eis, Peggy S.
APPLICANT: Hall, Jeff G.
APPLICANT: IP, Hon S.
APPLICANT: Ji, Lin
APPLICANT: Kaiser, Michael
APPLICANT: Kwiatkowski, Jr., Robert W.
APPLICANT: Lukowiak, Andrew A.
APPLICANT: Lyamichchev, Victor
APPLICANT: Lyamatcheva, Natalie E.
APPLICANT: Ma, Wupo
APPLICANT: Neri, Bruce P.
APPLICANT: Olson, Sarah M.
APPLICANT: Olson-Munoz, Marilyn C.
APPLICANT: Schaefer, James J.
APPLICANT: Skrzypczynski, Zbigniew
APPLICANT: Takova, Tsetska Y.
APPLICANT: Thompson, Lisa C.
APPLICANT: Vedvik, Kevin L.
TITLE OF INVENTION: RNA Detection Assays
FILE REFERENCE: FORS-06666
CURRENT APPLICATION NUMBER: US/10/084,839
CURRENT FILING DATE: 2002-02-26
NUMBER OF SEQ ID NOS: 4004
SOFTWARE: PatentIn version 3.1
SEQ ID NO 926
LENGTH: 17
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-084-839-926

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CACACGCTGGAAGGCG 1276
DB 1 CTACACTGAGAGGAGC 17

RESULT 472
US-10-084-839-952
Sequence 952, Application US/10084839
Publication No. US20030186238A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Allawi, Hatim
APPLICANT: Argue, Brad T.
APPLICANT: Bartholomay, Christian T.
APPLICANT: Chehak, LuAnne
APPLICANT: Curtis, Michelle L.
APPLICANT: Eie, Peggy S.
APPLICANT: Hall, Jeff G.
APPLICANT: IP, Hon S.
APPLICANT: J1, Lin
APPLICANT: Kaiser, Michael
APPLICANT: Kwiatkowski, Jr., Robert W.
APPLICANT: Lukowski, Andrew A.
APPLICANT: Lymichev, Victor E.
APPLICANT: Ma, WuPo
APPLICANT: Neri, Bruce P.
APPLICANT: Olson, Sarah M.
APPLICANT: Olson-Munoz, Marilyn C.
APPLICANT: Schaefer, James J.
APPLICANT: Skrzypczynski, Zbigniew
APPLICANT: Takova, Tsetska Y.
APPLICANT: Thompson, Lisa C.
APPLICANT: Vedvik, Kevin L.
TITLE OF INVENTION: RNA Detection Assays
FILE REFERENCE: PORS-0666
CURRENT APPLICATION NUMBER: US/10/084,839
CURRENT FILING DATE: 2002-02-26
NUMBER OF SEQ ID NOS: 4004
SOFTWARE: Patentin version 3.1
SEQ ID NO 952
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-084-839-952

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CACACGCTGGAAGGCG 1276
DB 1 CTACACTGAGAGGAGC 17

RESULT 473
US-10-430-882-226/C
Sequence 226, Application US/10430882
Publication No. US20030203870A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Lawrence Blatt

APPLICANT: James McSwigen
APPLICANT: Bharat Chowrira
APPLICANT: Peter Heberli
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
FILE REFERENCE: MBH00-878-H (400/112)
CURRENT APPLICATION NUMBER: US/10/430,882
CURRENT FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 09/827,395
PRIOR FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 09/780,533
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: PCT/US01/04273
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/181,797
PRIOR FILING DATE: 2000-02-11
PRIOR APPLICATION NUMBER: PCT/US02/10512
PRIOR FILING DATE: 2002-04-03
NUMBER OF SEQ ID NOS: 2617
SOFTWARE: Patentin version 3.0
SEQ ID NO 226
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-430-882-226

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1244 AGGTGTCGGCTGCAGC 1260
DB 17 AGCGGTCCAGGTGCAGC 1

RESULT 474
US-10-430-882-890/C
Sequence 890, Application US/10430882
Publication No. US20030203870A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Lawrence Blatt
APPLICANT: James McSwigen
APPLICANT: Bharat Chowrira
APPLICANT: Peter Heberli
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
FILE REFERENCE: MBH00-878-H (400/112)
CURRENT APPLICATION NUMBER: US/10/430,882
CURRENT FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 09/827,395
PRIOR FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 09/780,533
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: PCT/US01/04273
PRIOR FILING DATE: 2001-02-09
PRIOR APPLICATION NUMBER: 60/181,797
PRIOR FILING DATE: 2000-02-11
PRIOR APPLICATION NUMBER: PCT/US02/10512
PRIOR FILING DATE: 2002-04-03
NUMBER OF SEQ ID NOS: 2617
SOFTWARE: Patentin version 3.0
SEQ ID NO 890
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-430-882-890

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1243 CAGTGTCCGGCTGCAG 1259
DB 17 CAGCGTCCAGGTGCAG 1

```
RESULT 475
US-10-430-882-891/C
; Sequence 891, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-891

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1242 GCAGTGTCCGGCTGCA 1258
Db       17 GCAGCGGTCCAGTGCA 1

RESULT 476
US-10-430-882-956
; Sequence 956, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 956
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-10-430-882-956

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.4e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY      1359 GCAGCTGAGGCTTACCA 1375
Db       1 GCCGCTGGGGCTUCCCA 17

RESULT 477
US-10-430-882-979/C
; Sequence 979, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 979
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-979

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1283 CAGAGACCTCAGGGTG 1299
Db       17 CAGAGTCCCAAGGGTG 1

RESULT 478
US-10-430-882-980/C
; Sequence 980, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
```

; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 980
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-980

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1282 GCAGAGACCTCAGCGT 1298
Db 17 GCAGAGTCCCAAGGCT 1

RESULT 479
US-10-430-882-981/c
; Sequence 981, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haeblerl
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 981
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-981

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1281 GCAGAGACCTCAGCG 1297
Db 17 GCAGAGTCCCAAGGCT 1

RESULT 480
US-10-209-787-3366/c
; Sequence 3366, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787

; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3366

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1346 AGACTTCCCGAGCGCAG 1362
Db 17 AAACCTTCCCGAGTGAG 1

RESULT 481
US-10-209-787-3367
; Sequence 3367, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3367
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3367

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1346 AGACTTCCCGAGCGCAG 1362
Db 1 AAACCTTCCCGAGTGAG 17

RESULT 482
US-10-307-005-1143/c
; Sequence 1143, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:

```

; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1143
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Cucumis sativus
US-10-307-005-1143

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1191 CAGAGCCTGTGCAGAG 1207
Db      17  CACAACTTATGCAGAG 1
```

```

RESULT 483
US-10-307-005-1144
; Sequence 1144, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1144
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Cucumis sativus
US-10-307-005-1144
```

```

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1191 CAGAGCCTGTGCAGAG 1207
Db      1  CACAACTTATGCAGAG 17
```

```

RESULT 484
US-10-307-005-1163/C
; Sequence 1163, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1163
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Cucurbita sp.
US-10-307-005-1163

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1191 CAGAGCCTGTGCAGAG 1207
Db      17  CACAACTTATGCAGAG 1
```

```

RESULT 485
US-10-307-005-1164
; Sequence 1164, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1164
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Cucurbita sp.
US-10-307-005-1164
```

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1191 CAGAACCTGTGCAGAG 1207
Db 1 CACAACTATGCAGAG 17

RESULT 486
US-10-261-185-3366/c
; Sequence 3366, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:

; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3366

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1346 AGACTTCCCGAGGCGAG 1362
Db 17 AAACCTTCCCGAGGAG 1

RESULT 487
US-10-261-185-3367
; Sequence 3367, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385

; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3367
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3367

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1346 AGACTTCCCGAGGCGAG 1362
Db 1 AAACCTTCCCGAGGAG 17

RESULT 488
US-10-138-674-5055
; Sequence 5055, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5055
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5055

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.4e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1376 GAGCAGCGCGCTTTG 1392
Db 1 GAGCCAGCGCGCUUUG 17

RESULT 489
US-10-138-674-6456/c
; Sequence 6456, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6456
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6456

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1271 AGAGCTGAGGCGAG 1287
Db 17 AGAGCTGTGGCCAG 1

RESULT 490
US-10-138-674-6784/c
; Sequence 6784, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6784
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6784

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1228 TCACGATGCTGGCA 1244
Db 17 TCACGATGCTGGTA 1

RESULT 491
US-10-138-674-7221
; Sequence 7221, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7221
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7221

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1331 CTCTCCAGGCGAG 1347
Db 1 CAUCUCCAUAGCAGGG 17

RESULT 492
US-10-138-674-9271/c

; Sequence 9271, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9271
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-9271

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1329 CTCTCCAGGCGAG 1345
Db 17 CTCTCACGCGCAG 1

RESULT 493
US-10-676-154-566/c
; Sequence 566, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/676,154
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 566
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-566

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1377 AAGCAGCTGGCTTGC 1393
Db 17 ATGCACTGCATCTTGC 1

RESULT 494
US-10-287-949A-5055
; Sequence 5055, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim

; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Relating to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5055
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5055

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.4e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1376 GAGCAGCTGCTTTG 1392
DB 1 GAGCAGCTGCTTTG 17

RESULT 495
US-10-287-949A-6456/C
; Sequence 6456, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Relating to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6456
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6456

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1271 AGAGCTGAGGCGAG 1287
DB 17 AGAGCTGAGGCGAG 1

RESULT 496
US-10-287-949A-6784/C
; Sequence 6784, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Relating to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6784
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6784

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1228 TCCAGCATGCTGGA 1244
DB 17 TCCAGCATGCTGGA 1

RESULT 497
US-10-287-949A-7221
; Sequence 7221, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Relating to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7221
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7221

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1331 CTTCCAGGCGAG 1347
DB 1 CAUCCAGGCGAG 17

RESULT 498
US-10-287-949A-9271/C
; Sequence 9271, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Relating to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9271
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9271

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1329 CTCTTCTCAAGCAGC 1345
|||:|:|:|:|:|:|
Db 17 CTCTTCAACAGCGCAG 1

RESULT 499

US-10-712-672-109
; Sequence 109, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowitra, Bharat
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 109
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-109

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1241 GGCAGTGTCCGGCTGC 1257
|||:|:|:|:|:|:|
Db 1 GCGUGUGUCCGGCGCC 17

RESULT 500

US-10-712-672-110
; Sequence 110, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowitra, Bharat
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 110
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-110

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1242 GCAGTGTCCGGCTGCA 1258
|||:|:|:|:|:|:|
Db 1 GCGUGUGUCCGGCGCGCA 17

RESULT 501

US-10-712-672-144
; Sequence 144, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowitra, Bharat
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-144

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1242 GCAGTGTCCGGCTGCA 1258
|||:|:|:|:|:|:|
Db 1 GCAGAGUCCAGCGCAGCA 17

RESULT 502

US-10-712-672-385
; Sequence 385, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowitra, Bharat
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-385

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 3.4e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1382 GCTGCGTTTGTGAGC 1398

Db 1 GTCGCGCCGCGCGC 17

RESULT 503
US-10-712-672-838
Sequence 838, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: McSwigen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 838
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-838

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1243 CAGTGTCCGCGCTGCGC 1259
Db 1 CUGUGUCCGCGCGCGCAG 17

RESULT 504
US-10-712-672-1281/C
Sequence 1281, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: McSwigen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1281
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-1281

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1273 AGGCTGAGGCGAGAC 1289
Db 1 GAGCAGCTGAGGCGAGCT 17

Db 17 AGTCTGAGGCGAGTGC 1

RESULT 505
US-10-712-672-2106
Sequence 2106, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: McSwigen, Jim
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2106
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-2106

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1314 GAGCAGCTGAGGCGAGCT 1330
Db 1 GAGCAGCTGAGGCGAGCT 17

RESULT 506
US-10-669-841-5896
Sequence 5896, Application US/10669841
Publication No. US20040127446A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blat
APPLICANT: Dennis, Macejak
APPLICANT: James, McSwigen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Patrice, Lee
APPLICANT: Kenneth, Draper
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS AND HEPATITIS B VIRUS
FILE REFERENCE: 400/042US (MHB02-249-E)
CURRENT APPLICATION NUMBER: US/10/669,841
CURRENT FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: PCT/US02/09187
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/296,876
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 60/335,059
PRIOR FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: US 60/337,055
PRIOR FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 09/817,879
PRIOR FILING DATE: 2001-03-26
PRIOR APPLICATION NUMBER: US 09/740,332

```
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5896
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5896
```

```
Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.4e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1321 TAGGGGAGCTCTTCTCC 1337
Db      1 UAGGGAGAGUUUUC 17
```

RESULT 507

```
US-10-723-361-1460/c
; Sequence 1460, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1460
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1460
```

```
Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1369 CTTACCGAGAGAGCTG 1385
Db      17 CTTCCAGAGAGCTGCTG 1
```

RESULT 508

```
US-10-723-361-1959/c
; Sequence 1959, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1959
```

```
Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1376 GAAGCAGCTGCGTTTG 1392
Db      17 GCAGCAGCTGAGCTTG 1
```

RESULT 509

```
US-10-723-361-2588
; Sequence 2588, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
```

```
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 2588
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-2588

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1288 ACCCTCAGGTCGTCATG 1304
Db 1 AGCTCAGGTCGTCATG 17

RESULT 510
US-10-723-361-7525
Sequence 7525, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 7795
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-7795

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 7525
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-7525

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGAGCAACACTG 1269
Db 1 GCTGAGCAACACTG 17

RESULT 511
US-10-723-361-7795
Sequence 7795, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 7795
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-7795

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1250 CCGGCTGAGACAGC 1266
Db 1 CCGCTTACAGCAGC 17

RESULT 512

US-10-723-361-7796
; Sequence 7796, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 7796
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7796

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1251 CCGGCTGAGACAGC 1267
Db 1 CCGCTTACAGCAGC 17

RESULT 513

US-10-723-361-7799
; Sequence 7799, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 7799
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7799

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1254 CTGACGACAGCTGGA 1270
Db 1 CTTACAGCAGCAGCTGGA 17

RESULT 514

US-10-723-361-7840
; Sequence 7840, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669

;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeonica Sequence Listing Engine
;; SEQ ID NO 7840
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-7840

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1253 GCTGACGACAGCTGG 1269
Db 1 GCTGACGACAGCTGG 17

RESULT 515
US-10-723-361-7841
;; Sequence 7841, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; PRIOR FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeonica Sequence Listing Engine
;; SEQ ID NO 7841
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-7841

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1254 CTCGACGACAGCTGGA 1270

Db 1 CTCGACGACAGCTGGA 17

RESULT 516
US-10-723-361-7920/c
;; Sequence 7920, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; PRIOR FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeonica Sequence Listing Engine
;; SEQ ID NO 7920
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-7920

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1328 CCTCTCTCCAGGACG 1344
Db 17 CCTCTCTCCAGGACG 1

RESULT 517
US-10-723-361-8433/c
;; Sequence 8433, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361

```
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8433
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8433
```

```
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1305 GTCATCTGTGACGACT 1321
Db 17 GTCCTGTGACGACT 1
```

```
RESULT 518
US-10-723-361-8434/c
; Sequence 8434, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8434
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8434
```

```
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1304 GTCATCTGTGACGAC 1320
Db 17 GTCCTGTGACGACT 1
```

```
RESULT 519
US-10-723-361-8504
; Sequence 8504, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8504
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8504
```

```
Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1392 GCTGACCTGTGACGAC 1408
Db 1 GATGACGACTGTACG 17
```

```
RESULT 520
US-10-723-361-8506
; Sequence 8506, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8506
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8506

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1394 TGAGCTGCTGACGAC 1410
      ||||| ||||| |||||
Db       1 TGAGCAGCTGTACGCG 17

RESULT 521
US-10-723-361-8650
; Sequence 8650, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

US-10-723-361-8650

Query Match          4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1256 GCAGCAACGCTGAGG 1272
      ||||| ||||| |||||
Db       1 GCAGCTGCACTGAGG 17

RESULT 522
US-10-723-361-8651
; Sequence 8651, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomla Sequence Listing Engine
/ SEQ ID NO 8651
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-723-361-8651
```

```
Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1257 CAGCACAGCTGGAGAGA 1273
Db 1 CAGCTGAGCTGGAGAGA 17
```

```
RESULT 523
US-10-723-361-9231
/ Sequence 9231, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: GU, Yizhong
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OR INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomla Sequence Listing Engine
/ SEQ ID NO 9231
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-723-361-9231
```

```
Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1203 CAGAGGGCAGCCATCTGT 1219
Db 1 CAGAGGGCAGCCATCTGT 17
```

```
RESULT 524
US-10-723-361-9232
```

```
/ Sequence 9232, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: GU, Yizhong
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OR INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomla Sequence Listing Engine
/ SEQ ID NO 9232
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-723-361-9232
```

```
Query Match
Best Local Similarity 82.4%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1204 AGAGGGCAGCCATCTGT 1220
Db 1 AGAGGGCAGCCATCTGT 17
```

```
RESULT 525
US-10-723-361-9233
/ Sequence 9233, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: GU, Yizhong
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OR INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
```


	Matches	14;	Conservative	0;	Mismatches	3;	Indels	0;	Gaps	0;
Qy	1346	AGACTTCCCGAGGAG	1352							
Db	1	AAACTTCCCGAGGAG	17							

RESULT 529
US-10-712-633--92
Sequence 92, Application US/10712633
Publication No. US20040220128A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pamela
APPLICANT: Sandberg, Jennifer
APPLICANT: Gordon, Gildad
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
FILE REFERENCE: MEMB02-355PCT (400/047)
CURRENT APPLICATION NUMBER: US/10712,633

```

? PRIOR FILING DATE: 1995-10-26
? PRIOR APPLICATION NUMBER: US 08/584,040
? PRIOR FILING DATE: 1996-01-08
? PRIOR APPLICATION NUMBER: US 09/371,772
? PRIOR FILING DATE: 1999-08-10
? PRIOR APPLICATION NUMBER: US 09/708,690
? PRIOR FILING DATE: 2000-11-07
? PRIOR APPLICATION NUMBER: US 09/870,161
? PRIOR FILING DATE: 2001-05-29
? PRIOR APPLICATION NUMBER: US 60/334,461
? PRIOR FILING DATE: 2001-11-30
? PRIOR APPLICATION NUMBER: US 10/138,674
? PRIOR FILING DATE: 2002-05-03
? NUMBER OF SEQ ID NOS: 5989
? SOFTWARE: PatentIn version 3.0
? SEQ ID NO 92
? LENGTH: 17
? TYPE: RNA
? ORGANISM: Homo Sapiens
? US-10-712-633-92

```

Query Match	4.8%	Score 12.2;	DB 1;	length 17;
Best Local Similarity	70.6%	Pred. No. 3.4e+02;		
Matches 12; Conservative	2;	Mismatches 3;	Indels 0;	Gaps 0;

Qy	1331	CTTCTCAAGGCAGGAG	1347
		: :	
Db	1	CAUTCUCAUGCAGGGG	17

RESULT 530
US-10-712-633--3876/c
; Sequence 3876, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Glad
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RELEASE IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MMB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712.633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040

```

1 PRIOR FILLING DATE: 1996-01-08
2 PRIOR APPLICATION NUMBER: US 09/371,772Z
3 PRIOR FILING DATE: 1999-08-10
4 PRIOR APPLICATION NUMBER: US 09/708,690Q
5 PRIOR FILING DATE: 2000-11-07
6 PRIOR APPLICATION NUMBER: US 09/870,161Z
7 PRIOR FILING DATE: 2001-05-29
8 PRIOR APPLICATION NUMBER: US 60/334,461Z
9 PRIOR FILING DATE: 2001-11-30
10 PRIOR APPLICATION NUMBER: US 10/136,674Z
11 PRIOR FILING DATE: 2002-05-03
12 NUMBER OF SEQ ID NOS: 5989
13 SOFTWARE: PatentIn version 3.0
14 SEQ ID NO 3876
15     LENGTH: 17
16     TYPE: RNA
17     ORGANISM: Homo Sapiens
18     US-10-712-653-3876

```

Query Match	4.8%;	Score 12.2;	DB 1;	length 17;
Best Local Similarity	82.4%;	Pred. No. 3.4e+02;		
Matches 14; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

Qy	1271	AGAGGCTGAGGGCAGAG	1287
Db	17	AGAGGCTGTGGGCCAAG	1

```

RESULT 531
US-10-712-633--4542/c
Sequence 4542, Application US/10712633
Publication No. US20040220128A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pamela
APPLICANT: Sandberg, Jennifer
APPLICANT: Gordon, Gilad
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTR
TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND (
FILE REFERENCE: MEMB02-325PCT (400/047)
CURRENT APPLICATION NUMBER: US/10/712,633
CURRENT FILING DATE: 2003-11-13
PRIORITY APPLICATION NUMBER: US 60/005,974
PRIORITY FILING DATE: 1995-10-26
PRIORITY APPLICATION NUMBER: US 08/584,040
PRIORITY FILING DATE: 1996-01-08
PRIORITY APPLICATION NUMBER: US 09/371,772
PRIORITY FILING DATE: 1999-08-10
PRIORITY APPLICATION NUMBER: US 09/708,690
PRIORITY FILING DATE: 2000-11-07
PRIORITY APPLICATION NUMBER: US 09/870,161
PRIORITY FILING DATE: 2001-05-29
PRIORITY APPLICATION NUMBER: US 60/334,461
PRIORITY FILING DATE: 2001-11-30
PRIORITY APPLICATION NUMBER: US 10/138,674
PRIORITY FILING DATE: 2002-05-03
NUMBER OF SEQ ID NOS: 5989
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4542
LENGTH: 17
TYPE: RNA
ORGANISM: Homo Sapiens
US-10-712-633--4542

```

	Query Match	4.8%	Score 12.2	DB 1	Length 17
	Best Local Similarity	82.4%	Pred. No.	3.4e+02	
	Matches 14; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;
OY	1329 CTCTTCTCAAGGACGG	1345			
D6	17 CTCTTCACACGGCAGG	1			

RESULT 532

US-09-907-111-21
; Sequence 21, Application US/09907111
; Publication No. US20030003461A1
; GENERAL INFORMATION:
; APPLICANT: Pascretis, Nikos
; APPLICANT: Gold, Larry
; APPLICANT: Shatland, Timur
; APPLICANT: Javornik, Brenda
; TITLE OF INVENTION: Truncation SELEX Method
; FILE REFERENCE: NEX 79
; CURRENT APPLICATION NUMBER: US/09/907,111
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/275,850
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 351
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 21
; LENGTH: 15
; TYPE: RNA
; ORGANISM: E. coli
US-09-907-111-21

Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1255 TGCAGCAGCAGC 1266

Db 1 UGCAGCAGCAGC 12

RESULT 533

US-09-880-313A-236/c
; Sequence 236, Application US/09880313A
; Publication No. US20030044791A1
; GENERAL INFORMATION:
; APPLICANT: Flemington, Erik K
; TITLE OF INVENTION: Adaptors and Methods of Use
; FILE REFERENCE: 9397/1000
; CURRENT APPLICATION NUMBER: US/09/880,313A
; CURRENT FILING DATE: 2001-06-13
; NUMBER OF SEQ ID NOS: 276
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 236
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-09-880-313A-236

Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1251 CGGCTGCAGCA 1262

Db 15 CGGCTGCAGCA 4

RESULT 534

US-10-056-414-16/c
; Sequence 16, Application US/10056414
; Publication No. US20030003469A1
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; Draper, Kenneth G.
; McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS

RELATED TO LEVELS OF
NF-KB

NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700

CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/056,414
FILING DATE: 23-Jan-2002

CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994

APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994

APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-056-414-16

Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1189 CCCGAGGCTG 1200

Db 12 CCCGAGGCTG 1

RESULT 535

US-10-160-358-61/c
; Sequence 61, Application US/10160358
; Publication No. US2003019869A1
; GENERAL INFORMATION:
; APPLICANT: Genesance Pharmaceuticals, Inc.
; APPLICANT: Bieganski, Karyn
; APPLICANT: Capola, Gina-Marie
; APPLICANT: Koshiy, Beena
; APPLICANT: Monroe, Glen
; TITLE OF INVENTION: HAPLOTYPES OF THE TACR2 GENE
; FILE REFERENCE: TACR2 MMH-0225US
; CURRENT APPLICATION NUMBER: US/10/160,358
; CURRENT FILING DATE: 2002-05-30
; PRIOR APPLICATION NUMBER: PCT/US01/47394
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: 60/247,649
; PRIOR FILING DATE: 2000-11-09
; NUMBER OF SEQ ID NOS: 139

```
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 61
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-160-358-61

Query Match
Best Local Similarity 85.7%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1276 CTGAGGCGCAGAGAC 1289
15 CYGAGGCGCAGACAC 2

RESULT 536
US-10-339-674-149
; Sequence 149, Application US/10339674
; Publication No. US20030204318A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/339,674
; NUMBER OF SEQ ID NOS: 3537
; SOFTWARE: Proprietary
; SEQ ID NO 149
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Escherichia coli K-12 MG1655 complete genome.
; FEATURE:
; LOCATION: (183187)..(183202)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 198
US-10-339-674-149

Query Match
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 CAGCTGCGTTT 1391
3 CAGCTGCGTTT 14

RESULT 537
US-10-339-674-2906
; Sequence 2906, Application US/10339674
; Publication No. US20030204318A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/339,674
; NUMBER OF SEQ ID NOS: 3537
; SOFTWARE: Proprietary
; SEQ ID NO 2906
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Escherichia coli K-12 MG1655 complete genome.
; FEATURE:
; LOCATION: (3979641)..(3979656)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 3858
US-10-339-674-2906

Query Match
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 CAGCTGCGTTT 1391
|||||
```

```
DB 3 CAGCTGCGTTT 14

RESULT 538
US-09-866-108-8774
; Sequence 8774, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8774
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8774

Query Match
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1304 GGTCACTGTGCA 1315
6 GGTCACTGTGCA 17

RESULT 539
US-09-866-108-8775
; Sequence 8775, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```